Clustering O 0 0.00014127350004855543
of O 0 6.039609161234694e-06
missense O 0 0.003772928612306714
mutations O 0 0.00017497107910457999
in O 0 6.793883926548006e-07
the O 0 7.411209026031429e-06
ataxia B-Disease 1 0.9998306035995483
- I-Disease 1 0.9988657236099243
telangiectasia I-Disease 1 0.9998886585235596
gene O 0 6.3424758991459385e-06
in O 0 6.419023179660144e-08
a O 0 2.1833926666658954e-07
sporadic B-Disease 0 3.3614800486247987e-05
T I-Disease 1 0.6667611598968506
- I-Disease 1 0.8864949941635132
cell I-Disease 0 0.30572131276130676
leukaemia I-Disease 1 0.9806132316589355
. O 0 2.179411967517808e-05

Ataxia B-Disease 1 0.9995226860046387
- I-Disease 1 0.9989588260650635
telangiectasia I-Disease 1 0.9998395442962646
( O 0 0.00015496449486818165
A B-Disease 0 0.01203059870749712
- I-Disease 1 0.9983029365539551
T I-Disease 1 0.9998934268951416
) O 0 6.520163537970802e-07
is O 0 2.2548411138245683e-08
a O 0 1.8863784134737216e-07
recessive B-Disease 0 3.045688572456129e-05
multi I-Disease 0 0.009776939637959003
- I-Disease 1 0.9876940250396729
system I-Disease 0 0.16714058816432953
disorder I-Disease 1 0.983470618724823
caused O 0 8.075612277025357e-05
by O 0 6.994873729126994e-07
mutations O 0 1.6330119478880079e-06
in O 0 1.0070511535786864e-08
the O 0 1.892201240139002e-08
ATM O 0 2.6393510779598728e-05
gene O 0 3.8715270989087003e-07
at O 0 3.421971541683888e-07
11q22 O 0 4.094835094292648e-05
- O 0 0.000634646276012063
q23 O 0 0.0001358514855382964
( O 0 1.4407802950699988e-07
ref O 0 9.130355465458706e-05
. O 0 6.094902715858552e-08
3 O 0 2.731430868152529e-07
) O 0 2.9350292152230395e-07
. O 0 1.1156907930853777e-06

The O 0 3.3352262107655406e-05
risk O 0 0.001669936696998775
of O 0 1.9195103959646076e-05
cancer B-Disease 1 0.8038949370384216
, O 0 2.644131200213451e-06
especially O 0 4.242709565005498e-06
lymphoid B-Disease 0 0.0012632007710635662
neoplasias I-Disease 0 0.009960498660802841
, O 0 5.721253160118067e-07
is O 0 6.883703917992534e-08
substantially O 0 3.161685526720248e-06
elevated O 0 1.576285831106361e-05
in O 0 1.226958659117372e-07
A B-Disease 0 0.00026740095927380025
- I-Disease 1 0.9996545314788818
T I-Disease 1 0.9999936819076538
patients O 0 0.019531913101673126
and O 0 2.6941302166960668e-06
has O 0 1.6256279877779889e-06
long O 0 1.1085699952673167e-05
been O 0 2.130558868884691e-06
associated O 0 4.437484221853083e-06
with O 0 3.7551013519987464e-05
chromosomal O 1 0.9994149208068848
instability O 1 0.9521558284759521
. O 0 0.00012766638246830553

By O 0 1.1594465831876732e-05
analysing O 0 0.0019559666980057955
tumour B-Disease 1 0.9991641044616699
DNA O 0 0.00021637027384713292
from O 0 2.465311581545393e-06
patients O 0 1.2919502296426799e-05
with O 0 8.759133862668023e-08
sporadic B-Disease 0 9.137372217082884e-06
T I-Disease 0 0.1136278435587883
- I-Disease 0 0.079876609146595
cell I-Disease 0 0.09271396696567535
prolymphocytic I-Disease 1 0.9729519486427307
leukaemia I-Disease 1 0.9960066676139832
( O 0 4.913536486128578e-06
T B-Disease 0 0.11858994513750076
- I-Disease 0 0.02858501300215721
PLL I-Disease 0 0.009836031123995781
) O 0 3.405027371172764e-07
, O 0 4.345880810774361e-08
a O 0 7.685290626113783e-08
rare O 0 4.367179826658685e-06
clonal B-Disease 0 0.007160082925111055
malignancy I-Disease 0 0.38585034012794495
with O 0 6.506231784442207e-07
similarities O 0 1.0079534149554092e-06
to O 0 1.6475764752499344e-08
a O 0 9.15599187578664e-08
mature B-Disease 0 1.2697160855168477e-05
T I-Disease 0 0.021970970556139946
- I-Disease 0 0.04039516672492027
cell I-Disease 0 0.012312211096286774
leukaemia I-Disease 1 0.7413142323493958
seen O 0 2.440075604681624e-06
in O 0 1.1594242721457704e-07
A B-Disease 0 5.007883009966463e-05
- I-Disease 1 0.9519895315170288
T I-Disease 1 0.9996680021286011
, O 0 4.698282793924591e-07
we O 0 7.681257407909925e-09
demonstrate O 0 3.753686073082463e-08
a O 0 6.910985561603411e-09
high O 0 1.064171826214988e-07
frequency O 0 1.3905935958291593e-08
of O 0 1.6467973651401735e-08
ATM O 0 9.572705312166363e-05
mutations O 0 6.56292377243517e-06
in O 0 5.485462111209927e-07
T B-Disease 0 0.055266451090574265
- I-Disease 0 0.09815200418233871
PLL I-Disease 0 0.020883921533823013
. O 0 1.4188061868480872e-05

In O 0 8.765517122810706e-06
marked O 0 2.8368996936478652e-05
contrast O 0 4.543868271866813e-06
to O 0 2.347742622532678e-08
the O 0 1.4826470717821394e-08
ATM O 0 2.0191562725813128e-05
mutation O 0 9.208328037857427e-07
pattern O 0 3.8005208580216276e-07
in O 0 8.28855277745788e-08
A B-Disease 0 5.884396159672178e-05
- I-Disease 1 0.9867339134216309
T I-Disease 1 0.9997226595878601
, O 0 4.362990182471549e-07
the O 0 8.930865824652301e-09
most O 0 1.0157319429993095e-08
frequent O 0 8.833188758217148e-08
nucleotide O 0 6.337393756439269e-07
changes O 0 5.260452340394295e-08
in O 0 2.1533416827423935e-08
this O 0 1.2674358629283233e-07
leukaemia B-Disease 0 0.44353750348091125
were O 0 5.812763902213192e-06
missense O 0 0.0011643398320302367
mutations O 0 8.443620754405856e-05
. O 0 4.930434897687519e-06

These O 0 1.2251607586222235e-06
clustered O 0 2.7831560146296397e-05
in O 0 1.3826296196839394e-07
the O 0 1.610522026851413e-08
region O 0 7.0264114526708e-08
corresponding O 0 1.7968110554988925e-08
to O 0 2.082587879925768e-09
the O 0 5.903201483192788e-09
kinase O 0 1.703812586129061e-06
domain O 0 1.1695958335167234e-07
, O 0 3.094265821346198e-08
which O 0 9.051872140730666e-09
is O 0 5.574527062179868e-09
highly O 0 1.7566316401484983e-08
conserved O 0 3.065879283781214e-08
in O 0 9.437049364180439e-09
ATM O 0 1.6390082237194292e-05
- O 0 0.0003074105188716203
related O 0 2.627781213959679e-06
proteins O 0 5.8923038892544355e-08
in O 0 1.862964893462049e-08
mouse O 0 2.451107320666779e-06
, O 0 1.6244597134118521e-07
yeast O 0 1.3876521052225144e-06
and O 0 4.014073908820137e-07
Drosophila O 0 2.1102061964484164e-06
. O 0 1.9372027963981964e-06

The O 0 2.3087329736881657e-06
resulting O 0 6.86579824105138e-06
amino O 0 1.5654969729439472e-06
- O 0 0.00031404613400809467
acid O 0 6.914864570717327e-06
substitutions O 0 5.447374746836431e-07
are O 0 1.5465390745816876e-08
predicted O 0 2.524669753256603e-07
to O 0 6.0256390987945e-09
interfere O 0 4.0549728907990357e-08
with O 0 1.515264358431523e-08
ATP O 0 5.787506597698666e-05
binding O 0 1.577277203068661e-06
or O 0 2.8784279493265785e-07
substrate O 0 3.4390763175906613e-05
recognition O 0 6.2190956668928266e-06
. O 0 3.7021125081082573e-06

Two O 0 5.251970947028894e-07
of O 0 1.4914473922544857e-07
seventeen O 0 3.653559360827785e-06
mutated O 0 3.104617280769162e-05
T B-Disease 0 0.0026410797145217657
- I-Disease 0 0.0004387497319839895
PLL I-Disease 0 0.0002950457273982465
samples O 0 1.9004007754119812e-06
had O 0 1.0207916290028152e-07
a O 0 2.730523718241784e-08
previously O 0 7.073318784023286e-07
reported O 0 3.0239652915042825e-06
A B-Disease 0 2.642710751388222e-05
- I-Disease 1 0.8181230425834656
T I-Disease 1 0.9962707757949829
allele O 0 4.857388557866216e-05
. O 0 2.8962404030608013e-06

In O 0 5.983752089377958e-06
contrast O 0 2.3127009626477957e-05
, O 0 4.5584417307509284e-07
no O 0 6.914140016078818e-08
mutations O 0 1.2256854233783088e-06
were O 0 1.6009519754334178e-07
detected O 0 1.0558404710536706e-06
in O 0 7.56813012259272e-09
the O 0 1.490950474192232e-08
p53 O 0 2.719531551065302e-07
gene O 0 8.688815000823524e-08
, O 0 4.765838923503907e-08
suggesting O 0 6.324979153760069e-07
that O 0 3.7564294785852326e-08
this O 0 1.6555138415697002e-07
tumour B-Disease 1 0.9973255395889282
suppressor O 0 0.0007775012636557221
is O 0 1.7565604082392383e-07
not O 0 2.8118478212491027e-08
frequently O 0 3.157907997319853e-07
altered O 0 1.990546934393933e-06
in O 0 1.154053066443339e-07
this O 0 9.757063708093483e-07
leukaemia B-Disease 1 0.7906304597854614
. O 0 1.4822555385762826e-05

Occasional O 0 0.00037431425880640745
missense O 0 0.007947861216962337
mutations O 0 0.00044022087240591645
in O 0 7.290497592293832e-07
ATM O 0 0.00010044985538115725
were O 0 8.530162745046255e-07
also O 0 1.2944060756581166e-07
found O 0 1.3300537204941065e-07
in O 0 2.2658160503397085e-07
tumour B-Disease 1 0.9315635561943054
DNA O 0 4.139729207963683e-05
from O 0 4.077774974575732e-06
patients O 0 2.0529038010863587e-05
with O 0 2.2693777168569795e-07
B B-Disease 0 7.720394933130592e-05
- I-Disease 0 0.02297561801970005
cell I-Disease 0 0.005069585982710123
non I-Disease 0 0.004762225318700075
- I-Disease 1 0.9984500408172607
Hodgkins I-Disease 1 0.9999672174453735
lymphomas I-Disease 1 0.9391919374465942
( O 0 3.014075673490879e-07
B B-Disease 0 6.617659437324619e-06
- I-Disease 0 8.47499177325517e-05
NHL I-Disease 0 9.835213859332725e-06
) O 0 2.203296922687059e-08
and O 0 1.2882813038572749e-08
a O 0 5.661301116788309e-08
B B-Disease 0 8.638778126623947e-06
- I-Disease 0 0.0001934266183525324
NHL I-Disease 0 7.036174793029204e-05
cell O 0 3.185475725331344e-05
line O 0 1.3728066733165178e-05
. O 0 4.144127615290927e-06

The O 0 2.9563839234469924e-06
evidence O 0 2.2505716970044887e-06
of O 0 6.456399859189332e-08
a O 0 1.4393836522685888e-07
significant O 0 2.9610549745484605e-07
proportion O 0 2.592942109913565e-07
of O 0 9.934053224469608e-08
loss O 0 4.482998701860197e-05
- O 0 9.538034646539018e-05
of O 0 4.000323770014802e-07
- O 0 0.01056985929608345
function O 0 3.8379090483431355e-07
mutations O 0 5.920489911659388e-07
and O 0 4.330531666596471e-08
a O 0 5.547905956859722e-08
complete O 0 5.561482225857617e-07
absence O 0 8.41170958665316e-07
of O 0 1.1497287566442083e-08
the O 0 1.5712531720168954e-08
normal O 0 1.6420049320231556e-08
copy O 0 4.3692441664688886e-08
of O 0 5.510906397887538e-09
ATM O 0 2.9239147352200234e-06
in O 0 1.3852356595123183e-08
the O 0 1.1015071521569553e-08
majority O 0 1.5729540336906211e-07
of O 0 1.2520654024683608e-07
mutated O 0 0.0003498330479487777
tumours B-Disease 1 0.9791246056556702
establishes O 0 1.5966421415214427e-05
somatic O 0 9.920058801071718e-05
inactivation O 0 0.0011692964471876621
of O 0 2.3257431536194417e-08
this O 0 4.845025713962059e-09
gene O 0 3.275622262322031e-08
in O 0 4.289786748046254e-09
the O 0 1.3159775491544679e-08
pathogenesis O 0 6.076521003706148e-06
of O 0 8.600356693477806e-08
sporadic B-Disease 0 4.2032253986690193e-05
T I-Disease 0 0.49564605951309204
- I-Disease 0 0.027415219694375992
PLL I-Disease 0 0.002031902316957712
and O 0 6.881497824906546e-07
suggests O 0 3.1307345693676325e-07
that O 0 1.208758781956476e-08
ATM O 0 3.86255396733759e-06
acts O 0 1.8054309691706294e-07
as O 0 1.287834692220713e-07
a O 0 5.292867626849329e-06
tumour B-Disease 1 0.9943141341209412
suppressor O 0 0.0017499385867267847
. O 0 1.767438698152546e-05

As O 0 6.099588063079864e-06
constitutional O 0 1.2791462722816505e-05
DNA O 0 2.6607056497596204e-05
was O 0 1.0291604439771618e-06
not O 0 1.1181877646038174e-08
available O 0 1.2748007982565923e-08
, O 0 3.3188015891028044e-08
a O 0 1.4868432174353075e-07
putative O 0 0.0011527055175974965
hereditary O 0 0.4737666845321655
predisposition O 0 0.01668078638613224
to O 0 2.2275742139754584e-06
T B-Disease 0 0.3965185582637787
- I-Disease 0 0.04042050614953041
PLL I-Disease 0 0.0018958369037136436
will O 0 1.2667712212532933e-07
require O 0 7.907363652748245e-08
further O 0 5.056139684711525e-08
investigation O 0 9.727425549499458e-07
. O 0 3.098914476140635e-07
. O 0 1.7845416095951805e-06

Myotonic B-Disease 1 0.9996364116668701
dystrophy I-Disease 1 0.999828577041626
protein O 0 0.0005080962437205017
kinase O 0 0.0005212704418227077
is O 0 4.845088028559985e-07
involved O 0 3.5302059586683754e-07
in O 0 7.296755200059124e-09
the O 0 2.8210214164658964e-09
modulation O 0 2.033655199795703e-08
of O 0 3.9494199022271914e-09
the O 0 4.031351963362795e-08
Ca2 O 0 9.304436389356852e-05
+ O 0 5.224404958426021e-05
homeostasis O 0 0.0003358663525432348
in O 0 4.1135481296805665e-06
skeletal O 0 0.49626487493515015
muscle O 0 0.13271711766719818
cells O 0 8.892933692550287e-05
. O 0 3.3061830890801502e-06

Myotonic B-Disease 1 0.9997751116752625
dystrophy I-Disease 1 0.9999282360076904
( O 0 0.006999922450631857
DM B-Disease 1 0.9999231100082397
) O 0 2.6070752937812358e-05
, O 0 6.736971158716187e-07
the O 0 1.0766152769292603e-07
most O 0 1.0808316801558249e-06
prevalent O 0 0.007765913847833872
muscular B-Disease 1 0.9999364614486694
disorder I-Disease 1 0.9932247996330261
in O 0 1.1487944902910385e-05
adults O 0 0.0008137026452459395
, O 0 2.614530103528523e-06
is O 0 3.2362504498451017e-07
caused O 0 4.922339940094389e-06
by O 0 1.230788484463119e-07
( O 0 1.4470789722054178e-07
CTG O 0 0.0001027399703161791
) O 0 2.102881957455338e-08
n O 0 5.838153356307885e-07
- O 0 1.5229044038278516e-05
repeat O 0 7.144442975004495e-07
expansion O 0 9.494809916077429e-08
in O 0 2.7063087326695268e-09
a O 0 2.7724744722235073e-09
gene O 0 6.8790022567100095e-09
encoding O 0 5.242690281903606e-09
a O 0 1.3197554160626623e-08
protein O 0 4.5363329093106586e-08
kinase O 0 1.4251348829930066e-06
( O 0 1.9953124308358383e-07
DM B-Disease 1 0.9616352915763855
protein O 0 9.205544984070002e-07
kinase O 0 5.914185294386698e-06
; O 0 5.872282144991914e-07
DMPK O 0 0.001716008991934359
) O 0 2.809901467060172e-08
and O 0 1.4205490117547015e-08
involves O 0 7.636560184209884e-08
changes O 0 2.9156336012192696e-08
in O 0 1.6525554258350894e-08
cytoarchitecture O 0 6.757084338460118e-05
and O 0 2.242601567559177e-06
ion O 0 0.0002817497297655791
homeostasis O 0 0.0010531533043831587
. O 0 5.239976871962426e-06

To O 0 2.931942390205222e-06
obtain O 0 1.3263035043564741e-06
clues O 0 2.010075377256726e-06
to O 0 2.362972217895276e-08
the O 0 1.1556032575299469e-08
normal O 0 4.0537202039558906e-08
biological O 0 2.6424018528814486e-07
role O 0 3.535292947276503e-08
of O 0 8.480802726751335e-09
DMPK O 0 7.750905933789909e-05
in O 0 2.4937689246939954e-08
cellular O 0 6.832213330199011e-06
ion O 0 4.397211523610167e-05
homeostasis O 0 0.0003489470691420138
, O 0 9.104982723329158e-08
we O 0 7.647692257251038e-09
have O 0 1.09971027839606e-08
compared O 0 7.904800014557622e-08
the O 0 2.153390887826845e-08
resting O 0 1.744653309287969e-05
[ O 0 6.184014864629717e-07
Ca2 O 0 1.4198186363501009e-05
+ O 0 8.953620636020787e-06
] O 0 4.493439860198123e-07
i O 0 1.245201186605982e-08
, O 0 1.1251723996963392e-09
the O 0 5.365345945307354e-10
amplitude O 0 9.136623901895291e-09
and O 0 1.2235719104580767e-08
shape O 0 4.77475552429496e-08
of O 0 1.2217156175609034e-08
depolarization O 0 1.4634971194027457e-05
- O 0 0.0009739919332787395
induced O 0 0.00025466165971010923
Ca2 O 0 5.934686851105653e-05
+ O 0 7.398342859232798e-06
transients O 0 5.682201299350709e-05
, O 0 2.5108265688800202e-08
and O 0 3.922641322873233e-09
the O 0 1.1654528453419744e-09
content O 0 1.7797185947188154e-09
of O 0 1.602532884170671e-09
ATP O 0 4.410545898281271e-06
- O 0 1.1579349120438565e-05
driven O 0 7.021440637799969e-07
ion O 0 5.3049138841743115e-06
pumps O 0 1.626809762456105e-06
in O 0 3.6021951643760985e-08
cultured O 0 3.4047599910991266e-05
skeletal O 0 0.0037570588756352663
muscle O 0 0.00016112120647449046
cells O 0 4.823074846171949e-07
of O 0 9.911961917907774e-09
wild O 0 5.016046316086431e-07
- O 0 0.00025602642563171685
type O 0 2.3448976662621135e-06
and O 0 7.36600384243502e-07
DMPK O 0 0.0030273254960775375
[ O 0 2.230244035672513e-06
- O 0 9.498053987044841e-05
/ O 0 1.9830415112664923e-05
- O 0 0.00047488819109275937
] O 0 1.0485831808182411e-05
knockout O 0 0.00013688579201698303
mice O 0 0.00010340961307520047
. O 0 3.7151210108277155e-06

In O 0 5.8713021644507535e-06
vitro O 0 0.00015441005234606564
- O 0 0.0015416707610711455
differentiated O 0 0.00032974316854961216
DMPK O 0 0.005135345738381147
[ O 0 5.198430244490737e-06
- O 0 0.00018326098506804556
/ O 0 2.703834070416633e-05
- O 0 0.00020589996711350977
] O 0 7.747132144686475e-07
myotubes O 0 1.3362851859710645e-05
exhibit O 0 2.483121193108673e-07
a O 0 2.738085846942795e-08
higher O 0 2.627527919685235e-07
resting O 0 1.0915343409578782e-05
[ O 0 6.28744032837858e-07
Ca2 O 0 1.503737712482689e-05
+ O 0 4.0381196413363796e-06
] O 0 4.4933159415450064e-07
i O 0 2.1770214075900185e-08
than O 0 3.26438165387799e-09
do O 0 2.6784654494349525e-09
wild O 0 5.5228209561164476e-08
- O 0 3.600807394832373e-05
type O 0 3.1829081308387686e-06
myotubes O 0 0.0009557788725942373
because O 0 4.5383060864878644e-08
of O 0 5.115278423062364e-09
an O 0 2.4098993023358162e-08
altered O 0 3.704361972722836e-07
open O 0 7.409023083937427e-08
probability O 0 3.56065443796183e-09
of O 0 3.299435835657505e-09
voltage O 0 9.692116691439878e-07
- O 0 0.00011458931840024889
dependent O 0 2.275433416798478e-06
l O 0 3.915532579412684e-05
- O 0 5.664531636284664e-05
type O 0 6.764608997400501e-07
Ca2 O 0 7.66938228480285e-06
+ O 0 1.4942862662792322e-06
and O 0 9.179317572716172e-08
Na O 0 2.4857376047293656e-05
+ O 0 2.093554712701007e-06
channels O 0 7.278534894794575e-07
. O 0 1.0895570312641212e-06

The O 0 5.158606199984206e-06
mutant O 0 8.637418795842677e-05
myotubes O 0 0.0006058409926481545
exhibit O 0 6.755545655323658e-06
smaller O 0 3.8296059301501373e-07
and O 0 2.5073283893561893e-08
slower O 0 2.8338536139926873e-07
Ca2 O 0 5.686327313014772e-06
+ O 0 1.0178137017646804e-06
responses O 0 7.722157135958696e-08
upon O 0 2.4833928691236906e-08
triggering O 0 4.860197805101052e-06
by O 0 1.534484113108192e-07
acetylcholine O 0 6.145454972283915e-05
or O 0 2.8185041855977033e-07
high O 0 6.064491117285797e-06
external O 0 8.326354873133823e-06
K O 0 5.3609190217684954e-05
+ O 0 4.926928522763774e-05
. O 0 2.701133098526043e-06

In O 0 5.132734713697573e-06
addition O 0 3.802804712904617e-06
, O 0 2.8925862238793343e-07
we O 0 1.523962644967014e-08
observed O 0 1.2255899406454773e-08
that O 0 7.104241639410702e-10
these O 0 2.888851158289185e-09
Ca2 O 0 5.3626786211680155e-06
+ O 0 4.602333774528233e-06
transients O 0 0.0002310396230313927
partially O 0 2.6144525691051967e-05
result O 0 1.1052157589119815e-07
from O 0 1.6986705375643396e-08
an O 0 1.0767011282553085e-08
influx O 0 4.777725166604796e-07
of O 0 6.505794569733325e-09
extracellular O 0 5.601574457614333e-07
Ca2 O 0 3.856466264551273e-06
+ O 0 2.5564233396835334e-07
through O 0 7.3841190939560875e-09
the O 0 1.6858498597116522e-08
l O 0 3.4160944778705016e-05
- O 0 8.589688513893634e-05
type O 0 1.9747249098145403e-06
Ca2 O 0 1.5395971786347218e-05
+ O 0 6.794675300625386e-06
channel O 0 2.791720135064679e-06
. O 0 1.5911995205897256e-06

Neither O 0 4.508619895204902e-05
the O 0 4.94335893108655e-07
content O 0 2.745944698290259e-07
nor O 0 1.931116457853932e-07
the O 0 5.760846910618511e-09
activity O 0 1.364394375258371e-08
of O 0 1.136069638363324e-08
Na O 0 3.275507697253488e-05
+ O 0 1.9278129457234172e-06
/ O 0 7.054247816995485e-07
K O 0 8.505882647114049e-07
+ O 0 1.2742291346512502e-06
ATPase O 0 5.256382792140357e-06
and O 0 9.652115551261886e-08
sarcoplasmic O 0 6.32697920082137e-05
reticulum O 0 1.315540612267796e-05
Ca2 O 0 2.048380338237621e-05
+ O 0 8.860861271386966e-06
- O 0 0.0003584889345802367
ATPase O 0 0.00015847670147195458
are O 0 1.131338791537928e-07
affected O 0 3.215049559912586e-07
by O 0 4.943557314618374e-07
DMPK O 0 0.02002941630780697
absence O 0 5.039899770054035e-05
. O 0 7.87756380304927e-06

In O 0 2.332394842596841e-06
conclusion O 0 1.150586399489839e-06
, O 0 8.540722262750933e-08
our O 0 1.2756424361271002e-08
data O 0 6.092101756394186e-08
suggest O 0 1.3717141200686456e-07
that O 0 2.2642621999580115e-08
DMPK O 0 0.00017425150144845247
is O 0 2.6863457236459e-08
involved O 0 1.2107376790027047e-07
in O 0 2.563426804158553e-08
modulating O 0 3.777766096391133e-06
the O 0 1.9777518289743057e-08
initial O 0 5.512065825996615e-08
events O 0 6.765420668131128e-09
of O 0 9.585916949106377e-09
excitation O 0 1.1257149026278057e-06
- O 0 0.0015214772429317236
contraction O 0 6.856656546005979e-05
coupling O 0 2.7615897124633193e-05
in O 0 1.203723695653025e-05
skeletal O 1 0.7092592716217041
muscle O 0 0.034420110285282135
. O 0 2.4333180590474512e-06
. O 0 5.984916242596228e-06

Constitutional O 0 0.0013991525629535317
RB1 O 1 0.5270516276359558
- O 0 0.022186171263456345
gene O 0 5.316149690770544e-05
mutations O 0 3.4318396501475945e-05
in O 0 8.783364364717272e-07
patients O 0 0.00012807520397473127
with O 0 3.518640824040631e-06
isolated O 0 0.0003085636126343161
unilateral B-Disease 0 0.001459099119529128
retinoblastoma I-Disease 0 0.21344497799873352
. O 0 5.610047810478136e-05

In O 0 2.4682314688107e-05
most O 0 1.2837851500080433e-05
patients O 0 0.0001617205562070012
with O 0 1.1041680636481033e-06
isolated O 0 7.403930794680491e-05
unilateral B-Disease 0 0.00045424295240081847
retinoblastoma I-Disease 1 0.567374050617218
, O 0 8.142376464093104e-05
tumor B-Disease 0 0.015168064273893833
development O 0 1.9611417201303993e-07
is O 0 1.5738566006007204e-08
initiated O 0 5.187344527257665e-07
by O 0 8.541228169178794e-08
somatic O 0 5.8419591368874535e-05
inactivation O 0 0.002331286668777466
of O 0 4.681814047557964e-08
both O 0 3.257721914451395e-08
alleles O 0 1.579090849190834e-07
of O 0 2.7013593140168268e-08
the O 0 9.436500931769842e-07
RB1 O 0 0.03690192848443985
gene O 0 8.651836651552003e-06
. O 0 4.0754616748017725e-06

However O 0 1.7200576621689834e-05
, O 0 8.886230489224545e-07
some O 0 3.226918465770723e-08
of O 0 3.161342831958791e-08
these O 0 1.7382610906224727e-07
patients O 0 3.362608913448639e-05
can O 0 9.130599920581517e-08
transmit O 0 3.206738256267272e-05
retinoblastoma B-Disease 0 0.13181045651435852
predisposition O 0 0.003002376528456807
to O 0 1.9561021247227472e-07
their O 0 6.88220666233974e-07
offspring O 0 3.129279502900317e-05
. O 0 6.371381459757686e-06

To O 0 1.2520156360551482e-06
determine O 0 4.773226010001963e-07
the O 0 2.7876945196680936e-08
frequency O 0 7.023437120778908e-08
and O 0 3.730532327494984e-08
nature O 0 2.6310226886039345e-08
of O 0 1.1810372235743216e-08
constitutional O 0 4.194112989353016e-06
RB1 O 0 0.017496690154075623
- O 0 0.0017808108823373914
gene O 0 3.2220616503764177e-06
mutations O 0 5.759883606515359e-06
in O 0 7.652334375052305e-07
patients O 0 3.839645069092512e-05
with O 0 8.000258162610407e-07
isolated O 0 7.294971874216571e-05
unilateral B-Disease 0 0.0001920930080814287
retinoblastoma I-Disease 0 0.03535610809922218
, O 0 3.1835443792260776e-07
we O 0 9.121961852542881e-09
analyzed O 0 2.2534315746725042e-07
DNA O 0 1.5929440451145638e-06
from O 0 7.552384886366781e-07
peripheral O 0 0.00018636553431861103
blood O 0 3.313845445518382e-05
and O 0 2.638370460772421e-06
from O 0 4.443508805707097e-05
tumor B-Disease 0 0.35454580187797546
tissue O 0 0.0012102131731808186
. O 0 7.815187018422876e-06

The O 0 2.4959351776487892e-06
analysis O 0 1.5592240742989816e-06
of O 0 2.8614063012355473e-06
tumors B-Disease 1 0.9909441471099854
from O 0 1.1842571439046878e-06
54 O 0 8.473597517877351e-06
( O 0 1.2182954378658906e-07
71 O 0 4.577532763505587e-06
% O 0 6.451931255924137e-08
) O 0 1.014370809571119e-08
of O 0 2.222620132386055e-08
76 O 0 4.321369488025084e-05
informative O 0 2.4977445718832314e-05
patients O 0 0.0007734139799140394
showed O 0 1.850231274147518e-05
loss O 0 1.5315765267587267e-05
of O 0 8.186412259192366e-08
constitutional O 0 5.5575354053871706e-05
heterozygosity O 0 0.19211719930171967
( O 0 1.849790169217158e-05
LOH O 1 0.9995582699775696
) O 0 8.272757554550481e-07
at O 0 1.83160045708064e-06
intragenic O 0 0.0005002516554668546
loci O 0 1.575813803356141e-05
. O 0 3.3492765396658797e-06

Three O 0 5.5195632739923894e-06
of O 0 1.6152062016772106e-06
13 O 0 0.00010196609946433455
uninformative O 1 0.8949788212776184
patients O 0 0.015841718763113022
had O 0 5.811489245388657e-06
constitutional O 0 1.4207545063982252e-05
deletions O 0 0.00031356114777736366
. O 0 1.1320277735649142e-05

For O 0 2.352706133024185e-06
39 O 0 5.846588464919478e-06
randomly O 0 4.497346708376426e-06
selected O 0 3.864724567392841e-05
tumors B-Disease 1 0.988621175289154
, O 0 7.887997526268009e-07
SSCP O 0 0.0006566334632225335
, O 0 4.0179267557505227e-07
hetero O 0 0.00021859984553884715
- O 0 6.938943261047825e-05
duplex O 0 0.00011293094576103613
analysis O 0 1.0869525368661925e-07
, O 0 1.45023104636266e-08
sequencing O 0 1.4843213591575477e-07
, O 0 2.6812370990114687e-08
and O 0 1.2824390438481714e-08
Southern O 0 2.3749278099671756e-08
blot O 0 3.1672686873207567e-06
analysis O 0 5.304896788516089e-08
were O 0 7.396612033971905e-08
used O 0 3.730681541469494e-08
to O 0 1.0933484873021371e-07
identify O 0 1.106256058847066e-05
mutations O 0 2.6246274501318112e-05
. O 0 2.943050048997975e-06

Mutations O 0 0.000674234121106565
were O 0 3.576929429982556e-06
detected O 0 7.230139090097509e-06
in O 0 8.56700665963217e-08
21 O 0 8.614784974270151e-07
( O 0 5.01062444868694e-08
91 O 0 1.1673955668811686e-06
% O 0 4.738049597108329e-08
) O 0 2.608223859112968e-08
of O 0 1.6927266699440224e-07
23 O 0 0.0011382878292351961
tumors B-Disease 1 0.9990038275718689
with O 0 0.00025270687183365226
LOH O 1 0.9995996356010437
. O 0 8.76412887009792e-05

In O 0 7.223887678264873e-06
6 O 0 8.978982805274427e-06
( O 0 3.6485940313468745e-07
38 O 0 1.2089429901607218e-06
% O 0 5.949424064510822e-08
) O 0 1.5693661481464005e-08
of O 0 3.832411010762371e-08
16 O 0 9.937175491359085e-05
tumors B-Disease 1 0.9992189407348633
without O 0 1.6284011508105323e-05
LOH O 1 0.9998394250869751
, O 0 6.811841899434512e-07
one O 0 2.6664675800702753e-08
mutation O 0 6.247250894375611e-07
was O 0 6.194616162247257e-07
detected O 0 1.6266577631540713e-06
, O 0 3.814616889030731e-08
and O 0 5.2033726660738466e-08
in O 0 4.259166885844934e-08
9 O 0 1.5801527979419916e-06
( O 0 7.733550688726609e-08
56 O 0 6.011017603668733e-07
% O 0 2.1613036693679533e-08
) O 0 7.688938374883492e-09
of O 0 1.059515231105479e-08
the O 0 2.3188567865872756e-06
tumors B-Disease 1 0.9988662004470825
without O 0 1.5698664356023073e-05
LOH O 1 0.9998449087142944
, O 0 1.1586179198275204e-06
both O 0 1.6610171371667093e-07
mutations O 0 2.1056307559774723e-06
were O 0 4.899092687082884e-07
found O 0 3.001689037773758e-06
. O 0 4.005223672720604e-06

Thus O 0 2.2450656615546905e-05
, O 0 4.5961488126522454e-07
a O 0 3.854491481547484e-08
total O 0 2.5372370870968552e-08
of O 0 1.1248061149160549e-08
45 O 0 3.899488660863426e-07
mutations O 0 1.698970777397335e-06
were O 0 2.996004013766651e-07
identified O 0 4.4301314119366e-06
in O 0 2.599349727461231e-06
tumors B-Disease 1 0.9688345193862915
of O 0 1.5280877505574608e-06
36 O 0 0.0005601210868917406
patients O 0 0.0018547227373346686
. O 0 9.58495365921408e-06

Thirty O 0 3.361274866620079e-05
- O 0 0.00019485753728076816
nine O 0 8.756917964092281e-07
of O 0 3.098837453308079e-08
the O 0 4.734093295155617e-08
mutations O 0 7.161572170844011e-07
- O 0 1.6780064470367506e-05
including O 0 7.742183925074642e-07
34 O 0 2.4305813894898165e-06
small O 0 7.377772135441774e-07
mutations O 0 1.5985108348104404e-06
, O 0 4.2799328525688907e-08
2 O 0 2.5196428055096476e-07
large O 0 2.255939762108028e-06
structural O 0 0.0017659711884334683
alterations O 0 6.630066491197795e-05
, O 0 3.744762011592684e-07
and O 0 4.5152660277381074e-07
hypermethylation O 0 0.000778850051574409
in O 0 4.077993764894927e-07
3 O 0 5.990883073536679e-05
tumors O 1 0.9977021813392639
- O 0 0.0018292231252416968
were O 0 8.224174621318525e-07
not O 0 1.931742055205632e-08
detected O 0 5.755939582741121e-07
in O 0 6.471315483480566e-09
the O 0 2.6315143841770805e-08
corresponding O 0 1.4120795412964071e-06
peripheral O 0 0.0006659618811681867
blood O 0 0.00015612714923918247
DNA O 0 7.925668614916503e-05
. O 0 8.728221473575104e-06

In O 0 1.1187924428668339e-05
6 O 0 6.672043127764482e-06
( O 0 4.3962660356555716e-07
17 O 0 5.476842375173874e-07
% O 0 3.681223859075544e-08
) O 0 4.625714034034445e-09
of O 0 2.0579284942812137e-09
the O 0 3.5097418304985695e-08
36 O 0 1.8580216419650242e-05
patients O 0 4.3881846067961305e-05
, O 0 4.8430695898105114e-08
a O 0 5.3813909772770785e-08
mutation O 0 9.542756060909596e-07
was O 0 9.469631550018676e-07
detected O 0 7.489561539841816e-07
in O 0 1.0400592387327379e-08
constitutional O 0 9.991723572966293e-07
DNA O 0 6.895135811646469e-06
, O 0 1.7854578970855073e-07
and O 0 4.374897955017332e-08
1 O 0 3.6344939502441775e-08
of O 0 1.1783955145006075e-08
these O 0 3.332299414182671e-08
mutations O 0 1.834955696722318e-06
is O 0 2.5806558667795798e-08
known O 0 1.6400555580275977e-07
to O 0 2.973468227196463e-08
be O 0 2.6041375278396117e-08
associated O 0 2.8428672749214456e-07
with O 0 6.398120717676647e-07
reduced O 0 3.816689786617644e-05
expressivity O 0 0.0068810200318694115
. O 0 1.1555850505828857e-05

The O 0 3.686807303893147e-06
presence O 0 2.184097638746607e-06
of O 0 6.819122688739299e-08
a O 0 1.7148228437235957e-07
constitutional O 0 8.32320347399218e-06
mutation O 0 8.321885616169311e-06
was O 0 1.6870744730113074e-06
not O 0 3.568576900647713e-08
associated O 0 1.2997411147352977e-07
with O 0 6.089022974720137e-08
an O 0 1.3109863061799842e-07
early O 0 1.3453587826006697e-06
age O 0 9.286940439778846e-06
at O 0 2.6044737751362845e-05
treatment O 0 0.00015925351181067526
. O 0 7.519781320297625e-06

In O 0 9.353264431410935e-06
1 O 0 1.2939995031047147e-05
patient O 0 0.00014489056775346398
, O 0 1.1197359981451882e-06
somatic O 0 0.00044127629371359944
mosaicism O 1 0.7672607898712158
was O 0 1.0430290785734542e-05
demonstrated O 0 1.5113381550690974e-06
by O 0 1.4047598639876924e-08
molecular O 0 1.8077602703669982e-07
analysis O 0 8.766149584005234e-09
of O 0 6.359295312563518e-09
DNA O 0 8.991801223601215e-07
and O 0 1.2807382177015825e-07
RNA O 0 9.530332931717567e-07
from O 0 1.4972247299738228e-06
peripheral O 0 0.0007258370751515031
blood O 0 0.00011098371032858267
. O 0 4.951175924361451e-06

In O 0 1.7028432921506464e-05
2 O 0 3.961950642406009e-05
patients O 0 0.0003370206104591489
without O 0 1.8848535887627804e-07
a O 0 1.8796639267293358e-07
detectable O 0 1.2414431694196537e-05
mutation O 0 1.7102461242757272e-06
in O 0 1.630631061289023e-07
peripheral O 0 0.0004498280177358538
blood O 0 0.00018667287076823413
, O 0 2.028709786827676e-06
mosaicism O 0 0.12102115154266357
was O 0 9.248007700080052e-06
suggested O 0 2.5858348635665607e-06
because O 0 3.708369789023891e-08
1 O 0 1.5755807325490423e-08
of O 0 1.827126894227149e-08
the O 0 1.6392642692153458e-06
patients O 0 0.0032630932983011007
showed O 0 0.00922204926609993
multifocal O 1 0.9997143149375916
tumors B-Disease 1 0.9999421834945679
and O 0 9.249279742107319e-07
the O 0 6.971092858520933e-08
other O 0 1.0386363413772415e-07
later O 0 1.8626648170538829e-06
developed O 0 1.90316768566845e-05
bilateral B-Disease 0 0.00023702543694525957
retinoblastoma I-Disease 0 0.12366525083780289
. O 0 2.526854041207116e-05

In O 0 3.4792799397109775e-06
conclusion O 0 8.510847919751541e-07
, O 0 1.1203572114482085e-07
our O 0 1.6795402402181026e-08
results O 0 5.407968828308185e-08
emphasize O 0 1.1012723177827866e-07
that O 0 3.8516083655792954e-09
the O 0 7.916566069354758e-09
manifestation O 0 8.80969764693873e-07
and O 0 1.8216435648810148e-07
transmissibility O 0 8.012872422114015e-05
of O 0 1.255353367923817e-07
retinoblastoma B-Disease 0 0.0011201943270862103
depend O 0 1.792418231616466e-07
on O 0 7.286383407745234e-08
the O 0 1.994503229241218e-08
nature O 0 3.400973369593885e-08
of O 0 8.013611996204872e-09
the O 0 1.3171652213372909e-08
first O 0 1.076208775430132e-07
mutation O 0 5.407534899859456e-07
, O 0 2.7880984632133732e-08
its O 0 9.692957547713377e-09
time O 0 9.169899506389356e-09
in O 0 4.5051686825559045e-09
development O 0 2.770932283624461e-08
, O 0 3.210636734252148e-08
and O 0 1.3484112493244993e-08
the O 0 6.762594928488852e-09
number O 0 2.0562149316560863e-08
and O 0 6.352509274165641e-08
types O 0 1.7190750156714785e-07
of O 0 1.3712811153254734e-07
cells O 0 7.196054866653867e-06
that O 0 5.2701835784318973e-08
are O 0 1.393921564840639e-07
affected O 0 2.2249396351980977e-06
. O 0 4.7410424031113507e-07
. O 0 3.377415850991383e-06

Hereditary B-Disease 1 0.9997326731681824
deficiency I-Disease 1 0.9992868304252625
of I-Disease 0 1.0988275107592926e-06
the I-Disease 0 1.8675832791359426e-07
fifth I-Disease 0 7.3940118454629555e-06
component I-Disease 0 1.2082480225217296e-06
of I-Disease 0 4.994260649482385e-08
complement I-Disease 0 1.0246535566693638e-06
in O 0 2.8324592449280317e-07
man O 0 3.429601565585472e-05
. O 0 6.028381903888658e-06

I O 0 0.000996336224488914
. O 0 0.00015086171333678067

Clinical O 0 0.013864516280591488
, O 0 4.782090036314912e-05
immunochemical O 0 0.02687854692339897
, O 0 5.286248779157177e-06
and O 0 2.0332090571173467e-06
family O 0 7.83912582846824e-06
studies O 0 3.9751362237439025e-06
. O 0 3.5776083677774295e-06

The O 0 3.8421198951255064e-06
first O 0 2.999808884851518e-06
recognized O 0 6.132987891760422e-06
human O 0 4.596250164468074e-06
kindred O 0 0.004695706069469452
with O 0 0.0008271565311588347
hereditary B-Disease 1 0.999828577041626
deficiency I-Disease 1 0.9463326930999756
of I-Disease 0 9.747654416969453e-08
the I-Disease 0 1.0106690950806296e-07
fifth I-Disease 0 3.6439380437514046e-06
component I-Disease 0 9.478378046878788e-07
of I-Disease 0 6.266022012368921e-08
complement I-Disease 0 1.1613747119554318e-06
( O 0 1.878606781247072e-07
C5 O 0 0.0006173653528094292
) O 0 3.4736132192847435e-07
is O 0 1.9720550881174859e-07
described O 0 1.0986580491589848e-05
. O 0 5.208812126511475e-06

The O 0 9.6509857030469e-06
proband O 0 0.0014672420220449567
, O 0 7.906697874204838e-07
a O 0 1.146009509511714e-07
20 O 0 1.8215149566458422e-07
- O 0 3.165537418681197e-05
year O 0 1.0300972235199879e-06
- O 0 0.0002531440695747733
old O 0 6.663215026492253e-05
black O 0 0.0001657464454183355
female O 0 6.829510675743222e-05
with O 0 0.0012994162971153855
systemic B-Disease 1 0.9999912977218628
lupus I-Disease 1 0.9999933242797852
erythematosus I-Disease 1 0.9999892711639404
since O 0 0.00010636120714480057
age O 0 1.07076948552276e-05
11 O 0 3.525200554577168e-06
, O 0 1.4986961787144537e-06
lacked O 0 5.345492172637023e-05
serum O 0 0.0012678480707108974
hemolytic O 1 0.5766288638114929
complement O 0 1.269743165721593e-06
activity O 0 3.008481712640787e-07
, O 0 9.337556150512683e-08
even O 0 1.6865664065335295e-07
during O 0 1.2431115692379535e-06
remission O 0 0.00013799869338981807
. O 0 4.666115728468867e-06

C5 O 0 0.008939872495830059
was O 0 0.00010019643377745524
undetectable O 0 0.0009281761012971401
in O 0 3.30838958007007e-07
her O 0 1.2442252455002745e-06
serum O 0 4.165154678048566e-06
by O 0 3.530475112256681e-08
both O 0 1.5733562008790614e-07
immunodiffusion O 0 0.0010397507576271892
and O 0 6.32670198683627e-05
hemolytic O 1 0.988716721534729
assays O 0 0.00027901321300305426
. O 0 1.1013665243808646e-05

Other O 0 1.5186069504125044e-06
complement O 0 1.6058036180766067e-06
components O 0 1.9866345155605813e-06
were O 0 1.1751391326697558e-07
normal O 0 9.491713370834987e-08
during O 0 1.8700677628658013e-07
remission O 0 1.8764198102871887e-05
of O 0 4.067947884323075e-06
lupus O 1 0.9974985718727112
, O 0 1.18037496577017e-06
but O 0 2.5834194161689084e-07
C1 O 0 0.0014344333903864026
, O 0 4.4388460196387314e-07
C4 O 0 0.00022635688947048038
, O 0 6.458382699747744e-07
C2 O 0 0.0007190692704170942
, O 0 3.1711144288237847e-07
and O 0 4.3391804638304166e-07
C3 O 0 0.011791892349720001
levels O 0 3.850982920994284e-06
fell O 0 6.156507151899859e-05
during O 0 5.268196673569037e-06
exacerbations O 0 0.02250313013792038
. O 0 6.458588813984534e-06

A O 0 2.311660318810027e-05
younger O 0 4.973852992407046e-05
half O 0 5.2431760195759125e-06
- O 0 0.0013546561822295189
sister O 0 8.022328984225169e-05
, O 0 4.045409980335535e-07
who O 0 1.6327674075000687e-06
had O 0 8.937650477491843e-07
no O 0 1.0514323776078527e-06
underlying O 0 0.0038713852409273386
disease O 0 0.006172942463308573
, O 0 1.4046146361579304e-06
was O 0 6.526853667310206e-06
also O 0 5.768952746620926e-07
found O 0 7.049754913168726e-07
to O 0 1.936693507786913e-07
lack O 0 8.550779966753908e-06
immunochemically O 0 0.008080762811005116
detectable O 0 0.00029784513753838837
C5 O 0 0.0013863061321899295
. O 0 9.24571395444218e-06

By O 0 0.0003316290385555476
hemolytic O 1 0.9979641437530518
assay O 0 0.0004699839046224952
, O 0 2.7184889859199757e-06
she O 0 1.080284391719033e-06
exhibited O 0 2.6361622076365165e-06
1 O 0 1.822651398697417e-07
- O 0 4.4987842557020485e-05
2 O 0 1.689641351276805e-07
% O 0 6.884922409966521e-09
of O 0 1.2323447817763622e-09
the O 0 4.195916503135777e-09
normal O 0 2.2881229355675714e-08
serum O 0 1.4010987570145517e-06
C5 O 0 1.1030619134544395e-05
level O 0 6.46662954295607e-08
and O 0 1.529127935384622e-08
normal O 0 2.7053193463189018e-08
concentrations O 0 3.173891798269324e-07
of O 0 7.07649494557927e-09
other O 0 3.652186464364604e-08
complement O 0 9.736075980981695e-07
components O 0 9.63804359344067e-06
. O 0 4.814977728528902e-06

C5 O 0 0.009993966668844223
levels O 0 3.3920172427315265e-05
of O 0 2.876290352560318e-07
other O 0 2.956086291305837e-07
family O 0 1.829252596508013e-06
members O 0 1.3612340410418255e-07
were O 0 3.926146163735211e-08
either O 0 1.3907527574019696e-08
normal O 0 1.198679733249719e-08
or O 0 7.37460448263505e-09
approximately O 0 1.7759115067406128e-08
half O 0 1.6248345957592392e-07
- O 0 8.452474139630795e-05
normal O 0 1.8456670147770637e-07
, O 0 4.834975086964732e-08
consistent O 0 1.4288022498476494e-07
with O 0 1.369300434816978e-06
autosomal O 0 0.0004674826341215521
codominant O 0 0.019846998155117035
inheritance O 0 3.229134017601609e-05
of O 0 2.0472110406899446e-07
the O 0 2.1897371880186256e-06
gene O 0 2.61936875176616e-05
determining O 0 0.0005505171720869839
C5 B-Disease 1 0.9998733997344971
deficiency I-Disease 1 0.9998841285705566
. O 0 5.7497538364259526e-05

Normal O 0 0.006745605729520321
hemolytic O 1 0.9984524250030518
titers O 0 0.1584092080593109
were O 0 5.442848760139896e-06
restored O 0 6.522373496409273e-06
to O 0 5.520145407444943e-08
both O 0 1.0451624632423773e-07
homozygous O 0 4.61362797068432e-05
C5 B-Disease 1 0.9915414452552795
- I-Disease 1 0.9980044960975647
deficient I-Disease 1 0.9996182918548584
( O 0 6.608868261537282e-06
C5D B-Disease 1 0.9930852651596069
) O 0 3.060936251131352e-07
sera O 0 4.799052021553507e-06
by O 0 2.4889505567671222e-08
addition O 0 5.7192028890540314e-08
of O 0 3.917940105679918e-08
highly O 0 1.6467728300995077e-06
purified O 0 1.1581622857192997e-05
human O 0 2.082848823192762e-06
C5 O 0 0.00082662224303931
. O 0 8.44801888888469e-06

In O 0 4.932589035888668e-06
specific O 0 1.4103326293479768e-06
C5 O 0 0.0027702050283551216
titrations O 0 0.12572477757930756
, O 0 4.019469997729175e-06
however O 0 1.5272864573034894e-07
, O 0 4.538808440202047e-08
it O 0 7.09473946258754e-09
was O 0 2.344816607546818e-07
noted O 0 2.491927375558589e-07
that O 0 3.741190468531386e-09
when O 0 1.2267172166957607e-08
limited O 0 2.6123013086021274e-08
amounts O 0 1.3768800322111474e-08
of O 0 7.254291833902471e-09
C5 O 0 4.009625990875065e-05
were O 0 1.634512472037386e-07
assayed O 0 2.2565982362721115e-06
in O 0 6.285254983140476e-09
the O 0 4.485260163278326e-09
presence O 0 1.5249511875481403e-08
of O 0 5.205553321729894e-09
low O 0 1.2471097079469473e-06
dilutions O 0 3.65532650903333e-05
of O 0 4.707539957848894e-08
either O 0 8.961426942732942e-07
C5D B-Disease 1 0.9631190299987793
serum O 0 4.913176235277206e-05
, O 0 4.116261109743391e-08
curving O 0 1.017998101815465e-06
rather O 0 2.8650815053765655e-08
than O 0 9.547598267545254e-09
linear O 0 1.6992854057207296e-07
dose O 0 2.6105537926923716e-06
- O 0 2.20402107515838e-05
response O 0 1.3226426176515815e-07
plots O 0 7.922505318447293e-08
were O 0 5.270364766829516e-08
consistently O 0 4.4000620391670964e-07
obtained O 0 8.508724391731448e-08
, O 0 2.2725695103531507e-08
suggesting O 0 4.2027949120893027e-07
some O 0 5.919112666674664e-08
inhibitory O 0 2.528910590626765e-05
effect O 0 4.167352017248049e-06
. O 0 2.8628637664951384e-06

Further O 0 1.890480052679777e-05
studies O 0 1.1438030924182385e-05
suggested O 0 3.4424924706399906e-06
that O 0 4.461934111077426e-08
low O 0 1.763229647622211e-06
dilutions O 0 9.721842798171565e-05
of O 0 3.5108976703668304e-07
C5D B-Disease 1 0.9951820969581604
serum O 0 0.0001440979103790596
contain O 0 3.5600356795839616e-07
a O 0 2.1520919801787386e-07
factor O 0 1.986746156035224e-06
( O 0 1.5990643476015975e-07
or O 0 2.263783471789793e-07
factors O 0 2.4576468149462016e-07
) O 0 1.925293879878609e-08
interfering O 0 2.0463814109916711e-07
at O 0 3.706000839542867e-08
some O 0 3.9332421764015635e-09
step O 0 9.468912054444445e-08
in O 0 1.4180422169829399e-08
the O 0 2.184065266419566e-07
hemolytic O 0 0.22693195939064026
assay O 0 2.291504870299832e-06
of O 0 8.814792806788319e-08
C5 O 0 0.0008452124311588705
, O 0 1.9583289656566194e-07
rather O 0 1.3616437755104016e-08
than O 0 5.755981469235394e-09
a O 0 3.274810467246425e-08
true O 0 3.3875693361551384e-07
C5 O 0 0.0016116442857310176
inhibitor O 0 0.0002899495593737811
or O 0 3.2503658076166175e-06
inactivator O 0 0.0014486974105238914
. O 0 6.790192855987698e-06

Of O 0 2.220048918388784e-05
clinical O 0 0.002012274693697691
interest O 0 2.0603250959538855e-05
are O 0 2.9202567475294927e-07
( O 0 6.907180249982048e-08
a O 0 6.421116438559693e-08
) O 0 1.8747993379975014e-08
the O 0 1.4156559480227315e-08
documentation O 0 1.594745299371425e-06
of O 0 9.098504961002618e-06
membranous O 1 0.9978075623512268
glomerulonephritis B-Disease 1 0.9999816417694092
, O 0 0.07496577501296997
vasculitis B-Disease 1 0.9999744892120361
, O 0 0.0002457007358316332
and O 0 0.005395874381065369
arthritis B-Disease 1 0.9999954700469971
in O 0 9.611530913389288e-07
an O 0 2.008043225032452e-07
individual O 0 5.10262339048495e-07
lacking O 0 1.0870612641156185e-05
C5 O 0 0.0013264426961541176
( O 0 1.5281402454547788e-07
and O 0 5.318980100810222e-08
its O 0 5.1547129231721556e-08
biologic O 0 2.825203955580946e-05
functions O 0 4.26150705834516e-08
) O 0 5.3284335166381425e-08
, O 0 3.1227603614070176e-08
and O 0 1.060465848468084e-07
( O 0 9.611974149947855e-08
b O 0 3.4180945931439055e-06
) O 0 2.4137452925288017e-08
a O 0 3.2656160442456894e-08
remarkable O 0 1.4890371176079498e-06
propensity O 0 0.0006271085585467517
to O 0 8.829060789139476e-06
bacterial B-Disease 1 0.9909743666648865
infections I-Disease 1 0.9795258045196533
in O 0 1.4537515369283938e-07
the O 0 1.4638936818300863e-07
proband O 0 0.004781569819897413
, O 0 2.657303923569998e-07
even O 0 2.5918931001456258e-08
during O 0 2.1036040465105543e-08
periods O 0 2.95538047367927e-08
of O 0 1.3007773524975619e-08
low O 0 1.6194678664760431e-06
- O 0 9.145587682723999e-05
dose O 0 1.6436897567473352e-06
or O 0 1.4264925241036508e-08
alternate O 0 6.535982777222671e-08
- O 0 6.394885713234544e-05
day O 0 1.3068251064396463e-05
corticosteroid O 0 0.003981588874012232
therapy O 0 7.733525853836909e-05
. O 0 2.8321371701167664e-06

Other O 0 2.028210701610078e-06
observations O 0 3.2864663808140904e-06
indicate O 0 1.0410237791802501e-06
that O 0 2.6971376243523082e-08
the O 0 1.106793661165284e-07
C5D B-Disease 1 0.7763245701789856
state O 0 2.8725293077513925e-07
is O 0 8.128777650995289e-09
compatible O 0 1.260110451539731e-07
with O 0 1.172085859479921e-07
normal O 0 2.420878502107371e-07
coagulation O 0 3.958287197747268e-05
function O 0 4.120801833096266e-08
and O 0 3.5288724831161744e-08
the O 0 2.3088590594966263e-08
capacity O 0 3.232567848954204e-07
to O 0 1.915280201103542e-08
mount O 0 4.514914508035872e-06
a O 0 2.4044691144808894e-06
neutrophilic O 1 0.61043781042099
leukocytosis O 1 0.8612151741981506
during O 0 0.0003015233960468322
pyogenic B-Disease 1 0.9967707395553589
infection I-Disease 0 0.024551618844270706
. O 0 1.239840230482514e-06
. O 0 3.1239958389051026e-06

Susceptibility O 1 0.6635830998420715
to O 0 0.0035078509245067835
ankylosing B-Disease 1 0.9999696016311646
spondylitis I-Disease 1 0.9999932050704956
in O 0 0.00018799396639224142
twins O 0 0.0064107817597687244
: O 0 2.469073194788507e-07
the O 0 2.5800799718922462e-08
role O 0 8.470719592423848e-08
of O 0 1.9700939546396512e-08
genes O 0 2.653252408890694e-07
, O 0 3.1404201195073256e-07
HLA O 0 0.0003228557761758566
, O 0 3.11935593799717e-07
and O 0 1.2210706756832224e-07
the O 0 3.420931022901641e-07
environment O 0 1.9668517779791728e-05
. O 0 6.073253643990029e-06

OBJECTIVE O 0 2.0817562472075224e-05
To O 0 3.9588687172908976e-07
determine O 0 2.857084950846911e-07
the O 0 9.50004519495451e-08
relative O 0 3.3617759527260205e-06
effects O 0 2.4854527964635054e-06
of O 0 8.966063091975229e-08
genetic O 0 6.73600152367726e-06
and O 0 8.999728038361354e-07
environmental O 0 4.642133353627287e-05
factors O 0 1.761050043569412e-06
in O 0 1.7310429711869801e-06
susceptibility O 0 0.01957601122558117
to O 0 0.0030640691984444857
ankylosing B-Disease 1 0.999996542930603
spondylitis I-Disease 1 0.9999990463256836
( O 0 0.0003325909492559731
AS B-Disease 0 0.0011172646190971136
) O 0 5.5561513363500126e-06
. O 0 4.510959115577862e-06

METHODS O 0 9.926511120283976e-05
Twins O 0 0.0014848749851807952
with O 0 3.770869398067589e-06
AS B-Disease 0 1.8466245819581673e-05
were O 0 3.085838216065895e-07
identified O 0 2.695209957437328e-07
from O 0 1.59889133044544e-08
the O 0 4.081744009454269e-08
Royal O 0 3.4711265470832586e-05
National O 0 0.00020152727665845305
Hospital O 0 0.010561770759522915
for O 0 0.00047150327009148896
Rheumatic B-Disease 1 0.9998841285705566
Diseases I-Disease 1 0.5539350509643555
database O 0 0.0001511334121460095
. O 0 3.7339013942983e-05

Clinical O 0 0.008655717596411705
and O 0 2.3809434424038045e-05
radiographic O 0 0.02178768254816532
examinations O 0 9.204452362610027e-05
were O 0 1.5202878103082185e-06
performed O 0 3.0614123147643113e-07
to O 0 2.332646786840087e-08
establish O 0 9.76600063040678e-07
diagnoses O 0 0.0016051838174462318
, O 0 5.364458502299385e-06
and O 0 0.0003200293576810509
disease O 0 0.0408904030919075
severity O 0 0.00018261524382978678
was O 0 5.8558853197610006e-06
assessed O 0 1.262354817299638e-05
using O 0 2.520697819363704e-07
a O 0 1.64915235245644e-07
combination O 0 9.797746542972163e-07
of O 0 5.676027114986937e-08
validated O 0 5.1304546104802284e-06
scoring O 0 2.6375103061582195e-06
systems O 0 2.3319153115153313e-05
. O 0 3.2493742310180096e-06

HLA O 0 0.008453825488686562
typing O 0 0.00012840269482694566
for O 0 2.9754737624898553e-06
HLA O 0 0.0014682092005386949
- O 0 0.0004866138333454728
B27 O 0 9.771362965693697e-05
, O 0 8.426804356531647e-07
HLA O 0 0.0001478522754041478
- O 0 0.0001055341781466268
B60 O 0 2.5162949896184728e-05
, O 0 5.104755018692231e-08
and O 0 5.272817915624728e-08
HLA O 0 5.530366252060048e-05
- O 0 0.00022161619563121349
DR1 O 0 0.0016835082788020372
was O 0 2.7558166948438156e-07
performed O 0 2.0280772616843024e-08
by O 0 6.788985373873402e-09
polymerase O 0 2.0389293240441475e-06
chain O 0 1.829104348871624e-06
reaction O 0 3.2638414637631286e-08
with O 0 2.868891346707869e-09
sequence O 0 6.516288841851292e-09
- O 0 2.8563349587784614e-06
specific O 0 1.5566961053536943e-08
primers O 0 1.8559727550382377e-06
, O 0 5.3210907680067976e-08
and O 0 7.657533274141315e-08
zygosity O 0 0.00025434695999138057
was O 0 5.311634936333576e-07
assessed O 0 3.715439788720687e-06
using O 0 7.607228553752066e-07
microsatellite O 0 0.0025499004404991865
markers O 0 0.00042026760638691485
. O 0 1.0260821909469087e-05

Genetic O 0 0.0025856662541627884
and O 0 4.492811058298685e-06
environmental O 0 7.352763077506097e-06
variance O 0 2.7034937488679134e-07
components O 0 3.7569743653875776e-06
were O 0 2.578737792191532e-07
assessed O 0 4.73333966510836e-06
with O 0 6.071719838018907e-08
the O 0 2.7789136325395702e-08
program O 0 1.0946045847504138e-07
Mx O 0 2.7378320737625472e-05
, O 0 1.474766886389034e-08
using O 0 4.5136663295863855e-09
data O 0 1.0142489514919362e-08
from O 0 6.662120632938695e-09
this O 0 1.1014393841435322e-09
and O 0 1.1151165324463364e-08
previous O 0 3.7477342118563683e-08
studies O 0 5.5492819228675216e-08
of O 0 8.862417644195375e-08
twins O 0 0.00034969073021784425
with O 0 4.303517926018685e-06
AS B-Disease 0 0.0001665218878770247
. O 0 1.047763362294063e-05

RESULTS O 0 3.161344284308143e-05
Six O 0 1.098548864320037e-06
of O 0 2.424642104870145e-07
8 O 0 3.3623689432715764e-06
monozygotic O 0 0.0015995854046195745
( O 0 4.564436153486895e-07
MZ O 0 0.08374431729316711
) O 0 2.0994839644572494e-07
twin O 0 2.9156475648051128e-05
pairs O 0 8.106691893772222e-06
were O 0 1.2551307918329258e-05
disease O 0 0.0005142676527611911
concordant O 0 0.00039430527249351144
, O 0 8.48930199026654e-07
compared O 0 9.198173529512133e-07
with O 0 3.430911377222401e-08
4 O 0 8.044719379540766e-08
of O 0 2.2537147259527046e-08
15 O 0 4.2567955915728817e-07
B27 O 0 2.642544495756738e-05
- O 0 0.00012388054165057838
positive O 0 5.692506306331779e-07
dizygotic O 0 5.852531103300862e-05
( O 0 8.855996469492311e-08
DZ O 0 0.0007485777605324984
) O 0 1.0372684045023561e-07
twin O 0 9.395433153258637e-06
pairs O 0 6.237249863261241e-07
( O 0 4.260872898953494e-08
27 O 0 1.5144127019084408e-06
% O 0 5.090928212325707e-08
) O 0 8.045559773961486e-09
and O 0 6.020951737184532e-09
4 O 0 1.3868058701405062e-08
of O 0 7.877163810121601e-09
32 O 0 8.822073027658917e-07
DZ O 0 0.009441657923161983
twin O 0 6.616133032366633e-05
pairs O 0 1.813100311665039e-06
overall O 0 2.584345793366083e-06
( O 0 7.656277745127227e-08
12 O 0 1.3817304989061086e-07
. O 0 1.3593213665785697e-08
5 O 0 1.634437722941584e-07
% O 0 3.2804092597871204e-07
) O 0 3.6125302926848235e-07
. O 0 1.927708126459038e-06

Nonsignificant O 0 0.20970843732357025
increases O 0 0.000397416326450184
in O 0 1.1077710269091767e-06
similarity O 0 1.2752090015055728e-06
with O 0 8.86816664547041e-08
regard O 0 2.6529536967245804e-07
to O 0 5.678171532963461e-08
age O 0 3.7556847019004636e-06
at O 0 6.649440911132842e-05
disease O 0 0.007278775796294212
onset O 0 0.00015607177920173854
and O 0 2.634528470935038e-07
all O 0 1.2068190891056929e-08
of O 0 1.4521707214498747e-07
the O 0 1.7285030480707064e-05
disease O 0 0.0070562539622187614
severity O 0 3.925983401131816e-05
scores O 0 3.617783295339905e-05
assessed O 0 0.0005150407669134438
were O 0 8.338831321452744e-06
noted O 0 2.175844019802753e-05
in O 0 5.194634013605537e-06
disease O 0 0.0020165289752185345
- O 0 0.008364500477910042
concordant O 0 0.07033320516347885
MZ O 1 0.9924969673156738
twins O 0 0.00951465405523777
compared O 0 1.4539760741172358e-05
with O 0 3.0119865641609067e-06
concordant O 0 0.0103274742141366
DZ O 1 0.9614695906639099
twins O 0 0.019474977627396584
. O 0 1.6797132047940977e-05

HLA O 0 0.11769435554742813
- O 0 0.029618674889206886
B27 O 0 0.0013525194954127073
and O 0 3.5419452615315095e-06
B60 O 0 0.00010884667426580563
were O 0 2.7031225613427523e-07
associated O 0 2.2499830265587661e-07
with O 0 1.5693144916895108e-07
the O 0 2.1605490019283025e-06
disease O 0 0.0008795153116807342
in O 0 3.21074168141422e-07
probands O 0 0.041671235114336014
, O 0 4.673654530051863e-07
and O 0 5.460852392502602e-08
the O 0 3.4085715583387355e-08
rate O 0 8.287420882879815e-07
of O 0 4.539145948001533e-07
disease O 0 8.970319322543219e-05
concordance O 0 1.2260980838618707e-05
was O 0 2.210483671660768e-06
significantly O 0 1.558205781293509e-06
increased O 0 2.4028224743233295e-07
among O 0 1.7932612195181719e-07
DZ O 0 0.005600155331194401
twin O 0 5.300891643855721e-05
pairs O 0 6.224378807928588e-07
in O 0 1.4236302803283252e-08
which O 0 7.364259424491593e-09
the O 0 3.331307851794918e-08
co O 0 0.0001718662679195404
- O 0 0.006180400960147381
twin O 0 0.0016061861533671618
was O 0 1.3022528264627908e-06
positive O 0 6.714528666407205e-08
for O 0 1.7455862533211075e-08
both O 0 9.497399844349275e-08
B27 O 0 7.090389408404008e-05
and O 0 3.7580168736894848e-06
DR1 O 0 0.01401084940880537
. O 0 5.442859219328966e-06

Additive O 0 0.0003561853663995862
genetic O 0 0.0007325622718781233
effects O 0 8.117002289509401e-05
were O 0 3.3881349281728035e-07
estimated O 0 5.975934413982031e-07
to O 0 1.7685730213656825e-08
contribute O 0 1.435805359051301e-07
97 O 0 5.371151132749219e-07
% O 0 1.6489472898228996e-08
of O 0 4.478130755103393e-09
the O 0 2.107435115306089e-08
population O 0 1.4202733211732266e-07
variance O 0 1.6026872344809817e-06
. O 0 3.8897228478163015e-06

CONCLUSION O 0 8.092742064036429e-05
Susceptibility O 0 0.001444243942387402
to O 0 1.0424881793369423e-06
AS B-Disease 0 1.2416042409313377e-05
is O 0 9.472488926576261e-08
largely O 0 5.328687961991818e-07
genetically O 0 2.6030706976598594e-06
determined O 0 5.168939765098912e-07
, O 0 3.889482513841358e-08
and O 0 4.989110280462228e-08
the O 0 4.986494062109159e-08
environmental O 0 8.12615871836897e-06
trigger O 0 1.2013749255856965e-05
for O 0 2.7898039434148814e-07
the O 0 4.6446011765510775e-06
disease O 0 0.0010123400716111064
is O 0 2.1018858831212128e-07
probably O 0 2.901393145293696e-06
ubiquitous O 0 4.4372838601702824e-05
. O 0 1.1471830475784373e-05

HLA O 0 0.17624855041503906
- O 0 0.010408264584839344
B27 O 0 0.0005742147914133966
accounts O 0 2.1351011127990205e-06
for O 0 1.3680195820597874e-07
a O 0 9.782558407778197e-08
minority O 0 7.172829441515205e-07
of O 0 1.531325644066328e-08
the O 0 6.826461884656965e-08
overall O 0 1.412796427757712e-05
genetic O 0 0.00012171109847258776
susceptibility O 0 0.00026884605176746845
to O 0 5.563546210396453e-07
AS B-Disease 0 4.834296487388201e-05
. O 0 7.4918498285114765e-06

Cell O 0 0.00048037731903605163
cycle O 0 4.637222082237713e-05
- O 0 0.0008477979572489858
dependent O 0 9.096647772821598e-06
colocalization O 0 0.000134679808979854
of O 0 2.863995121060725e-07
BARD1 O 0 0.0021443322766572237
and O 0 6.831150471953151e-07
BRCA1 O 0 1.6987738490570337e-05
proteins O 0 3.735915399261103e-08
in O 0 1.1450062231688207e-08
discrete O 0 6.501691132143606e-07
nuclear O 0 0.00011792111035902053
domains O 0 1.4525486221828032e-05
. O 0 3.883440513163805e-06

Germ O 0 0.010566175915300846
- O 0 0.0016070097917690873
line O 0 1.1475287465145811e-05
mutations O 0 1.877273803074786e-06
of O 0 1.4884897758804527e-08
the O 0 8.332174417091665e-08
BRCA1 O 0 6.334405043162405e-05
gene O 0 8.067258363553265e-07
predispose O 0 8.704756510269362e-06
women O 0 3.004473114742723e-07
to O 0 2.7453443962599522e-08
early O 0 1.1263549595241784e-06
- O 0 0.49714943766593933
onset O 1 0.8241751790046692
breast B-Disease 1 0.9971350431442261
and I-Disease 1 0.8956180810928345
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9998370409011841
by O 0 2.541759840823943e-06
compromising O 0 0.0005795253091491759
the O 0 4.7446425810449e-07
genes O 0 2.888255039579235e-06
presumptive O 0 0.009607442654669285
function O 0 3.1344092121798894e-07
as O 0 3.3657204312476097e-07
a O 0 8.287370292237028e-06
tumor B-Disease 0 0.03455060347914696
suppressor O 0 0.0019060875056311488
. O 0 2.5086637833737768e-05

Although O 0 1.1253358934482094e-05
the O 0 7.316129426726548e-07
biochemical O 0 2.7683347070706077e-05
properties O 0 2.070145455945749e-06
of O 0 2.396629668055539e-07
BRCA1 O 0 0.0002284132206114009
polypeptides O 0 1.797924778657034e-05
are O 0 1.3120444464220782e-07
not O 0 3.565896378177058e-08
understood O 0 2.8804601015508524e-07
, O 0 1.5478965664783573e-08
their O 0 1.2514226988002974e-08
expression O 0 5.515515155707362e-08
pattern O 0 8.151340580297983e-08
and O 0 5.573265227099e-08
subcellular O 0 2.869188620024943e-06
localization O 0 4.159026048000669e-06
suggest O 0 2.9439098625516635e-07
a O 0 3.6891101728997455e-08
role O 0 2.2749054551240988e-07
in O 0 6.906442706622329e-08
cell O 0 2.013704761338886e-05
- O 0 0.0014628662029281259
cycle O 0 3.276951247244142e-05
regulation O 0 1.5867317415541038e-05
. O 0 3.5554046462493716e-06

When O 0 9.499937732471153e-05
resting O 0 0.010511455126106739
cells O 0 7.084273238433525e-05
are O 0 2.1231423374956648e-07
induced O 0 3.8184920413186774e-05
to O 0 9.89604131973465e-08
proliferate O 0 1.868945764726959e-05
, O 0 2.964724465925883e-08
the O 0 4.4572701085598965e-09
steady O 0 3.826641261639452e-07
- O 0 9.184059308608994e-06
state O 0 5.005179914974178e-08
levels O 0 2.702848789226664e-08
of O 0 5.287246640506282e-09
BRCA1 O 0 3.0803153094893787e-06
increase O 0 6.294627752367887e-08
in O 0 7.280628988581839e-09
late O 0 2.4991405211949314e-07
G1 O 0 4.0471113607054576e-05
and O 0 3.242280399717856e-08
reach O 0 2.242497565418944e-08
a O 0 1.202292931878901e-08
maximum O 0 1.5173850442806724e-07
during O 0 4.6100558392936364e-07
S O 0 0.00012299422814976424
phase O 0 1.3230013792053796e-05
. O 0 3.602969400162692e-06

Moreover O 0 0.0001470160932512954
, O 0 1.93692767425091e-06
in O 0 2.38353038639616e-07
S O 0 8.91414238139987e-05
phase O 0 1.1261131476203445e-05
cells O 0 1.1851443559862673e-05
, O 0 3.857220463032718e-07
BRCA1 O 0 3.465516783762723e-05
polypeptides O 0 5.099566351418616e-06
are O 0 7.437935067855506e-08
hyperphosphorylated O 0 5.295364462654106e-05
and O 0 1.0062911570685174e-07
accumulate O 0 1.5322876834034105e-06
into O 0 2.9636446186032117e-08
discrete O 0 6.428574010897137e-07
subnuclear O 0 0.0009580228943377733
foci O 0 0.0002157345588784665
termed O 0 3.303760604467243e-05
" O 0 6.00785426740913e-07
BRCA1 O 0 8.4588275058195e-05
nuclear O 0 0.000169077655300498
dots O 0 0.0003300938697066158
. O 0 8.687315130373463e-06

" O 0 5.036767470301129e-05
BRCA1 O 0 0.005029788240790367
associates O 0 0.006039842497557402
in O 0 1.1386075584596256e-06
vivo O 0 4.287521369406022e-05
with O 0 2.2548633182850608e-07
a O 0 1.1826984973595245e-06
structurally O 0 0.00010077904880745336
related O 0 2.2912250642548315e-05
protein O 0 6.4491291595913935e-06
termed O 0 0.00011888406879734248
BARD1 O 0 0.03087291307747364
. O 0 1.5243777852447238e-05

Here O 0 5.9239960137347225e-06
we O 0 1.362920016845237e-07
show O 0 5.973916472612473e-08
that O 0 3.625097111381592e-09
the O 0 4.823854649060877e-09
steady O 0 3.259916354636516e-07
- O 0 1.2437444638635498e-05
state O 0 1.2407895155774895e-07
levels O 0 4.694565447493915e-08
of O 0 1.4268544568096786e-08
BARD1 O 0 0.0004925588145852089
, O 0 7.364346288341039e-08
unlike O 0 6.374416727794596e-08
those O 0 7.290022363548587e-09
of O 0 3.567433637385875e-08
BRCA1 O 0 4.516222907113843e-05
, O 0 1.388883106301364e-07
remain O 0 2.3488853173603275e-07
relatively O 0 9.309050597039459e-08
constant O 0 2.1720863685459335e-07
during O 0 5.57595399186539e-07
cell O 0 3.032958738913294e-05
cycle O 0 2.2170024749357253e-05
progression O 0 0.0002486190351191908
. O 0 1.1197232197446283e-05

However O 0 1.9601893654908054e-05
, O 0 4.219037236907752e-06
immunostaining O 0 0.0029403287917375565
revealed O 0 2.5938348699128255e-05
that O 0 1.3349462335554563e-07
BARD1 O 0 0.0006267350981943309
resides O 0 4.060239007230848e-06
within O 0 4.490346938723633e-08
BRCA1 O 0 4.273499143891968e-05
nuclear O 0 2.0074348867638037e-05
dots O 0 7.592547262902372e-06
during O 0 3.9819056496526173e-07
S O 0 3.184895831509493e-05
phase O 0 3.44944879770992e-07
of O 0 1.3239508156459578e-08
the O 0 3.910668056050781e-08
cell O 0 4.997547421226045e-06
cycle O 0 6.573745849891566e-07
, O 0 1.163326217579197e-07
but O 0 6.547234754350484e-09
not O 0 2.7292517135180105e-09
during O 0 2.0188455351899393e-08
the O 0 9.399347078442588e-08
G1 O 0 0.0002542012371122837
phase O 0 1.2111101568734739e-05
. O 0 4.526330485532526e-06

Nevertheless O 0 0.00023301651526708156
, O 0 7.739121429040097e-06
BARD1 O 0 0.0016699256375432014
polypeptides O 0 1.6274199879262596e-05
are O 0 6.110570183182062e-08
found O 0 6.820136633223228e-08
exclusively O 0 2.210284044679156e-08
in O 0 4.046210033692432e-09
the O 0 2.8589768330533616e-09
nuclear O 0 4.303667822114221e-07
fractions O 0 1.0710561326732204e-08
of O 0 2.4697590639277678e-09
both O 0 8.960964414939099e-09
G1 O 0 2.907922498707194e-05
- O 0 4.719227581517771e-05
and O 0 4.942878035762988e-07
S O 0 0.00017592532094568014
- O 0 0.0009396009845659137
phase O 0 4.641978375730105e-05
cells O 0 3.2080595701700076e-05
. O 0 2.2852850634080824e-06

Therefore O 0 2.8311404093983583e-05
, O 0 1.4695352774651838e-06
progression O 0 7.087106041581137e-06
to O 0 1.393348583178522e-07
S O 0 7.35776629881002e-05
phase O 0 1.957002950803144e-06
is O 0 3.580521834578576e-08
accompanied O 0 1.4917560520189e-07
by O 0 6.3005951567163265e-09
the O 0 4.612207948895275e-09
aggregation O 0 1.827385460728692e-07
of O 0 3.2413343120651916e-08
nuclear O 0 2.52634308708366e-05
BARD1 O 0 0.0002371450245846063
polypeptides O 0 3.746612719623954e-06
into O 0 6.289292855399253e-07
BRCA1 O 0 7.764073234284297e-05
nuclear O 0 6.374045915436e-05
dots O 0 0.00015427569451276213
. O 0 8.121200153254904e-06

This O 0 1.2485471643230994e-06
cell O 0 2.5436258511035703e-05
cycle O 0 4.743258159578545e-06
- O 0 0.0003438322455622256
dependent O 0 4.337610334914643e-06
colocalization O 0 5.010309178032912e-05
of O 0 9.00036596362952e-08
BARD1 O 0 0.0024961496237665415
and O 0 1.159849375653721e-06
BRCA1 O 0 5.657308429363184e-05
indicates O 0 4.1561733610251395e-07
a O 0 2.4963387801335557e-08
role O 0 8.878270563172919e-08
for O 0 6.268639651807462e-08
BARD1 O 0 0.002155995462089777
in O 0 5.337517450243467e-07
BRCA1 O 0 0.00018950318917632103
- O 0 0.04122578352689743
mediated O 0 0.36266085505485535
tumor B-Disease 0 0.22056102752685547
suppression O 0 0.0001773826516000554
. O 0 1.049897946359124e-05

Ethnic O 0 5.998823689878918e-05
differences O 0 7.419585745083168e-05
in O 0 2.0328218397480669e-07
the O 0 1.9232335546348622e-07
HFE O 0 0.000332572526531294
codon O 0 8.56664792081574e-06
282 O 0 6.815820233896375e-05
( O 0 3.858607215079246e-06
Cys O 0 0.06190865486860275
/ O 0 0.0007494742167182267
Tyr O 0 0.038470830768346786
) O 0 2.0537279397103703e-06
polymorphism O 0 7.675755477976054e-05
. O 0 8.541603165213019e-06

Recent O 0 0.00012603311915881932
studies O 0 1.8196922610513866e-05
have O 0 1.1975517963946913e-06
shown O 0 2.9066054594295565e-06
that O 0 1.2241609510965645e-05
hereditary B-Disease 1 0.9999616146087646
hemochromatosis I-Disease 1 0.9999992847442627
( O 0 0.000910762173589319
HH B-Disease 1 0.9948201179504395
) O 0 2.8186675535835093e-06
is O 0 1.1918579900793702e-07
likely O 0 5.600159624918888e-07
to O 0 2.7416184877893102e-08
be O 0 4.306069101289722e-08
caused O 0 4.919116349810793e-07
by O 0 4.2804224165138294e-08
homozygosity O 0 0.00020949442114215344
for O 0 6.917569095321596e-08
a O 0 2.5080154841816693e-07
Cys282Tyr O 0 0.0008208405342884362
mutation O 0 8.103151571958733e-07
in O 0 1.4997521446957762e-08
the O 0 9.855656202262253e-08
HFE O 0 0.001120569882914424
gene O 0 1.0567410981821013e-06
located O 0 4.337628922712611e-07
4 O 0 2.1679754809156293e-06
. O 0 3.2377001843997277e-06

5 O 0 0.00011114130029454827
Mb O 0 0.0012579393805935979
telomeric O 0 0.004085449501872063
to O 0 6.751507953595137e-06
HLA O 0 0.005818348377943039
- O 0 0.001643779338337481
A O 0 2.2818767320131883e-05
. O 0 7.498347258660942e-06

Population O 0 8.855403393681627e-06
studies O 0 1.6551316548429895e-06
of O 0 4.812543963339522e-08
this O 0 1.3349048977318034e-08
polymorphism O 0 3.6920919228577986e-06
are O 0 2.7133499003184625e-08
facilitated O 0 1.0376320460636634e-06
by O 0 7.322606876414284e-08
the O 0 2.2474988981002753e-08
fact O 0 2.5001888559472718e-08
that O 0 2.579601421359712e-09
the O 0 2.1592558852034927e-08
Cys282Tyr O 0 0.00015022566367406398
mutation O 0 1.5046135786178638e-06
creates O 0 8.501065167365596e-07
a O 0 5.498445716511924e-07
Rsal O 0 0.0006512641557492316
restriction O 0 2.4785269943095045e-06
site O 0 3.425129534662119e-06
. O 0 1.959292376341182e-06

We O 0 5.744403097196482e-06
have O 0 3.9834284848438983e-07
studied O 0 2.0444950621367752e-07
the O 0 1.51504195855523e-08
codon O 0 4.810612495020905e-07
282 O 0 1.4545849808200728e-05
( O 0 4.197911778192065e-07
Cys O 0 0.019823657348752022
/ O 0 0.00012066483031958342
Tyr O 0 0.0027045540045946836
) O 0 9.324296712520663e-08
polymorphism O 0 1.2665589110838482e-06
in O 0 8.26881141335889e-09
different O 0 5.212061005011037e-09
ethnic O 0 5.185306690691505e-07
groups O 0 2.7333614980307175e-06
. O 0 5.665017397404881e-06

In O 0 4.29557940151426e-06
agreement O 0 3.1071847388375318e-06
with O 0 1.0634980895929402e-07
previous O 0 1.9163496745022712e-07
observations O 0 1.806133553827749e-07
the O 0 1.299604832638579e-07
Tyr O 0 0.0006889001233503222
allele O 0 4.291820459911833e-06
appeared O 0 7.225067975014099e-07
to O 0 2.3474157728742284e-08
be O 0 3.850905372360103e-08
rare O 0 9.032048069457232e-07
or O 0 2.7926765255870123e-07
absent O 0 6.364106411638204e-06
in O 0 1.5630472205430124e-07
Asiatic O 0 9.441417205380276e-05
( O 0 1.0410997930421217e-07
Indian O 0 1.5163072930590715e-06
, O 0 1.4434870365676034e-07
Chinese O 0 1.1828331736296605e-07
) O 0 1.7451026224080124e-07
populations O 0 1.2392598591759452e-06
. O 0 1.4397628547158092e-06

The O 0 2.1429302705655573e-06
highest O 0 3.999303771706764e-06
allele O 0 1.992816805795883e-06
frequency O 0 2.542988681852876e-07
( O 0 4.060297698060822e-08
7 O 0 6.32025276559034e-08
. O 0 8.290794717424887e-09
5 O 0 5.694668203659603e-08
% O 0 5.246724299468042e-08
) O 0 2.348504146709729e-08
was O 0 9.048388704968602e-08
found O 0 2.4397471065640275e-07
in O 0 2.5522260216348513e-07
Swedes O 0 0.0013515499886125326
. O 0 7.149457815103233e-06

Saamis O 0 0.03615261986851692
( O 0 5.512682491826126e-06
2 O 0 1.977615966097801e-06
% O 0 2.7661781132337637e-07
) O 0 4.254051688690197e-08
and O 0 1.133103140205094e-07
Mordvinians O 0 0.00011947775783482939
( O 0 1.8942197144156125e-08
1 O 0 2.6214351578346395e-08
. O 0 4.045059842638921e-09
8 O 0 3.626724165428641e-08
% O 0 1.2149209638323555e-08
) O 0 8.76663452942239e-09
had O 0 4.098282246900453e-08
significantly O 0 7.602436369325005e-08
lower O 0 8.412706620219979e-08
frequencies O 0 1.9414454044408558e-08
of O 0 1.7960093856572712e-08
the O 0 2.1866914323709352e-07
Tyr O 0 0.002820195397362113
allele O 0 2.3007780328043737e-05
. O 0 2.8408339858287945e-06

Comparisons O 0 8.52218181535136e-06
with O 0 7.428031949530123e-07
allele O 0 1.050609398589586e-06
frequencies O 0 1.4060604769383644e-07
based O 0 1.6018957182950544e-07
on O 0 3.475253436135972e-07
prevalence O 0 3.566345912986435e-05
estimates O 0 8.085119702627708e-07
of O 0 2.232862925666268e-07
HH B-Disease 1 0.7876902222633362
showed O 0 9.824732114793733e-05
some O 0 3.650667679266917e-08
disagreements O 0 3.5672476315085078e-06
with O 0 3.580139562586737e-08
the O 0 5.05393167316015e-08
RFLP O 0 5.3192838095128536e-05
data O 0 7.300997140191612e-07
, O 0 3.3546362487868464e-07
particularly O 0 3.6685830195892777e-07
in O 0 2.2828227486115793e-07
Finns O 0 0.0004316214472055435
. O 0 5.355032953957561e-06

The O 0 7.260998700076016e-06
newly O 0 0.0002455567300785333
described O 0 0.00012209982378408313
HFE O 0 0.02650396339595318
marker O 0 3.706717325258069e-05
provides O 0 1.9887829694198444e-07
a O 0 4.959584032349085e-08
new O 0 1.4385999236310454e-07
approach O 0 7.589961370513265e-08
to O 0 4.3602672583631374e-09
the O 0 4.3456713783029954e-09
screening O 0 1.1721752457560797e-07
of O 0 3.870965059604714e-08
HH B-Disease 0 0.027508575469255447
as O 0 1.3302604884302127e-07
well O 0 3.014492122588308e-08
as O 0 2.8753461833730398e-08
studies O 0 2.176830271594099e-08
of O 0 7.667600776528616e-09
the O 0 2.5572589379407873e-08
relationship O 0 3.0421713859141164e-07
between O 0 4.4812605182187326e-08
the O 0 2.83163302583489e-07
HFE O 0 0.04151616245508194
Tyr O 0 0.019592201337218285
allele O 0 5.350489573174855e-06
and O 0 1.2903417427878594e-06
different O 0 3.0034816518309526e-06
disorders O 1 0.8594242334365845
including O 0 0.02053510583937168
cancer B-Disease 1 0.9685630202293396

Autosomal B-Disease 1 0.9956061244010925
dominant I-Disease 1 0.9819989204406738
neurohypophyseal I-Disease 1 0.9998117089271545
diabetes I-Disease 1 0.9999613761901855
insipidus I-Disease 1 0.9994955062866211
associated O 0 0.000194175387150608
with O 0 4.358598459930363e-07
a O 0 2.1819460016558878e-07
missense O 0 4.636881567421369e-05
mutation O 0 7.063187581479724e-07
encoding O 0 1.5918628548661218e-07
Gly23 O 0 0.00012752001930493861
- O 0 0.00017778428446035832
- O 0 0.000471536535769701
> O 0 2.0740813852171414e-05
Val O 0 0.0007532074232585728
in O 0 8.701831575308461e-07
neurophysin O 0 0.0012229052372276783
II O 0 0.00074604811379686
. O 0 5.915939709666418e-06

Autosomal B-Disease 1 0.991378903388977
dominant I-Disease 1 0.9744468927383423
neurohypophyseal I-Disease 1 0.9996587038040161
diabetes I-Disease 1 0.9999264478683472
insipidus I-Disease 1 0.9991152882575989
( O 0 0.00012831590720452368
ADNDI B-Disease 0 0.45715010166168213
) O 0 2.944633251900086e-06
is O 0 1.233941134159977e-06
an O 0 0.00027790165040642023
inherited B-Disease 1 0.9999940395355225
disease I-Disease 1 0.9999656677246094
caused O 0 0.008516012690961361
by O 0 2.8576552722370252e-05
progressive O 0 0.41434866189956665
degeneration O 1 0.7746861577033997
of O 0 5.191536160964461e-07
the O 0 3.6582662232831353e-07
magnocellular O 0 0.003965609706938267
neurons O 0 1.1165881005581468e-05
of O 0 2.879303018232804e-08
the O 0 1.1217213824465944e-07
hypothalamus O 0 1.0700213351810817e-05
leading O 0 4.887351224169834e-06
to O 0 7.183550110312353e-08
decreased O 0 2.3541135760751786e-06
ability O 0 4.721594848433597e-08
to O 0 2.2571120528169786e-09
produce O 0 1.0792877702670012e-08
the O 0 6.216346548626461e-08
hormone O 0 8.93765809450997e-06
arginine O 0 2.393519207544159e-05
vasopressin O 0 6.792695785406977e-05
( O 0 1.2406468385961489e-06
AVP O 0 0.001129282172769308
) O 0 2.0123404738114914e-06
. O 0 1.8292246295459336e-06

Affected O 0 0.0011226293863728642
individuals O 0 1.313427128479816e-05
are O 0 3.834532265045709e-07
not O 0 1.991259779288157e-07
symptomatic O 0 0.00025557089247740805
at O 0 5.479713308886858e-06
birth O 0 2.2016385628376156e-05
, O 0 6.630633038184897e-07
but O 0 1.856853089066135e-07
usually O 0 1.5385620599772665e-06
develop O 0 0.0008952768985182047
diabetes B-Disease 1 0.9651162624359131
insipidus I-Disease 0 0.11729162186384201
at O 0 2.730420192165184e-06
1 O 0 7.709058422733506e-07
- O 0 0.0005348896374925971
6 O 0 1.18552534331684e-05
yr O 0 0.04613452032208443
of O 0 6.8937151809223e-07
age O 0 1.0775458576972596e-05
. O 0 3.0093019631749485e-06

The O 0 4.305890797695611e-06
genetic O 0 4.7701749281259254e-05
locus O 0 9.968928679882083e-06
of O 0 4.192158939986257e-07
the O 0 3.1505312563240295e-06
disease O 0 0.0005834355833940208
is O 0 6.220343351515112e-08
the O 0 2.2083756334723148e-07
AVP O 0 0.01759358122944832
- O 0 0.19284330308437347
neurophysin O 0 0.14963285624980927
II O 0 0.0020893875043839216
( O 0 4.383334157864738e-07
NPII O 0 0.0004949519643560052
) O 0 6.65385542220065e-08
gene O 0 5.929123503278788e-08
, O 0 1.3754048566738675e-08
and O 0 8.090775338587264e-08
mutations O 0 2.782839146675542e-06
that O 0 9.522177890630701e-08
cause O 0 1.335683737124782e-05
ADNDI B-Disease 0 0.07335778325796127
have O 0 9.594551784175565e-07
been O 0 2.1083363321849902e-07
found O 0 7.268117485637049e-08
in O 0 6.014983178204147e-09
both O 0 4.981139500870313e-09
the O 0 3.816448934657046e-09
signal O 0 4.581374568601859e-08
peptide O 0 1.1614904593670872e-07
of O 0 3.915950674837632e-09
the O 0 2.2753150474841277e-08
prepro O 0 0.0001043475785991177
- O 0 0.00023168331244960427
AVP O 0 0.00198821141384542
- O 0 0.00025646056747063994
NPII O 0 0.0006650291616097093
precursor O 0 1.986956476685009e-06
and O 0 8.26660766506393e-08
within O 0 1.1545021294523394e-07
NPII O 0 0.0010483204387128353
itself O 0 7.0638739089190494e-06
. O 0 2.187503923778422e-06

An O 0 1.5333884221035987e-05
affected O 0 3.7972804420860484e-05
girl O 0 0.00010896255844272673
who O 0 2.2520146103488514e-06
presented O 0 4.0790791899780743e-07
at O 0 2.81253505818313e-07
9 O 0 7.897044724813895e-07
months O 0 4.135440008212754e-07
of O 0 2.712645930103008e-08
age O 0 8.703757430339465e-07
and O 0 1.4458677810580411e-07
her O 0 1.8924106370832305e-06
similarly O 0 9.243915883416776e-06
affected O 0 3.6564840684150113e-06
younger O 0 1.0852765626623295e-05
brother O 0 2.8036653020535596e-05
and O 0 5.629181032418273e-07
father O 0 4.082136456418084e-06
were O 0 5.391448709701763e-08
all O 0 4.8367341243249484e-09
found O 0 1.2028530704810692e-07
to O 0 1.1049370307603112e-08
have O 0 1.0921890947201973e-08
a O 0 1.1350733686299463e-08
novel O 0 2.0732875327666989e-07
missense O 0 1.4671317330794409e-05
mutation O 0 1.2963657809450524e-06
( O 0 6.018106546434865e-08
G1758 O 0 1.4823262063146103e-05
- O 0 0.0002868321898858994
- O 0 0.0018943705363199115
> O 0 1.5941530364216305e-05
T O 0 0.0001185346336569637
) O 0 3.6254981239380868e-09
encoding O 0 3.270501647278934e-09
the O 0 1.7757684211971991e-09
amino O 0 2.902422480133282e-08
acid O 0 1.6462344376577676e-07
substitution O 0 6.530923712944059e-08
Gly23 O 0 2.3025253540254198e-05
- O 0 4.929362330585718e-05
- O 0 8.689084643265232e-05
> O 0 1.820447141653858e-05
Val O 0 0.00037061297916807234
within O 0 9.944961902874638e-07
NPII O 0 0.001792466500774026
. O 0 6.171987479319796e-06

The O 0 6.060195119061973e-06
mutation O 0 3.250288136769086e-05
was O 0 2.0013244466099422e-06
confirmed O 0 1.3271220495880698e-06
by O 0 9.590181804242093e-08
restriction O 0 9.28214205941913e-07
endonuclease O 0 9.775800572242588e-05
analysis O 0 4.4400499064067844e-06
. O 0 4.463782715902198e-06

A O 0 2.1403655409812927e-05
T1 O 0 0.0027535820845514536
- O 0 0.00034033425617963076
weighted O 0 1.068709752871655e-05
magnetic O 0 3.1543613658868708e-06
resonance O 0 2.808251565511455e-06
imaging O 0 7.734317478025332e-06
of O 0 3.868728626343909e-08
the O 0 3.761653033507173e-07
fathers O 0 0.00026879916549660265
pituitary O 0 0.15048377215862274
gland O 0 0.0005336030153557658
demonstrates O 0 6.832128747191746e-06
an O 0 7.503524557250785e-07
attenuated O 0 0.0011039779055863619
posterior O 0 0.019083907827734947
pituitary O 0 0.3581468462944031
bright O 0 0.00038674744428135455
spot O 0 5.226422945270315e-05
. O 0 1.2213181435072329e-05

This O 0 6.9861066549492534e-06
mutation O 0 0.00024544389452785254
may O 0 4.015504146082094e-06
be O 0 2.2487595785491976e-08
valuable O 0 9.219269969662491e-08
for O 0 2.0407270540090394e-08
developing O 0 8.206843631342053e-07
models O 0 1.3825664382238756e-06
of O 0 1.2504966662163497e-06
dominantly B-Disease 1 0.9768699407577515
inherited I-Disease 1 0.9994959831237793
neurodegeneration I-Disease 1 0.9999943971633911
, O 0 8.3756922322209e-06
as O 0 9.100138953499481e-08
the O 0 2.2444060832071955e-08
early O 0 1.5090296301423223e-07
age O 0 4.226070018376049e-07
of O 0 1.4855548613468272e-07
onset O 0 0.0006353179924190044
of O 0 2.1538551663979888e-05
symptoms O 0 0.01321699284017086
suggests O 0 7.905665029284137e-07
that O 0 1.049667108787844e-08
this O 0 1.40996210262756e-08
mutation O 0 3.718633706739638e-06
may O 0 6.11980794928968e-07
be O 0 6.107167394020507e-08
particularly O 0 5.078747449260845e-07
deleterious O 0 3.5986493003292708e-06
to O 0 2.322223657813538e-08
the O 0 2.5712353135531885e-07
magnocellular O 0 0.00428056763485074
neuron O 0 0.000554947298951447
. O 0 6.85612747020059e-07
. O 0 3.1913673410599586e-06

Frequent O 0 0.00022668928431812674
inactivation O 0 0.004032261203974485
of O 0 4.924847416987177e-06
PTEN O 0 0.042577408254146576
/ O 0 0.0007827161462046206
MMAC1 O 0 0.19470877945423126
in O 0 6.801964627811685e-05
primary O 0 0.2703421413898468
prostate B-Disease 1 0.9999667406082153
cancer I-Disease 1 0.9997414946556091
. O 0 0.00014077928790356964

Sporadic B-Disease 1 0.9886587262153625
prostate I-Disease 1 0.9999637603759766
carcinoma I-Disease 1 0.9999905824661255
is O 0 2.019173734879587e-05
the O 0 1.3636628182212007e-06
most O 0 1.4731890587427188e-06
common O 0 3.392020153114572e-05
male B-Disease 0 0.002359137637540698
cancer I-Disease 0 0.021792137995362282
in O 0 5.483009601903177e-08
the O 0 8.922986438619773e-08
Western O 0 6.839493948973541e-07
world O 0 1.0039902917924337e-06
, O 0 2.0268829814540368e-07
yet O 0 3.359664901836368e-08
many O 0 2.826197054162094e-09
of O 0 4.004481635178081e-09
the O 0 3.834575323935496e-08
major O 0 1.4825362768533523e-06
genetic O 0 1.1584035064515774e-06
events O 0 2.8708360133578026e-08
involved O 0 1.9570313725125743e-07
in O 0 1.5367739081284526e-08
the O 0 1.8068394780357266e-08
progression O 0 1.0034848401119234e-06
of O 0 4.767193573229633e-08
this O 0 1.6778791689375794e-07
often O 0 5.2633247833000496e-05
fatal O 1 0.9934713840484619
cancer B-Disease 1 0.9423757791519165
remain O 0 6.633860721194651e-06
to O 0 1.7346178537991364e-07
be O 0 1.0290780210198136e-06
elucidated O 0 0.0004367003566585481
. O 0 9.828463589656167e-06

Numerous O 0 8.417299977736548e-05
cytogenetic O 0 0.014995142817497253
and O 0 2.5005736461025663e-05
allelotype O 0 0.05134129896759987
studies O 0 1.5403533325297758e-05
have O 0 8.274950573650131e-07
reported O 0 6.678657427983126e-06
frequent O 0 2.045951305262861e-06
loss O 0 1.619687827769667e-05
of O 0 1.6360252175218193e-07
heterozygosity O 0 0.000746196776162833
on O 0 2.900447270803852e-06
chromosomal O 0 0.029839860275387764
arm O 0 0.022286362946033478
10q O 0 0.0010378971928730607
in O 0 1.0042622307082638e-05
sporadic B-Disease 0 0.13301444053649902
prostate I-Disease 1 0.9999722242355347
cancer I-Disease 1 0.9997218251228333
. O 0 0.00010638796811690554

Deletion O 0 0.0005561000434681773
mapping O 0 0.0001144706184277311
studies O 0 2.160209623980336e-05
have O 0 8.293264386338706e-07
unambiguously O 0 1.2334973689576145e-05
identified O 0 9.913892426993698e-07
a O 0 4.522156871189509e-08
region O 0 1.1586638493099599e-07
of O 0 5.8058329699406386e-08
chromosome O 0 0.00010516268230276182
10q23 O 0 5.459526437334716e-05
to O 0 3.1318627691234724e-08
be O 0 6.272465213896794e-09
the O 0 1.6284406711974952e-08
minimal O 0 5.461820364871528e-07
area O 0 3.415249238969409e-07
of O 0 4.655194345559721e-07
loss O 0 0.0010067448019981384
. O 0 1.4071476471144706e-05

A O 0 5.8904315665131435e-05
new O 0 0.00011944460857193917
tumor B-Disease 0 0.044720228761434555
suppressor O 0 0.00017110738554038107
gene O 0 2.322583895875141e-06
, O 0 5.658364443661412e-07
PTEN O 0 0.0013568926369771361
/ O 0 6.68984794174321e-05
MMAC1 O 0 0.015515349805355072
, O 0 1.299363475482096e-06
was O 0 1.4319630281534046e-06
isolated O 0 3.6650792480941163e-06
recently O 0 4.529936177277705e-06
at O 0 1.6524647605820064e-07
this O 0 3.863955377880757e-09
region O 0 5.6957865979256894e-08
of O 0 3.976474616251835e-08
chromosome O 0 3.4826251066988334e-05
10q23 O 0 8.485771104460582e-05
and O 0 2.0101010989037604e-07
found O 0 7.838035998020132e-08
to O 0 5.732315955242484e-09
be O 0 7.308567084862716e-09
inactivated O 0 1.1906395229743794e-06
by O 0 4.576099854602944e-08
mutation O 0 5.041377448833373e-07
in O 0 2.8882115543638065e-07
three O 0 0.0010591399623081088
prostate B-Disease 1 0.9999927282333374
cancer I-Disease 1 0.9997900128364563
cell O 0 0.0025145031977444887
lines O 0 0.0002420763048576191
. O 0 1.810196954465937e-05

We O 0 8.919674655771814e-06
screened O 0 0.00024690330610610545
80 O 0 0.0019897979218512774
prostate B-Disease 1 0.9998434782028198
tumors I-Disease 1 0.9994931221008301
by O 0 1.0091566764458548e-06
microsatellite O 0 0.0020124611910432577
analysis O 0 1.3162081131667946e-06
and O 0 9.103026741286158e-07
found O 0 1.41974123835098e-06
chromosome O 0 2.5936147721949965e-05
10q23 O 0 3.258341894252226e-05
to O 0 3.4101649504236775e-08
be O 0 7.773342858286014e-09
deleted O 0 3.0041354648346896e-07
in O 0 6.520455997360841e-08
23 O 0 3.3370431538060075e-06
cases O 0 7.3507862907717936e-06
. O 0 4.354532848083181e-06

We O 0 1.6961312212515622e-06
then O 0 2.0111478704620822e-07
proceeded O 0 1.4708992068790394e-07
with O 0 6.201328339727752e-09
sequence O 0 5.775534717145092e-09
analysis O 0 7.125904755156398e-09
of O 0 3.981488916338094e-09
the O 0 1.4560792571671755e-08
entire O 0 5.727744678551971e-07
PTEN O 0 0.0007531651062890887
/ O 0 2.367207343922928e-05
MMAC1 O 0 0.0006573933060280979
coding O 0 6.231236966414144e-06
region O 0 3.92676071214737e-07
and O 0 6.74799949251792e-08
tested O 0 4.060611900058575e-07
for O 0 1.9463470835034968e-08
homozygous O 0 1.1501583685458172e-06
deletion O 0 1.2073506923115929e-06
with O 0 1.6370819366784417e-07
new O 0 1.8810641222444247e-06
intragenic O 0 0.007180620450526476
markers O 0 1.59473238454666e-05
in O 0 2.5800849456913966e-08
these O 0 1.169218499796898e-08
23 O 0 7.648861810594099e-07
cases O 0 3.7450692502716265e-07
with O 0 1.196418224935769e-06
10q23 O 0 0.003948799800127745
loss O 0 0.0002737994655035436
of O 0 1.941951268236153e-06
heterozygosity O 0 0.004869773518294096
. O 0 1.425780646968633e-05

The O 0 1.609489117981866e-06
identification O 0 4.575637149173417e-07
of O 0 4.018355070911639e-08
the O 0 3.6373577927406586e-08
second O 0 4.6427533106907504e-07
mutational O 0 0.00016125002002809197
event O 0 1.2697335023403866e-06
in O 0 3.165270712202073e-08
10 O 0 5.2563901675739544e-08
( O 0 3.1018529966786446e-08
43 O 0 1.4537977222062182e-06
% O 0 1.1843688980661682e-06
) O 0 7.593242571601877e-06
tumors B-Disease 1 0.989922821521759
establishes O 0 0.00013012510316912085
PTEN O 0 0.029957033693790436
/ O 0 9.577671153238043e-05
MMAC1 O 0 0.013194194063544273
as O 0 8.193457290417427e-08
a O 0 2.2100607566244435e-08
main O 0 6.753226244882171e-08
inactivation O 0 5.099952613818459e-05
target O 0 7.777083510518423e-08
of O 0 2.4681781951585435e-08
10q O 0 2.9372931749094278e-05
loss O 0 3.4370408684480935e-05
in O 0 2.905502242356306e-06
sporadic B-Disease 0 0.27938807010650635
prostate I-Disease 1 0.9999920129776001
cancer I-Disease 1 0.9997637867927551
. O 0 9.732801117934287e-06
. O 0 9.483835128776263e-06

Risk O 0 0.005024886690080166
reversals O 0 0.0004999072407372296
in O 0 1.4369562677529757e-06
predictive O 0 3.941520844819024e-05
testing O 0 9.291722381021827e-05
for O 0 0.0006551834521815181
Huntington B-Disease 1 0.9999244213104248
disease I-Disease 1 0.9986491799354553
. O 0 4.404627179610543e-05

The O 0 1.0389568387836334e-06
first O 0 3.152290446450934e-07
predictive O 0 6.889863925607642e-06
testing O 0 1.5457684639841318e-05
for O 0 8.36054387036711e-05
Huntington B-Disease 1 0.9999823570251465
disease I-Disease 1 0.9967318773269653
( O 0 1.341822439826501e-06
HD B-Disease 0 0.00014373302110470831
) O 0 1.397899325183971e-07
was O 0 1.033457053267739e-07
based O 0 2.1644595449288317e-08
on O 0 1.57206851980618e-08
analysis O 0 1.2294436579907142e-08
of O 0 1.6569236649388586e-08
linked O 0 1.4310006008599885e-05
polymorphic O 0 3.846523759420961e-05
DNA O 0 3.3026328310370445e-05
markers O 0 3.074476626352407e-05
to O 0 3.767328493609057e-08
estimate O 0 2.3927771053422475e-07
the O 0 1.868965426865543e-08
likelihood O 0 6.378552370733814e-07
of O 0 2.9302794857244407e-08
inheriting O 0 3.213044328731485e-05
the O 0 1.7726196688272466e-07
mutation O 0 1.1590842632358545e-06
for O 0 5.592980869550956e-07
HD B-Disease 0 0.00026294609415344894
. O 0 7.516798632423161e-06

Limits O 0 1.7822161680669524e-05
to O 0 2.0884826312794758e-07
accuracy O 0 2.4857206426531775e-07
included O 0 1.841124230850255e-07
recombination O 0 1.7720088862915873e-06
between O 0 4.6494395888885265e-08
the O 0 4.1666019967578904e-08
DNA O 0 8.095195880741812e-06
markers O 0 9.7631254902808e-06
and O 0 2.225441591008348e-07
the O 0 8.816120811161454e-08
mutation O 0 3.2600798931525787e-06
, O 0 3.3379041042280733e-07
pedigree O 0 3.8930254959268495e-05
structure O 0 9.677893331172527e-07
, O 0 4.379021945055683e-08
and O 0 1.969425333925301e-08
whether O 0 1.836711227554133e-08
DNA O 0 4.786965632774809e-07
samples O 0 1.3837731671628717e-07
were O 0 2.8031140075768235e-08
available O 0 1.716570885434976e-08
from O 0 8.916062910202527e-08
family O 0 1.2924180055051693e-06
members O 0 2.146896576959989e-06
. O 0 2.710163926167297e-06

With O 0 2.2842043563287007e-06
direct O 0 7.455717536686279e-07
tests O 0 5.492261720974057e-07
for O 0 1.7661358597820254e-08
the O 0 3.4209399757401115e-08
HD B-Disease 0 8.932761556934565e-05
mutation O 0 2.9053526304778643e-06
, O 0 5.400938363209207e-08
we O 0 1.1802963051366078e-08
have O 0 1.731169696483903e-08
assessed O 0 5.445987198982039e-07
the O 0 3.435021822539852e-09
accuracy O 0 4.3141422878534286e-08
of O 0 1.4401699388599809e-08
results O 0 1.1788748111030145e-07
obtained O 0 5.5024646172796565e-08
by O 0 1.4414807125717743e-08
linkage O 0 5.612874360849673e-07
approaches O 0 2.112397794462595e-07
when O 0 1.1647760089772419e-07
requested O 0 2.3121849324070354e-07
to O 0 1.043180475335248e-08
do O 0 4.364486105856713e-09
so O 0 2.3547463978701444e-09
by O 0 3.925702429796729e-09
the O 0 2.0070279660444612e-08
test O 0 7.983163641256397e-07
individuals O 0 1.4116620832282933e-06
. O 0 4.013566922367318e-06

For O 0 4.093079041922465e-06
six O 0 2.936635610240046e-06
such O 0 3.368122065694479e-07
individuals O 0 8.369315764866769e-07
, O 0 2.427395315862668e-07
there O 0 4.175050349886078e-08
was O 0 9.284887028115918e-07
significant O 0 3.793163330101379e-07
disparity O 0 7.2831849138310645e-06
between O 0 1.3658295472396276e-07
the O 0 5.818820341119135e-07
tests O 0 1.2652715668082237e-05
. O 0 4.456237093108939e-06

Three O 0 3.759841774808592e-06
went O 0 2.3749471438350156e-06
from O 0 2.423296905362804e-07
a O 0 3.930016418962623e-07
decreased O 0 2.6495317797525786e-05
risk O 0 6.141613994259387e-06
to O 0 1.7059370804872742e-08
an O 0 5.453909324160122e-08
increased O 0 3.684719331431552e-06
risk O 0 7.527429715992184e-06
, O 0 3.965605444022913e-08
while O 0 4.838527090100797e-08
in O 0 4.58681048698395e-09
another O 0 1.5336055980696983e-08
three O 0 2.5859970165242885e-08
the O 0 5.196985171096458e-07
risk O 0 0.00029129424365237355
was O 0 1.6356727428501472e-05
decreased O 0 0.00013549816503655165
. O 0 3.9492897485615686e-06

Knowledge O 0 5.100909220345784e-06
of O 0 2.4736363002375583e-07
the O 0 2.7387815748625144e-07
potential O 0 8.9851764641935e-06
reasons O 0 1.82343015353581e-07
for O 0 1.0853693943602138e-08
these O 0 4.4998613724089864e-09
changes O 0 2.6476957515342292e-08
in O 0 1.0423152119187762e-08
results O 0 2.2481081884961895e-07
and O 0 2.1361366009386984e-07
impact O 0 2.270217578370648e-07
of O 0 1.4269089021468062e-08
these O 0 4.099454997685825e-08
risk O 0 1.21639195640455e-05
reversals O 0 2.6662659365683794e-05
on O 0 1.0337226967749302e-06
both O 0 1.9147596503898967e-06
patients O 0 3.3892789360834286e-05
and O 0 1.4358724342855567e-07
the O 0 1.4205387799393066e-07
counseling O 0 7.946695404825732e-06
team O 0 7.563044732705748e-07
can O 0 8.52332249223764e-09
assist O 0 1.0405280193026556e-07
in O 0 6.319948564481592e-09
the O 0 5.97398264190474e-09
development O 0 1.5138315490048626e-08
of O 0 9.21162079947635e-09
strategies O 0 5.555413054025848e-07
for O 0 7.678682578671214e-08
the O 0 1.5781408535531227e-07
prevention O 0 2.4677065084688365e-05
and O 0 5.55421593162464e-07
, O 0 2.2157909995712544e-07
where O 0 1.07227890566719e-07
necessary O 0 4.612184056895785e-08
, O 0 9.368740450099722e-08
management O 0 3.893632083418197e-07
of O 0 2.9388599998014797e-08
a O 0 8.36917251945124e-07
risk O 0 4.5582844904856756e-05
reversal O 0 4.916888428851962e-06
in O 0 1.719398845523301e-08
any O 0 8.14776157653796e-09
predictive O 0 7.973408742145693e-07
testing O 0 8.877641448634677e-07
program O 0 4.000377202828531e-07
. O 0 3.4194630416095606e-07
. O 0 2.250458010166767e-06

A O 0 2.2148151401779614e-05
novel O 0 1.270116899831919e-05
common O 0 2.048700480372645e-06
missense O 0 8.99823207873851e-05
mutation O 0 7.639307114004623e-06
G301C O 0 1.7346508684568107e-05
in O 0 1.0426910890259933e-08
the O 0 1.5511801620959886e-08
N O 0 4.753102530230535e-06
- O 0 0.0001465203968109563
acetylgalactosamine O 0 0.00032375205773860216
- O 0 6.026431583450176e-05
6 O 0 4.362359504739288e-06
- O 0 0.000983800389803946
sulfate O 0 0.0010794103145599365
sulfatase O 0 0.000704734236933291
gene O 0 9.400383760294062e-07
in O 0 2.500533184957021e-07
mucopolysaccharidosis B-Disease 0 0.000589426199439913
IVA I-Disease 0 0.028291938826441765
. O 0 1.1777306099247653e-05

Mucopolysaccharidosis B-Disease 1 0.7689483165740967
IVA I-Disease 1 0.9889074563980103
( O 0 0.0005058631068095565
MPS B-Disease 1 0.9790857434272766
IVA I-Disease 1 0.9997242093086243
) O 0 1.7106644008890726e-05
is O 0 1.029939994623419e-06
an O 0 1.162012449640315e-05
autosomal B-Disease 1 0.6970493197441101
recessive I-Disease 1 0.9895055890083313
lysosomal I-Disease 1 0.9999377727508545
storage I-Disease 1 0.9999266862869263
disorder I-Disease 1 0.9999032020568848
caused O 0 0.0026715088170021772
by O 0 9.274406693293713e-06
a O 0 0.0001655546948313713
genetic B-Disease 1 0.9582383036613464
defect I-Disease 1 0.9644199013710022
in O 0 5.353156780074642e-07
N O 0 5.3401727200252935e-05
- O 0 0.010781586170196533
acetylgalactosamine O 0 0.00612426083534956
- O 0 0.0002930837799794972
6 O 0 1.0920121894741897e-05
- O 0 0.009187554940581322
sulfate O 0 0.008725111372768879
sulfatase O 0 0.013490919023752213
( O 0 1.125941480495385e-06
GALNS O 0 0.0009413716616109014
) O 0 1.316991642852372e-06
. O 0 1.650525746299536e-06

In O 0 4.808351604879135e-06
previous O 0 4.152997462369967e-06
studies O 0 2.1515779735636897e-06
, O 0 1.8831035220046033e-07
we O 0 1.0976565434361873e-08
have O 0 1.2016371897516365e-08
found O 0 3.2296028962264245e-08
two O 0 1.79951378243004e-08
common O 0 4.162444611210958e-07
mutations O 0 2.6932621040032245e-06
in O 0 9.004246237509506e-08
Caucasians O 0 3.924440898117609e-05
and O 0 7.813442266524362e-07
Japanese O 0 1.2856523426307831e-05
, O 0 1.0587878023216035e-06
respectively O 0 9.611580935597885e-06
. O 0 4.160152911936166e-06

To O 0 3.0453143153863493e-06
characterize O 0 1.9602473912527785e-05
the O 0 4.022995483410341e-07
mutational O 0 9.883008897304535e-05
spectrum O 0 3.8963876249908935e-06
in O 0 1.970334473355706e-08
various O 0 9.04007002588969e-09
ethnic O 0 1.0371595493552377e-07
groups O 0 1.0879772105454322e-07
, O 0 1.1701091295890365e-07
mutations O 0 2.2635610719135002e-07
in O 0 7.886950648128277e-09
the O 0 2.4313681734611237e-08
GALNS O 0 0.0006346928421407938
gene O 0 2.7029318516724743e-07
in O 0 5.31009014537176e-08
Colombian O 0 0.00011883396655321121
MPS B-Disease 1 0.9688865542411804
IVA I-Disease 1 0.9999758005142212
patients O 0 0.08143601566553116
were O 0 2.271951188959065e-06
investigated O 0 4.163932680967264e-05
, O 0 3.5534583275875775e-07
and O 0 4.508325730512297e-07
genetic O 0 1.8415244085190352e-06
backgrounds O 0 2.5319106953247683e-06
were O 0 3.1848801995693066e-07
extensively O 0 4.839477583118423e-07
analyzed O 0 1.1790607459261082e-06
to O 0 1.3326102887845082e-08
identify O 0 1.1588792858674424e-07
racial O 0 2.1710073383474082e-07
origin O 0 1.1115473341760662e-07
, O 0 3.156835859385865e-08
based O 0 3.638023926555434e-08
on O 0 6.338421343343725e-08
mitochondrial O 0 8.848041943565477e-07
DNA O 0 2.885537696784013e-06
( O 0 8.235164727921074e-08
mtDNA O 0 7.716016057202069e-07
) O 0 2.0630746178085246e-07
lineages O 0 3.8459329516626894e-06
. O 0 3.1584072530677076e-06

Three O 0 6.518878308270359e-06
novel O 0 2.0056551875313744e-05
missense O 0 0.0018470592331141233
mutations O 0 0.00024895419483073056
never O 0 6.201843461894896e-06
identified O 0 4.351145435066428e-06
previously O 0 9.308852213507635e-07
in O 0 3.478631427356049e-08
other O 0 4.5601112219628703e-08
populations O 0 3.6837388961430406e-07
and O 0 1.1560798895970947e-07
found O 0 2.0469728667649179e-07
in O 0 1.1563705548667258e-08
16 O 0 5.915591216876237e-08
out O 0 1.1627180107609547e-08
of O 0 1.54855221978778e-08
19 O 0 2.1948239918856416e-06
Colombian O 0 8.300486661028117e-05
MPS B-Disease 0 0.13598178327083588
IVA I-Disease 1 0.9554968476295471
unrelated O 0 9.784398571355268e-05
alleles O 0 1.7823984990172903e-06
account O 0 5.097944040244329e-07
for O 0 4.319428512644663e-07
84 O 0 0.00010704126907512546
. O 0 4.5897322706878185e-06

2 O 0 1.6004059943952598e-05
% O 0 7.10117262769927e-07
of O 0 4.027701550057827e-08
the O 0 9.152604718565271e-08
alleles O 0 8.402441267207905e-07
in O 0 3.427052774895856e-08
this O 0 2.9108660370980033e-08
study O 0 1.2005305052298354e-06
. O 0 4.058481408719672e-06

The O 0 8.681575309310574e-06
G301C O 0 0.0005534909432753921
and O 0 2.1423356884042732e-06
S162F O 0 0.00016668281750753522
mutations O 0 3.920305516658118e-06
account O 0 3.5959627098236524e-07
for O 0 5.918610099797661e-07
68 O 0 0.00011704427743097767
. O 0 8.393083589908201e-06

4 O 0 3.11412732116878e-05
% O 0 3.692866812343709e-06
and O 0 1.2549743360068533e-06
10 O 0 2.0345028133306187e-06
. O 0 3.4519869132054737e-06

5 O 0 1.9688204702106304e-05
% O 0 1.8332221998207388e-06
of O 0 3.834371113953239e-07
mutations O 0 1.2370538570394274e-05
, O 0 2.645187748839817e-07
respectively O 0 1.3471177453538985e-06
, O 0 1.0664739846788507e-07
whereas O 0 1.0154958829389216e-07
the O 0 1.456640408292742e-08
remaining O 0 4.925072971673217e-07
F69V O 0 0.003077303059399128
is O 0 3.592294461896017e-08
limited O 0 2.68167177353007e-08
to O 0 6.790241258158858e-09
a O 0 4.2477111605876416e-08
single O 0 8.210006399167469e-07
allele O 0 1.0207045306742657e-05
. O 0 3.008395196957281e-06

The O 0 4.442819772521034e-06
skewed O 0 6.594604201382026e-05
prevalence O 0 0.0001679770793998614
of O 0 2.7848889772030816e-07
G301C O 0 5.5754186178091913e-05
in O 0 5.560512761348946e-08
only O 0 1.549952877155647e-08
Colombian O 0 3.654824467957951e-05
patients O 0 2.2229620299185626e-05
and O 0 1.275708569892231e-07
haplotype O 0 4.387906756164739e-06
analysis O 0 7.923019751387983e-08
by O 0 6.744048874907094e-08
restriction O 0 1.4950573756777885e-07
fragment O 0 1.3676690286956728e-06
length O 0 6.9433986027434e-07
polymorphisms O 0 1.451982188882539e-05
in O 0 3.450441710128871e-08
the O 0 6.836038579649539e-08
GALNS O 0 0.0022340859286487103
gene O 0 3.715482250754576e-07
suggest O 0 1.0981092657402769e-07
that O 0 1.662013282555108e-08
G301C O 0 1.1808132512669545e-05
originated O 0 1.4338390030843584e-07
from O 0 5.4107339053643955e-08
a O 0 3.0567125008928997e-07
common O 0 2.3211580355564365e-06
ancestor O 0 2.5073364668060094e-05
. O 0 8.675757271703333e-06

Investigation O 0 5.983809023746289e-05
of O 0 8.519301104570332e-07
the O 0 3.8830637549835956e-07
genetic O 0 6.2471895034832414e-06
background O 0 3.039347120648017e-07
by O 0 5.151056825525302e-08
means O 0 1.6342280417802613e-08
of O 0 6.360605375732575e-09
mtDNA O 0 3.159269681418664e-07
lineages O 0 5.495248274201003e-07
indicate O 0 2.493993065399991e-07
that O 0 6.950750197631805e-09
all O 0 1.1039174907523375e-08
our O 0 5.087303520667774e-07
patients O 0 7.38245626052958e-06
are O 0 2.189915271344489e-08
probably O 0 8.360781578176102e-08
of O 0 3.43878632236283e-08
native O 0 2.5847944016277324e-06
American O 0 5.671666076523252e-05
descent O 0 0.0031062031630426645

Low O 0 4.9416470574215055e-05
frequency O 0 2.078564648400061e-06
of O 0 5.877430453438137e-07
BRCA1 O 0 0.0002517329412512481
germline O 0 0.0009062193566933274
mutations O 0 1.1819895917142276e-05
in O 0 1.968528238194267e-07
45 O 0 2.032415068242699e-05
German O 1 0.918765664100647
breast B-Disease 1 0.9997686743736267
/ I-Disease 1 0.9998080134391785
ovarian I-Disease 1 0.9999967813491821
cancer I-Disease 1 0.9999232292175293
families O 0 0.0013904975494369864
. O 0 8.515895751770586e-05

In O 0 3.733875246325624e-06
this O 0 9.431996517150765e-08
study O 0 1.4134859327441518e-07
we O 0 2.3747737998291996e-08
investigated O 0 1.6387498362746555e-06
45 O 0 3.4328470519540133e-06
German O 0 0.35199952125549316
breast B-Disease 1 0.9998175501823425
/ I-Disease 1 0.9998904466629028
ovarian I-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9998815059661865
families O 0 7.016553354333155e-06
for O 0 1.6701759477655287e-06
germline O 0 0.02205563895404339
mutations O 0 1.3213545571488794e-05
in O 0 9.929146926879184e-08
the O 0 8.269207683042623e-07
BRCA1 O 0 0.00041548663284629583
gene O 0 5.397454970079707e-06
. O 0 3.202721472916892e-06

We O 0 3.820267011178657e-06
identified O 0 3.4602167033881415e-06
four O 0 7.609398267049983e-07
germline O 0 0.0017073488561436534
mutations O 0 1.6975172911770642e-05
in O 0 2.8149662512078066e-07
three O 0 1.8921429727924988e-05
breast B-Disease 1 0.9985237717628479
cancer I-Disease 0 0.4232877492904663
families O 0 3.6546678074955707e-06
and O 0 8.196315661734843e-07
in O 0 3.1895430652184587e-07
one O 0 3.371213824721053e-05
breast B-Disease 1 0.9997269511222839
- I-Disease 1 0.9999974966049194
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999878406524658
family O 0 4.979320146958344e-05
. O 0 9.529026812060692e-08
among O 0 1.3814684507451602e-07
these O 0 4.996345115415579e-09
were O 0 3.484727528757503e-08
one O 0 5.172302408595897e-08
frameshift O 0 0.0006118696182966232
mutation O 0 6.2061385506240185e-06
, O 0 1.1104687303031824e-07
one O 0 2.5391445390710032e-08
nonsense O 0 1.2856180546805263e-05
mutation O 0 1.7600006003704038e-06
, O 0 4.7709413308894e-08
one O 0 5.31284305438362e-09
novel O 0 9.933920352978021e-08
splice O 0 1.6059528206824325e-05
site O 0 2.578053909019218e-06
mutation O 0 1.7345711285088328e-06
, O 0 9.821334145954097e-08
and O 0 1.0762477842263252e-07
one O 0 3.1625765473108913e-07
missense O 0 0.0005037498194724321
mutation O 0 6.418572593247518e-05
. O 0 6.311973265837878e-06

The O 0 5.836121090396773e-06
missense O 0 0.0006892665987834334
mutation O 0 8.59629362821579e-05
was O 0 2.9795653517794563e-06
also O 0 2.235206579825899e-07
found O 0 2.285308227101268e-07
in O 0 7.267368573593558e-08
2 O 0 1.6686524304532213e-06
. O 0 2.370304173382465e-06

8 O 0 2.0250705347280018e-05
% O 0 6.859142445136968e-07
of O 0 6.584795642083918e-08
the O 0 3.434204742802649e-08
general O 0 3.197967828327819e-07
population O 0 3.246500668296903e-08
, O 0 5.2628106317342827e-08
suggesting O 0 5.738784238928929e-07
that O 0 8.869312395631823e-09
it O 0 1.6239463107581287e-08
is O 0 2.2384853082257905e-07
not O 0 2.761241148618865e-06
disease O 0 0.002772193867713213
associated O 0 1.7533533537061885e-05
. O 0 9.93718822428491e-06

The O 0 3.6157880458631553e-06
average O 0 3.644091702881269e-05
age O 0 2.024471905315295e-05
of O 0 1.2164197869424243e-05
disease O 0 0.1855398267507553
onset O 0 0.0003762863634619862
in O 0 3.4740637033792154e-07
those O 0 7.601477705065918e-07
families O 0 1.15455613922677e-05
harbouring O 1 0.6840235590934753
causative O 0 0.002171100350096822
mutations O 0 1.1295107469777577e-05
was O 0 6.011791242599429e-07
between O 0 2.9603322104776453e-07
32 O 0 3.356588786118664e-05
. O 0 1.0075804311782122e-05

3 O 0 8.70097428560257e-05
and O 0 2.0389359633554704e-05
37 O 0 0.00011700343748088926
. O 0 2.3544485884485766e-05

4 O 0 4.275925311958417e-05
years O 0 1.8000127965933643e-05
, O 0 4.80468884234142e-07
whereas O 0 3.3310894309579453e-07
the O 0 7.516273115015792e-08
family O 0 1.2174386938568205e-06
harbouring O 0 0.0006639882922172546
the O 0 1.2500169077611645e-07
missense O 0 9.47416338021867e-05
mutation O 0 6.197019501996692e-06
had O 0 2.9938189527456416e-07
an O 0 3.7231536964554834e-08
average O 0 1.7292790062128915e-06
age O 0 6.570211326106801e-07
of O 0 1.7679784036772617e-07
onset O 0 6.923575710970908e-05
of O 0 6.614754965994507e-07
51 O 0 0.00011633104440988973
. O 0 1.1321605597913731e-05

2 O 0 0.00021914180251769722
years O 0 0.00019785492622759193
. O 0 3.679728615679778e-05

These O 0 2.69806400865491e-06
findings O 0 6.976785243750783e-06
show O 0 5.1131843292751e-07
that O 0 8.646954086088954e-08
BRCA1 O 0 4.2772546294145286e-05
is O 0 6.110698080874499e-08
implicated O 0 2.413883885310497e-05
in O 0 2.2232814700373638e-08
a O 0 3.2637856861583714e-08
small O 0 1.7760952175649436e-07
fraction O 0 2.4219159513449995e-06
of O 0 1.6360798326786608e-05
breast B-Disease 1 0.9995865225791931
/ I-Disease 1 0.9999414682388306
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999746084213257
families O 0 4.834715946344659e-05
suggesting O 0 1.098643315344816e-05
the O 0 4.2644014541792785e-08
involvement O 0 2.4171326913347002e-06
of O 0 8.716784805073985e-08
another O 0 4.015511876787059e-06
susceptibility O 0 0.00048296735621988773
gene O 0 4.9920745368581265e-06
( O 0 2.1167627437534975e-06
s O 0 0.0006093090050853789
) O 0 1.3860457329428755e-05

Paternal O 0 0.10027530044317245
transmission O 0 0.11608222126960754
of O 0 0.15038393437862396
congenital B-Disease 1 0.9999157190322876
myotonic I-Disease 1 0.9999110698699951
dystrophy I-Disease 1 0.9999210834503174
. O 0 0.011471128091216087

We O 0 9.657843293098267e-06
report O 0 3.7330742088670377e-06
a O 0 7.846604148653569e-07
rare O 0 4.459842784854118e-06
case O 0 4.601333330356283e-06
of O 0 1.9726057871594094e-05
paternally O 1 0.9937839508056641
transmitted O 1 0.9953261613845825
congenital B-Disease 1 0.999984860420227
myotonic I-Disease 1 0.9999926090240479
dystrophy I-Disease 1 0.9999890327453613
( O 0 0.04607886075973511
DM B-Disease 1 0.9999319314956665
) O 0 0.00015455676475539804
. O 0 1.9958462871727534e-05

The O 0 7.5803195613843855e-06
proband O 0 0.0012527464423328638
is O 0 2.468701154612063e-07
a O 0 1.3452712721573334e-07
23 O 0 1.7158939726868994e-06
year O 0 1.480416926824546e-06
old O 0 0.000128318220959045
, O 0 4.480985444388352e-05
mentally B-Disease 1 0.999210000038147
retarded I-Disease 1 0.9996504783630371
male O 0 0.025031408295035362
who O 0 0.21444012224674225
suffers O 1 0.999636173248291
severe O 1 0.9992260932922363
muscular B-Disease 1 0.9998001456260681
weakness I-Disease 1 0.9944037199020386
. O 0 0.00012864400923717767

He O 0 4.802944022230804e-05
presented O 0 5.934771616011858e-05
with O 0 0.00012018128472846001
respiratory O 1 0.6994935870170593
and O 0 1.2029960089421365e-05
feeding O 0 0.00020028561993967742
difficulties O 0 0.0006647960399277508
at O 0 1.279663683817489e-05
birth O 0 7.327496132347733e-05
. O 0 8.02042632130906e-06

His O 0 5.828781650052406e-05
two O 0 4.777517824550159e-05
sibs O 1 0.9860674738883972
suffer O 0 0.17884069681167603
from O 0 5.337830225471407e-05
childhood O 0 0.024677127599716187
onset O 1 0.6106567978858948
DM B-Disease 1 0.9995637536048889
. O 0 0.00014298730820883065

Their O 0 5.5263362810364924e-06
late O 0 1.715370854071807e-05
father O 0 2.2796888515586033e-05
had O 0 2.946881920706801e-07
the O 0 1.8202815255108362e-08
adult O 0 2.3237174673340633e-07
type O 0 4.2115698306588456e-07
of O 0 5.684878487954848e-07
DM B-Disease 1 0.9999308586120605
, O 0 1.6883684565982549e-06
with O 0 5.346901730263198e-07
onset O 0 2.6122967028641142e-05
around O 0 1.0249022608377345e-07
30 O 0 9.069361794900033e-07
years O 0 1.7785305317374878e-06
. O 0 2.1074688447697554e-06

Only O 0 8.740672683416051e-07
six O 0 1.1128216783617972e-06
other O 0 1.206624915539578e-07
cases O 0 3.41823408689379e-07
of O 0 8.155367936524271e-08
paternal O 0 9.826352470554411e-05
transmission O 0 9.787383896764368e-05
of O 0 0.0007028020336292684
congenital B-Disease 1 0.9999898672103882
DM I-Disease 1 0.9999929666519165
have O 0 0.00011968779290327802
been O 0 1.1752431419154163e-05
reported O 0 7.850350812077522e-05
recently O 0 0.0001332554966211319
. O 0 6.617349754378665e-06

We O 0 2.7841213068313664e-06
review O 0 1.8226633073936682e-06
the O 0 1.2144093375354714e-07
sex O 0 1.854780180110538e-06
related O 0 6.660269264102681e-06
effects O 0 8.665329914947506e-06
on O 0 1.3832153626935906e-06
transmission O 0 0.00019035523291677237
of O 0 0.0005182545864954591
congenital B-Disease 1 0.9999037981033325
DM I-Disease 1 0.9999079704284668
. O 0 0.0007980935624800622

Decreased O 0 0.0030444117728620768
fertility O 0 0.00039594530244357884
of O 0 5.995994456498011e-07
males O 0 2.9596224067063304e-06
with O 0 7.873957770243578e-07
adult O 0 4.611881377059035e-05
onset O 0 0.1799081265926361
DM B-Disease 1 0.999972939491272
and O 0 9.396293535246514e-06
contraction O 0 8.745094419282395e-06
of O 0 2.3998081744025512e-08
the O 0 4.2463991434260606e-08
repeat O 0 1.6549422525713453e-06
upon O 0 1.2772449053954915e-07
male O 0 8.402609523727733e-07
transmission O 0 3.5701845035873703e-07
contribute O 0 8.208489532535168e-08
to O 0 3.498191514239579e-09
the O 0 8.04092703532433e-09
almost O 0 4.428055433436384e-08
absent O 0 2.302743041582289e-06
occurrence O 0 3.6696991401186096e-07
of O 0 1.1445971637158436e-07
paternal O 0 0.0003403981972951442
transmission O 0 0.00032807342358864844
of O 0 0.0008655937272123992
congenital B-Disease 1 0.9999045133590698
DM I-Disease 1 0.9999247789382935
. O 0 0.0010240591363981366

Also O 0 1.0489492524357047e-05
the O 0 3.0613216495112283e-07
fathers O 0 1.2754109093293664e-06
of O 0 3.079827948226921e-08
the O 0 1.2413411809575337e-07
reported O 0 3.42491184710525e-05
congenitally O 0 0.029630456119775772
affected O 0 4.412140242493479e-06
children O 0 1.2494368775151088e-06
showed O 0 4.0561599234933965e-06
, O 0 2.9145327928858933e-08
on O 0 2.5312917983910665e-08
average O 0 5.243853138381382e-07
, O 0 1.0576055586852817e-07
shorter O 0 2.078895704471506e-06
CTG O 0 8.76699632499367e-05
repeat O 0 1.690408225840656e-06
lengths O 0 5.224921551416628e-06
and O 0 3.0548270046892867e-07
hence O 0 1.469274593546288e-06
less O 0 4.493329925026046e-06
severe O 0 0.2638620436191559
clinical O 0 0.0828622356057167
symptoms O 0 0.002917742822319269
than O 0 8.341746848827825e-08
the O 0 3.002141966135241e-07
mothers O 0 2.4335073248948902e-05
of O 0 3.7084410564602877e-07
children O 0 8.163180609699339e-05
with O 0 0.005640865303575993
congenital B-Disease 1 0.999940037727356
DM I-Disease 1 0.9999210834503174
. O 0 0.0005881290417164564

We O 0 5.727936695620883e-06
conclude O 0 7.422271210089093e-06
that O 0 2.0451503246476932e-07
paternal O 0 3.02055268548429e-05
transmission O 0 5.647724901791662e-05
of O 0 0.0003110152611043304
congenital B-Disease 1 0.9999943971633911
DM I-Disease 1 0.9999972581863403
is O 0 6.217623740667477e-05
rare O 0 4.420828918227926e-05
and O 0 1.0318020713384612e-06
preferentially O 0 1.781293576641474e-05
occurs O 0 1.4780735568820091e-07
with O 0 2.2360060825121764e-07
onset O 0 3.7844187318114564e-05
of O 0 6.835640533608967e-07
DM B-Disease 1 0.9997838139533997
past O 0 1.9463566331978654e-06
30 O 0 9.901400517264847e-07
years O 0 3.227959268770064e-07
in O 0 1.4591319263956848e-08
the O 0 4.4585139136188445e-08
father O 0 2.8654585548792966e-06
. O 0 2.788585788948694e-07
. O 0 1.3385658803599654e-06

The O 0 1.8359258319833316e-05
RB1 O 0 0.10272455215454102
gene O 0 2.277402745676227e-05
mutation O 0 7.465710496035172e-06
in O 0 1.4533829073570814e-07
a O 0 7.334921292567742e-07
child O 0 0.00010628890595398843
with O 0 0.00020730473625008017
ectopic B-Disease 1 0.9993211030960083
intracranial I-Disease 1 0.9998770952224731
retinoblastoma I-Disease 1 0.99016934633255
. O 0 0.00022150928271003067

The O 0 1.9430628526606597e-05
RB1 O 0 0.05021795257925987
gene O 0 3.07278533000499e-05
mutation O 0 2.504778967704624e-05
was O 0 2.223944647994358e-06
investigated O 0 1.0172549082199112e-05
in O 0 6.691898590815981e-08
a O 0 2.356338910658451e-07
child O 0 2.2145975890452974e-05
with O 0 1.49074421642581e-05
ectopic B-Disease 1 0.9958123564720154
intracranial I-Disease 1 0.9995255470275879
retinoblastoma I-Disease 0 0.0073926071636378765
using O 0 4.564427626974066e-07
DNA O 0 4.8792485358717386e-06
obtained O 0 2.827895002610603e-07
from O 0 3.7783383532996595e-08
both O 0 3.0006443552110795e-08
the O 0 2.16549452147774e-07
pineal B-Disease 0 0.0007836437434889376
and I-Disease 0 7.256126264110208e-05
retinal I-Disease 1 0.97315514087677
tumours I-Disease 1 0.9995629191398621
of O 0 1.0260107501380844e-06
the O 0 7.795455530867912e-06
patient O 0 0.0006779606337659061
. O 0 1.2650568351091351e-05

A O 0 1.9421979231992736e-05
nonsense O 0 7.599854870932177e-05
mutation O 0 7.895539965829812e-06
in O 0 1.1384062759134395e-07
exon O 0 2.0546607629512437e-05
17 O 0 9.491674859418708e-07
( O 0 1.9554262209453555e-08
codon O 0 1.5494096317070216e-07
556 O 0 1.3039118584856624e-06
) O 0 5.845955719507856e-09
of O 0 3.791996050495072e-09
the O 0 3.6778970979867154e-08
RB1 O 0 0.004920147825032473
gene O 0 6.642962375735806e-07
was O 0 3.221298356947955e-07
found O 0 6.403309527058809e-08
to O 0 8.352378344511635e-09
be O 0 6.766904370181237e-09
present O 0 3.254895730719909e-08
homozygously O 0 4.179415191174485e-05
in O 0 3.548330695934965e-08
both O 0 5.979558892477144e-08
the O 0 7.538259865214059e-07
retinal B-Disease 0 0.007984202355146408
and I-Disease 0 1.021330535877496e-05
the I-Disease 0 3.9219637983478606e-05
pineal I-Disease 1 0.7299225330352783
tumours I-Disease 1 0.9996328353881836
. O 0 6.256606866372749e-05

The O 0 3.9723390727886e-06
same O 0 1.0591554655547952e-06
mutation O 0 7.605678547406569e-06
was O 0 6.572047368536005e-07
present O 0 1.5447665191459237e-07
heterozygously O 0 9.258501086151227e-05
in O 0 1.910099811652799e-08
the O 0 1.0384517246109226e-08
DNA O 0 6.695383945043432e-07
from O 0 4.263653252678523e-08
the O 0 4.855296609207471e-08
constitutional O 0 3.7716176848334726e-06
cells O 0 1.1908313126696157e-06
of O 0 4.088320082473729e-08
the O 0 4.3388325821069884e-07
patient O 0 3.107777956756763e-05
, O 0 2.425734066946461e-07
proving O 0 7.497975730075268e-06
it O 0 5.554849469291412e-09
to O 0 7.613156327579418e-09
be O 0 6.619763404103196e-09
of O 0 7.034806515093806e-08
germline O 0 0.0007951739244163036
origin O 0 5.469850293593481e-06
. O 0 5.922267519054003e-06

The O 0 3.488044058030937e-06
initial O 0 1.9536109903128818e-05
mutation O 0 1.995619822992012e-05
was O 0 1.4184636256686645e-06
shown O 0 2.0966767522168084e-07
to O 0 9.64274615711247e-09
have O 0 1.8957342362568852e-08
occurred O 0 4.800176967023617e-08
in O 0 2.3126496273562225e-08
the O 0 3.286129697244178e-07
paternally O 0 0.0011668941006064415
derived O 0 1.1142788025608752e-05
RB1 O 0 0.006819922477006912
allele O 0 2.086769563902635e-05
. O 0 4.973394879925763e-06

The O 0 5.7072761592280585e-06
mutation O 0 4.1327944927616045e-05
is O 0 1.1122345000558198e-07
in O 0 2.0809608258787193e-08
an O 0 2.0710892556508043e-08
area O 0 3.3707308944030956e-08
of O 0 8.130436768283289e-09
the O 0 1.4041383167295862e-08
gene O 0 3.469295606350897e-08
that O 0 1.3160696976655117e-09
encodes O 0 8.011411978259275e-09
the O 0 3.6397782565700254e-09
protein O 0 2.1823678864052454e-08
- O 0 8.188946594600566e-06
binding O 0 1.0586768439679872e-06
region O 0 2.3320647812852258e-07
known O 0 1.3441953683468455e-07
as O 0 1.084450573785034e-08
the O 0 2.5941087500314097e-08
pocket O 0 0.00021626836678478867
region O 0 6.561301120200369e-07
and O 0 2.48143578573945e-07
has O 0 1.540513494546758e-07
been O 0 1.6674721337039955e-07
detected O 0 1.093282321562583e-06
in O 0 1.0620524015791943e-08
other O 0 2.160285816898977e-08
cases O 0 6.792303111069486e-07
of O 0 9.18054070098151e-07
retinoblastoma B-Disease 0 0.08334745466709137
. O 0 2.4479886633343995e-06
. O 0 4.719065600511385e-06

Low O 0 0.00022487473324872553
levels O 0 3.7517149849009e-06
of O 0 1.5393325725199247e-07
beta O 0 2.417443965896382e-06
hexosaminidase O 0 8.665469067636877e-05
A O 0 2.4170444135052094e-07
in O 0 1.5832964095352509e-07
healthy O 0 4.466823611437576e-06
individuals O 0 4.916063289783779e-07
with O 0 2.795277032419108e-05
apparent O 1 0.5923426747322083
deficiency O 1 0.696148693561554
of O 0 2.8104358307246e-07
this O 0 5.127834015183907e-07
enzyme O 0 0.00010244901932310313
. O 0 7.491685209970456e-06

Appreciable O 0 0.0027884473092854023
beta O 0 0.00033299357164651155
hexosaminidase O 0 0.0038222442381083965
A O 0 4.054953024024144e-06
( O 0 2.1192441579387378e-07
hex O 0 2.0694404156529345e-05
A O 0 1.8424556458285224e-07
) O 0 4.1613123613615244e-08
activity O 0 4.4579952174217397e-08
has O 0 1.3666342724150127e-08
been O 0 2.05964560962002e-08
detected O 0 3.7007109199294064e-07
in O 0 5.8631776767015253e-08
cultured O 0 0.000334681011736393
skin O 0 0.0016126688569784164
fibroblasts O 0 0.00045531505020335317
and O 0 0.0013226551236584783
melanoma B-Disease 1 0.9999463558197021
tissue O 0 0.025553401559591293
from O 0 5.544887244468555e-06
healthy O 0 3.277013820479624e-05
individuals O 0 1.0279284197167726e-06
previously O 0 1.5088990039657801e-05
reported O 0 2.004200177907478e-05
as O 0 2.0888082872261293e-06
having O 0 0.00019560064538381994
deficiency B-Disease 0 0.031326763331890106
of I-Disease 0 2.8992467093758023e-08
hex I-Disease 0 5.247367516858503e-05
A I-Disease 0 1.4350634103266202e-07
activity O 0 9.33265980052056e-08
indistinguishable O 0 4.393554604575911e-07
from O 0 1.8391125067296343e-08
that O 0 8.304991361285374e-09
of O 0 1.4987776353336812e-07
patients O 0 0.00012452161172404885
with O 0 0.00015386799350380898
Tay B-Disease 1 0.9999946355819702
- I-Disease 1 0.9999828338623047
Sachs I-Disease 1 0.9999929666519165
disease I-Disease 1 0.9125517010688782
( O 0 6.935787951078964e-06
TSD B-Disease 0 0.07715623825788498
) O 0 3.5555842714529717e-06
. O 0 2.378113549639238e-06

Identification O 0 2.1247284166747704e-05
and O 0 1.4080560504226014e-06
quantitation O 0 0.00018642596842255443
of O 0 1.7830330989454524e-07
hex O 0 9.810258779907599e-05
A O 0 3.950206064473605e-07
, O 0 1.0611335454768778e-07
amounting O 0 8.770490467213676e-07
to O 0 5.7846765599833816e-08
3 O 0 1.1117059557363973e-06
. O 0 2.1152493445697473e-06

5 O 0 5.1045994041487575e-05
% O 0 9.256689736503176e-06
- O 0 0.0008677205187268555
6 O 0 5.791570583824068e-05
. O 0 8.401933882851154e-06

9 O 0 1.4131279385765083e-05
% O 0 4.603202228281589e-07
of O 0 3.425236272391885e-08
total O 0 1.6297370564188896e-07
beta O 0 1.0556331062616664e-06
hexosaminidase O 0 5.4794869356555864e-05
activity O 0 1.0829420915570154e-07
, O 0 2.1862176069475936e-08
has O 0 1.5418471832617797e-08
been O 0 5.477770237405366e-09
obtained O 0 1.0063061495202419e-08
by O 0 1.6273384417786474e-08
cellulose O 0 3.664876567199826e-05
acetate O 0 4.645037915906869e-05
gel O 0 0.00011437272769398987
electrophoresis O 0 1.8371219994151033e-05
, O 0 9.790398536324574e-08
DEAE O 0 3.428470154176466e-05
- O 0 1.2156554475950543e-05
cellulose O 0 2.0938017769367434e-05
ion O 0 7.338976502069272e-06
- O 0 3.164300142088905e-05
exchange O 0 1.0047307341665146e-06
chromatography O 0 1.5955827620928176e-05
, O 0 1.3592233472081716e-07
radial O 0 1.951707963598892e-05
immunodiffusion O 0 0.0002887991431634873
, O 0 4.0505443621441373e-07
and O 0 1.0281285085511627e-06
radioimmunoassay O 0 0.001629988313652575
. O 0 4.730122327600839e-06

Previous O 0 9.09547452465631e-05
family O 0 4.895964957540855e-05
studies O 0 3.435198550505447e-06
suggested O 0 4.357818852440687e-06
that O 0 2.003658217120119e-08
these O 0 9.364966579994416e-09
individuals O 0 3.036432474345929e-07
may O 0 7.739334364487149e-07
be O 0 2.4701279244254692e-08
compound O 0 4.819263494937331e-07
heterozygotes O 0 1.320739829679951e-05
for O 0 5.333538055651843e-08
the O 0 7.806450241787388e-08
common O 0 5.172105375095271e-07
mutant O 0 3.366806049598381e-05
TSD B-Disease 0 0.07761209458112717
gene O 0 7.273039273059112e-07
and O 0 1.2520797554316232e-07
a O 0 3.5680909604707267e-07
rare O 0 2.9579887268482707e-06
( O 0 1.2468011334476614e-07
allelic O 0 4.106187407160178e-05
) O 0 5.366113100535586e-07
mutant O 0 2.5421417376492172e-05
gene O 0 2.8824904347857228e-06
. O 0 2.455280991853215e-06

Thus O 0 2.0173221855657175e-05
, O 0 5.186354883335298e-07
the O 0 7.583811623135261e-08
postulated O 0 4.127789907215629e-06
rate O 0 7.602630489600415e-07
mutant O 0 1.4241039025364444e-05
gene O 0 3.963579331411893e-07
appears O 0 1.1075326966647481e-07
to O 0 3.6471026199080825e-09
code O 0 3.726640329659858e-09
for O 0 5.050325047051274e-09
the O 0 8.018199437742624e-09
expression O 0 2.3553406336418448e-08
of O 0 1.2953009331795329e-08
low O 0 1.0388984037490445e-06
amounts O 0 1.920775645203321e-07
of O 0 5.972344041538236e-08
hex O 0 0.00013147083518560976
A O 0 3.2270525025523966e-06
. O 0 4.074354365002364e-06

Heterozygotes O 0 0.004857624880969524
for O 0 5.3776384447701275e-06
the O 0 1.537772845949803e-06
rare O 0 2.2981508664088324e-05
mutant O 0 0.00012236252950970083
may O 0 2.181279114665813e-06
be O 0 1.2504300705984406e-08
indistinguishable O 0 6.51323432521167e-07
from O 0 1.1830735502371681e-07
heterozygotes O 0 1.5034180250950158e-05
for O 0 8.936373774304229e-08
the O 0 3.930087473236199e-07
common O 0 8.404288564634044e-06
TSD B-Disease 0 0.14830602705478668
mutant O 0 0.00034746716846711934
. O 0 1.00843599284417e-05

However O 0 1.4454349184234161e-05
, O 0 5.961924784969597e-07
direct O 0 1.5370970629646763e-07
visualization O 0 6.4251375988533255e-06
and O 0 3.145704852158815e-07
quantitation O 0 8.360495121451095e-05
of O 0 5.005141545666447e-08
hex O 0 3.418062988203019e-05
A O 0 7.863866358093219e-08
by O 0 1.518687398061047e-08
the O 0 7.519481926010485e-09
methods O 0 1.6538741931526602e-07
described O 0 4.806513061339501e-06
may O 0 8.82821780123777e-07
prevent O 0 9.457429541726015e-07
false O 0 9.612759868105059e-07
- O 0 0.0009366597514599562
positive O 0 3.194113560311962e-06
prenatal O 0 0.0002679213066585362
diagnosis O 0 4.02254045184236e-05
of O 0 3.029898039130785e-07
TSD B-Disease 0 0.30410853028297424
in O 0 3.1457757359021343e-06
fetuses O 0 0.0015147547237575054
having O 0 3.78737610162716e-07
the O 0 4.8015323272920796e-08
incomplete O 0 1.1667694707284681e-05
hex B-Disease 0 0.06389783322811127
A I-Disease 0 0.0002481614938005805
deficiency I-Disease 0 0.03447430580854416
of O 0 4.45855654618299e-08
the O 0 2.387167796769063e-07
type O 0 5.130611043568933e-06
described O 0 4.59879765912774e-06
in O 0 3.255876634966626e-08
the O 0 8.476715862570927e-08
four O 0 1.8094626739184605e-06
healthy O 0 0.00017759011825546622
individuals O 0 3.1295807275455445e-05

The O 0 4.374830314191058e-05
tumor B-Disease 0 0.03667101263999939
suppressor O 0 0.00025578297208994627
gene O 0 7.496996204281459e-06
Smad4 O 0 0.0005044094868935645
/ O 0 5.521776620298624e-05
Dpc4 O 0 0.0019618025980889797
is O 0 7.081250430474029e-08
required O 0 1.848819763949905e-08
for O 0 2.4173527179982557e-08
gastrulation O 0 0.00011414392793085426
and O 0 6.754810897291463e-07
later O 0 3.8929042034396844e-07
for O 0 1.0870728317513567e-07
anterior O 0 0.0001846660306910053
development O 0 1.0356315272019856e-07
of O 0 4.669880837582241e-08
the O 0 3.9557437503390247e-07
mouse O 0 0.00010342361929360777
embryo O 0 0.00010887188545893878
. O 0 1.1055842151108664e-05

Mutations O 0 0.0005758312763646245
in O 0 5.847965667271637e-07
the O 0 5.907540412408707e-07
SMAD4 O 0 0.02139499969780445
/ O 0 0.0019496441818773746
DPC4 O 1 0.9362432956695557
tumor B-Disease 0 0.21805965900421143
suppressor O 0 0.00017826737894210964
gene O 0 7.630763434463006e-07
, O 0 5.2517904691740114e-08
a O 0 2.4443599144774453e-08
key O 0 3.3489556017229916e-07
signal O 0 1.1653594356175745e-07
transducer O 0 6.242835752345854e-06
in O 0 2.6520526219542262e-08
most O 0 2.8799018281233657e-08
TGFbeta O 0 0.00011932096822420135
- O 0 0.0013272212818264961
related O 0 1.2596694432431832e-05
pathways O 0 2.3937113837746438e-06
, O 0 1.0947695017193837e-07
are O 0 3.975721529769771e-09
involved O 0 6.199415025776034e-08
in O 0 1.3591865410944592e-08
50 O 0 3.55118885408956e-07
% O 0 1.1736366332115722e-06
of O 0 5.8645990065997466e-05
pancreatic B-Disease 1 0.9999057054519653
cancers I-Disease 1 0.9896355271339417
. O 0 6.102310726419091e-05

Homozygous O 0 0.0022340784780681133
Smad4 O 0 0.04471016302704811
mutant O 0 0.003521340899169445
mice O 0 0.002117953496053815
die O 0 0.00018407641618978232
before O 0 5.005018124393246e-07
day O 0 5.748731268795382e-07
7 O 0 3.0496532872348325e-06
. O 0 1.951596004801104e-06

5 O 0 8.999124838737771e-05
of O 0 3.072964318562299e-05
embryogenesis O 0 0.0018857525428757071
. O 0 9.14776828722097e-05

Mutant O 0 0.0005900025134906173
embryos O 0 0.0002121653378708288
have O 0 1.9618501028162427e-06
reduced O 0 5.437593245005701e-06
size O 0 4.099227680853801e-06
, O 0 3.8758713571951375e-07
fail O 0 3.626400030043442e-06
to O 0 2.386024533507225e-08
gastrulate O 0 4.451813583727926e-05
or O 0 5.2143409590144074e-08
express O 0 2.0285304458411701e-07
a O 0 6.067991620284374e-08
mesodermal O 0 0.00027998400037176907
marker O 0 3.223961903131567e-05
, O 0 1.3836914547482593e-07
and O 0 1.5697366961830994e-07
show O 0 8.136922247103939e-07
abnormal O 0 2.8238868253538385e-05
visceral O 0 8.98028229130432e-05
endoderm O 0 0.0023569378536194563
development O 0 1.3440595466818195e-05
. O 0 7.200489562819712e-06

Growth B-Disease 1 0.9935733675956726
retardation I-Disease 1 0.9996428489685059
of O 0 3.3637418255239027e-06
the O 0 2.530578285586671e-06
Smad4 O 0 0.044605135917663574
- O 0 0.24557755887508392
deficient O 0 0.0010166042484343052
embryos O 0 8.170062528733979e-07
results O 0 7.523544809373561e-08
from O 0 6.681415243292577e-08
reduced O 0 2.3620316369488137e-06
cell O 0 3.216293771401979e-05
proliferation O 0 5.190779484109953e-05
rather O 0 6.368000526890683e-08
than O 0 6.704674149204948e-08
increased O 0 2.016080543398857e-06
apoptosis O 0 2.5083098080358468e-05
. O 0 3.8377697819669265e-06

Aggregation O 0 3.6528737837215886e-05
of O 0 1.3739230553255766e-06
mutant O 0 6.741496326867491e-05
Smad4 O 0 0.001122855581343174
ES O 0 0.00011643113975878805
cells O 0 4.61322269984521e-06
with O 0 5.152255511120529e-08
wild O 0 8.006722964637447e-07
- O 0 0.0001594861678313464
type O 0 3.3873027405206813e-06
tetraploid O 0 0.00018951529636979103
morulae O 0 0.0033989164512604475
rescues O 0 0.00020092214981559664
the O 0 2.018968643824337e-06
gastrulation B-Disease 0 0.016857419162988663
defect I-Disease 0 0.016599062830209732
. O 0 1.2306621101743076e-05

These O 0 1.6433511973446002e-06
results O 0 3.9978090171644e-06
indicate O 0 2.2052156509744236e-06
that O 0 8.753138303063679e-08
Smad4 O 0 0.0003178734623361379
is O 0 1.8702354509514407e-07
initially O 0 4.5009795712758205e-07
required O 0 8.91561580118605e-09
for O 0 4.261325958765383e-09
the O 0 4.461089275764607e-09
differentiation O 0 6.082151315922601e-08
of O 0 9.036450698829412e-09
the O 0 4.078148663211323e-08
visceral O 0 3.001257027790416e-05
endoderm O 0 0.0007431123522110283
and O 0 3.3810209743023734e-07
that O 0 1.2057215670324695e-08
the O 0 5.1255359068136386e-08
gastrulation B-Disease 0 0.0027476612012833357
defect I-Disease 0 0.0014851344749331474
in O 0 5.395790481088625e-08
the O 0 2.830293794886529e-07
epiblast O 0 0.051001548767089844
is O 0 1.2206015753690735e-07
secondary O 0 4.4010943156536086e-07
and O 0 3.6927008295606356e-07
non O 0 2.0757061065523885e-05
- O 0 0.003490024944767356
cell O 0 0.00011154900130350143
autonomous O 0 4.863861249759793e-06
. O 0 5.379336016630987e-06

Rescued O 0 0.009358618408441544
embryos O 0 0.0030934426467865705
show O 0 0.0011558711994439363
severe O 1 0.8603206276893616
anterior O 1 0.8247811198234558
truncations O 1 0.5509034991264343
, O 0 1.9967883417848498e-05
indicating O 0 8.620656444691122e-06
a O 0 6.766067883745563e-08
second O 0 2.2741201632925367e-07
important O 0 4.0638770570922134e-08
role O 0 1.2435769747298764e-07
for O 0 1.0076048795326642e-07
Smad4 O 0 0.0004888243856839836
in O 0 7.829009405213583e-07
anterior O 0 0.0025369133800268173
patterning O 0 0.0014332870487123728
during O 0 2.822669739543926e-05
embryogenesis O 0 0.0006799487746320665
. O 0 1.752814932842739e-05

Prevalence O 0 0.0021965140476822853
of O 0 3.6487092529569054e-06
p16 O 0 0.00019660996622405946
and O 0 4.5851784307160415e-06
CDK4 O 0 0.010949491523206234
germline O 0 0.019879009574651718
mutations O 0 4.797638757736422e-05
in O 0 5.104589604343346e-07
48 O 0 0.00017591725918464363
melanoma B-Disease 1 0.9997280240058899
- O 1 0.9316924214363098
prone O 0 0.381546288728714
families O 0 2.143731944670435e-05
in O 0 1.1924347518288414e-06
France O 0 3.593058863771148e-05
. O 0 7.168834144977154e-06

The O 0 5.228446389082819e-05
French O 0 0.02000335417687893
Familial B-Disease 1 0.9921824336051941
Melanoma I-Disease 1 0.999728262424469
Study O 0 0.00020230916561558843
Group O 0 0.0001555804192321375
. O 0 1.2450261237972882e-05

Germline O 1 0.543954610824585
mutations O 0 0.001021026517264545
in O 0 4.990195066056913e-07
the O 0 2.6378268103144364e-07
p16 O 0 2.0128100004512817e-05
and O 0 4.835491154153715e-07
CDK4 O 0 0.0021375135984271765
genes O 0 1.6287797279801453e-06
have O 0 4.588352808809759e-08
been O 0 4.834191358327189e-08
reported O 0 1.0599703870184385e-07
in O 0 4.1021435137622575e-09
a O 0 1.3038923718511342e-08
subset O 0 3.923908309388935e-07
of O 0 2.166249714719015e-06
melanoma B-Disease 1 0.9939164519309998
pedigrees O 0 0.0009444178431294858
, O 0 1.0472183475940255e-06
but O 0 5.592443130808533e-08
their O 0 1.7271337071633752e-07
prevalence O 0 5.488037641043775e-05
is O 0 6.992839729491607e-08
not O 0 2.7486871445603356e-08
well O 0 2.5977882955885434e-07
known O 0 3.6981955418013968e-06
. O 0 4.531690592557425e-06

We O 0 2.2718340915162116e-06
searched O 0 8.759058800933417e-06
for O 0 7.534617196824911e-08
such O 0 4.365345773749141e-08
germline O 0 0.0002981926081702113
mutations O 0 2.408255795671721e-06
in O 0 4.5892285527315835e-08
48 O 0 6.969590685912408e-06
French O 0 0.011607828550040722
melanoma B-Disease 1 0.9998570680618286
- O 1 0.90989089012146
prone O 0 0.16545625030994415
families O 0 3.6101025671086973e-06
selected O 0 2.7073537012256566e-07
according O 0 3.2607491817771006e-08
to O 0 3.6036640338465986e-09
two O 0 1.9990126887137194e-08
major O 0 5.72800672671292e-07
criteria O 0 2.4670114839864254e-07
families O 0 1.910034796992477e-07
with O 0 4.7869928465615885e-08
at O 0 1.5954952914398746e-07
least O 0 1.1887981266056613e-08
three O 0 6.763242765828181e-08
affected O 0 5.460638021759223e-07
members O 0 7.70653088011386e-08
( O 0 2.7023590476460413e-08
n O 0 4.8791926019475795e-06
= O 0 4.877163974015275e-06
20 O 0 1.778651324002567e-07
) O 0 2.6558998555969993e-08
or O 0 2.3302188623119946e-08
families O 0 8.000634466043266e-08
with O 0 2.274052235406998e-08
two O 0 8.668818196611028e-08
affected O 0 8.826937687445024e-07
members O 0 1.5474810766136216e-07
, O 0 3.323932773469096e-08
one O 0 3.354163613522587e-09
of O 0 7.560208459267415e-09
them O 0 3.262266901060684e-08
affected O 0 1.8370656107435934e-07
before O 0 5.303875028062066e-08
the O 0 1.0948276063516005e-08
age O 0 7.079926689357308e-08
of O 0 9.672974421448544e-09
50 O 0 1.0881203849066878e-07
( O 0 1.8472830376481397e-08
n O 0 1.343861072200525e-06
= O 0 6.794156888645375e-06
28 O 0 8.630680667920387e-07
) O 0 2.2529066612264614e-08
, O 0 8.274397167440384e-09
and O 0 8.683128882580604e-09
one O 0 1.6675191005788292e-08
additional O 0 8.184599664673442e-07
minor O 0 0.0001551617169752717
criterion O 0 0.0002564603346399963
. O 0 1.4323961295303889e-05

Sixteen O 0 2.6137469831155613e-05
different O 0 1.3763492461293936e-06
p16 O 0 0.00010628768359310925
germline O 0 0.0054476079531013966
mutations O 0 7.043545338092372e-05
were O 0 8.078799282884574e-07
found O 0 4.535623645551823e-07
in O 0 2.9793838507430337e-08
21 O 0 1.004405930871144e-06
families O 0 4.114048692827055e-07
, O 0 5.6271961312859275e-08
while O 0 5.5038185564626474e-08
one O 0 4.851399637573195e-08
germline O 0 0.0004015359445475042
mutation O 0 4.120427092857426e-06
, O 0 2.8053506184733124e-07
Arg24His O 0 0.00011236409045523033
, O 0 1.4521110358600708e-07
was O 0 4.5776099000249815e-07
detected O 0 5.483605036715744e-07
in O 0 1.2207698851796067e-08
the O 0 2.0502589848092612e-07
CDK4 O 0 0.007514530792832375
gene O 0 1.0428946552565321e-05
. O 0 4.081887709617149e-06

The O 0 1.1583495052036596e-06
frequency O 0 4.802865873898554e-07
of O 0 7.764603537907533e-08
p16 O 0 7.7237846198841e-06
gene O 0 4.465876202175423e-07
mutation O 0 2.6590888069222274e-07
in O 0 7.104164367888188e-09
our O 0 6.232181437582085e-09
sample O 0 2.0889064700213567e-08
( O 0 1.7227801407670995e-08
44 O 0 3.881612542500079e-07
% O 0 2.015490530027364e-08
) O 0 1.1387271570129087e-08
is O 0 4.567255906806622e-09
among O 0 1.648620084893082e-08
the O 0 1.4165824069323207e-08
highest O 0 2.3044433419272536e-06
rates O 0 2.0195327579131117e-06
yet O 0 1.9815830398783874e-07
reported O 0 8.646852620586287e-07
and O 0 3.769945067233493e-08
the O 0 3.861467234855809e-08
CDK4 O 0 0.003423100570216775
mutation O 0 1.3149459618944093e-06
is O 0 5.547797332638993e-09
the O 0 5.255956558869457e-09
second O 0 2.993185432842438e-07
mutation O 0 4.455413090909133e-06
detected O 0 2.8443419068935327e-06
in O 0 2.467886162094146e-08
this O 0 1.9587709232382622e-08
gene O 0 1.0222173614238272e-06
worldwide O 0 6.27220742899226e-06
. O 0 4.429493401403306e-06

In O 0 5.195208814257057e-06
summary O 0 6.007549927744549e-06
, O 0 2.583375078302197e-07
our O 0 3.716484187066271e-08
results O 0 7.172419458356671e-08
show O 0 6.769617755253421e-08
frequent O 0 1.279795611708323e-07
involvement O 0 3.2321884191333083e-07
of O 0 1.166022567389291e-08
the O 0 5.137516012609922e-08
p16 O 0 9.62842477747472e-06
gene O 0 5.327884764483315e-07
in O 0 5.091088723929715e-07
familial B-Disease 0 0.3324517607688904
melanoma I-Disease 1 0.9996329545974731
and O 0 6.039574600436026e-06
confirm O 0 1.2408527254592627e-06
the O 0 1.9628400238502763e-08
role O 0 6.551959330636237e-08
of O 0 8.478522772747965e-09
the O 0 4.190959401739747e-08
CDK4 O 0 0.0010959806386381388
gene O 0 4.33604469662896e-07
as O 0 5.2907200398522036e-08
a O 0 1.6034667851272388e-06
melanoma B-Disease 1 0.9775758981704712
- O 0 0.23926560580730438
predisposing O 0 0.0028089347761124372
gene O 0 3.5805335301120067e-06
. O 0 3.271373998359195e-07
. O 0 1.3628074384541833e-06

Progression O 0 0.00022759322018828243
of O 0 2.265972398163285e-06
somatic O 0 0.0005983134033158422
CTG O 0 0.003491321811452508
repeat O 0 3.5627050237962976e-05
length O 0 1.8554081862021121e-06
heterogeneity O 0 1.1419937436585315e-05
in O 0 5.19754017602736e-08
the O 0 2.104860641338746e-07
blood O 0 0.00011691320833051577
cells O 0 5.263655839371495e-05
of O 0 0.00016286106256302446
myotonic B-Disease 1 0.999981164932251
dystrophy I-Disease 1 0.999992847442627
patients O 1 0.9565085768699646
. O 0 0.00016096582112368196

The O 0 3.7754034565296024e-06
genetic O 0 2.497699279047083e-05
basis O 0 1.6010847048164578e-06
of O 0 0.00017906432913150638
myotonic B-Disease 1 0.9999915361404419
dystrophy I-Disease 1 0.999996542930603
( O 0 0.0029832415748387575
DM B-Disease 1 0.9999908208847046
) O 0 2.9584032290586038e-06
is O 0 1.4937114656277117e-08
the O 0 5.767872401918339e-09
expansion O 0 1.1821666845435175e-07
of O 0 2.3813052862919903e-08
an O 0 4.047937807172275e-07
unstable O 0 0.00021036692487541586
CTG O 0 0.001018179813399911
repeat O 0 2.0223524188622832e-06
in O 0 7.765223131173116e-09
the O 0 6.021606324679851e-09
34 O 0 3.309964426989609e-07
UTR O 0 3.5855837268172763e-06
of O 0 2.0939086908811078e-08
the O 0 2.138021812925217e-07
DM B-Disease 1 0.9928376078605652
protein O 0 9.556536042509833e-07
kinase O 0 4.411584995978046e-06
gene O 0 2.3741381482977886e-07
on O 0 2.949721817913087e-07
chromosome O 0 1.609235187061131e-05
19 O 0 1.576651084178593e-05
. O 0 4.593589892465388e-06

One O 0 2.2895562779012835e-06
of O 0 2.427208016797522e-07
the O 0 1.0873879574546663e-07
principal O 0 9.120936397266632e-07
features O 0 7.115096423149225e-08
of O 0 2.855708380877786e-08
the O 0 9.832596106207347e-07
DM B-Disease 1 0.999954342842102
mutation O 0 3.494148768368177e-05
is O 0 6.463780266585673e-08
an O 0 5.44888720810377e-08
extraordinarily O 0 2.0588837287505157e-05
high O 0 4.043862190883374e-06
level O 0 1.3203339221945498e-07
of O 0 5.817128467811017e-08
somatic O 0 0.0016367300413548946
mosaicism O 1 0.6548531651496887
, O 0 3.034084329556208e-06
due O 0 1.145093278864806e-06
to O 0 4.4679804744873763e-08
an O 0 1.0497335978243427e-07
extremely O 0 1.4141900237518712e-06
high O 0 1.5087747442521504e-06
degree O 0 3.66560698239482e-07
of O 0 3.6805147374252556e-08
somatic O 0 0.00017069283057935536
instability O 0 3.976982043241151e-05
both O 0 5.557798488098342e-08
within O 0 1.2253795311778504e-08
and O 0 1.2339336308286875e-07
between O 0 1.9271736562131991e-07
different O 0 1.7558770082359842e-07
tissues O 0 6.626918184338138e-05
. O 0 2.543275286370772e-06

This O 0 1.229956978932023e-05
instability O 0 0.0004398743330966681
appears O 0 5.92157857681741e-06
to O 0 2.144729904784981e-08
be O 0 2.6717710266410677e-09
biased O 0 4.08566194209925e-08
towards O 0 1.1672331545753423e-08
further O 0 9.233556141907684e-09
expansion O 0 7.744532837250517e-08
and O 0 1.7069460511720536e-08
continuous O 0 2.3693084827414168e-08
throughout O 0 1.2026415419086334e-08
the O 0 7.1188543948608185e-09
life O 0 3.595248898591308e-08
of O 0 8.115066840730378e-09
an O 0 3.752562349745858e-08
individual O 0 1.0565551633590076e-07
, O 0 1.786812049431319e-07
features O 0 5.116716010888922e-07
that O 0 6.17048883100324e-08
could O 0 3.0898371505827527e-07
be O 0 4.738031833539935e-08
associated O 0 2.0305355974414852e-07
with O 0 6.001955199508302e-08
the O 0 2.313801843456531e-07
progressive O 0 0.00015330681344494224
nature O 0 8.864071219250036e-07
of O 0 5.655569452756026e-07
the O 0 3.959310197387822e-05
disease O 0 0.009519059211015701
. O 0 1.1345644452376291e-05

Although O 0 1.6613797924946994e-05
increasing O 0 3.6819653814745834e-06
measured O 0 1.7524504301036359e-06
allele O 0 2.0404681890795473e-06
size O 0 2.8813992685172707e-06
between O 0 2.001562961595482e-06
patients O 0 9.661752847023308e-05
clearly O 0 3.804872790169611e-07
correlates O 0 5.936863658462244e-07
with O 0 1.1711361480593041e-07
an O 0 1.9397693051814713e-07
increased O 0 7.174894108175067e-06
severity O 0 0.0003406741307117045
of O 0 9.06449440662982e-06
symptoms O 0 0.004043589346110821
and O 0 5.339136350812623e-07
an O 0 2.6127702312805923e-07
earlier O 0 5.1608749345177785e-06
age O 0 1.6260373740806244e-06
of O 0 2.778978398509935e-07
onset O 0 0.00030333062750287354
, O 0 3.0261554684329894e-07
this O 0 3.90680421347156e-09
correlation O 0 2.386776145613112e-07
is O 0 2.209049299040089e-08
not O 0 3.2867417676385458e-09
precise O 0 2.2329283311250947e-08
and O 0 8.565274356442387e-08
measured O 0 4.803996489499696e-07
allele O 0 7.30231306533824e-07
length O 0 6.334341833280632e-07
cannot O 0 8.524529704345696e-08
be O 0 3.951077687247562e-09
used O 0 1.2269277149812297e-08
as O 0 8.436548348811357e-09
an O 0 6.819405484748131e-09
accurate O 0 3.6802555314352503e-07
predictor O 0 3.8043704989831895e-05
of O 0 1.088770247292814e-07
age O 0 4.913311386189889e-06
of O 0 2.2908536720933625e-06
onset O 0 0.003053785767406225
. O 0 2.4920464056776837e-05

In O 0 3.057615231227828e-06
order O 0 3.883808119553578e-07
to O 0 2.6610617709366124e-08
further O 0 3.093250811048165e-08
characterize O 0 6.039616096131795e-07
the O 0 3.6896732780178354e-08
dynamics O 0 9.416064131073654e-06
of O 0 6.066961759643164e-07
DM B-Disease 1 0.9997171759605408
CTG O 0 0.01635272614657879
repeat O 0 2.8047857995261438e-05
somatic O 0 0.00020718893210869282
instability O 0 0.000108250867924653
, O 0 1.890841616614125e-07
we O 0 1.1341513506124556e-08
have O 0 1.1353158413385245e-08
studied O 0 7.247545852351323e-08
repeat O 0 2.44446084707306e-07
length O 0 9.290957336816064e-08
changes O 0 2.4028906864259625e-08
over O 0 5.152167048549927e-08
time O 0 4.588475377431678e-08
in O 0 8.433581797362422e-07
111 O 0 0.48918914794921875
myotonic B-Disease 1 0.9999971389770508
dystrophy I-Disease 1 0.9999980926513672
patients O 0 0.15924066305160522
with O 0 1.8837981770047918e-06
varying O 0 1.9323562810313888e-05
clinical O 0 0.0007551432936452329
severity O 0 0.0002259577449876815
and O 0 1.5673373354729847e-06
CTG O 0 0.0035371342673897743
repeat O 0 7.799671948305331e-06
size O 0 4.272795877113822e-07
over O 0 2.177719160556535e-08
time O 0 2.844519286782088e-09
intervals O 0 8.305070409164728e-09
of O 0 3.659052172366728e-09
1 O 0 9.610818807459509e-08
- O 0 5.4677948355674744e-05
7 O 0 2.4331231998075964e-06
years O 0 2.6418954348628176e-06
. O 0 1.471184191359498e-06

We O 0 4.557243300951086e-06
have O 0 4.925660164190049e-07
found O 0 8.193192257976989e-08
a O 0 1.103942803837299e-08
direct O 0 1.5512364726077976e-08
progression O 0 3.3806341548370256e-07
of O 0 4.80968775917745e-09
the O 0 2.174357227602286e-08
size O 0 3.349971393618034e-07
heterogeneity O 0 3.218576011931873e-06
over O 0 1.3012765975872753e-07
time O 0 1.7983333933102585e-08
related O 0 1.2176529651242163e-07
to O 0 6.793233975344037e-09
initial O 0 2.2932356102955964e-07
CTG O 0 0.00012362541747279465
repeat O 0 2.3251968741533346e-06
size O 0 3.8289482517939177e-07
and O 0 2.3331718779218136e-08
the O 0 3.957563610157422e-09
time O 0 8.209769752909324e-09
interval O 0 6.619866610435565e-08
and O 0 2.121263698029452e-08
always O 0 1.1758898743607915e-08
biased O 0 1.6673720892868005e-07
towards O 0 8.834688003389601e-08
further O 0 1.9056970756992087e-07
expansion O 0 4.569276370602893e-06
. O 0 1.7240643046534387e-06

Attempts O 0 1.853236972237937e-05
to O 0 2.786514983199595e-07
mathematically O 0 1.3553236613006447e-06
model O 0 3.305620452920266e-07
the O 0 7.693665082797452e-08
dynamics O 0 5.171184602659196e-05
have O 0 2.9607923579533235e-07
proved O 0 7.506680503865937e-07
only O 0 7.269056911951566e-09
partially O 0 3.0710348255524877e-06
successful O 0 3.2719324849495024e-07
suggesting O 0 8.425205351159093e-07
that O 0 5.381880718857701e-09
individual O 0 2.6387318996512477e-08
specific O 0 5.351237319928259e-08
genetic O 0 4.00294402425061e-06
and O 0 6.440453717004857e-07
/ O 0 6.185405800351873e-05
or O 0 2.626160267027444e-06
environmental O 0 5.6796772696543485e-05
factors O 0 8.924218377615034e-07
also O 0 6.567824328840288e-08
play O 0 1.5812254616776045e-08
a O 0 5.7171636314024e-08
role O 0 6.022987122378254e-07
in O 0 3.6206836284691235e-07
somatic O 0 0.0010597899090498686
mosaicism O 0 0.13460470736026764
. O 0 2.24493214773247e-06
. O 0 5.862680154677946e-06

Aspartylglucosaminuria B-Disease 1 0.983320951461792
among O 0 0.00026460265507921576
Palestinian O 0 0.000361877609975636
Arabs O 0 0.00031872797990217805
. O 0 2.4035103706410155e-05

Aspartylglucosaminuria B-Disease 1 0.9991274476051331
( O 0 0.0014079723041504622
AGU B-Disease 1 0.9996370077133179
) O 0 6.978954388614511e-06
is O 0 2.3839872653752536e-07
a O 0 2.695993543966324e-06
rare O 0 0.0002969089837279171
disorder B-Disease 0 0.03244584798812866
of I-Disease 0 1.0036208095698385e-06
glycoprotein I-Disease 0 0.028653424233198166
metabolism I-Disease 0 0.0009153049904853106
caused O 0 2.684428727661725e-05
by O 0 1.0362099374106037e-06
the O 0 1.1224657100683544e-05
deficiency B-Disease 0 0.13490130007266998
of I-Disease 0 1.8280478286669677e-07
the I-Disease 0 3.4549902920844033e-06
lysosomal I-Disease 1 0.5765692591667175
enzyme I-Disease 0 0.00028111488791182637
aspartylglucosaminidase I-Disease 0 0.011581117287278175
( O 0 1.7605480024940334e-06
AGA O 0 0.00026741751935333014
) O 0 8.281890018224658e-07
. O 0 1.3463292134474614e-06

AGU B-Disease 1 0.9994761347770691
is O 0 0.0005839008954353631
inherited O 1 0.8138131499290466
as O 0 2.2348804122884758e-05
an O 0 6.722642137901857e-05
autosomal O 1 0.5199576616287231
recessive O 0 0.4787268042564392
trait O 0 0.002637831261381507
and O 0 5.022929144615773e-06
occurs O 0 4.3049365672231943e-07
with O 0 7.632672094359805e-08
a O 0 1.8499915199754469e-07
high O 0 5.012540441384772e-06
frequency O 0 1.1079004025305039e-07
in O 0 2.6001819364296352e-08
Finland O 0 7.0617588789900765e-06
because O 0 4.1348712898070517e-08
of O 0 1.5145046106113114e-08
a O 0 7.125906904548174e-07
founder O 0 0.0005633726832456887
effect O 0 1.491994407842867e-05
. O 0 4.117952357773902e-06

While O 0 5.714436338166706e-05
very O 0 2.2702745354763465e-06
few O 0 5.008588232158218e-06
patients O 0 0.00020373503502923995
with O 0 7.2408965934300795e-06
AGU B-Disease 1 0.9997532963752747
have O 0 1.2955204056197545e-06
been O 0 2.4469122195114323e-07
reported O 0 6.046607268217485e-07
from O 0 3.073314758239576e-08
non O 0 2.3190382307802793e-06
- O 0 0.000516907311975956
Finnish O 0 0.0024593474809080362
origin O 0 1.090937871595088e-06
, O 0 5.830257805428118e-07
we O 0 9.081531402443943e-07
diagnosed O 0 0.028103433549404144
the O 0 9.276920991396764e-07
disorder O 0 0.009716397151350975
in O 0 4.077741095898091e-07
8 O 0 1.724192770780064e-05
patients O 0 3.0464812880381942e-05
originating O 0 2.0685654078533844e-07
from O 0 1.0524801297151498e-07
3 O 0 9.371516398459789e-07
unrelated O 0 4.821663605980575e-05
families O 0 1.6573588936807937e-06
, O 0 7.68778321003083e-08
all O 0 1.1477962580386247e-08
Palestinian O 0 8.376821938327339e-07
Arabs O 0 7.652101317034976e-07
from O 0 4.938562270240254e-08
the O 0 2.8682089592280136e-08
region O 0 1.6719721429581114e-07
of O 0 1.6580814587996429e-07
Jerusalem O 0 3.36337870976422e-05
. O 0 8.232467735069804e-06

The O 0 7.535743498010561e-05
clinical O 0 0.06076553463935852
diagnosis O 0 0.10036547482013702
of O 0 6.163144280435517e-05
AGU B-Disease 1 0.9999709129333496
is O 0 1.2565296856337227e-05
often O 0 1.3070243767288048e-06
difficult O 0 5.22196501151484e-07
, O 0 1.382625640644619e-07
in O 0 6.188309242816104e-08
particular O 0 5.187052209976173e-08
early O 0 1.8317579986160126e-07
in O 0 1.6972519389923946e-08
the O 0 2.0915376097718763e-08
course O 0 3.103889412159333e-07
of O 0 1.9091933722847898e-07
the O 0 7.5378752626420464e-06
disease O 0 0.007150144316256046
, O 0 3.793394967033237e-07
and O 0 2.285595996909251e-07
most O 0 2.2273816568940674e-08
of O 0 5.8542379832715596e-08
the O 0 4.661841103370534e-06
patients O 0 0.0014261810574680567
are O 0 4.315777914598584e-06
diagnosed O 0 0.07181744277477264
after O 0 1.31561455418705e-06
the O 0 9.683907364888e-08
age O 0 7.546121878476697e-07
of O 0 8.722455646648086e-08
5 O 0 2.4494106583006214e-06
years O 0 7.62238687457284e-06
. O 0 5.4156248552317265e-06

However O 0 1.9057539248024113e-05
, O 0 9.678622063802322e-07
since O 0 6.383384061336983e-07
these O 0 5.442281292289408e-08
patients O 0 1.003743182081962e-05
excrete O 0 1.8362475202593487e-06
early O 0 5.753481957526674e-08
large O 0 7.984383643133697e-08
amounts O 0 3.354005073674671e-08
of O 0 1.107105784825535e-08
aspartylglucosamine O 0 5.4587508202530444e-05
in O 0 6.589758783093203e-08
urine O 0 1.5517165365963592e-06
, O 0 6.491592330348794e-08
biochemical O 0 2.9312072911125142e-06
screening O 0 6.019920988364902e-07
is O 0 1.2517402225853402e-08
easy O 0 4.73060026706662e-08
by O 0 1.300820144933823e-07
urine O 0 6.713229595334269e-06
chromatography O 0 0.00027015001978725195
. O 0 4.546658374238177e-07
. O 0 1.348930368294532e-06

Detection O 0 6.891201337566599e-05
of O 0 9.908485480991658e-07
heterozygous O 0 1.5774558050907217e-05
carriers O 0 7.975234439072665e-06
of O 0 9.434371150973675e-08
the O 0 5.863300884811906e-06
ataxia B-Disease 1 0.9998723268508911
- I-Disease 1 0.9997602105140686
telangiectasia I-Disease 1 0.9999336004257202
( O 0 2.8229931103851413e-06
ATM O 0 8.532126958016306e-05
) O 0 6.341493019590416e-08
gene O 0 4.047392465622579e-08
by O 0 2.0367140862731503e-08
G2 O 0 6.354485230986029e-05
phase O 0 4.220916707708966e-06
chromosomal O 0 0.0023317455779761076
radiosensitivity O 0 0.009518303908407688
of O 0 6.993572696956107e-06
peripheral O 0 0.19619132578372955
blood O 0 0.019338436424732208
lymphocytes O 0 0.06337888538837433
. O 0 1.0749921784736216e-05

In O 0 0.000319778046105057
ataxia B-Disease 1 0.9995868802070618
- I-Disease 1 0.9992844462394714
telangiectasia I-Disease 1 0.9999268054962158
( O 0 4.044704110128805e-05
A B-Disease 0 0.00871911272406578
- I-Disease 1 0.9996271133422852
T I-Disease 1 0.9999853372573853
) O 0 3.634741733549163e-05
patients O 0 0.00023830369173083454
, O 0 2.9954753699712455e-07
mutations O 0 6.309015248007199e-07
in O 0 6.220163495385123e-09
a O 0 2.1673431049862302e-08
single O 0 2.3148390937421937e-07
gene O 0 4.967115501131047e-07
, O 0 1.321686795563437e-07
ATM O 0 6.571326230186969e-05
, O 0 7.900201239863236e-07
result O 0 7.51235972984432e-07
in O 0 2.67378413809638e-06
an O 0 0.004091804381459951
autosomal B-Disease 1 0.9999862909317017
recessive I-Disease 1 0.9999854564666748
syndrome I-Disease 1 0.9999978542327881
that O 0 1.8866693380914512e-06
embraces O 0 3.0288339985418133e-05
a O 0 6.369859306687431e-07
variety O 0 4.7175666395560256e-07
of O 0 2.3351850586550427e-07
clinical O 0 2.2773854652768932e-05
features O 0 4.327701844886178e-06
and O 0 6.71372254146263e-06
manifests O 0 6.777347880415618e-05
extreme O 0 3.739053136087023e-05
radiosensitivity O 0 0.008260567672550678
and O 0 8.864054734658566e-07
a O 0 1.8943683244287968e-07
strong O 0 9.646241778682452e-07
pre O 0 4.82855575683061e-05
- O 0 0.002190973609685898
disposition O 0 0.00022519270714838058
to O 0 6.045729151082924e-06
malignancy B-Disease 0 0.04180236533284187
. O 0 9.818889338930603e-06

Heterozygotes O 0 0.001961349043995142
for O 0 1.4847405509499367e-06
the O 0 3.7409429864965205e-07
ATM O 0 0.000128871644847095
gene O 0 2.25794155994663e-06
have O 0 1.1858172399570321e-07
no O 0 3.966709982705652e-08
clinical O 0 1.4616090311392327e-06
expression O 0 9.926004196358917e-08
of O 0 5.66054509931746e-08
A B-Disease 0 0.00011917031224584207
- I-Disease 1 0.9953267574310303
T I-Disease 1 0.9999679327011108
but O 0 9.425336429558229e-06
may O 0 1.1276714758423623e-05
be O 0 3.2085606562759494e-06
cancer B-Disease 0 0.03529636189341545
prone O 0 0.00015405604790430516
with O 0 1.9940722495448426e-07
a O 0 8.681524263920437e-07
moderate O 0 0.00010175957868341357
increase O 0 1.701523160591023e-06
in O 0 7.110212862926346e-08
in O 0 3.763946097024018e-07
vitro O 0 0.00015578912280034274
radiosensitivity O 0 0.008167118765413761
. O 0 1.189164504467044e-05

We O 0 3.964054940297501e-06
performed O 0 2.2297826944850385e-06
a O 0 3.808368944646645e-07
blind O 0 1.4468430890701711e-05
chromosomal O 0 3.846465187962167e-05
analysis O 0 9.699934366835805e-08
on O 0 1.3517309582766757e-07
G2 O 0 0.00029662600718438625
- O 0 0.0001760753511916846
phase O 0 9.090976163861342e-06
lymphocytes O 0 0.00023874512407928705
from O 0 8.045993382665984e-08
7 O 0 4.783073563885409e-07
unrelated O 0 1.662292743276339e-05
A B-Disease 0 0.0010597576620057225
- I-Disease 1 0.9998633861541748
T I-Disease 1 0.9999923706054688
patients O 0 0.007886997424066067
, O 0 2.3011617145130003e-07
13 O 0 1.093885089176183e-06
obligate O 0 8.461533070658334e-06
A B-Disease 0 0.00010087067494168878
- I-Disease 1 0.9887596368789673
T I-Disease 1 0.9999116659164429
heterozygotes O 0 0.011723942123353481
( O 0 3.0810272733106103e-07
parents O 0 2.698470780160278e-07
of O 0 3.234423573417189e-08
the O 0 1.1677695965772728e-06
patients O 0 6.404754094546661e-05
) O 0 4.770404515852533e-08
, O 0 1.7650446437755818e-08
and O 0 2.2732848492523772e-08
14 O 0 1.2966374640654976e-07
normal O 0 1.2297438622965728e-08
controls O 0 4.4446910152373675e-08
following O 0 2.193786485804594e-08
X O 0 1.3897181361244293e-06
- O 0 3.3866421290440485e-05
irradiation O 0 7.061302085276111e-07
with O 0 2.8747376035198613e-08
1 O 0 7.515198063856587e-08
Gy O 0 7.084719254635274e-05
in O 0 8.46506242879741e-09
order O 0 4.794775687599895e-09
to O 0 2.6693871557625926e-09
evaluate O 0 7.979709693017867e-08
this O 0 1.4644173651490178e-09
cytogenetic O 0 5.577072897722246e-06
method O 0 3.9363811765724677e-08
as O 0 1.1455566273355089e-08
a O 0 1.2210632505116337e-08
tool O 0 2.5459078756284725e-07
for O 0 2.6446977940963734e-08
detection O 0 6.572366828550003e-07
of O 0 1.4219537547432992e-07
ATM O 0 0.0010492481524124742
carriers O 0 0.0003288995649199933
. O 0 5.409915502241347e-06

Both O 0 1.901034738693852e-05
A B-Disease 0 0.000390694011002779
- I-Disease 1 0.8748148083686829
T I-Disease 1 0.9988864064216614
homozygotes O 0 0.006999608129262924
and O 0 1.6797345097074867e-06
heterozygotes O 0 5.4583029850618914e-05
showed O 0 3.342667923789122e-06
significantly O 0 6.360352813317149e-07
increased O 0 7.874763241488836e-08
levels O 0 4.954157262204717e-08
of O 0 3.52903413158856e-08
radiation O 0 0.00014217256102710962
- O 0 0.0207851380109787
induced O 0 0.051307931542396545
chromatid O 1 0.9508156180381775
damage O 0 0.004573934245854616
relative O 0 2.7514336125022965e-06
to O 0 1.9351531932443322e-08
that O 0 5.400791369680746e-09
of O 0 2.8571466970106485e-08
normal O 0 4.1535028572070587e-07
controls O 0 4.149237156525487e-06
. O 0 2.312240894752904e-06

These O 0 1.8656869542610366e-06
results O 0 1.5742791674711043e-06
show O 0 2.3073938848483522e-07
that O 0 8.343620905293392e-09
the O 0 1.3107194440920011e-08
G2 O 0 6.5643856942188e-05
- O 0 0.00022949575213715434
phase O 0 9.183157089864835e-06
chromosomal O 0 0.005636740010231733
radiosensitivity O 0 0.02735055983066559
assay O 0 3.5295950510771945e-05
can O 0 3.350328725559848e-08
be O 0 3.50289841577478e-09
used O 0 4.12440881447651e-09
for O 0 4.890277072178151e-09
the O 0 7.601620666264353e-09
detection O 0 5.818348540742591e-07
of O 0 1.6370771049878385e-07
A B-Disease 0 0.00024731821031309664
- I-Disease 1 0.9915819764137268
T I-Disease 1 0.9996497631072998
heterozygotes O 0 0.01012365147471428
. O 0 9.890595720207784e-06

In O 0 4.7007397370180115e-06
combination O 0 1.1972700121987145e-05
with O 0 6.791020723539987e-07
molecular O 0 2.4756644052104093e-05
genetic O 0 2.6767749659484252e-05
analyses O 0 2.789577820294653e-06
, O 0 1.717994990713123e-07
this O 0 7.985780925423569e-09
test O 0 8.749246376282827e-07
may O 0 2.1544843775700429e-07
be O 0 1.4337283582577243e-09
of O 0 2.8125917150845225e-09
value O 0 4.166244238490435e-08
in O 0 1.3665482967439857e-08
studies O 0 8.859915823222764e-08
of O 0 1.3064992288036592e-07
familial B-Disease 0 0.0007547205896116793
and I-Disease 0 8.741508281673305e-06
sporadic I-Disease 0 0.0006047211936675012
cancers I-Disease 0 0.30049189925193787
aimed O 0 5.4770374845247716e-05
at O 0 1.382141931571823e-06
determination O 0 6.348541887746251e-07
of O 0 1.1036774161254925e-08
the O 0 3.076563714898839e-08
potential O 0 6.763332294212887e-07
involvement O 0 6.502614837700094e-07
of O 0 8.835581155608452e-08
ATM O 0 0.004980894736945629
mutations O 0 0.00011007540160790086
in O 0 6.834748091932852e-06
tumor B-Disease 0 0.43091458082199097
risk O 0 9.889409557217732e-05
or O 0 8.299672344946885e-07
development O 0 1.046815896188491e-06
. O 0 7.253284479702415e-07
. O 0 3.935544100386323e-06

Ataxia B-Disease 1 0.9993711113929749
- I-Disease 1 0.9978995323181152
telangiectasia I-Disease 1 0.9993783235549927
: O 0 8.95182711246889e-06
identification O 0 1.2192524536658311e-06
and O 0 1.5224946992020705e-07
detection O 0 2.1481910152942874e-06
of O 0 1.5495086813643866e-07
founder O 0 0.000310873263515532
- O 0 0.002072794595733285
effect O 0 1.19927983632806e-06
mutations O 0 2.2963124024499848e-07
in O 0 3.384141189499701e-09
the O 0 6.318189083032166e-09
ATM O 0 1.0434158866701182e-05
gene O 0 1.8677738466976734e-07
in O 0 2.3227995527008716e-08
ethnic O 0 8.122586905301432e-07
populations O 0 7.62365925766062e-06
. O 0 4.45866908194148e-06

To O 0 2.3975494514161255e-06
facilitate O 0 9.882514859782532e-07
the O 0 7.317357386682488e-08
evaluation O 0 1.517085479463276e-07
of O 0 2.5229820010963522e-08
ATM O 0 5.637543654302135e-05
heterozygotes O 0 5.81298372708261e-05
for O 0 2.982022238029458e-07
susceptibility O 0 2.010308344324585e-05
to O 0 8.178234622846503e-08
other O 0 7.26348787338793e-07
diseases O 0 0.002046179724857211
, O 0 3.0100574122116086e-07
such O 0 3.070637433211232e-07
as O 0 6.74678958603181e-05
breast B-Disease 1 0.9992672801017761
cancer I-Disease 1 0.6061591506004333
, O 0 7.994087809493067e-07
we O 0 4.330564706833684e-08
have O 0 3.2579887232486726e-08
attempted O 0 1.8268067378812702e-06
to O 0 1.9955230357027176e-08
define O 0 1.8344221075494715e-07
the O 0 3.3538963606360994e-08
most O 0 6.48578790674037e-08
common O 0 4.234550203818799e-07
mutations O 0 1.0109137065228424e-06
and O 0 2.0937966027645416e-08
their O 0 1.960770745768059e-08
frequencies O 0 4.277427194665506e-07
in O 0 2.5583431124687195e-06
ataxia B-Disease 1 0.999504566192627
- I-Disease 1 0.9983935952186584
telangiectasia I-Disease 1 0.9999079704284668
( O 0 7.568964974780101e-06
A B-Disease 0 0.0005299922195263207
- I-Disease 1 0.9832003116607666
T I-Disease 1 0.9995902180671692
) O 0 7.594057933602016e-07
homozygotes O 0 1.979904845939018e-05
from O 0 5.7455423529972904e-08
10 O 0 1.2673778826410853e-07
ethnic O 0 1.3111091448081424e-06
populations O 0 6.060142823116621e-06
. O 0 3.2322950573870912e-06

Both O 0 6.692537681374233e-06
genomic O 0 0.00016627961304038763
mutations O 0 3.2286781788570806e-05
and O 0 1.5706305589446856e-07
their O 0 8.235353732288786e-08
effects O 0 1.7168531485367566e-06
on O 0 9.772376330374755e-08
cDNA O 0 2.156808477593586e-06
were O 0 2.0685015442722943e-06
characterized O 0 4.948678542859852e-05
. O 0 9.870413123280741e-06

Protein O 0 1.4188467503117863e-05
- O 0 0.00013821454194840044
truncation O 0 4.899518899037503e-05
testing O 0 1.4817277360634762e-06
of O 0 9.746907281282802e-09
the O 0 4.28236379690361e-09
entire O 0 2.2900396245972843e-08
ATM O 0 2.533396127546439e-06
cDNA O 0 8.06989021384652e-07
detected O 0 8.683800274411624e-07
92 O 0 4.395222106268193e-07
( O 0 1.4248908719594056e-08
66 O 0 4.3809518501802813e-07
% O 0 2.3867892551265868e-08
) O 0 2.414256350391497e-08
truncating O 0 5.336699359759223e-06
mutations O 0 4.856788109464105e-07
in O 0 1.2543524441355203e-08
140 O 0 7.931174650366302e-07
mutant O 0 1.9045202861889265e-05
alleles O 0 7.841727892810013e-06
screened O 0 3.9369082514895126e-05
. O 0 7.343401648540748e-06

The O 0 8.640953637950588e-06
haplotyping O 0 0.00621057627722621
of O 0 1.2021542715956457e-05
patients O 0 0.0004870101111009717
with O 0 4.4610916916099086e-07
identical O 0 2.783837953757029e-05
mutations O 0 3.2556890801060945e-05
indicates O 0 1.6305390317938873e-06
that O 0 8.46023606726476e-09
almost O 0 3.5539440279563905e-09
all O 0 1.2692346063047921e-09
of O 0 3.375747459344325e-09
these O 0 2.559516820710428e-09
represent O 0 4.690770083470852e-08
common O 0 7.431518156408856e-07
ancestry O 0 7.469961929018609e-06
and O 0 3.1132751132645353e-07
that O 0 3.817528337890508e-08
very O 0 6.097042160035926e-08
few O 0 3.4250800240442913e-07
spontaneously O 0 4.373470073915087e-05
recurring O 0 9.009101631818339e-05
ATM O 0 0.0008444119011983275
mutations O 0 3.659219146356918e-05
exist O 0 1.5622633782186313e-06
. O 0 2.9299833386176033e-06

Assays O 0 0.0003182658401783556
requiring O 0 3.9325779653154314e-05
minimal O 0 5.796632649435196e-06
amounts O 0 3.7246314832373173e-07
of O 0 1.3243271368423848e-08
genomic O 0 1.8827206531568663e-06
DNA O 0 3.3137528134830063e-06
were O 0 1.1174653735679385e-07
designed O 0 5.124167614667385e-07
to O 0 5.835595118242054e-09
allow O 0 2.4691763300666025e-08
rapid O 0 5.037210826230876e-07
screening O 0 5.331900752025831e-07
for O 0 7.690643144542264e-08
common O 0 6.930854965503386e-07
ethnic O 0 4.392801656649681e-06
mutations O 0 7.635056681465358e-05
. O 0 8.004654773685616e-06

These O 0 1.8355665361013962e-06
rapid O 0 2.4955972548923455e-05
assays O 0 5.2107068768236786e-05
detected O 0 3.950349855585955e-05
mutations O 0 2.426380206088652e-06
in O 0 3.082484667515928e-08
76 O 0 5.793427590106148e-06
% O 0 5.388621815427541e-08
of O 0 5.085066945298422e-08
Costa O 0 0.00040555524174124
Rican O 0 0.009116234257817268
patients O 0 0.0003023195604328066
( O 0 1.0109139481073726e-07
3 O 0 2.2397837540211185e-07
) O 0 3.099499323866439e-08
, O 0 1.7854757672353117e-08
50 O 0 2.746150684629356e-08
% O 0 1.9128341577356878e-08
of O 0 5.6727369468489997e-08
Norwegian O 0 0.010995008051395416
patients O 0 0.0004393388226162642
( O 0 1.054543901091165e-07
1 O 0 1.3324746817033883e-07
) O 0 4.174111012389403e-08
, O 0 2.275657706718448e-08
25 O 0 8.787380068042694e-08
% O 0 1.946755467940875e-08
of O 0 8.022883690728122e-08
Polish O 0 0.1424129456281662
patients O 0 0.0005198100116103888
( O 0 8.69977583306536e-08
4 O 0 3.601783475914999e-07
) O 0 5.4126534365650514e-08
, O 0 1.64583013884112e-08
and O 0 2.762541839729238e-08
14 O 0 2.077939313949173e-07
% O 0 2.382236630182888e-08
of O 0 7.268699420137636e-08
Italian O 0 0.030072424560785294
patients O 0 0.002467784797772765
( O 0 1.4977403850480187e-07
1 O 0 3.1531052968603035e-07
) O 0 5.064498154183639e-08
, O 0 4.4619167027803996e-08
as O 0 1.2835892349016831e-08
well O 0 2.4110857310688516e-08
as O 0 4.4273463117860956e-08
in O 0 2.2068114446938125e-07
patients O 0 3.3305605029454455e-06
of O 0 3.8823372960905544e-08
Amish O 0 9.643068915465847e-05
/ O 0 0.00012025888281641528
Mennonite O 0 0.0003104284405708313
and O 0 1.4942862662792322e-06
Irish O 0 1.7186146578751504e-05
English O 0 1.489906480856007e-06
backgrounds O 0 3.2527004805160686e-05
. O 0 9.477163075644057e-06

Additional O 0 2.0744850189657882e-05
mutations O 0 5.671287726727314e-05
were O 0 5.839600589752081e-07
observed O 0 2.1715477771522274e-07
in O 0 2.795308340353131e-08
Japanese O 0 1.5997521813915228e-06
, O 0 1.338917883231261e-07
Utah O 0 3.3068106404243736e-06
Mormon O 0 9.940115432982566e-07
, O 0 8.841954013405484e-08
and O 0 1.4276825766046386e-07
African O 0 4.5431143007590435e-06
American O 0 6.115785799920559e-05
patients O 0 0.0004800459137186408
. O 0 4.907958555122605e-06

These O 0 1.3135120298102265e-06
assays O 0 8.16878309706226e-06
should O 0 9.148834578809328e-08
facilitate O 0 8.299389264720958e-08
screening O 0 3.9207810687003075e-07
for O 0 4.431790046055539e-08
A B-Disease 0 2.0551917259581387e-05
- I-Disease 1 0.7884247899055481
T I-Disease 1 0.9988522529602051
heterozygotes O 0 8.691380935488269e-05
in O 0 5.723535068113961e-08
the O 0 5.860192686668597e-08
populations O 0 1.1174414566994528e-06
studied O 0 2.073937594104791e-06
. O 0 4.2914260234283574e-07
. O 0 3.4573995435494e-06

The O 0 1.9477085515973158e-05
von B-Disease 1 0.814095139503479
Hippel I-Disease 1 0.9901943802833557
- I-Disease 1 0.9755405783653259
Lindau I-Disease 1 0.9988580942153931
tumor I-Disease 1 0.5429689884185791
suppressor O 0 0.00016080198111012578
gene O 0 6.941577908037289e-07
is O 0 8.432027520655083e-09
required O 0 6.3937628524968204e-09
for O 0 1.1641937192052865e-08
cell O 0 1.1366882972652093e-06
cycle O 0 2.8689731834674603e-07
exit O 0 8.039272074711334e-07
upon O 0 4.426767929999187e-07
serum O 0 4.186476144241169e-05
withdrawal O 0 1.5340714526246302e-05
. O 0 2.1466755697474582e-06

The O 0 8.408112080360297e-06
inactivation O 0 0.001045944751240313
of O 0 5.377409024731605e-07
the O 0 1.799618871700659e-06
von B-Disease 1 0.8995519280433655
Hippel I-Disease 1 0.9927430152893066
- I-Disease 1 0.9239183664321899
Lindau I-Disease 1 0.976362407207489
( I-Disease 0 6.867874617455527e-06
VHL I-Disease 0 0.01846744492650032
) I-Disease 0 4.368025656731334e-06
tumor I-Disease 0 0.0013966822298243642
suppressor O 0 0.00013273021613713354
gene O 0 4.006564722658368e-06
predisposes O 0 0.0004901462234556675
affected O 0 5.2131404117972124e-06
individuals O 0 1.6082252329852054e-07
to O 0 3.166170259305545e-08
the O 0 1.2770832427122514e-06
human O 0 0.004415643867105246
VHL B-Disease 1 0.9999504089355469
cancer I-Disease 1 0.9999850988388062
syndrome I-Disease 1 0.9991415739059448
and O 0 9.162627065961715e-06
is O 0 7.965352324390551e-07
associated O 0 1.982998355742893e-06
with O 0 1.3230619515525177e-05
sporadic B-Disease 1 0.601805567741394
renal I-Disease 1 0.9999935626983643
cell I-Disease 1 0.9997770190238953
carcinomas I-Disease 1 0.9999923706054688
( O 0 0.00024369107268285006
RCC B-Disease 1 0.9782102704048157
) O 0 5.71382770431228e-06
and O 0 3.453132012509741e-05
brain B-Disease 0 0.012479082681238651
hemangioblastomas I-Disease 0 0.011500248685479164
. O 0 1.1729703146556858e-05

VHL O 0 0.12683194875717163
- O 0 0.001972408965229988
negative O 0 2.7284779207548127e-05
786 O 0 0.00023372475698124617
- O 0 0.002211536979302764
0 O 0 1.544185943203047e-05
RCC B-Disease 0 0.17894548177719116
cells O 0 1.6545585822314024e-05
are O 0 6.003798347364864e-08
tumorigenic O 0 6.495020352303982e-05
in O 0 1.1187449899807689e-07
nude O 0 0.00041119256638921797
mice O 0 3.658953937701881e-05
which O 0 3.0558318542261986e-08
is O 0 1.360244628045848e-08
suppressed O 0 4.6222149308050575e-07
by O 0 1.5210819270805587e-08
the O 0 2.8714165267729186e-08
reintroduction O 0 7.991375241545029e-06
of O 0 2.7653100005409215e-06
VHL B-Disease 0 0.011206480674445629
. O 0 1.2214625712658744e-05

Remarkably O 0 0.0012285420671105385
, O 0 3.7549614262388786e-06
this O 0 5.075967735024278e-08
occurs O 0 8.603358736536393e-08
without O 0 3.436366924347567e-08
affecting O 0 3.2760917179075477e-07
the O 0 4.920190477264441e-08
growth O 0 1.3364075357458205e-06
rate O 0 4.0808805579217733e-07
and O 0 1.2433825702373724e-07
cell O 0 4.851663106819615e-06
cycle O 0 7.260274514919729e-07
profile O 0 6.531866347359028e-06
of O 0 3.368378287404994e-08
these O 0 3.93471495385711e-08
cells O 0 1.0723867944761878e-06
in O 0 1.1258947552050813e-07
culture O 0 4.922771950077731e-06
. O 0 7.790624295012094e-06

The O 0 3.958853085350711e-06
786 O 0 0.00029001259827055037
- O 0 0.0004058599879499525
0 O 0 1.8757651787382201e-06
cell O 0 1.1816379810625222e-05
line O 0 8.40903055632225e-07
, O 0 8.695329967167709e-08
like O 0 2.2202520710834506e-07
many O 0 1.3503513400792144e-06
cancer B-Disease 0 0.03353135660290718
cells O 0 8.556433385820128e-06
, O 0 1.9060588840602577e-07
fails O 0 4.876848151980084e-07
to O 0 5.414591885966047e-09
exit O 0 1.4462773378909333e-07
the O 0 2.2040030245307207e-08
cell O 0 1.3275943047119654e-06
cycle O 0 4.08419396080717e-07
upon O 0 5.516608894140518e-07
serum O 0 5.005714774597436e-05
withdrawal O 0 1.5744859410915524e-05
. O 0 2.4247610781458206e-06

Here O 0 1.011252879834501e-05
, O 0 7.458348818545346e-07
it O 0 2.445782243398753e-08
is O 0 6.268590091451642e-09
shown O 0 1.3021650424605014e-08
that O 0 2.0411619061633246e-09
reintroduction O 0 1.9388093619454594e-07
of O 0 5.707964767509566e-09
the O 0 2.0355800600668772e-08
wild O 0 1.6804426650196547e-06
- O 0 0.0037807330954819918
type O 0 1.3688259059563279e-05
VHL B-Disease 0 0.0006194993620738387
gene O 0 2.6784420015246724e-07
restores O 0 1.014637859952927e-06
the O 0 1.3508361540459646e-08
ability O 0 5.310231898647544e-08
of O 0 4.628699201703057e-08
VHL O 0 0.0011082448763772845
- O 0 0.0194486565887928
negative O 0 0.00014645111514255404
RCC B-Disease 1 0.9979344606399536
cancer I-Disease 0 0.4993099868297577
cells O 0 2.245726591354469e-06
to O 0 1.0276540507447862e-08
exit O 0 1.25460175581793e-07
the O 0 1.5464152625099814e-08
cell O 0 1.528517714177724e-06
cycle O 0 2.373017764512042e-07
and O 0 1.0188018251255926e-07
enter O 0 2.94799519906519e-07
G0 O 0 0.00015781426918692887
/ O 0 1.3571496310760267e-05
quiescence O 0 0.0001136123901233077
in O 0 7.198980824796308e-07
low O 0 3.687404387164861e-05
serum O 0 0.00011150794307468459
. O 0 3.5260445656604134e-06

Both O 0 4.860409171669744e-05
VHL O 0 0.15892353653907776
- O 0 0.006920970510691404
positive O 0 3.032536596947466e-06
and O 0 1.3384714065978187e-06
VHL O 0 0.002867508679628372
- O 0 0.0016723721055313945
negative O 0 1.1943481695197988e-05
RCC B-Disease 0 0.04692492261528969
cells O 0 2.926738034148002e-06
exit O 0 2.8105239380238345e-07
the O 0 4.146797394355417e-08
cell O 0 2.3875554688856937e-06
cycle O 0 5.110546794639959e-07
by O 0 2.6505793471187644e-07
contact O 0 5.514953500096453e-06
inhibition O 0 2.9131435439921916e-05
. O 0 3.771078127101646e-06

The O 0 9.286497515859082e-06
cyclin O 0 0.0010694533120840788
- O 0 0.000953720766119659
dependent O 0 1.292694651056081e-05
kinase O 0 3.508061854518019e-05
inhibitor O 0 4.254233863321133e-05
, O 0 2.276324693184506e-07
p27 O 0 1.6534260794287547e-05
, O 0 4.192782299128339e-08
accumulates O 0 4.209550183986721e-07
upon O 0 4.48497132765624e-08
serum O 0 4.954373707732884e-06
withdrawal O 0 1.0598395192573662e-06
, O 0 1.4968371431223204e-08
only O 0 1.337062460748939e-09
in O 0 2.9031463899542587e-09
the O 0 1.056488230233299e-08
presence O 0 1.161132701099632e-07
of O 0 6.984108580354587e-08
VHL B-Disease 0 0.0043828608468174934
, O 0 2.3073542365636968e-07
as O 0 1.9643980664341143e-08
a O 0 2.0505124709302436e-08
result O 0 4.3078934197637864e-08
of O 0 9.768813313826286e-09
the O 0 2.9181373761844043e-08
stabilization O 0 2.7000562567991437e-06
of O 0 5.3116906428840593e-08
the O 0 3.964460120187141e-07
protein O 0 2.1796010969410418e-06
. O 0 2.0667466742452234e-06

We O 0 5.556951691687573e-06
propose O 0 1.1377238479326479e-05
that O 0 7.299320259335218e-08
the O 0 4.503701944713612e-08
loss O 0 5.398968369263457e-06
of O 0 3.6510716228121964e-08
wild O 0 4.77538924315013e-06
- O 0 0.012626482173800468
type O 0 2.817339736793656e-05
VHL B-Disease 0 0.0012289093574509025
gene O 0 2.948068242858426e-07
results O 0 7.745271801695708e-08
in O 0 4.41771907944144e-09
a O 0 1.4637898892999601e-08
specific O 0 3.792634473143153e-08
cellular O 0 0.00028222103719599545
defect O 0 0.00042440954712219536
in O 0 3.305604820980079e-07
serum O 0 0.00010684232256608084
- O 0 0.0017155222594738007
dependent O 0 4.4428452383726835e-06
growth O 0 1.0850131957340636e-06
control O 0 1.980364601195106e-07
, O 0 9.283518664915391e-08
which O 0 6.222563087021626e-08
may O 0 1.6929604953475064e-06
initiate O 0 7.225752051454037e-05
tumor B-Disease 0 0.009969647042453289
formation O 0 7.813442789483815e-05
. O 0 1.0023821232607588e-05

This O 0 2.1718203697673744e-06
is O 0 3.707200164626556e-07
corrected O 0 7.851986993046012e-06
by O 0 3.07057241855091e-08
the O 0 9.37837363323979e-09
reintroduction O 0 6.967131298551976e-07
of O 0 2.352745376299481e-08
wild O 0 2.42762075686187e-06
- O 0 0.007663081865757704
type O 0 3.5795186704490334e-05
VHL B-Disease 0 0.006175389047712088
, O 0 1.1381472404536908e-06
implicating O 0 0.014745901338756084
VHL B-Disease 0 0.015932215377688408
as O 0 9.220993746339445e-08
the O 0 1.67275935325506e-08
first O 0 5.502049589267699e-07
tumor B-Disease 0 0.00029569369507953525
suppressor O 0 1.5663150406908244e-05
involved O 0 4.0052020722214365e-07
in O 0 8.776739335303319e-09
the O 0 8.496217063225231e-09
regulation O 0 8.224552772162497e-08
of O 0 3.4223237577180043e-08
cell O 0 7.216754511318868e-06
cycle O 0 6.091544264563709e-07
exit O 0 2.043437689280836e-06
, O 0 1.3820969968492136e-07
which O 0 1.795358528511315e-08
is O 0 5.608805420109775e-09
consistent O 0 1.8187405359526565e-08
with O 0 1.534035654060517e-08
its O 0 8.426404463079962e-08
gatekeeper O 0 2.9499675292754546e-05
function O 0 6.016006892650694e-08
in O 0 7.156254611118129e-08
the O 0 4.239651843818137e-06
kidney O 0 0.33823421597480774
. O 0 1.7902964373206487e-06
. O 0 5.275471266941167e-06

Piebaldism B-Disease 1 0.998023509979248
with O 0 0.005210279952734709
deafness B-Disease 1 0.9999532699584961
: O 0 9.554900316288695e-06
molecular O 0 2.0907691578031518e-05
evidence O 0 1.63495985816553e-06
for O 0 6.288801159826107e-07
an O 0 1.3670633961737622e-05
expanded O 0 0.006584700662642717
syndrome O 1 0.995901882648468
. O 0 4.3387539335526526e-05

In O 0 3.6832473142567324e-06
a O 0 1.096718051485368e-06
South O 0 3.0739356589037925e-06
African O 0 2.5393223950231913e-06
girl O 0 3.76491152564995e-06
of O 0 1.0265809180509677e-07
Xhosa O 0 0.0015262840315699577
stock O 0 5.9908088587690145e-05
with O 0 1.2954602425452322e-05
severe O 0 0.1674519032239914
piebaldism B-Disease 1 0.7936044931411743
and O 0 0.005978815723210573
profound O 1 0.9789982438087463
congenital O 1 0.9999982118606567
sensorineural B-Disease 1 0.9999963045120239
deafness I-Disease 1 0.9999991655349731
we O 0 2.163534918508958e-05
identified O 0 6.5096651269414e-06
a O 0 6.538226671182201e-08
novel O 0 1.6978373196252505e-07
missense O 0 5.789754595753038e-06
substitution O 0 1.3494228312538326e-07
at O 0 1.3297378131937876e-07
a O 0 3.711567941877547e-08
highly O 0 2.6411294129502494e-07
conserved O 0 1.165453866747157e-07
residue O 0 1.623126451022472e-07
in O 0 2.566752366206515e-09
the O 0 6.014639009066514e-09
intracellular O 0 1.5557632195850601e-06
kinase O 0 1.2764427310685278e-06
domain O 0 1.7167151256103352e-08
of O 0 4.380707352424906e-09
the O 0 4.9831758275331595e-08
KIT O 0 0.0002543229202274233
proto O 0 0.0029345639050006866
- O 0 0.011715153232216835
oncogene O 0 0.005238081328570843
, O 0 3.272673893661704e-06
R796G O 0 9.021394362207502e-05
. O 0 1.9647859517135657e-06

Though O 0 0.0002987056795973331
auditory B-Disease 0 0.021628495305776596
anomalies I-Disease 0 0.23371954262256622
have O 0 3.2144532724487362e-06
been O 0 6.338064508781827e-07
observed O 0 3.8538632907147985e-07
in O 0 8.889674063539132e-08
mice O 0 9.246842637367081e-06
with O 0 7.523960334765434e-07
dominant O 0 6.307676812866703e-05
white O 0 0.0004568954464048147
spotting O 0 0.06434962898492813
( O 0 5.8327991609985474e-06
W O 0 0.4025542438030243
) O 0 1.1910460671060719e-06
due O 0 8.606680239608977e-07
to O 0 1.4117264868218626e-07
KIT O 0 0.012874240055680275
mutations O 0 0.00017141702119261026
, O 0 3.8924612454138696e-05
deafness B-Disease 1 0.9999769926071167
is O 0 1.2763136965077138e-06
not O 0 9.10373216811422e-08
typical O 0 1.6228212871283176e-06
in O 0 5.232932380749844e-07
human O 0 1.1490530596347526e-05
piebaldism B-Disease 0 0.0132423285394907
. O 0 2.3637674530618824e-05

Thus O 0 3.491557436063886e-05
, O 0 1.0442005304867052e-06
the O 0 1.811011429708742e-07
occurrence O 0 1.025029723678017e-05
of O 0 1.0556165761954617e-05
sensorineural B-Disease 1 0.9999687671661377
deafness I-Disease 1 0.999996542930603
in O 0 1.791874092305079e-05
this O 0 3.5353269822735456e-07
patient O 0 2.3470756786991842e-05
extends O 0 2.6398151931061875e-06
considerably O 0 1.2479436009016354e-06
the O 0 2.0873052619663213e-08
phenotypic O 0 1.6175986274902243e-06
range O 0 5.055021574662533e-07
of O 0 1.2739870669520315e-07
piebaldism B-Disease 0 0.009907672181725502
due O 0 1.1335996532579884e-06
to O 0 4.178803081344995e-08
KIT O 0 0.00012983856140635908
gene O 0 4.259410388840479e-07
mutation O 0 2.138607015922389e-07
in O 0 2.369986340511332e-08
humans O 0 1.0230586156012578e-07
and O 0 2.482517516000371e-07
tightens O 0 0.00030166891519911587
the O 0 1.6460428753362066e-07
clinical O 0 6.231201041373424e-06
similarity O 0 3.7102489613971557e-07
between O 0 2.478855094523169e-07
piebaldism B-Disease 0 0.001210549846291542
and O 0 1.274742942314333e-07
the O 0 1.406843264106783e-08
various O 0 2.7641069877404334e-08
forms O 0 3.010889486176893e-06
of O 0 0.0017326823435723782
Waardenburg B-Disease 1 0.9999822378158569
syndrome I-Disease 1 0.9998437166213989
. O 0 6.031711563991848e-06
. O 0 1.0069292329717427e-05

Cycloheximide O 0 0.006185736507177353
facilitates O 0 2.567389492469374e-05
the O 0 2.9835754844498297e-07
identification O 0 1.8424661618610116e-07
of O 0 2.7317478057398148e-08
aberrant O 0 1.0799571100506e-05
transcripts O 0 3.983925580541836e-06
resulting O 0 1.9809983768936945e-06
from O 0 1.068359267719643e-07
a O 0 5.837635796979157e-08
novel O 0 2.879809244404896e-07
splice O 0 1.833656097005587e-05
- O 0 8.632923709228635e-05
site O 0 1.3567216683441075e-06
mutation O 0 4.444958392468834e-07
in O 0 2.6527912311280488e-08
COL17A1 O 0 0.0005254545831121504
in O 0 1.6915583955778857e-07
a O 0 1.6031320910769864e-06
patient O 0 7.58928872528486e-05
with O 0 3.0903887818567455e-05
generalized O 0 0.032323502004146576
atrophic B-Disease 1 0.9996374845504761
benign I-Disease 1 0.9910455346107483
epidermolysis I-Disease 1 0.9962112903594971
bullosa I-Disease 1 0.9935775399208069
. O 0 0.00042375244083814323

Patients O 0 0.37244871258735657
with O 0 0.00011313043796690181
generalized O 0 0.0801149383187294
atrophic B-Disease 1 0.9998230338096619
benign I-Disease 1 0.9955411553382874
epidermolysis I-Disease 1 0.9990617632865906
bullosa I-Disease 1 0.9981213212013245
often O 0 2.5673529307823628e-05
show O 0 2.176371026507695e-06
decreased O 0 6.539002697536489e-06
expression O 0 9.676651302470418e-08
of O 0 3.804865045253791e-08
type O 0 1.3229484466137365e-05
XVII O 1 0.8116345405578613
collagen O 0 0.0021604665089398623
, O 0 7.592189490424062e-07
a O 0 5.077163791611383e-07
transmembrane O 0 4.967912900610827e-05
hemidesmosomal O 0 0.0003118692256975919
protein O 0 1.9187689304089872e-07
encoded O 0 1.008729739737646e-07
by O 0 3.8352121123352845e-07
COL17A1 O 0 0.0008454314665868878
. O 0 5.050822892371798e-06

This O 0 1.3258090802992228e-06
report O 0 4.957172450303915e-07
documents O 0 5.418277169155772e-07
a O 0 5.8360324572959144e-08
novel O 0 1.9475564272397605e-07
splice O 0 8.99906808626838e-06
- O 0 0.00012563043856061995
site O 0 2.3583718302688794e-06
mutation O 0 3.6337456776891486e-07
in O 0 3.4716851615712585e-08
COL17A1 O 0 0.000316663266858086
in O 0 1.0359871538412335e-07
a O 0 6.696705554531945e-07
patient O 0 2.635849523358047e-05
with O 0 4.672109298553551e-06
generalized O 0 0.010909589938819408
atrophic B-Disease 1 0.9998941421508789
benign I-Disease 1 0.9546005725860596
epidermolysis I-Disease 1 0.9989047050476074
bullosa I-Disease 1 0.9973486661911011
, O 0 1.0507584192964714e-05
and O 0 3.458889636931417e-07
applies O 0 1.7307958444234828e-07
a O 0 3.120932490219275e-08
new O 0 1.9628743075372768e-07
methodology O 0 2.0329596850388043e-07
to O 0 1.2650468228514455e-08
define O 0 1.4585886276563542e-07
and O 0 6.263142182660886e-08
characterize O 0 4.003426568033319e-07
the O 0 1.5696477007054455e-08
resulting O 0 4.484099349610915e-07
mRNA O 0 5.916019745200174e-07
splice O 0 3.025964178959839e-05
variants O 0 8.339116902789101e-06
. O 0 3.1902109185466543e-06

Mutational O 0 0.0016414194833487272
analysis O 0 1.01858295238344e-05
of O 0 1.492369392508408e-06
COL17A1 O 0 0.03474697098135948
identified O 0 3.814200681517832e-05
a O 0 1.2318212156969821e-06
maternally O 0 0.007888076826930046
inherited O 0 0.006749108899384737
G O 0 0.0007155583007261157
- O 0 0.00028587065753526986
to O 0 3.107591908246832e-07
- O 0 0.003102006856352091
T O 0 0.00768607622012496
transversion O 0 5.170523581909947e-05
at O 0 4.9768399179583866e-08
the O 0 9.219425223250255e-09
- O 0 7.461083896487253e-06
1 O 0 6.157438292575534e-08
position O 0 2.665369258636474e-08
of O 0 2.2301533064705836e-08
exon O 0 2.228818448202219e-05
32 O 0 5.239531674305908e-06
. O 0 2.3457923816749826e-06

This O 0 1.3137550922692753e-06
acceptor O 0 1.2221033102832735e-05
splice O 0 9.214340389007702e-05
- O 0 0.0005252815899439156
site O 0 5.270659130474087e-06
mutation O 0 1.3652036159328418e-06
led O 0 4.2746950157379615e-07
to O 0 7.511283151018233e-09
the O 0 8.935841400159461e-09
formation O 0 2.630862923069799e-07
of O 0 1.8271759216759165e-08
aberrant O 0 1.1898632692464162e-05
transcripts O 0 3.008822659467114e-06
present O 0 2.4885429183996166e-07
at O 0 6.793482612010848e-07
extremely O 0 4.826295935345115e-06
low O 0 1.8131842807633802e-05
levels O 0 6.4222094806609675e-06
. O 0 2.2763365450373385e-06

Based O 0 8.617220373707823e-06
on O 0 5.569056042986631e-07
our O 0 9.064314809847929e-08
recent O 0 1.1439817626524018e-07
finding O 0 1.0064830746614462e-07
that O 0 1.9582703458809192e-08
cycloheximide O 0 8.175909897545353e-05
stabilized O 0 4.2174029658781365e-05
mutant O 0 3.868256499117706e-06
COL17A1 O 0 7.44621574995108e-05
transcripts O 0 1.4021774177308544e-06
in O 0 8.70889067527969e-08
keratinocytes O 0 3.141862543998286e-05
homozygous O 0 8.893140375221265e-07
for O 0 1.9208885149168964e-08
a O 0 1.309667965188055e-07
frameshift O 0 0.0010129759320989251
mutation O 0 3.83362157663214e-06
, O 0 9.380345034060156e-08
the O 0 3.875722853763364e-08
effects O 0 7.47156263969373e-07
of O 0 6.799897089848628e-09
the O 0 2.0387119548104238e-08
splice O 0 1.3859637874702457e-05
- O 0 0.00012455059913918376
site O 0 5.100754947306996e-07
mutation O 0 5.630030130987507e-08
on O 0 6.820211950753219e-09
splicing O 0 9.585318139215815e-08
of O 0 1.6282481141161043e-08
COL17A1 O 0 8.378420170629397e-05
transcripts O 0 6.045350460226473e-07
were O 0 2.142289012851961e-08
determined O 0 6.787535422603241e-09
using O 0 3.9799856743627515e-09
reverse O 0 2.9264430168041144e-07
transcriptase O 0 1.8533890397520736e-05
polymerase O 0 1.4884329175401945e-05
chain O 0 2.8615645533136558e-06
reaction O 0 2.140414245843658e-08
of O 0 1.0527824167994027e-09
total O 0 5.9980500566325645e-09
RNA O 0 3.9272919138966245e-08
from O 0 3.519596347700826e-08
keratinocytes O 0 3.398889930394944e-06
incubated O 0 2.6562574930721894e-06
for O 0 1.9069842949193117e-07
2 O 0 2.7108335416414775e-06
. O 0 4.0873292164178565e-06

5 O 0 3.059977098018862e-05
h O 0 0.0001488985144533217
in O 0 2.662699500888266e-07
the O 0 8.623056402257134e-08
presence O 0 4.1115188764706545e-07
or O 0 5.223458998671049e-08
absence O 0 2.200796416218509e-07
of O 0 1.6382978529350112e-08
10 O 0 3.633444123352092e-07
microg O 0 0.00027064731693826616
cycloheximide O 0 0.0002473825588822365
per O 0 2.2623728455073433e-06
ml O 0 0.00035309288068674505
. O 0 3.3352328046021285e-06

Using O 0 3.932212621293729e-06
this O 0 1.1685411749340346e-07
approach O 0 3.404011295060627e-07
, O 0 6.445092282092446e-08
an O 0 2.9577657656432166e-08
abnormally O 0 7.973044375830796e-06
spliced O 0 5.279624019749463e-06
transcript O 0 3.069108061026782e-06
was O 0 5.243452960712602e-07
identified O 0 2.1524594728816737e-07
that O 0 1.3798263642783581e-09
contains O 0 2.1403276928566584e-09
an O 0 2.2772239649526682e-09
extra O 0 9.632948660964757e-09
264 O 0 1.9567102071960107e-07
bases O 0 6.611551128798965e-08
upstream O 0 5.790737489519415e-08
from O 0 1.1929525811638086e-08
exon O 0 1.9558294752641814e-06
32 O 0 3.251142288718256e-07
, O 0 2.446001623468419e-08
resulting O 0 8.857465871869863e-08
in O 0 1.2772614077505295e-08
a O 0 1.3195823100886628e-07
premature O 0 3.0409057217184454e-05
termination O 0 5.1771962716884445e-06
codon O 0 1.036771323015273e-06
27 O 0 1.8009528730544844e-06
bp O 0 2.5580218789400533e-05
downstream O 0 1.22472033581289e-06
from O 0 3.259555114709656e-08
the O 0 3.814194826645689e-08
cryptic O 0 9.83497011475265e-06
splice O 0 4.1588446038076654e-05
site O 0 9.836901881499216e-06
. O 0 3.0737187444174197e-06

Three O 0 1.968110836969572e-06
other O 0 2.6201337277598213e-07
splice O 0 2.6419143978273496e-05
variants O 0 2.386522055530804e-06
, O 0 7.80944304779041e-08
including O 0 4.0662342826180975e-08
one O 0 8.665325346157715e-09
derived O 0 2.218494898897916e-08
from O 0 9.111738030753713e-09
the O 0 5.015670545560624e-09
skipping O 0 3.733750304490968e-07
of O 0 1.2838610174981113e-08
exon O 0 1.1514202924445271e-05
32 O 0 7.86315922596259e-07
, O 0 1.2877424637736112e-07
were O 0 2.090588964165363e-07
also O 0 8.841259955261194e-07
identified O 0 4.632506716006901e-06
. O 0 3.187446736774291e-06

These O 0 3.4323823001614073e-06
results O 0 6.784897777833976e-06
indicate O 0 8.209599400288425e-07
the O 0 6.028768240184945e-08
usefulness O 0 3.368495981703745e-06
of O 0 2.3181638653113623e-07
cycloheximide O 0 0.046003129333257675
treatment O 0 1.3709500308323186e-05
in O 0 2.21183604764974e-08
evaluating O 0 1.2136699751863489e-06
the O 0 4.335267433930312e-08
abnormal O 0 1.6374891629311605e-06
processing O 0 9.249265531252604e-08
of O 0 7.921822309242543e-09
mRNA O 0 4.866125280500455e-08
due O 0 3.824634120519477e-08
to O 0 3.1968006020122175e-09
splice O 0 2.317565758858109e-06
- O 0 0.00010836385627044365
site O 0 4.745909791381564e-06
mutations O 0 4.69547057946329e-06
, O 0 1.7597812984604388e-07
because O 0 1.3597056636172056e-07
( O 0 3.277447291338831e-08
i O 0 3.652701963119398e-08
) O 0 4.735987602089153e-09
aberrant O 0 3.368154182226135e-07
splicing O 0 1.9629453618108528e-07
often O 0 3.143605198374644e-08
generates O 0 5.996062668600644e-08
a O 0 1.0338059297509972e-07
premature O 0 1.361276827083202e-05
termination O 0 6.6160387177660596e-06
codon O 0 1.1894285307789687e-06
, O 0 1.0702233765869096e-07
( O 0 4.351745275243957e-08
ii O 0 5.1492675083864015e-06
) O 0 2.057595871463036e-08
transcripts O 0 3.1371604336527525e-07
with O 0 2.816856863319117e-07
premature O 0 4.191621337668039e-05
termination O 0 1.5792107660672627e-05
codons O 0 2.7475030037749093e-06
can O 0 2.3993505848807217e-08
occur O 0 8.876098966936752e-09
at O 0 8.704805765091805e-08
low O 0 3.3296996662102174e-06
or O 0 5.076994398223178e-07
undetectable O 0 0.0002496049564797431
levels O 0 4.2069453343174246e-07
due O 0 4.639429462827138e-08
to O 0 3.751107868765757e-09
nonsense O 0 4.837885398956132e-07
- O 0 5.535345735552255e-06
mediated O 0 2.233117356809089e-06
mRNA O 0 7.875349439245838e-08
decay O 0 2.845313815669215e-07
, O 0 4.876912740314765e-08
and O 0 5.2318544163654224e-08
( O 0 3.786165692076793e-08
iii O 0 2.9597993489005603e-05
) O 0 1.7584786959901066e-08
the O 0 7.3064065908567954e-09
levels O 0 2.1049928022875974e-08
of O 0 2.4340582882587114e-09
these O 0 2.1521457949091882e-09
transcripts O 0 2.972743402551714e-07
can O 0 1.444106079162566e-08
be O 0 1.2560810169759407e-08
increased O 0 1.1506583774689716e-07
by O 0 4.920505034533562e-07
cycloheximide O 0 0.000694690621457994
. O 0 4.882571829512017e-06

A O 0 2.9337517844396643e-05
deletion O 0 0.00023763140779919922
mutation O 0 2.2646183424512856e-05
in O 0 2.816969697505556e-07
COL17A1 O 0 0.0011121717980131507
in O 0 1.1647338737930113e-07
five O 0 2.58605695080405e-07
Austrian O 0 0.00019581802189350128
families O 0 3.5187683806725545e-06
with O 0 8.18733769847313e-06
generalized O 0 0.007013007532805204
atrophic B-Disease 1 0.9998113512992859
benign I-Disease 1 0.9311915040016174
epidermolysis I-Disease 1 0.99812251329422
bullosa I-Disease 1 0.9670543074607849
represents O 0 1.869364859885536e-05
propagation O 0 6.589827421521477e-07
of O 0 2.2486700856916286e-07
an O 0 8.556552870686573e-07
ancestral O 0 8.129311027005315e-05
allele O 0 3.82223297492601e-05
. O 0 5.921606771153165e-06

Patients O 0 0.3018347918987274
with O 0 0.00014540583651978523
generalized O 0 0.3215326964855194
atrophic B-Disease 1 0.999863862991333
benign I-Disease 1 0.9988877177238464
epidermolysis I-Disease 1 0.9993390440940857
bullosa I-Disease 1 0.9981714487075806
, O 0 3.030111111002043e-05
a O 0 7.259616268129321e-07
usually O 0 1.6848349559950293e-07
nonlethal O 0 1.7695314454613253e-05
form O 0 2.3528650672233198e-07
of O 0 5.0154341124653e-07
junctional B-Disease 0 0.2769329845905304
epidermolysis I-Disease 1 0.989504337310791
bullosa I-Disease 1 0.9790621995925903
, O 0 7.769752301101107e-06
have O 0 2.685910942545888e-07
generalized O 0 3.141770093861851e-06
blistering B-Disease 0 0.0005602652672678232
, O 0 8.70884396135807e-05
nail B-Disease 1 0.9995470643043518
dystrophy I-Disease 1 0.9998044371604919
, O 0 0.0003401071880944073
patchy B-Disease 1 0.9865503311157227
alopecia I-Disease 1 0.999976396560669
, O 0 0.00039483263390138745
and O 0 0.005399030167609453
dental B-Disease 1 0.9992490410804749
abnormalities I-Disease 1 0.9965150356292725
. O 0 7.117316999938339e-05

Skin B-Disease 1 0.9936138987541199
fragility I-Disease 1 0.7967820167541504
in O 0 6.367251444316935e-06
most O 0 1.1473078984636231e-06
cases O 0 1.0935526006505825e-05
is O 0 6.677732358184585e-07
due O 0 1.234568458130525e-06
to O 0 5.7061821934212276e-08
mutations O 0 7.553466048193513e-07
in O 0 6.833441812403862e-09
the O 0 1.6935945978957534e-08
gene O 0 1.2284573358556372e-07
encoding O 0 3.307736733404454e-07
type O 0 2.6720339519670233e-05
XVII O 1 0.9159932136535645
collagen O 0 0.010117732919752598
( O 0 5.426967618404888e-06
COL17A1 O 0 0.016886170953512192
) O 0 3.045116727662389e-06
. O 0 3.904284312739037e-06

Recently O 0 0.0006147484527900815
, O 0 9.521176025373279e-07
we O 0 3.010539373349275e-08
reported O 0 2.8046068223375187e-07
five O 0 5.668897173904952e-08
Austrian O 0 4.634817014448345e-05
families O 0 2.6092718599102227e-06
with O 0 4.813646228285506e-06
generalized O 0 0.014554053544998169
atrophic B-Disease 1 0.9998432397842407
benign I-Disease 1 0.9565808773040771
epidermolysis I-Disease 1 0.9986147880554199
bullosa I-Disease 1 0.9968576431274414
who O 0 0.000149742845678702
share O 0 4.086772150913021e-06
the O 0 1.7196686030729325e-07
same O 0 4.5108546942174144e-07
COL17A1 O 0 0.009848256595432758
mutation O 0 4.643492502509616e-05
. O 0 3.889701019943459e-06

Affected O 0 0.0007082974188961089
individuals O 0 1.0276588909619022e-05
in O 0 2.2681790312617522e-07
three O 0 1.3179862889955984e-07
families O 0 7.277008080563974e-07
are O 0 5.772486844080049e-08
homozygous O 0 9.669931841926882e-07
for O 0 7.240885935289043e-08
4003delTC O 0 6.197550828801468e-05
, O 0 9.827741820345182e-08
whereas O 0 3.2247896797343856e-08
those O 0 5.364448441014247e-09
in O 0 4.350448001844143e-09
two O 0 2.7540661307057235e-08
others O 0 8.321610494022025e-07
are O 0 2.0900108665955486e-07
compound O 0 9.543316082272213e-06
heterozygotes O 0 0.0004858129541389644
. O 0 6.034340913174674e-06

To O 0 2.992454028571956e-06
determine O 0 1.1751004649340757e-06
if O 0 6.415607600729345e-08
the O 0 1.809639904593041e-08
occurrence O 0 2.372366054714803e-07
of O 0 3.1022555191384527e-08
4003delTC O 0 7.458161417162046e-05
in O 0 3.042722340751425e-08
these O 0 1.3615503391406492e-08
unrelated O 0 1.225352389155887e-05
families O 0 1.3626683994516497e-06
signifies O 0 1.6481758393638302e-06
propagation O 0 9.449895799207297e-08
of O 0 3.1590523974500684e-08
an O 0 1.383934176146795e-07
ancestral O 0 3.830032710538944e-06
allele O 0 8.342095156876894e-07
or O 0 4.0384705357610073e-08
a O 0 1.3640658380609239e-07
mutational O 0 8.426817657891661e-05
hot O 0 4.690448804467451e-06
spot O 0 1.9478272861306323e-06
, O 0 1.4055966346404603e-07
haplotypes O 0 9.971828148991335e-06
were O 0 1.2828114392959833e-07
determined O 0 9.377035325996985e-08
for O 0 6.066232316470632e-08
polymorphisms O 0 1.724878529785201e-05
both O 0 6.412867747940254e-08
within O 0 5.4398011428702375e-08
and O 0 1.3090514130453812e-06
flanking O 0 0.005510800052434206
COL17A1 O 0 0.4199132025241852
. O 0 1.4580529750674032e-05

Five O 0 5.802593659609556e-05
intragenic O 0 0.02551906369626522
polymorphisms O 0 0.0014916621148586273
were O 0 8.789682510723651e-07
chosen O 0 1.3864784875750047e-07
based O 0 1.761816434964203e-07
on O 0 1.4065902576021472e-07
their O 0 5.111360792398045e-07
informativeness O 0 0.0007595040951855481
. O 0 4.698220891441451e-06

One O 0 1.4573707858289708e-06
of O 0 1.8629457088081836e-07
these O 0 3.673396165027043e-08
, O 0 5.089879806519093e-08
not O 0 1.3329153780716751e-08
previously O 0 4.3234962276983424e-07
reported O 0 8.228018373301893e-07
, O 0 7.551464165089783e-08
was O 0 4.4290271716818097e-07
2988 O 0 4.2418094380991533e-05
A O 0 3.89048437909878e-07
or O 0 2.0554018931306928e-07
C O 0 3.1131080504565034e-06
that O 0 1.290792628338977e-08
introduces O 0 4.3160562768207456e-07
a O 0 3.238497825464037e-08
new O 0 1.6013061099329207e-07
restriction O 0 1.7066049906588887e-07
site O 0 1.845330643845955e-07
for O 0 2.1742955880199588e-07
Eco0109 O 0 9.669311111792922e-05
I O 0 3.2453697258461034e-06
. O 0 2.4147664134943625e-06

All O 0 1.0136494665857754e-06
the O 0 4.354053544375347e-07
4003delTC O 0 0.0001333369582425803
alleles O 0 3.0775286177231465e-06
showed O 0 1.3555784335039789e-06
the O 0 1.340963073914736e-08
same O 0 1.636470869925688e-08
haplotype O 0 1.3548713013733504e-06
for O 0 1.6855734585874416e-08
these O 0 1.0048331056111692e-08
five O 0 3.465757743015274e-07
polymorphic O 0 0.00023455209156963974
markers O 0 0.0003772521740756929
. O 0 7.890977940405719e-06

Fourteen O 0 8.472696208627895e-05
microsatellite O 0 0.008324655704200268
polymorphisms O 0 0.002420224016532302
were O 0 1.441840367988334e-06
selected O 0 2.0208783269026753e-07
based O 0 8.428092712620128e-08
on O 0 5.506811362465669e-08
their O 0 2.984166513897435e-08
high O 0 4.052656549902167e-06
heterozygosity O 0 0.00018304445256944746
and O 0 5.786651868788795e-08
their O 0 1.4997178610087758e-08
location O 0 2.752485528390025e-08
within O 0 3.3602226778839395e-08
10q23 O 0 3.537311567924917e-05
- O 0 0.0005188496434129775
q25 O 0 0.00022390129743143916
near O 0 1.73481457750313e-05
COL17A1 O 0 0.0021686989348381758
. O 0 7.537501460319618e-06

Three O 0 7.248842393892119e-06
families O 0 1.2168722605565563e-05
shared O 0 7.303201527975034e-06
microsatellite O 0 0.007471370976418257
polymorphisms O 0 0.0016366738127544522
covering O 0 3.159053812851198e-05
at O 0 1.2034375913572148e-06
most O 0 4.256243002487281e-08
19 O 0 2.2508788788400125e-06
cM O 0 1.4534008187183645e-05
, O 0 7.947022595544695e-08
whereas O 0 6.29795380291398e-08
the O 0 1.25897363645322e-08
others O 0 1.660930024627305e-07
shared O 0 1.477498585700232e-07
smaller O 0 3.122749205886066e-07
regions O 0 5.8958224968819195e-08
consistent O 0 5.8930115898192525e-08
with O 0 6.690239473527981e-08
cross O 0 2.171942696804763e-06
- O 0 0.0001360713504254818
over O 0 2.3511626068284386e-07
events O 0 2.7488864517977163e-08
during O 0 3.6954695303847984e-08
passage O 0 5.017357196379635e-08
of O 0 5.678547854159888e-09
this O 0 2.1455019982852264e-09
mutation O 0 6.320144052551768e-08
through O 0 1.5044278711684456e-08
several O 0 1.0097711822254496e-07
generations O 0 7.951304723974317e-06
. O 0 5.090490049042273e-06

These O 0 2.0205191049171844e-06
results O 0 4.742923465528293e-06
indicate O 0 1.3956109796708915e-06
that O 0 7.170928739697047e-08
4003delTC O 0 7.164787530200556e-05
occurs O 0 5.59784325560031e-08
on O 0 1.8111869337644748e-08
a O 0 3.1216231377584336e-08
single O 0 3.050588190944836e-07
ancestral O 0 1.5875779354246333e-05
allele O 0 6.284901246544905e-06
. O 0 5.831753924212535e-07
. O 0 1.5286692587324069e-06

The O 0 5.167833933228394e-06
haptoglobin O 0 0.0016014978755265474
- O 0 0.001379386754706502
gene O 0 6.75642877467908e-06
deletion O 0 1.28113133541774e-05
responsible O 0 6.686407232336933e-06
for O 0 2.2754659312340664e-06
anhaptoglobinemia B-Disease 0 0.0038795126602053642
. O 0 7.296532658074284e-06

We O 0 5.142705958860461e-06
have O 0 6.559505436598556e-07
found O 0 1.4811850235219026e-07
an O 0 2.3884286548536693e-08
allelic O 0 8.853242434270214e-06
deletion O 0 2.431564553262433e-06
of O 0 3.251359004252663e-08
the O 0 9.798057476473332e-08
haptoglobin O 0 0.00021097778517287225
( O 0 1.5802523023467074e-07
Hp O 0 4.411365807754919e-06
) O 0 4.573638889837639e-08
gene O 0 2.5807048942283473e-08
from O 0 1.0540487593857506e-08
an O 0 1.4181477325792002e-08
individual O 0 1.9242058613144764e-07
with O 0 2.8533129352581454e-06
anhaptoglobinemia B-Disease 0 0.07456521689891815
. O 0 1.3432048035610933e-05

The O 0 3.5549435324355727e-06
Hp O 0 0.00010394635319244117
gene O 0 3.5054717955063097e-06
cluster O 0 3.3516473649797263e-06
consists O 0 6.155489273851344e-08
of O 0 2.1056111521033927e-08
coding O 0 1.0690926046663662e-06
regions O 0 2.5497243427707872e-08
of O 0 4.549718379820433e-09
the O 0 1.1330789639885097e-08
alpha O 0 5.392558932726388e-07
chain O 0 1.1376155271136668e-06
and O 0 3.580562690785882e-08
beta O 0 2.2045124126179871e-07
chain O 0 3.712000875566446e-07
of O 0 4.6183434854185634e-09
the O 0 2.750202732215712e-08
haptoglobin O 0 7.313470996450633e-05
gene O 0 5.585651479123044e-07
( O 0 1.882273359399278e-08
Hp O 0 1.6926441048781271e-06
) O 0 5.421805671090851e-09
and O 0 2.157628742338602e-09
of O 0 1.1011410672168154e-09
the O 0 5.471358921482761e-09
alpha O 0 2.9123555123078404e-07
chain O 0 6.298963626250043e-07
and O 0 3.1307219927612095e-08
beta O 0 2.154032188173005e-07
chain O 0 1.5154212462675787e-07
of O 0 4.0159475744872e-09
the O 0 4.8637311067523115e-08
haptoglobin O 0 0.00021630858827847987
- O 0 0.0005067071761004627
related O 0 1.1186995834577829e-05
gene O 0 1.5226238474497222e-06
( O 0 2.479328031768091e-07
Hpr O 0 9.352542838314548e-05
) O 0 4.1271654538377334e-08
, O 0 1.2078783306890273e-08
in O 0 7.670832857797905e-09
tandem O 0 1.660993348195916e-06
from O 0 9.492745789430046e-08
the O 0 7.26021909258634e-08
5 O 0 1.3045686273471802e-06
side O 0 9.59408043854637e-06
. O 0 6.320773991319584e-06

Southern O 0 4.268558768671937e-05
blot O 0 0.000327116169501096
and O 0 1.174228827949264e-06
PCR O 0 4.021301356260665e-05
analyses O 0 7.017383268248523e-06
have O 0 4.112016540602781e-07
indicated O 0 4.992660933567095e-07
that O 0 3.2733160626463587e-09
the O 0 3.3158389367571317e-09
individual O 0 2.2830137780260884e-08
with O 0 2.779569285848993e-07
anhaptoglobinemia B-Disease 0 0.009036636911332607
was O 0 2.649507450769306e-06
homozygous O 0 5.232687954048743e-07
for O 0 1.2904823876169758e-08
the O 0 2.1705906405600217e-08
gene O 0 1.344763234101265e-07
deletion O 0 1.947062173712766e-06
and O 0 1.0321096510779171e-07
that O 0 7.237541232996136e-09
the O 0 1.9009190665997266e-08
gene O 0 1.320019009654061e-07
deletion O 0 1.2938115787619608e-06
was O 0 1.100157476230379e-07
included O 0 4.403109343797951e-08
at O 0 4.179336698939551e-08
least O 0 4.233183137358765e-09
from O 0 1.6859914353517524e-08
the O 0 3.1849708648223896e-08
promoter O 0 1.389770295645576e-05
region O 0 1.405960006195528e-07
of O 0 1.4746094123552211e-08
Hp O 0 3.267805595896789e-06
to O 0 3.332845821546471e-08
Hpr O 0 8.821998562780209e-06
alpha O 0 2.712641560265183e-07
but O 0 7.853011574354696e-09
not O 0 2.970394374912644e-09
to O 0 9.927591193559238e-09
Hpr O 0 2.7568616133066826e-05
beta O 0 2.020866077145911e-06
( O 0 2.0735190275900095e-07
Hpdel O 0 6.0329064581310377e-05
) O 0 5.094084940537869e-07
. O 0 1.2287823665246833e-06

In O 0 1.1862218343594577e-05
addition O 0 4.066415840497939e-06
, O 0 2.0815411971852882e-07
we O 0 1.4373598311578917e-08
found O 0 3.8221909193225656e-08
seven O 0 3.8657415046827737e-08
individuals O 0 5.960736615406859e-08
with O 0 1.7636219240557693e-07
hypohaptoglobinemia B-Disease 0 0.0014319419860839844
in O 0 6.39754773601453e-08
three O 0 7.812974445187137e-08
families O 0 1.4862097259538132e-06
, O 0 1.0126507987706646e-07
and O 0 3.57296308095556e-08
the O 0 1.6973297434219603e-08
genotypes O 0 2.16615467252268e-06
of O 0 9.87279147324216e-09
six O 0 4.364246919408288e-08
of O 0 1.4111134483130172e-08
the O 0 1.695349638453081e-08
seven O 0 1.6682739101270272e-07
individuals O 0 1.6727601348520693e-07
were O 0 1.4064413278447319e-07
found O 0 1.9611454149526253e-07
to O 0 2.780727115236914e-08
be O 0 8.837535858674528e-08
Hp2 O 0 0.00018919787544291466
/ O 0 7.97197426436469e-05
Hpdel O 0 0.0006895714323036373
. O 0 4.688454282586463e-06

The O 0 1.1239738341828343e-05
phenotypes O 0 0.0004405407526064664
and O 0 2.3642041924176738e-06
genotypes O 0 4.827183875022456e-05
in O 0 7.027296078376821e-08
one O 0 7.279171043705901e-09
of O 0 4.138427822653057e-09
these O 0 3.032275097680781e-09
three O 0 2.6775063943773603e-08
families O 0 1.382685127282457e-06
showed O 0 5.3519493121712e-06
the O 0 5.5970208023836676e-08
father O 0 1.5456050732609583e-06
to O 0 1.9733430889345982e-08
be O 0 3.2770721247743495e-08
hypohaptoglobinemic B-Disease 0 5.547242108150385e-05
( O 0 9.437682990665053e-08
Hp2 O 0 4.0713053749641404e-05
) O 0 3.5573773260466623e-08
and O 0 1.0110007053754089e-07
Hp2 O 0 0.00015687657287344337
/ O 0 1.1367346814949997e-05
Hpdel O 0 0.00011970652121817693
, O 0 9.15131295187166e-08
the O 0 1.6273260072807716e-08
mother O 0 4.423429800226586e-07
to O 0 3.615560961733877e-09
be O 0 5.751481957361193e-09
Hp2 O 0 8.304301445605233e-06
- O 0 1.5276844351319596e-05
1 O 0 1.2233320489940525e-07
and O 0 1.4541399195877602e-07
Hp1 O 0 0.00016147033602464944
/ O 0 8.851046914060134e-06
Hp2 O 0 9.10710368771106e-05
, O 0 3.315460972430628e-08
one O 0 1.3578203006403555e-09
of O 0 1.5296347521953635e-09
the O 0 5.224771726375366e-09
two O 0 2.5046469787071146e-08
children O 0 3.0413187346312043e-07
to O 0 1.578540498314851e-08
be O 0 4.205581305427586e-08
hypohaptoglobinemic B-Disease 0 0.00011679610179271549
( O 0 1.465892864871421e-07
Hp2 O 0 4.30096588388551e-05
) O 0 4.3594049259354506e-08
and O 0 1.6413292769357213e-07
Hp2 O 0 0.00019714327936526388
/ O 0 1.4816379916737787e-05
Hpdel O 0 0.00028520531486719847
, O 0 5.3918398634777986e-08
and O 0 2.2692992374118148e-08
the O 0 1.1507204078498035e-08
other O 0 2.580788738271167e-08
child O 0 1.6470366972498596e-06
to O 0 2.538611987290551e-08
be O 0 2.1058841781496085e-08
Hp1 O 0 3.941401155316271e-05
and O 0 5.918288366046909e-07
Hp1 O 0 0.0004720744036603719
/ O 0 3.6752047890331596e-05
Hpdel O 0 0.0007018081960268319
, O 0 9.910831977322232e-08
showing O 0 4.807516802429745e-07
an O 0 3.939333126368183e-08
anomalous O 0 1.649959449423477e-05
inheritance O 0 1.3324013707460836e-05
of O 0 1.5516557994033064e-07
Hp O 0 0.00027360007516108453
phenotypes O 0 7.740373257547617e-05
in O 0 8.158261977087022e-08
the O 0 1.5763149008307664e-07
child O 0 2.958227378258016e-05
with O 0 6.847503300377866e-06
Hp1 O 0 0.03360413759946823
. O 0 2.211263563367538e-05

The O 0 9.677693924459163e-06
Hp2 O 0 0.004016147926449776
/ O 0 0.0005620409501716495
Hpdel O 0 0.030324053019285202
individuals O 0 8.21172034193296e-06
had O 0 1.2310144938965095e-06
an O 0 4.98004020244025e-08
extremely O 0 6.099973575146578e-07
low O 0 8.179995347745717e-07
level O 0 8.435956289076785e-08
of O 0 1.646037439684278e-08
Hp O 0 1.7793818187783472e-05
( O 0 4.6735166847611254e-08
mean O 0 7.465238383019823e-08
+ O 0 3.7952585785205883e-07
/ O 0 5.896732773180702e-07
- O 0 1.6031555787776597e-05
SD O 0 2.1957719582132995e-05
= O 0 9.389685828864458e-07
0 O 0 7.40879642080472e-08
. O 0 1.3835615320090255e-08
049 O 0 9.518628758087289e-06
+ O 0 5.385918484535068e-07
/ O 0 7.176182066359615e-07
- O 0 8.160786819644272e-06
0 O 0 1.1882998762757779e-07
. O 0 7.233511567505957e-09
043 O 0 7.018742053332971e-06
mg O 0 4.310303211241262e-06
/ O 0 1.2406989071678254e-06
ml O 0 1.598731250851415e-05
; O 0 1.1791942000627387e-07
n O 0 9.335621484751755e-07
= O 0 1.5437620959346532e-06
6 O 0 1.1997850890566042e-07
) O 0 5.591874518984241e-09
, O 0 7.136581992028823e-09
compared O 0 3.942467685646989e-08
with O 0 5.875343322969684e-09
the O 0 6.334406332797471e-09
level O 0 8.375210569511182e-08
( O 0 1.1423318291292617e-08
1 O 0 1.4299193829003798e-08
. O 0 4.834871170089627e-09
64 O 0 1.6457838114547485e-07
+ O 0 5.336865456229134e-07
/ O 0 8.697136308910558e-07
- O 0 4.999482825951418e-06
1 O 0 8.294657760643531e-08
. O 0 8.954780028602727e-09
07 O 0 5.312673465596163e-07
mg O 0 2.7899129690922564e-06
/ O 0 9.556089253237587e-07
ml O 0 4.011167675344041e-06
) O 0 8.001638462928895e-09
obtained O 0 1.0547445583597437e-08
from O 0 1.1893606099988574e-08
52 O 0 9.55474092734221e-07
healthy O 0 1.5632992926839506e-06
volunteers O 0 2.1288365132932086e-06
having O 0 7.45632178222877e-07
phenotype O 0 7.652913154743146e-06
Hp2 O 0 6.462362944148481e-05
, O 0 5.145802717265724e-08
whereas O 0 2.7439831740139198e-08
the O 0 1.3761738415496438e-08
serum O 0 4.310336407797877e-06
Hp O 0 3.5103491882182425e-06
level O 0 7.233832377551153e-08
of O 0 6.401255081556201e-09
an O 0 1.1834363711216156e-08
individual O 0 2.8292079790048774e-08
with O 0 5.564946832237183e-07
Hp1 O 0 0.0046678087674081326
/ O 0 0.00010343406756874174
Hpdel O 0 0.0014324970543384552
was O 0 3.0175610845617484e-06
0 O 0 3.6278943298384547e-06
. O 0 1.8197002873421297e-06

50 O 0 3.5089953598799184e-05
mg O 0 0.00045591199886985123
/ O 0 4.535891639534384e-05
ml O 0 0.00037091693957336247
, O 0 5.210195581639709e-07
which O 0 2.759819039965805e-08
was O 0 3.652311519886098e-08
approximately O 0 7.906304944071962e-09
half O 0 1.970447094379324e-08
the O 0 3.2465115040736237e-09
level O 0 1.3205863957921338e-08
of O 0 8.820457253477798e-09
Hp O 0 3.632564812505734e-06
in O 0 3.799020120709429e-08
control O 0 1.8104312005107204e-07
sera O 0 8.598315616836771e-06
from O 0 2.600697790455797e-08
the O 0 7.490454834169213e-08
Hp1 O 0 0.000887148198671639
phenotype O 0 1.6199875972233713e-05
( O 0 2.251441877376692e-08
1 O 0 2.987703595636049e-08
. O 0 7.081003783326878e-09
26 O 0 1.9549905516669241e-07
+ O 0 7.35539003926533e-07
/ O 0 8.843604746289202e-07
- O 0 1.2253757631697226e-05
0 O 0 8.260555262040725e-08
. O 0 6.200878477358174e-09
33 O 0 1.458662239883779e-07
mg O 0 3.863910023937933e-06
/ O 0 1.4186800854076864e-06
ml O 0 5.626258371194126e-06
; O 0 6.08274319802149e-08
n O 0 5.208625566410774e-07
= O 0 7.098321930243401e-07
9 O 0 7.32489837673711e-08
) O 0 3.184859931337769e-09
, O 0 2.4893669348102776e-09
showing O 0 8.204185064641933e-08
a O 0 2.7898753529598252e-08
gene O 0 4.20594261640872e-07
- O 0 0.0002005026617553085
dosage O 0 5.824341860716231e-05
effect O 0 1.9656913536891807e-06
. O 0 1.4830311556579545e-06

The O 0 3.839050805254374e-06
other O 0 1.130824898609717e-06
allele O 0 7.99537701823283e-06
( O 0 3.103158405792783e-07
Hp2 O 0 0.00015679535863455385
) O 0 4.8003236940985516e-08
of O 0 1.704756336096125e-08
individuals O 0 9.19166893709189e-08
with O 0 3.9209081137414614e-07
Hp2 O 0 0.009872441180050373
/ O 0 0.00018976916908286512
Hpdel O 0 0.00796999130398035
was O 0 2.049665908998577e-06
found O 0 2.4832704070831824e-07
to O 0 1.4361787314953744e-08
have O 0 1.1680794109736325e-08
, O 0 5.0378954341567805e-09
in O 0 1.867268339950101e-09
all O 0 2.00899541447086e-09
exons O 0 7.398177217510238e-07
, O 0 8.086794878181536e-08
no O 0 5.0431850695531466e-08
mutation O 0 1.6232735333687742e-07
, O 0 1.831090301607219e-08
by O 0 3.761598676987887e-08
DNA O 0 4.200821422273293e-06
sequencing O 0 1.3887804925616365e-05
. O 0 3.8717148527211975e-06

On O 0 2.949332611024147e-06
the O 0 1.3289430000895663e-07
basis O 0 3.78039288762011e-08
of O 0 2.1863593602233777e-08
the O 0 4.538392772701627e-08
present O 0 9.668625722270008e-08
study O 0 8.52574899568026e-08
, O 0 2.3922128278286436e-08
the O 0 1.4082742971766038e-08
mechanism O 0 8.371473114721084e-08
of O 0 5.320837104250131e-08
anhaptoglobinemia B-Disease 0 0.0009159644250757992
and O 0 9.985668469880693e-08
the O 0 1.3607766469192484e-08
mechanism O 0 8.27410033821252e-08
of O 0 2.521172959291107e-08
anomalous O 0 1.4050530808162875e-05
inheritance O 0 8.303153663291596e-06
of O 0 3.4451682040526066e-07
Hp O 0 0.00042422147816978395
phenotypes O 0 0.00017751750419847667
were O 0 1.0627818483044393e-06
well O 0 6.497029971797019e-07
explained O 0 9.909081200021319e-06
. O 0 4.203290245641256e-06

However O 0 2.0914452761644498e-05
, O 0 1.2879811492894078e-06
the O 0 1.0918292048245348e-07
mechanism O 0 7.070189553814998e-07
of O 0 4.5384101099443797e-07
hypohaptoglobinemia B-Disease 0 0.028580008074641228
remains O 0 0.00013745554315391928
unknown O 0 5.86924834351521e-05

ATM O 0 0.01213170774281025
mutations O 0 0.0015936107374727726
and O 0 1.0531089174037334e-05
phenotypes O 0 0.0011230866657570004
in O 0 5.941844574408606e-05
ataxia B-Disease 1 0.999922513961792
- I-Disease 1 0.9997900128364563
telangiectasia I-Disease 1 0.9999589920043945
families O 0 6.274555198615417e-05
in O 0 1.3677586707672162e-07
the O 0 6.238106209366379e-08
British O 0 4.902331056655385e-06
Isles O 0 6.58213548376807e-06
: O 0 3.1790474253057255e-08
expression O 0 1.263650428739993e-08
of O 0 4.594060243334752e-09
mutant O 0 7.623111741850153e-07
ATM O 0 5.272313046589261e-06
and O 0 1.6261306257092656e-07
the O 0 1.4661404179605597e-07
risk O 0 3.1664370908401906e-05
of O 0 3.321957774460316e-05
leukemia B-Disease 1 0.9999604225158691
, O 0 0.15741626918315887
lymphoma B-Disease 1 0.9999986886978149
, O 0 0.0012002523289993405
and O 0 0.048912934958934784
breast B-Disease 1 0.9996674060821533
cancer I-Disease 1 0.9004024863243103
. O 0 6.672924791928381e-05

We O 0 2.364086867601145e-06
report O 0 5.259639692667406e-07
the O 0 2.5239444312319392e-08
spectrum O 0 2.6680910991672135e-07
of O 0 2.5079359033952642e-08
59 O 0 9.355208931083325e-06
ATM O 0 0.00015433260705322027
mutations O 0 1.328704001934966e-05
observed O 0 1.770576432136295e-06
in O 0 1.9611281913967105e-06
ataxia B-Disease 1 0.9994694590568542
- I-Disease 1 0.9995160102844238
telangiectasia I-Disease 1 0.9999597072601318
( O 0 1.3007114830543287e-05
A B-Disease 0 0.0023737812880426645
- I-Disease 1 0.9996150732040405
T I-Disease 1 0.9999815225601196
) O 0 1.7829386706580408e-05
patients O 0 2.9190947316237725e-05
in O 0 2.683324495933448e-08
the O 0 1.4906638057254895e-07
British O 0 2.2300049749901518e-05
Isles O 0 0.00018025454482994974
. O 0 8.863878974807449e-06

Of O 0 2.88645696855383e-06
51 O 0 2.8965307137696072e-05
ATM O 0 0.0009543329360894859
mutations O 0 0.00013497835607267916
identified O 0 6.973274139454588e-06
in O 0 7.835853210735877e-08
families O 0 6.97024177043204e-07
native O 0 3.3856605341497925e-07
to O 0 1.1363903595906777e-08
the O 0 1.7126270179801395e-08
British O 0 3.4040735954476986e-06
Isles O 0 8.773261470196303e-06
, O 0 1.7412308750408556e-07
11 O 0 4.5198197540230467e-07
were O 0 3.8320243334055704e-07
founder O 0 0.00010421710612718016
mutations O 0 2.7002315619029105e-06
, O 0 3.940633064303256e-08
and O 0 2.8792591422188707e-08
2 O 0 3.366477230315468e-08
of O 0 8.491404912547296e-09
these O 0 6.933272622688946e-09
11 O 0 4.5853352048652596e-07
conferred O 0 5.656844223267399e-06
a O 0 4.3700859464479436e-07
milder O 0 0.00020105551811866462
clinical O 0 0.0001853571884566918
phenotype O 0 3.2124378776643425e-05
with O 0 1.723852420809635e-07
respect O 0 1.0381214110566361e-07
to O 0 6.569929666966345e-08
both O 0 1.281057393498486e-06
cerebellar B-Disease 1 0.5974072813987732
degeneration I-Disease 1 0.8690502047538757
and O 0 1.0411874427518342e-05
cellular O 0 0.0009038087446242571
features O 0 7.372872642008588e-05
. O 0 2.3362115825875662e-05

We O 0 3.5102957554045133e-06
report O 0 1.450288550586265e-06
, O 0 4.692936173000817e-08
in O 0 1.0076987244644897e-08
two O 0 2.9022730885230885e-08
A B-Disease 0 4.884319787379354e-05
- I-Disease 1 0.963688313961029
T I-Disease 1 0.9998558759689331
families O 0 6.51143500363105e-06
, O 0 9.065023931498217e-08
an O 0 2.6515419193628986e-08
ATM O 0 6.556315929628909e-05
mutation O 0 1.4062443369766697e-06
( O 0 3.076681309721607e-08
7271T O 0 7.805341738276184e-06
- O 0 0.00017426379781682044
- O 0 0.0012601580237969756
> O 0 2.139280150004197e-05
G O 0 0.00019556521147023886
) O 0 3.6849048257181494e-08
that O 0 1.5187048063580733e-08
may O 0 8.301906717633756e-08
be O 0 8.454122735201963e-09
associated O 0 3.383206959028939e-08
with O 0 3.47265185496326e-08
an O 0 2.4466368131470517e-07
increased O 0 1.1851341696456075e-05
risk O 0 0.00014921490219421685
of O 0 1.159523890237324e-05
breast B-Disease 1 0.9983471632003784
cancer I-Disease 0 0.2478659451007843
in O 0 2.2254796760989848e-07
both O 0 7.076963015606452e-07
homozygotes O 0 0.00301315076649189
and O 0 7.870153240219224e-06
heterozygotes O 0 0.001938851666636765
( O 0 8.247690743701241e-07
relative O 0 5.705871899408521e-06
risk O 0 1.722798879200127e-05
12 O 0 1.9372237147763371e-07
. O 0 1.2875075228180322e-08
7 O 0 1.4714548512984038e-07
; O 0 2.966512795410381e-07
P O 0 4.7812325647100806e-05
= O 0 8.135579264489934e-06
. O 0 1.0181762633010294e-07
0025 O 0 0.00023897924984339625
) O 0 4.220801486098935e-08
, O 0 3.505526535718673e-08
although O 0 1.6038944394836108e-08
there O 0 2.7683422221258525e-09
is O 0 5.820465887040882e-09
a O 0 6.87356234152503e-08
less O 0 2.4843272967700614e-06
severe O 0 0.0037713677156716585
A B-Disease 0 0.0011451550526544452
- I-Disease 1 0.9996242523193359
T I-Disease 1 0.9999701976776123
phenotype O 0 0.0001705223403405398
in O 0 3.914406576654983e-08
terms O 0 6.584431133660473e-08
of O 0 1.0428184538113783e-08
the O 0 6.365073801362087e-08
degree O 0 5.945651082583936e-06
of O 0 2.0221237718942575e-05
cerebellar B-Disease 1 0.985781729221344
degeneration I-Disease 1 0.9976986050605774
. O 0 0.0001973778271349147

This O 0 1.660524503677152e-06
mutation O 0 8.806826372165233e-06
( O 0 2.0615838991489e-07
7271T O 0 3.599262345233001e-05
- O 0 0.00048764742678031325
- O 0 0.004309454467147589
> O 0 3.6815221392316744e-05
G O 0 0.00010437055607326329
) O 0 3.0707482778780104e-08
also O 0 3.226479750040312e-09
allows O 0 2.93843260834592e-09
expression O 0 5.692526006129128e-09
of O 0 1.706941921142402e-09
full O 0 2.6273417219613293e-08
- O 0 1.008137951430399e-05
length O 0 1.7844193678229203e-07
ATM O 0 3.1908193705021404e-06
protein O 0 1.338356714342126e-08
at O 0 5.5562692224953025e-09
a O 0 3.1893463425802793e-09
level O 0 1.6578088235519317e-08
comparable O 0 1.8309073368527606e-07
with O 0 5.269660974249746e-08
that O 0 4.373713125005452e-08
in O 0 2.5326252739432675e-07
unaffected O 0 9.160356421489269e-05
individuals O 0 4.56051293440396e-06
. O 0 6.491099156846758e-06

In O 0 3.5487851164361928e-06
addition O 0 2.4165403829101706e-06
, O 0 1.4517594593144167e-07
we O 0 1.4478154675146016e-08
have O 0 7.3016139801040936e-09
studied O 0 7.854752226421624e-08
18 O 0 3.958064951348206e-07
A B-Disease 0 8.366252586711198e-05
- I-Disease 1 0.999467670917511
T I-Disease 1 0.9999953508377075
patients O 0 0.009102804586291313
, O 0 2.0842665549025696e-07
in O 0 3.8378239253233914e-08
15 O 0 3.3353234130117926e-07
families O 0 1.4435945558943786e-06
, O 0 2.1036096313764574e-06
who O 0 0.00010845792712643743
developed O 0 0.014262950047850609
leukemia B-Disease 1 0.999895453453064
, O 0 0.010769092477858067
lymphoma B-Disease 1 0.9999964237213135
, O 0 2.045352812274359e-05
preleukemic O 0 0.04452700912952423
T O 0 0.17323286831378937
- O 0 0.009759177453815937
cell O 0 0.001642953255213797
proliferation O 0 0.005092156585305929
, O 0 2.4636481612105854e-05
or O 0 0.03781752288341522
Hodgkin B-Disease 1 0.9999967813491821
lymphoma I-Disease 1 0.9999985694885254
, O 0 2.552293153712526e-05
mostly O 0 2.484012156855897e-06
in O 0 1.4812318340773345e-06
childhood O 0 0.000257859326666221
. O 0 1.0029615623352583e-05

A O 0 1.8137445294996724e-05
wide O 0 8.18043827166548e-06
variety O 0 4.892033871328749e-07
of O 0 1.1051356096913878e-07
ATM O 0 0.0005093521322123706
mutation O 0 7.5666334851121064e-06
types O 0 5.45183866051957e-07
, O 0 1.0458564503323942e-07
including O 0 6.466702870966401e-07
missense O 0 0.0003793800133280456
mutations O 0 1.2269613762327936e-05
and O 0 1.67505092463216e-07
in O 0 4.3374754454816866e-08
- O 0 0.00013909893459640443
frame O 0 4.545080810203217e-05
deletions O 0 7.484009256586432e-05
, O 0 2.894321937674249e-07
were O 0 1.129965099266883e-07
seen O 0 3.5785492968898325e-07
in O 0 8.361435988035737e-08
these O 0 4.852885240325122e-07
patients O 0 0.00013324787141755223
. O 0 4.081965471414151e-06

We O 0 2.2208926111488836e-06
also O 0 2.768637727967871e-07
show O 0 3.590945141240809e-08
that O 0 3.6142646653303245e-09
25 O 0 1.3832869960594962e-08
% O 0 3.106357171489549e-09
of O 0 2.3178503560927766e-09
all O 0 9.53813383830493e-09
A B-Disease 0 5.049391620559618e-05
- I-Disease 1 0.9979681372642517
T I-Disease 1 0.9999867677688599
patients O 0 0.0006367996684275568
carried O 0 3.1295613212023454e-07
in O 0 4.497289651794745e-08
- O 0 7.607947190990672e-05
frame O 0 2.5427334549021907e-05
deletions O 0 3.978939639637247e-05
or O 0 6.573344535354408e-07
missense O 0 0.0001600063405930996
mutations O 0 1.1209252079424914e-05
, O 0 3.822234972972183e-08
many O 0 5.754499543542124e-09
of O 0 7.268557755679694e-09
which O 0 5.81274726130232e-08
were O 0 4.813609280063247e-07
also O 0 3.859987600662862e-07
associated O 0 1.6991994300497026e-07
with O 0 3.089323996618987e-08
expression O 0 6.101799954194576e-08
of O 0 3.606994170013422e-08
mutant O 0 1.560154851176776e-05
ATM O 0 0.000263904279563576
protein O 0 3.442163915678975e-06
. O 0 2.5002589154610178e-06

The O 0 1.8898581402027048e-05
DMPK O 0 0.004115777090191841
gene O 0 2.4756644052104093e-05
of O 0 9.197662620863412e-06
severely O 1 0.953557014465332
affected O 0 0.3928743898868561
myotonic B-Disease 1 0.9999951124191284
dystrophy I-Disease 1 0.9999984502792358
patients O 1 0.990003228187561
is O 0 1.0557081623119302e-05
hypermethylated O 0 0.26992130279541016
proximal O 0 0.0023697216529399157
to O 0 1.0240073322620447e-07
the O 0 7.011631453224254e-08
largely O 0 8.388157652916561e-07
expanded O 0 2.7982907795376377e-06
CTG O 0 0.0010848359670490026
repeat O 0 3.659435242298059e-05
. O 0 4.841711415792815e-06

Using O 0 5.07709910380072e-06
methylation O 0 4.9833532102638856e-05
- O 0 0.0004899355699308217
sensitive O 0 2.148738713003695e-05
restriction O 0 1.5236537365126424e-06
enzymes O 0 1.071901124305441e-06
, O 0 4.7196049735021006e-08
we O 0 4.714348467160789e-09
characterized O 0 8.122116668118906e-08
the O 0 2.992024628056811e-09
methylation O 0 3.542016031587991e-07
pattern O 0 1.8847815397293743e-07
on O 0 5.413015102817553e-08
the O 0 1.938862403960684e-08
5 O 0 1.3010334498630982e-07
side O 0 9.684424639999634e-08
of O 0 6.6608754067942755e-09
the O 0 2.493631079403258e-08
CTG O 0 9.330212196800858e-05
repeat O 0 1.0551327704888536e-06
in O 0 1.4072538689902103e-08
the O 0 1.9360170355753326e-08
DMPK O 0 0.00017140884301625192
gene O 0 5.322745266767015e-08
of O 0 1.2077976840885185e-08
normal O 0 1.0955611884355676e-07
individuals O 0 1.1425544954590805e-07
and O 0 2.02639981239372e-07
of O 0 1.6903469486351241e-06
patients O 0 0.0026280342135578394
affected O 0 3.412819205550477e-05
with O 0 0.001421706867404282
myotonic B-Disease 1 0.9999972581863403
dystrophy I-Disease 1 0.9999889135360718
, O 0 8.15062867332017e-06
showing O 0 9.498878171143588e-06
expansions O 0 6.813077561673708e-06
of O 0 5.1669186262870426e-08
the O 0 2.1988054754729092e-07
repetitive O 0 0.00012712908210232854
sequence O 0 2.5282336082455004e-06
. O 0 5.2073123697482515e-06

The O 0 1.7832553567131981e-06
gene O 0 2.239788727820269e-06
segment O 0 9.888378826872213e-07
analyzed O 0 3.668985470994812e-07
corresponds O 0 6.914799399737603e-08
to O 0 5.98888183489521e-09
the O 0 1.0714116704946264e-08
genomic O 0 2.8290623959037475e-06
SacI O 0 0.00010780440788948908
- O 0 6.816419045208022e-05
HindIII O 0 4.364159030956216e-05
fragment O 0 6.208289278220036e-07
carrying O 0 2.4180840796361736e-07
exons O 0 1.1912517265955103e-06
11 O 0 4.805060029866581e-07
- O 0 8.967514440882951e-05
15 O 0 3.7703014186263317e-06
. O 0 2.4236858280346496e-06

There O 0 2.4144785584212514e-06
is O 0 1.5132174269183452e-07
constitutive O 0 4.81734696222702e-06
methylation O 0 2.6536495170148555e-06
in O 0 7.595624396117273e-08
intron O 0 4.114999683224596e-05
12 O 0 4.440734073796193e-07
at O 0 1.1090717322304045e-07
restriction O 0 3.293929040637522e-08
sites O 0 9.537515666124818e-09
of O 0 1.436965124668177e-08
SacII O 0 5.7134551752824336e-05
and O 0 3.6986645568504173e-07
HhaI O 0 0.00016266859893221408
, O 0 1.0961631602413036e-07
localized O 0 5.589541274275689e-07
1 O 0 3.5741557269375335e-08
, O 0 1.9378974869255217e-08
159 O 0 1.9610290564742172e-06
- O 0 9.167827374767512e-05
1 O 0 1.6116567280732852e-07
, O 0 3.187742336763222e-08
232 O 0 5.006058358958398e-07
bp O 0 1.4997947801020928e-05
upstream O 0 1.1089934304209237e-07
of O 0 3.1614859619111257e-09
the O 0 1.397608073716583e-08
CTG O 0 4.749721847474575e-05
repeat O 0 2.2226681721804198e-06
, O 0 5.470818464914373e-08
whereas O 0 4.520319762946201e-08
most O 0 1.0271681283313683e-08
, O 0 2.2465302507157503e-08
if O 0 7.079680397481525e-09
not O 0 8.530473549761552e-10
all O 0 7.498366927372047e-10
, O 0 4.309403056623751e-09
of O 0 2.341034255337604e-09
the O 0 4.90073492898091e-09
other O 0 4.421672805676735e-09
sites O 0 3.1288177382293725e-08
of O 0 5.192169894030485e-08
SacII O 0 0.00040719195385463536
, O 0 6.844426820862282e-07
HhaI O 0 0.00024461362045258284
, O 0 2.510267052002746e-07
and O 0 1.4971691086884675e-07
HpaII O 0 7.578896475024521e-05
in O 0 2.7524224677222264e-08
this O 0 4.566454325782843e-09
region O 0 5.158804228244662e-08
are O 0 1.2951477224021346e-08
unmethylated O 0 4.2662843043217435e-05
, O 0 9.640579889946821e-08
in O 0 2.284647315775601e-08
normal O 0 5.388663026906215e-08
individuals O 0 6.084309944753841e-08
and O 0 5.0525244432719774e-08
most O 0 2.3075561017549262e-08
of O 0 9.812327306235602e-08
the O 0 5.6859798860386945e-06
patients O 0 0.0007356677670031786
. O 0 5.26216581420158e-06

In O 0 2.5939559691323666e-06
a O 0 3.839552675799496e-07
number O 0 7.626923803627506e-08
of O 0 8.270771445495484e-08
young O 0 5.3586900321533903e-05
and O 0 1.973591497517191e-05
severely O 1 0.6479536890983582
affected O 0 0.00016487983521074057
patients O 0 0.0001953700848389417
, O 0 3.3125601817118877e-07
however O 0 5.0822158925711847e-08
, O 0 1.0442574804869764e-08
complete O 0 2.9855616645591e-08
methylation O 0 3.9297430021179025e-07
of O 0 1.0227011237873285e-08
these O 0 3.5205613979627515e-09
restriction O 0 4.732910596771944e-08
sites O 0 4.8418872466982066e-08
was O 0 1.1614351080879715e-07
found O 0 3.923608460354444e-08
in O 0 1.3143043098295948e-08
the O 0 2.0456282356917654e-07
mutated O 0 2.9687489586649463e-05
allele O 0 1.095149309549015e-05
. O 0 4.438576070242561e-06

In O 0 3.179083023496787e-06
most O 0 2.585659899523307e-07
of O 0 1.3094405915126117e-07
these O 0 1.994697953477953e-07
patients O 0 3.475110133877024e-05
, O 0 7.734848850304843e-08
the O 0 6.634972748997825e-08
onset O 0 5.6607950682519004e-05
of O 0 1.4238361245588749e-06
the O 0 0.00026021074154414237
disease O 1 0.9529356956481934
was O 0 0.08644404262304306
congenital O 1 0.9998323917388916
. O 0 0.0002575217804405838

Preliminary O 0 2.6518448066781275e-05
in O 0 2.761346422630595e-06
vivo O 0 0.00012266208068467677
footprinting O 0 0.0016195555217564106
data O 0 3.8762931353630847e-07
gave O 0 1.91143428196483e-07
evidence O 0 5.024664062602824e-08
for O 0 6.839335320307782e-09
protein O 0 1.937428173448552e-08
- O 0 9.927167411660776e-06
DNA O 0 2.5444446691835765e-06
contact O 0 1.6469394381601887e-07
in O 0 1.055827514306884e-08
normal O 0 3.4868087084305444e-08
genes O 0 7.098342535982738e-08
at O 0 8.737475098996583e-08
an O 0 7.3742704387314e-08
Sp1 O 0 0.00028260823455639184
consensus O 0 1.2558706430354505e-07
binding O 0 2.5749139354047657e-07
site O 0 7.855830830294508e-08
upstream O 0 4.271337061823033e-08
of O 0 2.7854607509425477e-09
the O 0 2.343063520982014e-08
CTG O 0 8.7878288468346e-05
repeat O 0 9.948063279807684e-07
and O 0 2.584991065646136e-08
for O 0 7.569154192310634e-09
a O 0 2.9220581510003285e-08
significant O 0 1.0282975893005641e-07
reduction O 0 4.953557777298556e-07
of O 0 4.9187618422763535e-09
this O 0 1.3497485351621208e-09
interaction O 0 9.963671665502716e-09
in O 0 1.9058637334978812e-08
cells O 0 1.6037316186157113e-07
with O 0 2.9383890876033547e-08
a O 0 4.7069025299606437e-07
hypermethylated O 0 0.030704239383339882
DMPK O 0 0.05634118616580963
gene O 0 2.6240172701363917e-06
. O 0 3.320964481190458e-07
. O 0 1.836711703617766e-06

The O 0 5.529764894163236e-05
hemochromatosis B-Disease 1 0.9989173412322998
gene O 0 2.970227251353208e-05
product O 0 2.5716376512718853e-06
complexes O 0 8.435102358816948e-07
with O 0 2.4434649859017554e-08
the O 0 3.30912435231312e-08
transferrin O 0 6.28814595984295e-05
receptor O 0 1.8147194396078703e-06
and O 0 8.250336236415023e-08
lowers O 0 1.2818914001400117e-05
its O 0 1.871933541508497e-08
affinity O 0 3.9827941122894117e-07
for O 0 3.9620218217351066e-08
ligand O 0 5.159501597518101e-06
binding O 0 4.9496702558826655e-06
. O 0 2.5283613922510995e-06

We O 0 5.4848369472892955e-06
recently O 0 2.175703048123978e-05
reported O 0 1.393739580635156e-06
the O 0 1.2907531043993004e-08
positional O 0 6.801280392210174e-07
cloning O 0 7.527398224738135e-07
of O 0 1.4896371247630213e-08
a O 0 1.7654998885063833e-07
candidate O 0 3.293281224614475e-06
gene O 0 2.9684756555070635e-06
for O 0 2.3828151825000532e-05
hereditary B-Disease 1 0.9997969269752502
hemochromatosis I-Disease 1 0.9999932050704956
called O 0 0.008721879683434963
HFE O 1 0.7408586144447327
. O 0 4.184408680885099e-05

The O 0 4.33894228990539e-06
gene O 0 6.748784926458029e-06
product O 0 1.5067329286466702e-06
, O 0 1.1098398289277611e-07
a O 0 6.491752913007076e-08
member O 0 1.5682866205679602e-07
of O 0 8.846977372911624e-09
the O 0 4.360053296181832e-08
major O 0 5.128350949235028e-06
histocompatibility O 0 0.23485316336154938
complex O 0 1.2625450835912488e-05
class O 0 1.3883556675864384e-05
I O 0 1.1764730061258888e-06
- O 0 0.00015882827574387193
like O 0 2.87667944576242e-06
family O 0 1.3055741874268278e-06
, O 0 1.2014258743420214e-07
was O 0 2.5281056537096447e-07
found O 0 7.709089544505332e-08
to O 0 7.92802001825521e-09
have O 0 1.1783415132526898e-08
a O 0 2.6482311454856244e-08
mutation O 0 4.2701722691163013e-07
, O 0 1.043063520000942e-07
Cys O 0 0.00027357868384569883
- O 0 3.505871063680388e-05
282 O 0 2.1797652152599767e-05
- O 0 0.00033891640487127006
- O 0 0.0015640640631318092
> O 0 2.2019074094714597e-05
Tyr O 0 0.0007769028306938708
( O 0 1.0848544462760401e-07
C282Y O 0 6.168498202896444e-06
) O 0 1.284777173538032e-08
, O 0 4.362330052742891e-09
in O 0 4.958824906253767e-09
85 O 0 3.2353958090425294e-07
% O 0 5.2021619012521114e-08
of O 0 1.7035870314430213e-07
patient O 0 6.734576891176403e-05
chromosomes O 0 9.266141569241881e-05
. O 0 1.1193078535143286e-05

This O 0 2.369915364397457e-06
mutation O 0 1.5256838196364697e-05
eliminates O 0 1.7114149159169756e-05
the O 0 1.6571770800055674e-07
ability O 0 2.1895230872814864e-07
of O 0 4.404671827273887e-08
HFE O 0 0.0004409532994031906
to O 0 3.442317009216822e-08
associate O 0 4.981845336260449e-07
with O 0 1.8798861844970816e-07
beta2 O 0 0.002007877454161644
- O 0 0.008670511655509472
microglobulin O 0 0.0073685660026967525
( O 0 2.0413291679233225e-07
beta2m O 0 0.00010958159691654146
) O 0 2.375711716240403e-08
and O 0 2.3420625439030118e-08
prevents O 0 1.3715797422264586e-06
cell O 0 2.6269837690051645e-05
- O 0 0.0017570280469954014
surface O 0 7.460181950591505e-05
expression O 0 5.199134193389909e-06
. O 0 2.5163076315948274e-06

A O 0 1.285494272451615e-05
second O 0 5.231134309724439e-06
mutation O 0 6.799031325499527e-06
that O 0 6.698257948301034e-08
has O 0 8.636833825903523e-08
no O 0 1.9449442945074225e-08
effect O 0 1.1092282647950924e-07
on O 0 4.288393995466322e-07
beta2m O 0 0.02945130318403244
association O 0 1.7222240785486065e-05
, O 0 3.688843435156741e-07
H63D O 0 0.0021487653721123934
, O 0 2.598945343379455e-07
was O 0 2.2475595073956356e-07
found O 0 4.610697601492575e-08
in O 0 3.2645559588928563e-09
eight O 0 1.3647456498233623e-08
out O 0 1.6004719327611383e-08
of O 0 2.6525128760113148e-08
nine O 0 7.2168368205893785e-06
patients O 0 3.531541005941108e-05
heterozygous O 0 3.412804119307111e-07
for O 0 4.351131011048892e-08
the O 0 2.3273457827599486e-07
C282Y O 0 0.00019339416758157313
mutant O 0 5.2224917453713715e-05
. O 0 3.5249652228230843e-06

In O 0 5.547521141124889e-06
this O 0 1.1119120557623319e-07
report O 0 2.8726498157993774e-07
, O 0 3.6917288781523894e-08
we O 0 4.573148082442913e-09
demonstrate O 0 3.8926884826651076e-08
in O 0 7.948156799386652e-09
cultured O 0 2.0997592855565017e-06
293 O 0 2.632940413604956e-05
cells O 0 3.699761919051525e-06
overexpressing O 0 0.00011017096403520554
wild O 0 1.8233134824185981e-06
- O 0 0.00023092972696758807
type O 0 2.208382966273348e-06
or O 0 2.472070264047943e-07
mutant O 0 1.3251454220153391e-05
HFE O 0 0.0003442149900365621
proteins O 0 6.494601478834738e-08
that O 0 4.478430071230832e-09
both O 0 9.092605779414953e-09
the O 0 1.3803536980105946e-08
wild O 0 1.1901217931153951e-06
- O 0 0.000468946760520339
type O 0 3.0733904168300796e-06
and O 0 9.03887325875985e-07
H63D O 0 0.01798468641936779
HFE O 0 0.002090499270707369
proteins O 0 2.8389632689140853e-07
form O 0 1.0868136257613514e-07
stable O 0 4.1146449802909046e-07
complexes O 0 3.867526743306371e-07
with O 0 3.844975182687449e-08
the O 0 2.624495323289011e-07
transferrin O 0 0.004487004596740007
receptor O 0 7.350942178163677e-05
( O 0 9.68975996329391e-07
TfR O 0 0.00030892714858055115
) O 0 6.894168791404809e-07
. O 0 2.2219687707547564e-06

The O 0 7.788522452756297e-06
C282Y O 0 0.0005552161019295454
mutation O 0 1.9604063709266484e-05
nearly O 0 1.8682135305425618e-06
completely O 0 1.3132151934769354e-06
prevents O 0 9.433252898816136e-07
the O 0 4.7427878513417454e-08
association O 0 3.9123773376559257e-07
of O 0 9.408150702938656e-09
the O 0 5.418190340833462e-08
mutant O 0 9.752648111316375e-06
HFE O 0 0.0003967425727751106
protein O 0 1.2935312554418488e-07
with O 0 6.391827156448926e-08
the O 0 1.3450304550133296e-06
TfR O 0 0.0010864597279578447
. O 0 6.64795197735657e-06

Studies O 0 2.7946693080593832e-05
on O 0 3.864282007270958e-06
cell O 0 6.296030915109441e-05
- O 0 0.001077555469237268
associated O 0 2.9547604754043277e-06
transferrin O 0 1.2911299563711509e-05
at O 0 1.2918903280478844e-07
37 O 0 2.742314961778902e-07
degrees O 0 1.0491230284515041e-07
C O 0 2.909006980189588e-06
suggest O 0 1.1321310466883006e-07
that O 0 5.255735846532161e-09
the O 0 2.2040829605884937e-08
overexpressed O 0 1.4413384633371606e-05
wild O 0 8.144500043272274e-07
- O 0 0.000228028729907237
type O 0 2.6765931124828057e-06
HFE O 0 0.00014083714631851763
protein O 0 1.0890214952041788e-07
decreases O 0 1.7053440615200088e-07
the O 0 4.653784912989067e-09
affinity O 0 1.3492426376160438e-07
of O 0 8.86200801630821e-09
the O 0 1.4043237683836196e-07
TfR O 0 7.954463944770396e-05
for O 0 1.8366923768553534e-06
transferrin O 0 0.0010471505811437964
. O 0 5.0964895308425184e-06

The O 0 1.1222997272852808e-05
overexpressed O 0 0.001564953476190567
H63D O 0 0.00870788935571909
protein O 0 3.262244263169123e-06
does O 0 1.1235007235654848e-07
not O 0 1.4235325807021582e-08
have O 0 6.940735097771267e-09
this O 0 1.2656373726827042e-09
effect O 0 3.934970393970616e-08
, O 0 1.2532285431632317e-08
providing O 0 4.546901521962354e-08
the O 0 4.702395361988465e-09
first O 0 8.02321675763551e-09
direct O 0 1.2454220765789614e-08
evidence O 0 1.3285399802498432e-07
for O 0 2.922504194202702e-08
a O 0 1.7668104135282192e-07
functional O 0 1.4187747865435085e-06
consequence O 0 1.6145423842317541e-06
of O 0 5.595526531010364e-08
the O 0 1.0263855756420526e-06
H63D O 0 0.15565048158168793
mutation O 0 3.331704283482395e-05
. O 0 5.33141928826808e-06

Addition O 0 1.0562671377556399e-05
of O 0 1.2182622413092759e-06
soluble O 0 4.632209675037302e-05
wild O 0 8.688384696142748e-06
- O 0 0.004511265549808741
type O 0 1.4181582628225442e-05
HFE O 0 0.0035042327363044024
/ O 0 6.801367999287322e-05
beta2m O 0 0.0013473185244947672
heterodimers O 0 0.00021293768077157438
to O 0 1.0304415809514467e-07
cultured O 0 2.184539334848523e-05
cells O 0 4.120226549275685e-06
also O 0 8.632847681155909e-08
decreased O 0 6.611305138903845e-07
the O 0 1.2969003648777289e-08
apparent O 0 7.465137628059892e-07
affinity O 0 2.4636659645693726e-07
of O 0 1.1469908578476407e-08
the O 0 2.1500666136375912e-08
TfR O 0 1.442331267753616e-05
for O 0 1.567433827176501e-08
its O 0 1.7285501030528394e-08
ligand O 0 8.443649903711048e-07
under O 0 1.0051977028524561e-07
steady O 0 1.666557977841876e-06
- O 0 4.808581434190273e-05
state O 0 3.476121719359071e-07
conditions O 0 4.926721999254369e-07
, O 0 1.4814146354069635e-08
both O 0 6.47278453058675e-09
in O 0 1.0428024665998237e-08
293 O 0 8.410397640545852e-06
cells O 0 1.7386702211297234e-06
and O 0 1.9757843006118492e-07
in O 0 6.391290412466333e-07
HeLa O 0 0.013195405714213848
cells O 0 6.681941158603877e-05
. O 0 3.1315009891841328e-06

Furthermore O 0 5.604652687907219e-05
, O 0 1.0043100928669446e-06
at O 0 2.006186576863911e-07
4 O 0 2.1738188138442638e-07
degrees O 0 5.783352321486745e-07
C O 0 1.1906965482921805e-05
, O 0 5.298799266029164e-08
the O 0 2.12664765797399e-08
added O 0 3.364834526564664e-07
soluble O 0 1.3169513977118186e-06
complex O 0 1.5625509774963575e-07
of O 0 1.1177744596579942e-07
HFE O 0 0.006249184254556894
/ O 0 4.6234978071879596e-05
beta2m O 0 0.00102088728453964
inhibited O 0 4.04042339141597e-06
binding O 0 7.716974437244062e-08
of O 0 1.2581862662841559e-08
transferrin O 0 8.799211173027288e-06
to O 0 4.5411724158839206e-08
HeLa O 0 0.00016159015649463981
cell O 0 1.661550959397573e-05
TfR O 0 4.13372072216589e-05
in O 0 2.1274347616895284e-08
a O 0 1.1968182889177115e-07
concentration O 0 2.928538560809102e-05
- O 0 0.0007098868954926729
dependent O 0 8.769680789555423e-06
manner O 0 3.857190677081235e-06
. O 0 3.811547912846436e-06

Scatchard O 0 0.0005636004498228431
plots O 0 9.323582162323873e-06
of O 0 2.70481422148805e-07
these O 0 2.8568090115754785e-08
data O 0 1.5216514270832704e-07
indicate O 0 2.5382351509506407e-07
that O 0 6.536068131168804e-09
the O 0 1.4486772670352366e-08
added O 0 2.575306723429094e-07
heterodimer O 0 3.254031253163703e-05
substantially O 0 9.065851372724865e-06
reduced O 0 2.5328188257844886e-07
the O 0 1.045754327577697e-08
affinity O 0 6.458308803303225e-07
of O 0 1.0630336788608474e-07
TfR O 0 0.00012127619265811518
for O 0 1.651388629397843e-06
transferrin O 0 0.0006089873495511711
. O 0 4.265062671038322e-06

These O 0 1.3984607676320593e-06
results O 0 1.2678133316512685e-06
establish O 0 3.9707302335045824e-07
a O 0 8.465389100820175e-08
molecular O 0 1.8323360109206988e-06
link O 0 1.8705596858126228e-06
between O 0 3.816116418420279e-07
HFE O 0 0.0047332970425486565
and O 0 4.723774793546909e-07
a O 0 9.031595027408912e-08
key O 0 9.344180966763815e-07
protein O 0 6.145540965007967e-08
involved O 0 9.765481934209674e-08
in O 0 1.0016073304086603e-07
iron O 0 0.0009269026340916753
transport O 0 6.9957068262738176e-06
, O 0 6.417541698056084e-08
the O 0 4.489867322376995e-08
TfR O 0 5.815223994432017e-05
, O 0 5.875200770333322e-08
and O 0 4.454875934811753e-08
raise O 0 2.3280917105239496e-07
the O 0 1.6698233906708992e-08
possibility O 0 7.899304250713612e-07
that O 0 3.961946148933748e-08
alterations O 0 5.619388957711635e-06
in O 0 3.5641416928910985e-08
this O 0 1.0616898471482727e-08
regulatory O 0 3.1241897886502557e-06
mechanism O 0 2.744446874203277e-06
may O 0 3.8343051755873603e-07
play O 0 1.5957777321773392e-08
a O 0 4.132332520612181e-08
role O 0 1.9702598308413144e-07
in O 0 1.625669376892347e-08
the O 0 2.0496332808761508e-07
pathogenesis O 0 0.001573687419295311
of O 0 8.333424921147525e-05
hereditary B-Disease 1 0.9999613761901855
hemochromatosis I-Disease 1 0.9999949932098389
. O 0 0.00012556313595268875
. O 0 2.5339411877212115e-05

Genomic O 0 0.0005874776979908347
organization O 0 5.725987193727633e-06
of O 0 2.1897632507261733e-07
the O 0 2.395622118456231e-07
UBE3A O 0 0.0005989441997371614
/ O 0 1.594562127138488e-05
E6 O 0 0.00038613282958976924
- O 0 0.0037010530941188335
AP O 0 0.0001120799861382693
gene O 0 7.360470135608921e-07
and O 0 3.0780847737332806e-07
related O 0 6.757904884580057e-06
pseudogenes O 0 0.00034596057957969606
. O 0 6.160743851069128e-06

The O 0 4.717112460639328e-06
UBE3A O 0 0.0013418683083727956
gene O 0 3.7878958210058045e-06
encodes O 0 3.8191819839994423e-07
the O 0 5.795245527906445e-08
E6 O 0 2.8817901693400927e-05
- O 0 0.00014719914179295301
AP O 0 7.858279786887579e-06
ubiquitin O 0 2.670491767275962e-06
- O 0 1.0857505913008936e-05
protein O 0 4.4092946183127424e-08
ligase O 0 5.383535608416423e-07
and O 0 2.1758426171913925e-08
has O 0 2.098682649886996e-08
recently O 0 2.368671943031586e-07
been O 0 1.4683785742874989e-08
shown O 0 1.53573953554087e-08
to O 0 5.658059798463455e-09
be O 0 6.749620951040924e-08
mutated O 0 0.00010947704868158326
in O 0 0.011669876985251904
Angelman B-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.9999994039535522
patients O 1 0.8412838578224182
who O 0 0.0001633347710594535
lack O 0 1.301698102906812e-05
15q11 O 0 0.0002922001585830003
- O 0 0.00563092203810811
q13 O 0 0.000277133280178532
deletions O 0 3.001577715622261e-05
or O 0 1.68508540809853e-06
chromosome O 0 5.22987284057308e-05
15 O 0 7.012927653704537e-06
paternal O 0 0.0004209500038996339
uniparental B-Disease 1 0.5204894542694092
disomy I-Disease 0 0.14196041226387024
. O 0 2.0134628357482143e-05

Previous O 0 1.396535662934184e-05
UBE3A O 0 0.0002538026019465178
cDNA O 0 1.0524332537897862e-05
analysis O 0 1.1274393045823672e-06
has O 0 2.354070289811716e-07
shown O 0 9.486465302188662e-08
a O 0 4.291663202593554e-08
coding O 0 1.5538327033937094e-06
region O 0 2.5776631673579686e-07
of O 0 3.794066927298445e-08
approximately O 0 4.6947621967774467e-07
2 O 0 2.046497684204951e-06
. O 0 3.6290846310294e-06

6 O 0 0.00010172155452892184
kb O 0 0.003335389541462064
and O 0 1.4554955214407528e-06
a O 0 2.06029852733991e-07
3 O 0 7.034490181467845e-07
- O 0 0.0022852872498333454
untranslated O 0 0.006913200486451387
region O 0 2.6032892037619604e-06
( O 0 6.070584390727163e-08
UTR O 0 1.1982876458205283e-05
) O 0 8.412093244203334e-09
of O 0 3.551653637856589e-09
< O 0 1.2354271348158363e-06
50 O 0 1.6690185589141038e-07
bp O 0 4.3353215005481616e-05
, O 0 2.487147199303763e-08
whereas O 0 2.3005773286399744e-08
Northern O 0 1.4145872029303064e-08
analysis O 0 1.917370795467832e-08
has O 0 2.580744506985866e-08
indicated O 0 3.61575587248808e-08
mRNA O 0 7.138909907666857e-09
sizes O 0 2.1684430251411868e-08
of O 0 4.698719191509326e-09
5 O 0 1.8443788007971307e-07
- O 0 8.05566887720488e-05
8 O 0 7.214166998892324e-06
kb O 0 0.0008875296334736049
. O 0 5.242510724201566e-06

We O 0 2.5387921596120577e-06
have O 0 1.9018118280200724e-07
analyzed O 0 1.1200688021517635e-07
additional O 0 1.469841226509061e-08
cDNA O 0 2.086052290906082e-07
clones O 0 1.7309554323219345e-06
and O 0 4.702451761318116e-08
provide O 0 2.0544469236938312e-08
evidence O 0 5.80513557224549e-08
for O 0 2.163671197763506e-08
an O 0 7.894765019500483e-08
additional O 0 6.950619990675477e-07
0 O 0 1.0535850378801115e-05
. O 0 4.4193075154908e-06

5 O 0 1.7050451788236387e-05
kb O 0 0.000265205540927127
of O 0 4.3265279714432836e-07
5 O 0 9.00945735793357e-07
- O 0 0.00016942287038546056
UTR O 0 4.5607841457240283e-05
and O 0 1.3649076890942524e-07
> O 0 7.556037644462776e-07
2 O 0 1.227334394116042e-07
kb O 0 2.763336306088604e-05
of O 0 6.302207822272976e-08
3 O 0 1.272645477001788e-06
- O 0 0.0011484738206490874
UTR O 0 0.0006303885602392256
. O 0 4.839302164327819e-06

We O 0 4.086246008228045e-06
have O 0 2.1962277685361187e-07
established O 0 3.888406752139417e-08
the O 0 6.4323550930112106e-09
genomic O 0 7.205890710793028e-07
organization O 0 7.768247911599246e-08
of O 0 2.280524213915669e-08
UBE3A O 0 0.00022467477538157254
and O 0 1.621099166015938e-08
the O 0 2.2807711275163456e-09
sequence O 0 3.859852437670952e-09
of O 0 2.136164667376761e-08
intron O 0 0.00018697712221182883
- O 0 0.0012863145675510168
exon O 0 0.00028947339160367846
borders O 0 2.0209457943565212e-05
. O 0 2.8727697554131737e-06

We O 0 5.070247425464913e-06
have O 0 4.536912854291586e-07
also O 0 4.633628236661025e-08
mapped O 0 2.273036017186314e-07
two O 0 2.143687005684569e-08
highly O 0 1.5551238163880043e-07
homologous O 0 3.683746001570398e-07
processed O 0 8.16552926607983e-07
pseudogenes O 0 1.4455218661169056e-05
, O 0 2.219542949433162e-07
UBE3AP1 O 0 0.00032997180824168026
and O 0 7.331963161050226e-07
UBE3AP2 O 0 0.0007451436831615865
, O 0 2.673505505867979e-08
to O 0 2.4778037399642017e-09
chromosomes O 0 5.489528831503776e-08
2 O 0 5.301022909520725e-08
and O 0 4.992365632006113e-08
21 O 0 4.128843045236863e-07
, O 0 3.564223405305711e-08
respectively O 0 3.9237585269802366e-07
, O 0 1.9874551782095295e-08
and O 0 3.348137767034132e-08
determined O 0 9.376016407713905e-08
their O 0 8.549279328917692e-08
genomic O 0 1.458651058783289e-05
organization O 0 7.344717687374214e-06
. O 0 4.740486019727541e-06

These O 0 1.799745859898394e-06
results O 0 2.5242318315576995e-06
will O 0 8.825745112517325e-08
form O 0 2.0645698484145214e-08
the O 0 4.2908832043053735e-09
basis O 0 5.739142494576299e-09
for O 0 1.6538294289603073e-08
studies O 0 7.579675553870402e-08
of O 0 4.619456106524922e-08
mutation O 0 2.0860136373812566e-06
and O 0 4.0311604720955074e-07
imprinting O 0 7.74554064264521e-05
of O 0 3.346387074998347e-06
UBE3A O 0 0.0313502661883831
. O 0 1.476437410019571e-05

Mutation O 0 0.0006472356617450714
spectrum O 0 8.395199984079227e-05
and O 0 3.3557412280060817e-06
genotype O 0 0.0002041445259237662
- O 0 0.00356192491017282
phenotype O 0 9.696411871118471e-05
analyses O 0 5.7966108215623535e-06
in O 0 5.306857019604649e-06
Cowden B-Disease 1 0.9984074234962463
disease I-Disease 0 0.19264015555381775
and O 0 1.8531945897848345e-05
Bannayan B-Disease 1 0.9792948961257935
- I-Disease 1 0.9999102354049683
Zonana I-Disease 1 0.9999773502349854
syndrome I-Disease 1 0.9998499155044556
, O 0 7.251870556501672e-06
two O 0 1.607949707249645e-05
hamartoma B-Disease 1 0.9976478219032288
syndromes I-Disease 1 0.9594634175300598
with O 0 0.00012573205458465964
germline O 1 0.9687842726707458
PTEN O 1 0.9596173167228699
mutation O 0 0.0005932929343543947
. O 0 1.863828583736904e-05

The O 0 0.0002496016095392406
tumour B-Disease 1 0.9993768334388733
suppressor O 0 0.020786050707101822
gene O 0 7.566432759631425e-05
PTEN O 0 0.006830007769167423
, O 0 3.9616824665245076e-07
which O 0 2.0493317265390942e-08
maps O 0 2.6543813191892696e-07
to O 0 4.328483953486284e-07
10q23 O 0 0.00015229202108457685
. O 0 3.1491524623561418e-06

3 O 0 8.969705049821641e-06
and O 0 4.2031155089716776e-07
encodes O 0 2.745575500284758e-07
a O 0 3.6761999666623524e-08
403 O 0 1.010530013445532e-06
amino O 0 3.655497096133331e-07
acid O 0 7.560492463198898e-07
dual O 0 1.5420788201936375e-07
specificity O 0 4.983499479749298e-07
phosphatase O 0 0.0001245564199052751
( O 0 4.759743532645189e-08
protein O 0 6.81220626574941e-08
tyrosine O 0 2.508573061277275e-06
phosphatase O 0 0.0003242626553401351
; O 0 8.235162454184319e-07
PTPase O 0 0.0003304392739664763
) O 0 8.917456995050088e-08
, O 0 5.220132592853588e-08
was O 0 1.9384175686809613e-07
shown O 0 9.809483003664354e-08
recently O 0 5.63113019325101e-07
to O 0 4.2854688686588815e-09
play O 0 7.763919285252996e-09
a O 0 4.925664853772105e-08
broad O 0 6.343849236145616e-06
role O 0 2.3447544208465843e-06
in O 0 6.92282867476024e-07
human O 0 2.4348699298570864e-05
malignancy B-Disease 0 0.22268123924732208
. O 0 1.4843985809420701e-05

Somatic O 0 0.056728314608335495
PTEN O 0 0.33197546005249023
deletions O 0 0.0008978439145721495
and O 0 9.899645192490425e-06
mutations O 0 2.5023344278451987e-05
were O 0 2.082770294009606e-07
observed O 0 1.586388833629826e-07
in O 0 4.6021572330801064e-08
sporadic B-Disease 0 3.324119097669609e-05
breast I-Disease 1 0.6068410873413086
, I-Disease 0 7.754054240649566e-05
brain I-Disease 0 0.13867157697677612
, I-Disease 0 0.00013956884504295886
prostate I-Disease 1 0.9995348453521729
and I-Disease 0 0.19226182997226715
kidney I-Disease 1 0.9999613761901855
cancer I-Disease 1 0.6981796026229858
cell O 0 0.00014782889047637582
lines O 0 1.1438989531598054e-05
and O 0 5.283459358906839e-07
in O 0 5.857767959582816e-08
several O 0 4.7542994252580684e-07
primary O 0 0.00016650235920678824
tumours B-Disease 1 0.9981921315193176
such O 0 6.0487336668302305e-06
as O 0 0.00015820162661839277
endometrial B-Disease 1 0.9998427629470825
carcinomas I-Disease 1 0.9999912977218628
, O 1 0.9872064590454102
malignant B-Disease 1 0.9999974966049194
melanoma I-Disease 1 0.9999982118606567
and O 1 0.9984387755393982
thyroid B-Disease 1 0.9999774694442749
tumours I-Disease 1 0.9999275207519531
. O 0 0.00039271320565603673

In O 0 8.324655937030911e-06
addition O 0 5.105931450088974e-06
, O 0 1.6646326912450604e-06
PTEN O 0 0.005232978146523237
was O 0 2.233892473668675e-06
identified O 0 9.557164730722434e-07
as O 0 1.4811321058516569e-08
the O 0 2.4149976241005788e-08
susceptibility O 0 8.34320508147357e-06
gene O 0 1.167126697509957e-07
for O 0 1.6744296260640112e-07
two O 0 6.076741556171328e-05
hamartoma B-Disease 1 0.9998902082443237
syndromes I-Disease 1 0.9999570846557617
Cowden B-Disease 1 0.9999676942825317
disease I-Disease 1 0.8375502228736877
( O 0 9.937461982190143e-07
CD B-Disease 0 2.718128598644398e-05
; O 0 8.032949153857771e-06
MIM O 0 0.011494704522192478
158350 O 0 0.00021895924874115735
) O 0 5.3462489546518555e-08
and O 0 1.5003708142558025e-07
Bannayan B-Disease 0 0.0007161975954659283
- I-Disease 0 0.023367533460259438
Zonana I-Disease 1 0.6424095630645752
( I-Disease 0 3.0524535077347537e-07
BZS I-Disease 0 0.00016762620361987501
) I-Disease 0 5.4961081019655467e-08
or I-Disease 0 1.1641397179573687e-07
Ruvalcaba I-Disease 0 0.0003198536578565836
- I-Disease 0 0.0043558687902987
Riley I-Disease 0 0.0019563680980354548
- I-Disease 1 0.9796608090400696
Smith I-Disease 1 0.9822996258735657
syndrome I-Disease 1 0.9931802749633789
( O 0 2.571385039118468e-06
MIM O 0 0.005100454669445753
153480 O 0 0.0006992758135311306
) O 0 1.4010893210070208e-06
. O 0 2.3236564175022068e-06

Constitutive O 0 0.00027717449120245874
DNA O 0 7.168074807850644e-05
from O 0 1.0636700835675583e-06
37 O 0 2.9853222258680034e-06
CD B-Disease 0 5.06395144839189e-06
families O 0 9.52741572746163e-07
and O 0 8.086825431519173e-08
seven O 0 3.4925801628560293e-07
BZS B-Disease 0 0.0005918045644648373
families O 0 7.064022611302789e-07
was O 0 3.089825497681886e-07
screened O 0 2.9138657282601343e-06
for O 0 1.658022824813088e-06
germline O 0 0.024612639099359512
PTEN O 0 0.09091117233037949
mutations O 0 8.90418523340486e-05
. O 0 5.359191618481418e-06

PTEN O 1 0.8486412167549133
mutations O 0 0.0011356112081557512
were O 0 3.1321908409154275e-06
identified O 0 1.7109052805608371e-06
in O 0 2.4882954363647514e-08
30 O 0 4.350068749658931e-08
of O 0 1.2699906903890223e-08
37 O 0 2.534578015911393e-06
( O 0 5.592890772732062e-08
81 O 0 3.3943133530556224e-06
% O 0 3.92783903180316e-08
) O 0 1.802461113697973e-08
CD B-Disease 0 8.318072559632128e-07
families O 0 1.2156020829934278e-06
, O 0 9.959950375559856e-08
including O 0 5.487879661814077e-07
missense O 0 2.9264838303788565e-05
and O 0 2.771842275706149e-07
nonsense O 0 6.659837708866689e-06
point O 0 6.869747721793829e-07
mutations O 0 1.397083792653575e-06
, O 0 5.588071161355401e-08
deletions O 0 4.567276846501045e-06
, O 0 1.0978579467746385e-07
insertions O 0 5.3390513130580075e-06
, O 0 7.990691130999039e-08
a O 0 5.189565754903924e-08
deletion O 0 4.00566295866156e-06
/ O 0 6.048266186553519e-06
insertion O 0 5.578109721682267e-06
and O 0 8.706497283128556e-07
splice O 0 8.632758544990793e-05
site O 0 2.0018182112835348e-05
mutations O 0 1.8949402146972716e-05
. O 0 2.9150303362257546e-06

These O 0 4.338123289926443e-06
mutations O 0 3.946813376387581e-05
were O 0 2.1272811068229203e-07
scattered O 0 2.5712549245326954e-07
over O 0 1.1219204054668808e-07
the O 0 1.5141694120757165e-08
entire O 0 1.0738323652503823e-07
length O 0 1.557082782710495e-07
of O 0 1.013642147995597e-07
PTEN O 0 0.006090677343308926
, O 0 3.4256288472533925e-07
with O 0 7.87677691960198e-08
the O 0 2.3814417104972563e-08
exception O 0 9.631114039621025e-08
of O 0 7.51449302782703e-09
the O 0 9.384851118454662e-09
first O 0 3.9451304445492497e-08
, O 0 6.138992603155202e-08
fourth O 0 1.5309452692235936e-06
and O 0 5.617383180833713e-07
last O 0 3.4850916108553065e-06
exons O 0 3.7069188692839816e-05
. O 0 4.863638423557859e-06

A O 0 1.0071328688354697e-05
hot O 0 8.601793524576351e-06
spot O 0 3.2534858291910496e-06
for O 0 2.804194991767872e-07
PTEN O 0 0.000618553371168673
mutation O 0 1.2123373380745761e-06
in O 0 1.9139399398682144e-08
CD B-Disease 0 3.4578447412059177e-06
was O 0 2.489122607585159e-06
identified O 0 4.616523199274525e-07
in O 0 1.2880331468068107e-08
exon O 0 4.96656002724194e-06
5 O 0 7.728772999371358e-08
that O 0 2.90875545871927e-09
contains O 0 3.4083229571990614e-09
the O 0 1.5625115423745228e-08
PTPase O 0 3.632094376371242e-05
core O 0 2.2112933493190212e-06
motif O 0 4.503341131112393e-07
, O 0 1.2015135553156142e-08
with O 0 9.059437644509671e-09
13 O 0 4.846950929504601e-08
of O 0 7.374322930076005e-09
30 O 0 2.3906261503725545e-07
( O 0 1.7634967264257284e-08
43 O 0 4.810598852600378e-07
% O 0 4.1688593910294e-08
) O 0 1.6723671336649204e-08
CD B-Disease 0 1.9152273580402834e-06
mutations O 0 5.674983185599558e-06
identified O 0 4.043273236220557e-07
in O 0 2.5847789686395117e-08
this O 0 9.806452538896338e-08
exon O 0 0.0002730778360273689
. O 0 9.17714260140201e-06

Seven O 0 6.9579418777721e-06
of O 0 4.97065514082351e-07
30 O 0 1.3453228575599496e-06
( O 0 1.116843222348507e-07
23 O 0 7.808093869243748e-07
% O 0 3.995442909854319e-08
) O 0 5.745802056367211e-09
were O 0 3.263534997799411e-09
within O 0 1.2763742285315516e-09
the O 0 1.0120440485650306e-08
core O 0 2.2409042230719933e-06
motif O 0 1.2855342674811254e-06
, O 0 4.186797042393664e-08
the O 0 1.0838363984078114e-08
majority O 0 2.2725700432602025e-07
( O 0 1.0970056862902311e-08
five O 0 1.1030439672765624e-08
of O 0 6.3279093076573645e-09
seven O 0 1.4018509375546273e-07
) O 0 1.424377238379293e-08
of O 0 6.749528491667434e-09
which O 0 2.2291072099278608e-08
were O 0 1.530543869421308e-07
missense O 0 9.847101318882778e-05
mutations O 0 1.2788242202077527e-05
, O 0 3.8202421137611964e-07
possibly O 0 1.8423993424221408e-06
pointing O 0 5.636827609123429e-06
to O 0 2.2198026528030823e-08
the O 0 2.6422069865361664e-08
functional O 0 5.885047471565485e-07
significance O 0 9.998513661457764e-08
of O 0 2.890054062731906e-08
this O 0 7.374860899744817e-08
region O 0 3.1527554256172152e-06
. O 0 2.430537506370456e-06

Germline O 1 0.9344948530197144
PTEN O 1 0.8798057436943054
mutations O 0 0.001857333118095994
were O 0 3.028987293873797e-06
identified O 0 3.2153943720913958e-06
in O 0 2.5089262223332298e-08
four O 0 2.8129582219094118e-08
of O 0 2.2890310091838728e-08
seven O 0 4.4520137976178376e-07
( O 0 1.5651311002784496e-07
57 O 0 5.987787517369725e-06
% O 0 2.93701162945581e-07
) O 0 2.982147293550952e-07
BZS B-Disease 0 0.000518213608302176
families O 0 5.802185569336871e-06
studied O 0 1.3399501767707989e-05
. O 0 3.871740773320198e-06

Interestingly O 0 0.0006555385189130902
, O 0 5.192107892071363e-06
none O 0 7.011731213424355e-07
of O 0 2.880588390041794e-08
these O 0 2.985868974292316e-08
mutations O 0 1.8015489331446588e-06
was O 0 3.4107898727597785e-07
observed O 0 1.7686242870240676e-07
in O 0 1.615376810093494e-08
the O 0 7.976468907600065e-08
PTPase O 0 0.0005319556803442538
core O 0 4.0891067328630015e-05
motif O 0 2.207538091170136e-05
. O 0 1.7987867977353744e-06

It O 0 2.478356918800273e-06
is O 0 2.264306004917671e-07
also O 0 6.751049852482538e-08
worthy O 0 2.3470492749311234e-07
of O 0 2.2992701076418598e-08
note O 0 3.853359942240786e-07
that O 0 4.449133506057024e-09
a O 0 6.519769613078097e-09
single O 0 3.76121107592553e-08
nonsense O 0 3.0566036457457813e-06
point O 0 6.144944109109929e-07
mutation O 0 4.5818904936822946e-07
, O 0 7.252842237903678e-08
R233X O 0 1.1498708772705868e-05
, O 0 5.632543675915258e-08
was O 0 2.0667059175139002e-07
observed O 0 4.8835310906270024e-08
in O 0 2.0906989472990745e-09
the O 0 1.0982094345024507e-08
germline O 0 5.0500799261499196e-05
DNA O 0 2.1377557004598202e-06
from O 0 4.9072195196231405e-08
two O 0 6.25170883949977e-08
unrelated O 0 1.3886695342080202e-05
CD B-Disease 0 1.9828317817882635e-05
families O 0 7.63623302191263e-06
and O 0 5.964558340565418e-07
one O 0 1.0502587883820524e-06
BZS B-Disease 0 0.035285450518131256
family O 0 3.331608968437649e-05
. O 0 4.967696895619156e-06

Genotype O 0 0.005868558771908283
- O 0 0.07242108881473541
phenotype O 0 0.005983664654195309
studies O 0 4.016404545836849e-06
were O 0 2.4412202037638053e-07
not O 0 1.0000245076469128e-08
performed O 0 3.481538612959412e-08
on O 0 2.7927928414328562e-08
this O 0 3.803818593439701e-09
small O 0 9.664034905654262e-08
group O 0 9.471564226259943e-07
of O 0 4.3745225752900296e-07
BZS B-Disease 0 0.009910537861287594
families O 0 2.6812407668330707e-05
. O 0 3.845562332571717e-06

However O 0 1.514398718427401e-05
, O 0 1.1021480759154656e-06
genotype O 0 5.5307613365584984e-05
- O 0 0.0008218445582315326
phenotype O 0 2.5288090910180472e-05
analysis O 0 1.9352940228145599e-07
inthe O 0 4.881009954260662e-05
group O 0 1.0989721204168745e-06
of O 0 2.679877120215224e-08
CD B-Disease 0 5.857220457983203e-06
families O 0 3.838037173409248e-06
revealed O 0 2.1254852526908508e-06
two O 0 1.6401456193193553e-08
possible O 0 8.932402550954066e-08
associations O 0 6.27478868864273e-08
worthy O 0 1.3921439290243143e-07
of O 0 4.9431583271086765e-09
follow O 0 1.8479383356861945e-08
- O 0 1.221051479660673e-05
up O 0 2.252976116778882e-07
in O 0 3.21900053279478e-08
independent O 0 5.866801870979543e-07
analyses O 0 9.293301445723046e-06
. O 0 4.077475296071498e-06

The O 0 4.49209574071574e-06
first O 0 1.7883629652715172e-06
was O 0 2.9401548999885563e-06
an O 0 3.5430531397651066e-07
association O 0 8.912404155125841e-06
noted O 0 8.705782761353476e-07
in O 0 1.173823793720885e-08
the O 0 9.654137045345124e-09
group O 0 1.4512416157685948e-07
of O 0 2.2060092419451394e-08
CD B-Disease 0 8.327745490532834e-06
families O 0 2.5767421902855858e-05
with O 0 0.0013804261106997728
breast B-Disease 1 0.9991806149482727
disease I-Disease 0 0.13323596119880676
. O 0 2.0860172298853286e-05

A O 0 2.8600572477444075e-05
correlation O 0 1.7173515516333282e-05
was O 0 3.5239568205724936e-06
observed O 0 4.5827121653019276e-07
between O 0 4.113569218588964e-08
the O 0 7.52450688423778e-08
presence O 0 1.3300375485414406e-06
/ O 0 1.4389597708941437e-05
absence O 0 1.1692585530909128e-06
of O 0 2.273584165379816e-08
a O 0 7.648351356692729e-07
PTEN O 0 0.008357140235602856
mutation O 0 1.3654952226715977e-06
and O 0 8.194957956675353e-08
the O 0 4.4603172710822037e-08
type O 0 1.1130424582006526e-06
of O 0 1.7025943179760361e-06
breast O 0 0.2687540650367737
involvement O 0 0.0004104060062672943
( O 0 4.946362878399668e-06
unaffected O 0 0.00047007258399389684
versus O 0 0.018641114234924316
benign O 1 0.6364168524742126
versus O 1 0.9209815263748169
malignant O 1 0.9996016621589661
) O 0 2.3992372007342055e-05
. O 0 9.886964107863605e-06

Specifically O 0 2.59753069258295e-05
and O 0 5.258777378003288e-07
more O 0 3.6707767492316634e-08
directly O 0 1.0576862052857905e-07
, O 0 1.1082575923637705e-07
an O 0 1.5797942864992365e-07
association O 0 4.2196529648208525e-06
was O 0 1.5690258123868261e-06
also O 0 1.0644742332033275e-07
observed O 0 4.3537543348293184e-08
between O 0 8.182054145322581e-09
the O 0 1.4866398778679013e-08
presence O 0 8.920944338797199e-08
of O 0 2.6523661489363803e-08
a O 0 2.515446112738573e-06
PTEN O 0 0.16420626640319824
mutation O 0 0.0003007083432748914
and O 0 0.010137940756976604
malignant B-Disease 1 0.999974250793457
breast I-Disease 1 0.9999092817306519
disease I-Disease 1 0.8525359034538269
. O 0 5.016309296479449e-05

Secondly O 0 0.0017791136633604765
, O 0 4.1909906940418296e-06
there O 0 1.358724404099121e-07
appeared O 0 5.203045816415397e-07
to O 0 1.3349253258354565e-08
be O 0 6.953031039813595e-09
an O 0 2.467024984298405e-08
interdependent O 0 3.935534186894074e-05
association O 0 2.693143869691994e-06
between O 0 1.3648426033796568e-07
mutations O 0 2.1492360247066244e-06
upstream O 0 7.60170962621487e-07
and O 0 3.276822013731362e-08
within O 0 3.957813188293358e-09
the O 0 2.0138919865075877e-08
PTPase O 0 9.979680180549622e-05
core O 0 5.597843937721336e-06
motif O 0 1.0054880021925783e-06
, O 0 2.159136514023885e-08
the O 0 6.277994568648637e-09
core O 0 5.272441399029049e-07
motif O 0 2.0567254921388667e-07
containing O 0 5.036187644691381e-08
the O 0 7.173196703291751e-09
majority O 0 4.7150972903864385e-08
of O 0 2.876689997322046e-08
missense O 0 0.00018962103058584034
mutations O 0 2.0960535039193928e-05
, O 0 1.2153790862612368e-07
and O 0 4.461321267967833e-08
the O 0 1.4466341013985584e-08
involvement O 0 1.2474949926399859e-06
of O 0 2.53854430809497e-08
all O 0 3.8868272156378225e-08
major O 0 5.740651431551669e-06
organ O 0 0.0015027826884761453
systems O 0 7.591098255943507e-05
( O 0 4.7509408318546775e-07
central O 0 7.960006200846692e-07
nervous O 0 5.672889164998196e-05
system O 0 2.92666527457186e-06
, O 0 3.347957317600958e-05
thyroid O 1 0.9964015483856201
, O 0 6.40266589471139e-05
breast O 1 0.8072872161865234
, O 0 0.000286363298073411
skin O 1 0.894146203994751
and O 0 0.10695838928222656
gastrointestinal O 1 0.9999420642852783
tract O 1 0.9867504239082336
) O 0 4.242323120706715e-05
. O 0 1.945777694345452e-05

However O 0 1.7733189451973885e-05
, O 0 3.925244413949258e-07
these O 0 1.3955196997983421e-08
observations O 0 1.1916772990616664e-07
would O 0 3.341024878977805e-08
need O 0 1.082099299054562e-08
to O 0 3.3093940920991827e-09
be O 0 3.745167287405593e-09
confirmed O 0 4.324299851532487e-08
by O 0 4.981557832905992e-09
studying O 0 7.541014923617695e-08
a O 0 2.2573368951839257e-08
larger O 0 5.3666820321041087e-08
number O 0 1.1497814256244965e-08
of O 0 4.060096259195234e-08
CD B-Disease 0 2.721559940255247e-05
families O 0 2.407929059700109e-05
. O 0 6.635505997110158e-06

Molecular O 1 0.5135108232498169
defects O 1 0.9961226582527161
leading O 0 0.00012186672392999753
to O 0 3.221034035050252e-07
human O 0 1.2212308320158627e-06
complement B-Disease 0 1.671636891842354e-05
component I-Disease 0 0.008205314166843891
C6 I-Disease 1 0.9999908208847046
deficiency I-Disease 1 0.9999063014984131
in O 0 3.9575363075528003e-07
an O 0 2.8649677119574335e-07
African O 0 9.94167203316465e-06
- O 0 0.01162034086883068
American O 0 6.205178942764178e-05
family O 0 3.680665395222604e-05
. O 0 8.241846444434486e-06

Complement B-Disease 0 0.003551769768819213
component I-Disease 1 0.6050845384597778
C6 I-Disease 1 0.9999425411224365
deficiency I-Disease 1 0.9999426603317261
( O 0 3.2873744203243405e-05
C6D B-Disease 1 0.5008677840232849
) O 0 6.2109047576086596e-06
was O 0 4.22988086938858e-05
diagnosed O 0 0.07810238003730774
in O 0 4.377936235755442e-08
a O 0 5.362783284112993e-08
16 O 0 5.093162371849758e-07
- O 0 0.000155125351739116
year O 0 1.554389882585383e-06
- O 0 0.00015376356896013021
old O 0 1.526513551652897e-05
African O 0 2.4459629912598757e-06
- O 0 8.883966802386567e-05
American O 0 7.819839083822444e-06
male O 0 1.2898057320853695e-05
with O 0 2.745445817708969e-05
meningococcal B-Disease 1 0.9988549947738647
meningitis I-Disease 1 0.9948691129684448
. O 0 2.899227911257185e-05

The O 0 0.00010485726670594886
patients O 0 0.007928874343633652
father O 0 2.522296563256532e-05
and O 0 2.0080739204786369e-07
two O 0 1.1451562897946133e-07
brothers O 0 8.02354552433826e-05
also O 0 5.342268423191854e-07
had O 0 1.215412112287595e-06
C6D B-Disease 0 0.0013345737243071198
, O 0 1.1270851274503002e-07
but O 0 1.7056898116152297e-08
gave O 0 7.072571150956719e-08
no O 0 1.1304928548838689e-08
history O 0 1.1857278536808735e-07
of O 0 1.6768918840170954e-06
meningitis B-Disease 1 0.9551947116851807
or O 0 1.1590296708163805e-05
other O 0 1.729852010612376e-05
neisserial B-Disease 1 0.9264907240867615
infection I-Disease 0 0.036271583288908005
. O 0 9.657724149292335e-06

By O 0 1.8316651448913035e-06
using O 0 4.98578572205588e-07
exon O 0 1.3203505659475923e-05
- O 0 1.8110758901457302e-05
specific O 0 1.0959227125795223e-07
polymerase O 0 9.147608579951338e-06
chain O 0 9.184672308037989e-06
reaction O 0 4.431443869634677e-07
( O 0 3.769110890061711e-08
PCR O 0 5.987998974887887e-06
) O 0 3.188861441572044e-08
/ O 0 1.9254613903285644e-07
single O 0 4.612500603684566e-08
- O 0 1.3077726180199534e-05
strand O 0 3.2640959943819325e-06
conformation O 0 5.273195711197332e-07
polymorphism O 0 1.6613466868875548e-06
as O 0 9.33826616034139e-09
a O 0 8.23315104980793e-09
screening O 0 1.4869070241729787e-07
step O 0 5.322460694401343e-08
and O 0 2.8482871616830607e-09
nucleotide O 0 3.0294959429966184e-08
sequencing O 0 3.064639741978681e-08
of O 0 7.218847297707498e-09
target O 0 6.622013870583032e-08
exons O 0 7.35962089493114e-07
, O 0 2.4122263297954305e-08
we O 0 2.9461488804116698e-09
determined O 0 1.337234145637467e-08
that O 0 1.7422192577498663e-09
the O 0 8.987359301215747e-09
proband O 0 9.515532292425632e-05
was O 0 1.458596869952089e-07
a O 0 2.0382218579584332e-08
compound O 0 2.7415251224738313e-07
heterozygote O 0 5.5247342061193194e-06
for O 0 3.43118635726114e-08
two O 0 3.500399543554522e-07
C6 O 0 0.2358924001455307
gene O 0 1.4677516446681693e-05
mutations O 0 2.6096919100382365e-05
. O 0 4.0637100937601645e-06

The O 0 2.645889253471978e-06
first O 0 8.370960244974412e-07
, O 0 3.0961552965891315e-07
1195delC O 0 2.5607088900869712e-05
located O 0 1.7802261709221057e-07
in O 0 2.3744568977690506e-08
exon O 0 6.723115802742541e-06
7 O 0 4.645858382446022e-07
, O 0 3.9770355897417176e-08
is O 0 4.964219257885816e-09
a O 0 1.7142086861099415e-08
novel O 0 3.527268290781649e-07
mutation O 0 7.861689823585039e-07
, O 0 3.672821691225181e-08
while O 0 4.593151459175715e-08
the O 0 9.874900896988947e-09
second O 0 1.4865554476273246e-07
, O 0 2.4047622559919546e-07
1936delG O 0 1.622628406039439e-05
in O 0 2.09367705394925e-08
exon O 0 4.3597310650511645e-06
12 O 0 3.3268764809690765e-07
, O 0 9.837044245841753e-08
has O 0 8.364035863905883e-08
been O 0 1.1009573341880241e-07
described O 0 6.115583914834133e-07
before O 0 2.1008217743201385e-07
to O 0 6.918387640553192e-08
cause O 0 2.2406093194149435e-06
C6D B-Disease 0 0.0003422862500883639
in O 0 4.752295623688951e-08
an O 0 1.2509779878655536e-07
unrelated O 0 3.443684181547724e-05
African O 0 1.5679377611377276e-05
- O 0 0.002375873504206538
American O 0 2.8417845896910876e-05
individual O 0 4.1635225898062345e-06
. O 0 6.5290073507640045e-06

Both O 0 7.025186641840264e-05
mutations O 0 0.0006295347702689469
result O 0 8.17030195321422e-06
in O 0 1.1327114179948694e-06
premature O 0 0.0003183720400556922
termination O 0 0.000177725130924955
codons O 0 3.3587180951144546e-05
and O 0 6.117839802755043e-06
C6 O 0 0.22038358449935913
null O 0 0.0002750642888713628
alleles O 0 3.97595067624934e-05
. O 0 4.7192725105560385e-06

Allele O 0 0.0001377183070871979
- O 0 0.00020194625540170819
specific O 0 8.804473168311233e-07
PCR O 0 5.896017682971433e-05
indicated O 0 2.6842617444344796e-06
that O 0 1.0610319733928009e-08
the O 0 1.063045473870261e-08
probands O 0 2.5648125301813707e-05
two O 0 1.0620913570846824e-07
brothers O 0 0.0001035961540765129
also O 0 1.2764207895088475e-06
inherited O 0 3.795159500441514e-05
the O 0 4.643182904828791e-08
1195delC O 0 0.00011591171642066911
mutation O 0 7.125132128749101e-07
from O 0 5.0417522601264864e-08
their O 0 6.709740318910917e-08
heterozygous O 0 2.13286421058001e-06
mother O 0 1.4183473240336752e-06
and O 0 2.352422256990394e-08
the O 0 2.1553550055841697e-08
1936delG O 0 3.501106766634621e-05
mutation O 0 4.2543277345430397e-07
from O 0 2.2103600727518824e-08
their O 0 8.107505777843471e-08
homozygous O 0 4.303698460716987e-06
father O 0 1.6052861155912979e-06
. O 0 1.5628877747531078e-07
. O 0 1.1028652124878136e-06

PAX6 O 1 0.827298641204834
mutations O 0 0.01985308527946472
reviewed O 0 0.001272976049222052
. O 0 0.00012275953486096114

Mutations O 0 0.0017280144384130836
in O 0 5.487442194862524e-06
PAX6 O 0 0.005161226261407137
are O 0 3.423956798087602e-07
responsible O 0 7.77660716266837e-07
for O 0 2.0818727364257938e-07
human O 0 4.116358013561694e-06
aniridia B-Disease 1 0.9852448105812073
and O 0 2.479283466527704e-06
have O 0 2.256478808249085e-07
also O 0 1.3123033681949892e-07
been O 0 1.403346345796308e-07
found O 0 3.5184893931727856e-07
in O 0 7.035281441858388e-07
patients O 0 0.00010455704614287242
with O 0 1.35586369651719e-05
Peters B-Disease 1 0.9994366765022278
anomaly I-Disease 1 0.9962785840034485
, O 0 0.0003742421686183661
with O 1 0.5106918215751648
congenital B-Disease 1 0.9999988079071045
cataracts I-Disease 1 0.9999960660934448
, O 0 0.0005071338964626193
with O 0 0.0005108009791001678
autosomal B-Disease 0 0.3336629271507263
dominant I-Disease 0 0.03336386755108833
keratitis I-Disease 1 0.998588502407074
, O 0 3.9757760532666e-05
and O 0 7.654081855434924e-06
with O 0 7.934083987493068e-05
isolated B-Disease 0 0.01708674244582653
foveal I-Disease 1 0.9995113611221313
hypoplasia I-Disease 1 0.9992368221282959
. O 0 0.00031115999445319176

No O 0 4.792698746314272e-06
locus O 0 1.4326446944323834e-05
other O 0 9.907712694712245e-08
than O 0 6.968461008227678e-08
chromosome O 0 2.852944817277603e-05
11p13 O 0 5.187973874853924e-05
has O 0 2.6330062041779456e-07
been O 0 2.25434092726573e-07
implicated O 0 4.7104240366024897e-05
in O 0 7.924845704110339e-07
aniridia B-Disease 1 0.9779595136642456
, O 0 1.2291809525777353e-06
and O 0 1.1737384966181708e-06
PAX6 O 0 0.014708573929965496
is O 0 9.445390958262578e-08
clearly O 0 1.2602377807979792e-07
the O 0 1.889914535979642e-08
major O 0 9.014794386530411e-07
, O 0 1.4357205202486512e-07
if O 0 1.468955623806778e-08
not O 0 2.6948530074122345e-09
only O 0 3.199301490397488e-09
, O 0 6.697031551539112e-08
gene O 0 3.2253774406854063e-07
responsible O 0 3.1306260552810272e-06
. O 0 4.375404841994168e-06

Twenty O 0 1.407118088536663e-05
- O 0 0.00017034455959219486
eight O 0 1.9936455828428734e-06
percent O 0 2.2821138827566756e-06
of O 0 8.146459862246047e-08
identified O 0 5.8738396546687e-06
PAX6 O 0 0.0011317713651806116
mutations O 0 3.840065346594201e-06
are O 0 4.24346815464105e-08
C O 0 3.7716858059866354e-05
- O 0 0.01604115590453148
T O 0 0.007420110981911421
changes O 0 8.356844460877255e-08
at O 0 1.7109364591760823e-07
CpG O 0 3.072920299018733e-05
dinucleotides O 0 0.00012939804582856596
, O 0 6.881997904883974e-08
20 O 0 3.7904939631516754e-08
% O 0 4.362563199578062e-09
are O 0 8.74582017917902e-10
splicing O 0 1.0451964271851466e-07
errors O 0 3.1393979043059517e-06
, O 0 4.908951467541556e-08
and O 0 1.3022868117218422e-08
more O 0 2.100347451516882e-09
than O 0 3.604791576350408e-09
30 O 0 4.4524632869524794e-08
% O 0 1.8891253006358966e-08
are O 0 1.3963664891036842e-08
deletion O 0 5.705871899408521e-06
or O 0 3.7757888549094787e-07
insertion O 0 8.204126970667858e-06
events O 0 1.7422487417206867e-06
. O 0 3.147765482935938e-06

There O 0 2.3266895823326195e-06
is O 0 1.81871328663874e-07
a O 0 2.821432758537412e-07
noticeably O 0 2.76543232757831e-05
elevated O 0 4.914245073450729e-05
level O 0 6.428763299481943e-08
of O 0 1.2534244753226176e-08
mutation O 0 2.156634621997e-07
in O 0 4.698504252331759e-09
the O 0 1.4771992518092247e-08
paired O 0 4.556595740723424e-06
domain O 0 2.587825917998998e-07
compared O 0 4.4749526750820223e-07
with O 0 4.052730773196345e-08
the O 0 2.3250823488751848e-08
rest O 0 4.6389516228373395e-08
of O 0 1.867404719746446e-08
the O 0 1.6907438293856103e-07
gene O 0 2.6246855213685194e-06
. O 0 2.0531892914732452e-06

Increased O 0 0.00012609994155354798
mutation O 0 2.9058986910968088e-05
in O 0 1.6031673055749707e-07
the O 0 1.1336501160030821e-07
homeodomain O 0 9.64606661000289e-05
is O 0 3.938243864354263e-08
accounted O 0 4.0753073449195654e-07
for O 0 1.0764012792208177e-08
by O 0 2.6687979826078845e-08
the O 0 1.2294734119677742e-07
hypermutable O 0 0.0003403790178708732
CpG O 0 4.16714210587088e-05
dinucleotide O 0 7.585664570797235e-05
in O 0 8.671000983895283e-08
codon O 0 2.1481234853126807e-06
240 O 0 3.8388311622838955e-06
. O 0 2.440112893964397e-06

Very O 0 4.350685230747331e-06
nearly O 0 1.6867752492544241e-06
all O 0 1.5376012640899717e-07
mutations O 0 1.0375319106969982e-05
appear O 0 1.1012215281880344e-06
to O 0 2.6607577296999807e-07
cause O 0 8.47615137899993e-06
loss O 0 1.089000579668209e-05
of O 0 2.3662060755214043e-08
function O 0 8.354449576586376e-09
of O 0 6.458602097580979e-09
the O 0 3.0304725839869207e-08
mutant O 0 5.6456824495398905e-06
allele O 0 7.779900670357165e-07
, O 0 2.439888113769939e-08
and O 0 6.673719354921559e-09
more O 0 9.44404887626149e-10
than O 0 2.4752482286061195e-09
80 O 0 4.4179991220971715e-08
% O 0 5.208573128356875e-09
of O 0 1.0117121362895887e-08
exonic O 0 4.747701677842997e-05
substitutions O 0 1.3762809203399229e-06
result O 0 2.376355894284643e-07
in O 0 9.88990933592504e-08
nonsense O 0 2.31618632824393e-05
codons O 0 3.839498458546586e-05
. O 0 3.7930001326458296e-06

In O 0 3.915399247489404e-06
a O 0 7.445954679496936e-07
gene O 0 5.144934789313993e-07
with O 0 5.402566216616833e-08
such O 0 3.4826676653665345e-08
extraordinarily O 0 4.876159437117167e-06
high O 0 1.0343538860979606e-06
sequence O 0 3.926543001853133e-08
conservation O 0 3.194803639416932e-07
throughout O 0 1.278865457976508e-08
evolution O 0 5.227256494322319e-08
, O 0 4.4922316533302364e-08
there O 0 9.903797781873891e-09
are O 0 3.456316832739503e-08
presumed O 0 6.423728336812928e-05
undiscovered O 0 0.0022981707006692886
missense O 0 0.0006423398153856397
mutations O 0 1.920938848343212e-05
, O 0 7.528684164981314e-08
these O 0 7.303048832341119e-09
are O 0 2.4783108898418504e-08
hypothesized O 0 1.6122899069159757e-06
to O 0 1.2141934568887791e-08
exist O 0 1.294204476920413e-08
in O 0 1.0373510050953882e-08
as O 0 5.9462475832106065e-08
- O 0 0.0002008520532399416
yet O 0 1.6007273870854988e-06
unidentified O 0 0.00015228678239509463
phenotypes O 0 7.971936429385096e-05
. O 0 5.679871151187399e-07
. O 0 2.6088214326591697e-06

Genetic O 0 0.0015288019785657525
heterogeneity O 0 0.0007338913273997605
and O 0 4.4039175008947495e-06
penetrance O 0 0.00021638759062625468
analysis O 0 3.500362879549357e-07
of O 0 3.949512006329314e-08
the O 0 2.2788965736708633e-07
BRCA1 O 0 0.00010709804337238893
and O 0 2.880242618630291e-06
BRCA2 O 0 0.0010821650503203273
genes O 0 2.056719131360296e-05
in O 0 6.422834121622145e-05
breast B-Disease 1 0.9992563128471375
cancer I-Disease 1 0.8789868950843811
families O 0 0.00012444482126738876
. O 0 3.532410119078122e-05

The O 0 0.022435814142227173
Breast B-Disease 1 0.9997212290763855
Cancer I-Disease 1 0.999427318572998
Linkage O 0 0.011090491898357868
Consortium O 0 0.008070843294262886
. O 0 7.13989938958548e-05

The O 0 2.957980086648604e-06
contribution O 0 6.6919760683958884e-06
of O 0 5.052862093180011e-07
BRCA1 O 0 0.00027446882450021803
and O 0 5.644961220241385e-06
BRCA2 O 0 0.030340392142534256
to O 0 0.0002242484624730423
inherited B-Disease 1 0.999985933303833
breast I-Disease 1 0.9999854564666748
cancer I-Disease 1 0.9999721050262451
was O 0 0.00016025429067667574
assessed O 0 6.913119432283565e-05
by O 0 4.814509111383813e-07
linkage O 0 1.7987653336604126e-05
and O 0 9.86862232821295e-07
mutation O 0 1.0714503559938748e-06
analysis O 0 5.524158552816516e-08
in O 0 5.2111097659235384e-08
237 O 0 1.3161128663341515e-05
families O 0 2.164205398003105e-06
, O 0 5.0480839064448446e-08
each O 0 4.487895832738786e-09
with O 0 2.4257262865035045e-08
at O 0 4.5785181868041036e-08
least O 0 7.931135748151519e-09
four O 0 7.525267164965044e-08
cases O 0 2.0221191334712785e-06
of O 0 9.665270226832945e-06
breast B-Disease 1 0.9960518479347229
cancer I-Disease 0 0.1360173374414444
, O 0 2.4056382130765996e-07
collected O 0 3.245912978400156e-07
by O 0 1.91106005331676e-06
the O 0 0.0004265932075213641
Breast B-Disease 1 0.9999240636825562
Cancer I-Disease 1 0.9987075328826904
Linkage O 0 0.0009700106456875801
Consortium O 0 0.0022897664457559586
. O 0 3.884462785208598e-05

Families O 0 0.0001792163384379819
were O 0 3.7965971841913415e-06
included O 0 8.883264968062576e-07
without O 0 2.7495451604409027e-07
regard O 0 1.1130642008083669e-07
to O 0 6.9946648473262485e-09
the O 0 1.8841268101255082e-08
occurrence O 0 2.3095653887139633e-06
of O 0 1.1833587450382765e-05
ovarian B-Disease 1 0.9995482563972473
or I-Disease 0 4.088026980753057e-05
other I-Disease 0 8.133483061101288e-05
cancers I-Disease 0 0.4337358772754669
. O 0 1.5588460883009247e-05

Overall O 0 0.0031613591127097607
, O 0 0.0005508951144292951
disease O 0 0.17789454758167267
was O 0 1.2649626114580315e-05
linked O 0 0.00011427200661273673
to O 0 2.5709707074383914e-07
BRCA1 O 0 4.3802614527521655e-05
in O 0 3.9647886751481565e-08
an O 0 2.6100002159523683e-08
estimated O 0 8.550417760488926e-07
52 O 0 5.074634827906266e-06
% O 0 7.556377568107564e-08
of O 0 4.095078764976279e-08
families O 0 1.2224367083035759e-06
, O 0 2.2067946758852486e-07
to O 0 4.7900343247420096e-08
BRCA2 O 0 9.010050234792288e-06
in O 0 1.0050670518069182e-08
32 O 0 3.2563090712756093e-07
% O 0 3.8237224941894965e-08
of O 0 1.908766833480513e-08
families O 0 1.3250834172140458e-06
, O 0 2.580073328317667e-07
and O 0 1.2727848286431254e-07
to O 0 2.3024913531344282e-08
neither O 0 1.9649495186513377e-07
gene O 0 7.293127168850333e-08
in O 0 1.0116290916073467e-08
16 O 0 1.5276826559329493e-07
% O 0 2.619445993445879e-08
( O 0 9.565862768567968e-09
95 O 0 9.615879292823593e-08
% O 0 4.501683648072685e-08
confidence O 0 4.3778362623925204e-07
interval O 0 2.454007130836544e-07
[ O 0 5.305767558638763e-07
CI O 0 0.00017500996182207018
] O 0 2.915217578447482e-07
6 O 0 5.709992834113109e-08
% O 0 1.7365238136335392e-08
- O 0 3.775421282625757e-05
28 O 0 1.9973601865785895e-06
% O 0 5.006726766509928e-08
) O 0 9.98166527210742e-09
, O 0 3.145260407677597e-08
suggesting O 0 1.6510737168573542e-06
other O 0 5.74615512505261e-07
predisposition O 0 0.0011736841406673193
genes O 0 9.835532182478346e-06
. O 0 3.1633262551622465e-06

The O 0 9.315866918768734e-06
majority O 0 1.9218916349927895e-05
( O 0 5.000595137971686e-07
81 O 0 5.008234893466579e-06
% O 0 9.836237779836665e-08
) O 0 1.22057661755548e-08
of O 0 2.6393157881443585e-08
the O 0 1.1164357601955999e-05
breast B-Disease 1 0.9991196990013123
- I-Disease 1 0.9999948740005493
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.999903678894043
families O 0 5.0001377530861646e-05
were O 0 2.9999059734109323e-06
due O 0 1.7715764215608942e-06
to O 0 2.0787598487004288e-07
BRCA1 O 0 6.827673496445641e-05
, O 0 9.149009372322325e-08
with O 0 5.660966095888398e-08
most O 0 5.4255014703130655e-08
others O 0 3.7800512586727564e-07
( O 0 5.078610954001306e-08
14 O 0 9.58866053224483e-07
% O 0 3.259838479152677e-07
) O 0 1.5106883211046807e-07
due O 0 6.814154858147958e-07
to O 0 5.062113359599607e-07
BRCA2 O 0 0.0004492347070481628
. O 0 4.251085101714125e-06

Conversely O 0 0.0007486573304049671
, O 0 3.145679556837422e-06
the O 0 1.7060744994523702e-07
majority O 0 4.909326207780396e-07
of O 0 4.0905508313926475e-08
families O 0 4.962441835232312e-07
with O 0 4.742819612602034e-07
male B-Disease 0 1.2949673873663414e-05
and I-Disease 0 9.924885489454027e-06
female I-Disease 0 0.015868518501520157
breast I-Disease 1 0.9969449639320374
cancer I-Disease 0 0.4273996353149414
were O 0 1.7913706642502802e-06
due O 0 1.5194934803730575e-06
to O 0 3.0741446721549437e-07
BRCA2 O 0 0.0001999470841838047
( O 0 6.243284360607504e-07
76 O 0 0.00011068840103689581
% O 0 2.7761993806052487e-06
) O 0 7.207175372059282e-07
. O 0 2.702890242289868e-06

The O 0 6.200175448611844e-06
largest O 0 0.00014493436901830137
proportion O 0 1.8540036762715317e-05
( O 0 2.5854996010821196e-07
67 O 0 4.543409431789769e-06
% O 0 6.993013101919132e-08
) O 0 1.0811977091407243e-08
of O 0 9.620793051112742e-09
families O 0 1.6019751001294935e-06
due O 0 6.380140007422597e-07
to O 0 9.886132801284475e-09
other O 0 3.379266644287782e-08
genes O 0 1.9188128419500572e-07
was O 0 4.2529367760835157e-07
found O 0 1.8184566386025836e-07
in O 0 1.9963531272537693e-08
families O 0 1.315695641324055e-07
with O 0 3.826377792393032e-08
four O 0 7.787533462533247e-08
or O 0 6.131163843292597e-08
five O 0 1.0644885151123162e-07
cases O 0 1.1092150771219167e-06
of O 0 1.8269547581439838e-06
female O 0 0.15747173130512238
breast B-Disease 1 0.9989381432533264
cancer I-Disease 0 0.2989389896392822
only O 0 5.484933467414521e-07
. O 0 5.7979045777756255e-06

These O 0 1.914873109853943e-06
estimates O 0 1.0197199117101263e-05
were O 0 6.097263849369483e-07
not O 0 5.890191090429653e-08
substantially O 0 2.461686335664126e-06
affected O 0 1.275579535331417e-07
either O 0 8.732873091332749e-09
by O 0 1.308261765586849e-08
changing O 0 2.2329693649680848e-07
the O 0 4.243014828375635e-08
assumed O 0 1.43855777423596e-06
penetrance O 0 1.6237119780271314e-05
model O 0 4.995580411559786e-07
for O 0 4.635824950582901e-07
BRCA1 O 0 4.26615406468045e-05
or O 0 4.734445369081186e-08
by O 0 5.0815376795299017e-08
including O 0 6.613064442717587e-07
or O 0 8.071183401625603e-07
excluding O 0 0.00019976208568550646
BRCA1 O 0 0.001059360452927649
mutation O 0 9.993372259486932e-06
data O 0 3.4357490221736953e-06
. O 0 4.7205421651597135e-06

Among O 0 5.308358231559396e-05
those O 0 5.318114290275844e-06
families O 0 1.8689013813855127e-05
with O 0 0.00012398583930917084
disease O 0 0.15144672989845276
due O 0 7.0334494921553414e-06
to O 0 3.0208815360310837e-07
BRCA1 O 0 0.00011321947386022657
that O 0 5.497481581073771e-08
were O 0 1.4702975192903978e-07
tested O 0 1.4448810361500364e-06
by O 0 1.2629324253055074e-08
one O 0 2.4651092278560327e-09
of O 0 3.735293407913787e-09
the O 0 3.813188875767537e-09
standard O 0 6.799990615036222e-08
screening O 0 2.045552207619039e-07
methods O 0 9.165111691800121e-08
, O 0 1.0310569109606149e-07
mutations O 0 1.2262502195881098e-06
were O 0 1.0923437798737723e-07
detected O 0 7.135345754250011e-07
in O 0 4.664697961231923e-09
the O 0 2.9222129160899613e-09
coding O 0 1.3466717518895166e-07
sequence O 0 8.337003087888206e-09
or O 0 8.556519048852351e-09
splice O 0 8.472219974464679e-07
sites O 0 4.486391702585024e-08
in O 0 5.769159372448485e-09
an O 0 9.26644272425392e-09
estimated O 0 3.542515969456872e-07
63 O 0 2.966692818517913e-06
% O 0 4.8112681838574645e-08
( O 0 1.2066809773614295e-08
95 O 0 6.126253992988495e-08
% O 0 4.367294437201963e-08
CI O 0 0.0001686119067016989
51 O 0 2.1274483970046276e-06
% O 0 9.341511031379923e-08
- O 0 8.192901441361755e-05
77 O 0 1.2408750080794562e-05
% O 0 4.221160168071947e-07
) O 0 2.705557449189655e-07
. O 0 1.0276422699462273e-06

The O 0 4.149735559622059e-06
estimated O 0 1.3099769603286404e-05
sensitivity O 0 2.4101352664729347e-06
was O 0 2.420603664177179e-07
identical O 0 1.0413459961000626e-07
for O 0 5.582060147446555e-09
direct O 0 1.3967873968567801e-08
sequencing O 0 3.9852105260251847e-07
and O 0 1.0890256874063198e-07
other O 0 1.1472823757685546e-07
techniques O 0 2.4391893020947464e-06
. O 0 2.375173608015757e-06

The O 0 5.678647994500352e-06
penetrance O 0 0.0006835733656771481
of O 0 2.0589425275829853e-06
BRCA2 O 0 0.0024615242145955563
was O 0 1.8935786556539824e-06
estimated O 0 2.4591378178229206e-07
by O 0 1.83995449987151e-08
maximizing O 0 6.065498610041686e-07
the O 0 2.2422922185683092e-08
LOD O 0 3.919204755220562e-05
score O 0 1.3186526359731943e-07
in O 0 6.359940840638956e-08
BRCA2 O 0 5.0279566494282335e-05
- O 0 0.0009291312890127301
mutation O 0 6.004038823448354e-06
families O 0 8.336878067893849e-07
, O 0 4.686710397550087e-08
over O 0 2.436748935963351e-08
all O 0 1.4808552606382364e-08
possible O 0 3.4353780620222096e-07
penetrance O 0 0.0003027392376679927
functions O 0 8.857911666382279e-07
. O 0 4.627667294698767e-06

The O 0 4.486563739192206e-06
estimated O 0 2.3919354134704918e-05
cumulative O 0 0.00011802135122707114
risk O 0 0.0015654630260542035
of O 0 3.44168147421442e-05
breast B-Disease 1 0.999423623085022
cancer I-Disease 1 0.6437076926231384
reached O 0 6.159615622891579e-06
28 O 0 3.974309947807342e-06
% O 0 7.964580106545327e-08
( O 0 1.8926415989994894e-08
95 O 0 1.7150794917597523e-07
% O 0 1.0157400254229287e-07
CI O 0 0.00011073929636040702
9 O 0 2.756061121544917e-07
% O 0 3.0199821310361585e-08
- O 0 2.4056156689766794e-05
44 O 0 1.0268192909279605e-06
% O 0 2.1303094399627298e-08
) O 0 4.053826607730571e-09
by O 0 5.48163736624474e-09
age O 0 9.392680055952951e-08
50 O 0 4.728714841917281e-08
years O 0 1.3147160871085362e-07
and O 0 5.751813958454477e-08
84 O 0 1.9926628738176078e-06
% O 0 4.3133194793654184e-08
( O 0 1.2507521240934238e-08
95 O 0 6.579309541621114e-08
% O 0 2.9576531446195986e-08
CI O 0 4.566472489386797e-05
43 O 0 3.28751525557891e-07
% O 0 2.3961858275356462e-08
- O 0 6.468741048593074e-06
95 O 0 3.5306405266055663e-07
% O 0 2.9491582509422187e-08
) O 0 6.7864478481283186e-09
by O 0 1.6420237614056532e-08
age O 0 3.459094273239316e-07
70 O 0 1.2262502195881098e-06
years O 0 2.211476839875104e-06
. O 0 2.5211959382431814e-06

The O 0 0.0003640374925453216
corresponding O 1 0.8576143383979797
ovarian B-Disease 1 0.9999961853027344
cancer I-Disease 1 0.999988317489624
risks O 1 0.8225740194320679
were O 0 1.7211736121680588e-05
0 O 0 3.469074363238178e-05
. O 0 8.945000445237383e-06

4 O 0 3.139852924505249e-05
% O 0 1.633256488275947e-06
( O 0 1.18618260103176e-07
95 O 0 1.962308999736706e-07
% O 0 1.0285938145671025e-07
CI O 0 5.944598888163455e-05
0 O 0 1.3190236813898082e-07
% O 0 1.864934340289892e-08
- O 0 7.633436325704679e-06
1 O 0 1.1553315459877922e-07
% O 0 1.7223957371470533e-08
) O 0 3.442610641002375e-09
by O 0 6.646775574381536e-09
age O 0 9.614871032681549e-08
50 O 0 3.452087327104891e-08
years O 0 5.62198216869092e-08
and O 0 2.5892644472946813e-08
27 O 0 4.2483839024498593e-07
% O 0 1.817936023940092e-08
( O 0 5.336506347930481e-09
95 O 0 6.477764458168167e-08
% O 0 7.646134747574251e-08
CI O 0 4.542896567727439e-05
0 O 0 1.0335476474665484e-07
% O 0 3.381510182975944e-08
- O 0 1.753845026541967e-05
47 O 0 4.980989160685567e-06
% O 0 5.378241141329454e-08
) O 0 1.1803390265185953e-08
by O 0 2.0663701860712536e-08
age O 0 4.938430606671318e-07
70 O 0 1.3483438578987261e-06
years O 0 2.9627317417180166e-06
. O 0 2.152678007405484e-06

The O 0 1.2219495147292037e-05
lifetime O 0 0.0010984103428199887
risk O 0 0.004452564753592014
of O 0 7.226660818560049e-05
breast B-Disease 1 0.9998587369918823
cancer I-Disease 1 0.9958319067955017
appears O 0 1.3891210073779803e-05
similar O 0 2.362305906444817e-07
to O 0 4.99143268939406e-08
the O 0 3.820009055743867e-07
risk O 0 3.806308450293727e-05
in O 0 3.644316848294693e-07
BRCA1 O 0 0.0005679359892383218
carriers O 0 9.93437206489034e-05
, O 0 8.627150691609131e-07
but O 0 9.037039916393041e-08
there O 0 2.0586361060281888e-08
was O 0 1.1946049482958188e-07
some O 0 6.738080315926709e-09
suggestion O 0 3.8966595639067236e-07
of O 0 1.3966062084591613e-08
a O 0 5.329175678525644e-07
lower O 0 0.0001515948388259858
risk O 0 3.253171962569468e-05
in O 0 1.8260266188008245e-07
BRCA2 O 0 0.00011962149437749758
carriers O 0 9.84386497293599e-06
< O 0 3.2098032534122467e-06
50 O 0 2.060781838508774e-07
years O 0 1.2445107699932123e-07
of O 0 1.401022302616184e-07
age O 0 1.2661093023780268e-05
. O 0 4.177462869847659e-06

Eye B-Disease 1 0.928425133228302
movement I-Disease 0 0.006172781810164452
abnormalities I-Disease 1 0.7266672849655151
correlate O 0 4.035299571114592e-05
with O 0 6.425346327887382e-06
genotype O 0 0.0034113277215510607
in O 0 6.13341762800701e-05
autosomal O 0 0.3743916451931
dominant O 0 0.32654789090156555
cerebellar B-Disease 1 0.999518632888794
ataxia I-Disease 1 0.9996857643127441
type I-Disease 0 0.02075747773051262
I I-Disease 0 0.00040591880679130554
. O 0 2.2174379409989342e-05

We O 0 4.111360340175452e-06
compared O 0 1.7720796677167527e-05
horizontal O 0 0.00013993331231176853
eye O 0 0.0029885221738368273
movements O 0 1.8520191815696307e-06
( O 0 4.642111406383265e-08
visually O 0 1.4796786445003818e-06
guided O 0 9.11726601771079e-06
saccades O 0 0.020674368366599083
, O 0 1.6256341268672259e-06
antisaccades O 0 0.0006264595431275666
, O 0 1.2927702641718497e-07
and O 0 5.4832394624781955e-08
smooth O 0 2.8587146516656503e-07
pursuit O 0 7.357666618190706e-06
) O 0 4.394266639451416e-08
in O 0 9.12507669426077e-09
control O 0 6.204975022683357e-08
subjects O 0 2.3211303812331607e-07
( O 0 3.006705640018481e-08
n O 0 2.3827378754504025e-06
= O 0 5.673148734786082e-06
14 O 0 1.5322510762416641e-06
) O 0 1.1754340079050962e-07
and O 0 1.344689280813327e-06
patients O 0 9.712885912449565e-06
with O 0 7.389208889208021e-08
three O 0 1.9423035269028333e-07
forms O 0 1.7401730474375654e-06
of O 0 5.296866675053025e-06
autosomal O 0 0.05953009054064751
dominant O 0 0.009486708790063858
cerebellar B-Disease 1 0.9402309656143188
ataxias I-Disease 1 0.9604995250701904
type I-Disease 0 0.00032148524769581854
I I-Disease 0 2.22301714529749e-05
spinocerebellar B-Disease 0 0.051303040236234665
ataxias I-Disease 0 0.003070114180445671
1 I-Disease 0 3.669275940865191e-07
and I-Disease 0 1.1081370843157856e-07
2 I-Disease 0 1.8202437956915674e-07
( O 0 6.873182201161399e-08
SCA1 B-Disease 0 0.0001500355574535206
, O 0 1.1337733951677365e-07
n O 0 1.202889052365208e-06
= O 0 1.0879932688112604e-06
11 O 0 2.6866180746765167e-07
; O 0 1.5020901855677948e-07
SCA2 B-Disease 0 0.00013670211774297059
, O 0 5.954657211759695e-08
n O 0 8.28712870770687e-07
= O 0 8.580806252211914e-07
10 O 0 5.8754807241712115e-08
) O 0 1.0494889401968521e-08
and O 0 1.6989126550015499e-07
SCA3 B-Disease 0 0.4691178500652313
/ O 0 7.218753307824954e-05
Machado B-Disease 0 0.0006855612155050039
- I-Disease 0 0.09054156392812729
Joseph I-Disease 0 0.09787870198488235
disease I-Disease 0 0.002476769033819437
( O 0 8.646646847410011e-07
MJD B-Disease 1 0.9879322648048401
) O 0 4.7449685780520667e-07
( O 0 6.548011555196354e-08
n O 0 4.931887815473601e-06
= O 0 9.090525054489262e-06
16 O 0 1.5877691339483135e-06
) O 0 4.840719043386343e-07
. O 0 1.8705275124375476e-06

In O 0 1.0814505913003813e-05
SCA1 B-Disease 0 0.0013689752668142319
, O 0 7.622319344591233e-07
saccade O 0 1.4176943295751698e-05
amplitude O 0 8.226018053392181e-07
was O 0 6.745135578967165e-07
significantly O 0 1.1990499615421868e-06
increased O 0 2.7842861527460627e-07
, O 0 1.1603036398355471e-07
resulting O 0 1.41944883580436e-06
in O 0 1.4252489108912414e-06
hypermetria B-Disease 0 0.00676099443808198
. O 0 1.3170520105632022e-05

The O 0 3.931511400878662e-06
smooth O 0 1.0857185770873912e-05
pursuit O 0 9.134614811046049e-05
gain O 0 0.0001450809504603967
was O 0 1.4321938579087146e-05
decreased O 0 4.708277265308425e-05
. O 0 3.540587613315438e-06

In O 0 8.420221092819702e-06
SCA2 B-Disease 0 0.0015163249336183071
, O 0 2.122641262758407e-06
saccade O 0 6.147952080937102e-05
velocity O 0 9.649153980717529e-06
was O 0 7.719940185779706e-06
markedly O 0 9.024905739352107e-05
decreased O 0 9.154032886726782e-05
. O 0 4.985185114492197e-06

The O 0 3.0878977668180596e-06
percentage O 0 1.1676677786454093e-05
of O 0 1.1914283959413297e-07
errors O 0 1.497478206147207e-05
in O 0 4.480974382659042e-07
antisaccades O 0 0.004517381079494953
was O 0 2.8938741252204636e-06
greatly O 0 9.631709190216498e-07
increased O 0 1.259060553593372e-07
and O 0 3.248178970238769e-08
was O 0 2.93169449605557e-07
significantly O 0 5.144615897734184e-07
correlated O 0 1.0615349310683087e-06
with O 0 3.761176117222931e-07
age O 0 2.0701154426205903e-05
at O 0 0.0002995355171151459
disease O 0 0.19188165664672852
onset O 0 0.0029955790378153324
. O 0 2.44893799390411e-05

In O 0 4.149791038798867e-06
addition O 0 2.372574726905441e-06
, O 0 1.2664909831983096e-07
a O 0 4.261376673753148e-08
correlation O 0 1.3593037806458597e-07
between O 0 3.727715736090431e-08
smooth O 0 1.409880837854871e-06
pursuit O 0 2.876798498618882e-05
gain O 0 8.513555258105043e-06
and O 0 6.31950527463232e-08
the O 0 6.797511442613313e-09
number O 0 6.4331522331428914e-09
of O 0 4.522372520909812e-08
trinucleotide O 0 0.001445807283744216
repeats O 0 7.532039944635471e-06
was O 0 2.916417770393309e-06
found O 0 2.6138045541301835e-06
. O 0 3.1505132938036695e-06

In O 0 5.594656249741092e-05
SCA3 B-Disease 1 0.9597458839416504
, O 0 5.775421868747799e-06
gaze B-Disease 0 0.000358283898094669
- I-Disease 0 0.01368048693984747
evoked I-Disease 0 0.005502641666680574
nystagmus I-Disease 0 0.37704992294311523
was O 0 7.366934823949123e-06
often O 0 1.2050793429807527e-07
present O 0 3.4422118488919295e-08
as O 0 3.292007377808659e-08
was O 0 4.7211264586621837e-07
saccade O 0 2.7859865440404974e-05
hypometria O 0 0.0001761853345669806
and O 0 9.407614953715893e-08
smooth O 0 3.621357222982624e-07
pursuit O 0 1.3430408216663636e-05
gain O 0 1.3222231245890725e-05
was O 0 3.386256139492616e-06
markedly O 0 3.6368710425449535e-05
decreased O 0 3.131172343273647e-05
. O 0 2.2309375253826147e-06

Three O 0 3.3774995245039463e-06
major O 0 5.78766230319161e-06
criteria O 0 6.993852821324253e-07
, O 0 3.952104421500735e-08
saccade O 0 2.2753727080271346e-06
amplitude O 0 8.843859689022793e-08
, O 0 2.9497098097408525e-08
saccade O 0 1.7225966075784527e-06
velocity O 0 2.520750683743245e-07
, O 0 4.0388403732549705e-08
and O 0 2.84890795398951e-08
presence O 0 2.4915390639534962e-08
of O 0 8.74690897489927e-09
gaze B-Disease 0 3.897193164448254e-05
- I-Disease 0 0.0035242238081991673
evoked I-Disease 0 0.0011502966517582536
nystagmus I-Disease 0 0.03300327807664871
, O 0 5.485728706844384e-07
permitted O 0 4.963918698308589e-08
the O 0 1.1404377886492512e-08
correct O 0 2.1992501331169478e-07
assignment O 0 1.2824284567614086e-07
of O 0 5.416606274621927e-09
90 O 0 3.975708295911318e-08
% O 0 7.2511654458651265e-09
of O 0 3.449242447217671e-09
the O 0 4.2653940823811354e-08
SCA1 B-Disease 0 0.00038588992902077734
, O 0 1.1983327397047105e-07
90 O 0 3.358819355980813e-08
% O 0 3.6117289159420807e-09
of O 0 2.193802028926939e-09
the O 0 2.423266209916619e-08
SCA2 B-Disease 0 0.0003372400824446231
, O 0 8.18736509700102e-08
and O 0 3.7527986052054985e-08
93 O 0 9.680107950771344e-07
% O 0 1.8970904847037673e-08
of O 0 1.3042106949967547e-08
the O 0 3.8318526662806107e-07
patients O 0 2.6571759008220397e-05
with O 0 3.865918927203893e-07
SCA3 B-Disease 1 0.9109395146369934
to O 0 6.761436566193879e-08
their O 0 4.138121667551786e-08
genetically O 0 2.9590241865662392e-06
confirmed O 0 3.048109419978573e-06
patient O 0 5.124493327457458e-06
group O 0 1.1949928193644155e-06
and O 0 3.9604435642104363e-07
, O 0 3.860716617509752e-07
therefore O 0 8.681426066914355e-08
, O 0 1.9052592392654333e-07
may O 0 1.9119302407943906e-07
help O 0 1.87137715101926e-07
orient O 0 4.719889329862781e-05
diagnoses O 0 0.00012428435729816556
of O 0 2.0859727101196768e-07
SCA1 B-Disease 0 0.02818315289914608
, O 0 2.654907575561083e-06
SCA2 B-Disease 0 0.0016210951143875718
, O 0 1.6292460713884793e-07
and O 0 2.46229888034577e-07
SCA3 B-Disease 1 0.71189284324646
at O 0 7.460824917870923e-07
early O 0 3.015737775058369e-07
clinical O 0 2.5425865715078544e-06
stages O 0 1.336410150543088e-06
of O 0 3.87830425552238e-07
the O 0 3.4286596928723156e-05
diseases O 0 0.0834365040063858
. O 0 2.4721696263441117e-06
. O 0 1.0773588655865751e-05

Genetic O 0 0.0001897780311992392
basis O 0 2.5444205675739795e-06
and O 0 3.8638727346551605e-06
molecular O 0 0.00012402661377564073
mechanism O 0 0.00015732116298750043
for O 0 0.0009870798094198108
idiopathic B-Disease 1 0.9999352693557739
ventricular I-Disease 1 0.9997958540916443
fibrillation I-Disease 1 0.9997239708900452
. O 0 0.0006498824805021286

Ventricular B-Disease 1 0.9983305335044861
fibrillation I-Disease 1 0.9977051615715027
causes O 0 0.0004589949385263026
more O 0 9.315800042486444e-08
than O 0 2.983387048516306e-08
300 O 0 1.765180002166744e-07
, O 0 6.632353688473813e-08
000 O 0 2.324130491615506e-06
sudden O 0 2.0100131223443896e-05
deaths O 0 4.2122469494643155e-06
each O 0 2.3889572986490748e-08
year O 0 1.8364910658874578e-07
in O 0 2.4696472422647275e-08
the O 0 9.177882276389937e-08
USA O 0 2.654506533872336e-05
alone O 0 1.1915518371097278e-05
. O 0 3.239096258766949e-06

In O 0 1.8706025457504438e-06
approximately O 0 5.679232231159403e-07
5 O 0 3.9828171338740503e-07
- O 0 5.325130405253731e-05
12 O 0 2.9495924991351785e-07
% O 0 1.4236954726243312e-08
of O 0 5.818301396232073e-09
these O 0 8.6667313325961e-09
cases O 0 8.124035275614006e-07
, O 0 1.4003009596308402e-07
there O 0 1.9814786256233674e-08
are O 0 1.8393722100995546e-08
no O 0 2.3627767120615317e-07
demonstrable O 0 0.009216281585395336
cardiac O 0 0.10582761466503143
or O 0 2.263315991513082e-06
non O 0 0.0015518240397796035
- O 1 0.9963743090629578
cardiac O 1 0.9869731068611145
causes O 0 3.1191557354759425e-05
to O 0 3.9677388485870324e-08
account O 0 9.877297202365298e-08
for O 0 1.747311806354901e-08
the O 0 1.128596860411335e-08
episode O 0 1.273795078304829e-07
, O 0 6.508887651079931e-08
which O 0 2.2646595709829853e-08
is O 0 3.4937389870037805e-08
therefore O 0 2.4304694079546607e-07
classified O 0 0.00029290749807842076
as O 0 0.0054819416254758835
idiopathic B-Disease 1 0.9999872446060181
ventricular I-Disease 1 0.9999678134918213
fibrillation I-Disease 1 0.9999724626541138
( O 0 0.0004552431928459555
IVF B-Disease 1 0.9946395754814148
) O 0 3.500422099023126e-05
. O 0 1.556885035824962e-05

A O 0 1.1581965736695565e-05
distinct O 0 3.950261543650413e-06
group O 0 5.579940534516936e-06
of O 0 1.4387800320037059e-06
IVF B-Disease 1 0.9996500015258789
patients O 0 0.06479460746049881
has O 0 1.944771838680026e-06
been O 0 3.7797158825014776e-07
found O 0 1.3976006130178575e-07
to O 0 1.4352011135088105e-08
present O 0 3.272500137541101e-08
with O 0 1.4137327752905549e-07
a O 0 1.099819314731576e-06
characteristic O 0 3.772941272472963e-05
electrocardiographic O 0 0.09906725585460663
pattern O 0 8.799770148470998e-05
. O 0 1.934175998030696e-05

Because O 0 6.297771506069694e-06
of O 0 1.105747102769783e-07
the O 0 5.715135387163173e-08
small O 0 9.271573730984528e-08
size O 0 2.1165881491924665e-07
of O 0 1.1783595432746097e-08
most O 0 3.573821771851726e-08
pedigrees O 0 7.413952062051976e-06
and O 0 1.3953206234873505e-07
the O 0 6.261733176415873e-08
high O 0 2.0421253793756478e-05
incidence O 0 0.00012504550977610052
of O 0 6.487736072813277e-07
sudden B-Disease 0 0.0016904379008337855
death I-Disease 0 3.082405964960344e-05
, O 0 5.156970246389392e-07
however O 0 5.487948229188078e-08
, O 0 5.7830330746355685e-08
molecular O 0 3.424192300371942e-06
genetic O 0 3.960828053095611e-06
studies O 0 3.5494079497766506e-07
of O 0 1.5675988151997444e-07
IVF B-Disease 1 0.5588637590408325
have O 0 7.189478310465347e-07
not O 0 2.3478593291770267e-08
yet O 0 1.0121815563479686e-07
been O 0 1.795342114974119e-07
done O 0 5.603974386758637e-07
. O 0 1.7586852436579647e-06

Because O 0 0.0012979035964235663
IVF B-Disease 1 0.9989054203033447
causes O 1 0.6964444518089294
cardiac O 1 0.9933196306228638
rhythm O 0 0.005350450519472361
disturbance O 0 0.006315522827208042
, O 0 8.222660881074262e-07
we O 0 3.9482166869220237e-08
investigated O 0 3.9302444747590926e-06
whether O 0 2.655125683759252e-07
malfunction O 0 1.663386501604691e-05
of O 0 1.33615314368285e-08
ion O 0 5.258553755993489e-06
channels O 0 5.05695027186448e-07
could O 0 1.247065711140749e-06
cause O 0 2.769178763628588e-06
the O 0 7.549239171567024e-07
disorder O 0 0.0006947545916773379
by O 0 2.0340476680758002e-07
studying O 0 3.4801926176442066e-06
mutations O 0 2.500800292182248e-06
in O 0 4.112141738232822e-08
the O 0 2.3541286964245955e-07
cardiac O 0 0.0007351072272285819
sodium O 0 9.031720765051432e-06
channel O 0 5.087975750939222e-06
gene O 0 6.057456630514935e-06
SCN5A O 0 0.001030080602504313
. O 0 3.913745786121581e-06

We O 0 6.0248416957620066e-06
have O 0 4.6893569560779724e-07
now O 0 8.33878814887612e-08
identified O 0 1.9154177266500483e-07
a O 0 6.815117359337819e-08
missense O 0 3.789271795540117e-05
mutation O 0 1.8330490547668887e-06
, O 0 2.949912314420544e-08
a O 0 4.6438916712077116e-08
splice O 0 5.123951632413082e-05
- O 0 0.03545823693275452
donor O 0 8.4913001046516e-05
mutation O 0 2.31668650485517e-06
, O 0 6.269584673646023e-08
and O 0 4.7182727058725504e-08
a O 0 1.237386300090293e-07
frameshift O 0 0.00010976094927173108
mutation O 0 7.371934884758957e-07
in O 0 5.748991949161564e-09
the O 0 7.51638484786099e-09
coding O 0 1.113672055907955e-06
region O 0 2.281003332882392e-07
of O 0 1.1293725776795327e-07
SCN5A O 0 0.002120658289641142
in O 0 1.6456912987905525e-07
three O 0 8.515589229318721e-07
IVF B-Disease 0 0.26460596919059753
families O 0 6.467498315032572e-05
. O 0 1.1810183423222043e-05

We O 0 1.9089889065071475e-06
show O 0 3.5797984310192987e-07
that O 0 1.968403751106962e-08
sodium O 0 5.3417437584357685e-08
channels O 0 2.0238266174033015e-08
with O 0 7.636876908634349e-09
the O 0 2.1221985946340283e-08
missense O 0 2.3033819161355495e-05
mutation O 0 5.583416168519761e-06
recover O 0 3.5508979635778815e-05
from O 0 1.488872243271544e-07
inactivation O 0 0.0002750443236436695
more O 0 3.874266951697791e-08
rapidly O 0 8.844043009048619e-07
than O 0 4.779546092237297e-09
normal O 0 7.7113053720268e-09
and O 0 5.917416334710879e-09
that O 0 3.5500551387457335e-09
the O 0 4.002040299155851e-08
frameshift O 0 0.0003089978126809001
mutation O 0 3.218373421987053e-06
causes O 0 4.7147648274403764e-07
the O 0 1.2010414884855436e-08
sodium O 0 6.176312012939889e-07
channel O 0 2.061507302641985e-07
to O 0 1.1271383826283454e-08
be O 0 1.705709351540463e-08
non O 0 4.274689217709238e-06
- O 0 0.0016747883055359125
functional O 0 1.593570959812496e-05
. O 0 4.7632629502913915e-06

Our O 0 6.414129529730417e-06
results O 0 6.174872851261171e-06
indicate O 0 1.5245317399603664e-06
that O 0 5.737055275290004e-08
mutations O 0 1.132640136347618e-06
in O 0 6.511793060326454e-08
cardiac O 0 0.00011308266402920708
ion O 0 1.1380602700228337e-05
- O 0 6.640417996095493e-05
channel O 0 7.452454724443669e-07
genes O 0 7.210840635707427e-08
contribute O 0 4.209786652609182e-08
to O 0 5.513261402967373e-09
the O 0 2.7851646322574197e-08
risk O 0 3.38783570441592e-06
of O 0 8.027935649579376e-08
developing O 0 3.603060758905485e-05
IVF B-Disease 0 0.13058866560459137
. O 0 1.9098795291938586e-06
. O 0 4.04532738684793e-06

Molecular O 0 0.000308345741359517
heterogeneity O 0 0.0004751746018882841
in O 0 4.4195185182616115e-06
mucopolysaccharidosis B-Disease 0 0.008709786459803581
IVA I-Disease 0 0.13600175082683563
in O 0 7.46707428334048e-07
Australia O 0 3.4543205629233853e-07
and O 0 3.761620348541328e-08
Northern O 0 5.10291506827798e-08
Ireland O 0 2.9287380698406196e-07
: O 0 3.4972725160287155e-08
nine O 0 1.0477712208967205e-07
novel O 0 4.4242736407795746e-07
mutations O 0 6.577652698069869e-07
including O 0 2.5684832394290424e-07
T312S O 0 0.00011341937351971865
, O 0 2.283203883735041e-07
a O 0 6.386452611195637e-08
common O 0 2.4491885142197134e-07
allele O 0 8.149969517035061e-07
that O 0 6.599922386385515e-08
confers O 0 1.5770692698424682e-05
a O 0 9.730527381179854e-06
mild O 0 0.014945561066269875
phenotype O 0 0.0020877595525234938
. O 0 2.586303889984265e-05

Mucopolysaccharidosis B-Disease 1 0.8828468918800354
IVA I-Disease 1 0.9917547702789307
( O 0 0.0006066469941288233
MPS B-Disease 1 0.9708913564682007
IVA I-Disease 1 0.9997032284736633
) O 0 2.3559783585369587e-05
is O 0 1.5068794709804934e-06
an O 0 1.8718941646511666e-05
autosomal B-Disease 1 0.8601414561271667
recessive I-Disease 1 0.9877015948295593
lysosomal I-Disease 1 0.9999504089355469
storage I-Disease 1 0.9999175071716309
disorder I-Disease 1 0.9999288320541382
caused O 0 0.0042307679541409016
by O 0 5.490007424668875e-06
a O 0 0.0001091738959075883
genetic B-Disease 1 0.9429324269294739
defect I-Disease 1 0.9703283309936523
in O 0 7.106964972081187e-07
N O 0 7.07023500581272e-05
- O 0 0.002902533859014511
acetylgalactosamine O 0 0.002555495360866189
- O 0 0.0008553528459742665
6 O 0 1.4201300473359879e-05
- O 0 0.015080573037266731
sulfate O 0 0.005860627628862858
sulfatase O 0 0.007143877912312746
( O 0 1.20691322536004e-06
GALNS O 0 0.0006751514738425612
) O 0 1.177293370346888e-06
. O 0 2.135589738827548e-06

Previous O 0 3.5634155210573226e-05
studies O 0 9.457841770199593e-06
of O 0 1.8850400920200627e-06
patients O 0 9.768624295247719e-05
from O 0 1.1562331536651982e-07
a O 0 1.2138720251186896e-07
British O 0 5.947165391262388e-06
- O 0 0.0028535029850900173
Irish O 0 0.00010531391308177263
population O 0 8.850322785747267e-08
showed O 0 1.0579481113381917e-06
that O 0 4.989821444922882e-09
the O 0 1.553457096292732e-08
I113F O 0 5.995546962367371e-05
mutation O 0 1.236123580383719e-06
is O 0 5.505884193013344e-09
the O 0 7.619300745886903e-09
most O 0 1.7647989736246927e-08
common O 0 9.804507783428562e-08
single O 0 4.432280604760308e-07
mutation O 0 1.4109371477388777e-05
among O 0 3.730761454789899e-05
MPS B-Disease 1 0.9936129450798035
IVA I-Disease 1 0.999985933303833
patients O 0 0.0425151064991951
and O 0 2.7658691124088364e-06
produces O 0 2.2120413632364944e-05
a O 0 5.275525472825393e-05
severe O 0 0.3113768398761749
clinical O 0 0.004867128562182188
phenotype O 0 0.0018550932873040438
. O 0 2.2822599930805154e-05

We O 0 5.090412287245272e-06
studied O 0 1.6740872524678707e-05
mutations O 0 8.09338871476939e-06
in O 0 4.5497294820506795e-08
the O 0 4.2612143147380266e-08
GALNS O 0 0.0005274932482279837
gene O 0 2.4548310761929315e-07
from O 0 4.0198731454665904e-08
23 O 0 8.115409286801878e-07
additional O 0 3.22369669447653e-06
MPS B-Disease 1 0.9732268452644348
IVA I-Disease 1 0.9999767541885376
patients O 0 0.01696423999965191
( O 0 6.049778988881371e-08
15 O 0 9.899477504404786e-08
from O 0 6.13305886076887e-08
Australia O 0 8.724152422701081e-08
, O 0 7.167343607505927e-09
8 O 0 2.265661969147459e-08
from O 0 9.171875703373189e-09
Northern O 0 4.727470326315597e-08
Ireland O 0 4.243601949838194e-07
) O 0 2.0928665023234316e-08
, O 0 1.049586995094387e-08
with O 0 1.9208702184414506e-08
various O 0 1.2244770175584563e-07
clinical O 0 0.00024907622719183564
phenotypes O 0 0.004071980249136686
( O 0 1.5092529793037102e-05
severe O 0 0.00985186081379652
, O 0 7.740588898741407e-07
16 O 0 2.4149253476934973e-06
cases O 0 1.9268131836724933e-06
; O 0 5.654065375892969e-07
intermediate O 0 2.4235216642409796e-06
, O 0 4.117875960218953e-07
4 O 0 2.321833335372503e-06
cases O 0 7.366568752331659e-06
; O 0 6.691689122817479e-06
mild O 0 0.00024130109522957355
, O 0 5.355975645215949e-07
3 O 0 2.2473716398963006e-06
cases O 0 7.508423095714534e-06
) O 0 2.232142151115113e-06
. O 0 4.154859652771847e-06

We O 0 2.5638773877290078e-06
found O 0 8.792507628641033e-07
two O 0 9.081482232886628e-08
common O 0 6.857010248495499e-07
mutations O 0 1.437877472199034e-06
that O 0 5.503742350754237e-09
together O 0 1.888638756497585e-08
accounted O 0 7.025138302196865e-07
for O 0 1.404218785694411e-08
32 O 0 3.8985774608590873e-07
% O 0 1.2097643775632605e-08
of O 0 6.637007832210884e-09
the O 0 2.0473938988629925e-08
44 O 0 2.3722534479020396e-06
unrelated O 0 1.7794394807424396e-05
alleles O 0 2.389072506048251e-06
in O 0 2.744905316376389e-07
these O 0 5.816218617837876e-07
patients O 0 0.000158771057613194
. O 0 4.427039584697923e-06

One O 0 4.250720394338714e-06
is O 0 2.5685591253932216e-07
the O 0 1.362466548471275e-07
T312S O 0 0.00011868153524119407
mutation O 0 3.186777803421137e-06
, O 0 4.641447759468065e-08
a O 0 2.519730735173198e-08
novel O 0 1.8893257447416545e-07
mutation O 0 3.6312582096797996e-07
found O 0 9.956075786021756e-08
exclusively O 0 3.583907925985841e-07
in O 0 1.2863362144344137e-06
milder O 0 0.005874576512724161
patients O 0 0.0010722189908847213
. O 0 8.29858527140459e-06

The O 0 2.203061285399599e-06
other O 0 2.941939669653948e-07
is O 0 2.232983753458484e-08
the O 0 2.490118511389028e-08
previously O 0 8.515751233062474e-07
described O 0 2.7254980068391887e-06
I113F O 0 2.2296349925454706e-05
that O 0 4.2306666614422284e-08
produces O 0 1.4896934317221167e-06
a O 0 7.849726898712106e-06
severe O 0 0.02251395955681801
phenotype O 0 0.001255616545677185
. O 0 2.08698238566285e-05

The O 0 6.4690621002228e-06
I113F O 0 0.00024019749253056943
and O 0 1.0572481414783397e-06
T312S O 0 8.904618880478665e-05
mutations O 0 4.206659014016623e-06
accounted O 0 1.9694718957907753e-06
for O 0 6.911450611823966e-08
8 O 0 5.538189498111024e-07
( O 0 5.221257737275664e-08
18 O 0 2.357341202241514e-07
% O 0 4.7016982307468425e-08
) O 0 2.3856788544662777e-08
and O 0 3.078970678416226e-08
6 O 0 3.4556583727862744e-07
( O 0 1.58428967722557e-08
14 O 0 8.758499348004989e-08
% O 0 1.7986558020766097e-08
) O 0 3.0200444367523005e-09
of O 0 4.62294424963261e-09
44 O 0 7.982706051734567e-07
unrelated O 0 1.905850149341859e-05
alleles O 0 4.10747634305153e-06
, O 0 1.2970730267625186e-06
respectively O 0 2.0201214283588342e-05
. O 0 4.915584668196971e-06

The O 0 4.2745018618006725e-06
relatively O 0 6.115273663453991e-06
high O 0 2.1404981453088112e-05
residual O 0 0.00015407103637699038
GALNS O 0 0.0032313952688127756
activity O 0 5.477714921653387e-07
seen O 0 1.379508063337198e-07
when O 0 9.691589752947039e-09
the O 0 3.769425216404443e-09
T312S O 0 7.135087116694194e-07
mutant O 0 2.1988621767832228e-07
cDNA O 0 1.4177804530390858e-07
is O 0 2.4862838898798145e-08
overexpressed O 0 3.435526195971761e-06
in O 0 2.312896718592583e-08
mutant O 0 3.3491039630462183e-06
cells O 0 5.209832920627377e-07
provides O 0 2.2726736048639395e-08
an O 0 1.3396899589679379e-08
explanation O 0 3.5752126592569766e-08
for O 0 2.7907267607929498e-08
the O 0 4.806783522326441e-07
mild O 0 0.0022519459016621113
phenotype O 0 0.00038087923894636333
in O 0 3.3980536500166636e-06
patients O 0 8.121129212668166e-05
with O 0 4.4952400912734447e-07
this O 0 4.843780629926187e-07
mutation O 0 4.2204686906188726e-05
. O 0 6.7563451011665165e-06

The O 0 1.534986040496733e-06
distribution O 0 6.962196152926481e-07
and O 0 9.698047165329626e-08
relative O 0 9.321256300154346e-08
frequencies O 0 7.888800723776512e-09
of O 0 2.6857092105814218e-09
the O 0 2.0922557908420458e-08
I113F O 0 1.1119878763565794e-05
and O 0 1.7797849238831986e-07
T312S O 0 1.463554235670017e-05
mutations O 0 3.8188980511222326e-07
in O 0 1.0381209669674263e-08
Australia O 0 6.990226353309481e-08
corresponded O 0 1.393187858411693e-07
to O 0 3.688756411435179e-09
those O 0 6.893844606281618e-09
observed O 0 3.743876320072559e-08
in O 0 4.005436426979259e-09
Northern O 0 3.798803049903654e-08
Ireland O 0 8.263484687631717e-07
and O 0 1.5660538110751077e-07
are O 0 1.2045699548934863e-08
unique O 0 1.391171888798226e-08
to O 0 4.027238542647638e-09
these O 0 1.8574999316456342e-09
two O 0 3.585592978083696e-08
populations O 0 3.4155814887526503e-07
, O 0 7.830459480828722e-08
suggesting O 0 5.332419164005842e-07
that O 0 7.563222936823877e-09
both O 0 3.472228016221379e-08
mutations O 0 1.2160497817603755e-06
were O 0 2.8458268275244336e-07
probably O 0 3.002316759648238e-07
introduced O 0 1.1366878283070037e-07
to O 0 1.0604614075759855e-08
Australia O 0 5.550435844270396e-08
by O 0 2.0520227295151017e-08
Irish O 0 1.8743614873528713e-06
migrants O 0 3.182384773481317e-07
during O 0 2.9328010242579694e-08
the O 0 2.1452821741263506e-08
19th O 0 2.594644001874258e-06
century O 0 5.2178907026245724e-06
. O 0 4.295087819627952e-06

Haplotype O 0 0.0005799856153316796
analysis O 0 4.193297172605526e-06
using O 0 1.060415797837777e-06
6 O 0 2.3922825675981585e-06
RFLPs O 0 8.537173562217504e-05
provides O 0 5.952193404823447e-08
additional O 0 2.2220055129196226e-08
data O 0 2.728998182988107e-08
that O 0 4.644615358984083e-09
the O 0 1.4448416685297616e-08
I113F O 0 1.1313898539810907e-05
mutation O 0 5.588528324551589e-07
originated O 0 6.724705059468761e-08
from O 0 3.7295361465794485e-08
a O 0 2.664363591975416e-07
common O 0 2.885884441639064e-06
ancestor O 0 3.4342690923949704e-05
. O 0 9.457751730224118e-06

The O 0 1.9600195173552493e-06
other O 0 3.171840319282637e-07
9 O 0 5.431505769593059e-07
novel O 0 8.931924071475805e-07
mutations O 0 3.7683025766455103e-06
identified O 0 4.1103623971139314e-07
in O 0 1.2562918705327775e-08
these O 0 2.538703824939148e-08
23 O 0 7.679848204134032e-05
patients O 0 6.840649439254776e-05
were O 0 6.055827839190897e-08
each O 0 9.040622472866744e-09
limited O 0 1.0529600302788822e-07
to O 0 1.4129962089270975e-08
a O 0 8.295448594708432e-08
single O 0 1.3743764384344104e-06
family O 0 1.4988582734076772e-05
. O 0 7.4649983616836835e-06

These O 0 8.98273299299035e-07
data O 0 4.1385447957509314e-07
provide O 0 1.461937699787086e-07
further O 0 4.6383057394905336e-08
evidence O 0 7.55363984694668e-08
for O 0 2.2941360811046252e-08
extensive O 0 8.115781042761228e-07
allelic O 0 0.0002139838325092569
heterogeneity O 0 0.00039365325937978923
in O 0 2.6121624614461325e-06
MPS B-Disease 0 0.31656414270401
IVA I-Disease 1 0.9897963404655457
in O 0 1.7592823269296787e-06
British O 0 0.00011240354069741443
- O 1 0.6050220727920532
Irish O 0 0.27681854367256165
patients O 0 0.0007072853622958064
and O 0 1.459628009570224e-07
provide O 0 4.546901521962354e-08
evidence O 0 9.737359363271025e-08
for O 0 6.383064743431532e-09
their O 0 1.1576328340368036e-08
transmission O 0 2.7637810262604035e-07
to O 0 8.98554208816904e-09
Australia O 0 4.4709214108706874e-08
by O 0 2.2427883550335537e-08
British O 0 1.913658934427076e-06
- O 0 0.000634941563475877
Irish O 0 5.689429599442519e-05
migrants O 0 6.181130174809368e-06
. O 0 2.138651780114742e-07
. O 0 1.2374293874017894e-06

Identification O 0 1.984212576644495e-05
of O 0 1.6951431689449237e-06
constitutional O 0 5.893089473829605e-05
WT1 O 0 0.127523273229599
mutations O 0 0.00017967114399652928
, O 0 6.993786314524186e-07
in O 0 8.930305739340838e-07
patients O 0 9.686457633506507e-05
with O 0 1.2556096407934092e-05
isolated O 0 0.0668267011642456
diffuse B-Disease 1 0.9976442456245422
mesangial I-Disease 1 0.9999977350234985
sclerosis I-Disease 1 0.9999974966049194
, O 0 2.7551608582143672e-05
and O 0 5.879112450202229e-07
analysis O 0 1.5535317743342603e-07
of O 0 3.062396274344792e-07
genotype O 0 0.00022222514962777495
/ O 0 0.00014072359772399068
phenotype O 0 4.5762899389956146e-05
correlations O 0 6.309921445790678e-06
by O 0 4.4564142598346734e-08
use O 0 1.524579040790286e-08
of O 0 9.28753429718654e-09
a O 0 1.7621879067064583e-07
computerized O 0 0.0001826727093430236
mutation O 0 1.7908731024363078e-05
database O 0 1.507873457740061e-05
. O 0 6.827621291449759e-06

Constitutional O 0 0.00020491387112997472
mutations O 0 4.740155418403447e-05
of O 0 1.4157497219002835e-07
the O 0 1.6393488522226107e-07
WT1 O 0 0.0004261406429577619
gene O 0 3.0532103778568853e-07
, O 0 1.2422999517980315e-08
encoding O 0 3.116500835176339e-08
a O 0 3.162838879688934e-07
zinc O 0 0.0013677040114998817
- O 0 0.0005565788596868515
finger O 0 0.0001167346490547061
transcription O 0 1.4411242545975256e-06
factor O 0 4.0596708572593343e-07
involved O 0 5.173674253455829e-07
in O 0 1.1961615200561937e-06
renal O 1 0.9719544053077698
and O 0 8.605731636635028e-06
gonadal O 1 0.8955370783805847
development O 0 4.906124104309129e-06
, O 0 7.673424988752231e-07
are O 0 3.631057055031306e-08
found O 0 1.4095377309786272e-07
in O 0 4.511207052360078e-08
most O 0 6.083677703827561e-07
patients O 0 1.9270835764473304e-05
with O 0 3.1068204862094717e-06
Denys B-Disease 1 0.9987127780914307
- I-Disease 1 0.9999445676803589
Drash I-Disease 1 0.9999611377716064
syndrome I-Disease 1 0.999934196472168
( O 0 2.312930519110523e-05
DDS B-Disease 1 0.9998658895492554
) O 0 4.685156000050483e-06
, O 0 2.423133537376998e-06
or O 0 3.4177042834926397e-05
diffuse B-Disease 1 0.9486127495765686
mesangial I-Disease 1 0.9999936819076538
sclerosis I-Disease 1 0.999997615814209
( O 0 0.0007860152400098741
DMS B-Disease 1 0.998981773853302
) O 0 4.780948074767366e-06
associated O 0 2.817525455611758e-06
with O 0 1.2049879387632245e-06
pseudohermaphroditism B-Disease 1 0.9831908345222473
and O 0 5.662247076543281e-06
/ O 0 0.0006383996224030852
or O 0 0.000608413596637547
Wilms B-Disease 1 0.9998816251754761
tumor I-Disease 1 0.6805715560913086
( O 0 1.0515353096707258e-05
WT B-Disease 1 0.968532145023346
) O 0 3.817120614257874e-06
. O 0 2.02581350094988e-06

Most O 0 3.3825104765128344e-05
mutations O 0 0.0009572610724717379
in O 0 3.4680258977459744e-05
DDS B-Disease 1 0.999971866607666
patients O 0 0.37652355432510376
lie O 0 4.278417327441275e-05
in O 0 3.168321427438059e-07
exon O 0 3.997972817160189e-05
8 O 0 5.486696750267583e-07
or O 0 3.692094807661306e-08
exon O 0 2.9390557756414637e-06
9 O 0 1.3765603057436238e-07
, O 0 1.4574434992198348e-08
encoding O 0 1.023618807494131e-07
zinc O 0 0.0003792552452068776
finger O 0 1.341200368187856e-05
2 O 0 3.852400993764604e-07
or O 0 1.0110313723998843e-06
zinc O 0 0.00423852913081646
finger O 0 2.8768972697434947e-05
3 O 0 1.4042862517271715e-07
, O 0 3.474745469134177e-08
respectively O 0 2.3755130484914844e-07
, O 0 2.676873123164114e-08
with O 0 2.4104600981900148e-08
a O 0 9.123218802642441e-08
hot O 0 4.042466116516152e-06
spot O 0 3.537421889632242e-06
( O 0 1.7205380231644085e-07
R394W O 0 8.181983503163792e-06
) O 0 3.9272322283068206e-08
in O 0 2.1099207714314616e-08
exon O 0 1.1315635674691293e-05
9 O 0 3.6033061405760236e-06
. O 0 2.891396661652834e-06

We O 0 2.2783822259953013e-06
analyzed O 0 2.2250605979934335e-06
a O 0 5.637670597025135e-08
series O 0 6.637846183821239e-08
of O 0 9.611332529857464e-08
24 O 0 1.2738701116177253e-05
patients O 0 1.955969310074579e-05
, O 0 4.639482398260952e-08
10 O 0 7.694545445247059e-08
with O 0 9.300582064497576e-07
isolated B-Disease 0 0.0002602330641821027
DMS I-Disease 1 0.9590578079223633
( O 0 8.84495511854766e-06
IDMS B-Disease 0 0.2745952010154724
) O 0 1.7192226664519694e-07
, O 0 4.170744460907372e-08
10 O 0 6.793015927542001e-08
with O 0 1.0498112033019424e-06
DDS B-Disease 1 0.9986171722412109
, O 0 8.136527185342857e-07
and O 0 1.3302350510002725e-07
4 O 0 1.047475052473601e-06
with O 0 1.1498259482323192e-05
urogenital B-Disease 1 0.9967406392097473
abnormalities I-Disease 1 0.9841734170913696
and O 0 9.84873895504279e-06
/ O 0 0.0005670027458108962
or O 0 6.791167106712237e-05
WT B-Disease 1 0.9871706366539001
. O 0 2.272943856951315e-05

We O 0 8.356767466466408e-06
report O 0 8.488973435305525e-06
WT1 O 0 0.000517389620654285
heterozygous O 0 2.2306261598714627e-05
mutations O 0 1.570874337630812e-05
in O 0 3.389644120943558e-07
16 O 0 2.4134604245773517e-05
patients O 0 0.00011332996655255556
, O 0 9.769227204969866e-08
4 O 0 1.729579821585503e-07
of O 0 1.7323233691968198e-07
whom O 0 9.43942359299399e-06
presented O 0 7.577009455417283e-06
with O 0 1.2279305337870028e-05
IDMS B-Disease 1 0.7442935705184937
. O 0 1.7218515495187603e-05

One O 0 7.009056389506441e-06
male O 0 1.5032115697977133e-05
and O 0 6.174209374876227e-07
two O 0 9.7862232451007e-07
female O 0 0.00036093773087486625
IDMS B-Disease 1 0.9977856874465942
patients O 0 0.0014262668555602431
with O 0 8.015318599063903e-06
WT1 O 1 0.6884769797325134
mutations O 0 0.0010447013191878796
underwent O 0 0.0035783725325018167
normal O 0 1.0380069397797342e-05
puberty O 0 0.00030041064019314945
. O 0 9.778790627024136e-06

Two O 0 2.4265827960334718e-05
mutations O 0 0.0006902887835167348
associated O 0 9.542333827994298e-06
with O 0 1.869544803412282e-06
IDMS B-Disease 0 0.4303470551967621
are O 0 3.898484379760703e-08
different O 0 4.207681314483125e-09
from O 0 6.721024448097523e-08
those O 0 2.5159377514683e-07
described O 0 2.2928183170733973e-05
in O 0 2.243507515231613e-05
DDS B-Disease 1 0.9999250173568726
patients O 0 0.11835914105176926
. O 0 2.2773918317398056e-05

No O 0 3.306704820715822e-05
WT1 O 0 0.02053176425397396
mutations O 0 0.00022388911747839302
were O 0 1.9289493593532825e-06
detected O 0 3.0763933409616584e-06
in O 0 1.4684738758319327e-08
the O 0 1.4823275940045733e-08
six O 0 6.685583002763451e-07
other O 0 6.44450528852758e-06
IDMS B-Disease 1 0.9993718266487122
patients O 0 0.003269111504778266
, O 0 8.485691296300502e-07
suggesting O 0 1.089542820409406e-05
genetic O 0 4.265200914232992e-06
heterogeneity O 0 2.310619856871199e-05
of O 0 1.4762126738787629e-06
this O 0 8.741058991290629e-06
disease O 0 0.02498445101082325
. O 0 1.443184373783879e-05

We O 0 5.135540504852543e-06
analyzed O 0 2.9448519853758626e-05
genotype O 0 0.00016030229744501412
/ O 0 0.0002567088813520968
phenotype O 0 0.00025739806005731225
correlations O 0 4.9614274757914245e-05
, O 0 1.2241932267897937e-07
on O 0 1.751790001947029e-08
the O 0 4.562031641341946e-09
basis O 0 3.2227340795998316e-09
of O 0 4.740045245199553e-09
the O 0 1.304837748961063e-08
constitution O 0 8.467859657912413e-08
of O 0 1.1797538945756969e-08
a O 0 1.2528023773938912e-07
WT1 O 0 0.00029572274070233107
mutation O 0 1.6452754891815857e-07
database O 0 5.0136261364741586e-08
of O 0 2.8331500701028745e-08
84 O 0 2.5997464035754092e-05
germ O 0 0.0005647759535349905
- O 0 0.0006975645665079355
line O 0 9.662891898187809e-06
mutations O 0 2.135088607246871e-06
, O 0 1.5051568880153354e-08
to O 0 2.869640969294096e-09
compare O 0 5.3250097664658824e-08
the O 0 5.242100087343715e-09
distribution O 0 2.95940250083504e-08
and O 0 1.0436187380946649e-07
type O 0 4.6802156816738716e-07
of O 0 1.2562013296246732e-07
mutations O 0 7.685299351578578e-06
, O 0 1.115168046794679e-07
according O 0 2.9659911859880594e-08
to O 0 2.488637207420652e-08
the O 0 1.544560177535459e-07
different O 0 1.1562258350750199e-06
symptoms O 0 0.00046494018170051277
. O 0 7.016332347120624e-06

This O 0 4.4508519749797415e-06
demonstrated O 0 3.41262057190761e-05
( O 0 2.0738293926569895e-07
1 O 0 2.193914383497031e-07
) O 0 2.842194213314997e-08
the O 0 1.661968873634123e-08
association O 0 3.9401379581249785e-07
between O 0 2.6944739772716275e-08
mutations O 0 3.2395979587818147e-07
in O 0 7.099910881436244e-09
exons O 0 1.2408576139932848e-06
8 O 0 2.8134229523857357e-07
and O 0 1.4327483199849667e-07
9 O 0 6.082123036321718e-07
and O 0 7.551491876256478e-07
DMS B-Disease 0 0.2807747423648834
; O 0 7.137918487387651e-07
( O 0 3.5646447571480167e-08
2 O 0 3.1426401392309344e-07
) O 0 2.3448791353075649e-07
among O 0 6.207772003108403e-06
patients O 0 6.833835504949093e-05
with O 0 2.1646139884978766e-06
DMS B-Disease 1 0.7924400568008423
, O 0 2.6663207108867937e-07
a O 0 1.8167297000104554e-08
higher O 0 3.588267816212465e-08
frequency O 0 8.83712836241557e-09
of O 0 6.329261559301358e-09
exon O 0 7.046521659503924e-06
8 O 0 6.670590551038913e-07
mutations O 0 1.1270158211118542e-06
among O 0 3.036814746337768e-07
46 O 0 2.1566112991422415e-05
, O 0 8.079585313680582e-06
XY O 1 0.9301673173904419
patients O 0 0.0004459222254808992
with O 0 6.355102186716977e-07
female O 0 1.7779195331968367e-05
phenotype O 0 6.5295803324261215e-06
than O 0 4.7588084584049284e-08
among O 0 4.986170552001568e-07
46 O 0 1.4683761946798768e-05
, O 0 4.459710908122361e-06
XY O 1 0.9577304720878601
patients O 0 0.0009981014300137758
with O 0 6.230448548194545e-07
sexual O 0 7.3168657763744704e-06
ambiguity O 0 7.4546046562318224e-06
or O 0 1.868496838142164e-06
male O 0 2.1587698938674293e-05
phenotype O 0 4.26892947871238e-05
; O 0 3.8265829971351195e-07
and O 0 2.644310086452606e-07
( O 0 5.835308769519543e-08
3 O 0 1.3663793652085587e-07
) O 0 3.0209385215584916e-08
statistically O 0 3.1916181342239724e-07
significant O 0 5.5701509182881637e-08
evidence O 0 7.51975761659196e-08
that O 0 1.1180300241164787e-08
mutations O 0 2.333132584908526e-07
in O 0 1.7764298476663498e-08
exons O 0 1.1896486284967978e-06
8 O 0 1.0705092279295059e-07
and O 0 1.4761712741062638e-08
9 O 0 8.348034441496566e-08
preferentially O 0 2.3236886192989914e-07
affect O 0 5.3686580514522575e-08
amino O 0 6.785026585021114e-08
acids O 0 5.081275844531774e-08
with O 0 3.4206446564155613e-09
different O 0 2.1839157149372568e-09
functions O 0 2.5478479770413287e-08
. O 0 9.199438721907427e-08
. O 0 1.2580346719914814e-06

The O 0 1.9110102584818378e-05
185delAG O 0 0.009754607453942299
BRCA1 O 0 0.0033867850434035063
mutation O 0 1.712464654701762e-05
originated O 0 5.675101419910789e-07
before O 0 1.0464950150890218e-07
the O 0 1.3018397027053652e-08
dispersion O 0 1.2478615190048004e-06
of O 0 3.289584782351085e-08
Jews O 0 5.922669288338511e-07
in O 0 1.526423787368003e-08
the O 0 2.550142674806466e-08
diaspora O 0 3.5808545817417325e-06
and O 0 3.3919499742296466e-07
is O 0 2.9472802864916048e-08
not O 0 2.0317941107350634e-08
limited O 0 2.2350276651650347e-07
to O 0 3.5200736192564364e-07
Ashkenazim O 0 0.0006856148247607052
. O 0 5.7856805142364465e-06

The O 0 1.3422316442301963e-05
185delAG O 0 0.0014929892495274544
mutation O 0 7.333375106099993e-05
in O 0 1.4834795365459286e-06
BRCA1 O 0 0.00023583610891364515
is O 0 2.5500872880002134e-07
detected O 0 3.199406137355254e-06
in O 0 5.5265090281864104e-08
Ashkenazi O 0 6.006803232594393e-05
Jews O 0 1.2909840734209865e-06
both O 0 1.2507884150636528e-07
in O 0 5.247545118436392e-07
familial B-Disease 1 0.529604434967041
breast I-Disease 1 0.9995054006576538
and I-Disease 1 0.974361777305603
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9997506737709045
and O 0 2.0952884369762614e-06
in O 0 1.3068830639895168e-07
the O 0 1.6247557255155698e-07
general O 0 3.3890537451952696e-06
population O 0 1.7574243429407943e-06
. O 0 4.488832473725779e-06

All O 0 3.524087787809549e-06
tested O 0 7.314803951885551e-05
Ashkenazi O 0 0.0010148832807317376
mutation O 0 1.828829408623278e-05
carriers O 0 1.1220150554436259e-05
share O 0 1.3560745060203772e-07
the O 0 7.318722072824357e-09
same O 0 9.180364912708683e-09
allelic O 0 3.7679503748222487e-06
pattern O 0 1.3358851447264897e-06
at O 0 3.7807757280461374e-07
the O 0 5.271631380310282e-07
BRCA1 O 0 0.00014693004777655005
locus O 0 8.279173925984651e-05
. O 0 9.810129085963126e-06

Our O 0 3.4633135328476783e-06
previous O 0 2.6058999083033996e-06
study O 0 5.865481966793595e-07
showed O 0 1.0958157190543716e-06
that O 0 1.07800595117169e-08
this O 0 8.042491117521422e-09
Ashkenazi O 0 0.0001557372888782993
mutation O 0 2.622386091388762e-06
also O 0 9.07088733015371e-08
occurs O 0 1.7346104996818212e-08
in O 0 8.003087970109846e-09
Iraqi O 0 1.7375202787661692e-07
Jews O 0 1.8667337542410678e-07
with O 0 4.835537836811454e-08
a O 0 1.7573194099895773e-07
similar O 0 9.877294360194355e-07
allelic O 0 0.0007238069083541632
pattern O 0 9.365573350805789e-05
. O 0 1.7525975636090152e-05

We O 0 2.1871198896405986e-06
extended O 0 9.203315016748093e-07
our O 0 3.935135239885312e-08
analysis O 0 2.3036509588791887e-08
to O 0 5.413022918787647e-09
other O 0 5.889491561106297e-09
non O 0 3.9853702560321835e-07
- O 0 2.3104545107344165e-05
Ashkenazi O 0 5.6949120335048065e-06
subsets O 0 1.4012708504651528e-07
354 O 0 3.550836424892623e-07
of O 0 6.982002087596584e-09
Moroccan O 0 4.012640602013562e-06
origin O 0 6.759412229939699e-08
, O 0 2.154417977351386e-08
200 O 0 6.252113848859153e-08
Yemenites O 0 4.415713920025155e-05
and O 0 6.167594079897754e-08
150 O 0 1.7250118844458484e-07
Iranian O 0 1.3432563719106838e-06
Jews O 0 2.9909247132309247e-06
. O 0 1.550123556626204e-06

Heteroduplex O 0 0.0017022223910316825
analysis O 0 3.5980524444312323e-06
complemented O 0 3.575759365048725e-06
by O 0 4.9537888457962254e-08
direct O 0 3.3232353757739475e-08
DNA O 0 1.774906621676564e-07
sequencing O 0 2.2145002276374726e-07
of O 0 6.475898572944061e-08
abnormally O 0 2.3220136426971294e-05
migrating O 0 1.4210930885383277e-06
bands O 0 2.3163836431194795e-06
were O 0 2.926002196090849e-07
employed O 0 6.533834948641015e-06
. O 0 2.1942064449831378e-06

Four O 0 2.066048864435288e-06
of O 0 4.5042773422210303e-07
Moroccan O 0 0.00010014199506258592
origin O 0 8.801047783890681e-07
( O 0 8.202996326645007e-08
1 O 0 3.88621934632738e-08
. O 0 4.854655344388448e-09
1 O 0 2.1094942681543216e-08
% O 0 2.4994069036665678e-08
) O 0 1.0580975207119536e-08
and O 0 1.1520556064681386e-08
none O 0 1.5356048876924433e-08
of O 0 4.308992274104639e-09
the O 0 2.5612274967556914e-08
Yemenites O 0 0.00010222085984423757
or O 0 1.200121459987713e-07
Iranians O 0 6.376471901603509e-07
was O 0 1.1056753379534712e-07
a O 0 1.9028053799274858e-08
carrier O 0 1.0292606020811945e-06
of O 0 1.4006583448633592e-08
the O 0 2.0840955983203457e-07
185delAG O 0 0.0005436482024379075
mutation O 0 2.0665849660872482e-05
. O 0 2.7760484044847544e-06

BRCA1 O 0 0.014024908654391766
allelic O 0 0.001598873408511281
patterns O 0 0.00010250217746943235
were O 0 2.267725676574628e-06
determined O 0 6.406980332940293e-07
for O 0 2.3630443379829558e-08
four O 0 1.32661002183454e-08
of O 0 1.2138809069028866e-08
these O 0 4.64160399005209e-09
individuals O 0 4.2094015384464e-08
and O 0 2.0863300420614905e-08
for O 0 1.1738282346129836e-08
12 O 0 1.1190139304062541e-07
additional O 0 9.103819564870719e-08
non O 0 3.139329237455968e-06
- O 0 0.0006399826379492879
Ashkenazi O 0 0.000510898360516876
185delAG O 0 0.00019801610324066132
mutation O 0 4.171351974946447e-06
carriers O 0 1.570741005707532e-05
who O 0 1.8274136891704984e-05
had O 0 0.0006205099052749574
breast B-Disease 1 0.9949020147323608
/ I-Disease 1 0.9992357492446899
ovarian I-Disease 1 0.9999902248382568
cancer I-Disease 1 0.9996320009231567
. O 0 8.686682122061029e-05

Six O 0 4.180890755378641e-05
non O 0 0.0002127193147316575
- O 0 0.05494876205921173
Ashkenazi O 0 0.025214726105332375
individuals O 0 1.6914532352529932e-06
shared O 0 8.5550595940731e-07
the O 0 1.683100521177039e-07
common O 0 1.3757560282101622e-06
Ashkenazi O 0 0.0002635489800013602
haplotype O 0 2.4907634724513628e-05
, O 0 7.781476085710892e-08
four O 0 3.8187881301610105e-08
had O 0 3.483499142475921e-07
a O 0 1.407042446999185e-07
closely O 0 2.207311354140984e-06
related O 0 9.473097634327132e-06
pattern O 0 7.968521458678879e-06
, O 0 6.323267029983981e-07
and O 0 2.7958955683971e-07
the O 0 6.191627477392103e-08
rest O 0 3.10020908500519e-07
( O 0 5.743570241634188e-08
n O 0 3.860222932416946e-06
= O 0 5.5541809160786215e-06
6 O 0 3.7389096974038694e-07
) O 0 1.9852008037446467e-08
displayed O 0 2.161450680659982e-07
a O 0 1.3590575065336452e-07
distinct O 0 1.8467989093551296e-06
BRCA1 O 0 0.00021811349142808467
allelic O 0 0.0009866405744105577
pattern O 0 0.0001699049462331459
. O 0 1.7015951016219333e-05

We O 0 3.19272498927603e-06
conclude O 0 4.4718435674440116e-06
that O 0 5.2225622937385197e-08
the O 0 5.9231780369373155e-08
185delAG O 0 0.0002589660871308297
BRCA1 O 0 0.0001876393798738718
mutation O 0 1.7156058902401128e-06
occurs O 0 5.84233603717621e-08
in O 0 6.00238792003438e-09
some O 0 1.0480627032904977e-08
non O 0 3.368357965882751e-06
- O 0 0.0027807450387626886
Ashkenazi O 0 0.004005764611065388
populations O 0 6.777536896152014e-07
at O 0 1.0966630270559108e-07
rates O 0 2.5297188699369144e-07
comparable O 0 1.4266113623762067e-07
with O 0 2.6505050598757407e-08
that O 0 2.5240021628292197e-08
of O 0 4.463491904971306e-07
Ashkenazim O 0 0.0016343069728463888
. O 0 1.5079008335305844e-05

The O 0 4.537641416391125e-06
majority O 0 2.211478886238183e-06
of O 0 6.051636347592648e-08
Jewish O 0 3.407123585930094e-06
185delAG O 0 0.0002335645694984123
mutation O 0 4.7098437789827585e-06
carriers O 0 1.411460561939748e-05
have O 0 7.296118553767883e-08
a O 0 5.974246874984601e-08
common O 0 4.4692083633890434e-07
allelic O 0 0.00014132050273474306
pattern O 0 1.1645394806691911e-05
, O 0 3.308623206521588e-07
supporting O 0 2.3486172722186893e-06
the O 0 5.884396969690897e-08
founder O 0 5.2244893595343456e-05
effect O 0 2.9387177846729173e-07
notion O 0 2.0111173171244445e-07
, O 0 6.948738473511185e-08
but O 0 7.687706471415368e-09
dating O 0 8.296682807440448e-08
the O 0 2.4571960466346354e-08
mutations O 0 6.034946977706568e-07
origin O 0 3.516623436894406e-08
to O 0 9.303455783538084e-09
an O 0 1.159900531177982e-08
earlier O 0 1.531586235614668e-07
date O 0 8.990345889969831e-08
than O 0 5.180289619488576e-08
currently O 0 1.422240075044101e-06
estimated O 0 7.203388577181613e-06
. O 0 3.590257847463363e-06

However O 0 1.5444746168213896e-05
, O 0 2.4969727974166744e-07
the O 0 1.3613685290181365e-08
different O 0 6.8609589121138015e-09
allelic O 0 9.256566954718437e-06
pattern O 0 2.2389945115719456e-06
at O 0 2.7892215825886524e-07
the O 0 7.855216921370811e-08
BRCA1 O 0 1.473375414207112e-05
locus O 0 2.01236548491579e-06
even O 0 7.616398534082691e-08
in O 0 5.726852325693699e-09
some O 0 9.179524695923647e-09
Jewish O 0 1.8703473187997588e-06
mutation O 0 4.62958723801421e-06
carriers O 0 1.5097899449756369e-05
, O 0 3.1507488529314287e-07
might O 0 1.6780360567736352e-07
suggest O 0 3.034289974834792e-08
that O 0 3.7140308606353756e-09
the O 0 3.1800542643622975e-08
mutation O 0 1.0533241265875404e-06
arose O 0 1.0402101224826765e-06
independently O 0 2.798944933601888e-07
. O 0 3.327860156332463e-07
. O 0 2.937217914222856e-06

Crystal O 0 0.006440653465688229
structure O 0 3.0126699130050838e-05
of O 0 6.642772518716811e-07
the O 0 5.22367099620169e-06
hemochromatosis B-Disease 1 0.9997246861457825
protein O 0 1.086100655811606e-05
HFE O 0 0.0007908386760391295
and O 0 2.4647491159157653e-07
characterization O 0 5.660781994265562e-07
of O 0 1.120555559452896e-08
its O 0 2.3015516603663855e-08
interaction O 0 9.01412633425025e-08
with O 0 8.008143481674779e-07
transferrin O 0 0.001501472550444305
receptor O 0 3.926297722500749e-05
. O 0 2.3781860818417044e-06

HFE O 0 0.30733269453048706
is O 0 5.617122496914817e-06
an O 0 1.0724635330916499e-06
MHC O 0 0.0030371013563126326
- O 0 0.00461417343467474
related O 0 1.7404885511496104e-05
protein O 0 1.2828529349917517e-07
that O 0 6.502569149802184e-09
is O 0 5.7414637488761855e-09
mutated O 0 4.029703859487199e-07
in O 0 3.553545724344076e-08
the O 0 9.306668857789191e-07
iron B-Disease 1 0.5870647430419922
- I-Disease 1 0.9982082843780518
overload I-Disease 1 0.9997178912162781
disease I-Disease 1 0.9990260601043701
hereditary B-Disease 1 0.9998656511306763
hemochromatosis I-Disease 1 0.999975323677063
. O 0 0.0022423069458454847

HFE O 0 0.010247059166431427
binds O 0 4.312514283810742e-05
to O 0 1.2836941323257633e-06
transferrin O 0 0.00036611143150366843
receptor O 0 1.5722533134976402e-05
( O 0 2.2372347530108527e-07
TfR O 0 6.293371552601457e-05
) O 0 4.256340702113448e-08
and O 0 3.229473577448516e-08
reduces O 0 1.1637329180302913e-06
its O 0 1.4190974617633856e-08
affinity O 0 3.016361915797461e-07
for O 0 7.064643625653844e-08
iron O 0 7.364503835560754e-05
- O 0 3.416808249312453e-05
loaded O 0 1.9966475520050153e-05
transferrin O 0 0.00011225196794839576
, O 0 2.7121967605125974e-07
implicating O 0 0.0003166140231769532
HFE O 0 0.005651485174894333
in O 0 1.3331742820810177e-06
iron O 0 0.0016677298117429018
metabolism O 0 0.00014067247684579343
. O 0 6.012914582242956e-06

The O 0 3.143541107419878e-05
2 O 0 8.112645446090028e-05
. O 0 2.9828957849531434e-05

6 O 0 8.004799019545317e-05
A O 0 1.5210697711154353e-05
crystal O 0 0.0009149945108219981
structure O 0 4.0257154978462495e-06
of O 0 3.781186705964501e-07
HFE O 0 0.008284581825137138
reveals O 0 4.132256435696036e-06
the O 0 3.421925498514611e-08
locations O 0 9.946509749170218e-08
of O 0 6.820662861173332e-07
hemochromatosis B-Disease 1 0.9999128580093384
mutations O 0 8.294599683722481e-05
and O 0 4.935280912832241e-07
a O 0 9.0751416337298e-07
patch O 0 0.00500096008181572
of O 0 3.2943884775704646e-07
histidines O 0 0.00302622327581048
that O 0 8.302382070723979e-08
could O 0 6.335061186746316e-08
be O 0 4.4590646730569006e-09
involved O 0 8.619784352958959e-08
in O 0 1.70174885738561e-07
pH O 0 0.00020358743495307863
- O 0 0.0036046544555574656
dependent O 0 2.4037395633058622e-05
interactions O 0 7.902357538114302e-06
. O 0 4.7124813136179e-06

We O 0 4.25576627094415e-06
also O 0 6.838333206360403e-07
demonstrate O 0 8.178622579180228e-07
that O 0 8.19588024114637e-08
soluble O 0 1.1865725355164614e-05
TfR O 0 0.00010105185356223956
and O 0 7.914121056273871e-07
HFE O 0 0.0027038580738008022
bind O 0 3.885666956193745e-06
tightly O 0 8.298976581500028e-07
at O 0 7.689381220643554e-08
the O 0 1.1455217219236147e-08
basic O 0 4.3177561082075044e-08
pH O 0 1.6079399074442335e-06
of O 0 7.017729508618231e-09
the O 0 2.3720575725860726e-08
cell O 0 8.65287620399613e-06
surface O 0 2.2799756607128074e-06
, O 0 1.8109818711309345e-07
but O 0 1.5973521172440996e-08
not O 0 3.6713212470118606e-09
at O 0 3.555003402766488e-08
the O 0 9.922066368517335e-08
acidic O 0 8.283644274342805e-05
pH O 0 2.7981999664916657e-05
of O 0 1.6447152972887125e-07
intracellular O 0 0.00021685419778805226
vesicles O 0 0.0005523301661014557
. O 0 9.126712939178105e-06

TfR O 0 0.21386589109897614
HFE O 0 0.13914969563484192
stoichiometry O 0 0.0009854199597612023
( O 0 3.0764929306315025e-06
2 O 0 1.0130186183232581e-06
1 O 0 2.9323265948733024e-07
) O 0 4.1922866955701465e-08
differs O 0 1.0758228796703406e-07
from O 0 1.1324311799398856e-07
TfR O 0 9.354086796520278e-05
transferrin O 0 4.073433592566289e-05
stoichiometry O 0 3.7309348499547923e-06
( O 0 4.249478280371477e-08
2 O 0 7.395934886744726e-08
2 O 0 1.6817944015201647e-07
) O 0 1.318613129797086e-08
, O 0 9.56896517578798e-09
implying O 0 8.449967481283238e-08
a O 0 4.548946552773714e-09
different O 0 4.575955447894131e-10
mode O 0 6.931183627045812e-09
of O 0 3.1851759008105773e-09
binding O 0 1.0989012366735551e-07
for O 0 6.974897104328193e-08
HFE O 0 0.000356424308847636
and O 0 3.906709764578409e-07
transferrin O 0 8.427813736489043e-05
to O 0 1.4236309198167874e-07
TfR O 0 4.86906646983698e-05
, O 0 5.2602516120714427e-08
consistent O 0 4.682438969894065e-08
with O 0 1.2240994884393785e-08
our O 0 2.561041867465974e-08
demonstration O 0 4.81544589092664e-07
that O 0 3.933814696210902e-08
HFE O 0 0.0001602295524207875
, O 0 2.5563673489159555e-07
transferrin O 0 6.239702634047717e-05
, O 0 1.7547488084801444e-07
and O 0 4.275743208381755e-07
TfR O 0 0.0001723630412016064
form O 0 2.0135391309850093e-07
a O 0 4.3854166165147035e-07
ternary O 0 1.786969369277358e-05
complex O 0 3.0577601137338206e-05
. O 0 4.782156793226022e-06

Identification O 0 8.004868504940532e-06
of O 0 2.5933377401088364e-07
three O 0 1.5466311253931053e-07
novel O 0 1.7615657270653173e-06
mutations O 0 3.186954245393281e-06
and O 0 6.919694328644255e-08
a O 0 4.4885140937367396e-08
high O 0 6.447355644922936e-07
frequency O 0 1.665745408274688e-08
of O 0 6.466737811905432e-09
the O 0 5.839483918634869e-08
Arg778Leu O 0 0.00024203544307965785
mutation O 0 4.675577201851411e-06
in O 0 4.6889857685528114e-07
Korean O 0 0.009219369851052761
patients O 0 0.0014799610944464803
with O 0 3.3730146242305636e-05
Wilson B-Disease 1 0.6474152207374573
disease I-Disease 0 0.0773136243224144
. O 0 1.4538569303113036e-05

Four O 0 1.865220838226378e-05
mutations O 0 0.00010543256939854473
- O 0 0.0005417295615188777
- O 0 0.004313737619668245
R778L O 0 0.0003964253410231322
, O 0 3.1547233447781764e-07
A874V O 0 6.74136754241772e-06
, O 0 8.535739226545047e-08
L1083F O 0 4.983920916856732e-06
, O 0 2.281229072309543e-08
and O 0 1.714849773293281e-08
2304delC O 0 1.00995957836858e-05
- O 0 2.3118278477340937e-05
- O 0 1.6025807781261392e-05
in O 0 1.199603794077575e-08
the O 0 1.2871097077038485e-08
copper O 0 6.5929725678870454e-06
- O 0 5.777746991952881e-06
transporting O 0 4.85939153804793e-06
enzyme O 0 1.0735390105764964e-06
, O 0 4.307556267235668e-08
P O 0 1.4259995623433497e-05
- O 0 9.521441097604111e-05
type O 0 2.8868369099654956e-06
ATPase O 0 9.491534729022533e-05
( O 0 1.4297032180365932e-07
ATP7B O 0 0.00025078788166865706
) O 0 4.836644507122401e-08
, O 0 1.4797089775697714e-08
were O 0 2.7297529570091683e-08
identified O 0 3.6999276176175044e-07
in O 0 1.5982456602614548e-07
Korean O 0 0.004829630255699158
Patients O 0 0.00046327500604093075
with O 0 2.010645948757883e-05
Wilson B-Disease 0 0.44191110134124756
disease I-Disease 0 0.02345210500061512
. O 0 1.2171960406703874e-05

Arg778Leu O 0 0.07593272626399994
, O 0 4.553954568109475e-06
the O 0 1.62761537580991e-07
most O 0 9.619365215485232e-08
frequently O 0 4.188674154192995e-07
reported O 0 1.264961838387535e-06
mutation O 0 1.1586018899834016e-07
of O 0 6.681233788441432e-09
this O 0 5.183083739979111e-09
enzyme O 0 9.298817644776136e-07
, O 0 8.863246137025271e-08
was O 0 1.7145823960618145e-07
found O 0 3.6112343337890707e-08
in O 0 2.721869840627278e-09
six O 0 2.2884197647954352e-08
of O 0 1.4687847382788277e-08
eight O 0 2.958563982247142e-06
unrelated O 0 0.012308829464018345
patients O 0 0.0003111404075752944
studied O 0 2.07705079446896e-06
, O 0 7.445543559470025e-08
an O 0 1.7415755948491096e-08
allele O 0 1.3408944710135984e-07
frequency O 0 4.042570722617711e-08
of O 0 8.449741528693266e-08
37 O 0 1.1046588952012826e-05
. O 0 3.643264108177391e-06

5 O 0 2.365684304095339e-05
% O 0 1.306295303038496e-06
, O 0 1.1401359500951003e-07
which O 0 1.57084265595131e-08
is O 0 7.50486695011432e-09
considerably O 0 1.8440375981754187e-07
higher O 0 5.69634117653095e-08
than O 0 6.477044678376842e-09
those O 0 1.1648666919938933e-08
in O 0 1.854654385624599e-08
other O 0 9.402215539466852e-08
Asian O 0 9.669834071246441e-06
populations O 0 6.6948996391147375e-06
. O 0 3.3977621569647454e-06

The O 0 1.121105810852896e-06
novel O 0 1.4136128356767586e-06
single O 0 3.1558067803416634e-07
nucleotide O 0 3.3112696655734908e-06
deletion O 0 9.880546713247895e-06
, O 0 3.5843078194375266e-07
2304delC O 0 6.143510836409405e-05
, O 0 1.993193876614896e-07
was O 0 2.329748554075195e-07
found O 0 2.118848101417825e-07
in O 0 7.63998286856804e-08
one O 0 1.0513782626730972e-06
patient O 0 0.00015167289529927075
. O 0 8.362379048776347e-06

Since O 0 1.4396488040802069e-05
a O 0 1.2950102927788976e-06
mutation O 0 1.979897206183523e-06
at O 0 1.8511138932808535e-07
cDNA O 0 1.201055056299083e-06
nucleotide O 0 1.146652448369423e-05
2302 O 0 0.0005835187039338052
( O 0 2.4316796043422073e-07
2302insC O 0 2.3208580387290567e-05
) O 0 5.62943966997409e-08
had O 0 1.20938068448595e-07
been O 0 8.617515590003677e-08
previously O 0 8.322880944433564e-07
described O 0 1.392865215166239e-06
, O 0 5.2017053775443856e-08
this O 0 2.4636475082218112e-09
region O 0 3.617121535626211e-08
of O 0 9.986159454911103e-09
the O 0 7.167934512608554e-08
ATP7B O 0 0.016233714297413826
gene O 0 1.7653665054240264e-06
may O 0 9.143249144472065e-07
be O 0 4.497958627780463e-08
susceptible O 0 6.860778285044944e-06
to O 0 1.1560700130530677e-07
gene O 0 2.108956778101856e-06
rearrangements O 0 0.0037937851157039404
causing O 0 0.03635208308696747
Wilson B-Disease 0 0.42963162064552307
disease I-Disease 0 0.03668157756328583
. O 0 1.5921565136522986e-05

Disruption O 0 0.0001260982535313815
of O 0 2.8032457066728966e-07
splicing O 0 2.521804162824992e-06
regulated O 0 6.589840495507815e-07
by O 0 3.671000570193428e-08
a O 0 8.180730759477228e-08
CUG O 0 0.00022176349011715502
- O 0 0.0001842896017478779
binding O 0 4.003066351287998e-06
protein O 0 1.7913210967890336e-06
in O 0 4.702237220044481e-06
myotonic B-Disease 1 0.999195396900177
dystrophy I-Disease 1 0.9996790885925293
. O 0 0.00013969973952043802

Myotonic B-Disease 1 0.9997937083244324
dystrophy I-Disease 1 0.9999372959136963
( O 0 0.00943146925419569
DM B-Disease 1 0.9999431371688843
) O 0 7.359295705100521e-05
is O 0 1.3562586218540673e-06
caused O 0 2.7548810521693667e-06
by O 0 2.6639105143999586e-08
a O 0 7.144184621665772e-08
CTG O 0 0.00013036391464993358
expansion O 0 4.508626716415165e-07
in O 0 9.731971672977124e-09
the O 0 1.0988212117979401e-08
3 O 0 4.1478818957330077e-07
untranslated O 0 0.00010341838788008317
region O 0 2.453440686167596e-07
of O 0 7.39805088301182e-08
the O 0 3.2097450457513332e-06
DM B-Disease 1 0.9995301961898804
gene O 0 4.378507219371386e-05
. O 0 7.241510957101127e-06

One O 0 1.980335355256102e-06
model O 0 3.1815516194910742e-06
of O 0 2.3368518213828793e-06
DM B-Disease 1 0.9999048709869385
pathogenesis O 0 0.158978670835495
suggests O 0 5.660459919454297e-06
that O 0 5.119888513149817e-08
RNAs O 0 2.2302078832581174e-06
from O 0 1.3015715616404577e-08
the O 0 4.3755798984079775e-09
expanded O 0 6.541121422287688e-08
allele O 0 7.815836511326779e-08
create O 0 3.269230930413869e-08
a O 0 3.3185674652713715e-08
gain O 0 1.0082793551191571e-06
- O 0 1.3745109754381701e-05
of O 0 5.562995042396324e-08
- O 0 0.0003485148772597313
function O 0 1.0513706172332604e-07
mutation O 0 1.1389057874566788e-07
by O 0 7.324950868081714e-09
the O 0 1.2297204143862928e-08
inappropriate O 0 3.8880884289937967e-07
binding O 0 7.776950639026836e-08
of O 0 6.812177932857821e-09
proteins O 0 2.0500745989693314e-08
to O 0 9.768720055092217e-09
the O 0 1.4122583991138526e-07
CUG O 0 0.0007276168907992542
repeats O 0 1.4087522686168086e-05
. O 0 1.9731492102437187e-06

Data O 0 1.5167142919381149e-05
presented O 0 1.107122534449445e-05
here O 0 4.318127082569845e-07
indicate O 0 2.5526495051053644e-07
that O 0 8.34409874528319e-09
the O 0 1.673822147552073e-08
conserved O 0 4.125749626382458e-07
heterogeneous O 0 2.0130557459197007e-05
nuclear O 0 0.00033299895585514605
ribonucleoprotein O 0 0.0012888028286397457
, O 0 8.194432439267985e-07
CUG O 0 0.00040744474972598255
- O 0 3.8612652133451775e-05
binding O 0 3.972601234636386e-07
protein O 0 3.685565630462406e-08
( O 0 1.153278006427172e-08
CUG O 0 4.240478665451519e-05
- O 0 0.00025333696976304054
BP O 0 0.0005416364292614162
) O 0 9.511722254273991e-08
, O 0 6.373772265533262e-08
may O 0 9.689708946325482e-08
mediate O 0 2.1624434793920955e-06
the O 0 6.374271066533765e-08
trans O 0 3.0283574233180843e-05
- O 0 0.0018107193754985929
dominant O 0 6.535835836984916e-06
effect O 0 9.371546383363238e-08
of O 0 7.999410023273867e-09
the O 0 9.62041113439227e-08
RNA O 0 3.128608341285144e-06
. O 0 1.7290894902544096e-06

CUG O 0 0.12123434990644455
- O 0 0.07411160320043564
BP O 0 0.08296389132738113
was O 0 1.3897755707148463e-05
found O 0 4.1860542410177004e-07
to O 0 1.5443989198615782e-08
bind O 0 2.0144514678577252e-07
to O 0 6.194684321059185e-09
the O 0 3.068412368634199e-08
human O 0 7.738042768323794e-06
cardiac O 0 0.14845046401023865
troponin O 1 0.8479759693145752
T O 0 0.4138650596141815
( O 0 3.295532167157944e-07
cTNT O 0 2.0240011508576572e-05
) O 0 2.3583975661267687e-08
pre O 0 1.3384267276705941e-06
- O 0 8.527831596438773e-06
messenger O 0 5.658806685460149e-07
RNA O 0 9.15208033802628e-08
and O 0 9.836402803387045e-09
regulate O 0 6.797785800927159e-08
its O 0 1.8658807832139246e-08
alternative O 0 1.9416627594637248e-07
splicing O 0 3.0689971026731655e-06
. O 0 2.29090619541239e-06

Splicing O 0 6.664543616352603e-05
of O 0 4.413158421812113e-06
cTNT O 0 0.0012046924093738198
was O 0 1.1587015251279809e-05
disrupted O 0 0.00011152262595715001
in O 0 3.2233187994279433e-06
DM B-Disease 1 0.9999514818191528
striated O 1 0.9961982369422913
muscle O 0 0.037041861563920975
and O 0 5.564076559494424e-07
in O 0 9.475669315861524e-08
normal O 0 2.039315205593084e-07
cells O 0 8.246173024417658e-07
expressing O 0 3.294344708137942e-07
transcripts O 0 5.711952439924062e-07
that O 0 7.918003319673517e-08
contain O 0 8.606556889390049e-07
CUG O 0 0.0004016500315628946
repeats O 0 1.4007249774294905e-05
. O 0 2.725588956309366e-06

Altered O 0 0.000160167837748304
expression O 0 3.417651214476791e-06
of O 0 1.6541486047572107e-07
genes O 0 7.403738777611579e-07
regulated O 0 5.38246297310252e-07
posttranscriptionally O 0 3.872903835144825e-05
by O 0 1.5404252451389766e-07
CUG O 0 0.0024114728439599276
- O 0 0.0018310140585526824
BP O 0 0.002714207163080573
therefore O 0 2.1205319455930294e-07
may O 0 2.185513494623592e-07
contribute O 0 2.793795204070193e-07
to O 0 6.234668603610771e-07
DM B-Disease 1 0.9995546936988831
pathogenesis O 0 0.01916882023215294
. O 0 1.1113752407254651e-06
. O 0 4.137552423344459e-06

Identification O 0 1.0030553312390111e-05
of O 0 4.4073655658394273e-07
a O 0 4.735750849249598e-07
novel O 0 1.6548981420783093e-06
nonsense O 0 2.9587099561467767e-05
mutation O 0 2.1205532902968116e-06
and O 0 3.590554698007509e-08
a O 0 2.89061645730726e-08
missense O 0 2.0725751710415352e-06
substitution O 0 3.230847767099476e-08
in O 0 8.764243553116557e-09
the O 0 1.7301795551816213e-08
vasopressin O 0 6.719974408042617e-06
- O 0 0.00017539836699143052
neurophysin O 0 0.0008632811950519681
II O 0 6.0253059928072616e-05
gene O 0 5.7036469769400355e-08
in O 0 3.2135758498696987e-09
two O 0 7.158067028001369e-09
Spanish O 0 9.8035877726943e-07
kindreds O 0 0.00022802309831604362
with O 0 5.2871495427098125e-05
familial B-Disease 1 0.9368093609809875
neurohypophyseal I-Disease 1 0.999371349811554
diabetes I-Disease 1 0.9991292357444763
insipidus I-Disease 1 0.9802639484405518
. O 0 0.00010583661060081795

Familial B-Disease 1 0.9977647066116333
neurohypophyseal I-Disease 1 0.9992764592170715
diabetes I-Disease 1 0.9998674392700195
insipidus I-Disease 1 0.9988449811935425
( O 0 0.0005938804824836552
FNDI B-Disease 1 0.9996359348297119
) O 0 8.396742487093434e-06
is O 0 5.693754587809963e-07
an O 0 3.090920927206753e-06
autosomal B-Disease 0 0.180542454123497
dominant I-Disease 1 0.761161744594574
disease I-Disease 1 0.9742582440376282
caused O 0 0.016263846307992935
by O 0 0.0019334383541718125
deficiency O 1 0.9766527414321899
in O 0 2.3812015115254326e-07
the O 0 6.785588766433648e-07
antidiuretic O 0 0.10704857856035233
hormone O 0 9.653934102971107e-05
arginine O 0 2.9201191864558496e-05
vasopressin O 0 4.820458707399666e-05
( O 0 1.7863571599718853e-07
AVP O 0 5.7747831306187436e-05
) O 0 1.269588700836266e-08
encoded O 0 7.2477503998413795e-09
by O 0 8.059182654562846e-09
the O 0 2.110017405243525e-08
AVP O 0 0.00018953914695885032
- O 0 0.0021064176689833403
neurophysin O 0 0.012293714098632336
II O 0 0.00035396040766499937
( O 0 1.6794592738733627e-07
AVP O 0 0.00020583187870215625
- O 0 0.0006013141828589141
NPII O 0 0.0007605825667269528
) O 0 6.264241392273107e-08
gene O 0 1.3367933604513382e-07
on O 0 2.3072728083661787e-07
chromosome O 0 5.4041589464759454e-05
20p13 O 0 0.0003622146905399859
. O 0 6.580654371646233e-06

In O 0 4.131153218622785e-06
this O 0 9.93937874227413e-08
study O 0 2.0839843273279257e-07
, O 0 3.7597480684326e-08
we O 0 3.47008111134528e-09
analyzed O 0 7.127361811853916e-08
two O 0 1.1329406746085624e-08
families O 0 2.951472026779811e-07
with O 0 2.512027492684865e-07
FNDI B-Disease 0 0.4286171495914459
using O 0 2.3682511951506058e-08
direct O 0 8.906302362277074e-09
automated O 0 4.935849915455037e-07
fluorescent O 0 2.307113163624308e-06
, O 0 4.7516429901861557e-08
solid O 0 2.7707270078281e-07
phase O 0 2.0662507438373723e-07
, O 0 1.1502201857638283e-08
single O 0 2.025788425896735e-08
- O 0 8.377178346563596e-06
stranded O 0 7.777378527862311e-07
DNA O 0 8.251358707411782e-08
sequencing O 0 2.4130086373475024e-08
of O 0 8.209628532540592e-09
PCR O 0 4.2778824536071625e-06
- O 0 4.6411769289989024e-05
amplified O 0 1.877076647360809e-05
AVP O 0 0.000475640466902405
- O 0 0.0007515390170738101
NPII O 0 0.0021882462315261364
DNA O 0 4.9735826905816793e-05
. O 0 6.107795343268663e-06

In O 0 2.0930795017193304e-06
one O 0 1.0897674940224533e-07
of O 0 3.330215392338687e-08
the O 0 1.264260873767853e-07
families O 0 2.4704067982384004e-06
, O 0 1.1011437663910328e-06
affected O 0 1.62534900027822e-06
individuals O 0 3.3672870358714135e-07
presented O 0 1.279916773455625e-06
a O 0 1.4579447338292084e-07
novel O 0 5.991632292534632e-07
nonsense O 0 4.858233296545222e-06
mutation O 0 4.761141667586344e-07
in O 0 9.702761261110027e-09
exon O 0 2.6609607175487326e-06
3 O 0 3.811264193132047e-08
of O 0 5.420088822205571e-09
the O 0 1.3536422649451652e-08
gene O 0 4.2337344297038726e-08
, O 0 9.577035164909375e-09
consisting O 0 3.0137389472884024e-08
in O 0 1.132299054518171e-08
a O 0 4.4009180300008666e-08
G O 0 1.5606758097419515e-05
to O 0 7.094553211572929e-08
T O 0 8.383934618905187e-05
transition O 0 1.7903357729665004e-07
at O 0 9.693332003735122e-08
nucleotide O 0 1.1397481785024866e-06
2101 O 0 1.0043810107163154e-05
, O 0 2.0690952950985775e-08
which O 0 2.379887398262781e-09
produces O 0 2.1231539193422577e-08
a O 0 7.451976813399597e-09
stop O 0 4.934221564667496e-08
signal O 0 2.9951323199384206e-08
in O 0 4.90825646792814e-09
codon O 0 4.62653247268463e-07
82 O 0 6.096906872699037e-06
( O 0 2.3570490270685696e-07
Glu O 0 0.0023149498738348484
) O 0 1.1772581842706131e-07
of O 0 1.9414589758071088e-07
NPII O 0 0.0028415245469659567
. O 0 7.813353477104101e-06

The O 0 1.8594595530885272e-05
premature O 0 0.0010289420606568456
termination O 0 0.0004306740593165159
eliminates O 0 6.9718953454867e-05
part O 0 2.7602987984209904e-07
of O 0 2.877765581388303e-08
the O 0 7.238593724423481e-08
C O 0 1.3684460100193974e-05
- O 0 0.00029698654543608427
terminal O 0 4.162899131188169e-06
domain O 0 3.729009989683618e-08
of O 0 2.3677001692590238e-08
NPII O 0 0.0002830682205967605
, O 0 7.364402421217164e-08
including O 0 3.462981723600933e-08
a O 0 1.8907906351728343e-08
cysteine O 0 3.529738137331151e-07
residue O 0 6.569678703272075e-07
in O 0 1.3233449003280384e-08
position O 0 1.0090857927025354e-07
85 O 0 3.280340479250299e-07
, O 0 3.220112176904877e-08
which O 0 1.0772434499983774e-08
could O 0 4.075412007864543e-08
be O 0 6.2179332793732556e-09
involved O 0 8.546491869765305e-08
in O 0 1.5999773950170493e-08
the O 0 3.699708273074975e-08
correct O 0 1.7541123042974505e-06
folding O 0 9.471534576732665e-05
of O 0 4.3392796555963287e-07
the O 0 2.8300446501816623e-06
prohormone O 0 0.011675367131829262
. O 0 1.1252650438109413e-05

In O 0 2.2348344828060362e-06
the O 0 1.7309046995706012e-07
second O 0 9.013298836180184e-07
family O 0 1.6226509842454107e-06
, O 0 2.536850196577234e-08
a O 0 1.668597704451713e-08
G279A O 0 1.4679496871394804e-06
substitution O 0 5.046957696208665e-08
at O 0 8.708425980330503e-08
position O 0 8.639964477197282e-08
- O 0 5.348571448848816e-06
1 O 0 1.2500104062951323e-08
of O 0 1.3291978628870993e-09
the O 0 3.911628354558161e-09
signal O 0 6.42888622337523e-08
peptide O 0 9.193209393743018e-07
was O 0 1.7016904507727304e-07
observed O 0 6.417174347461696e-08
in O 0 7.144167923911482e-09
all O 0 2.702987877967189e-08
affected O 0 1.9201104350941023e-06
individuals O 0 1.139420078288822e-06
. O 0 2.598742412374122e-06

This O 0 2.2853241716802586e-06
missense O 0 0.00041205226443707943
mutation O 0 3.4298958780709654e-05
, O 0 5.585299618360295e-07
which O 0 2.147993143353233e-07
replaces O 0 0.0004916014149785042
Ala O 0 0.010353214107453823
with O 0 1.7654911061981693e-06
Thr O 0 0.03664238750934601
, O 0 8.013116712390911e-07
is O 0 4.457612590158533e-08
frequent O 0 2.1996036139171338e-06
among O 0 3.7837729905731976e-05
FNDI B-Disease 1 0.9999840259552002
patients O 0 0.03904508799314499
and O 0 1.3335226185517968e-06
is O 0 1.3347997196433425e-07
thought O 0 2.466559578806482e-07
to O 0 1.4629915945363337e-08
reduce O 0 4.164016900176648e-07
the O 0 6.806956331928404e-09
efficiency O 0 1.5656729601687402e-07
of O 0 2.2599563109793053e-08
cleavage O 0 2.877945553336758e-05
by O 0 3.4045405072902213e-07
signal O 0 2.568355967014213e-06
peptidases O 0 0.0001984970149351284
. O 0 4.0568920667283237e-07
. O 0 1.854727088357322e-06

Genetic O 0 0.0007289525819942355
heterogeneity O 0 0.00028431264217942953
of O 0 9.58469718170818e-06
Saethre B-Disease 1 0.7263736724853516
- I-Disease 1 0.9994645714759827
Chotzen I-Disease 1 0.9998970031738281
syndrome I-Disease 1 0.9998013377189636
, O 0 3.6349488254927564e-06
due O 0 9.680958328317502e-07
to O 0 4.318274804404609e-08
TWIST O 0 2.2640395400230773e-05
and O 0 9.915604096022435e-06
FGFR O 0 0.25400108098983765
mutations O 0 0.00010591303725959733
. O 0 4.898461611446692e-06

Thirty O 0 3.7339261325541884e-05
- O 0 0.0008039434324018657
two O 0 5.5221744332811795e-06
unrelated O 0 0.018553005531430244
patients O 0 0.00017286585352849215
with O 0 1.5459056612598943e-07
features O 0 5.104608931105759e-07
of O 0 7.493662792512623e-07
Saethre B-Disease 1 0.8465420007705688
- I-Disease 1 0.9996726512908936
Chotzen I-Disease 1 0.9999425411224365
syndrome I-Disease 1 0.9997536540031433
, O 0 2.8226725135027664e-06
a O 0 3.6396418181539048e-06
common O 0 7.947230187710375e-05
autosomal B-Disease 0 0.13220356404781342
dominant I-Disease 0 0.02086002379655838
condition I-Disease 0 0.00025118677876889706
of O 0 6.891454177093692e-06
craniosynostosis B-Disease 1 0.9997846484184265
and O 0 0.011734819039702415
limb B-Disease 1 0.9888240694999695
anomalies I-Disease 0 0.30352210998535156
, O 0 1.0467520041856915e-06
were O 0 2.0514988818831625e-07
screened O 0 2.1982928046782035e-06
for O 0 2.2388654485894222e-07
mutations O 0 1.6300508605127106e-06
in O 0 6.409199215795525e-08
TWIST O 0 3.796824239543639e-05
, O 0 2.9147440727683716e-06
FGFR2 O 0 0.014379795640707016
, O 0 1.823711727411137e-06
and O 0 7.371425454039127e-06
FGFR3 O 0 0.016092702746391296
. O 0 7.981511771504302e-06

Nine O 0 1.7465874407207593e-05
novel O 0 6.362019121297635e-06
and O 0 8.342684623130481e-07
three O 0 9.768943982635392e-07
recurrent O 0 0.0012512755347415805
TWIST O 0 0.0004192466731183231
mutations O 0 4.2838270019274205e-05
were O 0 6.089877047088521e-07
found O 0 4.0182678162636876e-07
in O 0 6.641392502615417e-08
12 O 0 2.209653302998049e-06
families O 0 2.1039440980530344e-05
. O 0 1.2592441635206342e-05

Seven O 0 4.284624083084054e-05
families O 0 2.2101838112575933e-05
were O 0 1.343466578873631e-06
found O 0 2.93182324639929e-07
to O 0 9.297760783510967e-09
have O 0 1.319564102431059e-08
the O 0 2.7995927354140804e-08
FGFR3 O 0 0.002255437197163701
P250R O 0 0.0002251141268061474
mutation O 0 1.5768727053000475e-06
, O 0 5.2585463095056184e-08
and O 0 2.7066198171610267e-08
one O 0 1.3571245460752834e-08
individual O 0 1.0291786622929067e-07
was O 0 5.378630021368735e-07
found O 0 1.4272917780999705e-07
to O 0 1.2983978336933433e-08
have O 0 2.201431748005689e-08
an O 0 4.7148546400421765e-08
FGFR2 O 0 0.0004910333664156497
VV269 O 0 5.5143194913398474e-05
- O 0 8.002341928659007e-05
270 O 0 1.558670737722423e-05
deletion O 0 0.000150746971485205
. O 0 8.246123798016924e-06

To O 0 2.202332325396128e-06
date O 0 1.574776320012461e-06
, O 0 8.387152661271102e-08
our O 0 2.3827682937849204e-08
detection O 0 4.454574593637517e-07
rate O 0 9.878333884216772e-08
for O 0 1.9745028723150426e-08
TWIST O 0 4.765880021295743e-06
or O 0 6.816806603637815e-07
FGFR O 0 0.006106746848672628
mutations O 0 3.3179394449689426e-06
is O 0 2.6384903151210892e-08
68 O 0 1.0451580010339967e-06
% O 0 2.0483000184867706e-08
in O 0 1.524558612686633e-08
our O 0 2.646520158577914e-07
Saethre B-Disease 0 0.039916567504405975
- I-Disease 1 0.9988635778427124
Chotzen I-Disease 1 0.9999468326568604
syndrome I-Disease 1 0.9999542236328125
patients O 0 0.000530719175003469
, O 0 1.1104200581257828e-07
including O 0 1.880626854244838e-07
our O 0 9.34090493842632e-08
five O 0 3.215213382645743e-06
patients O 0 0.0001020564668579027
elsewhere O 0 1.4565383708031732e-06
reported O 0 2.7935604975937167e-06
with O 0 7.496242915294715e-07
TWIST O 0 0.0007009966066107154
mutations O 0 0.0001273333909921348
. O 0 6.941452284081606e-06

More O 0 8.702927516424097e-07
than O 0 1.0844964748457642e-07
35 O 0 1.6254871582077612e-07
different O 0 1.1348828543589207e-08
TWIST O 0 1.2320149835431948e-05
mutations O 0 7.673559593968093e-06
are O 0 3.80572160452175e-08
now O 0 1.3761008688106813e-07
known O 0 2.2762074536331056e-07
in O 0 2.8428612353081917e-08
the O 0 8.503905490897523e-08
literature O 0 2.203786152676912e-06
. O 0 3.5041882711084327e-06

The O 0 4.544925559457624e-06
most O 0 9.689262014944688e-07
common O 0 1.0134444892173633e-06
phenotypic O 0 4.55218741990393e-06
features O 0 6.819693680881755e-07
, O 0 9.055985827899349e-08
present O 0 2.5245896040360094e-08
in O 0 8.895165493072454e-09
more O 0 4.3559782447744055e-09
than O 0 7.040239946576321e-09
a O 0 2.0995836180759397e-08
third O 0 1.6972495586742298e-07
of O 0 6.569904087427858e-08
our O 0 7.797474950166361e-07
patients O 0 1.0095165634993464e-05
with O 0 1.1673170519088671e-07
TWIST O 0 9.858705016085878e-05
mutations O 0 9.125251381192356e-06
, O 0 8.040639443152031e-08
are O 0 2.7972015814725637e-08
coronal B-Disease 0 0.0002108352055074647
synostosis I-Disease 0 0.006439341232180595
, O 0 7.358981974903145e-07
brachycephaly B-Disease 0 0.0002976353862322867
, O 0 8.928721513257187e-07
low B-Disease 0 0.00010978009959217161
frontal I-Disease 1 0.9690418839454651
hairline I-Disease 1 0.9999492168426514
, O 0 0.0003548127715475857
facial B-Disease 1 0.8505735397338867
asymmetry I-Disease 0 0.026147956028580666
, O 0 0.0006723213591612875
ptosis B-Disease 1 0.999453604221344
, O 0 7.326636841753498e-05
hypertelorism B-Disease 1 0.8252677321434021
, O 0 6.1409523368638474e-06
broad B-Disease 0 7.716671098023653e-05
great I-Disease 0 3.0937761039240286e-05
toes I-Disease 0 0.0159414354711771
, O 0 1.2619362905752496e-06
and O 0 2.961474592666491e-06
clinodactyly B-Disease 0 0.002200415590777993
. O 0 8.778609299042728e-06

Significant O 0 4.910309871775098e-05
intra O 0 0.00028176960768178105
- O 0 0.0033659646287560463
and O 0 6.226763616723474e-06
interfamilial O 0 0.0021260573994368315
phenotypic O 0 4.5416487409966066e-05
variability O 0 8.060940308496356e-05
is O 0 7.128830503688732e-08
present O 0 5.209668785255417e-08
for O 0 5.489958354587543e-08
either O 0 3.722131509675819e-07
TWIST O 0 0.00019559114298317581
mutations O 0 5.9109250287292525e-05
or O 0 7.369962986558676e-06
FGFR O 0 0.15842753648757935
mutations O 0 0.00015677459305152297
. O 0 4.293556230550166e-06

The O 0 4.720262950286269e-06
overlap O 0 8.511549822287634e-06
in O 0 5.742232929151214e-07
clinical O 0 2.423932346573565e-05
features O 0 1.1499654419822036e-06
and O 0 2.2510732833325164e-07
the O 0 7.711986427239026e-08
presence O 0 3.449113421538641e-07
, O 0 2.997841619389874e-08
in O 0 4.5953920668750925e-09
the O 0 5.487212906274408e-09
same O 0 1.232009427809544e-08
genes O 0 3.239399859467085e-08
, O 0 8.957359298733536e-09
of O 0 6.827279186438773e-09
mutations O 0 2.1329630328636995e-07
for O 0 1.1719379244823358e-08
more O 0 5.181087114891625e-09
than O 0 1.552032458107533e-08
one O 0 1.2373791946629353e-07
craniosynostotic B-Disease 0 0.03206392377614975
condition I-Disease 0 1.5081235687830485e-05
- O 0 3.6817047657677904e-05
such O 0 5.009582793036316e-08
as O 0 1.3890871741750743e-07
Saethre B-Disease 0 0.00012741379032377154
- I-Disease 0 0.0008314395090565085
Chotzen I-Disease 0 0.0008161599980667233
, I-Disease 0 4.5342483190324856e-07
Crouzon I-Disease 0 8.485569560434669e-05
, I-Disease 0 2.4736692694204976e-07
and I-Disease 0 7.624813065376657e-07
Pfeiffer I-Disease 0 0.10602717101573944
syndromes I-Disease 0 0.13862067461013794
- O 0 0.0002996823168359697
support O 0 6.785621167182398e-07
the O 0 3.611262044955765e-08
hypothesis O 0 2.578319708845811e-07
that O 0 1.09685505123025e-08
TWIST O 0 2.315540086783585e-06
and O 0 8.195236773644865e-07
FGFRs O 0 0.0004556013154797256
are O 0 1.937295124321281e-08
components O 0 1.0803260863667674e-07
of O 0 5.827108573441819e-09
the O 0 8.20992696048961e-09
same O 0 1.1614280204241823e-08
molecular O 0 8.640620876576577e-07
pathway O 0 2.7430004934103636e-07
involved O 0 8.628634162732851e-08
in O 0 4.811504528134947e-09
the O 0 8.622970781857475e-09
modulation O 0 3.198943829829659e-07
of O 0 8.366538963855419e-07
craniofacial O 1 0.9967427849769592
and O 0 7.714654930168763e-05
limb O 0 0.08833929896354675
development O 0 2.676782060007099e-06
in O 0 7.056744379951851e-07
humans O 0 1.2951102235092549e-06
. O 0 3.2508171443623723e-07
. O 0 3.300707930975477e-06

Mutation O 0 0.00021311581076588482
analysis O 0 1.3389358173299115e-05
of O 0 1.4149713024380617e-05
UBE3A O 1 0.9693536162376404
in O 0 0.4368537366390228
Angelman B-Disease 1 0.9999847412109375
syndrome I-Disease 1 0.9999927282333374
patients O 1 0.887422502040863
. O 0 0.0001806334184948355

Angelman B-Disease 1 0.9999618530273438
syndrome I-Disease 1 0.9999852180480957
( O 0 0.0008800798677839339
AS B-Disease 0 0.0023574470542371273
) O 0 2.743952336459188e-06
is O 0 3.20631073691402e-07
caused O 0 3.5171447052562144e-06
by O 0 3.416767242470087e-07
chromosome O 0 8.060593972913921e-05
15q11 O 0 0.00023833982413634658
- O 0 0.0008426310960203409
q13 O 0 0.00012076359416823834
deletions O 0 1.5515284758294e-05
of O 0 2.6015172238658124e-07
maternal O 0 3.319949610158801e-05
origin O 0 2.1350774659367744e-07
, O 0 1.0938386196812644e-07
by O 0 3.040121043795807e-07
paternal O 0 0.00013845897046849132
uniparental B-Disease 0 0.49160781502723694
disomy I-Disease 0 0.22473978996276855
( O 0 4.134574282943504e-06
UPD B-Disease 1 0.991416871547699
) O 0 2.516902384286368e-07
15 O 0 1.2083867773071688e-07
, O 0 2.8568743815071684e-08
by O 0 1.4438518292081426e-07
imprinting O 0 0.015935812145471573
defects O 1 0.9299995303153992
, O 0 5.446906925499206e-07
and O 0 1.563126375003776e-07
by O 0 2.2175962044457265e-07
mutations O 0 2.212052550021326e-06
in O 0 5.91814135475488e-08
the O 0 1.027437406264653e-06
UBE3A O 0 0.00905274786055088
gene O 0 1.2898094610136468e-05
. O 0 4.672795512306038e-06

UBE3A O 0 0.0041747079230844975
encodes O 0 1.3639888493344188e-05
a O 0 1.3610215319204144e-06
ubiquitin O 0 1.7521597328595817e-05
- O 0 5.205204070080072e-05
protein O 0 1.3640384111113235e-07
ligase O 0 1.096410528589331e-06
and O 0 6.443175237791365e-08
shows O 0 2.197725734731648e-07
brain O 0 2.7816353394882753e-05
- O 0 7.281536818481982e-05
specific O 0 5.135923970556178e-07
imprinting O 0 0.00021822936832904816
. O 0 3.7654790503438562e-06

Here O 0 5.824544587085256e-06
we O 0 2.66140744997756e-07
describe O 0 7.545538664999185e-07
UBE3A O 0 0.00017691205721348524
coding O 0 7.890255801612511e-06
- O 0 0.0003003155579790473
region O 0 3.6748933780472726e-06
mutations O 0 4.31743274020846e-06
detected O 0 1.3453087603920721e-06
by O 0 4.184114388294802e-08
SSCP O 0 0.000104225953691639
analysis O 0 8.689047348298118e-08
in O 0 7.456045381104559e-08
13 O 0 3.497350689940504e-06
AS B-Disease 0 3.9489259506808594e-05
individuals O 0 1.140885729000729e-06
or O 0 1.933579824253684e-06
families O 0 2.5340525098727085e-05
. O 0 1.1453683327999897e-05

Two O 0 1.8703937030295492e-06
identical O 0 3.5129983189108316e-06
de O 0 6.342421329463832e-06
novo O 0 8.01796431915136e-06
5 O 0 6.050425440662366e-07
- O 0 5.037468872615136e-05
bp O 0 3.362935967743397e-05
duplications O 0 4.061734216520563e-06
in O 0 5.95347664500423e-08
exon O 0 9.901590601657517e-06
16 O 0 5.765828632320336e-07
were O 0 3.8628598986178986e-07
found O 0 1.4157593568597804e-06
. O 0 1.9666945263452362e-06

Among O 0 1.8519542209105566e-05
the O 0 3.479690633412247e-07
other O 0 1.0930710914180963e-07
11 O 0 4.822661026082642e-07
unique O 0 2.887316554733843e-07
mutations O 0 2.071498329314636e-06
, O 0 5.325751217810648e-08
8 O 0 2.448681470923475e-07
were O 0 7.363363607737483e-08
small O 0 1.035175287711354e-07
deletions O 0 2.804855057547684e-06
or O 0 2.0805209999252838e-07
insertions O 0 2.554928323661443e-05
predicted O 0 1.8204349544248544e-05
to O 0 1.0597742772233687e-07
cause O 0 2.9372263270488475e-06
frameshifts O 0 0.0004557733773253858
, O 0 1.1367637853254564e-07
1 O 0 9.780991661045846e-08
was O 0 1.5242206075072318e-07
a O 0 2.021781675409784e-08
mutation O 0 1.4048274010747264e-07
to O 0 2.4654289720871247e-09
a O 0 4.771330441855071e-09
stop O 0 4.5552951632998884e-08
codon O 0 1.3788476849185827e-07
, O 0 1.780741598622626e-08
1 O 0 2.6931381569283985e-08
was O 0 4.516510543339791e-08
a O 0 2.1714477327350323e-08
missense O 0 2.1393167116912082e-05
mutation O 0 1.4712921938553336e-06
, O 0 5.078301512639882e-08
and O 0 7.140016577977804e-08
1 O 0 4.3954150896752253e-07
was O 0 1.7406644019501982e-06
predicted O 0 6.120904345152667e-06
to O 0 5.536278635531744e-08
cause O 0 2.696073693186918e-07
insertion O 0 6.135943522167508e-07
of O 0 4.7877417586050797e-08
an O 0 1.582633757379881e-07
isoleucine O 0 0.00017878504877444357
in O 0 6.880934222408541e-08
the O 0 3.683267735254958e-08
hect O 0 3.814578667515889e-05
domain O 0 5.3801592514446384e-08
of O 0 5.403078873200684e-09
the O 0 2.2711873270964134e-08
UBE3A O 0 0.0001444525842089206
protein O 0 6.482003556129712e-08
, O 0 6.064495128299541e-09
which O 0 1.2980652108751656e-09
functions O 0 1.9175820931138787e-09
in O 0 1.0386161264364091e-08
E2 O 0 1.2958049410372041e-05
binding O 0 3.593974042814807e-07
and O 0 2.0456224092413322e-07
ubiquitin O 0 1.920132854138501e-05
transfer O 0 4.2508663682383485e-06
. O 0 5.267503183858935e-06

Eight O 0 7.902048309915699e-06
of O 0 6.483437573479023e-07
the O 0 5.748763669544132e-07
cases O 0 1.0499539712327532e-05
were O 0 4.814412932319101e-06
familial O 0 0.004880987107753754
, O 0 9.283992881137237e-07
and O 0 2.611813556541165e-07
five O 0 3.165612270095153e-07
were O 0 1.4245790680433856e-06
sporadic O 0 2.4886619939934462e-05
. O 0 5.6805765780154616e-06

In O 0 5.322660399542656e-06
two O 0 2.742032393143745e-06
familial O 0 0.06884896755218506
cases O 0 2.8241560357855633e-05
and O 0 8.953584824666905e-07
one O 0 1.9366731862646702e-07
sporadic O 0 8.540298949810676e-06
case O 0 5.140739631315228e-06
, O 0 5.84027475269977e-07
mosaicism O 0 0.0031558554619550705
for O 0 1.1728635627150652e-06
UBE3A O 0 0.08428576588630676
mutations O 0 4.046347748953849e-05
was O 0 1.7799812894736533e-06
detected O 0 3.1084325655683642e-06
in O 0 1.3100496687457053e-08
the O 0 4.184745350244157e-08
mother O 0 3.3945530049095396e-06
of O 0 3.276072035873767e-08
three O 0 4.03394466275131e-07
AS B-Disease 0 0.00016296606918331236
sons O 0 0.0004341857274994254
, O 0 2.4666303488629637e-07
in O 0 2.9158226055869818e-08
the O 0 1.095732571343433e-07
maternal O 0 4.036065365653485e-05
grandfather O 0 1.788543158909306e-05
of O 0 3.422049488222001e-08
two O 0 1.6606655606210552e-07
AS B-Disease 0 8.237188012572005e-06
first O 0 2.6961043886331026e-07
cousins O 0 2.0827930711675435e-05
, O 0 7.885088848524902e-08
and O 0 3.7768185023878686e-08
in O 0 1.0204253442225308e-08
the O 0 3.862277608845943e-08
mother O 0 2.953424882434774e-06
of O 0 7.507991028887773e-08
an O 0 1.5023252899482031e-06
AS B-Disease 0 0.0007653374341316521
daughter O 0 0.0029266371857374907
. O 0 1.0164441846427508e-05

The O 0 1.4954595144445193e-06
frequencies O 0 5.088875241199275e-07
with O 0 1.7764018878096977e-07
which O 0 3.6611975673395136e-08
we O 0 2.2398216614760713e-08
detected O 0 8.741507144804928e-07
mutations O 0 4.5046300556350616e-07
were O 0 3.031073703141374e-08
5 O 0 7.031532334167423e-08
( O 0 2.493245787604792e-08
14 O 0 1.7441294630771154e-07
% O 0 2.0856498750276842e-08
) O 0 2.6936146646505676e-09
of O 0 1.7174216493387462e-09
35 O 0 1.1376270236951314e-07
in O 0 3.12128349833074e-08
sporadic O 0 1.540917423881183e-06
cases O 0 1.16521096060751e-06
and O 0 2.576684892119374e-07
8 O 0 1.2624190048882156e-06
( O 0 1.0534060379541188e-07
80 O 0 2.01412490241637e-07
% O 0 4.6761378769133444e-08
) O 0 3.8810101798958385e-09
of O 0 7.305305249616367e-09
10 O 0 1.321136124943223e-07
in O 0 4.1054650523619785e-07
familial O 0 0.0033280011266469955
cases O 0 4.186452133581042e-05
. O 0 3.6689052649307996e-06
. O 0 9.651619620854035e-06

The O 0 5.89347182540223e-05
hemochromatosis B-Disease 1 0.9982225298881531
845 O 0 0.10234228521585464
G O 0 0.008206028491258621
- O 0 0.0061849188059568405
- O 0 0.0022095837630331516
> O 0 3.2529708278161706e-06
A O 0 1.0618441592669114e-07
and O 0 2.530229892272473e-08
187 O 0 8.869077419149107e-07
C O 0 3.078224608543678e-06
- O 0 6.902540189912543e-05
- O 0 0.00024445971939712763
> O 0 1.285934467887273e-05
G O 0 0.00012624407827388495
mutations O 0 1.364932813885389e-06
: O 0 7.110863720072302e-08
prevalence O 0 1.3947972547612153e-05
in O 0 9.395117217536608e-08
non O 0 2.5760198695934378e-05
- O 0 0.015585738234221935
Caucasian O 0 0.004569689277559519
populations O 0 2.6498955776332878e-05
. O 0 3.078189138250309e-06

Hemochromatosis B-Disease 1 0.9961860775947571
, O 0 0.0006763512501493096
the O 0 0.0018980026943609118
inherited B-Disease 1 0.9999774694442749
disorder I-Disease 1 0.999936580657959
of I-Disease 0 6.876248517073691e-05
iron I-Disease 1 0.9319796562194824
metabolism I-Disease 0 0.0009244529064744711
, O 0 2.228851371910423e-06
leads O 0 1.3843628039467148e-05
, O 0 8.579292511967651e-07
if O 0 4.4647094910033047e-07
untreated O 0 0.0029345133807510138
, O 0 1.8339359542096645e-07
to O 0 1.8757334885322052e-07
progressive O 0 0.0010990096488967538
iron B-Disease 0 0.17019392549991608
overload I-Disease 0 0.01590210758149624
and O 0 9.8300197350909e-06
premature B-Disease 0 0.0014099624240770936
death I-Disease 0 5.771986616309732e-05
. O 0 5.610040261672111e-06

The O 0 0.0001589402527315542
hemochromatosis B-Disease 1 0.9994021654129028
gene O 0 0.00016493358998559415
, O 0 7.227291916933609e-06
HFE O 0 0.01401250995695591
, O 0 3.04079003399238e-06
recently O 0 2.461438452883158e-05
has O 0 3.986240812992037e-07
been O 0 1.572879142486272e-07
identified O 0 6.843944220236153e-07
, O 0 4.688614296810556e-08
and O 0 8.304155585392436e-08
characterization O 0 4.835205231756845e-07
of O 0 1.1969343738371663e-08
this O 0 6.095225657531955e-09
gene O 0 1.6982534134513116e-07
has O 0 5.2181114540417184e-08
shown O 0 5.303844829995796e-08
that O 0 2.7128308488499897e-09
it O 0 9.79005432277802e-10
contains O 0 2.1289272567059925e-09
two O 0 9.759910213347212e-09
mutations O 0 2.9865816486562835e-07
that O 0 5.7250608698211636e-09
result O 0 2.3685222672042983e-08
in O 0 7.817055447389976e-09
amino O 0 7.387447453766072e-08
acid O 0 2.683575814899086e-07
substitutions O 0 5.385046364381196e-08
- O 0 5.892399030926754e-07
cDNA O 0 1.1362759977373571e-07
nucleotides O 0 4.1609482082094473e-07
845 O 0 7.0421747295768e-06
G O 0 1.579501258675009e-05
- O 0 5.365337710827589e-05
- O 0 8.735425944905728e-05
> O 0 2.6854934276343556e-06
A O 0 2.334418951477346e-07
( O 0 6.138898811514082e-08
C282Y O 0 4.084106876689475e-06
) O 0 9.77789138545404e-09
and O 0 9.026408065437863e-09
187 O 0 7.358393077083747e-07
C O 0 1.069105292117456e-05
- O 0 0.00013525380927603692
- O 0 0.0010989183792844415
> O 0 3.8023976230761036e-05
G O 0 0.0001473789307055995
( O 0 7.443952085850469e-07
H63D O 0 0.0004524609830696136
) O 0 7.498130116800894e-07
. O 0 1.8939758774649817e-06

Although O 0 0.0026012444868683815
hemochromatosis B-Disease 1 0.999782145023346
is O 0 8.6495265350095e-06
common O 0 1.7769740452422411e-06
in O 0 2.322711480928774e-07
Caucasians O 0 7.71339691709727e-05
, O 0 2.589677592368389e-07
affecting O 0 1.349618855783774e-06
> O 0 6.3120514823822305e-06
= O 0 6.77408115734579e-06
1 O 0 2.3516558655956032e-07
/ O 0 2.2540430109074805e-06
300 O 0 3.967678878780134e-07
individuals O 0 1.880099098627852e-08
of O 0 6.033286759077328e-09
northern O 0 9.301081860257909e-08
European O 0 4.347489550582395e-07
origin O 0 1.465887322638082e-07
, O 0 7.412259606098814e-08
it O 0 1.0736250111165191e-08
has O 0 4.5045265295584613e-08
not O 0 1.4270150394679604e-08
been O 0 9.613990670231942e-08
recognized O 0 1.1566048385702743e-07
in O 0 3.86032574795081e-08
other O 0 4.899522423329472e-07
populations O 0 7.748441021249164e-06
. O 0 3.7449087813001825e-06

The O 0 2.150683485524496e-06
present O 0 3.59937985194847e-07
study O 0 1.2406037797063618e-07
used O 0 3.3534167442894613e-08
PCR O 0 2.4804046461213147e-06
and O 0 1.1099351127086265e-07
restriction O 0 1.8373056320797332e-07
- O 0 2.7729956855182536e-05
enzyme O 0 9.44644170886022e-07
digestion O 0 2.569649382166972e-07
to O 0 2.114770580874392e-09
analyze O 0 2.61987569416533e-08
the O 0 9.918121879337605e-10
frequency O 0 2.2002302202395185e-09
of O 0 1.4017453864312301e-09
the O 0 7.808621305116503e-09
845 O 0 5.815129406983033e-05
G O 0 5.564116145251319e-05
- O 0 0.00012120820611016825
- O 0 0.00017392350127920508
> O 0 1.453977915844007e-06
A O 0 6.279027076061539e-08
and O 0 2.851843738937987e-08
187 O 0 5.715004363082699e-07
C O 0 2.5517640551697696e-06
- O 0 3.808352994383313e-05
- O 0 9.32499096961692e-05
> O 0 5.72520093555795e-06
G O 0 4.23744713771157e-05
mutations O 0 7.980285658959474e-07
in O 0 1.528932536132288e-08
HLA O 0 2.1694913812098093e-05
- O 0 1.3712076906813309e-05
typed O 0 8.672917033436534e-07
samples O 0 7.653240885474588e-08
from O 0 2.1028899510611154e-08
non O 0 8.868755685398355e-07
- O 0 0.00014477358490694314
Caucasian O 0 0.00010278858098899946
populations O 0 5.526587187887344e-07
, O 0 2.5218175991881253e-08
comprising O 0 2.7743283226300264e-07
Australian O 0 6.960490736673819e-06
Aboriginal O 0 2.7266521556157386e-06
, O 0 1.036412058397218e-07
Chinese O 0 3.60409195820921e-08
, O 0 5.951773474066613e-08
and O 0 3.569986972706829e-07
Pacific O 0 3.7436242564581335e-05
Islanders O 0 0.0005238368175923824
. O 0 4.51808864454506e-06

Results O 0 3.4515913284849375e-05
showed O 0 2.4795581339276396e-05
that O 0 7.123610856751839e-08
the O 0 6.107877936756267e-08
845 O 0 0.00035672972444444895
G O 0 0.0006196277681738138
- O 0 0.0008756867027841508
- O 0 0.0005673283594660461
> O 0 5.215631972532719e-06
A O 0 6.365717695189232e-07
mutation O 0 1.0852616014744854e-06
was O 0 2.2317941272831376e-07
present O 0 2.5070367115631598e-08
in O 0 1.0413515383334015e-08
these O 0 9.184708105181016e-09
populations O 0 8.448645871794724e-08
( O 0 8.67549765359854e-09
allele O 0 2.9144104018996586e-08
frequency O 0 1.580634467757136e-08
0 O 0 8.919226246462131e-08
. O 0 6.265243435166212e-09
32 O 0 2.2062096149966237e-07
% O 0 3.953114457999618e-08
) O 0 1.2384389513897531e-08
, O 0 1.2348159827979543e-08
and O 0 4.0026737480047814e-08
, O 0 5.2003368722353116e-08
furthermore O 0 2.207842868529042e-07
, O 0 4.846118883961026e-08
it O 0 4.321379254434987e-09
was O 0 6.325232959625282e-08
always O 0 3.406082171864e-08
seen O 0 5.901031130406409e-08
in O 0 3.3205347360620863e-09
conjunction O 0 1.4401319958778913e-07
with O 0 3.805428150371881e-07
HLA O 0 0.011738237924873829
haplotypes O 0 0.00017947833111975342
common O 0 5.76574109345529e-07
in O 0 5.8609412434407204e-08
Caucasians O 0 2.2782978703617118e-05
, O 0 1.5185374024895282e-07
suggesting O 0 4.2131887312280014e-07
that O 0 1.25086421220999e-08
845 O 0 4.934367098030634e-05
G O 0 0.0002465974830556661
- O 0 0.0020555483642965555
- O 0 0.0032812203280627728
> O 0 1.1626862942648586e-05
A O 0 1.272521785722347e-06
may O 0 6.715104632348812e-07
have O 0 1.7318500411533932e-08
been O 0 8.4702467262332e-09
introduced O 0 1.4953590365962555e-08
into O 0 3.138175719286096e-09
these O 0 6.525143980695702e-09
populations O 0 1.5933984798266465e-07
by O 0 3.067581815230369e-07
Caucasian O 0 0.0002266609517391771
admixture O 0 0.0007722831796854734
. O 0 2.0449488147278316e-05

187 O 0 0.00024104607291519642
C O 0 0.00037838422576896846
- O 0 0.001339999958872795
- O 0 0.0035828088875859976
> O 0 3.2574716897215694e-05
G O 0 7.822604675311595e-05
was O 0 3.662713652374805e-07
present O 0 1.1963271262516173e-08
at O 0 1.5440072331784904e-08
an O 0 8.097503112480808e-09
allele O 0 8.637756110374539e-08
frequency O 0 2.6630724292431296e-08
of O 0 3.178319829544307e-08
2 O 0 2.6215459456579993e-06
. O 0 3.328943876113044e-06

68 O 0 0.0004385191423352808
% O 0 2.5199531137332087e-06
in O 0 7.786642441942604e-08
the O 0 1.8840335513914397e-08
two O 0 2.679136024141826e-08
populations O 0 3.3302222846032237e-07
analyzed O 0 9.175779496217729e-07
( O 0 7.999169326922129e-08
Australian O 0 3.902080607076641e-06
Aboriginal O 0 1.1065968465118203e-05
and O 0 4.517842171480879e-07
Chinese O 0 8.780717735135113e-07
) O 0 5.088239731776412e-07
. O 0 1.2886163176517584e-06

In O 0 1.8691027889872203e-06
the O 0 3.735677012173255e-07
Australian O 0 3.5250156997790327e-06
Aboriginal O 0 1.4338297660287935e-06
samples O 0 1.4005414072926214e-07
, O 0 2.0808576195463502e-08
187 O 0 5.471381427923916e-07
C O 0 5.073812189948512e-06
- O 0 8.515171793987975e-05
- O 0 0.0004968977300450206
> O 0 8.848624929669313e-06
G O 0 0.0001739457220537588
was O 0 1.0409880815132055e-06
found O 0 6.883271197466456e-08
to O 0 6.014937437015533e-09
be O 0 8.011350693948316e-09
associated O 0 5.4557922624098865e-08
with O 0 2.6047939627460437e-07
HLA O 0 0.006235181353986263
haplotypes O 0 0.0003425506583880633
common O 0 9.507256777396833e-07
in O 0 9.459291305802253e-08
Caucasians O 0 3.820767960860394e-05
, O 0 3.1136434586187534e-07
suggesting O 0 7.450770453942823e-07
that O 0 5.397537528040175e-09
it O 0 3.815895599501573e-09
was O 0 6.641721483902074e-08
introduced O 0 1.0862934374245015e-07
by O 0 1.0090453628208707e-07
recent O 0 2.8858487439720193e-06
admixture O 0 0.00018144665227737278
. O 0 8.950973096943926e-06

In O 0 1.203208057631855e-06
the O 0 6.226647286666775e-08
Chinese O 0 3.715520335845213e-08
samples O 0 5.5054144354471646e-08
analyzed O 0 1.1991077997208777e-07
, O 0 2.6625951221603827e-08
187 O 0 9.722093636810314e-07
C O 0 5.826339020131854e-06
- O 0 0.00014123482105787843
- O 0 0.0005009541055187583
> O 0 1.979147782549262e-05
G O 0 0.0002729474217630923
was O 0 7.350467399191984e-07
present O 0 2.6869042102362073e-08
in O 0 2.1849002607154944e-08
association O 0 5.314503255249292e-07
with O 0 3.725498132212124e-08
a O 0 6.894794779555014e-08
wide O 0 1.889988311631896e-06
variety O 0 2.553530862314801e-07
of O 0 2.7869987206941005e-07
HLA O 0 0.03620331361889839
haplotypes O 0 0.00034053123090416193
, O 0 1.4358903399624978e-07
showing O 0 4.338029953032674e-07
this O 0 4.7480894771467774e-09
mutation O 0 1.9739914591809793e-07
to O 0 9.73906466583685e-09
be O 0 6.561423404605193e-09
widespread O 0 2.1708437714096362e-07
and O 0 3.2492488344360027e-07
likely O 0 6.026400569680845e-07
to O 0 1.133377303119687e-08
predate O 0 2.919008693424985e-06
the O 0 1.3106894236614153e-08
more O 0 1.0904863678717902e-08
genetically O 0 1.0507166052775574e-06
restricted O 0 2.1317733001069428e-07
845 O 0 9.978863090509549e-05
G O 0 0.00013006891822442412
- O 0 0.0004078682977706194
- O 0 0.0006508933729492128
> O 0 2.1670639398507774e-05
A O 0 4.649014499591431e-06
mutation O 0 2.2289312255452387e-05
. O 0 4.8986903493641876e-06

Genotype O 0 0.01849309541285038
- O 0 0.12839791178703308
phenotype O 0 0.00704480754211545
correlations O 0 0.002473234897479415
in O 0 0.00023223333118949085
attenuated B-Disease 1 0.7554800510406494
adenomatous I-Disease 1 0.9997259974479675
polyposis I-Disease 1 0.9995830655097961
coli I-Disease 1 0.9988389611244202
. O 0 0.00046642107190564275

Germ O 0 0.023311294615268707
- O 0 0.0020129201002418995
line O 0 2.6897690986515954e-05
mutations O 0 5.825005700899055e-06
of O 0 9.958868218973294e-08
the O 0 1.5420023373735603e-06
tumor B-Disease 0 0.0032301791943609715
suppressor O 0 0.00016813090769574046
APC O 0 0.00025722364080138505
are O 0 4.853158088735654e-07
implicated O 0 0.0006534099811688066
in O 0 2.8170603400212713e-05
attenuated B-Disease 1 0.864811360836029
adenomatous I-Disease 1 0.9999758005142212
polyposis I-Disease 1 0.9999804496765137
coli I-Disease 1 0.9999586343765259
( O 0 0.000517678156029433
AAPC B-Disease 1 0.9996547698974609
) O 0 1.1607712622208055e-06
, O 0 1.9077154433944088e-07
a O 0 9.86627014754049e-07
variant O 0 9.569017856847495e-05
of O 0 0.00020855410548392683
familial B-Disease 1 0.9999412298202515
adenomatous I-Disease 1 0.9999728202819824
polyposis I-Disease 1 0.9999847412109375
( O 0 0.001116220373660326
FAP B-Disease 1 0.5659985542297363
) O 0 7.839267709641717e-06
. O 0 5.593286459770752e-06

AAPC B-Disease 1 0.9990808963775635
is O 0 5.3496019972953945e-05
recognized O 0 4.71930388812325e-06
by O 0 1.0031120467601795e-07
the O 0 3.3202198324033816e-08
occurrence O 0 2.1478948042386037e-07
of O 0 2.0391473398717608e-08
< O 0 5.564571438299026e-06
100 O 0 5.4102122248878e-07
colonic B-Disease 0 0.02635333687067032
adenomas I-Disease 0 0.07144927978515625
and O 0 3.5831595823765383e-07
a O 0 1.9000948725533817e-07
later O 0 4.647768946597353e-06
onset O 0 0.006878905929625034
of O 0 0.05820079147815704
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999984860420227
( O 0 3.087962568315561e-06
age O 0 4.577340405376162e-06
> O 0 1.1445668860687874e-05
40 O 0 1.1227974709981936e-06
years O 0 3.530331014189869e-06
) O 0 7.567496140836738e-07
. O 0 1.5740811249997932e-06

The O 0 5.168770258023869e-06
aim O 0 6.043832399882376e-06
of O 0 1.4469107156855898e-07
this O 0 3.262963943484465e-08
study O 0 1.9149739216572925e-07
was O 0 1.425445930181013e-07
to O 0 1.496737311867946e-08
assess O 0 4.38459846918704e-06
genotype O 0 3.566107989172451e-05
- O 0 0.003736431710422039
phenotype O 0 0.00015447469195351005
correlations O 0 9.795507503440604e-05
in O 0 7.273397386597935e-06
AAPC B-Disease 1 0.9973899722099304
families O 0 0.00023490971943829209
. O 0 1.871355198090896e-05

By O 0 5.749401225330075e-06
protein O 0 2.00602494260238e-06
- O 0 4.97433211421594e-05
truncation O 0 2.0937797671649605e-05
test O 0 1.3733912282987149e-06
( O 0 2.3567787721390232e-08
PTT O 0 1.2631765002879547e-06
) O 0 9.37165012260266e-09
assay O 0 1.6472787933707878e-07
, O 0 5.03499419934883e-09
the O 0 1.4087516708727321e-09
entire O 0 1.4933240422010385e-08
coding O 0 3.215767208075704e-07
region O 0 3.7563790300509936e-08
of O 0 4.637851880318067e-09
the O 0 3.5838493062101406e-08
APC B-Disease 0 1.8710856238612905e-05
gene O 0 1.0000535155541002e-07
was O 0 1.0858915544531555e-07
screened O 0 1.4636497098763357e-06
in O 0 9.337039585943785e-08
affected O 0 4.7215320364557556e-07
individuals O 0 1.4017278715527937e-07
from O 0 4.298880753594858e-07
11 O 0 4.094183532288298e-05
AAPC B-Disease 1 0.9995373487472534
kindreds O 0 0.0033931320067495108
, O 0 6.941424999240553e-07
and O 0 1.244015948032029e-07
their O 0 1.1000546606965145e-07
phenotypic O 0 1.0987858331645839e-05
differences O 0 9.253477401216514e-06
were O 0 3.3856392747111386e-06
examined O 0 0.00015657693438697606
. O 0 1.3262276297609787e-05

Five O 0 1.1142107723571826e-05
novel O 0 8.564655217924155e-06
germ O 0 0.0011669108644127846
- O 0 0.0005661424365825951
line O 0 1.8910588551079854e-05
APC B-Disease 0 0.0002547653275541961
mutations O 0 9.280804079025984e-06
were O 0 3.3561431678208464e-07
identified O 0 7.028475579318183e-07
in O 0 1.1684208089945969e-07
seven O 0 4.071270268468652e-06
kindreds O 0 0.0026376680471003056
. O 0 1.1184201866853982e-05

Mutations O 0 0.0021176987793296576
were O 0 5.070141014584806e-06
located O 0 4.263873165655241e-07
in O 0 1.1314614134505518e-08
three O 0 5.63829072319777e-09
different O 0 1.4837496786768156e-09
regions O 0 1.1850718628636514e-08
of O 0 5.077233744543719e-09
the O 0 6.120951212551518e-08
APC B-Disease 0 0.0001874551671789959
gene O 0 4.1582666199246887e-07
( O 0 2.3955779582252035e-08
1 O 0 5.010089054735545e-08
) O 0 1.2228626111721042e-08
at O 0 1.2403678972816579e-08
the O 0 2.643798513446427e-09
5 O 0 1.447959085965067e-08
end O 0 1.2615937627913354e-08
spanning O 0 1.5389217367101082e-07
exons O 0 1.3053214615865727e-06
4 O 0 2.238639069673809e-07
and O 0 9.005654533211782e-08
5 O 0 1.323909657457989e-07
, O 0 3.989259766967734e-08
( O 0 8.237344140127334e-09
2 O 0 2.3266615301054117e-08
) O 0 6.0393885448206674e-09
within O 0 2.0108510412342184e-09
exon O 0 2.8363185720081674e-06
9 O 0 5.889505700906739e-07
, O 0 6.064312429998608e-08
and O 0 2.9424946035305766e-08
( O 0 1.1673511046694784e-08
3 O 0 3.519079427860561e-08
) O 0 5.0765653902828944e-09
at O 0 1.0248490944775313e-08
the O 0 4.8846651168332755e-09
3 O 0 8.665578121735962e-08
distal O 0 2.7238889742875472e-05
end O 0 3.541238982052164e-07
of O 0 4.82525557288227e-08
the O 0 3.5085179206362227e-07
gene O 0 3.846864274237305e-06
. O 0 3.095333795499755e-06

Variability O 0 0.0005777461919933558
in O 0 6.179658385008224e-07
the O 0 9.519072108332693e-08
number O 0 2.6502277705731103e-07
of O 0 0.00015930741210468113
colorectal B-Disease 1 0.9999997615814209
adenomas I-Disease 1 0.9999940395355225
was O 0 0.0005581204895861447
most O 0 1.1341165873091086e-06
apparent O 0 4.222908683004789e-05
in O 0 1.1042170200425971e-07
individuals O 0 1.568699588005984e-07
with O 0 4.849567858400405e-07
mutations O 0 6.563650003954535e-06
in O 0 8.791872829760905e-08
region O 0 6.341528546727204e-07
1 O 0 3.036073508155823e-07
, O 0 2.5841563910944387e-07
and O 0 9.796709719012142e-07
upper O 0 0.003358483547344804
- O 1 0.9982193112373352
gastrointestinal O 1 0.9985464215278625
manifestations O 0 0.00018469664792064577
were O 0 1.910422497530817e-06
more O 0 6.682956836812082e-07
severe O 0 0.00021736380585934967
in O 0 1.7421378117887798e-07
them O 0 8.025597821870178e-07
. O 0 5.393245828599902e-06

In O 0 1.2114740457036532e-05
individuals O 0 1.9642277493403526e-06
with O 0 1.2491998404584592e-06
mutations O 0 1.0231048690911848e-05
in O 0 6.038377620143365e-08
either O 0 1.0814105166900845e-07
region O 0 3.4010454896815645e-07
2 O 0 3.2519363912797417e-07
or O 0 1.115923353722792e-07
region O 0 1.2180559849639394e-07
3 O 0 1.1406590516571669e-07
, O 0 1.1632458551957825e-08
the O 0 2.350071248713448e-09
average O 0 7.648002053883829e-08
number O 0 7.252880962482777e-09
of O 0 1.2029907736632595e-07
adenomas B-Disease 0 0.1704663634300232
tended O 0 8.696715667610988e-06
to O 0 1.1746457140304756e-08
be O 0 9.385209054357802e-09
lower O 0 3.932352399260708e-07
than O 0 9.10920050500863e-09
those O 0 1.362688273331969e-08
in O 0 7.721769890167707e-09
individuals O 0 2.3377333846497095e-08
with O 0 1.0576196984857233e-07
mutations O 0 1.777391048563004e-06
in O 0 5.8108298617298715e-08
region O 0 5.049297442383249e-07
1 O 0 2.8646724103964516e-07
, O 0 1.8801246426392026e-07
although O 0 1.2967549878339923e-07
age O 0 1.1547789426913369e-06
at O 0 8.025445822568145e-06
diagnosis O 0 0.0006605770904570818
was O 0 4.76085097034229e-06
similar O 0 2.169764684367692e-06
. O 0 4.904692559648538e-06

In O 0 7.860484402044676e-06
all O 0 2.6564171093923505e-06
AAPC B-Disease 1 0.996992826461792
kindreds O 0 0.001922577852383256
, O 0 8.484558406962606e-07
a O 0 1.4656455959993764e-07
predominance O 0 1.8783730411087163e-05
of O 0 3.463500775069406e-07
right O 0 4.998393342248164e-05
- O 1 0.9923681616783142
sided O 1 0.9999476671218872
colorectal B-Disease 1 0.9999992847442627
adenomas I-Disease 1 0.9999891519546509
and O 0 0.046386074274778366
rectal B-Disease 1 0.9999250173568726
polyp I-Disease 1 0.9997005462646484
sparing O 0 0.02004067413508892
was O 0 0.00010042314534075558
observed O 0 1.4980509149609134e-05
. O 0 5.528423571377061e-06

No O 0 0.00024356423818971962
desmoid B-Disease 1 0.9887164831161499
tumors I-Disease 1 0.9997981190681458
were O 0 5.017423518438591e-06
found O 0 1.214620624523377e-06
in O 0 9.405606249401899e-08
these O 0 2.80713010170075e-07
kindreds O 0 0.0013570826267823577
. O 0 1.446808619220974e-05

Our O 0 5.648563728755107e-06
data O 0 2.0566776584018953e-06
suggest O 0 2.0075235624972265e-06
that O 0 7.629265752484571e-08
, O 0 1.0285879170623957e-07
in O 0 3.565645556591335e-07
AAPC B-Disease 1 0.9973964691162109
families O 0 4.718831405625679e-06
, O 0 3.9739951773754e-08
the O 0 5.526253232801537e-09
location O 0 1.3196346237975831e-08
of O 0 8.842185650337342e-09
the O 0 1.3836385903687187e-07
APC B-Disease 0 0.0012744002742692828
mutation O 0 1.4254543202696368e-05
may O 0 2.336112402190338e-06
partially O 0 1.2646298273466527e-05
predict O 0 1.0403400665381923e-06
specific O 0 1.2066549004430271e-07
phenotypic O 0 6.794500677642645e-06
expression O 0 2.7064188543590717e-06
. O 0 2.5884280603349907e-06

This O 0 2.5150504825433018e-06
should O 0 4.658867283069412e-07
help O 0 1.7107684868733486e-07
in O 0 8.172508003667645e-09
the O 0 7.222565212572363e-09
design O 0 2.2249534481488809e-07
of O 0 7.490112352570577e-08
tailored O 0 0.0003962968476116657
clinical O 0 0.0003166901005897671
- O 0 0.07083140313625336
management O 0 5.030047395848669e-05
protocols O 0 2.4087701149255736e-06
in O 0 1.3944821297684484e-08
this O 0 2.5633570821526064e-09
subset O 0 1.759509444809737e-07
of O 0 1.5906214230199112e-06
FAP B-Disease 1 0.9062570333480835
patients O 0 0.0019654780626296997
. O 0 1.1370860875103972e-06
. O 0 3.0135752240312286e-06

Wilms B-Disease 1 0.998458743095398
' I-Disease 0 0.12173725664615631
tumor I-Disease 0 0.045488059520721436
1 O 0 1.0843284599104663e-06
and O 0 4.566988138776651e-07
Dax O 0 0.0019183260155841708
- O 0 0.0001453307195333764
1 O 0 2.1629662683153583e-07
modulate O 0 6.477751526290376e-07
the O 0 1.7556031295384855e-08
orphan O 0 1.4469907000602689e-05
nuclear O 0 7.1525673774885945e-06
receptor O 0 5.538416303352278e-07
SF O 0 0.0002946673193946481
- O 0 1.600805808266159e-05
1 O 0 6.250731132695364e-08
in O 0 1.1970667124217016e-08
sex O 0 2.7167345706402557e-07
- O 0 1.474249529564986e-05
specific O 0 1.6689007509285148e-07
gene O 0 1.0681386584110442e-06
expression O 0 1.769884192981408e-06
. O 0 2.103124188579386e-06

Products O 0 0.0001097355125239119
of O 0 2.7315556963003473e-06
steroidogenic O 0 0.05671532824635506
factor O 0 8.596502993896138e-06
1 O 0 4.098353372228303e-07
( O 0 1.295142055823817e-07
SF O 0 0.006729928310960531
- O 0 0.0007473053992725909
1 O 0 6.059173642825044e-07
) O 0 8.994462064038089e-08
and O 0 2.868600404326571e-06
Wilms B-Disease 1 0.9978911280632019
tumor I-Disease 0 0.007751354947686195
1 O 0 9.868763299891725e-07
( O 0 3.0446850018961413e-07
WT1 O 0 0.0005041285767219961
) O 0 7.32923055579704e-08
genes O 0 5.2234391034744476e-08
are O 0 2.314369362821367e-09
essential O 0 7.532716672642437e-09
for O 0 1.5768794270343278e-08
mammalian O 0 2.258979293401353e-06
gonadogenesis O 0 0.00013119007053319365
prior O 0 2.6046649281852297e-07
to O 0 5.1272568413196495e-08
sexual O 0 3.6737858408741886e-06
differentiation O 0 1.0911564459092915e-05
. O 0 5.424034043244319e-06

In O 0 5.5342106861644424e-06
males O 0 7.10228187017492e-06
, O 0 4.4438013446779223e-07
SF O 0 0.008869309909641743
- O 0 0.00017155830573756248
1 O 0 1.6271327751837816e-07
participates O 0 2.592296652892401e-07
in O 0 9.124606847876748e-09
sexual O 0 1.4098711176302459e-07
development O 0 2.005275412386709e-08
by O 0 1.3974775114888871e-08
regulating O 0 5.482110054799705e-07
expression O 0 1.9148821195358323e-08
of O 0 5.7471059022873305e-09
the O 0 5.152294590970996e-08
polypeptide O 0 8.961206185631454e-05
hormone O 0 6.840003334218636e-05
Mullerian O 0 0.0021258369088172913
inhibiting O 0 0.0002967038017231971
substance O 0 1.6347650671377778e-05
( O 0 6.651964667980792e-07
MIS O 0 0.001462432905100286
) O 0 1.0693211152101867e-06
. O 0 1.60383547154197e-06

Here O 0 9.963092452380806e-06
, O 0 6.91193690727232e-07
we O 0 2.3887476885420256e-08
show O 0 3.8106755084754695e-08
that O 0 1.8793103961911584e-08
WT1 O 0 3.717599611263722e-05
- O 0 0.0001335852430202067
KTS O 0 0.0036020930856466293
isoforms O 0 3.6974091699448763e-07
associate O 0 7.143339075810218e-07
and O 0 6.452140866031186e-08
synergize O 0 7.392113911919296e-05
with O 0 3.226026592528797e-07
SF O 0 0.06068728119134903
- O 0 0.00032438882044516504
1 O 0 2.8276633656787453e-07
to O 0 4.33625153561934e-08
promote O 0 5.571961878558795e-07
MIS O 0 0.0007215239456854761
expression O 0 3.356880824867403e-06
. O 0 2.1551677491515875e-06

In O 0 6.688990197289968e-06
contrast O 0 3.065141208935529e-05
, O 0 3.0326957585202763e-06
WT1 O 0 0.007131344173103571
missense O 0 0.0020852237939834595
mutations O 0 0.00010898688196903095
, O 0 8.478847917103849e-07
associated O 0 1.488073280597746e-06
with O 0 8.930909984883328e-07
male B-Disease 0 3.0462490030913614e-05
pseudohermaphroditism I-Disease 1 0.8342766165733337
in O 0 5.881865945411846e-06
Denys B-Disease 1 0.9720145463943481
- I-Disease 1 0.9995703101158142
Drash I-Disease 1 0.9999198913574219
syndrome I-Disease 1 0.999742329120636
, O 0 2.6513575903663877e-06
fail O 0 4.59840748590068e-06
to O 0 3.066522324957077e-08
synergize O 0 0.0002141228032996878
with O 0 9.081721827897127e-07
SF O 0 0.25679096579551697
- O 0 0.0032122766133397818
1 O 0 4.537840140983462e-06
. O 0 2.059997086689691e-06

Additionally O 0 6.639202183578163e-05
, O 0 9.304964692091744e-07
the O 0 1.608303392686139e-07
X O 0 4.9916718126041815e-05
- O 0 0.013490824028849602
linked O 0 0.00047430390259251
, O 0 2.815210677908908e-07
candidate O 0 6.202258759913093e-07
dosage O 0 3.9548453969473485e-06
- O 0 4.6717726945644245e-05
sensitive O 0 2.2319059098663274e-06
sex O 0 5.394132358560455e-07
- O 0 2.682790727703832e-05
reversal O 0 6.262536771828309e-06
gene O 0 1.245819305495388e-07
, O 0 3.1848372827880667e-08
Dax O 0 0.00025122344959527254
- O 0 2.4144088456523605e-05
1 O 0 7.311219718530992e-08
, O 0 2.222238570936952e-08
antagonizes O 0 2.2245958462008275e-06
synergy O 0 5.708870389753429e-07
between O 0 8.926135564024662e-08
SF O 0 0.045456744730472565
- O 0 0.0007773367105983198
1 O 0 7.137755346775521e-07
and O 0 3.672048478620127e-07
WT1 O 0 0.00020826161198783666
, O 0 6.95376343173848e-08
most O 0 1.003974858804213e-08
likely O 0 2.278506983088846e-08
through O 0 2.4529429598629804e-09
a O 0 6.313539024915826e-09
direct O 0 1.6564559501830445e-08
interaction O 0 6.704571831050998e-08
with O 0 7.257754077727441e-07
SF O 1 0.6908710598945618
- O 0 0.011777831241488457
1 O 0 9.526429494144395e-06
. O 0 3.756848855118733e-06

We O 0 3.652552777566598e-06
propose O 0 1.2337785847194027e-05
that O 0 1.6156300830516557e-07
WT1 O 0 7.418751192744821e-05
and O 0 2.518924304695247e-07
Dax O 0 0.0011666674399748445
- O 0 0.00012129341484978795
1 O 0 2.2955482847919484e-07
functionally O 0 1.922743422255735e-06
oppose O 0 3.3076418048949563e-07
each O 0 4.846023582416592e-09
other O 0 5.013939485820629e-09
in O 0 9.034657466600038e-09
testis O 0 7.73459851188818e-06
development O 0 2.357560902055411e-08
by O 0 2.5898620137354555e-08
modulating O 0 2.24469094973756e-05
SF O 0 0.018862033262848854
- O 0 0.000127147271996364
1 O 0 6.361930218190537e-07
- O 0 0.00024089722137432545
mediated O 0 0.00015040698053780943
transactivation O 0 0.0003787721798289567
. O 0 6.078626029193401e-07
. O 0 1.6046709561123862e-06

A O 0 3.953872874262743e-05
mouse O 0 0.0001100718291127123
model O 0 1.730224903440103e-05
for O 0 6.851467333035544e-05
Prader B-Disease 1 0.9999550580978394
- I-Disease 1 0.9999712705612183
Willi I-Disease 1 0.9999898672103882
syndrome I-Disease 1 0.9999233484268188
imprinting O 0 0.06844370067119598
- O 1 0.6364227533340454
centre O 0 0.002862420864403248
mutations O 0 0.00022961919603403658
. O 0 1.3794918231724296e-05

Imprinting O 0 0.0006913412362337112
in O 0 2.910285957113956e-06
the O 0 5.84866313602106e-07
15q11 O 0 0.0001103934773709625
- O 0 0.0008007384603843093
q13 O 0 0.00018157766317017376
region O 0 3.338620615522814e-07
involves O 0 2.7447325123830524e-07
an O 0 5.0266290685385684e-08
imprinting O 0 4.9310267058899626e-05
centre O 0 1.0645840120560024e-05
( O 0 1.5608144110501598e-07
IC O 0 7.747948984615505e-05
) O 0 6.978383737532567e-08
, O 0 1.4897139521963254e-08
mapping O 0 1.7258427931210463e-07
in O 0 2.6493324867260526e-08
part O 0 4.1504211623077936e-08
to O 0 6.187882206631912e-09
the O 0 2.171837110154229e-08
promoter O 0 6.170380856929114e-06
and O 0 5.0110259053326445e-08
first O 0 7.280728908654055e-08
exon O 0 1.2609760233317502e-05
of O 0 6.367721425704076e-07
SNRPN O 0 0.005475825630128384
. O 0 9.381036761624273e-06

Deletion O 0 0.00037026795325800776
of O 0 9.438832080377324e-07
this O 0 1.242956955138652e-07
IC O 0 0.00012981588952243328
abolishes O 0 0.00019860037718899548
local O 0 4.6883641857675684e-07
paternally O 0 0.0001303066237596795
derived O 0 2.89537922526506e-07
gene O 0 1.4156242400531482e-07
expression O 0 9.73271809812104e-08
and O 0 1.0329780764095631e-07
results O 0 3.578645419111126e-06
in O 0 5.137357584317215e-05
Prader B-Disease 1 0.9999892711639404
- I-Disease 1 0.9999948740005493
Willi I-Disease 1 0.9999977350234985
syndrome I-Disease 1 0.9999864101409912
( O 0 0.0010853703133761883
PWS B-Disease 1 0.9997420907020569
) O 0 2.7502492230269127e-05
. O 0 7.212543550849659e-06

We O 0 5.530263933906099e-06
have O 0 3.352058399741509e-07
created O 0 1.7819009201502922e-07
two O 0 5.411848746916803e-08
deletion O 0 2.331799805688206e-05
mutations O 0 5.671693543263245e-06
in O 0 1.0455313770307839e-07
mice O 0 1.1532862117746845e-05
to O 0 8.088615288670553e-08
understand O 0 1.5115371070351102e-06
PWS B-Disease 1 0.916839063167572
and O 0 3.1654221288590634e-07
the O 0 2.8017776543265427e-08
mechanism O 0 9.781457777080504e-08
of O 0 4.102803075056727e-08
this O 0 1.1611858496962668e-07
IC O 0 0.0008765432285144925
. O 0 7.1173208198160864e-06

Mice O 0 0.010853024199604988
harbouring O 0 0.021304186433553696
an O 0 3.497176976452465e-06
intragenic O 0 0.0021533300168812275
deletion O 0 8.472777699353173e-05
in O 0 3.591301549477066e-07
Snrpn O 0 0.0006965841166675091
are O 0 1.5658088159398176e-07
phenotypically O 0 5.8369249018142e-05
normal O 0 2.688722418042744e-07
, O 0 8.041789101298491e-08
suggesting O 0 8.428315823039156e-07
that O 0 2.2718761982787328e-08
mutations O 0 5.921438059885986e-07
of O 0 9.990640137402806e-08
SNRPN O 0 0.05301056429743767
are O 0 8.187693367744941e-08
not O 0 1.8617997810110865e-08
sufficient O 0 1.9808915396879456e-07
to O 0 3.883904469148547e-07
induce O 0 0.00010892900172621012
PWS B-Disease 1 0.975925862789154
. O 0 2.4329945517820306e-05

Mice O 0 0.0020656813867390156
with O 0 1.6649693179715541e-06
a O 0 3.8945862002037757e-07
larger O 0 5.158111093805928e-07
deletion O 0 3.9698511500319e-06
involving O 0 3.1647446121496614e-06
both O 0 3.055365880300087e-07
Snrpn O 0 0.0008136150427162647
and O 0 4.925580014969455e-07
the O 0 4.089245067007141e-07
putative O 0 0.0025670654140412807
PWS O 1 0.9997181296348572
- O 0 0.2157169133424759
IC O 0 0.03480163961648941
lack O 0 5.131237230671104e-06
expression O 0 4.699492706095043e-08
of O 0 5.895065768868335e-09
the O 0 5.54904922012156e-08
imprinted O 0 0.0004390997055452317
genes O 0 1.1852094985442818e-06
Zfp127 O 0 7.201949483714998e-05
( O 0 4.464453695618431e-08
mouse O 0 1.4660399756394327e-06
homologue O 0 1.7945322952073184e-06
of O 0 9.876676188014244e-08
ZNF127 O 0 0.0020308210514485836
) O 0 1.7082170700177812e-07
, O 0 1.334928327878515e-07
Ndn O 0 0.00030635463190265
and O 0 5.512716825251118e-07
Ipw O 0 0.00014395562175195664
, O 0 1.4207581955361093e-07
and O 0 1.1482959649811164e-07
manifest O 0 2.192901092712418e-06
several O 0 2.2961745571592473e-07
phenotypes O 0 8.48882264108397e-05
common O 0 1.1441979950177483e-05
to O 0 3.6753273889189586e-05
PWS B-Disease 1 0.9998026490211487
infants O 1 0.6486608982086182
. O 0 2.777052577584982e-05

These O 0 1.8876791045840946e-06
data O 0 1.7825956319938996e-06
demonstrate O 0 2.4755740923865233e-06
that O 0 2.056497372393551e-08
both O 0 1.7071480229446934e-08
the O 0 1.2917235281406647e-08
position O 0 5.505697941998733e-08
of O 0 5.275883285804639e-09
the O 0 2.816716282438847e-08
IC O 0 4.461818389245309e-05
and O 0 2.3688414785283385e-07
its O 0 2.9884329677543064e-08
role O 0 8.288300534786686e-08
in O 0 3.0225970615305187e-09
the O 0 3.82849307811739e-09
coordinate O 0 1.0422859020309261e-07
expression O 0 6.293979026850138e-08
of O 0 1.507621938401371e-08
genes O 0 1.1082512685334223e-07
is O 0 6.506923888593974e-09
conserved O 0 7.485656539074625e-08
between O 0 5.855309836988454e-08
mouse O 0 1.7954729628399946e-05
and O 0 5.45990417322173e-07
human O 0 6.450995897466782e-07
, O 0 1.0063506294955005e-07
and O 0 2.0721688542835182e-07
indicate O 0 2.1968897101487528e-07
that O 0 7.0452235156892584e-09
the O 0 2.4729938985501576e-08
mouse O 0 4.641864506993443e-06
is O 0 1.4165985717795593e-08
a O 0 3.185141039807604e-08
suitable O 0 2.0502471897998475e-07
model O 0 2.1379463532866794e-07
system O 0 2.2537130917044124e-07
in O 0 2.8822920938864627e-08
which O 0 1.4372447232346985e-08
to O 0 9.520085164638203e-09
investigate O 0 3.086909714511421e-07
the O 0 1.3183264258032068e-08
molecular O 0 6.535920533679018e-07
mechanisms O 0 9.970879943921318e-08
of O 0 1.8884298569332714e-08
imprinting O 0 3.446920891292393e-05
in O 0 5.366364774772592e-08
this O 0 3.0863422928462114e-09
region O 0 1.8743486762673456e-08
of O 0 5.736559671731811e-09
the O 0 5.641058820060607e-08
genome O 0 3.5337163808435434e-06
. O 0 3.5933331332671514e-07
. O 0 2.253290631415439e-06

Mutations O 0 0.00016319994756486267
of O 0 4.809612619283143e-07
the O 0 1.936398064117384e-07
ATM O 0 6.0292426496744156e-05
gene O 0 2.3528900783276185e-06
detected O 0 4.772611646330915e-06
in O 0 2.435453154703282e-07
Japanese O 0 0.001355740474537015
ataxia B-Disease 1 0.9999430179595947
- I-Disease 1 0.9999704360961914
telangiectasia I-Disease 1 0.9999946355819702
patients O 1 0.5241091251373291
: O 0 6.52170001558261e-07
possible O 0 3.16927042831594e-07
preponderance O 0 1.4676341379527003e-05
of O 0 3.2370959246463826e-08
the O 0 2.553569267149669e-08
two O 0 1.0666693128769111e-07
founder O 0 0.0003379778063390404
mutations O 0 1.5836507373023778e-05
4612del165 O 0 5.075620356365107e-05
and O 0 1.6324823945979006e-06
7883del5 O 0 0.0001654253137530759
. O 0 2.9745572192041436e-06

The O 0 6.3792363107495476e-06
ATM O 0 0.0002859442902263254
( O 0 1.6389374195568962e-06
A O 0 0.0001337619178229943
- O 1 0.9004708528518677
T O 1 0.9995573163032532
, O 0 2.0750237581523834e-06
mutated O 0 3.138290594506543e-06
) O 0 4.216214932739604e-08
gene O 0 1.1157552393115111e-07
on O 0 1.9397174355617608e-07
human O 0 3.2842231121321674e-06
chromosome O 0 0.00017187905905302614
11q22 O 0 0.000870285730343312
. O 0 7.543253559560981e-06

3 O 0 4.7898440243443474e-05
has O 0 6.70063627694617e-06
recently O 0 2.1697522242902778e-05
been O 0 4.226585872402211e-07
identified O 0 5.341188398233498e-07
as O 0 9.362430830606172e-09
the O 0 9.740402262536918e-09
gene O 0 5.8318704532211996e-08
responsible O 0 1.0798028426961537e-07
for O 0 5.7069875936122116e-08
the O 0 1.4479529681921122e-06
human O 0 0.002230464480817318
recessive B-Disease 1 0.9931731820106506
disease I-Disease 1 0.9993126392364502
ataxia B-Disease 1 0.9999816417694092
- I-Disease 1 0.9999645948410034
telangiectasia I-Disease 1 0.9999877214431763
( O 0 0.00016838376177474856
A B-Disease 0 0.0322144590318203
- I-Disease 1 0.9993584752082825
T I-Disease 1 0.9998107552528381
) O 0 2.2281468773144297e-05
. O 0 5.86102532906807e-06

In O 0 3.438184648985043e-06
order O 0 6.14031648638047e-07
to O 0 2.9054190164856664e-08
define O 0 1.8117231093128794e-07
the O 0 2.406908805596686e-08
types O 0 2.938838292720902e-07
of O 0 8.465435712423641e-07
disease O 0 0.002445609774440527
- O 0 0.006292286794632673
causing O 0 0.00013959813804831356
ATM O 0 0.00032437770278193057
mutations O 0 3.2286011446558405e-06
in O 0 3.4423035089048426e-08
Japanese O 0 8.41296605358366e-06
A B-Disease 0 0.0015806863084435463
- I-Disease 1 0.9997187256813049
T I-Disease 1 0.999992847442627
patients O 0 0.00717592379078269
as O 0 1.8132112700186553e-07
well O 0 4.8738904467882094e-08
as O 0 1.260335924513356e-08
to O 0 4.974057166151624e-09
look O 0 6.015857678676184e-08
for O 0 1.399758353670677e-08
possible O 0 1.4392148273145722e-07
mutational O 0 6.887102063046768e-05
hotspots O 0 2.589843461464625e-05
, O 0 1.4200388420704257e-07
reverse O 0 1.126583811128512e-06
- O 0 1.916344444907736e-05
transcribed O 0 5.515261705113517e-07
RNA O 0 7.352627307000148e-08
derived O 0 1.7620576997501303e-08
from O 0 1.2333942756015404e-08
ten O 0 9.17928275612212e-08
patients O 0 3.910335635737283e-06
belonging O 0 2.343658422887529e-07
to O 0 8.344257729220317e-09
eight O 0 1.1032906854779867e-07
unrelated O 0 7.337982424360234e-06
Japanese O 0 1.2741398677462712e-05
A B-Disease 0 0.00019714198424480855
- I-Disease 1 0.9823289513587952
T I-Disease 1 0.9998219609260559
families O 0 1.7155294699477963e-05
was O 0 8.549187668904779e-07
analyzed O 0 1.2059398386554676e-06
for O 0 1.7366073734592646e-07
mutations O 0 4.494434335811093e-07
by O 0 1.418329009794661e-08
the O 0 4.232894568190204e-08
restriction O 0 4.6523493324457377e-07
endonuclease O 0 4.465747042559087e-05
fingerprinting O 0 9.399661212228239e-05
method O 0 3.0595986117987195e-06
. O 0 4.450555024959613e-06

As O 0 9.237625818059314e-06
has O 0 1.390829083902645e-06
been O 0 5.372893383537303e-07
reported O 0 1.3479659628501395e-06
by O 0 8.054422551140306e-08
others O 0 4.228013210649806e-07
, O 0 1.385902095307756e-07
mutations O 0 6.785821824450977e-07
that O 0 1.2240526814366604e-08
lead O 0 8.06876698788983e-07
to O 0 1.5266333974750523e-08
exon O 0 1.2953984878549818e-05
skipping O 0 9.04223634279333e-06
or O 0 3.1150690915637824e-07
premature O 0 7.98740529717179e-06
protein O 0 6.067111968377503e-08
truncation O 0 3.874857611663174e-06
were O 0 1.8406625201805582e-07
also O 0 1.1854746162498486e-07
predominant O 0 3.604979497140448e-07
in O 0 2.256346931517328e-08
our O 0 2.869657009796356e-07
mutants O 0 2.7556576242204756e-05
. O 0 2.331325276827556e-06

Six O 0 8.450549103145022e-06
different O 0 5.957343773843604e-07
mutations O 0 1.1029147572116926e-05
were O 0 3.273999027442187e-07
identified O 0 3.743608658623998e-07
on O 0 4.179034007734117e-08
12 O 0 5.395398972041221e-08
of O 0 1.0363246261135828e-08
the O 0 7.48061808053535e-08
16 O 0 3.5127234241372207e-06
alleles O 0 9.097983820538502e-06
examined O 0 8.380466169910505e-05
. O 0 1.3122927157382946e-05

Four O 0 8.383252861676738e-06
were O 0 1.4997614243839053e-06
deletions O 0 3.113931234111078e-05
involving O 0 1.2237337614351418e-05
a O 0 1.5865521163505036e-06
loss O 0 2.9767830710625276e-05
of O 0 2.2745078709363042e-08
a O 0 3.481113708403427e-08
single O 0 1.1337679239886711e-07
exon O 0 2.7760437660617754e-05
exon O 0 3.203440428478643e-05
7 O 0 3.945281719097693e-07
, O 0 3.246946533863593e-08
exon O 0 2.1509993075596867e-06
16 O 0 1.569066085949089e-07
, O 0 3.17663513271782e-08
exon O 0 3.8448470149887726e-06
33 O 0 8.809269615994708e-07
or O 0 2.2266515031788003e-07
exon O 0 2.8863227271358483e-05
35 O 0 7.992800419742707e-06
. O 0 4.307940344006056e-06

The O 0 3.4976640108652646e-06
others O 0 2.240162757516373e-06
were O 0 1.3186362934902718e-07
minute O 0 2.659643882907403e-07
deletions O 0 7.971204468049109e-06
, O 0 1.2886945910395298e-07
4649delA O 0 8.076442099991255e-06
in O 0 2.830346801374617e-08
exon O 0 5.174037141841836e-06
33 O 0 9.718737601360772e-07
and O 0 9.861503968977559e-08
7883del5 O 0 1.1753282706195023e-05
in O 0 1.2586667708092136e-07
exon O 0 5.531046190299094e-05
55 O 0 2.0545821826090105e-05
. O 0 3.2979262414301047e-06

The O 0 7.032952908048173e-06
mutations O 0 7.121587259462103e-05
4612del165 O 0 0.00015823646390344948
and O 0 1.030658268064144e-06
7883del5 O 0 5.2138981118332595e-05
were O 0 3.2346954981221643e-07
found O 0 5.8945516911990126e-08
in O 0 4.2863517180080635e-09
more O 0 1.6604344565962492e-09
than O 0 2.61239430088267e-09
two O 0 1.4399667236375535e-08
unrelated O 0 3.8019163639546605e-06
families O 0 9.297513656747469e-07
; O 0 6.20669084128167e-07
44 O 0 3.1811239296075655e-06
% O 0 2.198736268610446e-07
( O 0 2.9716654026401557e-08
7 O 0 1.1221108309200645e-07
of O 0 1.1467065519354946e-08
16 O 0 3.294398140951671e-07
) O 0 5.555495619091744e-09
of O 0 2.6241753214861774e-09
the O 0 2.370339124979637e-08
mutant O 0 5.651791525451699e-06
alleles O 0 8.456697173642169e-07
had O 0 2.054902097370359e-07
one O 0 3.973273265955868e-09
of O 0 7.380514865928944e-09
the O 0 5.169462014009696e-08
two O 0 1.306347598983848e-06
mutations O 0 4.526281918515451e-05
. O 0 3.650818371170317e-06

The O 0 7.3975525083369575e-06
4612del165 O 0 0.0009373289649374783
mutations O 0 3.0021905331523158e-05
in O 0 3.553457617044842e-08
three O 0 1.6925902457387565e-08
different O 0 7.1318329020186866e-09
families O 0 2.5917157131516433e-07
were O 0 7.798502821287912e-08
all O 0 8.15702883016911e-09
ascribed O 0 4.995761742065952e-07
to O 0 4.623808447234978e-09
the O 0 8.864171618938599e-09
same O 0 1.4428498218421737e-07
T O 0 0.005980273243039846
- O 0 0.00031068213866092265
- O 0 0.0004423363134264946
> O 0 1.0467939546288108e-06
A O 0 2.1779435144253512e-08
substitution O 0 1.1059702487159484e-08
at O 0 8.955121977294311e-09
the O 0 5.568161931535087e-09
splice O 0 5.679238711309154e-06
donor O 0 1.7786355783755425e-06
site O 0 3.1808613698558474e-07
in O 0 1.008464280971566e-07
intron O 0 0.0001315786939812824
33 O 0 1.7947179003385827e-05
. O 0 2.959390940304729e-06

Microsatellite O 0 0.004134090151637793
genotyping O 0 0.0008296571904793382
around O 0 9.77845161287405e-07
the O 0 1.9545041141100228e-07
ATM O 0 4.7272624215111136e-05
locus O 0 3.076491702813655e-05
also O 0 8.468649639326031e-07
indicated O 0 6.345751444314374e-07
that O 0 4.5810923943179205e-09
a O 0 3.563625483593569e-08
common O 0 2.677670636330731e-07
haplotype O 0 1.6176609278772958e-05
was O 0 1.3312177316038287e-06
shared O 0 1.4994425612258055e-07
by O 0 2.6841229683327583e-08
the O 0 3.7558489651701166e-08
mutant O 0 4.66369101559394e-06
alleles O 0 8.328398735102382e-07
in O 0 7.761968134900599e-08
both O 0 8.048147606132261e-07
mutations O 0 2.8767764888470992e-05
. O 0 4.6086452130111866e-06

This O 0 2.291091959705227e-06
suggests O 0 3.7832605812582187e-06
that O 0 2.0354789853627153e-08
these O 0 5.965294924692444e-09
two O 0 4.9703512416954254e-08
founder O 0 0.0007701569702476263
mutations O 0 3.2812698918860406e-05
may O 0 5.24178346950066e-07
be O 0 1.3070296844830409e-08
predominant O 0 1.525493047438431e-07
among O 0 1.2003422966699873e-07
Japanese O 0 9.149161996901967e-06
ATM O 0 0.0003445544571150094
mutant O 0 0.00010537017078604549
alleles O 0 1.3915302588429768e-05
. O 0 4.322512722865213e-06

W474C O 0 0.0005804069223813713
amino O 0 1.200891438202234e-05
acid O 0 9.098392183659598e-06
substitution O 0 3.362723930422362e-07
affects O 0 3.729984712208534e-07
early O 0 3.3470776372723776e-08
processing O 0 2.2723309456296192e-08
of O 0 2.0580737114528347e-09
the O 0 3.137648807438609e-09
alpha O 0 3.927464220510046e-08
- O 0 8.239035196311306e-07
subunit O 0 1.6232030830565236e-08
of O 0 5.893222354558247e-09
beta O 0 2.229046174306859e-07
- O 0 3.901164745911956e-05
hexosaminidase O 0 0.00013968908751849085
A O 0 1.8698965220664832e-07
and O 0 1.4615586962918314e-07
is O 0 5.423328630627111e-08
associated O 0 4.5078530774844694e-07
with O 0 2.667475428097532e-06
subacute O 1 0.8778209686279297
G B-Disease 0 0.05409723147749901
( I-Disease 0 4.673071543948026e-06
M2 I-Disease 0 0.005372182931751013
) I-Disease 0 4.233664185449015e-06
gangliosidosis I-Disease 0 0.0015705468831583858
. O 0 7.390056907752296e-06

Mutations O 0 0.0005693028215318918
in O 0 5.21520632901229e-07
the O 0 1.875672523965477e-07
HEXA O 0 0.004264369141310453
gene O 0 3.7708875311182055e-07
, O 0 4.9465822549166205e-09
encoding O 0 3.5055451874654864e-09
the O 0 1.872164867577908e-09
alpha O 0 3.1335837036294834e-08
- O 0 6.433658086280047e-07
subunit O 0 1.777083902254617e-08
of O 0 3.6575102946301286e-09
beta O 0 1.752034819446635e-07
- O 0 1.5638284821761772e-05
hexosaminidase O 0 4.5625376515090466e-05
A O 0 1.5637748163044307e-07
( O 0 2.8669509433143503e-08
Hex O 0 5.579227035923395e-06
A O 0 1.468835790774392e-07
) O 0 1.9839481169015016e-08
, O 0 6.141789299363154e-09
that O 0 3.546698268408477e-09
abolish O 0 4.527032899659389e-07
Hex O 0 3.4365059491392458e-06
A O 0 8.412946783664665e-08
enzyme O 0 1.388356281495362e-06
activity O 0 9.868367669696454e-07
cause O 0 0.00012113749835407361
Tay B-Disease 1 0.9999663829803467
- I-Disease 1 0.9999241828918457
Sachs I-Disease 1 0.9999945163726807
disease I-Disease 0 0.38092729449272156
( O 0 1.4182688801156473e-06
TSD B-Disease 0 0.055920183658599854
) O 0 2.769036200334085e-07
, O 0 1.2133072857523075e-07
the O 0 3.15673105433234e-07
fatal O 0 0.013597790151834488
infantile B-Disease 0 0.008153649047017097
form I-Disease 0 8.094455097307218e-07
of I-Disease 0 3.955321403736889e-07
G I-Disease 0 0.0014043239643797278
( I-Disease 0 6.125723075456335e-07
M2 I-Disease 0 0.0009309269953519106
) I-Disease 0 3.847877394491661e-07
gangliosidosis I-Disease 0 0.0002263515052618459
, I-Disease 0 3.2315259090864856e-07
Type I-Disease 0 1.0709028401834075e-06
1 I-Disease 0 2.07645848604443e-06
. O 0 3.346227458678186e-06

Less O 0 0.0014966283924877644
severe O 1 0.717292308807373
, O 0 6.036071863491088e-05
subacute O 1 0.9441013932228088
( O 0 1.9250028344686143e-05
juvenile O 1 0.751327395439148
- O 1 0.9734781384468079
onset O 1 0.5481110215187073
) O 0 8.283642273454461e-06
and O 0 4.0635321056470275e-05
chronic O 1 0.9754119515419006
( O 0 6.597278456865752e-07
adult O 0 6.242889412533259e-06
- O 0 0.1730399876832962
onset O 0 0.005938087590038776
) O 0 4.2720907345028536e-07
variants O 0 5.206336481933249e-07
are O 0 4.593755775772479e-08
characterized O 0 1.1550939689186634e-06
by O 0 8.705851683998844e-08
a O 0 1.0890359902759883e-07
broad O 0 6.497267349914182e-06
spectrum O 0 1.03146930996445e-05
of O 0 5.193323886487633e-07
clinical O 0 0.0002149742067558691
manifestations O 0 2.7944668545387685e-05
and O 0 9.172839554594248e-07
are O 0 1.0901666058771298e-07
associated O 0 2.520820316931349e-07
with O 0 1.204257955578214e-07
residual O 0 3.3210264518857e-05
levels O 0 1.8127289536096214e-07
of O 0 1.802653670779364e-08
Hex O 0 3.0100740332272835e-05
A O 0 1.4685601854580455e-06
enzyme O 0 1.0209352694801055e-05
activity O 0 2.0187010250083404e-06
. O 0 2.5562433165760012e-06

We O 0 6.751269665983273e-06
identified O 0 8.341001375811175e-06
a O 0 8.265131441476115e-07
1422 O 0 0.0010182283585891128
G O 0 0.0002840249508153647
- O 0 0.00043612669105641544
- O 0 0.001340086804702878
> O 0 1.6661142581142485e-05
C O 0 5.9385110944276676e-06
( O 0 1.749059030942135e-08
amino O 0 5.369702194002457e-08
acid O 0 8.500522312715475e-07
W474C O 0 1.5072000678628683e-06
) O 0 2.4180708546595042e-09
substitution O 0 4.662882968631266e-09
in O 0 1.6949608383498571e-09
the O 0 2.202127813433208e-09
first O 0 1.2859882936311351e-08
position O 0 1.6170538685855718e-08
of O 0 7.531969714591469e-09
exon O 0 3.730063554030494e-06
13 O 0 1.468377774926921e-07
of O 0 2.3251311986882683e-08
HEXA O 0 0.00025007801013998687
of O 0 2.9350843533393345e-08
a O 0 1.2086219669527054e-07
non O 0 5.8439459280634765e-06
- O 0 0.0005686293006874621
Jewish O 0 4.076931145391427e-05
proband O 0 0.023929744958877563
who O 0 1.0109385584655683e-05
manifested O 0 5.647093530569691e-06
a O 0 3.973411821789341e-07
subacute O 0 0.009014186449348927
variant O 0 1.2788535059371497e-05
of O 0 4.4044537617082824e-07
G B-Disease 0 0.0013792902464047074
( I-Disease 0 1.9354874893906526e-06
M2 I-Disease 0 0.0015581607585772872
) I-Disease 0 2.088184828608064e-06
gangliosidosis I-Disease 0 0.0006173297297209501
. O 0 4.632348009181442e-06

On O 0 4.461429398361361e-06
the O 0 5.017826083530963e-07
second O 0 4.7747421376698185e-06
maternally O 0 0.004437651950865984
inherited O 0 0.008118624798953533
allele O 0 4.888740022579441e-06
, O 0 1.0794487081966508e-07
we O 0 1.2066601939864086e-08
identified O 0 1.8855583050481073e-07
the O 0 1.1698480051336446e-07
common O 0 1.8441607608110644e-05
infantile O 1 0.9739635586738586
disease O 0 0.15347833931446075
- O 0 0.002311921212822199
causing O 0 7.102848030626774e-05
4 O 0 1.1906814734174986e-06
- O 0 0.00022593812900595367
bp O 0 0.00013097509508952498
insertion O 0 2.6566021915641613e-06
, O 0 1.5690002896917576e-07
+ O 0 6.846328233223176e-06
TATC O 0 0.0008705876534804702
1278 O 0 0.0001371434045722708
, O 0 7.123679068854472e-08
in O 0 6.986054756907834e-08
exon O 0 2.3644122848054394e-05
11 O 0 3.8408597902162e-06
. O 0 2.4875396320567233e-06

Pulse O 0 0.0001516144984634593
- O 0 0.00035252244560979307
chase O 0 3.421591463848017e-05
analysis O 0 3.167970987760782e-07
using O 0 1.751493527990533e-07
proband O 0 0.00012373155914247036
fibroblasts O 0 2.2061198251321912e-05
revealed O 0 2.4567050331825158e-06
that O 0 4.805579489897127e-09
the O 0 6.551257314413306e-09
W474C O 0 1.6493237353643053e-06
- O 0 3.6711032862513093e-06
containing O 0 6.810517305666508e-08
alpha O 0 7.51379332086799e-08
- O 0 4.442631791334861e-07
subunit O 0 3.1141954792701654e-08
precursor O 0 1.938935128009689e-07
was O 0 5.1248811416826356e-08
normally O 0 1.0308421671822998e-08
synthesized O 0 6.22251548065833e-08
, O 0 7.800849743944127e-09
but O 0 3.0294193820168402e-09
not O 0 2.1384503057220172e-09
phosphorylated O 0 1.9243655913214752e-07
or O 0 1.6167268412914382e-08
secreted O 0 3.160378696520638e-07
, O 0 2.7808649605276514e-08
and O 0 1.0998842725484792e-08
the O 0 2.111160490869679e-08
mature O 0 1.1072218057961436e-06
lysosomal O 0 5.228371810517274e-05
alpha O 0 6.151687443889386e-07
- O 0 9.549370588501915e-06
subunit O 0 4.652464724586025e-07
was O 0 5.304831347530126e-07
not O 0 8.534453144193321e-08
detected O 0 5.853272341482807e-06
. O 0 1.537579237265163e-06

When O 0 4.100940259377239e-06
the O 0 2.5111481249950884e-07
W474C O 0 1.201333634526236e-05
- O 0 5.504277396539692e-06
containing O 0 1.0206183986838369e-07
alpha O 0 9.493307118191296e-08
- O 0 9.762127319845604e-07
subunit O 0 8.641315929480697e-08
was O 0 2.5368822775817534e-07
transiently O 0 1.5643548977095634e-05
co O 0 1.9782590243266895e-05
- O 0 4.4887645344715565e-05
expressed O 0 1.4892174249325763e-07
with O 0 3.848274587880951e-09
the O 0 2.868065118732943e-09
beta O 0 6.974830313311031e-08
- O 0 1.8013582803177997e-06
subunit O 0 2.7608402675127763e-08
to O 0 3.5611911197719337e-09
produce O 0 1.637451241265353e-08
Hex O 0 3.0210510431061266e-06
A O 0 9.083976948431882e-08
( O 0 4.364113692645333e-08
alphabeta O 0 1.5870178685872816e-05
) O 0 2.073231364363437e-08
in O 0 1.722251141700326e-08
COS O 0 0.001369898091070354
- O 0 8.902546687750146e-05
7 O 0 1.4566551271855133e-06
cells O 0 5.96336917624285e-07
, O 0 7.760129427936135e-09
the O 0 3.194313924481662e-09
mature O 0 7.628436549111939e-08
alpha O 0 1.2417982020451745e-07
- O 0 4.497350801102584e-06
subunit O 0 1.524092709814795e-07
was O 0 1.0482769852160345e-07
present O 0 1.2791264936140578e-08
, O 0 1.221133150153264e-08
but O 0 3.4740545995504135e-09
its O 0 3.453323627056193e-09
level O 0 2.8563620801946854e-08
was O 0 3.261843772861539e-08
much O 0 1.1323746385016875e-08
lower O 0 3.1479675044465694e-07
than O 0 2.5867010755575848e-09
that O 0 9.340701545568209e-10
from O 0 1.6630843369114245e-09
normal O 0 3.0512115056779976e-09
alpha O 0 3.663705072654011e-08
- O 0 1.662226281951007e-06
subunit O 0 1.3556245903600939e-07
transfections O 0 1.967677235370502e-05
, O 0 1.483625844400649e-08
although O 0 4.50773018911832e-09
higher O 0 1.0216736789914194e-08
than O 0 2.1407766670478168e-09
in O 0 3.140630644438147e-09
those O 0 1.87353013103575e-08
cells O 0 4.439950771484291e-07
transfected O 0 2.1778787413495593e-05
with O 0 3.568168338574651e-08
an O 0 1.6961356763545155e-08
alpha O 0 4.288410764274886e-07
- O 0 2.2687621822115034e-05
subunit O 0 5.949417527517653e-07
associated O 0 1.403623627993511e-06
with O 0 4.636953235603869e-06
infantile O 0 0.2334703654050827
TSD B-Disease 1 0.7762678861618042
. O 0 3.115826621069573e-05

Furthermore O 0 4.5295251766219735e-05
, O 0 7.315207994906814e-07
the O 0 3.9551508734803065e-08
precursor O 0 9.278115840061218e-07
level O 0 3.2990723042303216e-08
of O 0 2.4314597002472738e-09
the O 0 4.939190390018666e-09
W474C O 0 1.1287248753433232e-06
alpha O 0 7.884652575285145e-08
- O 0 1.1651976592474966e-06
subunit O 0 4.232393990832861e-08
was O 0 5.0256897310418935e-08
found O 0 1.5922751117614098e-08
to O 0 2.6502309236065003e-09
accumulate O 0 9.169935424324649e-07
in O 0 3.3655127573695154e-09
comparison O 0 1.0462131605493141e-08
to O 0 1.226599599668532e-09
the O 0 1.876358179941917e-09
normal O 0 1.2436085938816177e-08
alpha O 0 1.1120732779090758e-07
- O 0 4.3480513340909965e-06
subunit O 0 3.347930714880931e-07
precursor O 0 3.175882966388599e-06
levels O 0 1.1219391353733954e-06
. O 0 7.791587677274947e-07

We O 0 3.3820958833530312e-06
conclude O 0 5.628308372251922e-06
that O 0 7.460099737954806e-08
the O 0 5.583649809182134e-08
1422 O 0 0.00033588349469937384
G O 0 6.776094232918695e-05
- O 0 0.0003253452596254647
- O 0 0.003524997504428029
> O 0 4.915219687973149e-05
C O 0 4.7328790969913825e-05
mutation O 0 2.0335116914793616e-06
is O 0 2.0976621328827605e-08
the O 0 3.231691891869559e-08
cause O 0 5.792393835690746e-07
of O 0 8.647811711171016e-08
Hex B-Disease 0 0.009459619410336018
A I-Disease 0 0.0007716082036495209
enzyme I-Disease 1 0.9980839490890503
deficiency I-Disease 1 0.9973491430282593
in O 0 2.7608729169514845e-07
the O 0 1.4505015997201554e-06
proband O 0 0.01406116783618927
. O 0 1.0841365110536572e-05

The O 0 4.146444098296342e-06
resulting O 0 9.282149221689906e-06
W474C O 0 2.2089448975748383e-05
substitution O 0 6.026923529134365e-07
clearly O 0 2.9562696113316633e-07
interferes O 0 1.6959292281626404e-07
with O 0 1.3949501997956304e-08
alpha O 0 1.2730895093682193e-07
- O 0 1.8558168903837213e-06
subunit O 0 4.7506190981039254e-08
processing O 0 1.6139145486704365e-07
, O 0 1.896848011995189e-08
but O 0 5.291645344129847e-09
because O 0 1.7154441200872839e-09
the O 0 8.323541855759231e-10
base O 0 4.5279481497573215e-08
substitution O 0 8.832699904814945e-08
falls O 0 1.584856363479048e-05
at O 0 3.8030513849207637e-08
the O 0 3.681769777941213e-09
first O 0 1.346267985979921e-08
position O 0 3.001388648726788e-08
of O 0 7.986208139243445e-09
exon O 0 5.362493993743556e-06
13 O 0 1.9031652698231483e-07
, O 0 2.397685427979468e-08
aberrant O 0 1.377063313157123e-06
splicing O 0 2.512573928470374e-06
may O 0 1.0388448572484776e-06
also O 0 3.6342857612226e-08
contribute O 0 9.491188990295996e-08
to O 0 3.8727080209355336e-08
Hex B-Disease 0 0.00017333113646600395
A I-Disease 0 3.300888420199044e-05
deficiency I-Disease 0 0.04275696352124214
in O 0 4.346336979210719e-08
this O 0 4.569889355821033e-08
proband O 0 0.0005134668899700046
. O 0 6.761094368812337e-07
. O 0 1.920546310429927e-06

Two O 0 2.0797106117242947e-05
frequent O 0 0.0002122444420820102
missense O 0 0.012797805480659008
mutations O 0 0.009059046395123005
in O 0 0.0007625615689903498
Pendred B-Disease 1 0.9997552037239075
syndrome I-Disease 1 0.9998931884765625
. O 0 0.0003584108198992908

Pendred B-Disease 1 0.999871015548706
syndrome I-Disease 1 0.9999735355377197
is O 0 0.005137463100254536
an O 0 0.1017400324344635
autosomal B-Disease 1 0.999980092048645
recessive I-Disease 1 0.9999953508377075
disorder I-Disease 1 0.9999990463256836
characterized O 1 0.6843308210372925
by O 0 0.00043736983207054436
early O 0 0.06215234473347664
childhood O 1 0.9963485598564148
deafness B-Disease 1 0.9999912977218628
and O 1 0.9291456937789917
goiter B-Disease 1 0.9999728202819824
. O 0 0.0010358223225921392

A O 0 7.631813787156716e-06
century O 0 2.2519500362250255e-06
after O 0 1.126545043916849e-06
its O 0 3.914862034548605e-08
recognition O 0 2.988994936004019e-07
as O 0 2.952198485672852e-07
a O 0 2.2489695766125806e-05
syndrome O 1 0.9103286862373352
by O 0 1.7171790887005045e-06
Vaughan O 0 0.003380462294444442
Pendred O 0 0.0074882498010993
, O 0 1.0035901141236536e-06
the O 0 1.576708768880053e-06
disease O 0 0.0010570262093096972
gene O 0 2.179405782953836e-06
( O 0 3.1068242378751165e-07
PDS O 0 0.0007265962194651365
) O 0 8.927838024419543e-08
was O 0 1.7959962406166596e-07
mapped O 0 1.2180252042526263e-06
to O 0 1.7722747713833087e-07
chromosome O 0 3.25294240610674e-05
7q22 O 0 0.00028202199609950185
- O 0 0.004532825201749802
q31 O 0 0.0008035539067350328
. O 0 4.0779809751256835e-06

1 O 0 2.0313898858148605e-05
and O 0 3.8125076571304817e-06
, O 0 1.1822428405139362e-06
recently O 0 9.242436135536991e-06
, O 0 3.897458000778897e-08
found O 0 2.3039234520183527e-08
to O 0 2.9697089232172402e-09
encode O 0 7.396244683377518e-08
a O 0 3.0926022986932367e-07
putative O 0 0.00022220375831238925
sulfate O 0 0.008559038862586021
transporter O 0 0.0036141120363026857
. O 0 9.481158485868946e-06

We O 0 3.5881769235857064e-06
performed O 0 1.960365125341923e-06
mutation O 0 1.2522185670604813e-06
analysis O 0 4.694037158969877e-08
of O 0 1.5412149778626372e-08
the O 0 1.3420817879250535e-07
PDS B-Disease 0 0.005187655333429575
gene O 0 2.3255229280039202e-06
in O 0 2.0683721402292576e-07
patients O 0 1.0528176972002257e-05
from O 0 6.706759592134404e-08
14 O 0 8.095041721389862e-07
Pendred B-Disease 0 9.794610377866775e-05
families O 0 1.987336446518384e-07
originating O 0 7.856460371158391e-08
from O 0 3.0444351040159745e-08
seven O 0 1.4926055769137747e-07
countries O 0 4.6123247443574655e-08
and O 0 1.2176147379250324e-07
identified O 0 1.0282254834237392e-06
all O 0 1.4277328830303304e-07
mutations O 0 1.4174618627293967e-05
. O 0 2.8854826723545557e-06

The O 0 9.785255315364338e-06
mutations O 0 5.8858444390352815e-05
include O 0 3.4904525136880693e-07
three O 0 3.649192237276111e-08
single O 0 1.3201335491430655e-07
base O 0 1.1588830375330872e-06
deletions O 0 7.19792888048687e-06
, O 0 3.283278360299846e-08
one O 0 6.941714758568196e-09
splice O 0 4.552682185021695e-06
site O 0 1.3902165392210009e-06
mutation O 0 7.075943813106278e-07
and O 0 1.8779259391976666e-07
10 O 0 1.1544684639375191e-06
missense O 0 0.0005958964466117322
mutations O 0 0.00010196999210165814
. O 0 5.167725248611532e-06

One O 0 7.678486326767597e-06
missense O 0 0.0020157096441835165
mutation O 0 0.0001847713574534282
( O 0 7.730105835435097e-07
L236P O 0 0.0001421774213667959
) O 0 2.114695547561496e-07
was O 0 2.42148331608405e-07
found O 0 8.069523005360679e-08
in O 0 9.320595850681457e-09
a O 0 4.188641966607065e-08
homozygous O 0 7.947248263917572e-07
state O 0 3.205264675898434e-08
in O 0 9.188772409629564e-09
two O 0 5.24888648101296e-08
consanguineous O 0 0.005456016398966312
families O 0 1.4589098100259434e-05
and O 0 4.198552403522626e-07
in O 0 2.3115294567332967e-08
a O 0 9.13169699856553e-08
heterozygous O 0 7.209458203760732e-07
state O 0 6.910040184493482e-08
in O 0 6.438946709153015e-09
five O 0 4.581837487194207e-08
additional O 0 5.727482630391023e-07
non O 0 4.4571741455001757e-05
- O 0 0.016394048929214478
consanguineous O 0 0.060873936861753464
families O 0 6.059700172045268e-05
. O 0 8.758089279581327e-06

Another O 0 5.37327432539314e-05
missense O 0 0.0029066381976008415
mutation O 0 0.00020310118270572275
( O 0 1.2397077853165683e-06
T416P O 0 8.596875704824924e-05
) O 0 1.9816000929040456e-07
was O 0 2.003761920832403e-07
found O 0 6.249324258078559e-08
in O 0 5.614499531958472e-09
a O 0 3.407512139119717e-08
homozygous O 0 9.083366876438959e-07
state O 0 6.576837563443405e-08
in O 0 1.774726321457365e-08
one O 0 3.559597061553177e-08
family O 0 5.442680048872717e-07
and O 0 8.81322890222691e-08
in O 0 2.2341552607940685e-08
a O 0 3.882848176317566e-08
heterozygous O 0 4.935859578836244e-07
state O 0 3.815730309497667e-08
in O 0 1.4044839069526915e-08
four O 0 3.8322068007801136e-07
families O 0 1.6623005649307743e-05
. O 0 7.966165867401287e-06

Pendred B-Disease 1 0.9542651176452637
patients O 0 0.0420355424284935
in O 0 7.339889975810365e-07
three O 0 3.0097012881924456e-07
non O 0 2.425143975415267e-05
- O 0 0.01271180622279644
consanguineous O 0 0.04318145290017128
families O 0 6.90289289195789e-06
were O 0 1.8466846540832194e-07
shown O 0 4.083363691620434e-08
to O 0 4.012463694635926e-09
be O 0 7.63364393918664e-09
compound O 0 1.8844562532649434e-07
heterozygotes O 0 5.583464371738955e-06
for O 0 1.529042492620647e-07
L236P O 0 6.917630526004359e-05
and O 0 2.0388963548612082e-06
T416P O 0 0.00019212964980397373
. O 0 2.62551679952594e-06

In O 0 4.582913788908627e-06
total O 0 1.66194570283551e-06
, O 0 2.436652266624151e-07
one O 0 1.9347323743090783e-08
or O 0 1.342222066824661e-08
both O 0 6.539172314745656e-09
of O 0 7.351600661564817e-09
these O 0 1.6040321071386643e-08
mutations O 0 1.8881255527958274e-06
were O 0 1.5447503187715483e-07
found O 0 1.4092394451381551e-07
in O 0 1.362498558421521e-08
nine O 0 5.039387573901877e-08
of O 0 1.3558594247342626e-08
the O 0 6.005963371080725e-08
14 O 0 1.5237786783472984e-06
families O 0 6.669434696959797e-06
analyzed O 0 3.6778168578166515e-05
. O 0 6.699364348605741e-06

The O 0 3.0147966754157096e-06
identification O 0 1.351436139884754e-06
of O 0 7.791619793806603e-08
two O 0 1.4562021988240303e-07
frequent O 0 6.0306133491394576e-06
PDS B-Disease 0 0.012751927599310875
mutations O 0 7.1450135692430194e-06
will O 0 1.695524254330394e-08
facilitate O 0 1.1070681438241081e-07
the O 0 1.757223770937344e-07
molecular O 0 0.00021900495630688965
diagnosis O 0 0.013238048180937767
of O 0 0.0002602154854685068
Pendred B-Disease 1 0.9999480247497559
syndrome I-Disease 1 0.9999525547027588
. O 0 0.00021550410019699484

Insertional O 0 0.014464863575994968
mutation O 0 0.0001526529958937317
by O 0 1.0775515875138808e-06
transposable O 0 0.0004278921987861395
element O 0 4.467045073397458e-06
, O 0 4.350052620338829e-07
L1 O 0 0.00018727332644630224
, O 0 1.5365738192940626e-07
in O 0 1.8550577962628267e-08
the O 0 2.0598622541001532e-07
DMD B-Disease 1 0.992786705493927
gene O 0 8.830305660012527e-07
results O 0 2.5412384729861515e-07
in O 0 1.8067314044856175e-07
X B-Disease 0 0.001232756651006639
- I-Disease 1 0.9914041757583618
linked I-Disease 1 0.9852970242500305
dilated I-Disease 1 0.9981160163879395
cardiomyopathy I-Disease 1 0.9993740916252136
. O 0 6.836104148533195e-05

X B-Disease 0 0.03710508346557617
- I-Disease 1 0.9937587976455688
linked I-Disease 1 0.9980904459953308
dilated I-Disease 1 0.999758780002594
cardiomyopathy I-Disease 1 0.9999457597732544
( O 0 2.3522472474724054e-05
XLDCM B-Disease 0 0.22529037296772003
) O 0 5.585918074757501e-07
is O 0 5.121871282653956e-08
a O 0 3.298286799235939e-07
clinical O 0 4.0045546484179795e-05
phenotype O 0 1.3581568964582402e-05
of O 0 2.8327565360086737e-07
dystrophinopathy B-Disease 0 0.032768916338682175
which O 0 4.165085272234137e-07
is O 0 1.390935011613692e-07
characterized O 0 5.27184556631255e-06
by O 0 1.5370633263955824e-06
preferential O 0 0.0012641691137105227
myocardial B-Disease 1 0.9945092797279358
involvement I-Disease 0 0.00023022906680125743
without O 0 1.452560013603943e-06
any O 0 2.830423397881532e-07
overt O 0 3.837280019070022e-05
clinical O 0 0.0014067930169403553
signs O 0 0.0017828402342274785
of O 0 0.0003893823886755854
skeletal B-Disease 1 0.9998651742935181
myopathy I-Disease 1 0.9999613761901855
. O 0 0.0011733555002138019

To O 0 2.4723372007429134e-06
date O 0 1.385002633469412e-06
, O 0 1.3168366308491386e-07
several O 0 5.491990151540449e-08
mutations O 0 1.1643511470538215e-06
in O 0 6.910909888802053e-08
the O 0 8.268976671388373e-06
Duchenne B-Disease 1 0.9999576807022095
muscular I-Disease 1 0.9999374151229858
dystrophy I-Disease 1 0.9998540878295898
gene O 0 0.00029408608679659665
, O 0 8.528044418198988e-05
DMD O 1 0.9999493360519409
, O 0 9.876966942101717e-06
have O 0 3.9976768562155485e-07
been O 0 4.2916224174405215e-07
identified O 0 2.531461632315768e-06
in O 0 5.174710508981661e-07
patients O 0 2.538912303862162e-05
with O 0 6.149364253360545e-07
XLDCM B-Disease 0 0.13492952287197113
, O 0 6.149892328721762e-07
but O 0 3.3047530934027236e-08
a O 0 3.562116646094182e-08
pathogenic O 0 2.1275366179906996e-07
correlation O 0 2.57801886505149e-08
of O 0 5.4598290333274235e-09
these O 0 1.4608445120245506e-08
cardiospecific O 0 0.0002873506164178252
mutations O 0 3.1284830583899748e-06
in O 0 2.2442225144914119e-07
DMD O 1 0.9778615832328796
with O 0 4.83243013604806e-07
the O 0 8.263011181952606e-07
XLDCM B-Disease 1 0.7496730089187622
phenotype O 0 0.0007683636504225433
has O 0 2.517656639611232e-06
remained O 0 4.5271290218806826e-06
to O 0 9.165373882069616e-08
be O 0 4.084404281456955e-07
elucidated O 0 0.00012839020928367972
. O 0 5.291539764584741e-06

We O 0 3.724127282112022e-06
report O 0 9.939859637597692e-07
here O 0 2.4355175654022787e-08
the O 0 4.41875558365723e-09
identification O 0 1.6868019869775708e-08
of O 0 4.8534980479075784e-09
a O 0 1.4061485309468935e-08
unique O 0 2.7751212883231346e-08
de O 0 5.871033295079542e-07
novo O 0 1.7032895129887038e-06
L1 O 0 2.3930855604703538e-05
insertion O 0 1.1191840485480498e-06
in O 0 1.8334910478756683e-08
the O 0 4.025581645805687e-08
muscle O 0 1.3037531061854679e-05
exon O 0 6.788121027057059e-06
1 O 0 2.6131937147511053e-07
in O 0 2.8618680403269536e-07
DMD O 1 0.9778253436088562
in O 0 4.295921769426059e-07
three O 0 1.8886262296291534e-06
XLDCM B-Disease 1 0.8961923718452454
patients O 0 0.00025629703304730356
from O 0 7.807597057762905e-08
two O 0 1.420129649432056e-07
unrelated O 0 6.681960803689435e-05
Japanese O 0 0.00011739257024601102
families O 0 5.090574995847419e-05
. O 0 1.1366740181983914e-05

The O 0 3.163163455610629e-06
insertion O 0 3.364848089404404e-05
was O 0 1.6111662262119353e-06
a O 0 5.95105831280307e-08
5 O 0 8.279656782406164e-08
- O 0 3.711662793648429e-05
truncated O 0 1.0369217307015788e-06
form O 0 2.2423691348194552e-08
of O 0 8.571416465485981e-09
human O 0 5.997503649268765e-08
L1 O 0 1.9778270143433474e-05
inversely O 0 5.419231001724256e-06
integrated O 0 1.7207805740326876e-06
in O 0 1.2822531481049282e-08
the O 0 1.446821684680799e-08
5 O 0 2.0957170931978908e-07
- O 0 0.0003737177758011967
untranslated O 0 0.00020773090363945812
region O 0 2.0182935145385272e-07
in O 0 7.692575465512164e-09
the O 0 5.413004799947885e-08
muscle O 0 1.8824097423930652e-05
exon O 0 8.115393939078785e-06
1 O 0 2.9593414296869014e-07
, O 0 4.212742510389944e-08
which O 0 9.905800624210315e-09
affected O 0 3.0737602685348975e-08
the O 0 4.072565840118614e-09
transcription O 0 2.0486366736349737e-07
or O 0 4.7107466372153795e-08
the O 0 2.1935269600703577e-08
stability O 0 2.6309581357963907e-07
of O 0 4.79508024398001e-08
the O 0 4.769107704305497e-07
muscle O 0 0.00022163962421473116
form O 0 5.7604545133926877e-08
of O 0 6.54249348031044e-08
dystrophin O 0 7.395195279968902e-05
transcripts O 0 3.6684712085843785e-06
but O 0 3.692517580589083e-08
not O 0 2.7215896203358625e-09
that O 0 1.118353520901394e-09
of O 0 5.303042893700649e-09
the O 0 3.5323850511304045e-07
brain O 0 0.0011526993475854397
or O 0 2.619586666696705e-06
Purkinje O 1 0.7216283679008484
cell O 0 0.0025871386751532555
form O 0 3.4396766750433017e-06
, O 0 2.217324436060153e-06
probably O 0 2.2611909571423894e-06
due O 0 2.8525789730338147e-07
to O 0 6.031595223277009e-09
its O 0 1.1818687362108449e-08
unique O 0 2.6702338118411717e-08
site O 0 1.4420065497233736e-07
of O 0 1.2663205950502743e-07
integration O 0 3.364177609910257e-05
. O 0 8.324394912051503e-06

We O 0 6.4902201302174944e-06
speculate O 0 1.0099315659317654e-05
that O 0 4.0748055596395716e-08
this O 0 3.617989019488732e-09
insertion O 0 1.673174949701206e-07
of O 0 1.046708231200455e-08
an O 0 1.7312720146378524e-08
L1 O 0 1.7639562429394573e-05
sequence O 0 5.132394065299195e-08
in O 0 4.0848874505172716e-07
DMD O 1 0.9983447790145874
is O 0 2.835116106325586e-07
responsible O 0 7.55724101964006e-07
for O 0 2.56591174974119e-08
some O 0 3.957752792160818e-09
of O 0 6.538997787686185e-09
the O 0 1.3263721676537443e-08
population O 0 2.1968514118952953e-08
of O 0 9.820060142828879e-08
Japanese O 0 0.00031148918787948787
patients O 0 7.665996963623911e-05
with O 0 1.2953140640092897e-06
XLDCM B-Disease 0 0.0168913621455431
. O 0 1.3334590676095104e-06
. O 0 3.605010988394497e-06

Severe O 1 0.9026483297348022
early O 0 0.001366136595606804
- O 1 0.997645914554596
onset O 1 0.9995550513267517
obesity B-Disease 1 0.9999526739120483
, O 0 0.04014001414179802
adrenal B-Disease 1 0.9998589754104614
insufficiency I-Disease 1 0.9997791647911072
and O 0 0.00019774629618041217
red O 0 0.1477607935667038
hair O 1 0.6364599466323853
pigmentation O 0 0.12741033732891083
caused O 0 7.700322021264583e-05
by O 0 1.0318727618141565e-05
POMC O 1 0.9254822134971619
mutations O 0 0.0001412274141330272
in O 0 1.6038018202380044e-06
humans O 0 5.414013685367536e-06
. O 0 4.146321771258954e-06

Sequential O 0 3.48984613083303e-05
cleavage O 0 0.00028629752341657877
of O 0 3.714025922363362e-07
the O 0 1.1278194733677083e-07
precursor O 0 1.3688774060938158e-06
protein O 0 1.0157845764524609e-07
pre O 0 3.3015703593264334e-06
- O 0 0.00012559462629724294
pro O 0 4.450799315236509e-05
- O 0 0.003602622076869011
opiomelanocortin O 0 0.0060662697069346905
( O 0 2.288861224997163e-07
POMC O 0 8.807897393126041e-05
) O 0 1.3170095236603174e-08
generates O 0 3.301048678849838e-08
the O 0 1.8471348894877337e-08
melanocortin O 0 0.00022120958601590246
peptides O 0 1.0840248251042794e-05
adrenocorticotrophin O 0 0.0003670095175039023
( O 0 2.666544673957105e-07
ACTH O 0 1.5478823115699925e-05
) O 0 2.3003009275157638e-08
, O 0 4.84807891609762e-08
melanocyte O 0 0.00021083219326101243
- O 0 0.0015477808192372322
stimulating O 0 0.00021677686891052872
hormones O 0 5.991534635541029e-06
( O 0 3.636477075019684e-08
MSH O 0 5.69578587601427e-05
) O 0 6.953614573035338e-09
alpha O 0 2.7677208080945093e-08
, O 0 3.888738664414859e-09
beta O 0 2.0500040776028072e-08
and O 0 8.275627294551668e-09
gamma O 0 8.46471124305026e-08
as O 0 5.282378090498696e-09
well O 0 2.2589035086895137e-09
as O 0 2.0484514084984085e-09
the O 0 1.104526159423358e-08
opioid O 0 3.143004505545832e-05
- O 0 0.00012335799692664295
receptor O 0 4.686022748501273e-06
ligand O 0 8.053382771322504e-06
beta O 0 8.731127309147269e-06
- O 0 0.0006448553176596761
endorphin O 0 0.002162665594369173
. O 0 5.321341177477734e-06

While O 0 1.4227789506549016e-05
a O 0 1.2503178368206136e-06
few O 0 3.2613934308756143e-07
cases O 0 1.2851357951149112e-06
of O 0 1.658380142544047e-06
isolated O 0 0.035302937030792236
ACTH B-Disease 1 0.9989407658576965
deficiency I-Disease 1 0.9944612979888916
have O 0 2.377274313403177e-06
been O 0 1.954259460035246e-06
reported O 0 2.6904821424977854e-05
( O 0 1.8942794213216985e-06
OMIM O 0 0.2975664436817169
201400 O 0 0.00374871538951993
) O 0 3.0748398671676114e-07
, O 0 1.0014124995905149e-07
an O 0 5.282139454720891e-07
inherited O 0 0.2928416132926941
POMC O 1 0.9933854937553406
defect O 0 0.2994493842124939
has O 0 1.508487002865877e-06
not O 0 8.388560246430643e-08
been O 0 2.5146351845251047e-07
described O 0 1.728596430439211e-06
so O 0 1.799797502144429e-07
far O 0 1.5393428611787385e-06
. O 0 2.661483677002252e-06

Recent O 0 8.461748075205833e-05
studies O 0 9.147330274572596e-06
in O 0 2.297760488545464e-07
animal O 0 6.497792242043943e-07
models O 0 1.3405639265329228e-06
elucidated O 0 1.7141393982456066e-05
a O 0 7.173473193233804e-08
central O 0 2.8203935187320894e-08
role O 0 4.5577028373600115e-08
of O 0 1.3884070781955415e-08
alpha O 0 9.828976317294291e-07
- O 0 0.0003055454872082919
MSH O 0 0.0022153554018586874
in O 0 1.2472905375204846e-08
the O 0 4.182357127291425e-09
regulation O 0 2.503271367970683e-08
of O 0 5.807436753713091e-09
food O 0 4.3141749728192735e-08
intake O 0 3.2058697030379335e-08
by O 0 2.766199269643721e-09
activation O 0 4.74989434451345e-08
of O 0 3.9313672317575765e-09
the O 0 7.662807632868862e-08
brain O 0 3.312524495413527e-05
melanocortin O 0 0.0002037445519817993
- O 0 5.1591559895314276e-05
4 O 0 5.776319085271098e-07
- O 0 0.00014086590090300888
receptor O 0 3.555662487997324e-06
( O 0 6.43746318473859e-08
MC4 O 0 0.00035158623359166086
- O 0 0.0010273164371028543
R O 0 0.0006963179912418127
; O 0 2.025014538276082e-07
refs O 0 3.3884689401020296e-06
3 O 0 1.3669149723227747e-07
- O 0 1.0603889677440748e-05
5 O 0 7.062151041736797e-08
) O 0 2.7490212328729058e-09
and O 0 1.7070623803405738e-09
the O 0 2.0497841202171685e-09
linkage O 0 3.3775660313040134e-07
of O 0 1.4794754576996638e-07
human O 0 1.4049593119125348e-05
obesity B-Disease 0 0.2628617286682129
to O 0 1.2218710310207825e-07
chromosome O 0 1.690828321443405e-05
2 O 0 1.4629112854436244e-07
in O 0 1.4545859627901336e-08
close O 0 1.1057871773800798e-07
proximity O 0 8.93935663270895e-08
to O 0 8.081302738105478e-09
the O 0 3.522087510532401e-08
POMC O 0 0.000773838022723794
locus O 0 9.051951565197669e-06
, O 0 2.0976945336315111e-07
led O 0 5.215161991145578e-07
to O 0 4.14078860089262e-09
the O 0 5.655664381265524e-09
proposal O 0 1.777267755187495e-07
of O 0 1.4234565526294318e-08
an O 0 9.45272589092383e-08
association O 0 1.3674499541593832e-06
of O 0 2.3280739469555556e-07
POMC O 0 0.05296511575579643
with O 0 2.0523517378023826e-05
human O 0 0.0002745536039583385
obesity B-Disease 1 0.9656606316566467
. O 0 4.405853906064294e-05

The O 0 2.714074980758596e-06
dual O 0 4.643254669645103e-06
role O 0 8.05738579856552e-07
of O 0 6.833587917753903e-08
alpha O 0 1.795028651940811e-06
- O 0 0.000332119147060439
MSH O 0 0.0015437816036865115
in O 0 3.363191325433945e-08
regulating O 0 5.7600522040957e-07
food O 0 9.825061653145895e-08
intake O 0 1.8438161930589558e-07
and O 0 2.498396511896317e-08
influencing O 0 9.417501132702455e-06
hair O 0 0.0012535242130979896
pigmentation O 0 0.0002627215872053057
predicts O 0 3.901373202097602e-05
that O 0 4.5151324457037845e-08
the O 0 2.2784445263823727e-07
phenotype O 0 5.949487240286544e-05
associated O 0 1.4453371477429755e-06
with O 0 3.9209831470543577e-07
a O 0 1.0289974852639716e-05
defect O 0 0.023756805807352066
in O 0 1.4255249425332295e-06
POMC O 0 0.15805968642234802
function O 0 6.330126893772103e-07
would O 0 3.8143483038766135e-07
include O 0 1.1291273040114902e-05
obesity B-Disease 1 0.9493805766105652
, O 0 4.58320255347644e-06
alteration O 0 5.2136641897959635e-05
in O 0 3.1051556561578764e-06
pigmentation O 0 0.059297725558280945
and O 0 0.002874816535040736
ACTH B-Disease 1 0.9963600039482117
deficiency I-Disease 1 0.9643706679344177
. O 0 1.4469480447587557e-05

The O 0 4.291959612601204e-06
observation O 0 8.055656508076936e-06
of O 0 3.6389403135217435e-07
these O 0 7.550779628218152e-07
symptoms O 0 0.00017708097584545612
in O 0 2.716985214590295e-08
two O 0 1.0718289900069067e-07
probands O 0 0.0012860236456617713
prompted O 0 4.094828454981325e-06
us O 0 1.414375958574965e-07
to O 0 3.2150104800621193e-09
search O 0 1.139733196708903e-08
for O 0 1.4363129352545911e-08
mutations O 0 2.387386359714583e-07
within O 0 1.7775008132048242e-08
their O 0 2.9019420821896347e-07
POMC O 0 0.004237035755068064
genes O 0 3.054997932849801e-06
. O 0 1.7041832052200334e-06

Patient O 0 0.003924780525267124
1 O 0 1.0998697689501569e-05
was O 0 3.6036358324054163e-06
found O 0 3.540725685979851e-07
to O 0 8.099062753785802e-09
be O 0 3.0244426962866555e-09
a O 0 1.0233742742116192e-08
compound O 0 1.4388730562586716e-07
heterozygote O 0 6.9354309744085185e-06
for O 0 1.777436509087238e-08
two O 0 4.5469185749880126e-08
mutations O 0 9.619793672754895e-07
in O 0 1.724137810299453e-08
exon O 0 1.7312084310106002e-05
3 O 0 8.443520869150234e-07
( O 0 9.586560878460659e-08
G7013T O 0 1.4748852663615253e-05
, O 0 4.162877189628489e-07
C7133delta O 0 0.00010749469947768375
) O 0 2.3881828070670963e-08
which O 0 3.3476887928429733e-09
interfere O 0 1.4266285042197069e-08
with O 0 1.3874453808071507e-09
appropriate O 0 3.148307614608825e-09
synthesis O 0 1.1626603679815162e-08
of O 0 3.07061931437147e-08
ACTH O 0 4.923260348732583e-05
and O 0 4.0306144910573494e-07
alpha O 0 1.1043660379073117e-05
- O 0 0.0010477968025952578
MSH O 0 0.03230666741728783
. O 0 7.1125982685771305e-06

Patient O 0 0.0037101279012858868
2 O 0 7.365241344814422e-06
was O 0 3.980913788836915e-06
homozygous O 0 3.4961701658176025e-06
for O 0 4.661995944843511e-08
a O 0 7.665980206184031e-08
mutation O 0 4.3223707280048984e-07
in O 0 3.5301784606645015e-08
exon O 0 2.8775337341357954e-05
2 O 0 1.0796622973430203e-06
( O 0 1.2116561265429482e-07
C3804A O 0 6.403201950888615e-06
) O 0 4.4447418190429744e-08
which O 0 6.054742840433391e-08
abolishes O 0 0.00015108312072698027
POMC O 0 0.005571179557591677
translation O 0 7.380154784186743e-06
. O 0 4.500937848206377e-06

These O 0 3.1037936878419714e-06
findings O 0 6.737196599715389e-06
represent O 0 1.8820747982317698e-07
the O 0 3.781849855499786e-08
first O 0 3.741434895232487e-08
examples O 0 7.136952717701206e-08
of O 0 7.834552917529436e-08
a O 0 6.267125172598753e-06
genetic B-Disease 0 0.49356016516685486
defect I-Disease 1 0.7723172307014465
within O 0 8.935487016970001e-08
the O 0 4.783442477673816e-07
POMC O 0 0.03628343716263771
gene O 0 7.113583251339151e-07
and O 0 7.447929561976707e-08
define O 0 2.5840208195404557e-07
a O 0 2.221514421307802e-07
new O 0 6.5916363382712e-05
monogenic B-Disease 1 0.9996402263641357
endocrine I-Disease 1 0.9998867511749268
disorder I-Disease 0 0.4572064280509949
resulting O 0 1.1324747902108356e-05
in O 0 9.177809374705248e-07
early O 0 5.501514169736765e-05
- O 1 0.9977293610572815
onset O 1 0.9972033500671387
obesity B-Disease 1 0.9999521970748901
, O 0 0.01673341728746891
adrenal B-Disease 1 0.9997618794441223
insufficiency I-Disease 1 0.9998487234115601
and O 0 9.747855074238032e-05
red O 0 0.023855937644839287
hair O 0 0.24101310968399048
pigmentation O 0 0.008725667372345924
. O 0 1.92183802028012e-06
. O 0 3.302064669696847e-06

A O 0 4.2135925468755886e-05
European O 0 6.260456575546414e-05
multicenter O 0 0.1608305722475052
study O 0 2.5346082111354917e-05
of O 0 2.119005876011215e-05
phenylalanine B-Disease 1 0.9994713664054871
hydroxylase I-Disease 1 0.9998993873596191
deficiency I-Disease 1 0.9998782873153687
: O 0 3.4903825962828705e-07
classification O 0 3.5809901532957156e-07
of O 0 1.723453912916284e-08
105 O 0 4.7205421651597135e-06
mutations O 0 2.3301358851313125e-06
and O 0 4.7115015888721246e-08
a O 0 3.8183436856797925e-08
general O 0 1.4192495711995434e-07
system O 0 1.0645757697602676e-07
for O 0 9.83348016347918e-08
genotype O 0 1.4490315152215771e-05
- O 0 0.00021160897449590266
based O 0 4.651466952054761e-06
prediction O 0 6.271478014241438e-06
of O 0 2.0756706362590194e-06
metabolic O 0 0.011728495359420776
phenotype O 0 0.0005960878916084766
. O 0 9.82867004495347e-06

Phenylketonuria B-Disease 1 0.991685688495636
( O 0 0.0005140764988027513
PKU B-Disease 1 0.8431553244590759
) O 0 1.3903509170631878e-05
and O 0 6.627562106586993e-05
mild B-Disease 1 0.6543353199958801
hyperphenylalaninemia I-Disease 1 0.9999589920043945
( O 0 0.0006731519242748618
MHP B-Disease 1 0.999933123588562
) O 0 4.544371222436894e-06
are O 0 9.267680525226751e-07
allelic B-Disease 0 0.22692809998989105
disorders I-Disease 1 0.996856689453125
caused O 0 7.756147533655167e-05
by O 0 4.71036912585987e-07
mutations O 0 2.8797344384656753e-06
in O 0 1.705514129923813e-08
the O 0 3.2354233070464034e-08
gene O 0 4.7542903303110506e-07
encoding O 0 2.1400016976258485e-06
phenylalanine O 0 0.0011502172565087676
hydroxylase O 0 0.28106534481048584
( O 0 2.5509472834528424e-05
PAH O 1 0.9946295022964478
) O 0 3.4329257232457167e-06
. O 0 2.93553216579312e-06

Previous O 0 6.370546179823577e-05
studies O 0 1.9989698557765223e-05
have O 0 8.071660317909846e-07
suggested O 0 1.2320984978941851e-06
that O 0 8.780071780734033e-09
the O 0 2.3733159437711038e-08
highly O 0 1.2659684216487221e-06
variable O 0 1.2069824151694775e-05
metabolic O 0 0.018051929771900177
phenotypes O 0 0.004557110369205475
of O 0 0.003974385093897581
PAH B-Disease 1 0.9999909400939941
deficiency I-Disease 1 0.9994693398475647
correlate O 0 0.00037341751158237457
with O 0 0.00037985193193890154
PAH O 1 0.999581515789032
genotypes O 0 0.013657850213348866
. O 0 2.3851474907132797e-05

We O 0 3.632131665654015e-06
identified O 0 7.568763066956308e-06
both O 0 7.753162662993418e-07
causative O 0 0.00021258510241750628
mutations O 0 1.7285112335230224e-05
in O 0 4.3052565956713806e-07
686 O 0 0.22200681269168854
patients O 0 0.000523377675563097
from O 0 1.2454071907086472e-07
seven O 0 7.545301627942536e-07
European O 0 5.2174377742630895e-06
centers O 0 6.440474862756673e-06
. O 0 5.61423075851053e-06

On O 0 2.067026571239694e-06
the O 0 7.684396763352197e-08
basis O 0 1.8592517747606507e-08
of O 0 6.9258971890917564e-09
the O 0 1.6655580026281314e-08
phenotypic O 0 8.016273227440252e-07
characteristics O 0 5.0470827517301586e-08
of O 0 3.0944427464874025e-08
297 O 0 0.00020250964735168964
functionally O 0 0.01002898346632719
hemizygous O 1 0.9472293257713318
patients O 0 0.001069918042048812
, O 0 5.533343738761687e-08
105 O 0 1.5399493236145645e-07
of O 0 7.564016968331089e-09
the O 0 5.6862344166574985e-08
mutations O 0 1.2376040103845298e-06
were O 0 1.0465947752891225e-07
assigned O 0 2.5949802306968195e-07
to O 0 9.647768806075874e-09
one O 0 3.040295792899883e-09
of O 0 4.293339017635844e-09
four O 0 3.4064981946357875e-08
arbitrary O 0 7.432241204696766e-07
phenotype O 0 6.404156010830775e-05
categories O 0 2.6127925593755208e-05
. O 0 1.1722904673661105e-05

We O 0 3.470481487966026e-06
proposed O 0 6.492350166809047e-06
and O 0 3.9340702073786815e-07
tested O 0 1.2991876019441406e-06
a O 0 2.1300170516269645e-08
simple O 0 2.2823172685093596e-08
model O 0 8.18402341451474e-08
for O 0 2.6157014332284234e-08
correlation O 0 1.5246931184265122e-07
between O 0 1.3969263079616212e-07
genotype O 0 1.457660982850939e-05
and O 0 9.026941825140966e-07
phenotypic O 0 2.1294141333783045e-05
outcome O 0 1.5037104276416358e-05
. O 0 7.343583547481103e-06

The O 0 5.741017957916483e-06
observed O 0 1.5494937542825937e-05
phenotype O 0 8.560684364056215e-05
matched O 0 1.2114555829612073e-05
the O 0 2.638672356169991e-07
predicted O 0 1.7743372154654935e-05
phenotype O 0 1.6802467143861577e-05
in O 0 9.141020029801439e-08
79 O 0 8.450403583992738e-06
% O 0 5.3442199998698925e-08
of O 0 1.9284620123016794e-08
the O 0 9.986754179180934e-08
cases O 0 1.8408660480417893e-06
, O 0 2.3541242910596338e-07
and O 0 1.0650063586581382e-07
in O 0 1.4271864579029625e-08
only O 0 2.2148323175485984e-09
5 O 0 2.7930379786766935e-08
of O 0 7.358098486065501e-08
184 O 0 0.0007750478107482195
patients O 0 0.0002196105197072029
was O 0 2.614659422306431e-07
the O 0 3.696463934943495e-08
observed O 0 8.455825764031033e-07
phenotype O 0 2.2248311779549113e-06
more O 0 5.850696371823005e-09
than O 0 6.114566630799345e-09
one O 0 3.994061970047369e-09
category O 0 8.091932812703817e-08
away O 0 8.305137555453257e-08
from O 0 4.5184322061686544e-08
that O 0 3.424785433026045e-08
expected O 0 1.0093415312439902e-06
. O 0 1.6841439673953573e-06

Among O 0 2.317226790182758e-05
the O 0 4.891044795840571e-07
seven O 0 9.555469659972005e-07
contributing O 0 1.1032356269424781e-05
centers O 0 6.931165330570366e-07
, O 0 6.329759116852074e-08
the O 0 2.3122526116026165e-08
proportion O 0 5.541264158637205e-07
of O 0 2.9424282388390566e-07
patients O 0 3.8499409129144624e-05
for O 0 1.9979458443231124e-07
whom O 0 2.174182554881554e-06
the O 0 4.933195896228426e-08
observed O 0 1.12705345145514e-06
phenotype O 0 7.897776413301472e-06
did O 0 5.0584066713099674e-08
not O 0 2.437672952382286e-09
match O 0 6.002917274372521e-08
the O 0 4.224007099651317e-08
predicted O 0 9.587193744664546e-06
phenotype O 0 7.378754162346013e-06
was O 0 1.821370716470483e-07
4 O 0 1.5197616676232428e-07
% O 0 1.0194705168942164e-07
- O 0 0.00021848523465450853
23 O 0 4.56803854831378e-06
% O 0 1.299836611678984e-07
( O 0 4.0295610403973114e-08
P O 0 1.1370297215762548e-05
< O 0 4.567746600514511e-06
. O 0 3.746790611103279e-08
0001 O 0 6.350283456413308e-06
) O 0 1.8136551815928215e-08
, O 0 1.2911668179071967e-08
suggesting O 0 2.0711809156637173e-07
that O 0 6.115604911371975e-09
differences O 0 1.2635111090730788e-07
in O 0 4.099781403255065e-09
methods O 0 1.360475643252812e-08
used O 0 1.3189175085415172e-08
for O 0 2.1131427274667658e-08
mutation O 0 7.193709734565346e-07
detection O 0 4.769158294948284e-06
or O 0 3.821101472567534e-06
phenotype O 0 0.0001396918814862147
classification O 0 9.513255645288154e-05
may O 0 4.036949121655198e-06
account O 0 1.4961442218464072e-07
for O 0 5.579529727128829e-08
a O 0 1.1430449831095757e-07
considerable O 0 4.2367355490569025e-07
proportion O 0 9.397193139193405e-07
of O 0 3.958109857649106e-07
genotype O 0 0.000792511273175478
- O 0 0.3531676232814789
phenotype O 0 0.0019377678399905562
inconsistencies O 0 0.0014206403866410255
. O 0 1.4928639757272322e-05

Our O 0 4.879922926193103e-06
data O 0 1.4251660331865423e-06
indicate O 0 4.875439003626525e-07
that O 0 2.3858335751469895e-08
the O 0 3.3982831837420235e-07
PAH O 1 0.9974960684776306
- O 0 0.02109202742576599
mutation O 0 1.706328839645721e-05
genotype O 0 1.5084773622220382e-05
is O 0 1.828385443047864e-08
the O 0 9.371971643190591e-09
main O 0 1.1323534465645935e-07
determinant O 0 2.2205535969987977e-06
of O 0 4.101231070308131e-07
metabolic O 0 0.0020118635147809982
phenotype O 0 6.128799577709287e-05
in O 0 4.7190695795507054e-07
most O 0 1.15130378617323e-05
patients O 0 0.03925531357526779
with O 0 0.017960868775844574
PAH B-Disease 1 0.9999771118164062
deficiency I-Disease 1 0.9990631937980652
. O 0 3.8672496884828433e-05

In O 0 4.755007012136048e-06
the O 0 5.971222662992659e-07
present O 0 4.908385449198249e-07
study O 0 1.9065151946051628e-07
, O 0 2.3199261178774577e-08
the O 0 1.1793083842803753e-08
classification O 0 5.171340831111593e-07
of O 0 1.428622340426955e-07
105 O 0 0.0020185960456728935
PAH O 1 0.9999679327011108
mutations O 0 0.0002737811882980168
may O 0 4.589412299083051e-07
allow O 0 2.1310652797978946e-08
the O 0 8.37365732309081e-09
prediction O 0 1.8395270728888136e-07
of O 0 7.1310988225548044e-09
the O 0 3.4832655870786766e-08
biochemical O 0 1.9126802726532333e-05
phenotype O 0 3.6792625905945897e-06
in O 0 2.012786026739377e-08
> O 0 8.48133879571833e-07
10 O 0 1.0584653153955514e-07
, O 0 9.290461377986503e-08
000 O 0 7.476394898731087e-07
genotypes O 0 1.1391221960366238e-05
, O 0 1.841789725176568e-07
which O 0 8.740875756529931e-08
may O 0 4.2908035879918316e-07
be O 0 6.384075046383941e-09
useful O 0 8.181944011198539e-09
for O 0 8.916041238649086e-09
the O 0 4.4654925090981124e-08
management O 0 1.9383207927603507e-06
of O 0 6.623870376643026e-07
hyperphenylalaninemia B-Disease 1 0.9944677352905273
in O 0 1.5772631741128862e-05
newborns O 0 0.008427229709923267
. O 0 1.1644916412478779e-05

Somatic O 0 0.01614682748913765
instability O 0 0.0005948880570940673
of O 0 4.5336949483498756e-07
the O 0 2.5275943471569917e-07
CTG O 0 0.00046649263822473586
repeat O 0 8.085235094767995e-06
in O 0 6.690877540904694e-08
mice O 0 1.217176304635359e-06
transgenic O 0 1.3598410077975132e-06
for O 0 2.3548784611193696e-07
the O 0 2.6058620278490707e-05
myotonic B-Disease 1 0.9999902248382568
dystrophy I-Disease 1 0.9999877214431763
region O 0 0.0003962454793509096
is O 0 2.6867203359870473e-06
age O 0 1.994721606024541e-05
dependent O 0 5.275592229736503e-06
but O 0 8.16793033209251e-08
not O 0 1.0087082280563209e-08
correlated O 0 2.354494625933512e-07
to O 0 6.862594936762889e-09
the O 0 1.90744930961273e-08
relative O 0 6.123451044004469e-07
intertissue O 0 0.00030397012596949935
transcription O 0 5.391882950789295e-06
levels O 0 2.3533793864771724e-06
and O 0 2.855106686183717e-06
proliferative O 0 0.09210947155952454
capacities O 0 0.00019549287389963865
. O 0 9.158581633528229e-06

A O 0 7.666062447242439e-05
( O 0 5.629532097373158e-06
CTG O 0 0.0013147395802661777
) O 0 8.167912710632663e-07
nexpansion O 0 4.481152063817717e-05
in O 0 2.87802919274327e-08
the O 0 1.1336842575815353e-08
3 O 0 2.43863723881077e-07
- O 0 0.0005884225247427821
untranslated O 0 0.0015951321693137288
region O 0 8.068512897807523e-07
( O 0 6.971186650162053e-08
UTR O 0 5.978983153909212e-06
) O 0 6.813269504135633e-09
of O 0 2.831884282628039e-09
the O 0 6.473280222962785e-08
DM O 1 0.9856017231941223
protein O 0 1.4861176396152587e-06
kinase O 0 1.1335120689182077e-05
gene O 0 4.028347291296086e-07
( O 0 6.753612780130425e-08
DMPK O 0 0.00014000176452100277
) O 0 2.2403341404242383e-08
is O 0 1.2028365858895995e-08
responsible O 0 1.4583328038497712e-06
for O 0 1.264668389922008e-05
causing O 1 0.8296294212341309
myotonic B-Disease 1 0.9999897480010986
dystrophy I-Disease 1 0.9999918937683105
( O 0 0.003758263774216175
DM B-Disease 1 0.9999408721923828
) O 0 5.974879604764283e-05
. O 0 1.1044670827686787e-05

Major O 0 0.001051601255312562
instability O 0 0.0008970717317424715
, O 0 1.2237011333127157e-06
with O 0 2.1608857991850527e-07
very O 0 2.2522451459394688e-08
large O 0 5.789754453644491e-08
expansions O 0 6.851271336927311e-07
between O 0 3.2868374688632684e-08
generations O 0 1.0161940053876606e-06
and O 0 1.6391408053095802e-07
high O 0 2.5013705453602597e-06
levels O 0 1.156762579057613e-07
of O 0 3.923623381751895e-08
somatic O 0 0.00031364127062261105
mosaicism O 0 0.13484571874141693
, O 0 1.7427440752726397e-06
is O 0 2.1336302324925782e-07
observed O 0 3.5984505757369334e-06
in O 0 3.625518274930073e-06
patients O 0 0.00034151243744418025
. O 0 8.180126314982772e-06

There O 0 6.674792530247942e-06
is O 0 3.4334587439843745e-07
a O 0 1.5438475031714916e-07
good O 0 9.645307130767833e-08
correlation O 0 9.332196526656844e-08
between O 0 5.630320387695065e-08
repeat O 0 4.370705028122757e-06
size O 0 1.4782640391786117e-06
( O 0 2.363585416276237e-08
at O 0 4.088288818593355e-08
least O 0 9.695861002967376e-09
in O 0 5.984590956131797e-08
leucocytes O 0 0.002133871428668499
) O 0 3.2581883147031476e-07
, O 0 3.8720881434528565e-07
clinical O 0 3.173529330524616e-05
severity O 0 0.00013641019177157432
and O 0 2.144942072845879e-06
age O 0 9.595682058716193e-06
of O 0 5.656666417053202e-06
onset O 0 0.009464215487241745
. O 0 2.723971920204349e-05

The O 0 3.292004475952126e-05
trinucleotide O 0 0.06191597506403923
repeat O 0 0.00039361388189718127
instability O 0 0.0003406088799238205
mechanisms O 0 1.0028908036474604e-05
involved O 0 4.858714873989811e-06
in O 0 1.4790678051213035e-06
DM B-Disease 1 0.9998962879180908
and O 0 8.609384167357348e-06
other O 0 2.8595402454811847e-06
human O 0 0.00035764765925705433
genetic B-Disease 1 0.9975605010986328
diseases I-Disease 1 0.9997033476829529
are O 0 5.84608687859145e-06
unknown O 0 3.813211515080184e-05
. O 0 1.1065905709983781e-05

We O 0 6.21781509835273e-06
studied O 0 1.785276435839478e-05
somatic O 0 0.00040671671740710735
instability O 0 7.591409666929394e-05
by O 0 1.4628386679760297e-07
measuring O 0 3.43987335327256e-06
the O 0 9.510760179409772e-08
CTG O 0 0.00021053809905424714
repeat O 0 1.9044686041524983e-06
length O 0 1.275599146310924e-07
at O 0 3.3393746434740024e-08
several O 0 1.2199691035164051e-08
ages O 0 1.54027688381575e-07
in O 0 5.496356703105221e-09
various O 0 1.4647449475546637e-08
tissues O 0 7.929048706500907e-07
of O 0 9.149633051208639e-09
transgenic O 0 1.475881344958907e-05
mice O 0 7.567340617242735e-06
carrying O 0 8.9756599663815e-07
a O 0 1.292051763357449e-07
( O 0 8.007305751789318e-08
CTG O 0 0.0001001283380901441
) O 0 5.862562701963725e-08
55expansion O 0 1.028000951919239e-05
surrounded O 0 8.206969255297736e-07
by O 0 1.0541432615696067e-08
45 O 0 6.343864100699648e-08
kb O 0 1.6338923160219565e-05
of O 0 2.6084675752713338e-08
the O 0 7.532634072049404e-08
human O 0 6.2557687670050655e-06
DM B-Disease 1 0.9998407363891602
region O 0 4.008571067970479e-06
, O 0 4.935935038474781e-08
using O 0 4.2378786702101934e-08
small O 0 4.062746086219704e-07
- O 0 0.0009727454744279385
pool O 0 0.00012086830975022167
PCR O 0 0.00031212862813845277
. O 0 7.028454092505854e-06

These O 0 1.4088529496802948e-05
mice O 0 0.0004990674206055701
have O 0 4.2775332076416817e-07
been O 0 9.841134840371524e-08
shown O 0 3.491580358172541e-08
to O 0 6.779823369384985e-09
reproduce O 0 2.159614638230778e-07
the O 0 1.999920229422969e-08
intergenerational O 0 3.5470362490741536e-05
and O 0 9.1292560000511e-07
somatic O 0 8.127869659801945e-05
instability O 0 5.603607405646471e-06
of O 0 9.682832313728795e-09
the O 0 2.801590603951354e-08
55 O 0 1.3131362948115566e-06
CTG O 0 9.261080413125455e-05
repeat O 0 2.8099232167733135e-06
suggesting O 0 7.18560556833836e-07
that O 0 4.640214434914469e-09
surrounding O 0 2.0954267654360592e-08
sequences O 0 1.3153074185368041e-08
and O 0 2.6102194183863503e-08
the O 0 2.2955543244052024e-08
chromatin O 0 1.0604739145492204e-05
environment O 0 1.7986528746405384e-06
are O 0 3.782592727930023e-08
involved O 0 5.644469638355076e-07
in O 0 4.111793430183752e-07
instability O 0 0.00015573506243526936
mechanisms O 0 4.209913095110096e-05
. O 0 8.636719030619133e-06

As O 0 5.42644556844607e-06
observed O 0 1.6792251926744939e-06
in O 0 2.1002684036375285e-08
some O 0 3.704225370881886e-09
of O 0 5.163369287686237e-09
the O 0 9.31939041493024e-08
tissues O 0 1.0014532563218381e-05
of O 0 6.5136832745338324e-06
DM B-Disease 1 0.9999974966049194
patients O 0 0.11367326229810715
, O 0 4.7478746978413255e-07
there O 0 2.7030496951852e-08
is O 0 1.520284342859668e-08
a O 0 6.791267281869295e-08
tendency O 0 9.2176503585506e-07
for O 0 6.738558511187875e-08
repeat O 0 2.4268222205137135e-06
length O 0 5.184006113267969e-07
and O 0 2.536966974275856e-07
somatic O 0 7.845112850191072e-05
mosaicism O 0 0.01671861857175827
to O 0 1.1605006022818998e-07
increase O 0 1.5025888444597513e-07
with O 0 3.2872012667439776e-08
the O 0 2.6044306267181128e-08
age O 0 3.061435620566044e-07
of O 0 4.8643435945905367e-08
the O 0 5.71629016121733e-07
mouse O 0 0.00013559807848650962
. O 0 9.218018021783791e-06

Furthermore O 0 0.00015229752170853317
, O 0 1.9822439298877725e-06
we O 0 6.261231533244427e-08
observed O 0 8.995851885629236e-08
no O 0 5.105492473234108e-09
correlation O 0 1.4963177363824798e-08
between O 0 6.9569043859019075e-09
the O 0 2.03848635749182e-08
somatic O 0 5.430111559689976e-05
mutation O 0 1.078388868336333e-05
rate O 0 3.5334230688022217e-06
and O 0 1.5655652532586828e-05
tissue O 0 0.016045860946178436
proliferation O 0 0.022259321063756943
capacity O 0 4.313114914111793e-05
. O 0 4.9538680286786985e-06

The O 0 3.1532335924566723e-06
somatic O 0 0.0005876301438547671
mutation O 0 4.357695797807537e-05
rates O 0 3.5927923818235286e-06
in O 0 3.847616270036269e-08
different O 0 1.6709385874946747e-08
tissues O 0 3.954980911657913e-06
were O 0 1.647307072971671e-07
also O 0 8.088538550055091e-08
not O 0 3.6602878505931358e-09
correlated O 0 8.334208700944146e-08
to O 0 2.6592794633018e-09
the O 0 7.232270338164426e-09
relative O 0 2.6091049676324474e-07
inter O 0 2.2332100343191996e-05
- O 0 0.0587095245718956
tissue O 0 0.0001898565678857267
difference O 0 3.0028434139239835e-07
in O 0 1.4067815357066138e-08
transcriptional O 0 2.647999792770861e-07
levels O 0 4.375398532374675e-08
of O 0 2.3335893217790726e-09
the O 0 4.704727718518598e-09
three O 0 4.0602277096013495e-08
genes O 0 3.3395664900126576e-07
( O 0 7.557876813280018e-08
DMAHP O 0 0.0004641223349608481
, O 0 4.922218295178027e-07
DMPK O 0 0.0009423340670764446
and O 0 3.2159604756998306e-07
59 O 0 6.38153596810298e-06
) O 0 2.395253773102013e-08
surrounding O 0 1.0987210430357663e-07
the O 0 7.15030523679161e-08
repeat O 0 9.044987564266194e-06
. O 0 5.338616801964235e-07
. O 0 1.9138797142659314e-06

A O 0 2.063624924630858e-05
novel O 0 1.1141481081722304e-05
missense O 0 0.0014092937344685197
mutation O 0 0.00010726646723924205
in O 0 2.6498184979573125e-06
patients O 0 0.00011462647671578452
from O 0 5.327696612766886e-07
a O 0 2.4803312044241466e-06
retinoblastoma B-Disease 0 0.04786134511232376
pedigree O 0 0.001008343417197466
showing O 0 4.86332610307727e-05
only O 0 1.4881950960443646e-07
mild O 0 6.711285095661879e-05
expression O 0 3.4757107414407074e-07
of O 0 1.1500977592504569e-07
the O 0 1.2080729902663734e-05
tumor B-Disease 0 0.3633723258972168
phenotype O 0 0.0005422973190434277
. O 0 1.4770613233849872e-05

We O 0 3.7797879031131743e-06
have O 0 2.752977081854624e-07
used O 0 2.2527434140329206e-08
single O 0 2.322073022753557e-08
strand O 0 1.6148566146512167e-06
conformation O 0 9.67041046351369e-07
polymorphism O 0 2.256290599689237e-06
analysis O 0 5.805002700753903e-08
to O 0 1.2047078890020657e-08
study O 0 3.2132035698850814e-08
the O 0 9.55619761100479e-09
27 O 0 2.724056002989528e-07
exons O 0 2.3444833630037465e-07
of O 0 1.4598751540972899e-08
the O 0 1.1083695738989263e-07
RB1 O 0 0.0069207544438540936
gene O 0 5.804658940178342e-07
in O 0 3.0999544264886936e-08
individuals O 0 8.294578890399862e-08
from O 0 1.0073031120327869e-07
a O 0 6.648361932093394e-07
family O 0 1.57264312292682e-05
showing O 0 0.0001250432396773249
mild O 0 0.00024515806580893695
expression O 0 4.2253850551787764e-07
of O 0 6.779696803960178e-08
the O 0 3.326275191284367e-06
retinoblastoma B-Disease 0 0.2815970480442047
phenotype O 0 0.001502819824963808
. O 0 2.0099480025237426e-05

In O 0 6.536483851959929e-06
this O 0 4.051433108998026e-07
family O 0 3.895644567819545e-06
affected O 0 1.4122909988145693e-06
individuals O 0 8.753177098697051e-07
developed O 0 5.328183397068642e-05
unilateral B-Disease 0 0.09051118046045303
tumors I-Disease 1 0.9999276399612427
and O 0 3.624750888775452e-06
, O 0 3.220951043658715e-07
as O 0 2.5361824640413033e-08
a O 0 3.740300158483478e-08
result O 0 7.065883522727745e-08
of O 0 2.0739710393513633e-08
linkage O 0 8.798767339612823e-06
analysis O 0 4.0372506759922544e-07
, O 0 7.616331458848435e-07
unaffected O 0 2.5951116185751744e-05
mutation O 0 4.292459379939828e-06
carriers O 0 1.7021468011080287e-05
were O 0 4.1330110889248317e-07
also O 0 1.9872605605542049e-07
identified O 0 2.674250936252065e-07
within O 0 1.9991803767993588e-08
the O 0 5.162402203495731e-07
pedigree O 0 0.0005016105715185404
. O 0 8.470914508507121e-06

A O 0 7.710111276537646e-06
single O 0 1.0106524541697581e-06
band O 0 2.4197988750529476e-06
shift O 0 5.222512413638469e-07
using O 0 1.6682675152424054e-07
SSCP O 0 0.00027896586107090116
was O 0 3.835526740658679e-07
identified O 0 1.251325301154793e-07
in O 0 9.164933700844813e-09
exon O 0 3.591757831600262e-06
21 O 0 3.5427288480605057e-07
which O 0 9.559077973619878e-09
resulted O 0 2.5327364028271404e-07
in O 0 1.0489846324901464e-08
a O 0 5.017557924702487e-08
missense O 0 1.3390098501986358e-05
mutation O 0 4.574171157400997e-07
converting O 0 5.033085699324147e-07
a O 0 2.4729735059736413e-07
cys O 0 0.0013859060127288103
- O 0 0.00023631396470591426
- O 0 0.00015383072604890913
> O 0 3.4288816550542833e-06
arg O 0 3.2892996387090534e-05
at O 0 6.964302201595274e-08
nucleotide O 0 3.3343249583595025e-07
position O 0 9.819572710512148e-08
28 O 0 1.8814483837559237e-07
in O 0 2.4425609979061846e-08
the O 0 1.4399698500255909e-07
exon O 0 0.0002656780125107616
. O 0 9.458049134991597e-06

The O 0 1.0450728950672783e-05
mutation O 0 2.8538182959891856e-05
destroyed O 0 1.1634160728135612e-05
an O 0 7.656481102458201e-07
NdeI O 0 0.001830868422985077
restriction O 0 7.595154329465004e-06
enzyme O 0 1.2454845091269817e-05
site O 0 4.6090099203865975e-06
. O 0 2.6573318336886587e-06

Analysis O 0 7.460486358468188e-06
of O 0 5.006430683351937e-07
all O 0 1.1044276249094764e-07
family O 0 1.6389469692512648e-06
members O 0 1.4554036908975831e-07
demonstrated O 0 5.188131240174698e-07
that O 0 3.6540657166739265e-09
the O 0 1.3769063222923705e-08
missense O 0 3.8242858863668516e-05
mutation O 0 6.130063866294222e-06
co O 0 7.91579659562558e-05
- O 0 0.00019977064221166074
segregated O 0 4.5946384489070624e-05
with O 0 1.7415877664461732e-05
patients O 0 0.0013425815850496292
with O 0 0.00011415198241593316
tumors B-Disease 1 0.9999279975891113
or O 0 9.617833711672574e-06
who O 0 1.5641297068214044e-05
, O 0 4.6394825403694995e-07
as O 0 7.242599053824961e-08
a O 0 3.865571684968927e-08
result O 0 4.8212999814722934e-08
of O 0 1.4525841862678135e-08
linkage O 0 6.586945801245747e-06
analysis O 0 5.586141469393624e-07
had O 0 1.6862057918842766e-06
been O 0 3.121397469385556e-07
predicted O 0 1.0008805020333966e-06
to O 0 1.0586021836900272e-08
carry O 0 1.0518720472418863e-07
the O 0 2.528165623516543e-07
predisposing O 0 0.0003591737768147141
mutation O 0 2.4015882445382886e-05
. O 0 3.9136748455348425e-06

These O 0 1.0254512972096563e-06
observations O 0 1.3570879673352465e-06
point O 0 3.5084775618088315e-07
to O 0 1.184448095159496e-08
another O 0 1.618732525798805e-08
region O 0 2.6370212680149052e-08
of O 0 5.8491678167627015e-09
the O 0 1.0660794913519567e-07
RB1 O 0 0.027831297367811203
gene O 0 4.7443259632018453e-07
where O 0 1.420443851429809e-07
mutations O 0 5.187314968679857e-07
only O 0 4.660704266967741e-09
modify O 0 4.529425154942146e-07
the O 0 1.2022653983478904e-08
function O 0 5.948467496352805e-09
of O 0 3.746946308780252e-09
the O 0 1.3267364984415053e-08
gene O 0 1.5731414748643147e-07
and O 0 1.442364094828008e-07
raise O 0 1.1535220210134867e-06
important O 0 2.426735257188284e-08
questions O 0 9.175082027468306e-08
for O 0 9.742264239775977e-08
genetic O 0 3.7487286590476288e-06
counseling O 0 6.8389281295822e-06
in O 0 1.4309839002635272e-07
families O 0 5.566353706853988e-07
with O 0 4.146774301716505e-07
these O 0 4.2195782157250505e-07
distinctive O 0 4.532990715233609e-05
phenotypes O 0 0.0001754047116264701
. O 0 1.3551672282119398e-06
. O 0 7.642462151125073e-06

Maternal B-Disease 0 0.12908712029457092
disomy I-Disease 1 0.7581729888916016
and O 0 0.010564560070633888
Prader B-Disease 1 0.9999558925628662
- I-Disease 1 0.9999788999557495
Willi I-Disease 1 0.9999948740005493
syndrome I-Disease 1 0.9999645948410034
consistent O 0 1.7448444850742817e-05
with O 0 1.439578795725538e-06
gamete O 0 0.0009506139904260635
complementation O 0 0.3979875147342682
in O 0 5.537106630981725e-07
a O 0 2.395098874785617e-07
case O 0 1.446374199076672e-06
of O 0 4.5746858745587815e-07
familial O 0 0.014192871749401093
translocation O 0 0.0013782030437141657
( O 0 4.4685646116704447e-07
3 O 0 6.268281254051544e-07
; O 0 3.434205382291111e-07
15 O 0 5.245028660283424e-07
) O 0 5.056274687831319e-08
( O 0 2.927257369833569e-08
p25 O 0 3.799973455897998e-06
; O 0 2.590554402104317e-07
q11 O 0 1.3820358617522288e-05
. O 0 3.931159042735999e-08
2 O 0 3.6899234601150965e-07
) O 0 3.529829086801328e-07
. O 0 1.1318412589389482e-06

Maternal B-Disease 1 0.5958176255226135
uniparental I-Disease 1 0.9944485425949097
disomy I-Disease 1 0.9829618334770203
( I-Disease 0 0.0002002779656322673
UPD I-Disease 1 0.998314380645752
) I-Disease 0 1.171975782199297e-06
for I-Disease 0 1.744139410675416e-07
chromosome I-Disease 0 1.229477311426308e-05
15 I-Disease 0 1.735656951495912e-07
is O 0 9.49071399247714e-09
responsible O 0 1.1130430266348412e-07
for O 0 2.8906713467335976e-08
an O 0 3.024674910534486e-08
estimated O 0 1.033468379318947e-06
30 O 0 1.9463382727735734e-07
% O 0 1.7967391130468968e-08
of O 0 2.9526590950013087e-08
cases O 0 5.447652256407309e-06
of O 0 7.126783748390153e-05
Prader B-Disease 1 0.9999920129776001
- I-Disease 1 0.9999946355819702
Willi I-Disease 1 0.9999974966049194
syndrome I-Disease 1 0.9999841451644897
( O 0 0.0006413757218979299
PWS B-Disease 1 0.999620795249939
) O 0 3.405198367545381e-05
. O 0 1.6479842088301666e-05

We O 0 6.433384896809002e-06
report O 0 1.933483872562647e-06
on O 0 2.7418545300861297e-07
an O 0 5.2714806741960274e-08
unusual O 0 2.500449625131296e-07
case O 0 3.2936910088210425e-07
of O 0 1.0999329447258788e-07
maternal B-Disease 0 6.282398680923507e-05
disomy I-Disease 0 0.001267279963940382
15 I-Disease 0 1.4508806316371192e-06
in O 0 5.153833058102464e-07
PWS B-Disease 1 0.9844707250595093
that O 0 1.6877650921287568e-07
is O 0 2.698012302460029e-08
most O 0 1.252427939135714e-08
consistent O 0 4.470520664767719e-08
with O 0 5.942233727296298e-08
adjacent O 0 7.910830959190207e-07
- O 0 0.00017452669271733612
1 O 0 5.575598152063321e-07
segregation O 0 6.662637019871909e-07
of O 0 2.2552367084927027e-08
a O 0 4.037370047171862e-07
paternal O 0 0.00036415894282981753
t O 0 0.010839901864528656
( O 0 1.0855995924430317e-07
3 O 0 2.8748945624101907e-07
; O 0 1.609896287391166e-07
15 O 0 2.0898275465697225e-07
) O 0 2.5976538253758008e-08
( O 0 1.2556402140262435e-08
p25 O 0 2.6338302632211708e-06
; O 0 1.526517650063397e-07
q11 O 0 6.553261755470885e-06
. O 0 6.917421746521768e-09
2 O 0 1.4281122950876579e-08
) O 0 3.0430749031751247e-09
with O 0 3.5492022654182165e-09
simultaneous O 0 1.0043736864417951e-07
maternal O 0 1.4801889847149141e-05
meiotic O 0 0.0007697039982303977
nondisjunction O 0 0.006319147534668446
for O 0 1.580755792929267e-06
chromosome O 0 7.992807513801381e-05
15 O 0 7.429296147165587e-06
. O 0 5.1516544772312045e-06

The O 0 4.1377166780875996e-05
patient O 0 0.0008253200212493539
( O 0 1.7986322973229107e-06
J O 0 0.001856818562373519
. O 0 3.884085799654713e-07
B O 0 1.4468581866822205e-05
. O 0 2.4285037980575908e-08
) O 0 7.53593631941385e-09
, O 0 3.5611096294019262e-09
a O 0 8.321720201820426e-09
17 O 0 3.210132319964032e-07
- O 0 3.140937042189762e-05
year O 0 1.0643133236953872e-06
- O 0 0.0005124762537889183
old O 0 0.00010043509973911569
white O 0 2.831204801623244e-05
male O 0 1.2168292187197949e-06
with O 0 8.611096973254462e-07
PWS B-Disease 1 0.9975582361221313
, O 0 1.3144293689038022e-06
was O 0 8.862280083121732e-07
found O 0 1.5774396899814747e-07
to O 0 8.888635605330819e-09
have O 0 2.729513681742901e-08
47 O 0 5.780055403192819e-07
chromosomes O 0 7.926561806925747e-07
with O 0 9.762874242369435e-08
a O 0 5.312410280566837e-07
supernumerary O 0 0.002033122116699815
, O 0 1.5849974488446605e-06
paternal O 0 5.198621147428639e-05
der O 0 0.006873438134789467
( O 0 7.782455924143505e-08
15 O 0 5.54602266333859e-08
) O 0 3.447335084061365e-09
consisting O 0 7.135915414124838e-09
of O 0 4.54771464930559e-09
the O 0 3.635298284621058e-08
short O 0 5.8299792726757005e-06
arm O 0 0.0004808666417375207
and O 0 2.263796403667584e-07
the O 0 1.3299521128828928e-07
proximal O 0 0.0005588678759522736
long O 0 5.5074771807994694e-05
arm O 0 0.0003132130659651011
of O 0 2.837829242707812e-07
chromosome O 0 3.5170385672245175e-05
15 O 0 1.5541838820354315e-06
, O 0 6.878414069433347e-07
and O 0 3.096119144174736e-06
distal O 0 0.050149980932474136
chromosome O 0 0.06330255419015884
arm O 0 0.311691015958786
3p O 1 0.7269612550735474
. O 0 3.967110751545988e-05

The O 0 3.551494228304364e-05
t O 0 0.036086976528167725
( O 0 4.799875341632287e-07
3 O 0 3.119403402251919e-07
; O 0 1.5666348929244123e-07
15 O 0 2.73242079629199e-07
) O 0 4.163170075344169e-08
was O 0 7.27180591297838e-08
present O 0 1.1009190004074298e-08
in O 0 3.95140942188732e-09
the O 0 8.032312592831659e-09
balanced O 0 4.0972827264340594e-07
state O 0 8.607231904989021e-08
in O 0 6.000662011729219e-08
the O 0 1.193153707390593e-06
patients O 0 0.00038966533611528575
father O 0 6.6488396441855e-06
and O 0 9.879912568067084e-07
a O 0 1.761678163347824e-06
sister O 0 0.00015152838022913784
. O 0 8.271193109976593e-06

Fluorescent O 0 9.663098171586171e-05
in O 0 8.484453246637713e-07
situ O 0 8.774801244726405e-06
hybridization O 0 2.5115989501500735e-06
analysis O 0 4.6148065280249284e-07
demonstrated O 0 3.5972152545582503e-06
that O 0 3.2421134221749526e-08
the O 0 3.265078021286172e-07
PWS B-Disease 1 0.998512327671051
critical O 0 1.1509680007293355e-05
region O 0 1.4444264024859876e-06
resided O 0 2.2425888346333522e-06
on O 0 4.009344678479465e-08
the O 0 2.3019907757770852e-08
derivative O 0 3.19911941915052e-06
chromosome O 0 1.103609065467026e-05
3 O 0 2.2340236682794057e-07
and O 0 1.2191740950129315e-07
that O 0 1.9441245058260392e-08
there O 0 1.0992991406055808e-08
was O 0 3.003084145802859e-07
no O 0 1.8096917742127516e-08
deletion O 0 6.801799372624373e-07
of O 0 4.347746340727099e-08
the O 0 9.168484211841132e-07
PWS B-Disease 1 0.9978565573692322
region O 0 2.451102318445919e-06
on O 0 9.914934651078511e-08
the O 0 1.2726361298120992e-08
normal O 0 1.976643027035152e-08
pair O 0 2.8126663664806983e-07
of O 0 7.034363136426691e-08
15s O 0 8.43036177684553e-05
present O 0 7.731912319286494e-07
in O 0 9.532696481073799e-07
J O 0 0.0023641437292099
. O 0 1.5558429367956705e-05

B O 0 0.013178643770515919
. O 0 0.0004548215656541288

Methylation O 0 3.411146462894976e-05
analysis O 0 1.748997533468355e-06
at O 0 4.996443294658093e-07
exon O 0 4.730104137706803e-06
alpha O 0 1.204755335493246e-07
of O 0 4.012532528463453e-09
the O 0 1.0166623098939453e-08
small O 0 1.3083571559491247e-07
nuclear O 0 7.099705544533208e-05
ribonucleoprotein O 0 0.0019512427970767021
- O 0 0.0006681181839667261
associated O 0 1.7855220448836917e-06
polypeptide O 0 2.9618076951010153e-06
N O 0 9.862311344477348e-06
( O 0 6.731480794996969e-08
SNRPN O 0 6.286281859502196e-05
) O 0 5.172973516209822e-08
gene O 0 8.210682267417724e-08
showed O 0 2.8810782737309637e-07
a O 0 1.897991808164079e-08
pattern O 0 4.901957595393469e-07
characteristic O 0 3.8255575418588705e-07
of O 0 2.351794314847666e-08
only O 0 1.347994604827818e-08
the O 0 1.3971063594908628e-07
maternal O 0 3.823862789431587e-05
chromosome O 0 2.7731648515327834e-05
15 O 0 2.204425300078583e-06
in O 0 1.023922891363327e-06
J O 0 0.003542246064171195
. O 0 1.4125985217106063e-05

B O 0 0.007499911822378635
. O 0 0.00027737539494410157

Maternal B-Disease 0 0.055669140070676804
disomy I-Disease 0 0.174075648188591
was O 0 1.5831401469768025e-05
confirmed O 0 7.479661121578829e-07
by O 0 2.68003024217478e-08
polymerase O 0 2.6159566459682537e-06
chain O 0 1.5344855910370825e-06
reaction O 0 3.071919962849279e-08
analysis O 0 3.971773132604994e-09
of O 0 6.170415733919299e-09
microsatellite O 0 1.6587739082751796e-05
repeats O 0 2.2091509777055762e-07
at O 0 3.133416370815212e-08
the O 0 7.225803511090589e-09
gamma O 0 6.732321367053373e-07
- O 0 7.03729601809755e-05
aminobutyric O 0 0.00034537632018327713
acid O 0 7.527946308982791e-06
receptor O 0 8.878504900167172e-07
beta3 O 0 9.078215043700766e-06
subunit O 0 2.961724021588452e-07
( O 0 1.9106286686110252e-07
GABRB3 O 0 0.0001298192364629358
) O 0 4.564188316180662e-07
locus O 0 1.2622657777683344e-05
. O 0 4.58435670225299e-06

A O 0 9.720435627968982e-05
niece O 0 0.021902693435549736
( O 0 2.3383790903608315e-06
B O 0 2.2797648853156716e-05
. O 0 5.235148492488406e-08
B O 0 3.5686837236426072e-06
. O 0 9.278521950761842e-09
) O 0 2.5685400473207665e-09
with O 0 3.713463980759002e-09
45 O 0 3.476256793533139e-08
chromosomes O 0 1.6257321533430513e-07
and O 0 2.3665668535954865e-08
the O 0 1.3904663198616163e-08
derivative O 0 7.106484076757624e-07
3 O 0 1.4720920660238335e-07
but O 0 2.3693898398846613e-08
without O 0 1.850590791718787e-08
the O 0 3.4474815890916943e-08
der O 0 0.0003146865637972951
( O 0 3.5190861780165505e-08
15 O 0 6.017372555788825e-08
) O 0 2.355183426061558e-08
demonstrated O 0 3.1187670401777723e-07
a O 0 9.455214211584462e-08
phenotype O 0 7.116580945876194e-06
consistent O 0 1.667139883920754e-07
with O 0 1.1304921798682699e-07
that O 0 4.788353891171937e-08
reported O 0 1.5326806988014141e-06
for O 0 2.0217939322719758e-07
haploinsufficiency O 0 0.00023453307221643627
of O 0 2.7507780941959936e-07
distal O 0 0.0007979041547514498
3 O 0 2.6310275643481873e-05
p O 0 0.0005914235953241587
. O 0 6.3003240029502194e-06

Uniparental B-Disease 1 0.9984017014503479
disomy I-Disease 1 0.9978985786437988
associated O 0 0.0010573354084044695
with O 0 6.605824637517799e-06
unbalanced O 0 7.906011887826025e-05
segregation O 0 6.9063762566656806e-06
of O 0 1.1632974405983987e-07
non O 0 8.60050568007864e-06
- O 0 0.0007524623651988804
Robertsonian O 0 0.0027081407606601715
translocations O 0 0.0005361443036235869
has O 0 9.608158961782465e-07
been O 0 3.107710142558062e-07
reported O 0 3.4496074476919603e-06
previously O 0 1.3374824447964784e-06
but O 0 5.815220660565501e-08
has O 0 1.2673173443999985e-07
not O 0 1.3978267432435132e-08
, O 0 1.3561231249070715e-08
to O 0 5.2523585480912516e-09
our O 0 9.55495771393089e-09
knowledge O 0 2.375770691287471e-08
, O 0 4.4773305063472435e-08
been O 0 4.2035924963101934e-08
observed O 0 6.999177770694587e-08
in O 0 1.4043633811411382e-08
a O 0 2.0031544067933282e-07
case O 0 8.004059054655954e-06
of O 0 1.718467137834523e-05
PWS B-Disease 1 0.9991620779037476
. O 0 6.901500455569476e-05

Furthermore O 0 0.00013513585145119578
, O 0 2.178229578930768e-06
our O 0 1.920638226238225e-07
findings O 0 9.222521271112782e-07
are O 0 1.3879650317960568e-08
best O 0 4.4506972329827477e-08
interpreted O 0 7.330697826546384e-08
as O 0 1.4373159551439585e-08
true O 0 8.146786001361761e-08
gamete O 0 2.3552458515041508e-05
complementation O 0 0.011803011409938335
resulting O 0 4.890393392997794e-05
in O 0 3.6120761706115445e-06
maternal B-Disease 0 0.0027586924843490124
UPD I-Disease 1 0.9982512593269348
15 I-Disease 0 8.374537719646469e-05
and O 0 0.00014623133756686002
PWS B-Disease 1 0.995794415473938

Schwartz B-Disease 1 0.7655436396598816
- I-Disease 1 0.9982190728187561
Jampel I-Disease 1 0.9996040463447571
syndrome I-Disease 1 0.9997840523719788
type I-Disease 0 2.9993801945238374e-05
2 I-Disease 0 2.13341559174296e-06
and O 0 5.899989901081426e-06
Stuve B-Disease 1 0.7168334722518921
- I-Disease 1 0.9993886947631836
Wiedemann I-Disease 1 0.9999716281890869
syndrome I-Disease 1 0.9973601698875427
: O 0 2.1099032210258883e-07
a O 0 2.7086193199465924e-07
case O 0 1.5904455494819558e-06
for O 0 1.988762079463413e-07
" O 0 2.9083696517773205e-07
lumping O 0 8.528393664164469e-05
" O 0 1.176834302896168e-06
. O 0 2.3666427750868024e-06

Recent O 0 0.00011608526983764023
studies O 0 1.954701292561367e-05
demonstrated O 0 9.253672033082694e-06
the O 0 4.10037763742821e-08
existence O 0 6.020816556429054e-08
of O 0 1.590541920393207e-08
a O 0 1.9268870232735935e-07
genetically O 0 7.3819637691485696e-06
distinct O 0 2.008780768392171e-07
, O 0 2.3692052764090477e-07
usually O 0 5.064662644826967e-08
lethal O 0 9.135248433267407e-07
form O 0 2.763711748343667e-08
of O 0 1.878890998341376e-08
the O 0 7.433814630530833e-07
Schwartz B-Disease 0 0.0923878625035286
- I-Disease 1 0.9996844530105591
Jampel I-Disease 1 0.9999465942382812
syndrome I-Disease 1 0.9998487234115601
( O 0 1.0513087545405142e-05
SJS B-Disease 1 0.9168010950088501
) O 0 4.955291501573811e-07
of O 0 1.1457564141892362e-06
myotonia B-Disease 1 0.9927404522895813
and O 0 0.0025668812450021505
skeletal B-Disease 1 0.9985564351081848
dysplasia I-Disease 1 0.9997813105583191
, O 0 8.69839914230397e-06
which O 0 2.8442721600185905e-07
we O 0 1.6657476464843057e-07
called O 0 5.948906618868932e-06
SJS B-Disease 0 0.34774598479270935
type I-Disease 0 7.743757123535033e-06
2 I-Disease 0 4.6038790060265455e-06
. O 0 3.7639351830875967e-06

This O 0 0.00010729368659667671
disorder O 1 0.7572062611579895
is O 0 1.002591488941107e-06
reminiscent O 0 1.5510373486904427e-05
of O 0 2.547712369960209e-07
another O 0 7.965284567035269e-06
rare O 0 0.0002463389828335494
condition O 0 2.8280319384066388e-05
, O 0 1.7845437128016783e-07
the O 0 1.048396370606497e-06
Stuve B-Disease 1 0.9368327260017395
- I-Disease 1 0.9999513626098633
Wiedemann I-Disease 1 0.9999891519546509
syndrome I-Disease 1 0.9998804330825806
( O 0 4.142792022321373e-06
SWS B-Disease 0 0.042869988828897476
) O 0 1.580268786938177e-07
, O 0 3.711150498020288e-08
which O 0 7.318261996402953e-09
comprises O 0 2.0578595183451398e-07
campomelia B-Disease 0 0.0003346136654727161
at O 0 1.4660315628134413e-06
birth O 0 1.5910274669295177e-05
with O 0 4.839665780309588e-05
skeletal B-Disease 1 0.9983175992965698
dysplasia I-Disease 1 0.9997908473014832
, O 0 0.00012782584235537797
contractures B-Disease 1 0.9852356910705566
, O 0 4.823958079214208e-06
and O 0 1.2226652188473963e-06
early B-Disease 0 3.175713118253043e-06
death I-Disease 0 5.346286707208492e-05
. O 0 9.154991857940331e-06

To O 0 1.6938616909101256e-06
test O 0 1.3349427945286152e-06
for O 0 4.960918076335474e-08
possible O 0 2.707684245706332e-07
nosologic O 0 0.00021461436699610204
identity O 0 1.0181660172747797e-06
between O 0 5.955928941148159e-07
these O 0 1.5539570767941768e-06
disorders O 0 0.3698468506336212
, O 0 5.167657946003601e-07
we O 0 2.1330498256588726e-08
reviewed O 0 4.871261012340256e-07
the O 0 9.635704678601087e-09
literature O 0 3.0953458463045536e-08
and O 0 3.2119537252128794e-08
obtained O 0 4.6560241884208153e-08
a O 0 9.755686036783118e-09
follow O 0 1.2828304640777333e-08
- O 0 5.752796369051794e-06
up O 0 6.067597979608763e-08
of O 0 4.879311177319323e-09
the O 0 7.95231080985559e-09
only O 0 3.353894717506023e-09
two O 0 1.423693305468987e-07
surviving O 0 0.0014135747915133834
patients O 0 0.00010295317770214751
, O 0 1.1814251621444782e-07
one O 0 4.074898640737956e-08
with O 0 9.120510640059365e-07
SJS B-Disease 1 0.5216347575187683
type I-Disease 0 7.176476515269314e-07
2 I-Disease 0 1.4652317759100697e-07
at O 0 2.2305495406271802e-07
age O 0 4.0853277027963486e-07
10 O 0 8.441219989663296e-08
years O 0 1.7404390462161246e-07
and O 0 2.3404638227475516e-08
another O 0 3.8863085194407176e-08
with O 0 3.5068651982328447e-07
SWS B-Disease 0 0.002398370997980237
at O 0 1.4693670209453558e-06
age O 0 1.4932036265236093e-06
7 O 0 1.548322529743018e-06
years O 0 2.634852762639639e-06
. O 0 2.345031816730625e-06

Patients O 1 0.5240926742553711
reported O 0 0.0002571588847786188
as O 0 1.1649510724964784e-06
having O 0 2.928882395281107e-06
either O 0 3.1003858111944282e-06
neonatal O 1 0.9758742451667786
SJS B-Disease 1 0.9987340569496155
or O 0 3.273924085078761e-05
SWS B-Disease 0 0.026606902480125427
presented O 0 2.9374755285971332e-06
a O 0 1.3307831636666378e-07
combination O 0 5.425014251159155e-07
of O 0 8.518970417981109e-08
a O 0 6.597917035833234e-06
severe O 0 0.00880107469856739
, O 0 1.361620979878353e-05
prenatal O 0 0.023276399821043015
- O 1 0.9976412057876587
onset O 1 0.9996589422225952
neuromuscular B-Disease 1 0.9999873638153076
disorder I-Disease 1 0.9995150566101074
( O 0 7.839361933292821e-05
with O 0 0.07974610477685928
congenital B-Disease 1 0.9999934434890747
joint I-Disease 1 0.9914625287055969
contractures I-Disease 1 0.999990701675415
, O 0 0.28061771392822266
respiratory O 1 0.9137367010116577
and O 0 1.4652985555585474e-05
feeding O 0 0.0002966347965411842
difficulties O 0 0.0009945560013875365
, O 0 1.1085393225584994e-06
tendency O 0 5.735912509408081e-06
to O 0 3.9018991060402186e-07
hyperthermia B-Disease 0 0.4757479727268219
, O 0 9.620995342629612e-07
and O 0 6.987212941567122e-07
frequent O 0 2.584010871942155e-06
death O 0 8.278074346890207e-06
in O 0 2.46520045266152e-07
infancy O 0 1.5152136256801896e-05
) O 0 2.794753939383554e-08
with O 0 2.9641419985182438e-08
a O 0 1.5364580008281337e-07
distinct O 0 1.250743594027881e-06
campomelic B-Disease 0 0.14314840734004974
- I-Disease 1 0.9639642834663391
metaphyseal I-Disease 1 0.9971408843994141
skeletal I-Disease 1 0.9970436692237854
dysplasia I-Disease 1 0.9972001314163208
. O 0 6.442795711336657e-05

The O 0 3.1485249110119184e-06
similarity O 0 2.5490642201475566e-06
of O 0 1.1954574574701837e-07
the O 0 2.0266782030375907e-07
clinical O 0 1.3670034604729153e-05
and O 0 1.5499196024393314e-06
radiographic O 0 0.058758411556482315
findings O 0 2.2326647012960166e-05
is O 0 1.0347390855258709e-07
so O 0 3.5774910145391914e-08
extensive O 0 8.726613600629207e-07
that O 0 2.4538456955269794e-07
these O 0 2.7079008759756107e-06
disorders O 0 0.48513755202293396
appear O 0 5.425472409115173e-06
to O 0 6.357648629773394e-08
be O 0 1.934750848420208e-08
a O 0 5.727641649855286e-08
single O 0 6.459294468186272e-07
entity O 0 1.3155682609067298e-05
. O 0 6.4682349147915374e-06

The O 0 1.8404131196803064e-06
follow O 0 6.131877512416395e-07
- O 0 2.506810415070504e-05
up O 0 1.6115613732381462e-07
observation O 0 1.0272723471871359e-07
of O 0 8.438415299849567e-09
an O 0 1.6993737972370582e-08
identical O 0 4.5619734123647504e-07
and O 0 1.229458206353229e-07
unique O 0 9.65069872904678e-08
pattern O 0 1.7859035779110854e-06
of O 0 4.273107606422855e-06
progressive O 1 0.9924846291542053
bone B-Disease 1 0.9999626874923706
dysplasia I-Disease 1 0.9991310238838196
in O 0 8.456261184619507e-07
the O 0 4.653086023154174e-07
two O 0 8.701120350451674e-06
patients O 0 0.0005338403861969709
( O 0 1.414494761320384e-07
one O 0 6.30056149475422e-08
with O 0 2.668040224307333e-06
SJS B-Disease 1 0.9723016023635864
type I-Disease 0 5.616619091597386e-06
2 I-Disease 0 3.4484884281482664e-07
, O 0 6.007372377325737e-08
one O 0 1.870420440752696e-08
with O 0 4.908244477519474e-07
SWS B-Disease 0 0.016519885510206223
) O 0 2.610354385979008e-07
surviving O 0 8.360848369193263e-06
beyond O 0 7.556174637102231e-07
infancy O 0 1.1432925930421334e-05
adds O 0 1.1579672900552396e-06
to O 0 8.426336961520065e-09
the O 0 7.2126673522632245e-09
evidence O 0 7.136571866794839e-08
in O 0 1.3093802486707773e-08
favor O 0 2.1831054652921011e-07
of O 0 6.704981103666796e-08
identity O 0 4.870006250712322e-06
. O 0 3.7196446101006586e-06

The O 0 4.589977834257297e-06
hypothesis O 0 1.3361322999116965e-05
that O 0 4.3838946339747054e-07
SWS B-Disease 0 0.0033549342770129442
and O 0 1.2121362487960141e-05
SJS B-Disease 1 0.9700062274932861
type I-Disease 0 4.427187377586961e-06
2 I-Disease 0 3.5613769000519824e-07
are O 0 2.2588357850850116e-08
the O 0 8.910112825333272e-08
same O 0 1.8179274547946989e-06
disorder O 0 0.0033821158576756716
should O 0 3.323463815263494e-08
be O 0 4.8134598529259165e-09
testable O 0 1.1625699158912539e-07
by O 0 3.712899143692994e-08
molecular O 0 1.1759659628296504e-06
methods O 0 2.506480427655333e-07
. O 0 3.5620564631244633e-07
. O 0 1.6734347809688188e-06

A O 0 4.0670835005585104e-05
mouse O 0 0.00014655754785053432
model O 0 2.157687231374439e-05
of O 0 7.41211770218797e-05
severe O 1 0.9982239603996277
von B-Disease 1 0.9999953508377075
Willebrand I-Disease 1 0.9999953508377075
disease I-Disease 1 0.9999791383743286
: O 0 0.002154833637177944
defects O 1 0.9984489679336548
in O 0 6.70236986479722e-05
hemostasis O 1 0.9966337084770203
and O 0 0.025433847680687904
thrombosis B-Disease 1 0.9997077584266663
. O 0 0.00018844548321794719

von B-Disease 1 0.9974683523178101
Willebrand I-Disease 1 0.9982646107673645
factor I-Disease 0 0.004720490425825119
( I-Disease 0 0.00012843709555454552
vWf I-Disease 1 0.6610234379768372
) I-Disease 0 0.003804526524618268
deficiency I-Disease 1 0.9995290040969849
causes O 1 0.7459308505058289
severe O 1 0.999640703201294
von B-Disease 1 0.9999959468841553
Willebrand I-Disease 1 0.9999921321868896
disease I-Disease 1 0.9999152421951294
in O 0 3.654559623100795e-05
humans O 0 4.970216104993597e-05
. O 0 1.5655996321584098e-05

We O 0 1.3623864560941001e-06
generated O 0 6.818620477133663e-07
a O 0 1.9185750943506719e-07
mouse O 0 3.566482291716966e-06
model O 0 4.108892426302191e-07
for O 0 8.718031807575244e-08
this O 0 6.072646385746339e-08
disease O 0 7.674313565075863e-06
by O 0 1.7130124874142894e-08
using O 0 1.3945889065780648e-07
gene O 0 9.123407380684512e-07
targeting O 0 9.187773684971035e-06
. O 0 4.630059720511781e-06

vWf B-Disease 0 0.3584924638271332
- I-Disease 1 0.894851565361023
deficient I-Disease 1 0.8055945038795471
mice O 0 0.0006170221022330225
appeared O 0 4.714459464594256e-06
normal O 0 1.9788996041825158e-07
at O 0 1.9138018103603827e-07
birth O 0 1.2802513538190397e-06
; O 0 8.634033576981892e-08
they O 0 2.003405974448924e-08
were O 0 6.868765467515914e-08
viable O 0 1.5657268477298203e-06
and O 0 1.3866348353985813e-06
fertile O 0 6.097243749536574e-05
. O 0 9.34558738663327e-06

Neither O 0 0.0009553399868309498
vWf O 0 0.0177841205149889
nor O 0 0.0003790691262111068
vWf O 0 0.005888053681701422
propolypeptide O 0 0.017866767942905426
( O 0 1.460145904275123e-05
von B-Disease 1 0.8984535932540894
Willebrand I-Disease 1 0.9975506663322449
antigen O 0 0.11955317854881287
II O 0 0.0033921136055141687
) O 0 2.1556188301019574e-07
were O 0 4.377251983100905e-08
detectable O 0 4.3711114017241925e-07
in O 0 5.0468105250445205e-09
plasma O 0 3.0980979772721184e-06
, O 0 3.852617851407558e-07
platelets O 0 0.0002969822962768376
, O 0 1.6972933281067526e-07
or O 0 7.128707579795446e-07
endothelial O 0 0.004706537816673517
cells O 0 9.648008472140646e-07
of O 0 1.7055986845093685e-08
the O 0 1.7976927324525604e-07
homozygous O 0 6.300715176621452e-05
mutant O 0 0.00029348782845772803
mice O 0 0.00023195806716103107
. O 0 4.5249062168295495e-06

The O 0 1.574005545990076e-05
mutant O 0 0.002018233062699437
mice O 0 0.010628045536577702
exhibited O 0 0.013127397745847702
defects O 1 0.9556276798248291
in O 0 1.7070198055080255e-06
hemostasis O 0 0.10592856258153915
with O 0 2.4428045435342938e-06
a O 0 4.4534672269946896e-06
highly O 0 0.0005021945107728243
prolonged O 1 0.8266748785972595
bleeding O 1 0.9748311042785645
time O 0 5.012918791180709e-07
and O 0 1.5111911579879234e-06
spontaneous O 0 7.606815779581666e-05
bleeding O 0 0.07539623230695724
events O 0 5.125496826963172e-08
in O 0 9.726997873826804e-09
approximately O 0 4.743864323586422e-08
10 O 0 2.01406152200434e-07
% O 0 2.6239047201670473e-07
of O 0 9.373241027788026e-07
neonates O 0 0.006969934795051813
. O 0 1.090607293008361e-05

As O 0 4.22964467361453e-06
in O 0 4.2560162683003e-07
the O 0 5.043320356890035e-07
human O 0 2.3879563741502352e-05
disease O 0 0.0007412031409330666
, O 0 1.5691573196363606e-07
the O 0 7.823815906249365e-08
factor O 0 1.6430517462140415e-06
VIII O 0 0.0002918813843280077
level O 0 6.050564138604386e-07
in O 0 3.0442958376397655e-08
these O 0 2.1725332643995898e-08
mice O 0 5.531656825041864e-06
was O 0 4.280063308215176e-07
reduced O 0 9.617482419344014e-07
strongly O 0 3.248167388392176e-07
as O 0 1.616295186579464e-08
a O 0 2.8687013653438953e-08
result O 0 6.379756456453833e-08
of O 0 2.3422501271852525e-08
the O 0 1.0274506934138117e-07
lack O 0 3.8994215856291703e-07
of O 0 6.84214356283519e-08
protection O 0 8.90122555574635e-06
provided O 0 1.15291709334997e-06
by O 0 4.054636065120576e-06
vWf O 0 0.0019932209979742765
. O 0 6.223717718967237e-06

Defective O 1 0.9951700568199158
thrombosis B-Disease 1 0.9991543292999268
in O 0 2.1498186470125802e-05
mutant O 0 0.0012226529652252793
mice O 0 0.0005224531050771475
was O 0 3.158208301101695e-06
also O 0 1.6517873291377327e-07
evident O 0 4.963558808412927e-07
in O 0 8.980470589392553e-09
an O 0 1.0393195637448116e-08
in O 0 4.816189402845339e-08
vivo O 0 2.0785091692232527e-05
model O 0 4.859697583015077e-06
of O 0 5.951326238573529e-05
vascular B-Disease 1 0.9998217225074768
injury I-Disease 1 0.8081585168838501
. O 0 5.162552042747848e-05

In O 0 1.8334512787987478e-06
this O 0 5.2075229461934214e-08
model O 0 2.726548586906574e-07
, O 0 4.4279541810965384e-08
the O 0 4.456303770439263e-08
exteriorized O 0 0.00032713112886995077
mesentery O 0 0.000746235076803714
was O 0 1.1448639725131216e-06
superfused O 0 6.028448842698708e-05
with O 0 1.0924151183644426e-06
ferric O 0 0.007245607674121857
chloride O 0 8.200387128454167e-06
and O 0 3.3381390096565156e-08
the O 0 7.310351879397103e-09
accumulation O 0 8.45478552946588e-07
of O 0 8.334351520034033e-08
fluorescently O 0 0.06667422503232956
labeled O 0 0.0005755424499511719
platelets O 0 0.0026831335853785276
was O 0 8.153421049428289e-07
observed O 0 1.5040568257518316e-07
by O 0 1.0828450314193105e-07
intravital O 0 0.00014193699462339282
microscopy O 0 1.1065410035371315e-05
. O 0 4.418911430548178e-06

We O 0 3.374511607034947e-06
conclude O 0 8.683364285388961e-06
that O 0 8.802158646403768e-08
these O 0 2.1727652566028155e-08
mice O 0 2.8139188543718774e-06
very O 0 4.212662219060803e-08
closely O 0 3.5149655559507664e-06
mimic O 0 0.007315260358154774
severe O 0 0.3637809455394745
human O 0 0.004668402951210737
von B-Disease 1 0.9999978542327881
Willebrand I-Disease 1 0.9999970197677612
disease I-Disease 1 0.9998581409454346
and O 0 6.522081093862653e-06
will O 0 3.4299046092201024e-07
be O 0 3.020212702153913e-08
very O 0 8.817731433907738e-09
useful O 0 1.1898734442183923e-08
for O 0 1.3187187342111883e-08
investigating O 0 1.8801690657710424e-06
the O 0 2.5310987084026237e-08
role O 0 6.241808137019689e-08
of O 0 1.6333089547515556e-08
vWf O 0 2.5112463845289312e-05
in O 0 3.568787931840234e-08
normal O 0 1.1065741745142077e-07
physiology O 0 3.870921318593901e-06
and O 0 6.4057525150929e-07
in O 0 2.5910435397236142e-06
disease O 0 0.00035232031950727105
models O 0 9.817465070227627e-06
. O 0 1.1256934158154763e-06
. O 0 4.9582017709326465e-06

Oral O 0 0.001972382888197899
contraceptives O 0 0.006913868710398674
and O 0 5.855416475242237e-06
the O 0 4.264237304596463e-06
risk O 0 0.0014094816287979484
of O 0 0.0007942413212731481
hereditary B-Disease 1 0.9999302625656128
ovarian I-Disease 1 0.9999972581863403
cancer I-Disease 1 0.9999021291732788
. O 0 0.000484507909277454

Hereditary B-Disease 1 0.9997239708900452
Ovarian I-Disease 1 0.9999688863754272
Cancer I-Disease 1 0.9997788071632385
Clinical O 0 0.12907403707504272
Study O 0 0.00017801241483539343
Group O 0 0.0002071768685709685
. O 0 2.0683099137386307e-05

BACKGROUND O 0 0.00019145339319948107
Women O 0 2.4243530788226053e-05
with O 0 2.1942735202173935e-06
mutations O 0 1.0687606845749542e-05
in O 0 3.765446265902028e-08
either O 0 4.711393586376289e-08
the O 0 7.8881726039981e-08
BRCA1 O 0 3.5329623642610386e-05
or O 0 1.3222731354289863e-07
the O 0 1.3798540976495133e-07
BRCA2 O 0 0.00010146947170142084
gene O 0 3.9273302832043555e-07
have O 0 2.336467552765953e-08
a O 0 1.146265233842314e-07
high O 0 4.9502457841299474e-05
lifetime O 0 0.0007696754182688892
risk O 0 0.006418860051780939
of O 0 0.006302026100456715
ovarian B-Disease 1 0.9999908208847046
cancer I-Disease 1 0.9997249245643616
. O 0 0.00012821867130696774

Oral O 0 0.0075756567530334
contraceptives O 1 0.6841782927513123
protect O 0 0.41152557730674744
against O 1 0.9927334785461426
ovarian B-Disease 1 0.9999984502792358
cancer I-Disease 1 0.9999315738677979
in O 0 1.9677072486956604e-06
general O 0 5.18327306053834e-06
, O 0 7.116819915609085e-07
but O 0 7.37559275876265e-08
it O 0 4.9131734236596e-09
is O 0 8.858086708585233e-09
not O 0 1.1384297060601511e-08
known O 0 2.0313297000029706e-07
whether O 0 7.445245131521006e-08
they O 0 4.847690249221159e-08
also O 0 2.6065308134093357e-07
protect O 0 4.817145054403227e-06
against O 0 9.360196600027848e-06
hereditary B-Disease 0 0.01634940691292286
forms I-Disease 0 0.00015859687118791044
of I-Disease 0 0.11423313617706299
ovarian I-Disease 1 0.9999945163726807
cancer I-Disease 1 0.9998563528060913
. O 0 0.0001987634605029598

METHODS O 0 2.430074891890399e-05
We O 0 7.506988595196162e-07
enrolled O 0 1.1602351150941104e-05
207 O 0 4.275399260222912e-05
women O 0 1.6872636479092762e-05
with O 0 0.00046072073746472597
hereditary B-Disease 1 0.9999803304672241
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999593496322632
and O 0 3.882896180584794e-06
161 O 0 1.2173296454420779e-05
of O 0 1.632848523058783e-07
their O 0 2.1470879119078745e-07
sisters O 0 4.2660308281483594e-06
as O 0 1.8520314171155405e-08
controls O 0 5.741631170508299e-08
in O 0 7.047010974758905e-09
a O 0 3.9754883829346e-08
case O 0 2.118580596288666e-06
- O 0 0.0009653221350163221
control O 0 6.215550001797965e-06
study O 0 3.3520532269903924e-06
. O 0 2.4931850930443034e-06

All O 0 2.2260705918597523e-06
the O 0 2.8518873023131164e-06
patients O 0 3.87381951441057e-05
carried O 0 3.3116913300546e-07
a O 0 2.1551748830006545e-07
pathogenic O 0 6.345525434880983e-06
mutation O 0 1.2709170960079064e-06
in O 0 4.091666738759159e-08
either O 0 5.018544015911175e-07
BRCA1 O 0 0.00015088992950040847
( O 0 2.7822133574773034e-07
179 O 0 5.465557842398994e-05
women O 0 9.787719136511441e-06
) O 0 1.761510759479279e-07
or O 0 4.040205112687545e-07
BRCA2 O 0 0.00016321784642059356
( O 0 2.4977634893730283e-07
28 O 0 5.083702944830293e-06
women O 0 3.634006134234369e-06
) O 0 5.397868676482176e-07
. O 0 1.756383881001966e-06

The O 0 4.976891432306729e-06
control O 0 1.047899331751978e-05
women O 0 3.053188947887975e-06
were O 0 3.516513515933184e-07
enrolled O 0 2.465344323354657e-06
regardless O 0 1.708345820361501e-07
of O 0 2.5424498062420753e-08
whether O 0 2.8851474098701146e-07
or O 0 9.493252406400643e-08
not O 0 1.521714665386753e-08
they O 0 2.74085518725542e-08
had O 0 2.2958745660162094e-07
either O 0 4.956492034580151e-07
mutation O 0 9.0281646407675e-06
. O 0 3.779488679356291e-06

Lifetime O 0 0.00043886207276955247
histories O 0 6.217078771442175e-05
of O 0 1.9354688447492663e-06
oral O 0 9.316173236584291e-05
- O 0 0.024420760571956635
contraceptive O 0 0.0008260072208940983
use O 0 1.4354945676586794e-07
were O 0 4.2286014689807416e-08
obtained O 0 4.8677684105769004e-08
by O 0 2.9974696502677034e-08
interview O 0 7.139334456951474e-07
or O 0 1.6736880326106984e-08
by O 0 1.694360385329219e-08
written O 0 1.7489588444163928e-08
questionnaire O 0 7.784658464515815e-07
and O 0 7.507261301498147e-08
were O 0 9.43316535995109e-08
compared O 0 1.066969957719266e-06
between O 0 6.269991672525066e-07
patients O 0 2.812561251630541e-05
and O 0 3.371258685547218e-07
control O 0 8.327629075211007e-07
women O 0 6.875777671666583e-07
, O 0 7.414380576165058e-08
after O 0 5.638696620735573e-07
adjustment O 0 7.34881950847921e-07
for O 0 3.6690828153496113e-08
year O 0 2.0774518816324417e-07
of O 0 4.318027890803933e-08
birth O 0 5.077510650153272e-06
and O 0 1.3710591701965313e-06
parity O 0 4.21914883190766e-05
. O 0 7.211856882349821e-06

RESULTS O 0 3.2780200854176655e-05
The O 0 1.0343636631660047e-06
adjusted O 0 5.509479160537012e-05
odds O 0 0.0003403983428142965
ratio O 0 4.692038055509329e-05
for O 0 0.004646435379981995
ovarian B-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999747276306152
associated O 0 7.892905159678776e-06
with O 0 2.7954848746958305e-07
any O 0 1.951506511943535e-08
past O 0 8.799556638905415e-08
use O 0 2.921796138366517e-08
of O 0 1.0784444270939275e-07
oral O 0 4.341929161455482e-05
contraceptives O 0 0.0008195200935006142
was O 0 3.4438353395671584e-06
0 O 0 5.662878265866311e-06
. O 0 2.903325139413937e-06

5 O 0 2.037163358181715e-05
( O 0 9.638076789997285e-07
95 O 0 7.395200327664497e-07
percent O 0 8.256629371317104e-06
confidence O 0 1.203462829835189e-06
interval O 0 1.7265901419705187e-07
, O 0 2.418427236250409e-08
0 O 0 3.1568959002470365e-08
. O 0 2.9117863675764966e-09
3 O 0 1.1366289243142091e-08
to O 0 4.616538262780523e-09
0 O 0 9.31141173055039e-08
. O 0 2.1793397309011198e-08
8 O 0 4.006462859251769e-07
) O 0 3.481668784388603e-07
. O 0 1.2880340136689483e-06

The O 0 3.141886554658413e-05
risk O 0 0.0007400135509669781
decreased O 0 2.5813116735662334e-05
with O 0 1.8577900107175083e-07
increasing O 0 5.672108613907767e-07
duration O 0 3.4450764019311464e-07
of O 0 1.8775082821775868e-08
use O 0 5.4805944671443285e-08
( O 0 6.188002288354255e-08
P O 0 9.143143870460335e-06
for O 0 5.981099349128272e-08
trend O 0 8.967240887614025e-07
, O 0 5.7720356494428415e-08
< O 0 8.489431024827354e-07
0 O 0 1.6051009765760682e-07
. O 0 1.0344504808301735e-08
001 O 0 4.130885372433113e-06
) O 0 1.2087265410798409e-08
; O 0 5.920713253004806e-09
use O 0 2.0505388498293087e-09
for O 0 2.723115954950117e-09
six O 0 2.887927053052408e-08
or O 0 1.5828579336130133e-08
more O 0 1.1588478621149534e-08
years O 0 4.816621412828681e-07
was O 0 7.64383003115654e-07
associated O 0 8.940584450556344e-08
with O 0 6.778983152599949e-09
a O 0 6.43963673496728e-08
60 O 0 6.767022000531142e-07
percent O 0 8.702448212716263e-06
reduction O 0 2.514251355023589e-05
in O 0 1.8043069758277852e-06
risk O 0 0.00011470761091914028
. O 0 9.223733286489733e-06

Oral O 0 0.0008142001461237669
- O 0 0.00995318777859211
contraceptive O 0 0.0032245279289782047
use O 0 1.0235557965643238e-05
protected O 0 0.002013445133343339
against O 1 0.5731098055839539
ovarian B-Disease 1 0.9999986886978149
cancer I-Disease 1 0.999656081199646
both O 0 3.5879673987437855e-07
for O 0 3.2939928473751934e-07
carriers O 0 6.015483904775465e-06
of O 0 3.3090298501292637e-08
the O 0 4.018831134544598e-07
BRCA1 O 0 0.00036720657953992486
mutation O 0 4.7451949285459705e-06
( O 0 1.468177543983984e-07
odds O 0 1.989436350413598e-05
ratio O 0 4.5449115759765846e-07
, O 0 5.95211417930841e-08
0 O 0 8.692958886058477e-08
. O 0 7.423971659648032e-09
5 O 0 2.024467526950957e-08
; O 0 2.2034356561562163e-08
95 O 0 7.678272595512681e-08
percent O 0 7.966370390022348e-07
confidence O 0 2.425645959647227e-07
interval O 0 4.979622403311623e-08
, O 0 1.0882175160986662e-08
0 O 0 1.7051757339459073e-08
. O 0 1.780414593532953e-09
3 O 0 9.184848437371329e-09
to O 0 2.9857993855131326e-09
0 O 0 3.5438738166249095e-08
. O 0 4.625819727266389e-09
9 O 0 3.731770448212046e-08
) O 0 4.889400440077907e-09
and O 0 6.115790984750902e-09
for O 0 7.74228503530594e-09
carriers O 0 6.321758974081604e-07
of O 0 1.1761769336260386e-08
the O 0 2.0299702896409144e-07
BRCA2 O 0 0.00034494290594011545
mutation O 0 2.4791252144495957e-06
( O 0 9.52551957311698e-08
odds O 0 1.529617657070048e-05
ratio O 0 2.369684324321497e-07
, O 0 2.994367065412007e-08
0 O 0 8.295575071315398e-08
. O 0 3.174005058781404e-09
4 O 0 2.1261609361999945e-08
; O 0 1.5174190792777154e-08
95 O 0 6.262712304305751e-08
percent O 0 8.072714763329714e-07
confidence O 0 2.6961043886331026e-07
interval O 0 3.4938452131427766e-08
, O 0 9.3385326138673e-09
0 O 0 2.9623841157899733e-08
. O 0 3.3061700044356712e-09
2 O 0 1.5381697693328533e-08
to O 0 4.301322409361319e-09
1 O 0 1.8656708178355075e-08
. O 0 1.0204914246969565e-08
1 O 0 8.740992285538596e-08
) O 0 1.206469590897541e-07
. O 0 4.758340992339072e-07

CONCLUSIONS O 0 0.0002724703517742455
Oral O 0 0.00035692568053491414
- O 0 0.02330278977751732
contraceptive O 0 0.0037792029324918985
use O 0 2.1361192921176553e-06
may O 0 1.6731444247852778e-06
reduce O 0 2.8356532766338205e-06
the O 0 4.812411020793661e-07
risk O 0 0.0003645796386990696
of O 0 0.0016060146735981107
ovarian B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9997958540916443
in O 0 1.104650436900556e-06
women O 0 3.66114909411408e-06
with O 0 8.030061735553318e-07
pathogenic O 0 2.2254520445130765e-05
mutations O 0 1.9205169792257948e-06
in O 0 6.624641457619873e-08
the O 0 8.158119726431323e-07
BRCA1 O 0 0.0003670598962344229
or O 0 1.887160397018306e-05
BRCA2 O 0 0.0023692958056926727
gene O 0 7.58237365516834e-05

A O 0 5.308328036335297e-05
Japanese O 0 0.00018989169620908797
family O 0 3.7304984289221466e-05
with O 0 5.461348337121308e-06
adrenoleukodystrophy B-Disease 1 0.9996893405914307
with O 0 9.371390774504107e-07
a O 0 1.0806476069546989e-07
codon O 0 1.1123920558020473e-06
291 O 0 9.315014722233173e-06
deletion O 0 1.1094171895820182e-05
: O 0 1.3697284373392904e-07
a O 0 2.3050317565775913e-07
clinical O 0 1.144554880738724e-05
, O 0 8.95324376415374e-07
biochemical O 0 8.592498488724232e-05
, O 0 9.011855013341119e-07
pathological O 0 8.024120324989781e-05
, O 0 6.697133017041779e-07
and O 0 2.4466557988489512e-06
genetic O 0 5.524631342268549e-05
report O 0 1.1627971616690047e-05
. O 0 4.6048844524193555e-06

We O 0 3.742352419067174e-06
report O 0 1.1060187716793735e-06
a O 0 2.5005709858305636e-07
Japanese O 0 1.2219098607602064e-05
family O 0 2.0903864424326457e-05
with O 0 6.840394780738279e-05
adrenoleukodystrophy B-Disease 1 0.9999901056289673
( O 0 0.0008628124487586319
ALD B-Disease 1 0.9999850988388062
) O 0 9.522211144030734e-07
with O 0 8.426854236631698e-08
a O 0 3.468911913273587e-08
three O 0 4.835989741991398e-08
base O 0 1.209348852171388e-06
pair O 0 5.084832537249895e-06
deletion O 0 1.1053016351070255e-05
( O 0 1.5418626730934193e-07
delGAG O 0 2.561410110502038e-05
291 O 0 1.1792580153269228e-05
) O 0 5.4627378176519414e-08
in O 0 3.1424839619376144e-08
the O 0 1.7920781374414219e-06
ALD B-Disease 1 0.9996421337127686
gene O 0 4.428478132467717e-05
. O 0 8.163931852323003e-06

A O 0 1.911629988171626e-05
variety O 0 2.3373422664008103e-06
of O 0 6.475738132394326e-07
phenotypes O 0 0.0001336113637080416
were O 0 5.35311642124725e-07
observed O 0 3.41716827279015e-07
within O 0 2.1717088571904242e-08
this O 0 5.0231310666504214e-08
family O 0 9.241201951226685e-06
. O 0 5.210734798311023e-06

While O 0 2.285879963892512e-05
the O 0 2.72121769739897e-06
proband O 0 0.0370844304561615
( O 0 3.0637127110821893e-06
patient O 0 2.809071338560898e-05
1 O 0 5.58089141122764e-07
) O 0 8.079672397798277e-08
was O 0 3.2137867833625933e-07
classified O 0 1.999567302846117e-06
as O 0 1.3790608477393107e-07
having O 0 5.316353508533211e-07
a O 0 1.1350650908070747e-07
rare O 0 1.228563178301556e-06
intermediate O 0 9.632159390093875e-07
type O 0 4.7593351837349473e-07
of O 0 1.3112737917708728e-07
adult O 0 3.6342218663776293e-05
cerebral O 0 0.14757511019706726
and O 0 5.9004851209465414e-06
cerebello O 1 0.5104721188545227
- O 1 0.9009954333305359
brain O 0 0.3183797001838684
stem O 0 0.00015370009350590408
forms O 0 8.282182193397603e-07
, O 0 5.957003281764628e-07
his O 0 2.589119276308338e-06
younger O 0 5.442891051643528e-05
brother O 0 0.00011950737098231912
( O 0 4.711600070095301e-07
patient O 0 5.665422577294521e-06
2 O 0 3.7859425106034905e-07
) O 0 1.2954471628745523e-07
and O 0 3.3150504918921797e-07
nephew O 0 0.0021791551262140274
( O 0 5.439748065327876e-07
patient O 0 7.110326350812102e-06
3 O 0 6.047719693924591e-07
) O 0 1.5572177858302894e-07
had O 0 1.3471640158968512e-06
a O 0 6.139377092040377e-06
childhood O 0 0.01388576626777649
ALD B-Disease 1 0.9998985528945923
type O 0 0.001033141976222396
. O 0 3.244094841647893e-05

Another O 0 0.00032186953467316926
nephew O 0 0.3932938575744629
( O 0 1.322103344136849e-05
patient O 0 7.727363117737696e-05
4 O 0 1.5274131328624208e-06
) O 0 6.127844187631126e-08
of O 0 7.219772157895932e-08
patient O 0 8.753205293032806e-06
1 O 0 3.6703991668218805e-07
was O 0 1.5154240600168123e-06
classified O 0 3.1746290005685296e-06
as O 0 1.9980906529326603e-07
having O 0 1.0324419008611585e-06
an O 0 7.871232128309202e-07
adolescent O 0 0.0022340710274875164
form O 0 8.83259781403467e-06
. O 0 9.476196282776073e-06

The O 0 4.641209216060815e-06
tau O 0 2.160862641176209e-05
level O 0 5.402766873885412e-07
in O 0 3.918380642176089e-08
the O 0 1.2862487608344964e-07
cerebrospinal O 0 0.02765205316245556
fluid O 0 0.0008327083778567612
( O 0 2.2888882540428312e-06
CSF O 1 0.9764674305915833
) O 0 6.887367476338113e-07
in O 0 2.557703737693373e-07
patient O 0 6.549600129801547e-06
1 O 0 3.6710119388772e-07
was O 0 5.204018407312105e-07
as O 0 4.867053249313358e-08
high O 0 1.827786149988242e-06
as O 0 2.2286309686592176e-08
that O 0 1.5743250258992703e-08
of O 0 7.083222044457216e-07
patients O 0 0.0020538002718240023
with O 0 0.0010267068864777684
Alzheimers B-Disease 1 0.9999829530715942
disease I-Disease 1 0.817505419254303
( O 0 3.982702764915302e-06
AD B-Disease 0 0.0003779398975893855
) O 0 4.602869012160227e-06
. O 0 5.544252417166717e-06

His O 0 0.0003579274925868958
brain O 0 0.012403091415762901
magnetic O 0 2.8731024940498173e-05
resonance O 0 3.088974335696548e-05
image O 0 3.510354144964367e-05
( O 0 1.0627270512486575e-06
MRI O 0 0.0003199366037733853
) O 0 5.836198511133261e-07
showed O 0 5.791697549284436e-05
abnormalities B-Disease 0 0.005268378648906946
in I-Disease 0 5.772211508769942e-08
the I-Disease 0 1.2303731011797936e-07
bilateral I-Disease 0 5.932451313128695e-05
cerebellar I-Disease 0 0.15604567527770996
hemispheres I-Disease 0 0.002640198217704892
and O 0 0.00014851467858534306
brain O 0 0.3169092535972595
stem O 0 0.0013597749639302492
, O 0 7.207107159956649e-07
but O 0 6.391827156448926e-08
not O 0 8.323846500957188e-09
in O 0 2.2361335894061085e-08
the O 0 8.49811499392672e-07
cerebral O 0 0.3419438302516937
white O 0 0.00036024401197209954
matter O 0 4.86765713958448e-07
, O 0 6.249896244980846e-08
where O 0 2.8122929762730564e-08
marked O 0 4.4887113404001866e-07
reductions O 0 4.950547918269876e-06
of O 0 3.73845310264187e-08
the O 0 6.16587726653961e-07
cerebral O 0 0.04254617542028427
blood O 0 1.580825846758671e-05
flow O 0 5.364236130844802e-07
and O 0 9.939967071659339e-08
oxygen O 0 1.3611240774480393e-06
metabolism O 0 4.699187741152855e-07
were O 0 4.410051701597695e-08
clearly O 0 8.882521740360971e-08
demonstrated O 0 1.2489897471823497e-07
by O 0 1.8779127586299182e-08
positron O 0 2.1012032448197715e-05
emission O 0 3.2713696782593615e-06
tomography O 0 2.033225064224098e-05
( O 0 6.2575304582424e-07
PET O 0 4.159626041655429e-05
) O 0 7.390271434815077e-07
. O 0 2.2184071895026136e-06

In O 0 8.281630289275199e-05
patients O 0 0.0011095379013568163
2 O 0 1.0098654001922114e-06
and O 0 3.316714014545141e-07
3 O 0 3.989602532783465e-07
, O 0 6.457003820514728e-08
the O 0 2.7611511299596714e-08
autopsy O 0 1.2861356481153052e-05
findings O 0 3.5651187317853328e-06
showed O 0 2.4977040084195323e-05
massive O 0 0.0014319869223982096
demyelination B-Disease 1 0.9976517558097839
of I-Disease 0 1.566811192788009e-06
the I-Disease 0 5.601566044788342e-06
cerebral I-Disease 1 0.6936823725700378
white I-Disease 0 8.5483341536019e-05
matter I-Disease 0 8.919838734300356e-08
with O 0 7.298512372244659e-08
sparing O 0 1.228198925673496e-06
of O 0 2.4599064119001923e-08
the O 0 7.637929400061694e-08
U O 0 0.000230078338063322
- O 0 0.009274137206375599
fibers O 0 0.0002447757578920573
, O 0 8.83790747252533e-08
compatible O 0 1.5632186034508777e-07
with O 0 8.578206944775957e-08
the O 0 1.1485281703471628e-07
findings O 0 5.6089538702508435e-06
of O 0 4.636900484911166e-06
childhood O 0 0.03612056374549866
ALD B-Disease 1 0.9997437596321106
. O 0 0.00019403453916311264

Oleic O 0 0.044211603701114655
and O 0 4.004871516372077e-05
erucic O 0 0.2312786728143692
acids O 0 4.9690690502757207e-05
( O 0 4.1696318930917187e-07
Lorenzos O 0 0.00020267539366614074
Oil O 0 5.501543455466162e-06
) O 0 5.321405538438739e-08
were O 0 3.1604866279622e-08
administered O 0 1.363338810733694e-07
to O 0 4.4729258519282666e-08
patients O 0 2.603110488053062e-06
1 O 0 5.6249959357046464e-08
and O 0 1.1587643200527964e-07
4 O 0 3.758723607916181e-07
, O 0 1.136713905225406e-07
but O 0 4.3962113949191917e-08
sufficient O 0 2.2228813634228572e-07
effectiveness O 0 3.339268232593895e-06
was O 0 5.35103367838019e-07
not O 0 5.967880412072191e-08
obtained O 0 1.0558495660006884e-06
. O 0 2.044278062385274e-06

The O 0 7.726900548732374e-06
findings O 0 2.1406471205409616e-05
in O 0 1.3977326318581618e-07
this O 0 1.996170340134995e-08
family O 0 5.693700586562045e-07
suggest O 0 3.017616450051719e-07
that O 0 3.2576160435837664e-08
delGAG291 O 0 3.6924961023032665e-05
is O 0 1.4860161101637459e-08
part O 0 1.5585440493737224e-08
of O 0 1.723904219375072e-08
the O 0 1.4427713779241458e-07
cause O 0 2.2217061541596195e-06
of O 0 1.8171668614286318e-07
Japanese O 0 0.0013320974539965391
ALD B-Disease 1 0.9998959302902222
with O 0 1.1167840057169087e-05
phenotypic O 0 0.00010303646558895707
variations O 0 2.876578946597874e-05
. O 0 5.5253349273698404e-06

Moreover O 0 0.00020970942568965256
, O 0 2.711575689318124e-06
although O 0 1.647208023314306e-07
the O 0 1.7740664048915278e-08
scale O 0 1.1116582072645542e-06
of O 0 3.573889983954359e-08
the O 0 4.148434840089976e-08
study O 0 1.5957951404743653e-07
is O 0 2.4245792928923038e-08
limited O 0 1.1745363792670105e-07
, O 0 4.22455457282922e-08
there O 0 5.745966369374855e-09
is O 0 7.164227433520409e-09
a O 0 6.677503705532217e-08
possibility O 0 1.2230874517626944e-06
that O 0 7.96698103044946e-08
PET O 0 3.599694900913164e-05
can O 0 1.8807935475706472e-07
detect O 0 2.3343764041783288e-05
an O 0 6.631644851040619e-07
insidious B-Disease 0 0.02033594436943531
lesion I-Disease 0 0.34443098306655884
which O 0 1.0642347092471027e-07
is O 0 4.2155075874461545e-08
undetectable O 0 8.842997885949444e-06
by O 0 4.298651035128387e-08
computed O 0 1.1379496527297306e-06
tomogram O 0 0.00033264452940784395
( O 0 2.7486643716656545e-07
CT O 0 0.00041174149373546243
) O 0 4.2759264573533073e-08
or O 0 4.675754539107402e-08
MRI O 0 1.1373724191798829e-05
analysis O 0 7.564423754047311e-08
, O 0 1.1644684150269313e-07
and O 0 3.1598720084957677e-08
that O 0 3.1023603686008983e-09
the O 0 4.331487613029594e-09
higher O 0 8.947441898499164e-08
level O 0 2.1602446054203028e-08
of O 0 1.0302289688013389e-08
tau O 0 6.721107865814702e-07
reflects O 0 3.152864280764334e-08
the O 0 7.0088077563923434e-09
process O 0 2.3682511951506058e-08
of O 0 6.109102059781435e-07
neuronal B-Disease 0 0.0048967101611196995
degeneration I-Disease 1 0.9563454389572144
in O 0 0.00016388812218792737
ALD B-Disease 1 0.9998351335525513
. O 0 0.0002634748525451869

Lorenzos O 0 0.08062364161014557
Oil O 0 0.0003459876461420208
should O 0 8.671345881339221e-07
be O 0 1.5074494541522654e-08
given O 0 6.561110765801459e-09
in O 0 2.9547027047271968e-09
the O 0 8.219155134270295e-09
early O 0 2.0711296144781954e-07
stage O 0 4.6591208047175314e-06
. O 0 3.8493453757837415e-07
. O 0 2.3915160909382394e-06

Nonsense O 0 0.0007438290631398559
mutation O 0 0.000125753998872824
in O 0 5.824766731166164e-07
exon O 0 2.2886631995788775e-05
4 O 0 2.3479178423713165e-07
of O 0 5.257082236198585e-08
human O 0 1.6245635947598203e-07
complement O 0 6.298614607658237e-07
C9 O 0 0.04841698333621025
gene O 0 1.8399672399027622e-06
is O 0 1.7425058729259035e-08
the O 0 3.0224374114595776e-08
major O 0 3.143025878671324e-06
cause O 0 2.31311878451379e-06
of O 0 3.005874589234736e-07
Japanese O 0 0.0003962636401411146
complement B-Disease 0 0.001141179003752768
C9 I-Disease 1 0.9991746544837952
deficiency I-Disease 1 0.99480140209198
. O 0 1.1980568160652183e-05

Deficiency B-Disease 1 0.9935030341148376
of I-Disease 0 1.0582103868728154e-06
the I-Disease 0 2.6020060772680154e-07
ninth I-Disease 0 2.361185397603549e-05
component I-Disease 0 1.3212336398282787e-06
of I-Disease 0 5.930367663609104e-08
human I-Disease 0 3.592223265513894e-07
complement I-Disease 0 1.304546231040149e-06
( O 0 5.617854412776069e-07
C9 O 0 0.10846713185310364
) O 0 1.4233852141387615e-07
is O 0 1.3202137161272276e-08
the O 0 2.1776402903128655e-08
most O 0 1.7897757231821743e-07
common O 0 1.2730005437333602e-05
complement B-Disease 0 0.4973009526729584
deficiency I-Disease 1 0.9991950392723083
in O 0 2.295040388844427e-07
Japan O 0 9.560916623740923e-06
but O 0 2.404675001344003e-07
is O 0 1.262894357978439e-07
rare O 0 1.2960999811184593e-06
in O 0 5.793919299890149e-08
other O 0 2.3342855115515704e-07
countries O 0 9.018759214995953e-07
. O 0 3.7677421005355427e-06

We O 0 2.760585630312562e-06
studied O 0 1.5720122519269353e-06
the O 0 6.007979891364812e-08
molecular O 0 6.487655923592683e-07
basis O 0 6.303373822902358e-08
of O 0 9.822811080084648e-07
C9 B-Disease 1 0.9991493225097656
deficiency I-Disease 1 0.7729301452636719
in O 0 5.5765934092733005e-08
four O 0 2.525512741158309e-07
Japanese O 0 0.00010304982424713671
C9 B-Disease 1 0.9779324531555176
- I-Disease 1 0.9970663189888
deficient I-Disease 1 0.9902688264846802
patients O 0 0.017497938126325607
who O 0 5.392092134570703e-05
had O 0 0.0002308535622432828
suffered O 1 0.5706466436386108
from O 0 0.00048614369006827474
meningococcal B-Disease 1 0.9996734857559204
meningitis I-Disease 1 0.9992181062698364
. O 0 0.00011098857794422656

Direct O 0 3.386543312444701e-06
sequencing O 0 3.3900139442266664e-06
of O 0 1.992222706803659e-07
amplified O 0 5.910430445510428e-06
C9 O 0 0.00018276403716299683
cDNA O 0 9.33953970161383e-07
and O 0 1.5537897013473412e-07
DNA O 0 2.606304860819364e-06
revealed O 0 8.900148600332614e-07
a O 0 1.9678482843232814e-08
nonsense O 0 5.518218699762656e-07
substitution O 0 6.138559172086389e-08
( O 0 3.055062691714738e-08
CGA O 0 4.434848506207345e-06
- O 0 0.0001311067899223417
- O 0 0.000366421474609524
> O 0 1.0948370800178964e-05
TGA O 0 0.00022095514577813447
) O 0 1.1396419807851998e-08
at O 0 7.801891577230435e-09
codon O 0 2.1068080613417806e-08
95 O 0 1.4212320209594509e-08
in O 0 3.903898981860721e-09
exon O 0 6.179935212458076e-07
4 O 0 4.365878680800961e-08
in O 0 4.226470728951881e-09
the O 0 1.3349279015528737e-08
four O 0 6.766738920305215e-07
C9 B-Disease 1 0.875413179397583
- I-Disease 1 0.9183329939842224
deficient I-Disease 0 0.07093709707260132
individuals O 0 4.339372480899328e-06
. O 0 3.232486278648139e-06

An O 0 4.466150585358264e-06
allele O 0 6.1404716689139605e-06
- O 0 3.13307173200883e-05
specific O 0 9.251029808865496e-08
polymerase O 0 6.525228855025489e-06
chain O 0 1.114541373681277e-05
reaction O 0 2.4586478275523405e-07
system O 0 8.612684609943244e-08
designed O 0 1.0360894293626188e-06
to O 0 1.2768643919969236e-08
detect O 0 1.0201985105595668e-06
exclusively O 0 2.6569486166749812e-08
only O 0 1.8721184602554786e-09
one O 0 1.74579195544311e-09
of O 0 2.410909694106067e-09
the O 0 1.0912104109195297e-08
normal O 0 2.762810424883355e-08
and O 0 3.6697194616408524e-08
mutant O 0 4.27319764639833e-06
alleles O 0 1.5916623397060903e-06
indicated O 0 6.270337848945928e-07
that O 0 2.2555282086500483e-09
all O 0 7.050314221324072e-10
the O 0 4.3324792642351895e-09
four O 0 4.822293249162612e-07
patients O 0 2.1055398974567652e-05
were O 0 6.264265550726122e-08
homozygous O 0 4.788910814568226e-07
for O 0 8.860216560435674e-09
the O 0 8.018138153431664e-09
mutation O 0 1.0651689308360801e-07
in O 0 9.355184182879839e-09
exon O 0 8.769798114371952e-06
4 O 0 3.038645672859275e-07
and O 0 1.0385235071908028e-07
that O 0 1.4095346223541583e-08
the O 0 1.7630965132298115e-08
parents O 0 3.2927928828030417e-07
of O 0 2.1008257533594588e-07
patient O 0 1.7764146832632832e-05
2 O 0 1.1268523394392105e-06
were O 0 8.284900445687526e-07
heterozygous O 0 9.95430673356168e-06
. O 0 2.192507963627577e-06

The O 0 5.072162821306847e-06
common O 0 3.7004217574576614e-06
mutation O 0 2.111732101184316e-06
at O 0 8.886826208254206e-08
codon O 0 2.1075965150885168e-07
95 O 0 1.2787610614850564e-07
in O 0 1.3572877044509823e-08
exon O 0 2.871156539185904e-06
4 O 0 4.021299844225723e-07
might O 0 7.413418501300839e-08
be O 0 2.8928430761965274e-09
responsible O 0 3.458915287524178e-08
for O 0 4.0452857064110503e-08
most O 0 6.450085834330821e-07
Japanese O 0 0.002732512541115284
C9 B-Disease 1 0.9997180104255676
deficiency I-Disease 1 0.981279730796814
. O 0 1.2613600119948387e-06
. O 0 4.02919886255404e-06

BRCA1 O 0 0.00616542948409915
required O 0 2.8578390356415184e-06
for O 0 5.142501322552562e-07
transcription O 0 5.364934622775763e-06
- O 0 0.0015287203714251518
coupled O 0 0.0002883014385588467
repair O 0 0.001961474074050784
of O 0 1.93995947483927e-06
oxidative O 0 0.06035145744681358
DNA O 0 0.0061017246916890144
damage O 0 0.015267902053892612
. O 0 3.637439294834621e-05

The O 0 0.00043425755575299263
breast B-Disease 1 0.999128520488739
and I-Disease 1 0.9620435237884521
ovarian I-Disease 1 0.9999990463256836
cancer I-Disease 1 0.9999886751174927
susceptibility O 0 0.06371545046567917
gene O 0 2.3188515115180053e-05
BRCA1 O 0 0.0001607302256161347
encodes O 0 2.4176515580620617e-06
a O 0 3.2857394671736984e-06
zinc O 0 0.04292169213294983
finger O 0 9.784416761249304e-05
protein O 0 1.321555771482963e-07
of O 0 4.29897895060094e-08
unknown O 0 1.7194404335896252e-06
function O 0 5.654582651004603e-07
. O 0 2.315431856914074e-06

Association O 0 6.849840428913012e-05
of O 0 3.83532210435078e-07
the O 0 2.869495574486791e-07
BRCA1 O 0 4.5072654756950215e-05
protein O 0 7.415003011601584e-08
with O 0 1.4390578506606744e-08
the O 0 2.721798608718018e-08
DNA O 0 8.631219316157512e-06
repair O 0 0.0005373245221562684
protein O 0 1.0011773383666878e-06
Rad51 O 0 0.00022947980323806405
and O 0 2.1943894523701601e-07
changes O 0 1.896001755596899e-08
in O 0 1.8132496615308469e-09
the O 0 2.428215406524714e-09
phosphorylation O 0 3.035812312646158e-08
and O 0 2.542566157615056e-08
cellular O 0 1.3493086044036318e-06
localization O 0 2.783720844945492e-07
of O 0 6.8629879557136064e-09
the O 0 1.3097298356967713e-08
protein O 0 4.421826815814711e-08
after O 0 3.1505803121945064e-07
exposure O 0 1.0900060942731216e-06
to O 0 7.816772118474091e-09
DNA O 0 1.84088696641993e-06
- O 0 0.00033930904464796185
damaging O 0 0.0005320953787304461
agents O 0 2.840433126038988e-06
are O 0 1.3777101237621991e-08
consistent O 0 2.6440671874183863e-08
with O 0 1.9974271125988707e-08
a O 0 6.862519086325847e-08
role O 0 3.8961059090070194e-07
for O 0 1.1614450556862721e-07
BRCA1 O 0 4.483152588363737e-05
in O 0 5.165992433830979e-07
DNA O 0 0.00021946193010080606
repair O 0 0.07364813983440399
. O 0 4.486984835239127e-05

Here O 0 7.375095719908131e-06
, O 0 6.623920967285812e-07
it O 0 1.3754836380996949e-08
is O 0 5.083696574814667e-09
shown O 0 1.808908400846576e-08
that O 0 1.5674995523795587e-08
mouse O 0 2.1913872842560522e-05
embryonic O 0 0.0015127799706533551
stem O 0 0.013992088846862316
cells O 0 0.000182996824150905
deficient B-Disease 0 0.0006046344642527401
in I-Disease 0 3.8788002143519407e-07
BRCA1 I-Disease 0 0.00014818804629612714
are O 0 1.3276989818677976e-07
defective O 0 0.00010704096348490566
in O 0 4.743357706615825e-08
the O 0 3.703619455563967e-08
ability O 0 7.259568945983119e-08
to O 0 2.3521609104903973e-09
carry O 0 1.0477648970663722e-08
out O 0 1.6544129621820503e-08
transcription O 0 2.8174048338769353e-07
- O 0 0.00012937892461195588
coupled O 0 4.0200244256993756e-05
repair O 0 0.0002179394941776991
of O 0 2.657965580965538e-07
oxidative O 0 0.003915794193744659
DNA O 0 0.0025142841041088104
damage O 0 0.05355498194694519
, O 0 8.654335488245124e-07
and O 0 3.639801491317485e-07
are O 0 4.268291320386197e-08
hypersensitive O 0 3.821351128863171e-05
to O 0 1.9704403086961975e-07
ionizing O 0 0.00012946492643095553
radiation O 0 2.4205273803090677e-05
and O 0 3.097307228472346e-07
hydrogen O 0 1.475991120969411e-05
peroxide O 0 0.0017626472981646657
. O 0 4.439660187927075e-06

These O 0 2.830989387803129e-06
results O 0 5.489666818903061e-06
suggest O 0 2.9875723157601897e-06
that O 0 1.626430048418115e-07
BRCA1 O 0 2.84319648926612e-05
participates O 0 1.212782535731094e-06
, O 0 9.519271770841442e-08
directly O 0 3.927996061747763e-08
or O 0 9.583398252743791e-08
indirectly O 0 2.088421751977876e-06
, O 0 4.104141382299531e-08
in O 0 2.1854337006743663e-08
transcription O 0 7.775998938086559e-07
- O 0 0.0013833590783178806
coupled O 0 0.00012637634063139558
repair O 0 0.0007825311040505767
of O 0 4.394086374759354e-07
oxidative O 0 0.03372557461261749
DNA O 0 0.003055892651900649
damage O 0 0.010556419380009174
. O 0 1.8425591861159774e-06
. O 0 5.045003035775153e-06

Truncation O 0 0.0037417623680084944
mutations O 0 0.0006289545563049614
in O 0 5.547952923734556e-07
the O 0 1.512011493787213e-07
transactivation O 0 0.00023039511870592833
region O 0 1.0534678267504205e-06
of O 0 1.0796175331506674e-07
PAX6 O 0 0.006343776825815439
result O 0 1.76632636339491e-06
in O 0 2.327039396732289e-07
dominant O 0 2.1260135326883756e-05
- O 0 0.010213237255811691
negative O 0 2.120586759701837e-05
mutants O 0 8.267198427347466e-05
. O 0 7.318862117244862e-06

PAX6 O 0 0.3891116678714752
is O 0 3.481224894130719e-06
a O 0 4.2974789948857506e-07
transcription O 0 1.1557563084352296e-06
factor O 0 1.0567224251190055e-07
with O 0 5.183103279904344e-09
two O 0 7.446520733367379e-09
DNA O 0 1.1132823374282452e-06
- O 0 6.544016650877893e-05
binding O 0 1.9410178992984584e-06
domains O 0 6.222788329068862e-07
( O 0 5.31690069749402e-08
paired O 0 2.5240321974706603e-06
box O 0 4.911779342364753e-06
and O 0 1.1931571179957245e-06
homeobox O 0 0.00011587248445721343
) O 0 1.9334928325065448e-08
and O 0 7.645096999908674e-09
a O 0 2.4464682724101294e-08
proline O 0 9.89767249848228e-06
- O 0 5.1738479669438675e-05
serine O 0 7.257253400894115e-06
- O 0 6.0852380556752905e-05
threonine O 0 1.3174513696867507e-05
( O 0 1.7730592105635878e-07
PST O 0 6.006276453263126e-05
) O 0 1.0364140479168782e-07
- O 0 1.9669043467729352e-05
rich O 0 2.51060964728822e-06
transactivation O 0 9.427318582311273e-05
domain O 0 4.340796749602305e-06
. O 0 2.8018339435220696e-06

PAX6 O 1 0.6452771425247192
regulates O 0 0.006917707156389952
eye O 0 0.014849076047539711
development O 0 3.927243142243242e-06
in O 0 2.970119226120005e-07
animals O 0 2.1900764579640963e-07
ranging O 0 1.7215817251781118e-06
from O 0 3.433560209487041e-07
jellyfish O 0 7.30474857846275e-06
to O 0 2.5102472989146918e-08
Drosophila O 0 8.770368253863126e-08
to O 0 6.240998118300922e-08
humans O 0 3.760975175737258e-07
. O 0 1.0873834526137216e-06

Heterozygous O 0 0.0010462040081620216
mutations O 0 0.0004037291510030627
in O 0 4.0149427604774246e-07
the O 0 1.9229162262490718e-07
human O 0 1.1623320688158856e-06
PAX6 O 0 0.002739860210567713
gene O 0 1.2814740557587356e-06
result O 0 1.7285886144691176e-07
in O 0 1.2260809256758876e-08
various O 0 3.980336771292059e-08
phenotypes O 0 2.403345388302114e-05
, O 0 6.242212293727789e-07
including O 0 2.420024247840047e-05
aniridia B-Disease 1 0.9997640252113342
, O 0 0.0010066056856885552
Peters B-Disease 1 0.9996871948242188
anomaly I-Disease 1 0.9991511106491089
, O 0 0.00030355772469192743
autosomal B-Disease 0 0.06968909502029419
dominant I-Disease 0 0.01397057343274355
keratitis I-Disease 1 0.9983673691749573
, O 0 0.00017549106269143522
and O 0 0.0007974175969138741
familial B-Disease 1 0.9845384359359741
foveal I-Disease 1 0.9988491535186768
dysplasia I-Disease 1 0.999129593372345
. O 0 0.00013254089572001249

It O 0 3.270770775998244e-06
is O 0 3.5462136338537675e-07
believed O 0 5.493917001331283e-07
that O 0 5.339448883034947e-09
the O 0 5.6462439168569745e-09
mutated O 0 2.8556684128488996e-07
allele O 0 1.3204609672357037e-07
of O 0 2.8550768860213793e-08
PAX6 O 0 0.00025996429030783474
produces O 0 6.956030915716838e-07
an O 0 1.3564017820044683e-07
inactive O 0 9.944735211320221e-06
protein O 0 1.7492617132575106e-07
and O 0 1.5359452163465903e-06
aniridia B-Disease 1 0.9828599095344543
is O 0 2.110290552082006e-06
caused O 0 2.3258990040631033e-05
due O 0 2.206740873589297e-06
to O 0 5.269218945613829e-07
genetic O 0 7.914520392660052e-05
haploinsufficiency O 0 0.038975104689598083
. O 0 3.293716144980863e-05

However O 0 1.490694467065623e-05
, O 0 3.8690686210429703e-07
several O 0 1.0135010342082751e-07
truncation O 0 5.904182035010308e-05
mutations O 0 3.666488191811368e-05
have O 0 2.1562911456385336e-07
been O 0 1.1124699739184507e-07
found O 0 7.898665899119806e-08
to O 0 5.871164887594205e-09
occur O 0 5.402419400724057e-09
in O 0 3.657105729359955e-09
the O 0 3.1480929862937046e-08
C O 0 1.60196050273953e-05
- O 0 0.0008952090865932405
terminal O 0 9.080682502826676e-06
half O 0 1.0800417982181898e-07
of O 0 9.154943825251394e-08
PAX6 O 0 0.0060312035493552685
in O 0 1.2776605444742017e-06
patients O 0 1.9267254174337722e-05
with O 0 7.546028655269765e-07
Aniridia B-Disease 1 0.9549159407615662
resulting O 0 5.662591775035253e-06
in O 0 7.041290217557616e-08
mutant O 0 5.137299012858421e-06
proteins O 0 5.2789260962526896e-08
that O 0 5.8189897345073405e-09
retain O 0 6.831319865341356e-08
the O 0 4.8889154946607505e-09
DNA O 0 7.144067808440013e-07
- O 0 4.09285603382159e-05
binding O 0 8.44803082600265e-07
domains O 0 8.153242561093066e-07
but O 0 2.5476145637526315e-08
have O 0 2.6510511119681723e-08
lost O 0 4.3022399154324376e-07
most O 0 3.278471050194298e-09
of O 0 6.480048053703058e-09
the O 0 1.4525058134040592e-07
transactivation O 0 0.00018611515406519175
domain O 0 6.054239293007413e-06
. O 0 5.043001237936551e-06

It O 0 4.061617801198736e-06
is O 0 3.081168244989385e-07
not O 0 2.387964137540166e-08
clear O 0 5.160782734492386e-08
whether O 0 2.4316001656643493e-08
such O 0 2.0070586970177828e-08
mutants O 0 6.264113835641183e-06
really O 0 2.68624916088811e-07
behave O 0 2.2143989042433532e-07
as O 0 2.4644430496323366e-08
loss O 0 1.935269665409578e-06
- O 0 1.0822956028277986e-05
of O 0 8.463387501933539e-08
- O 0 0.00026400291244499385
function O 0 1.6995463170133007e-07
mutants O 0 2.84744669443171e-06
as O 0 7.068943119747928e-08
predicted O 0 1.5438255331901019e-06
by O 0 5.490543912856083e-07
haploinsufficiency O 0 0.0007693387451581657
. O 0 4.819235982722603e-06

Contrary O 0 2.108642365783453e-05
to O 0 3.4941226090268174e-07
this O 0 1.546839989430282e-08
theory O 0 3.469077114459651e-08
, O 0 1.3553086652962065e-08
our O 0 8.20421242053726e-09
data O 0 3.504403878196172e-08
showed O 0 3.3753926231838705e-07
that O 0 3.5604577064418663e-09
these O 0 2.3756063782798265e-09
mutants O 0 8.113930789477308e-07
are O 0 2.3787995573343323e-08
dominant O 0 7.789656137902057e-07
- O 0 3.789582842728123e-05
negative O 0 3.474620484666957e-07
in O 0 2.6033081468312957e-08
transient O 0 2.4743492303969106e-06
transfection O 0 0.00032670662039890885
assays O 0 1.2708173017017543e-05
when O 0 1.7243802119537577e-07
they O 0 1.587701881078374e-08
are O 0 1.1793219734101967e-08
coexpressed O 0 1.0548266800469719e-05
with O 0 1.282583923511993e-07
wild O 0 4.94030018671765e-06
- O 0 0.00426171999424696
type O 0 4.7683370212325826e-05
PAX6 O 0 0.005077166948467493
. O 0 6.698642209812533e-06

We O 0 4.516430180956377e-06
found O 0 9.684910082796705e-07
that O 0 2.2359627038781582e-08
the O 0 3.084048927348704e-08
dominant O 0 3.5348587061889702e-06
- O 0 0.0017022305401042104
negative O 0 2.863246209017234e-06
effects O 0 1.9677297586895293e-06
result O 0 4.812075715676656e-08
from O 0 7.533579093887965e-09
the O 0 8.392444961202727e-09
enhanced O 0 1.2455941487132804e-06
DNA O 0 4.327602709963685e-06
binding O 0 1.2177684993730509e-06
ability O 0 2.0556586832753965e-07
of O 0 1.776426472588355e-08
these O 0 7.521120437559148e-08
mutants O 0 2.9515937058022246e-05
. O 0 2.443167886667652e-06

Kinetic O 0 7.793536497047171e-05
studies O 0 4.308141342335148e-06
of O 0 1.3437774271096714e-07
binding O 0 1.0479946013219887e-06
and O 0 2.0938072964327148e-07
dissociation O 0 3.22978085023351e-05
revealed O 0 1.9097665244771633e-06
that O 0 3.184617014539981e-09
various O 0 2.8760631654023427e-09
truncation O 0 5.007213076169137e-06
mutants O 0 3.6805049603572115e-06
have O 0 2.632247309009017e-08
3 O 0 5.769910771391551e-08
- O 0 1.228736527991714e-05
5 O 0 1.292055458179675e-07
- O 0 1.9972587324446067e-05
fold O 0 1.5676243947382318e-06
higher O 0 4.8444736222563733e-08
affinity O 0 3.620835187234661e-08
to O 0 6.017619180731515e-10
various O 0 1.0207303891007768e-09
DNA O 0 2.0185554205909284e-07
- O 0 3.6847300179942977e-06
binding O 0 1.4083968835620908e-07
sites O 0 2.8652236139237175e-08
when O 0 2.0142723045069033e-08
compared O 0 1.3162767231733596e-07
with O 0 1.816251504749289e-08
the O 0 4.863564484480776e-08
wild O 0 3.176915697622462e-06
- O 0 0.002006433205679059
type O 0 3.9896240195957944e-05
PAX6 O 0 0.004407842643558979
. O 0 1.146126669482328e-05

These O 0 1.3344310900720302e-06
results O 0 1.2509284488260164e-06
provide O 0 1.5886915605278773e-07
a O 0 7.204186402987034e-08
new O 0 2.0539950185138878e-07
insight O 0 4.4110490193816076e-07
into O 0 1.4357159017208687e-08
the O 0 1.1070803829227316e-08
role O 0 4.083511484509472e-08
of O 0 2.208590110797104e-08
mutant O 0 1.595523463038262e-05
PAX6 O 0 0.0012240270152688026
in O 0 9.337553592558834e-07
causing O 0 0.0003720250679180026
aniridia B-Disease 1 0.953490138053894
. O 0 2.116254108841531e-06
. O 0 2.7761013825511327e-06

Reversal O 0 0.20039084553718567
of O 0 0.03372427448630333
severe O 1 0.9998973608016968
hypertrophic B-Disease 1 0.9999593496322632
cardiomyopathy I-Disease 1 0.9999808073043823
and O 0 6.083793050493114e-05
excellent O 0 0.00013063382357358932
neuropsychologic O 0 0.04229901358485222
outcome O 0 4.190171239315532e-06
in O 0 6.87035139890213e-08
very B-Disease 0 4.980818957278643e-08
- I-Disease 0 0.00013311312068253756
long I-Disease 0 1.2353680176602211e-05
- I-Disease 0 0.001245902618393302
chain I-Disease 0 0.00012213148875162005
acyl I-Disease 0 0.00022268775501288474
- I-Disease 0 0.001117367879487574
coenzyme I-Disease 0 0.00010495130845811218
A I-Disease 0 3.872985325870104e-05
dehydrogenase I-Disease 0 0.010561584495007992
deficiency I-Disease 0 0.27727070450782776
. O 0 8.343786248588003e-06

Very B-Disease 0 1.0145711712539196e-05
- I-Disease 0 0.0007961041410453618
long I-Disease 0 2.800771289912518e-05
- I-Disease 0 0.0005785153480246663
chain I-Disease 0 2.588581628515385e-05
acyl I-Disease 0 3.339704926474951e-05
- I-Disease 0 0.00014815032773185521
coenzyme I-Disease 0 9.672453415987547e-06
A I-Disease 0 9.668916618466028e-07
dehydrogenase I-Disease 0 5.096884342492558e-05
( I-Disease 0 1.1779627584473928e-06
VLCAD I-Disease 0 0.30966874957084656
) I-Disease 0 2.966117244795896e-05
deficiency I-Disease 0 0.07111366093158722
is O 0 1.1467069782611361e-07
a O 0 2.319604391232133e-06
disorder O 0 0.005465297494083643
of O 0 3.9503413518104935e-07
fatty O 0 0.00017737047164700925
acid O 0 2.1041929358034395e-05
beta O 0 1.0582034519757144e-06
oxidation O 0 2.076733835565392e-06
that O 0 9.383010990404728e-08
reportedly O 0 1.9540788343874738e-05
has O 0 9.913913601167224e-08
high O 0 2.597946831883746e-06
rates O 0 7.329970799219154e-07
of O 0 1.7181605471705552e-07
morbidity O 0 0.006382799241691828
and O 0 1.403681562806014e-05
mortality O 0 0.0005522667779587209
. O 0 6.036885224602884e-06

We O 0 3.2008831567509333e-06
describe O 0 2.018481382037862e-06
the O 0 4.555634092184846e-08
outcome O 0 1.3773193074939627e-07
of O 0 7.564391779624202e-09
a O 0 3.7179024303668484e-08
5 O 0 1.1258582333084632e-07
- O 0 5.100502312416211e-05
year O 0 1.5285512517948519e-06
- O 0 0.0002245955402031541
old O 0 8.86015041032806e-05
girl O 0 0.0001495954202255234
with O 0 0.0001415367005392909
VLCAD B-Disease 1 0.9999847412109375
deficiency I-Disease 1 0.9999438524246216
who O 0 8.154648639902007e-06
was O 0 3.8574484051423497e-07
first O 0 3.7794485763242847e-08
seen O 0 2.5712867568472575e-07
at O 0 4.447523593853475e-08
5 O 0 4.3691940732060175e-08
months O 0 2.3510861524300708e-07
of O 0 6.196187740670211e-08
age O 0 2.0649380530812778e-05
with O 0 0.0062073757871985435
severe O 1 0.9998801946640015
hypertrophic B-Disease 1 0.9999693632125854
cardiomyopathy I-Disease 1 0.9999897480010986
, O 0 0.04925629124045372
hepatomegaly B-Disease 1 0.9999955892562866
, O 0 0.15588587522506714
encephalopathy B-Disease 1 0.9995393753051758
, O 0 4.521454684436321e-05
and O 0 7.174529309850186e-05
hypotonia B-Disease 1 0.847332775592804
. O 0 4.001431807409972e-05

Biochemical O 0 0.19861093163490295
studies O 0 0.017256179824471474
indicated O 1 0.9563024640083313
VLCAD B-Disease 1 0.9999762773513794
deficiency I-Disease 1 0.9999852180480957
caused O 0 0.0011830030707642436
by O 0 2.737626800808357e-06
a O 0 5.314281679602573e-06
stable O 0 5.190492083784193e-05
yet O 0 8.760528544371482e-06
inactive O 0 0.0002845336857717484
enzyme O 0 8.484694990329444e-05
. O 0 6.672081781289307e-06

Molecular O 0 0.0004264742601662874
genetic O 0 7.218945393105969e-05
analysis O 0 8.984343935480865e-07
of O 0 2.464382475864113e-07
her O 0 8.74459419719642e-06
VLCAD O 0 0.022240735590457916
gene O 0 1.5275209079845808e-06
revealed O 0 2.1679134079022333e-06
a O 0 1.376262304120246e-07
T1372C O 0 4.5894797949586064e-05
( O 0 1.3944959675882274e-07
F458L O 0 1.0641433618729934e-05
) O 0 4.8889830850384897e-08
missense O 0 1.0081129403261002e-05
mutation O 0 9.60007128014695e-07
and O 0 2.1667484872978093e-07
a O 0 1.461151896364754e-06
1668 O 0 0.038547154515981674
ACAG O 0 0.026101140305399895
1669 O 0 0.000843672314658761
splice O 0 0.00014812278095632792
site O 0 1.6102700101328082e-05
mutation O 0 1.5753330444567837e-05
. O 0 3.270711204095278e-06

After O 0 0.00010767969070002437
initial O 0 6.755847425665706e-05
treatment O 0 7.318829739233479e-05
with O 0 8.352149052370805e-07
intravenous O 0 3.48461871908512e-05
glucose O 0 1.1155440006405115e-05
and O 0 5.858404392711236e-07
carnitine O 0 0.0014703995548188686
, O 0 1.610854525324612e-07
the O 0 7.716680272551457e-08
patient O 0 8.336653081641998e-06
has O 0 1.3933353670836368e-07
thrived O 0 1.1714192851286498e-06
on O 0 2.8658902806455444e-08
a O 0 5.222721810582698e-08
low O 0 2.443643325023004e-06
- O 0 0.0005811049486510456
fat O 0 1.0243437827739399e-05
diet O 0 1.496718056159807e-07
supplemented O 0 5.054654650393786e-08
with O 0 7.77223174708297e-09
medium O 0 4.4721326730723376e-07
- O 0 0.0001206339948112145
chain O 0 2.046144800260663e-05
triglyceride O 0 2.6410805730847642e-05
oil O 0 1.133235514316766e-06
and O 0 2.238338083770941e-07
carnitine O 0 0.00021313430625014007
and O 0 2.1293432439506432e-07
avoidance O 0 1.6374176993849687e-05
of O 0 2.6708076461545716e-07
fasting O 0 2.6372275897301733e-05
. O 0 3.195180170223466e-06

Her O 0 0.0028868396766483784
ventricular O 1 0.884404718875885
hypertrophy O 1 0.6336861252784729
resolved O 0 0.00029649652424268425
significantly O 0 1.393986076436704e-05
over O 0 2.7734179752769705e-07
1 O 0 2.526360560750618e-07
year O 0 4.6351573246283806e-07
, O 0 1.068773016754676e-07
and O 0 4.448143329227605e-07
cognitively O 0 0.003203014610335231
, O 0 4.6623074467788683e-07
she O 0 3.1686508350503573e-07
is O 0 6.741654345887582e-09
in O 0 3.2349400935771655e-09
the O 0 1.0054562515904308e-08
superior O 0 2.2352085579768755e-05
range O 0 2.28613293984381e-06
for O 0 9.259887860935123e-07
age O 0 3.1371862860396504e-05
. O 0 7.188235940702725e-06

Clinical O 0 0.009622444398701191
recognition O 0 0.0002697197487577796
of O 0 0.001009630155749619
VLCAD B-Disease 1 0.9999926090240479
deficiency I-Disease 1 0.9999903440475464
is O 0 3.429018988754251e-06
important O 0 2.402304914994602e-07
because O 0 8.817936958394057e-08
it O 0 4.990582613828565e-09
is O 0 4.38656000412152e-09
one O 0 3.2867104593492513e-09
of O 0 5.195416097336647e-09
the O 0 4.998272729039854e-08
few O 0 5.247094918559014e-07
directly O 0 2.9566450393758714e-05
treatable O 1 0.9806485772132874
causes O 0 0.00021821874543093145
of O 0 6.613736331928521e-05
cardiomyopathy B-Disease 1 0.9999344348907471
in O 0 4.441692908585537e-06
children O 0 1.4184003703121562e-05
. O 0 1.5215337043628097e-06
. O 0 6.90563228999963e-06

Cloning O 0 0.0002957348187919706
of O 0 8.3217065593999e-07
a O 0 5.611557867268857e-07
novel O 0 6.879864145048487e-07
member O 0 1.7750217295997572e-07
of O 0 5.512630352200176e-09
the O 0 2.606269333682576e-08
low O 0 4.142847501498181e-06
- O 0 0.0002817338681779802
density O 0 8.84839755599387e-06
lipoprotein O 0 0.19562943279743195
receptor O 0 0.00011621706653386354
family O 0 1.1657483810267877e-05
. O 0 3.9477081372751854e-06

A O 0 5.870971563126659e-06
gene O 0 1.5514073083977564e-06
encoding O 0 2.1747747780409554e-07
a O 0 9.895399699644258e-08
novel O 0 5.456353733279684e-07
transmembrane O 0 1.055312532116659e-05
protein O 0 1.677930328014554e-07
was O 0 1.0115986981418246e-07
identified O 0 4.922837959497883e-08
by O 0 3.1618236917552167e-09
DNA O 0 6.162937182807582e-08
sequence O 0 4.5119277203298225e-09
analysis O 0 1.1709524905256785e-08
within O 0 6.679246045138143e-09
the O 0 2.053321139783293e-07
insulin B-Disease 0 0.0002460627001710236
- I-Disease 1 0.9614748954772949
dependent I-Disease 1 0.7468340992927551
diabetes I-Disease 1 0.9999829530715942
mellitus I-Disease 1 0.9999265670776367
( O 0 2.1196688976488076e-05
IDDM B-Disease 0 0.12833434343338013
) O 0 5.839706886945351e-07
locus O 0 1.1522133718244731e-05
IDDM4 O 0 0.0015741834649816155
on O 0 7.137638021958992e-06
chromosome O 0 0.00021982590260449797
11q13 O 0 0.0005518362740986049
. O 0 6.618151473958278e-06

Based O 0 8.649428309581708e-06
on O 0 1.1833956250484334e-06
its O 0 7.495056024708902e-07
chromosomal O 0 0.000905636406969279
position O 0 1.867178639258782e-06
, O 0 7.868997897730878e-08
this O 0 5.190483598482842e-09
gene O 0 5.570969463519759e-08
is O 0 3.705398432529705e-09
a O 0 2.3572642504632313e-08
candidate O 0 3.510894259761699e-07
for O 0 2.3824259187676944e-07
conferring O 0 0.00020703054906334728
susceptibility O 0 0.006918571889400482
to O 0 2.9010865546297282e-05
diabetes B-Disease 1 0.7246391177177429
. O 0 2.0529529138002545e-05

The O 0 4.962658294971334e-06
gene O 0 5.12811629960197e-06
, O 0 3.0848966048324655e-07
termed O 0 5.141249403095571e-06
low O 0 3.838135398837039e-06
- O 0 9.459457214688882e-05
density O 0 7.90314004461834e-07
lipoprotein O 0 0.0023202155716717243
receptor O 0 5.938069534749957e-06
related O 0 1.238372533407528e-06
protein O 0 9.983649107425663e-08
5 O 0 1.657098209761898e-07
( O 0 4.7735078112509655e-08
LRP5 O 0 0.00019672921916935593
) O 0 1.066904964375226e-08
, O 0 2.9347468899487694e-09
encodes O 0 4.368791994835419e-09
a O 0 2.46030396056085e-09
protein O 0 2.6998381308374064e-09
of O 0 2.8743576407919136e-09
1615 O 0 6.758181825716747e-06
amino O 0 9.847989446143401e-08
acids O 0 2.6468173430771458e-08
that O 0 5.731176089263101e-10
contains O 0 1.2699270524052508e-09
conserved O 0 1.6420237614056532e-08
modules O 0 6.325873158630202e-08
which O 0 9.067631090431405e-09
are O 0 3.1886102647149528e-09
characteristic O 0 1.9207970325396673e-08
of O 0 3.247985658205721e-09
the O 0 4.645893625365716e-08
low O 0 7.0319874794222414e-06
- O 0 0.0006388489273376763
density O 0 4.432083642313955e-06
lipoprotein O 0 0.09925799071788788
( O 0 3.50157574757759e-06
LDL O 0 0.001422904315404594
) O 0 6.300933819147758e-07
receptor O 0 7.985988304426428e-06
family O 0 4.936207915307023e-06
. O 0 2.9388847906375304e-06

These O 0 1.7592051335668657e-06
modules O 0 6.228610345715424e-06
include O 0 1.104457737710618e-06
a O 0 1.34818549213378e-07
putative O 0 4.766084657603642e-06
signal O 0 2.157321574713933e-07
peptide O 0 2.738243551902997e-07
for O 0 7.073971186599692e-09
protein O 0 6.37981489859385e-09
export O 0 2.6509196615620567e-08
, O 0 1.085383871668455e-08
four O 0 1.278539087934405e-07
epidermal O 0 0.0007725374307483435
growth O 0 9.120065442402847e-06
factor O 0 1.4782823427594849e-06
( O 0 1.6741485353577445e-07
EGF O 0 8.353155863005668e-05
) O 0 4.3434528862462685e-08
repeats O 0 1.526287576325558e-07
with O 0 4.397226049945857e-08
associated O 0 2.0921964960507466e-07
spacer O 0 3.937597739422927e-06
domains O 0 1.010462597150763e-06
, O 0 8.815347740664947e-08
three O 0 1.6470870889406797e-07
LDL O 0 0.0007103463285602629
- O 0 0.0035716453567147255
receptor O 0 1.4057044609216973e-05
( O 0 1.244553544665905e-07
LDLR O 0 0.0001481418585171923
) O 0 3.294155348498862e-08
repeats O 0 1.5991955137906189e-07
, O 0 8.832797604441112e-09
a O 0 6.479849989915465e-09
single O 0 5.167450822796127e-08
transmembrane O 0 3.848658707283903e-06
spanning O 0 1.421529532308341e-06
domain O 0 6.835972499175114e-07
, O 0 9.278242885102372e-08
and O 0 6.756563664112036e-08
a O 0 2.3051504172144632e-07
cytoplasmic O 0 2.2920401534065604e-05
domain O 0 4.944565716868965e-06
. O 0 2.474165285093477e-06

The O 0 1.4159321608531172e-06
encoded O 0 6.190175554365851e-07
protein O 0 3.201934930530115e-07
has O 0 2.7228839627468915e-08
a O 0 1.3400119236450792e-08
unique O 0 4.6518522367478e-08
organization O 0 7.134285340271163e-08
of O 0 3.729415354314369e-08
EGF O 0 0.0007770704105496407
and O 0 1.8232038883070345e-06
LDLR O 0 0.00844404473900795
repeats O 0 2.3458437681256328e-06
; O 0 2.551179534293624e-07
therefore O 0 5.131542124559019e-08
, O 0 1.1968937485562492e-07
LRP5 O 0 0.009068562649190426
likely O 0 2.343945197935682e-06
represents O 0 2.436280226447707e-07
a O 0 2.839587764924545e-08
new O 0 1.2116930747652077e-07
category O 0 8.46794065978429e-08
of O 0 4.666924624530111e-08
the O 0 5.26340329543018e-07
LDLR O 0 0.043157756328582764
family O 0 2.5948567781597376e-05
. O 0 5.297003099258291e-06

Both O 0 8.596553016104735e-06
human O 0 3.794262738665566e-06
and O 0 7.122048373275902e-07
mouse O 0 7.252343493746594e-05
LRP5 O 0 0.04011239856481552
cDNAs O 0 0.0018988982774317265
have O 0 3.7728264601355477e-07
been O 0 1.6163451732609246e-07
isolated O 0 3.0325719535539974e-07
and O 0 1.2832733986556377e-08
the O 0 6.3416107920488685e-09
encoded O 0 3.320720054489357e-08
mature O 0 3.6550684967551206e-07
proteins O 0 1.5100912520438214e-08
are O 0 2.529089826452946e-09
95 O 0 3.079845711795315e-08
% O 0 1.676944272333003e-08
identical O 0 4.794298433807853e-07
, O 0 1.8918733246664488e-07
indicating O 0 6.53982397125219e-07
a O 0 7.201068541462519e-08
high O 0 3.1366389521281235e-06
degree O 0 5.634713602375996e-07
of O 0 4.165235267805656e-08
evolutionary O 0 2.9637037641805364e-06
conservation O 0 1.1090881343989167e-05
. O 0 5.137800371812773e-07
. O 0 2.8155134259577608e-06

The O 0 3.878968982462538e-06
APC B-Disease 0 0.00019516286556608975
variants O 0 6.314688562270021e-06
I1307K O 0 9.093878179555759e-05
and O 0 9.01390080798592e-07
E1317Q O 0 8.817316847853363e-05
are O 0 1.796095574491119e-07
associated O 0 1.2538578630483244e-05
with O 0 0.019235465675592422
colorectal B-Disease 1 1.0
tumors I-Disease 1 0.9999997615814209
, O 0 6.1030670622130856e-05
but O 0 4.3829831497532723e-07
not O 0 2.085999817325046e-08
always O 0 2.615661642835221e-08
with O 0 3.483371813217673e-08
a O 0 2.0240473475041654e-07
family O 0 2.808881163218757e-06
history O 0 3.5672305784828495e-06
. O 0 1.179992705147015e-05

Classical O 0 0.3657837212085724
familial B-Disease 1 0.99980229139328
adenomatous I-Disease 1 0.9998807907104492
polyposis I-Disease 1 0.9999451637268066
( O 0 0.0010955558391287923
FAP B-Disease 0 0.339682400226593
) O 0 1.6137573766172864e-06
is O 0 6.361967308521344e-08
a O 0 2.637791567394743e-07
high O 0 0.0002552720543462783
- O 1 0.9433811902999878
penetrance O 1 0.9953994154930115
autosomal B-Disease 1 0.798445999622345
dominant I-Disease 0 0.3375551998615265
disease I-Disease 0 0.11605169624090195
that O 0 3.687686103148735e-07
predisposes O 0 0.00016268085164483637
to O 0 5.565351202108104e-08
hundreds O 0 9.584235840520705e-07
or O 0 2.2766569429677475e-07
thousands O 0 1.2908529242849909e-05
of O 0 0.00037333459476940334
colorectal B-Disease 1 0.9999997615814209
adenomas I-Disease 1 0.9999974966049194
and I-Disease 1 0.5757957100868225
carcinoma I-Disease 1 0.9999980926513672
and O 0 1.4394661775440909e-05
that O 0 1.2419698691701342e-07
results O 0 4.5054116526443977e-07
from O 0 1.0891066182239229e-07
truncating O 0 7.371918036369607e-05
mutations O 0 3.1280653729481855e-06
in O 0 4.2020612767146304e-08
the O 0 2.89661670649366e-07
APC B-Disease 0 0.0008019598317332566
gene O 0 1.0248889338981826e-05
. O 0 3.1150473205343587e-06

A O 0 3.9870647015050054e-05
variant O 0 9.043927275342867e-05
of O 0 3.783246256716666e-06
FAP B-Disease 0 0.24725036323070526
is O 0 4.976505442755297e-05
attenuated B-Disease 1 0.6142125725746155
adenomatous I-Disease 1 0.9999628067016602
polyposis I-Disease 1 0.9999618530273438
coli I-Disease 1 0.9995594620704651
, O 0 2.4898563424358144e-06
which O 0 2.5608073883631732e-08
results O 0 1.923919512591965e-07
from O 0 1.508006732819922e-07
germ O 0 0.00021843564172741026
- O 0 0.0006124962237663567
line O 0 4.395873475004919e-06
mutations O 0 9.159770684163959e-07
in O 0 6.1109641791290414e-09
the O 0 5.642842193509523e-09
5 O 0 4.381294615996012e-08
and O 0 3.109031965209397e-08
3 O 0 7.679810209992866e-08
regions O 0 2.5817683990680962e-08
of O 0 1.3301774792751075e-08
the O 0 1.687024848706642e-07
APC B-Disease 0 0.0003855791874229908
gene O 0 5.3219605433696415e-06
. O 0 2.583360355856712e-06

Attenuated B-Disease 1 0.9885181784629822
adenomatous I-Disease 1 0.9996716976165771
polyposis I-Disease 1 0.9999172687530518
coli I-Disease 1 0.9999568462371826
patients O 1 0.9950613379478455
have O 0 1.2256784430064727e-05
" O 0 9.509922733741405e-07
multiple O 0 3.7394347600638866e-05
" O 0 0.003491353476420045
colorectal B-Disease 1 0.9999994039535522
adenomas I-Disease 1 0.999990701675415
( O 0 6.137042419140926e-06
typically O 0 6.203246698532894e-07
fewer O 0 5.648777801070537e-07
than O 0 2.4259716013830257e-08
100 O 0 4.391417718352386e-08
) O 0 1.1265924193537558e-08
without O 0 1.6085451193248446e-08
the O 0 2.4220694783139152e-08
florid O 0 0.00016351661179214716
phenotype O 0 5.530142971110763e-06
of O 0 9.21847913559759e-08
classical O 0 1.5145980796660297e-05
FAP B-Disease 0 0.007288739550858736
. O 0 1.1286805602139793e-05

Another O 0 1.6256921298918314e-05
group O 0 1.7508567907498218e-05
of O 0 1.834425574998022e-06
patients O 0 0.00016831104585435241
with O 0 6.310832532108179e-07
multiple O 0 8.604100730735809e-05
adenomas B-Disease 1 0.979814350605011
has O 0 2.6928562419925584e-06
no O 0 2.2350936035309132e-07
mutations O 0 7.274676363522303e-07
in O 0 1.2518857950283291e-08
the O 0 6.05596639502437e-08
APC B-Disease 0 8.237389556597918e-05
gene O 0 3.317662731205928e-07
, O 0 4.9069200258600176e-08
and O 0 4.1067725220500506e-08
their O 0 1.2711484487226699e-07
phenotype O 0 1.664703813730739e-05
probably O 0 2.0239798459442682e-07
results O 0 4.471254300142391e-08
from O 0 1.6373730815644194e-08
variation O 0 1.0509595682606232e-07
at O 0 9.159799674307578e-08
a O 0 9.66619211340003e-08
locus O 0 4.124457063880982e-06
, O 0 1.9482956759020453e-07
or O 0 8.886893709814103e-08
loci O 0 5.483333325173589e-07
, O 0 6.637567651068821e-08
elsewhere O 0 1.809882093084525e-07
in O 0 2.1236765235244093e-08
the O 0 1.3313328395270219e-07
genome O 0 1.5390172848128714e-05
. O 0 5.044329100201139e-06

Recently O 0 0.001797473174519837
, O 0 3.583795887607266e-06
however O 0 1.8527457257278002e-07
, O 0 3.3643782870740324e-08
a O 0 4.8203251168388306e-08
missense O 0 1.9788627469097264e-05
variant O 0 5.922205218666932e-06
of O 0 3.413679792174662e-07
APC B-Disease 0 0.0013115290785208344
( O 0 7.200243885563395e-07
I1307K O 0 6.786738958908245e-05
) O 0 5.096057975606527e-08
was O 0 1.7463629831127037e-07
described O 0 2.2438587166107027e-07
that O 0 9.421150970467806e-09
confers O 0 9.969708116841502e-07
an O 0 1.7436735788578517e-07
increased O 0 1.8978355001308955e-05
risk O 0 0.005221208091825247
of O 0 0.022980157285928726
colorectal B-Disease 1 0.9999998807907104
tumors I-Disease 1 0.9999995231628418
, O 0 2.245318319182843e-05
including O 0 1.7374770322931e-05
multiple O 0 0.0002778465277515352
adenomas B-Disease 1 0.9503090381622314
, O 0 5.832381702930434e-06
in O 0 2.2532262846652884e-06
Ashkenazim O 0 0.013794663362205029
. O 0 2.7365113055566326e-05

We O 0 3.681319412862649e-06
have O 0 2.752932459770818e-07
studied O 0 1.982664343813667e-07
a O 0 1.7873087898578888e-08
set O 0 1.4785100255210182e-08
of O 0 4.273798026588338e-08
164 O 0 0.0003631116996984929
patients O 0 0.00027040488203056157
with O 0 1.0969409231620375e-05
multiple O 1 0.6463422179222107
colorectal B-Disease 1 0.9999998807907104
adenomas I-Disease 1 0.9999949932098389
and I-Disease 0 0.0012019140413030982
/ I-Disease 0 0.15465766191482544
or I-Disease 0 0.003377507673576474
carcinoma I-Disease 1 0.9999767541885376
and O 0 3.3934361454157624e-06
analyzed O 0 9.840054190135561e-06
codons O 0 1.027649068419123e-05
1263 O 0 0.000281551037915051
- O 0 0.0006231949664652348
1377 O 0 0.0003884293546434492
( O 0 9.21137868203914e-08
exon O 0 5.726838935515843e-06
15G O 0 1.3134395885572303e-05
) O 0 5.971179994901377e-09
of O 0 1.4526249092483567e-09
the O 0 5.707768480078812e-09
APC B-Disease 0 3.6336248285806505e-06
gene O 0 7.071167829053593e-08
for O 0 5.349247444996763e-08
germ O 0 7.632596680196002e-05
- O 0 0.00016125185356941074
line O 0 9.2279742602841e-06
variants O 0 4.750655534735415e-06
. O 0 2.641708988448954e-06

Three O 0 0.00011125475430162624
patients O 0 0.001179078477434814
with O 0 2.4558283939768444e-07
the O 0 1.5974806899521354e-07
I1307K O 0 5.937539754086174e-05
allele O 0 1.9948095086874673e-06
were O 0 3.8586813388974406e-07
detected O 0 1.4279319202614715e-06
, O 0 1.576419350612923e-08
each O 0 1.0756378898690855e-08
of O 0 2.3373328872366983e-07
Ashkenazi O 0 0.0013158287620171905
descent O 0 0.0003787581517826766
. O 0 1.571045140735805e-05

Four O 0 0.0002955417730845511
patients O 0 0.01771244965493679
had O 0 7.02257830198505e-06
a O 0 4.4270760213294125e-07
germ O 0 0.000649387133307755
- O 0 0.0006344941793940961
line O 0 6.290838427958079e-06
E1317Q O 0 2.215785025327932e-05
missense O 0 1.2075086488039233e-05
variant O 0 9.768199333848315e-07
of O 0 3.34048948502641e-08
APC O 0 6.405829481082037e-05
that O 0 7.017572301037944e-08
was O 0 4.024277302505652e-07
not O 0 1.0313928378025139e-08
present O 0 1.3218968142325593e-08
in O 0 9.871323314314395e-09
controls O 0 2.762795361377357e-07
; O 0 6.266859031711647e-08
one O 0 4.5598915754396785e-09
of O 0 9.917521914815097e-09
these O 0 2.312535052340081e-08
individuals O 0 3.7370776340139855e-07
had O 0 7.948195843709982e-07
an O 0 1.0368668057481045e-07
unusually O 0 8.604049071436748e-06
large O 0 1.6817463688312273e-07
number O 0 2.816952893169855e-08
of O 0 1.9827871255984064e-07
metaplastic B-Disease 0 0.179349884390831
polyps I-Disease 0 0.05771132931113243
of I-Disease 0 2.0985390847272356e-07
the I-Disease 0 1.4629101769969566e-06
colorectum I-Disease 0 0.008363462053239346
. O 0 7.6228957368584815e-06

There O 0 2.3064224023983115e-06
is O 0 2.931532492311817e-07
increasing O 0 6.880566161271418e-07
evidence O 0 4.915613089906401e-07
that O 0 1.8397161127836625e-08
there O 0 5.039182848776136e-09
exist O 0 2.079889505068877e-08
germ O 0 4.7552864998579025e-05
- O 0 7.483238005079329e-05
line O 0 8.130592732413788e-07
variants O 0 6.691592346896869e-08
of O 0 5.017354975933586e-09
the O 0 2.9634579234993907e-08
APC B-Disease 0 2.786765071505215e-05
gene O 0 1.7895335702178272e-07
that O 0 1.1703876090507492e-08
predispose O 0 9.66898141996353e-07
to O 0 8.249183558461937e-09
the O 0 9.71909841496199e-09
development O 0 9.31427237560456e-08
of O 0 1.34540766794089e-06
multiple O 0 0.4839579463005066
colorectal B-Disease 1 0.9999998807907104
adenomas I-Disease 1 0.9999984502792358
and I-Disease 1 0.8793488144874573
carcinoma I-Disease 1 0.9999991655349731
, O 0 3.28914902638644e-05
but O 0 2.914083552241209e-07
without O 0 8.147796393132012e-08
the O 0 4.914685192147772e-08
florid O 0 0.000215193213080056
phenotype O 0 5.617133410851238e-06
of O 0 4.725802682514768e-08
classical O 0 4.716141120297834e-06
FAP B-Disease 0 0.0026166627649217844
, O 0 2.2547126832250797e-07
and O 0 7.276911873077552e-08
possibly O 0 2.1185186938055267e-07
with O 0 7.960873915635602e-08
importance O 0 4.625138899427839e-06
for O 0 0.08454189449548721
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999971389770508
risk O 0 0.011998099274933338
in O 0 1.1693727941519683e-07
the O 0 6.753922576763216e-08
general O 0 1.3220806067693047e-06
population O 0 4.263930293291196e-07
. O 0 4.1932625549634395e-07
. O 0 2.318607130291639e-06

Genomic O 0 0.000430285872425884
structure O 0 1.0367009963374585e-05
of O 0 1.3680773918167688e-06
the O 0 2.902124288084451e-05
human O 0 0.18870924413204193
congenital B-Disease 1 0.999992847442627
chloride I-Disease 1 0.99981290102005
diarrhea I-Disease 1 0.9999916553497314
( O 0 0.00041765483911149204
CLD B-Disease 1 0.9918689727783203
) O 0 1.66704867297085e-05
gene O 0 1.2594327927217819e-05
. O 0 5.8483678913034964e-06

Congenital B-Disease 1 0.9999573230743408
chloride I-Disease 1 0.9996147155761719
diarrhea I-Disease 1 0.9999710321426392
( O 0 0.0004047136753797531
CLD B-Disease 1 0.9980387091636658
) O 0 1.798223274818156e-05
is O 0 6.04506169565866e-07
caused O 0 3.768906253753812e-06
by O 0 3.152125316319143e-07
mutations O 0 1.811341007851297e-06
in O 0 1.7118431117069122e-08
a O 0 9.67332951518074e-08
gene O 0 1.6452597151328519e-07
which O 0 3.364846890008266e-08
encodes O 0 1.355602876174089e-06
an O 0 8.222667020163499e-06
intestinal O 1 0.8572471141815186
anion O 0 0.009892424568533897
transporter O 0 0.03212203457951546
. O 0 1.430790507583879e-05

We O 0 4.931173407385359e-06
report O 0 1.0945143458229722e-06
here O 0 3.172971574372241e-08
the O 0 4.634978179041127e-09
complete O 0 2.639456653241723e-08
genomic O 0 1.788954818948696e-06
organization O 0 7.08160214912823e-08
of O 0 6.743274827414325e-09
the O 0 2.1740753197718732e-08
human O 0 2.7029318516724743e-07
CLD B-Disease 0 0.004922300111502409
gene O 0 1.752444092062433e-07
which O 0 6.506663208227792e-09
spans O 0 3.1101978947845055e-07
approximately O 0 1.671666041147546e-07
39kb O 0 0.0003195556055288762
, O 0 1.224113930220483e-07
and O 0 4.656690677506958e-08
comprises O 0 2.6207985115433985e-07
21 O 0 2.382705815762165e-06
exons O 0 2.5175528207910247e-05
. O 0 5.422725735115819e-06

All O 0 1.9370772861293517e-06
exon O 0 0.0001318799186265096
/ O 0 2.765197496046312e-05
intron O 0 0.00011491221812320873
boundaries O 0 2.2279726863416727e-07
conform O 0 2.5317558538517915e-07
to O 0 1.0824047436130968e-08
the O 0 2.2810725752719918e-08
GT O 0 3.481950989225879e-05
/ O 0 0.0005596696282736957
AG O 1 0.9756073951721191
rule O 0 2.4297320123878308e-05
. O 0 6.827790457464289e-06

An O 0 1.4776325087950681e-06
analysis O 0 3.849892493690277e-07
of O 0 5.18589473585962e-08
the O 0 9.200667250297556e-08
putative O 0 6.905687769176438e-05
promoter O 0 2.922782914538402e-05
region O 0 7.060427265059843e-08
sequence O 0 6.679717223789794e-09
shows O 0 2.1847460729418344e-08
a O 0 4.3827654394590354e-08
putative O 0 3.8046608096919954e-05
TATA O 0 0.03828297555446625
box O 0 2.3352780772256665e-05
and O 0 3.1682097301199974e-07
predicts O 0 6.861890597065212e-06
multiple O 0 5.69085614188225e-07
transcription O 0 1.8744615317700664e-06
factor O 0 4.341912358540867e-07
binding O 0 5.837184176016308e-07
sites O 0 9.623032610761584e-07
. O 0 1.8773883994072094e-06

The O 0 3.853245743812295e-06
genomic O 0 6.954804121050984e-05
structure O 0 5.449751370179001e-06
was O 0 2.881605780657992e-07
determined O 0 4.64637217589825e-08
using O 0 1.289453877006963e-08
DNA O 0 3.374938728484267e-07
from O 0 1.667356919199392e-08
several O 0 5.172200889802525e-09
sources O 0 1.2295514828508658e-08
including O 0 5.7711769585466755e-08
multiple O 0 4.207045662951714e-07
large O 0 1.6898989088076632e-06
- O 0 0.007878107950091362
insert O 0 3.271405876148492e-05
libaries O 0 2.942715582321398e-05
and O 0 3.6469515407588915e-08
genomic O 0 5.543187739931454e-07
DNA O 0 1.3508112033377984e-06
from O 0 6.94000902967673e-07
Finnish O 0 0.03325421363115311
CLD B-Disease 1 0.9968876242637634
patients O 0 0.008102865889668465
and O 0 2.7561161459743744e-06
controls O 0 2.7442103601060808e-05
. O 0 7.310518867598148e-06

Exon O 0 0.0011343677761033177
- O 0 0.0003835189563687891
specific O 0 8.453422992715787e-07
primers O 0 6.810266495449468e-05
developed O 0 6.667514298897004e-06
in O 0 5.2078306111980055e-08
this O 0 4.067225223280957e-09
study O 0 1.8400809764784753e-08
will O 0 3.988953611866464e-09
facilitate O 0 6.14414616961767e-08
mutation O 0 3.734704705493641e-07
screening O 0 4.617945421614422e-07
studies O 0 1.8463622097897314e-07
of O 0 3.738667260222428e-07
patients O 0 4.40802687080577e-05
with O 0 1.5831454902581754e-06
the O 0 6.0234386182855815e-05
disease O 0 0.02467147819697857
. O 0 1.7016909623635e-05

Genomic O 0 2.4740074877627194e-05
sequencing O 0 2.921311534009874e-06
of O 0 1.20654448210189e-07
a O 0 1.9899648862065078e-07
BAC O 0 1.388188775308663e-05
clone O 0 0.0002377839555265382
H O 0 0.2960098087787628
_ O 0 1.0049328921013512e-05
RG364P16 O 0 4.543130489764735e-05
revealed O 0 1.0361250133428257e-06
the O 0 9.72102576213274e-09
presence O 0 1.997381460228098e-08
of O 0 3.0854359067689074e-09
another O 0 3.6770554601162075e-08
, O 0 6.429155519072083e-08
highly O 0 8.769832504640362e-08
homologous O 0 3.4508141766309564e-07
gene O 0 3.301451911852382e-08
3 O 0 8.997855793779763e-09
of O 0 7.005747093558057e-09
the O 0 1.024101123903165e-07
CLD B-Disease 0 0.1417972296476364
gene O 0 1.2755908755934797e-06
, O 0 2.6086963700322485e-08
with O 0 1.3742379678660654e-08
a O 0 1.9546208207543714e-08
similar O 0 4.09729743466869e-08
genomic O 0 5.216134468355449e-06
structure O 0 8.770867339080723e-07
, O 0 1.3482882366133708e-07
recently O 0 4.5394895096251275e-06
identified O 0 7.509601687161194e-07
as O 0 2.1212035505868698e-07
the O 0 2.3833150407881476e-05
Pendred B-Disease 1 0.9999872446060181
syndrome I-Disease 1 0.9999923706054688
gene O 0 2.644117375893984e-05
( O 0 2.891068788812845e-06
PDS B-Disease 0 0.040751244872808456
) O 0 1.4432876014325302e-06
. O 0 4.241708211338846e-07
. O 0 1.9583471839723643e-06

The O 0 1.128246913140174e-05
APCI1307K O 0 0.033435359597206116
allele O 0 0.00042059505358338356
and O 0 0.0007608504383824766
cancer B-Disease 1 0.9573943614959717
risk O 0 0.00025518907932564616
in O 0 7.652832323401526e-08
a O 0 1.447007207389106e-07
community O 0 2.226326785148558e-07
- O 0 0.00017332452989649028
based O 0 1.8585799352877075e-06
study O 0 3.9138623719736643e-07
of O 0 3.970949649101385e-07
Ashkenazi O 0 0.00046140988706611097
Jews O 0 3.408648990443908e-05
. O 0 4.407488631841261e-06

Mutations O 0 0.0014778879703953862
in O 0 6.526200195366982e-06
APC O 0 0.00099693622905761
are O 0 1.4433400110647199e-06
classically O 0 0.07496245950460434
associated O 0 6.486615893663839e-05
with O 0 0.0004018288746010512
familial B-Disease 1 0.9999653100967407
adenomatous I-Disease 1 0.9999864101409912
polyposis I-Disease 1 0.9999933242797852
( O 0 0.00042916423990391195
FAP B-Disease 0 0.18545877933502197
) O 0 6.99155918937322e-07
, O 0 1.8322907635592856e-07
a O 0 1.2609558552867384e-06
highly O 0 0.00019351276569068432
penetrant O 1 0.9961917400360107
autosomal B-Disease 1 0.9997647404670715
dominant I-Disease 1 0.9949240684509277
disorder I-Disease 1 0.9999788999557495
characterized O 0 0.018342461436986923
by O 0 7.698941772105172e-05
multiple O 0 0.3825080394744873
intestinal O 1 0.9999738931655884
polyps B-Disease 1 0.9968867897987366
and O 0 8.982203326013405e-06
, O 0 1.1307881777611328e-06
without O 0 1.0657048505890998e-06
surgical O 0 0.0037499626632779837
intervention O 0 8.463283847959246e-06
, O 0 1.2275367566871864e-07
the O 0 6.799704976856447e-08
development O 0 5.554880317504285e-06
of O 0 0.047416869550943375
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999920129776001
( O 0 0.00010143202962353826
CRC B-Disease 0 0.1640157848596573
) O 0 1.4339883819047827e-05
. O 0 8.340293788933195e-06

APC B-Disease 0 0.004237917251884937
is O 0 3.750097903321148e-06
a O 0 2.2252694179769605e-05
tumour O 1 0.9987947940826416
- O 0 0.040566761046648026
suppressor O 0 0.0010902181966230273
gene O 0 1.5493579894609866e-06
, O 0 9.085865571023533e-08
and O 0 3.102646246588847e-07
somatic O 0 0.00035188885522075
loss O 0 0.008143475279211998
occurs O 0 1.4624142750108149e-05
in O 0 2.6115196305909194e-05
tumours B-Disease 1 0.9992873072624207
. O 0 7.125968113541603e-05

The O 0 2.0196435798425227e-05
germline O 0 0.062254905700683594
T O 0 0.1248636245727539
- O 0 0.0004283557937014848
to O 0 2.320926881793639e-07
- O 0 4.35863112215884e-05
A O 0 4.1151787399940076e-07
transversion O 0 2.4730312361498363e-05
responsible O 0 2.062024293536524e-07
for O 0 7.911932442539182e-09
the O 0 1.423855700011245e-08
APC O 0 7.663942596991546e-06
I1307K O 0 4.801102477358654e-06
allele O 0 6.720524936554284e-08
converts O 0 5.241682998757824e-08
the O 0 5.6159885630790995e-09
wild O 0 2.2013652767327585e-07
- O 0 1.29425870909472e-05
type O 0 1.2679508643032023e-07
sequence O 0 1.3393271380834904e-08
to O 0 1.3163766077184391e-08
a O 0 7.281061584762938e-07
homopolymer O 1 0.5955482721328735
tract O 0 0.06901770830154419
( O 0 6.047425813449081e-07
A8 O 0 0.010915781371295452
) O 0 2.05298647415475e-07
that O 0 2.209955418663867e-08
is O 0 6.827320930824499e-08
genetically O 0 5.042457632953301e-05
unstable O 0 0.0007384309428744018
and O 0 7.631631888216361e-06
prone O 0 0.007525342516601086
to O 0 1.7256616047234274e-06
somatic O 0 0.0015335030620917678
mutation O 0 0.00012244144454598427
. O 0 1.0882343303819653e-05

The O 0 6.852317710581701e-06
I1307K O 0 0.00041690299985930324
allele O 0 3.085334901697934e-05
was O 0 1.7135047301053419e-06
found O 0 3.892600091148779e-07
in O 0 1.5030460076559393e-07
6 O 0 8.265192263934296e-06
. O 0 4.172060471319128e-06

1 O 0 2.3791273633833043e-05
% O 0 1.441022391190927e-06
of O 0 3.9338226542895427e-07
unselected O 0 0.005506402812898159
Ashkenazi O 0 0.00391022814437747
Jews O 0 5.552984021051088e-06
and O 0 1.9177883814336383e-07
higher O 0 3.0121074701128236e-07
proportions O 0 9.985075166696333e-07
of O 0 5.691073567959393e-08
Ashkenazim O 0 0.000271881785010919
with O 0 2.8809129162254976e-06
family O 0 1.0529221071919892e-05
or O 0 2.591016254882561e-07
personal O 0 4.585383976518642e-06
histories O 0 6.048745035514003e-06
of O 0 8.870702004060149e-07
CRC B-Disease 0 0.011847385205328465
( O 0 1.7392505924362922e-06
ref O 0 0.002016340848058462
. O 0 1.326888963149031e-07
2 O 0 5.464738137561653e-07
) O 0 3.2934713090071455e-07
. O 0 9.138437349065498e-07

To O 0 3.0210539989639074e-06
evaluate O 0 6.675760232610628e-06
the O 0 6.145060638118593e-08
role O 0 1.8066434392949304e-07
of O 0 4.795263208734468e-08
I1307K O 0 0.0001570569002069533
in O 0 2.784429398161592e-06
cancer B-Disease 0 0.0027770635206252337
, O 0 1.4686229121707584e-07
we O 0 2.4037021262302005e-08
genotyped O 0 3.0819326639175415e-05
5 O 0 1.4461740249771537e-07
, O 0 2.014928099924873e-07
081 O 0 0.00040139516931958497
Ashkenazi O 0 0.0001409642572980374
volunteers O 0 2.466731984895887e-06
in O 0 1.764788848390708e-08
a O 0 9.34864061719054e-08
community O 0 6.819791451562196e-07
survey O 0 1.7695803762762807e-05
. O 0 4.2204537749057636e-06

Risk O 0 0.006495133973658085
of O 0 2.841922832885757e-05
developing O 0 0.29125452041625977
colorectal B-Disease 1 0.9999912977218628
, I-Disease 0 0.0019365011248737574
breast I-Disease 1 0.8402655720710754
and I-Disease 0 1.272859844902996e-05
other I-Disease 0 8.991939466795884e-06
cancers I-Disease 0 0.17702394723892212
were O 0 5.06067465266824e-07
compared O 0 2.4781581942079356e-06
between O 0 4.091511698334216e-07
genotyped O 0 0.004251166246831417
I1307K O 0 0.0003425136092118919
carriers O 0 1.1729502148227766e-05
and O 0 1.2828125761643605e-07
non O 0 3.172256583638955e-06
- O 0 0.00031334030791185796
carriers O 0 1.0865802323678508e-05
and O 0 3.2114943593342105e-08
their O 0 7.019590686496713e-09
first O 0 6.041752698138225e-08
- O 0 8.792975859250873e-05
degree O 0 5.931447049078997e-06
relatives O 0 3.7686946598114446e-05
. O 0 2.344808081033989e-06

Sperm O 0 0.000310085597448051
DNA O 0 4.4576758227776736e-05
analysis O 0 1.380242565574008e-06
in O 0 2.5781275780900614e-07
a O 0 1.865873855422251e-06
Friedreich B-Disease 1 0.5199614763259888
ataxia I-Disease 1 0.891435980796814
premutation O 1 0.6825429797172546
carrier O 0 0.0017224596813321114
suggests O 0 2.87366310658399e-06
both O 0 9.829823000018223e-08
meiotic O 0 0.00012356435763649642
and O 0 4.7355970878015796e-07
mitotic O 0 6.440338620450348e-05
expansion O 0 2.922532075899653e-06
in O 0 6.889930403986e-08
the O 0 3.580454119855858e-07
FRDA B-Disease 0 0.003262793878093362
gene O 0 7.08855941411457e-06
. O 0 2.466804971845704e-06

Friedreich B-Disease 1 0.9975391626358032
ataxia I-Disease 1 0.9984040856361389
is O 0 0.00016072823200374842
usually O 0 2.1297208149917424e-05
caused O 0 2.6648116545402445e-05
by O 0 1.1033812086225225e-07
an O 0 3.577054386028067e-08
expansion O 0 2.6294080157640565e-07
of O 0 3.7328739210806816e-08
a O 0 3.344034382735117e-07
GAA O 0 0.0002627300564199686
trinucleotide O 0 0.006116009317338467
repeat O 0 9.483012036071159e-06
in O 0 5.2492669766479594e-08
intron O 0 2.921796294685919e-05
1 O 0 5.845869566201145e-08
of O 0 2.2684943701278826e-08
the O 0 3.569224418242811e-07
FRDA B-Disease 0 0.004988859873265028
gene O 0 7.461652785423212e-06
. O 0 2.3954057724040467e-06

Occasionally O 0 8.12060316093266e-05
, O 0 1.4649875765826437e-06
a O 0 2.0232039332768181e-07
fully O 0 4.6105128603812773e-07
expanded O 0 2.82627496517307e-07
allele O 0 4.832038484892109e-07
has O 0 8.798113526609086e-08
been O 0 7.88332954471116e-08
found O 0 7.342999452930599e-08
to O 0 1.5087294968907372e-08
arise O 0 4.785546252605855e-07
from O 0 2.843674629104953e-08
a O 0 1.232865542988293e-07
premutation O 0 8.893459744285792e-05
of O 0 6.013677733562872e-08
100 O 0 1.4904151157679735e-07
or O 0 2.5928628133442544e-07
less O 0 7.113712285899965e-07
triplet O 0 0.0003401255526114255
repeats O 0 2.434881571389269e-05
. O 0 5.103156581753865e-06

We O 0 4.33460763815674e-06
have O 0 4.877620085608214e-07
examined O 0 1.5715221479695174e-06
the O 0 1.2756521172718749e-08
sperm O 0 4.7116989776441187e-07
DNA O 0 5.296510607877281e-07
of O 0 6.44447837316875e-08
a O 0 1.5534266140093678e-06
premutation O 0 0.01531574409455061
carrier O 0 0.0008060713298618793
. O 0 6.928608399903169e-06

This O 0 1.012086727314454e-06
mans O 0 2.2732168872607872e-05
leucocyte O 0 0.0012231440050527453
DNA O 0 5.732026693294756e-05
showed O 0 4.4929397517989855e-06
one O 0 1.8609405572078686e-08
normal O 0 3.081779098579318e-08
allele O 0 1.0640825109931029e-07
and O 0 1.3368770090949056e-08
one O 0 4.592745739273596e-09
allele O 0 4.191583258261744e-08
of O 0 5.692503801668636e-09
approximately O 0 9.24224607956603e-08
100 O 0 2.2357332341016445e-07
repeats O 0 4.723666734207654e-06
. O 0 2.6183952286373824e-06

His O 0 2.674937786650844e-05
sperm O 0 4.561023524729535e-05
showed O 0 6.625097739743069e-06
an O 0 4.7879790798788235e-08
expanded O 0 2.6037906764031504e-07
allele O 0 2.305867212726298e-07
in O 0 9.453371418999268e-09
a O 0 3.5346118920642766e-08
tight O 0 1.0866991715374752e-06
range O 0 1.0542421335912877e-07
centering O 0 6.159048666631861e-07
on O 0 6.575320554702557e-08
a O 0 2.3399550741487474e-08
size O 0 1.1091161411513895e-07
of O 0 1.9380786753231405e-08
approximately O 0 2.9935992529317446e-07
320 O 0 3.0352095564012416e-05
trinucleotide O 0 0.0028392095118761063
repeats O 0 1.9569806681829505e-05
. O 0 3.995019142166711e-06

His O 0 0.00027196784503757954
affected O 0 0.0001159991734311916
son O 0 0.0004849473189096898
has O 0 5.693233333659009e-07
repeat O 0 8.563230267100153e-07
sizes O 0 3.071627361350693e-07
of O 0 4.2179685522114596e-08
1040 O 0 2.557129118940793e-05
and O 0 1.0994921240126132e-06
540 O 0 8.767087274463847e-05
. O 0 5.516295004781568e-06

These O 0 1.1965197472818545e-06
data O 0 7.582067382827518e-07
suggest O 0 4.5587242425426666e-07
that O 0 2.184300207375145e-08
expansion O 0 3.267785189109418e-07
occurs O 0 2.932185871884485e-08
in O 0 4.619929772076148e-09
two O 0 9.142009815832353e-09
stages O 0 8.816043077786162e-07
, O 0 3.874193055253272e-08
the O 0 4.1748888790493766e-09
first O 0 2.0084986118718007e-08
during O 0 4.802072695042625e-08
meiosis O 0 5.994490379634954e-07
followed O 0 1.0064485422844882e-07
by O 0 1.875307198417886e-08
a O 0 3.4806621584948516e-08
second O 0 3.752105044441123e-07
mitotic O 0 0.00017718080198392272
expansion O 0 4.952875679009594e-05
. O 0 4.9452964958618395e-06

We O 0 3.414425918890629e-06
also O 0 4.787262355421262e-07
show O 0 1.1147937328814805e-07
that O 0 4.12754896927936e-09
in O 0 2.466172155379809e-09
all O 0 1.360049406429198e-09
informative O 0 2.9104506893418147e-07
carrier O 0 5.275620787870139e-05
father O 0 4.229092155583203e-06
to O 0 4.998597091798729e-08
affected O 0 2.9940534318484424e-07
child O 0 1.2383135299387504e-06
transmissions O 0 4.877225023847132e-07
, O 0 4.605590930850667e-08
with O 0 2.8235259463826878e-08
the O 0 2.3119087089185086e-08
notable O 0 4.832803597309976e-07
exception O 0 9.421155056088537e-08
of O 0 1.1382234710310968e-08
the O 0 5.905197397737538e-08
premutation O 0 0.002389086177572608
carrier O 0 3.53500472556334e-05
, O 0 1.7761012216510608e-08
the O 0 5.779733136535015e-09
expansion O 0 4.7321344709416735e-07
size O 0 3.7515683288802393e-06
decreases O 0 7.0210244302870706e-06
. O 0 1.8942023416457232e-07
. O 0 1.4769732388231205e-06

The O 0 7.31661430108943e-06
R496H O 0 0.0007413825369440019
mutation O 0 1.0230063708149828e-05
of O 0 2.727828132265131e-07
arylsulfatase O 0 0.0033834727946668863
A O 0 3.5543366720958147e-06
does O 0 8.205638550862204e-07
not O 0 9.614731197871151e-07
cause O 0 0.0001801861508283764
metachromatic B-Disease 1 0.9976345300674438
leukodystrophy I-Disease 1 0.9995220899581909
. O 0 8.575833635404706e-05

Deficiency B-Disease 1 0.996557354927063
of I-Disease 0 1.2633050573640503e-05
arylsulfatase I-Disease 0 0.10938073694705963
A I-Disease 0 2.8043712518410757e-05
( O 0 3.4888626032625325e-06
ARSA O 0 0.08415664732456207
) O 0 2.2538408757100115e-06
enzyme O 0 1.7430931620765477e-05
activity O 0 9.209740710502956e-06
causes O 0 0.0010597172658890486
metachromatic B-Disease 1 0.9997637867927551
leukodystrophy I-Disease 1 0.9999376535415649
( O 0 0.0005143117741681635
MLD B-Disease 1 0.9989394545555115
) O 0 1.9930044800275937e-05
. O 0 9.09061145648593e-06

A O 0 4.978073320671683e-06
number O 0 2.5005925863297307e-07
of O 0 1.8647534716365044e-07
ARSA O 0 0.026070913299918175
gene O 0 3.214508524251869e-06
mutations O 0 1.8130537000615732e-06
responsible O 0 1.3085233376841643e-06
for O 0 1.6990614994938369e-06
MLD B-Disease 1 0.9991883635520935
have O 0 2.4385963115491904e-06
been O 0 1.3954099813417997e-06
identified O 0 8.070035619311966e-06
. O 0 4.718084255728172e-06

Recently O 0 0.0004817672888748348
, O 0 1.6868332295416621e-06
the O 0 1.7629491821935517e-07
R496H O 0 4.783102485816926e-05
mutation O 0 1.2062066616636002e-06
of O 0 2.3218389344492607e-07
ARSA O 0 0.3658212125301361
was O 0 7.416306743834866e-06
proposed O 0 1.0178496268054005e-06
to O 0 2.2109249542268117e-08
be O 0 1.0925766957825545e-08
a O 0 1.296819220897305e-07
cause O 0 2.3194297682493925e-06
of O 0 6.611929279642936e-07
MLD B-Disease 1 0.9991356730461121
( O 0 2.7951300580753013e-06
Draghia O 0 0.0006344763096421957
et O 0 1.1244691449974198e-05
al O 0 8.886976502253674e-06
. O 0 5.874125008631381e-08
, O 0 1.3064594384104566e-07
1997 O 0 2.7807514015876222e-06
) O 0 4.58773627087794e-07
. O 0 2.058245627267752e-06

We O 0 3.8461453186755534e-06
have O 0 6.332197699521203e-07
investigated O 0 4.822730261366814e-06
the O 0 1.1204769378991841e-07
R496H O 0 0.0001598977396497503
mutation O 0 2.2237536541069858e-06
and O 0 1.215345548644109e-07
found O 0 1.3206852145231096e-07
this O 0 5.528846269697851e-09
mutation O 0 2.900193294408382e-07
at O 0 1.5591407986903505e-07
a O 0 9.179773030609795e-08
relatively O 0 1.9098381187632185e-07
high O 0 1.6135218174895272e-06
frequency O 0 6.943346164689501e-08
in O 0 1.134227112231656e-08
an O 0 3.1279945744699944e-08
African O 0 2.950959867575875e-07
American O 0 5.18489628120733e-07
population O 0 5.5433790890901946e-08
( O 0 3.3243132691040955e-08
f O 0 6.111495622462826e-06
= O 0 3.04079003399238e-06
0 O 0 1.6365666510864685e-07
. O 0 6.7228040911970766e-09
09 O 0 4.276962499716319e-07
, O 0 3.624303701599274e-08
n O 0 2.635081500557135e-06
= O 0 4.416282536112703e-06
61 O 0 4.178980816504918e-06
subjects O 0 1.950898422364844e-06
) O 0 4.137159805850388e-07
. O 0 1.0346635690439143e-06

The O 0 1.4177011507854331e-05
ARSA O 0 0.15690945088863373
enzyme O 0 0.0001014658046187833
activity O 0 1.4907022887200583e-06
in O 0 1.0962969554384472e-07
subjects O 0 6.179711817821953e-07
with O 0 9.053705696260295e-08
and O 0 1.3767861162250483e-07
without O 0 3.6589145935295164e-08
the O 0 2.595603376676081e-08
R496H O 0 2.248677992611192e-05
mutation O 0 8.923426548790303e-07
was O 0 4.815229885934968e-07
determined O 0 3.1054912597028306e-07
and O 0 1.8190706896348274e-07
found O 0 3.3493901696601824e-07
to O 0 2.458743253441753e-08
be O 0 6.158319365567877e-08
normal O 0 5.692853619621019e-07
. O 0 1.3160059779693256e-06

It O 0 3.071837227253127e-06
is O 0 4.6299709310915205e-07
therefore O 0 9.669714273741192e-08
concluded O 0 1.2060191920681973e-06
that O 0 8.000600182356266e-09
the O 0 1.5322811464102415e-08
R496H O 0 1.8127502698916942e-05
mutation O 0 5.758047905146668e-07
of O 0 1.1215075090831306e-07
ARSA O 0 0.18248187005519867
does O 0 2.3832461693018558e-07
not O 0 9.272966394746618e-09
negatively O 0 1.927671888779514e-07
influence O 0 3.3271803090428875e-08
the O 0 4.9145887359713925e-09
activity O 0 1.4096769973548362e-08
of O 0 3.082543287291628e-08
ARSA O 0 0.023681679740548134
and O 0 9.782182814888074e-07
is O 0 5.881008391384057e-08
not O 0 2.9205704521473308e-08
a O 0 3.5303881418258243e-07
cause O 0 1.702835288597271e-05
of O 0 1.8566966900834814e-05
MLD B-Disease 1 0.9973268508911133

Down O 0 9.814909572014585e-05
- O 0 0.00019953650189563632
regulation O 0 2.4019800548558123e-06
of O 0 2.2224341478249698e-07
transmembrane O 0 5.265844811219722e-05
carbonic O 0 0.0012860094429925084
anhydrases O 0 0.008033988997340202
in O 0 3.607894905144349e-05
renal B-Disease 1 0.9999274015426636
cell I-Disease 1 0.993061363697052
carcinoma I-Disease 1 0.9999958276748657
cell O 0 0.003195542376488447
lines O 0 1.2970017451152671e-05
by O 0 4.675937645970407e-07
wild O 0 5.268623681331519e-06
- O 0 0.00953738298267126
type O 0 9.957949805539101e-05
von B-Disease 1 0.6871433258056641
Hippel I-Disease 1 0.9373438358306885
- I-Disease 1 0.5518580079078674
Lindau I-Disease 0 0.41790974140167236
transgenes O 0 0.0031730039045214653
. O 0 1.2220613825775217e-05

To O 0 5.557455097005004e-06
discover O 0 1.3688063518202398e-05
genes O 0 1.640050754758704e-06
involved O 0 9.102687954509747e-07
in O 0 5.177415118851059e-07
von B-Disease 1 0.7877121567726135
Hippel I-Disease 1 0.9935858845710754
- I-Disease 1 0.8125444650650024
Lindau I-Disease 1 0.7765587568283081
( O 0 9.227166515302088e-07
VHL B-Disease 0 0.00023681535094510764
) O 0 7.043533400974411e-08
- O 0 3.6223329516360536e-05
mediated O 0 0.00013923323422204703
carcinogenesis O 0 0.03781551495194435
, O 0 5.00489363730594e-07
we O 0 8.801436734984236e-08
used O 0 7.784125955367927e-06
renal B-Disease 1 0.9995031356811523
cell I-Disease 1 0.8794347643852234
carcinoma I-Disease 1 0.9999926090240479
cell O 0 0.0017453234177082777
lines O 0 1.8756702047539875e-05
stably O 0 0.0002504516742192209
transfected O 0 0.0006479015573859215
with O 0 2.5139758008663193e-07
wild O 0 3.4956833587784786e-06
- O 0 0.010293443687260151
type O 0 8.532777428627014e-05
VHL O 0 0.012668236158788204
- O 0 0.0017924272688105702
expressing O 0 7.903028017608449e-05
transgenes O 0 0.0003299073432572186
. O 0 6.0036377362848725e-06

Large O 0 1.4228236977942288e-05
- O 0 0.00010771295637823641
scale O 0 7.619385087309638e-06
RNA O 0 1.0083119832415832e-06
differential O 0 1.8174300748796668e-06
display O 0 9.038907364811166e-07
technology O 0 2.5014442144311033e-06
applied O 0 1.5789461826898332e-07
to O 0 8.425597108896454e-09
these O 0 5.373685496579128e-09
cell O 0 1.3829356930727954e-06
lines O 0 6.81407641422993e-07
identified O 0 3.7654467632819433e-07
several O 0 2.479067262584067e-08
differentially O 0 8.029403034015559e-06
expressed O 0 3.604913842991664e-07
genes O 0 5.270998215678446e-08
, O 0 9.93259074988373e-09
including O 0 3.202038101335347e-08
an O 0 2.4340780058196287e-08
alpha O 0 2.2875483409734443e-06
carbonic O 0 0.00018982488836627454
anhydrase O 0 0.0005718623287975788
gene O 0 1.0796561582537834e-06
, O 0 3.589565551465057e-07
termed O 0 3.01231393677881e-05
CA12 O 0 0.002777589252218604
. O 0 7.429481229337398e-06

The O 0 1.4706328101965482e-06
deduced O 0 2.720968495850684e-06
protein O 0 1.8943178758945578e-07
sequence O 0 5.781456025033549e-08
was O 0 2.3385948111354082e-07
classified O 0 6.173950168886222e-07
as O 0 2.1975637309878948e-08
a O 0 1.6194118046541917e-08
one O 0 2.9461560302479484e-08
- O 0 0.000295224686851725
pass O 0 3.7089646411914146e-06
transmembrane O 0 5.630495070363395e-05
CA O 0 4.670037469622912e-06
possessing O 0 3.2257942166324938e-06
an O 0 8.48750616455618e-08
apparently O 0 1.5001219253463205e-06
intact O 0 5.33709965111484e-07
catalytic O 0 3.8640320099148084e-07
domain O 0 6.164923860296767e-08
in O 0 1.0399858751952706e-08
the O 0 5.1649674759346453e-08
extracellular O 0 2.0804960513487458e-05
CA O 0 4.66451165266335e-05
module O 0 9.618693729862571e-05
. O 0 4.861519300902728e-06

Reintroduced O 0 0.0003654641914181411
wild O 0 0.00010538001515669748
- O 0 0.017185645177960396
type O 0 7.718517736066133e-05
VHL B-Disease 0 0.009959020651876926
strongly O 0 3.490946028250619e-06
inhibited O 0 2.688319682420115e-06
the O 0 1.7693322362788422e-08
overexpression O 0 8.421646384704218e-07
of O 0 9.718282178994286e-09
the O 0 3.76706985605324e-08
CA12 O 0 0.00036584801273420453
gene O 0 1.3572804391515092e-07
in O 0 1.8427995129854935e-08
the O 0 2.4189074565583724e-07
parental O 0 0.0010208425810560584
renal B-Disease 1 0.9999337196350098
cell I-Disease 1 0.998029887676239
carcinoma I-Disease 1 0.9999914169311523
cell O 0 0.039532918483018875
lines O 0 0.00031121046049520373
. O 0 3.731530159711838e-05

Similar O 0 1.4757518329133745e-05
results O 0 4.788673777511576e-06
were O 0 4.012133274500229e-07
obtained O 0 2.967070145132311e-07
with O 0 4.748291075884481e-07
CA9 O 0 0.05499407276511192
, O 0 1.842107621996547e-07
encoding O 0 1.0722624921299939e-07
another O 0 8.678485983182327e-07
transmembrane O 0 0.00015359152166638523
CA O 0 4.218614776618779e-06
with O 0 7.62314229518779e-08
an O 0 1.5187315227649378e-07
intact O 0 1.1541884305188432e-05
catalytic O 0 1.0859183021239005e-05
domain O 0 3.4357751701463712e-06
. O 0 3.7710349261033116e-06

Although O 0 1.0964504326693714e-05
both O 0 3.322779775771778e-07
domains O 0 7.408343662973493e-07
of O 0 2.7762860455027294e-08
the O 0 1.0999015387369582e-07
VHL B-Disease 0 0.000648325018119067
protein O 0 1.5289477062196966e-07
contribute O 0 1.1282809708745845e-07
to O 0 8.720405730855418e-09
regulation O 0 3.9093553283464644e-08
of O 0 2.1312200004786064e-08
CA12 O 0 0.001016551977954805
expression O 0 1.8284069369656208e-07
, O 0 1.1847011371912686e-08
the O 0 6.355330484097976e-09
elongin O 0 2.1773510525235906e-05
binding O 0 3.408019608741597e-07
domain O 0 1.3903819251481764e-07
alone O 0 4.297388898066856e-07
could O 0 2.0600174366336432e-07
effectively O 0 2.2633050775766606e-06
regulate O 0 8.579336281400174e-06
CA9 O 0 0.009541933424770832
expression O 0 1.0136493983736727e-05
. O 0 4.164134224993177e-06

We O 0 4.049218205182115e-06
mapped O 0 4.762606477015652e-05
CA12 O 0 0.004877692088484764
and O 0 6.08964955972624e-06
CA9 O 0 0.028230665251612663
loci O 0 7.221139640023466e-06
to O 0 2.1944606487522833e-07
chromosome O 0 2.2562351659871638e-05
bands O 0 8.596372936153784e-06
15q22 O 0 7.226137677207589e-05
and O 0 2.7141809368913528e-06
17q21 O 0 0.0002900137333199382
. O 0 2.7602616228250554e-06

2 O 0 1.771892129909247e-05
respectively O 0 3.111277328571305e-05
, O 0 1.013616497402836e-06
regions O 0 9.666262030805228e-07
prone O 0 0.00011142759467475116
to O 0 6.909024818924081e-08
amplification O 0 1.07148252936895e-05
in O 0 5.7904610883952046e-08
some O 0 2.011362738585376e-07
human O 0 3.081859176745638e-05
cancers B-Disease 0 0.3185243308544159
. O 0 1.8350978280068375e-05

Additional O 0 1.7014150216709822e-05
experiments O 0 2.650547685334459e-05
are O 0 2.486471828433423e-07
needed O 0 1.764475001664323e-07
to O 0 5.124829449698609e-09
define O 0 5.358714005865295e-08
the O 0 1.0809028339053839e-08
role O 0 1.2712587249552598e-07
of O 0 7.768796450591253e-08
CA O 0 2.5277047825511545e-05
IX O 0 0.0004653547948691994
and O 0 2.7793701065093046e-06
CA O 0 3.357936657266691e-05
XII O 0 0.0007262798026204109
enzymes O 0 8.902974855118373e-07
in O 0 4.864025626716284e-09
the O 0 3.3713527525236486e-09
regulation O 0 4.2999793947728904e-08
of O 0 1.162906571039457e-08
pH O 0 2.742346168815857e-06
in O 0 4.009128584669952e-09
the O 0 5.237063227525596e-09
extracellular O 0 1.125698872783687e-06
microenvironment O 0 3.8459478673757985e-05
and O 0 6.542843067336435e-08
its O 0 4.227762673281177e-08
potential O 0 1.5379503111034865e-06
impact O 0 1.9572792098188074e-06
on O 0 2.176167799916584e-05
cancer B-Disease 0 0.13364054262638092
cell O 0 0.0003485410998109728
growth O 0 4.7132412873907015e-05
. O 0 7.772316166665405e-06

A O 0 4.866222752752947e-06
gene O 0 1.5230639291985426e-06
encoding O 0 3.731044841970288e-07
a O 0 1.8028501358458016e-07
transmembrane O 0 1.123461697716266e-05
protein O 0 1.3823051858707913e-07
is O 0 2.0335621186973185e-08
mutated O 0 2.6988748231815407e-06
in O 0 3.2483610539202346e-06
patients O 0 0.008680539205670357
with O 0 0.019459186121821404
diabetes B-Disease 1 0.9999926090240479
mellitus I-Disease 1 0.9999802112579346
and O 1 0.6744595170021057
optic B-Disease 1 0.9999899864196777
atrophy I-Disease 1 0.9998981952667236
( O 0 0.34597161412239075
Wolfram B-Disease 1 0.999958872795105
syndrome I-Disease 1 0.9999862909317017
) O 0 8.467891166219488e-05
. O 0 2.5277144231949933e-05

Wolfram B-Disease 1 0.9996528625488281
syndrome I-Disease 1 0.9999594688415527
( O 0 0.0006178983603604138
WFS B-Disease 1 0.989834725856781
; O 0 0.0003961316542699933
OMIM O 1 0.9872152805328369
222300 O 0 0.13823668658733368
) O 0 2.397956450295169e-06
is O 0 4.86806584376609e-07
an O 0 2.0719899112009443e-05
autosomal B-Disease 1 0.9438934922218323
recessive I-Disease 1 0.9997263550758362
neurodegenerative I-Disease 1 0.9999891519546509
disorder I-Disease 1 0.9983116388320923
defined O 0 6.01918509346433e-06
by O 0 2.5414617539354367e-06
young O 0 0.00023154352675192058
- O 1 0.5605139136314392
onset O 0 0.03581639751791954
non O 0 0.003894199151545763
- O 1 0.9673510193824768
immune O 0 0.1252833902835846
insulin B-Disease 0 0.0005735704326070845
- I-Disease 1 0.6511531472206116
dependent I-Disease 0 0.12385117262601852
diabetes I-Disease 1 0.9999494552612305
mellitus I-Disease 1 0.999855637550354
and O 0 0.008765757083892822
progressive O 1 0.9872841835021973
optic B-Disease 1 0.9999548196792603
atrophy I-Disease 1 0.9981568455696106
. O 0 0.00020868501451332122

Linkage O 0 0.0005083183641545475
to O 0 2.3041709482640726e-06
markers O 0 5.059779869043268e-05
on O 0 2.136867124136188e-06
chromosome O 0 0.00038494495674967766
4p O 1 0.8533573150634766
was O 0 6.191725788085023e-06
confirmed O 0 5.587643840954115e-07
in O 0 2.7942315128370865e-08
five O 0 2.4556246103202284e-07
families O 0 5.806923581985757e-06
. O 0 7.152035777835408e-06

On O 0 1.2574829497680184e-06
the O 0 5.8848343087447574e-08
basis O 0 2.332050819120468e-08
of O 0 3.398334058601904e-08
meiotic O 0 0.0036638255696743727
recombinants O 1 0.6998834013938904
and O 0 0.000497654196806252
disease O 0 0.014095265418291092
- O 0 0.02706703171133995
associated O 0 2.124546153936535e-05
haplotypes O 0 3.186879985150881e-05
, O 0 1.4913079837697296e-07
the O 0 1.0647179493616932e-07
WFS B-Disease 0 0.022827191278338432
gene O 0 9.181994187201781e-07
was O 0 2.580986517841666e-07
localized O 0 5.306688422024308e-07
to O 0 1.3203899307256961e-08
a O 0 4.4210679561729194e-08
BAC O 0 2.9587504286610056e-06
/ O 0 2.6237046313326573e-06
P1 O 0 6.011450750520453e-05
contig O 0 1.8219703633803874e-05
of O 0 1.5152096466408693e-08
less O 0 2.7581876338445e-08
than O 0 3.117987290579549e-08
250 O 0 8.436397820332786e-07
kb O 0 0.0008405505213886499
. O 0 4.491508661885746e-06

Mutations O 0 0.0011973115615546703
in O 0 8.3417455698509e-07
a O 0 3.040576075363788e-07
novel O 0 1.1580832506297156e-06
gene O 0 5.443370127977687e-07
( O 0 6.038780497874541e-08
WFS1 O 0 0.00010636241495376453
) O 0 2.038548529981199e-08
encoding O 0 1.5876111092438805e-08
a O 0 5.825944882076328e-08
putative O 0 2.792458144540433e-05
transmembrane O 0 2.8315966119407676e-05
protein O 0 3.20777274964712e-07
were O 0 4.192222746723928e-08
found O 0 5.393752999793833e-08
in O 0 7.950612612717123e-09
all O 0 1.7893828641035725e-08
affected O 0 9.961592013496556e-07
individuals O 0 9.66943645153151e-08
in O 0 6.979448130550736e-08
six O 0 3.2183854727918515e-06
WFS B-Disease 0 0.36706551909446716
families O 0 9.401609531778377e-06
, O 0 2.4154243760676763e-07
and O 0 6.020574971898895e-08
these O 0 1.3005392318632403e-08
mutations O 0 1.1248896498727845e-06
were O 0 2.215032424146557e-07
associated O 0 8.131942195177544e-07
with O 0 1.1797638990174164e-06
the O 0 5.4661421017954126e-05
disease O 0 0.09522507339715958
phenotype O 0 0.0008042337722145021
. O 0 2.798499190248549e-05

WFS1 O 1 0.5642054080963135
appears O 0 0.0001146430877270177
to O 0 3.7496403137993184e-07
function O 0 7.330516638148765e-08
in O 0 3.0643004578223554e-08
survival O 0 2.7209061954636127e-06
of O 0 7.781431321518539e-08
islet O 0 0.0018947554053738713
beta O 0 1.143037479778286e-05
- O 0 0.00959622859954834
cells O 0 1.6256208255072124e-05
and O 0 7.702716402491205e-07
neurons O 0 4.1741979657672346e-05
. O 0 4.554713370907848e-07
. O 0 2.1799980913783656e-06

Stable O 0 0.0002734748995862901
interaction O 0 3.0332944334077183e-06
between O 0 3.1428680813405663e-07
the O 0 8.559509723227166e-08
products O 0 7.588309927086812e-07
of O 0 1.3798404197018499e-08
the O 0 1.0662787275350638e-07
BRCA1 O 0 0.0001418191532138735
and O 0 3.7784723190270597e-06
BRCA2 O 0 0.03817335516214371
tumor B-Disease 0 0.007476648781448603
suppressor O 0 3.884773832396604e-05
genes O 0 2.386088908679085e-07
in O 0 3.198009679294955e-08
mitotic O 0 7.376410940196365e-05
and O 0 1.1109978913736995e-05
meiotic O 0 0.15779487788677216
cells O 0 0.00024329246662091464
. O 0 6.37435914541129e-06

BRCA1 O 0 0.0736851692199707
and O 0 3.0029405024833977e-05
BRCA2 O 0 0.003086531301960349
account O 0 2.65858670900343e-06
for O 0 2.933895757450955e-07
most O 0 1.3365460915792937e-07
cases O 0 9.0892427806466e-07
of O 0 2.936025964572764e-07
familial O 0 0.004975692834705114
, O 0 4.850881396123441e-06
early O 0 2.4488304916303605e-05
onset O 0 0.05286088585853577
breast B-Disease 0 0.27740785479545593
and I-Disease 0 5.7284687500214204e-05
/ I-Disease 0 0.43711909651756287
or I-Disease 1 0.8847044110298157
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9996044039726257
and O 0 4.495591667819099e-07
encode O 0 2.685378035494068e-07
products O 0 1.079079652299697e-06
that O 0 7.5817538913725e-09
each O 0 1.2423710060716076e-08
interact O 0 3.037515909909416e-07
with O 0 6.709023523399082e-07
hRAD51 O 0 0.0006391426431946456
. O 0 5.2006116675329395e-06

Results O 0 3.85771672881674e-05
presented O 0 8.219695700972807e-06
here O 0 1.740611565992367e-07
show O 0 1.1515596298750097e-07
that O 0 2.7074252173520108e-08
BRCA1 O 0 1.3266337191453204e-05
and O 0 7.114010713848984e-07
BRCA2 O 0 0.00012854297528974712
coexist O 0 2.6327354589739116e-06
in O 0 3.092602085530416e-08
a O 0 1.3354019756661728e-07
biochemical O 0 3.417795596760698e-05
complex O 0 2.1153500711079687e-06
and O 0 5.952306310064159e-07
colocalize O 0 0.0004973251488991082
in O 0 2.1518989967717062e-07
subnuclear O 0 0.00022818225261289626
foci O 0 1.4892436411173549e-05
in O 0 3.9476066859833736e-08
somatic O 0 2.187676727771759e-05
cells O 0 1.9431997770880116e-06
and O 0 2.3858060416159788e-08
on O 0 2.672424592731204e-08
the O 0 9.31323906883108e-09
axial O 0 1.46864977068617e-06
elements O 0 7.691479453342254e-08
of O 0 2.3823463379812893e-07
developing O 0 5.911618427489884e-05
synaptonemal O 0 0.004535789135843515
complexes O 0 0.0001114913757191971
. O 0 7.225727131299209e-06

Like O 0 7.205699512269348e-05
BRCA1 O 0 0.0019955821335315704
and O 0 6.6482375586929265e-06
RAD51 O 0 0.0257878340780735
, O 0 2.6244126729579875e-06
BRCA2 O 0 4.7279481805162504e-05
relocates O 0 7.504621407861123e-06
to O 0 1.30123694930262e-07
PCNA O 0 0.00032356538577005267
+ O 0 1.2746509128191974e-06
replication O 0 3.936802386306226e-07
sites O 0 5.249086498793076e-08
following O 0 4.185088187114161e-08
exposure O 0 5.787302939097572e-07
of O 0 1.1111674247388237e-08
S O 0 2.754204615484923e-05
phase O 0 1.9789270027104067e-06
cells O 0 1.7924933217727812e-06
to O 0 1.0951224282962357e-07
hydroxyurea O 0 0.0003455485275480896
or O 0 1.7523433371025021e-06
UV O 0 0.0009348788298666477
irradiation O 0 4.866666495217942e-05
. O 0 3.4845729715016205e-06

Thus O 0 3.745463254745118e-05
, O 0 4.965726020600414e-06
BRCA1 O 0 0.0002094075462082401
and O 0 1.1857680419780081e-06
BRCA2 O 0 0.00020713184494525194
participate O 0 2.9886672336942866e-07
, O 0 1.6582838213707873e-07
together O 0 7.2087637192908e-08
, O 0 4.33533315913337e-08
in O 0 1.0093586411130673e-08
a O 0 7.696718284933013e-08
pathway O 0 1.1145613143526134e-06
( O 0 2.6928512397716986e-07
s O 0 0.0008750102133490145
) O 0 2.3405358717809577e-07
associated O 0 7.599014395509585e-08
with O 0 8.90350015936292e-09
the O 0 6.4818772571584304e-09
activation O 0 1.2044417019296816e-07
of O 0 1.0619552348600791e-08
double O 0 2.0123886770306854e-06
- O 0 0.00031926020164974034
strand O 0 0.00010525959805818275
break O 0 1.9516985048539937e-05
repair O 0 0.0005735127488151193
and O 0 3.322820987250452e-07
/ O 0 1.2902042726636864e-05
or O 0 5.218798264650104e-07
homologous O 0 1.43097058753483e-05
recombination O 0 6.695929187117144e-05
. O 0 5.82072971155867e-06

Dysfunction O 0 0.4409814774990082
of O 0 1.6897441810215241e-06
this O 0 1.289148201522039e-07
pathway O 0 6.233293333934853e-06
may O 0 6.888536177029891e-07
be O 0 5.767784472254789e-09
a O 0 1.5585499113512924e-08
general O 0 1.9422607522301405e-07
phenomenon O 0 9.216463467964786e-07
in O 0 2.4814706733877756e-08
the O 0 2.3967754003706432e-08
majority O 0 4.114590126391704e-07
of O 0 3.4359540990180903e-08
cases O 0 1.2504966662163497e-06
of O 0 2.3360880732070655e-06
hereditary B-Disease 1 0.8743561506271362
breast I-Disease 1 0.7572540044784546
and I-Disease 0 0.00017372840375173837
/ I-Disease 1 0.8399913311004639
or I-Disease 1 0.9896710515022278
ovarian I-Disease 1 0.9999984502792358
cancer I-Disease 1 0.9998738765716553
. O 0 7.953367457957938e-06
. O 0 1.3020606274949387e-05

A O 0 1.4091042430663947e-05
novel O 0 1.107659045374021e-05
Arg362Ser O 0 0.0018043923191726208
mutation O 0 7.716164873272646e-06
in O 0 5.4466013921228296e-08
the O 0 4.0541532797533364e-08
sterol O 0 4.7827648813836277e-05
27 O 0 6.248416866583284e-06
- O 0 0.00039023556746542454
hydroxylase O 0 0.0009982550982385874
gene O 0 1.1997727824564208e-06
( O 0 1.0669012340258632e-07
CYP27 O 0 0.0001250306231668219
) O 0 1.7243614536255336e-08
: O 0 5.791596535686949e-09
its O 0 5.636044075885138e-09
effects O 0 8.901618997469996e-08
on O 0 7.5841839475288e-09
pre O 0 5.7954548537964e-07
- O 0 3.925475994037697e-06
mRNA O 0 4.4633978291130916e-08
splicing O 0 2.3181993924481503e-07
and O 0 7.984291983120784e-08
enzyme O 0 1.385717382618168e-06
activity O 0 7.08377569935692e-07
. O 0 8.748513096179522e-07

A O 0 3.464251130935736e-05
novel O 0 1.2858583431807347e-05
C O 0 4.3537460442166775e-05
to O 0 7.122347511767657e-08
A O 0 1.0884733114835399e-07
mutation O 0 1.6046769246713666e-07
in O 0 5.832524241355941e-09
the O 0 1.4176852580760624e-08
sterol O 0 4.501564762904309e-05
27 O 0 7.046931841614423e-06
- O 0 0.0018086658092215657
hydroxylase O 0 0.0054568881168961525
gene O 0 1.0229409781459253e-06
( O 0 7.516702993370927e-08
CYP27 O 0 0.00012308139412198216
) O 0 2.8770523741172838e-08
was O 0 4.113019969054221e-08
identified O 0 2.172947688450222e-08
by O 0 5.004184622237062e-09
sequencing O 0 2.1702084040953196e-07
amplified O 0 6.687619134027045e-06
CYP27 O 0 0.00011384946265025064
gene O 0 1.512226361910507e-07
products O 0 2.7638495225801307e-07
from O 0 2.8740684498984592e-08
a O 0 1.7308039446106704e-07
patient O 0 1.2122437510697637e-05
with O 0 6.681231297989143e-06
cerebrotendinous B-Disease 1 0.9995145797729492
xanthomatosis I-Disease 1 0.9992412328720093
( O 0 1.961483394552488e-05
CTX B-Disease 0 0.43461504578590393
) O 0 3.1668701012677047e-06
. O 0 2.759456492640311e-06

The O 0 4.872254976362456e-06
mutation O 0 1.8930744772660546e-05
changed O 0 9.756896588442032e-07
the O 0 6.141475239473948e-08
adrenodoxin O 0 4.933416494168341e-05
cofactor O 0 1.2539742328954162e-06
binding O 0 5.198343160373042e-07
residue O 0 1.1490631095512072e-06
362Arg O 0 9.85471524472814e-06
to O 0 6.600488688945916e-08
362Ser O 0 2.8669111998169683e-05
( O 0 1.2558994910705223e-07
CGT O 0 0.00023203568707685918
362Arg O 0 4.9638030759524554e-05
to O 0 1.42302951644524e-07
AGT O 0 0.004828163422644138
362Ser O 0 0.00022797002748120576
) O 0 4.8169610522563744e-08
, O 0 1.3111545626998122e-08
and O 0 4.683984400344343e-08
was O 0 4.303992113818822e-07
responsible O 0 2.7861876787937945e-06
for O 0 4.49295248472481e-06
deficiency O 0 0.021347198635339737
in O 0 2.5740094500292798e-08
the O 0 4.6918081864077976e-08
sterol O 0 0.00019636024080682546
27 O 0 6.844180461484939e-06
- O 0 0.00047477526823058724
hydroxylase O 0 0.0008242943440563977
activity O 0 1.8631749298947398e-07
, O 0 2.359486295233637e-08
as O 0 9.029489156375803e-09
confirmed O 0 3.9590453582150076e-08
by O 0 2.607252191921816e-09
expression O 0 3.958809724480261e-09
of O 0 1.2778772484622891e-09
mutant O 0 1.1791333776045576e-07
cDNA O 0 1.1737459004734774e-07
into O 0 7.968622384169066e-08
COS O 0 0.001722854096442461
- O 0 0.0002595697296783328
1 O 0 4.263248683855636e-06
cells O 0 7.123907835193677e-06
. O 0 1.416184659319697e-06

Quantitative O 0 9.79797332547605e-05
analysis O 0 1.1818273378594313e-05
showed O 0 2.5742810976225883e-05
that O 0 5.0118288186240534e-08
the O 0 1.1123507448473902e-08
expression O 0 1.9394912342818316e-08
of O 0 8.823755059950145e-09
CYP27 O 0 7.084449316607788e-05
gene O 0 9.129676215025029e-08
mRNA O 0 2.0737298100925727e-08
in O 0 8.23315104980793e-09
the O 0 4.871548497931144e-08
patient O 0 4.139884822507156e-06
represented O 0 2.8424410629668273e-06
52 O 0 3.970017496612854e-05
. O 0 8.385122782783583e-06

5 O 0 9.631786269892473e-06
% O 0 7.055559763102792e-07
of O 0 5.249096446391377e-08
the O 0 8.934959083717331e-08
normal O 0 4.6301693146233447e-07
level O 0 1.685411689322791e-06
. O 0 2.1213299987721257e-06

As O 0 2.6112084015039727e-06
the O 0 2.1969063368487696e-07
mutation O 0 1.0386258963990258e-06
occurred O 0 1.2981406882772717e-07
at O 0 2.8909139970778597e-08
the O 0 4.8556185738846125e-09
penultimate O 0 6.331769100142992e-07
nucleotide O 0 2.2091381879363325e-07
of O 0 1.4447479657064832e-08
exon O 0 1.8000197087530978e-05
6 O 0 1.2741684258799069e-06
( O 0 4.115437235441277e-08
- O 0 1.5205331692413893e-05
2 O 0 1.5780294404521555e-07
position O 0 3.349632393678803e-08
of O 0 6.425598275683342e-09
exon O 0 2.8555259632412344e-06
6 O 0 3.35745880875038e-07
- O 0 2.2363383322954178e-05
intron O 0 5.262150807539001e-05
6 O 0 3.352442092818819e-07
splice O 0 2.0279185264371336e-06
site O 0 1.4832389183538908e-07
) O 0 2.1490407231539166e-09
of O 0 1.0111599335616006e-09
the O 0 9.14480047242705e-09
gene O 0 7.439084726001965e-08
, O 0 2.59138879243892e-08
we O 0 7.057448403458011e-09
hypothesized O 0 4.39644225025404e-07
that O 0 4.990135415994246e-09
the O 0 5.239434130999143e-08
mutation O 0 8.392803465540055e-06
may O 0 1.3096657767164288e-06
partially O 0 3.802717856160598e-06
affect O 0 5.031578709235873e-08
the O 0 2.4691231281792625e-09
normal O 0 6.452543832580204e-09
splicing O 0 5.5437173074324164e-08
efficiency O 0 1.7654561190738605e-07
in O 0 1.335078092523645e-08
exon O 0 3.1858876354817767e-06
6 O 0 5.179371100894059e-07
and O 0 5.419306248199973e-08
cause O 0 1.2099216917249578e-07
alternative O 0 1.786988335084061e-08
splicing O 0 2.847539803951804e-07
elsewhere O 0 3.584858063732099e-07
, O 0 1.511330260939303e-08
which O 0 5.873943109691027e-09
resulted O 0 3.1734231242808164e-07
in O 0 5.68718938609436e-08
decreased O 0 1.5734010503365425e-06
transcript O 0 3.8126097479107557e-07
in O 0 6.379172390325039e-08
the O 0 6.121279056969797e-07
patient O 0 6.875237886561081e-05
. O 0 5.866136234544683e-06

Transfection O 0 0.0032092963811010122
of O 0 8.458901902486105e-06
constructed O 0 0.00021908266353420913
minigenes O 0 0.011935900896787643
, O 0 1.0110150014952524e-06
with O 0 2.394793057192146e-07
or O 0 1.0034315778284508e-07
without O 0 3.2218014922591465e-08
the O 0 1.2524494330534708e-08
mutation O 0 1.98472449142173e-07
, O 0 1.2254005810063973e-08
into O 0 3.605962106689731e-08
COS O 0 0.011600942350924015
- O 0 0.00018034498498309404
1 O 0 8.11183497262391e-07
cells O 0 1.4012563269716338e-06
confirmed O 0 1.6194495344734605e-07
that O 0 1.720326325838073e-09
the O 0 5.489107390843628e-09
mutant O 0 2.3693050934525672e-06
minigene O 0 0.00013719114940613508
was O 0 2.9579419447145483e-07
responsible O 0 1.1039474401286498e-07
for O 0 5.1966053682406255e-09
a O 0 1.0279148199288102e-08
mRNA O 0 3.8741415409049296e-08
species O 0 1.1503999530759756e-08
alternatively O 0 4.0917679910990046e-08
spliced O 0 1.627265987735882e-06
at O 0 3.688920742206392e-07
an O 0 6.397230123411646e-08
activated O 0 2.554343518568203e-05
cryptic O 0 3.1217355171975214e-06
5 O 0 7.34596881102334e-08
splice O 0 1.9718661405931925e-06
site O 0 2.0735190275900095e-07
88 O 0 5.512380312211462e-07
bp O 0 8.93638025445398e-06
upstream O 0 1.5601625591443735e-07
from O 0 5.1251034527410866e-09
the O 0 2.4219435346140017e-09
3 O 0 2.6152426002568063e-08
end O 0 4.391199937003876e-08
of O 0 5.2953438967051625e-08
exon O 0 3.6117642594035715e-05
6 O 0 5.119818524690345e-06
. O 0 2.4369244329136563e-06

Our O 0 3.047914560738718e-06
data O 0 1.085742042050697e-06
suggest O 0 4.612949453530746e-07
that O 0 9.814682400133279e-09
the O 0 1.4694992778174765e-08
C O 0 1.4474173894996056e-06
to O 0 6.399827334746533e-09
A O 0 3.9690714714879505e-08
mutation O 0 9.985382831700917e-08
at O 0 1.2605547716759702e-08
the O 0 3.381573243643743e-09
penultimate O 0 7.594376825181826e-07
nucleotide O 0 2.0410000445281185e-07
of O 0 1.1473804129025211e-08
exon O 0 3.5737818961933954e-06
6 O 0 1.1657073173410026e-07
of O 0 6.132658381119427e-09
the O 0 2.794348752388487e-08
CYP27 O 0 0.00047652452485635877
gene O 0 2.418485394173331e-07
not O 0 6.640097804933021e-09
only O 0 1.0579280562694748e-08
causes O 0 2.4481075797666563e-06
the O 0 1.4194569075698382e-06
deficiency B-Disease 0 0.03140132129192352
in I-Disease 0 2.5229720534980515e-08
the I-Disease 0 5.4738563903811155e-08
sterol I-Disease 0 0.00028292444767430425
27 I-Disease 0 1.1679071576509159e-05
- I-Disease 0 0.0008331850403919816
hydroxylase I-Disease 0 0.0006983607891015708
activity I-Disease 0 1.937306848276421e-07
, O 0 3.723906516484021e-08
but O 0 9.966408143213812e-09
also O 0 5.440102057718832e-08
partially O 0 1.994615331568639e-06
leads O 0 2.3253888059571182e-07
to O 0 3.0380409299368694e-09
alternative O 0 2.5146704274447984e-08
pre O 0 6.189691248437157e-07
- O 0 1.1638348951237276e-06
mRNA O 0 1.5191103486245083e-08
splicing O 0 4.2293599733511655e-08
of O 0 8.676853902045423e-09
the O 0 5.252721990700593e-08
gene O 0 6.476615226347349e-07
. O 0 8.857227271619195e-07

To O 0 2.0068537196493708e-06
our O 0 2.948802091395919e-07
knowledge O 0 2.0375227904878557e-07
, O 0 4.565245959042841e-08
this O 0 2.5849600238103676e-09
is O 0 2.81416956404712e-09
the O 0 5.8225202437256485e-09
first O 0 1.0991800536430674e-07
report O 0 3.024836985332513e-07
regarding O 0 2.5645252321737644e-07
effects O 0 3.950477207581571e-07
on O 0 2.945369281803778e-08
pre O 0 2.1386508706200402e-06
- O 0 2.573340225353604e-06
mRNA O 0 1.2852061637147472e-08
splicing O 0 1.5826648436245705e-08
of O 0 1.8440573512634728e-09
a O 0 1.0426175478528421e-08
mutation O 0 6.07030656851748e-08
at O 0 2.391017694947095e-08
the O 0 1.3879808413719275e-08
- O 0 3.231512528145686e-05
2 O 0 2.4769008177827345e-07
position O 0 4.859159830061799e-08
of O 0 6.808462682528216e-09
a O 0 5.803607905363606e-08
5 O 0 2.7087793341706856e-07
splice O 0 3.448959250818007e-05
site O 0 8.18679927760968e-06
. O 0 1.8444807210471481e-06

ATM O 0 0.005858397576957941
germline O 1 0.5265321135520935
mutations O 0 0.0013891998678445816
in O 0 4.530152182269376e-06
classical O 0 0.0006278390646912158
ataxia B-Disease 1 0.9999372959136963
- I-Disease 1 0.999953031539917
telangiectasia I-Disease 1 0.9999904632568359
patients O 0 0.343111515045166
in O 0 3.1910582265481935e-07
the O 0 2.4136258502949204e-07
Dutch O 0 0.0007276126998476684
population O 0 3.954898147640051e-06
. O 0 4.496064320846926e-06

Germline O 0 0.46688878536224365
mutations O 0 0.0003374500956851989
in O 0 3.1197515681924415e-07
the O 0 9.717210502913076e-08
ATM O 0 0.00011591844668146223
gene O 0 7.296326316463819e-07
are O 0 2.4576273460752418e-08
responsible O 0 9.381629979543504e-07
for O 0 4.207726306049153e-06
the O 0 0.004832160659134388
autosomal B-Disease 1 0.9999825954437256
recessive I-Disease 1 0.9999973773956299
disorder I-Disease 1 0.9999997615814209
ataxia B-Disease 1 0.9999978542327881
- I-Disease 1 0.999993085861206
telangiectasia I-Disease 1 0.9999912977218628
( O 0 0.00043860316509380937
A B-Disease 0 0.06032374128699303
- I-Disease 1 0.9997028708457947
T I-Disease 1 0.9998390674591064
) O 0 7.957798516144976e-06
. O 0 6.4148757701332215e-06

In O 0 4.284504939278122e-06
our O 0 7.085849915711151e-07
study O 0 9.388629109707836e-07
, O 0 1.27868304389267e-07
we O 0 7.626250742021057e-09
have O 0 6.706513122622937e-09
determined O 0 6.9766774579704816e-09
the O 0 3.028431283524924e-09
ATM O 0 2.975050847453531e-06
mutation O 0 2.4750190164013475e-07
spectrum O 0 3.054931880797085e-07
in O 0 1.747281785924315e-08
19 O 0 3.177805183440796e-07
classical O 0 6.268359129535384e-07
A B-Disease 0 0.0007562022074125707
- I-Disease 1 0.9995946288108826
T I-Disease 1 0.9999929666519165
patients O 0 0.002893777098506689
, O 0 1.2074319499788544e-07
including O 0 7.448398520182309e-08
some O 0 2.1109189063395206e-08
immigrant O 0 2.2776850528316572e-05
populations O 0 8.202415529012796e-07
, O 0 8.59389572838154e-08
as O 0 2.157880629738429e-08
well O 0 1.1616672956904495e-08
as O 0 8.194328771082837e-09
12 O 0 1.8773075538547346e-08
of O 0 2.6551045806399998e-08
Dutch O 0 2.8512880817288533e-05
ethnic O 0 1.358307599730324e-06
origin O 0 2.8375334295560606e-06
. O 0 4.114591774850851e-06

Both O 0 2.4709418084967183e-06
the O 0 2.9696943215640204e-07
protein O 0 2.2870088400850364e-07
truncation O 0 4.0998256736202165e-06
test O 0 6.6552325961311e-07
( O 0 4.2302310987452074e-08
PTT O 0 5.786480869574007e-06
) O 0 1.4834561135046442e-08
and O 0 8.903771053780929e-09
the O 0 4.167450384784388e-09
restriction O 0 5.835687133526335e-08
endonuclease O 0 2.0107609088881873e-05
fingerprinting O 0 6.32117735221982e-05
( O 0 2.0617216023310903e-07
REF O 0 0.0001831048575695604
) O 0 1.0140787765067216e-08
method O 0 5.341363795707821e-09
were O 0 1.3248855346148503e-08
used O 0 9.553719593213827e-09
and O 0 2.4066931558763827e-08
compared O 0 1.4790070679282508e-07
for O 0 5.477038822476743e-09
their O 0 6.440715072386638e-09
detection O 0 2.693185194857506e-07
efficiency O 0 3.5674412401931477e-07
, O 0 2.8472184609995566e-08
identifying O 0 1.3816701311952784e-06
76 O 0 6.342609140119748e-06
% O 0 2.5870921405157787e-08
and O 0 2.8568143406459967e-08
60 O 0 8.061385159408019e-08
% O 0 7.176248484341841e-09
of O 0 4.594831182203052e-09
the O 0 1.3745584226398933e-07
mutations O 0 6.929513801878784e-06
, O 0 1.3392833579928265e-06
respectively O 0 1.3672537534148432e-05
. O 0 6.645511803071713e-06

Most O 0 0.00024900498101487756
patients O 0 0.0059271459467709064
were O 0 1.9776516637648456e-06
found O 0 6.312554319265473e-07
to O 0 4.110102835852558e-08
be O 0 5.7412478327023564e-08
compound O 0 3.349183771206299e-06
heterozygote O 0 0.0003313370398245752
. O 0 5.9185126701777335e-06

Seventeen O 0 0.0001430291886208579
mutations O 0 0.00038415013113990426
were O 0 1.313013626713655e-06
distinct O 0 4.531620163561456e-07
, O 0 5.38276658801351e-08
of O 0 1.05710098452505e-08
which O 0 1.7701287546856292e-08
10 O 0 9.318927141066524e-08
were O 0 1.847463124704518e-07
not O 0 1.1189136017719647e-07
reported O 0 3.653657358881901e-06
previously O 0 5.6951080296130385e-06
. O 0 3.95050619772519e-06

Mutations O 0 0.0025014278944581747
are O 0 8.521113272763614e-07
small O 0 1.3263237406135886e-06
deletions O 0 2.770199535007123e-05
or O 0 1.0145168971575913e-06
point O 0 2.5229467155440943e-06
mutations O 0 1.2438298654160462e-05
frequently O 0 5.719660407521587e-07
affecting O 0 3.2763086892373394e-06
splice O 0 6.627354014199227e-05
sites O 0 9.346620572614484e-06
. O 0 5.609221261693165e-06

Moreover O 0 0.00029332752455957234
, O 0 4.74723128718324e-06
a O 0 1.5761856957396958e-06
16 O 0 1.2924185284646228e-05
. O 0 4.820509275305085e-06

7 O 0 5.263841740088537e-05
- O 0 0.0011357372859492898
kb O 0 0.0012780154356732965
genomic O 0 2.2896630980540067e-05
deletion O 0 5.018083356844727e-06
of O 0 2.001480936542066e-08
the O 0 1.4408814585920027e-08
3 O 0 6.513271699759571e-08
end O 0 5.142054959605957e-08
of O 0 5.938718405928967e-09
the O 0 2.0753599727640903e-08
gene O 0 2.688960876184865e-07
, O 0 7.842746185815486e-08
most O 0 4.017489274588115e-08
likely O 0 2.448004465804843e-07
a O 0 1.6027691174258507e-08
result O 0 2.4620375072004208e-08
of O 0 5.968811667145246e-09
recombination O 0 9.5595066795795e-07
between O 0 5.402051073133407e-08
two O 0 3.476031551485903e-08
LINE O 0 2.9571790491900174e-06
elements O 0 6.77967022966186e-07
, O 0 1.1747799817385385e-06
was O 0 2.5963022380892653e-06
identified O 0 9.970848623197526e-06
. O 0 3.202687821612926e-06

The O 0 4.274815637472784e-06
most O 0 7.600651201755682e-07
frequently O 0 1.90892342288862e-06
found O 0 1.2088507901353296e-06
mutation O 0 3.3444378004787723e-06
, O 0 1.3934349851751904e-07
identified O 0 3.7418243437059573e-07
in O 0 1.4065078879355042e-08
three O 0 6.428469134789339e-08
unrelated O 0 1.695016362646129e-05
Turkish O 0 8.716086085769348e-06
A B-Disease 0 0.0010804000776261091
- I-Disease 1 0.9965932965278625
T I-Disease 1 0.999935507774353
individuals O 0 7.563942745036911e-06
, O 0 1.1263259693805594e-06
was O 0 2.9159700716263615e-06
previously O 0 4.162522145634284e-06
described O 0 8.575734113946964e-07
to O 0 6.626471371617981e-09
be O 0 3.2705265162746855e-09
a O 0 1.89414386397857e-08
Turkish O 0 3.098523620792548e-06
A B-Disease 0 0.00011685737990774214
- I-Disease 1 0.98696368932724
T I-Disease 1 0.9996987581253052
founder O 0 0.02846577949821949
mutation O 0 6.154587026685476e-05
. O 0 5.47667241335148e-06

The O 0 3.353690544827259e-06
presence O 0 2.0351567400211934e-06
of O 0 6.258986218199425e-08
a O 0 2.1810866712712595e-07
founder O 0 9.861450962489471e-05
mutation O 0 1.8610578536026878e-06
among O 0 2.8302397936386114e-07
relatively O 0 1.1519484388600176e-07
small O 0 5.368463362742659e-08
ethnic O 0 5.1336662920675735e-08
population O 0 1.972748542300451e-08
groups O 0 1.2394266946103016e-08
in O 0 5.896730659316063e-09
Western O 0 8.298265186112985e-08
Europe O 0 2.387884876497992e-07
could O 0 3.7857397217067046e-08
indicate O 0 2.126680165304151e-08
a O 0 9.98299753973697e-09
high O 0 1.3271385341795394e-06
carrier O 0 8.561265531170648e-06
frequency O 0 8.991494837573555e-08
in O 0 2.1588359544466584e-08
such O 0 1.340618354106482e-07
communities O 0 1.8736875517788576e-06
. O 0 4.265957613824867e-06

In O 0 5.4996839025989175e-05
patients O 0 0.00039914040826261044
of O 0 2.8342427071947895e-07
Dutch O 0 0.00015762507973704487
ethnic O 0 1.6439562386949547e-06
origin O 0 1.556447273287631e-06
, O 0 3.9781704685992736e-07
however O 0 1.033738925571015e-07
, O 0 3.764958123042561e-08
no O 0 4.1860701571749814e-08
significant O 0 3.413614422242972e-07
founder O 0 6.576585292350501e-05
effect O 0 1.2706251482086373e-06
could O 0 1.4455231678311975e-07
be O 0 4.491734628686572e-08
identified O 0 2.851457793440204e-06
. O 0 2.7268552003079094e-06

The O 0 4.1031503315025475e-06
observed O 0 1.1069979336753022e-05
genetic O 0 1.4623167771787848e-05
heterogeneity O 0 2.3034433979773894e-05
including O 0 1.3299006695888238e-06
the O 0 1.571652603615803e-07
relative O 0 1.2108952205380774e-06
high O 0 1.5835562408028636e-06
percentage O 0 5.704771979253564e-07
of O 0 1.893074852432619e-08
splice O 0 1.9015604266314767e-05
- O 0 0.0008877211948856711
site O 0 8.958573744166642e-06
mutations O 0 4.403997081681155e-06
had O 0 1.1229672480794761e-07
no O 0 1.0659001681290192e-08
reflection O 0 1.257982802371771e-07
on O 0 3.294313160040474e-07
the O 0 1.0334052831240115e-06
phenotype O 0 0.00013539665087591857
. O 0 6.931536518095527e-06

All O 0 2.725744343479164e-05
patients O 0 0.004374508745968342
manifested O 0 5.867899744771421e-05
classical O 0 3.711147655849345e-06
A B-Disease 0 9.900363511405885e-05
- I-Disease 1 0.8591670393943787
T I-Disease 1 0.9948524832725525
and O 0 8.648617608741915e-07
increased O 0 8.538733027307899e-07
cellular O 0 9.736078027344774e-06
radioresistant O 0 0.00023950684408191592
DNA O 0 1.0643972018442582e-05
synthesis O 0 4.864468792220578e-06
. O 0 2.5527911020617466e-06

Determination O 0 2.79558589681983e-05
of O 0 3.401558217319689e-07
the O 0 8.268057882787616e-08
genomic O 0 3.630324044934241e-06
structure O 0 1.499346637956478e-07
of O 0 8.748910929057274e-09
the O 0 7.210606867147362e-08
COL4A4 O 0 0.0013886396773159504
gene O 0 2.7538570179785893e-07
and O 0 6.707706035058436e-08
of O 0 2.6279590770172945e-07
novel O 0 0.00015097856521606445
mutations O 0 0.01584041863679886
causing O 1 0.5422853827476501
autosomal B-Disease 1 0.9961254000663757
recessive I-Disease 1 0.9995930790901184
Alport I-Disease 1 0.9999737739562988
syndrome I-Disease 1 0.9999330043792725
. O 0 0.0005036576185375452

Autosomal B-Disease 1 0.9990271329879761
recessive I-Disease 1 0.9997106194496155
Alport I-Disease 1 0.9999734163284302
syndrome I-Disease 1 0.9999666213989258
is O 0 3.1330480851465836e-05
a O 0 4.678272671299055e-05
progressive O 1 0.9137616753578186
hematuric B-Disease 1 0.9998061060905457
glomerulonephritis I-Disease 1 0.9999758005142212
characterized O 0 0.005820914171636105
by O 0 1.5691597582190298e-05
glomerular B-Disease 1 0.9201457500457764
basement I-Disease 1 0.6945372819900513
membrane I-Disease 0 0.15366464853286743
abnormalities I-Disease 1 0.9492133259773254
and O 0 5.426864390756236e-06
associated O 0 3.6065928270545555e-06
with O 0 9.826109135246952e-07
mutations O 0 4.761441687151091e-06
in O 0 2.9484045427352612e-08
either O 0 6.699305288293544e-08
the O 0 1.1103374220056139e-07
COL4A3 O 0 0.003035946749150753
or O 0 2.3889853650871373e-07
the O 0 8.830813413851502e-08
COL4A4 O 0 0.0015048632631078362
gene O 0 2.647878432071593e-07
, O 0 1.271013339021465e-08
which O 0 1.4801712078238438e-09
encode O 0 1.4319526897565993e-08
the O 0 2.779390939622317e-08
alpha3 O 0 9.8124859505333e-05
and O 0 3.8310159311549796e-07
alpha4 O 0 0.0012545089703053236
type O 0 2.0782514184247702e-05
IV O 0 0.06048130244016647
collagen O 0 0.004741935525089502
chains O 0 0.0002448481391184032
, O 0 1.7855136320577003e-06
respectively O 0 1.3901824786444195e-05
. O 0 3.190703864675015e-06

To O 0 3.2012555948313093e-06
date O 0 3.1508948268310633e-06
, O 0 3.119129701190104e-07
mutation O 0 4.857756152887305e-07
screening O 0 3.924814109268482e-07
in O 0 1.0587879906154285e-08
the O 0 5.9332836421788215e-09
two O 0 2.687319522465259e-08
genes O 0 2.9640864340763073e-07
has O 0 2.7345583930582507e-07
been O 0 5.193408014747547e-07
hampered O 0 3.3636832085903734e-05
by O 0 8.27518960022644e-08
the O 0 7.329565931968318e-08
lack O 0 2.7336329821991967e-07
of O 0 5.3647067232986956e-08
genomic O 0 2.121545549016446e-05
structure O 0 4.2559490793792065e-06
information O 0 1.793016508599976e-06
. O 0 5.788953785668127e-06

We O 0 5.388475074141752e-06
report O 0 1.6116364349727519e-06
here O 0 5.8454681095554406e-08
the O 0 1.0161891772497711e-08
complete O 0 3.0670488371242755e-08
characterization O 0 4.714270005479193e-07
of O 0 9.628981167963957e-09
the O 0 7.64833441024848e-09
48 O 0 1.284009698565569e-07
exons O 0 1.95875855979466e-07
of O 0 7.118243328108065e-09
the O 0 2.848641678099284e-08
COL4A4 O 0 0.00039333701715804636
gene O 0 1.3930311126841843e-07
, O 0 1.2230818136060861e-08
a O 0 1.643772229442675e-08
comprehensive O 0 7.58700764436071e-07
gene O 0 3.7855920709262136e-07
screen O 0 2.7095284167444333e-06
, O 0 6.275925557019946e-08
and O 0 1.0739199751697015e-08
the O 0 3.299637230114172e-09
subsequent O 0 4.215571536292373e-08
detection O 0 2.2676080391192954e-07
of O 0 1.2723716302787125e-08
10 O 0 4.638403083845333e-08
novel O 0 2.8919160399709654e-07
mutations O 0 1.1941964430661756e-06
in O 0 1.8161343007250252e-07
eight O 0 0.00047055454342626035
patients O 1 0.8719756603240967
diagnosed O 1 0.9891380667686462
with O 0 0.0035650318022817373
autosomal B-Disease 1 0.997178316116333
recessive I-Disease 1 0.9995063543319702
Alport I-Disease 1 0.9999665021896362
syndrome I-Disease 1 0.9998990297317505
. O 0 0.0006802810239605606

Furthermore O 0 0.00010939200001303107
, O 0 1.5442215044458862e-06
we O 0 5.09728259601161e-08
identified O 0 8.851706922996527e-08
a O 0 5.5275601873461255e-09
glycine O 0 4.588825959217502e-07
to O 0 4.913136120165973e-09
alanine O 0 6.182877427818312e-07
substitution O 0 2.475098703769163e-08
in O 0 4.072503667629235e-09
the O 0 1.1200746996564703e-08
collagenous O 0 0.00022709988115821034
domain O 0 2.400019525339303e-07
that O 0 1.473934574391933e-08
is O 0 3.4559612061002554e-08
apparently O 0 5.629632369164028e-07
silent O 0 1.2576520020957105e-06
in O 0 8.586338751115363e-09
the O 0 1.9416084739987127e-08
heterozygous O 0 2.1892840322834672e-06
carriers O 0 1.0276843568135519e-05
, O 0 1.1825681411892219e-07
in O 0 6.462622081926384e-08
11 O 0 1.9936226181016536e-06
. O 0 1.993849082282395e-06

5 O 0 1.6521746147191152e-05
% O 0 5.876181035091577e-07
of O 0 6.116295026004082e-08
all O 0 2.8241615268598252e-08
control O 0 2.8215322345204186e-07
individuals O 0 1.0777823433727463e-07
, O 0 6.197877411295849e-08
and O 0 6.422194331889841e-08
in O 0 2.160780177007382e-08
one O 0 2.466888560093139e-08
control O 0 1.7666991425357992e-07
individual O 0 1.4382763424691802e-07
homozygous O 0 1.0844225926120998e-06
for O 0 2.1299275232422588e-08
this O 0 1.634892221602513e-08
glycine O 0 2.4048862542258576e-05
substitution O 0 3.813940566033125e-06
. O 0 3.2355271741835168e-06

There O 0 1.2912493730254937e-05
has O 0 2.4626915546832606e-06
been O 0 2.7372615818421764e-07
no O 0 1.7890620540583768e-08
previous O 0 3.8825891834903814e-08
finding O 0 6.0580930494325e-08
of O 0 3.815880944557648e-09
a O 0 1.410376349042508e-08
glycine O 0 1.7970445469472907e-06
substitution O 0 7.339148311302779e-08
that O 0 1.4785042523612901e-08
is O 0 1.2943328187020597e-08
not O 0 8.81769768312779e-09
associated O 0 1.2091268786207365e-07
with O 0 4.8713253875121154e-08
any O 0 8.259121386799961e-08
obvious O 0 5.263229923002655e-06
phenotype O 0 2.5338493287563324e-05
in O 0 5.895788035559235e-07
homozygous O 0 5.0586313591338694e-05
individuals O 0 4.817769877263345e-06
. O 0 5.406130185292568e-06

Founder O 0 0.0237113069742918
BRCA1 O 0 0.02375132590532303
and O 0 1.931991573655978e-05
BRCA2 O 0 0.001990825403481722
mutations O 0 2.159888026653789e-05
in O 0 4.842049179387686e-07
French O 0 0.00029185882885940373
Canadian O 0 0.16547618806362152
breast B-Disease 1 0.9995322227478027
and I-Disease 1 0.9829748272895813
ovarian I-Disease 1 0.999997615814209
cancer I-Disease 1 0.9999260902404785
families O 0 0.0014690888347104192
. O 0 6.864952592877671e-05

We O 0 3.1188130833470495e-06
have O 0 3.774352421714866e-07
identified O 0 3.418181790948438e-07
four O 0 4.1241118964308043e-08
mutations O 0 2.510180934223172e-07
in O 0 2.8618358793863763e-09
each O 0 2.9877018636881303e-09
of O 0 7.086006093004471e-08
the O 0 9.727957149152644e-06
breast B-Disease 1 0.9943564534187317
cancer I-Disease 1 0.5919031500816345
- O 0 0.15829503536224365
susceptibility O 0 0.0016462650382891297
genes O 0 1.485647089793929e-06
, O 0 6.325534513962339e-07
BRCA1 O 0 4.9811103963293135e-05
and O 0 5.284255735205079e-07
BRCA2 O 0 5.670363316312432e-05
, O 0 7.344427643829476e-08
in O 0 2.795574971514725e-08
French O 0 4.766850543092005e-05
Canadian O 0 0.12020502984523773
breast B-Disease 1 0.9992092847824097
cancer I-Disease 1 0.9549795389175415
and O 0 0.02082730270922184
breast B-Disease 1 0.9999058246612549
/ I-Disease 1 0.9999260902404785
ovarian I-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999504089355469
families O 0 0.00011442400136729702
from O 0 2.1767324142274447e-05
Quebec O 0 0.0016159312799572945
. O 0 1.8893266314989887e-05

To O 0 7.948454367578961e-06
identify O 0 5.972088547423482e-05
founder O 0 0.0011379647767171264
effects O 0 6.47651613689959e-05
, O 0 1.2669403304244042e-07
we O 0 1.3688386424348664e-08
examined O 0 5.947069325884513e-07
independently O 0 4.9035143945275195e-08
ascertained O 0 1.6923131624935195e-06
French O 0 3.2785206713015214e-05
Canadian O 0 0.007401815615594387
cancer B-Disease 0 0.04161020740866661
families O 0 3.437465636579873e-07
for O 0 2.1329848109985505e-08
the O 0 8.148631103210846e-09
distribution O 0 1.7099374360896036e-08
of O 0 9.958313285096665e-09
these O 0 1.765408264020607e-08
eight O 0 1.0861936061701272e-06
mutations O 0 3.107564407400787e-05
. O 0 5.1697265917027835e-06

Mutations O 0 0.001752918236888945
were O 0 4.202055606583599e-06
found O 0 1.0081688515128917e-06
in O 0 6.215007175569554e-08
41 O 0 8.133167170853994e-07
of O 0 1.1315309222936776e-07
97 O 0 2.764171949820593e-05
families O 0 3.179997656843625e-05
. O 0 5.494726792676374e-06

Six O 0 3.2281855055771302e-06
of O 0 4.110746374408336e-07
eight O 0 1.8457423038853449e-06
mutations O 0 5.0969897529284935e-06
were O 0 7.101552057520166e-08
observed O 0 1.365751387538694e-07
at O 0 7.244864264066564e-08
least O 0 8.192598244249893e-08
twice O 0 3.6409055610420182e-06
. O 0 2.3674758722336264e-06

The O 0 1.8716889826464467e-05
BRCA1 O 0 0.005136851686984301
C4446T O 0 0.001968865981325507
mutation O 0 6.0260292229941115e-05
was O 0 1.7739364466251573e-06
the O 0 5.981133455179588e-08
most O 0 5.761717858376869e-08
common O 0 4.273378522157145e-07
mutation O 0 1.9933813746320084e-06
found O 0 1.9740383550015395e-07
, O 0 4.991232671613943e-08
followed O 0 7.541619595485827e-08
by O 0 1.2549955386020883e-07
the O 0 1.2567086287162965e-06
BRCA2 O 0 0.0012127552181482315
8765delAG O 0 0.002067052060738206
mutation O 0 4.739586074720137e-05
. O 0 5.213374151935568e-06

Together O 0 9.655605936131906e-06
, O 0 9.069639190784073e-07
these O 0 3.2837419894349296e-08
mutations O 0 1.4082709185458953e-06
were O 0 1.0129888750043392e-07
found O 0 8.364722248188627e-08
in O 0 1.41861029590018e-08
28 O 0 2.3392304626668192e-07
of O 0 3.001526138746158e-08
41 O 0 5.322427114151651e-06
families O 0 3.4854770092351828e-06
identified O 0 1.6541123386559775e-06
to O 0 3.57788003668702e-08
have O 0 5.8172062722405826e-08
a O 0 3.819761218437634e-07
mutation O 0 1.6419775420217775e-05
. O 0 5.194024652155349e-06

The O 0 6.72439773552469e-06
odds O 0 0.0001704353780951351
of O 0 2.0392529620494315e-07
detection O 0 1.558167014081846e-06
of O 0 2.3301833351752066e-08
any O 0 4.242187490177685e-09
of O 0 4.373877704466622e-09
the O 0 1.7661525575363157e-08
four O 0 6.35333265108784e-07
BRCA1 O 0 0.0004255990497767925
mutations O 0 9.381073141412344e-06
was O 0 2.7454234441393055e-06
18 O 0 1.1639220247161575e-05
. O 0 6.229787231859518e-06

7x O 0 0.028324341401457787
greater O 0 2.5074918085010722e-05
if O 0 3.6381493373482954e-07
one O 0 2.491657902226052e-08
or O 0 2.44054909614988e-08
more O 0 1.5611263393111585e-08
cases O 0 5.926160611124942e-06
of O 0 0.008737319149076939
ovarian B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999793767929077
were O 0 1.4535547052219044e-05
also O 0 1.5222086631183629e-06
present O 0 9.81725136739442e-08
in O 0 5.0397908069044206e-08
the O 0 3.405313293569634e-07
family O 0 1.9430053725955077e-05
. O 0 7.492628810723545e-06

The O 0 7.583711067127297e-06
odds O 0 7.10057865944691e-05
of O 0 1.4374261070315697e-07
detection O 0 2.127115749317454e-06
of O 0 2.9634579234993907e-08
any O 0 3.632045553203511e-09
of O 0 3.2929852178398278e-09
the O 0 1.093439738752977e-08
four O 0 3.850803125260427e-07
BRCA2 O 0 0.0002349133137613535
mutations O 0 3.0491705729218666e-06
was O 0 6.199106792337261e-07
5 O 0 2.0333429802121827e-06
. O 0 2.9865980195609154e-06

3x O 0 0.0011605367762967944
greater O 0 1.4605299838876817e-05
if O 0 2.6283751708433556e-07
there O 0 1.2553815764704268e-08
were O 0 1.1562161894573819e-08
at O 0 1.2881707256440222e-08
least O 0 4.542824783015931e-09
five O 0 3.2668122429413415e-08
cases O 0 1.7618343690628535e-06
of O 0 3.225942418794148e-05
breast B-Disease 1 0.9994750618934631
cancer I-Disease 0 0.3702528476715088
in O 0 3.7418777765196864e-07
the O 0 1.5567471791655407e-06
family O 0 4.0305421862285584e-05
. O 0 1.332293322775513e-05

Interestingly O 0 0.00029078396619297564
, O 0 1.6957138768702862e-06
the O 0 9.96928264385133e-08
presence O 0 2.1930902960320964e-07
of O 0 5.2539341766077996e-08
a O 0 1.6095653336378746e-05
breast B-Disease 1 0.9836554527282715
cancer I-Disease 0 0.33779972791671753
case O 0 3.821560767391929e-06
< O 0 1.522268485132372e-05
36 O 0 3.4409822546876967e-06
years O 0 8.659875447847298e-07
of O 0 9.550844737304942e-08
age O 0 2.721996452237363e-06
was O 0 8.441459726782341e-07
strongly O 0 2.3081774713773484e-07
predictive O 0 3.566951534139662e-07
of O 0 9.301238002024093e-09
the O 0 3.738645659723261e-08
presence O 0 8.18336829411237e-08
of O 0 3.422191419133469e-09
any O 0 2.442079871656233e-09
of O 0 5.473331121663705e-09
the O 0 1.8414185731785437e-08
eight O 0 9.826389941736124e-07
mutations O 0 1.0301001566404011e-05
screened O 0 4.2443385609658435e-05
. O 0 4.650038590625627e-06

Carriers O 0 0.00022322557924780995
of O 0 3.596628062041418e-07
the O 0 1.1398597621337103e-07
same O 0 6.488522075187575e-08
mutation O 0 4.2063356886501424e-07
, O 0 1.66282489999503e-08
from O 0 1.4031799722147298e-08
different O 0 5.782214262950447e-09
families O 0 8.607049153397384e-07
, O 0 2.27858137691328e-07
shared O 0 4.3508160274541297e-07
similar O 0 4.406920197652653e-07
haplotypes O 0 0.00014652627578470856
, O 0 9.752142204888514e-07
indicating O 0 1.2416080608090851e-06
that O 0 3.8008955982604675e-09
the O 0 8.592170530619114e-09
mutant O 0 2.504824578863918e-06
alleles O 0 5.789058263871993e-07
were O 0 2.390737847690616e-07
likely O 0 2.0426085711733322e-07
to O 0 5.016072446295539e-09
be O 0 3.3103157992542265e-09
identical O 0 1.1846982062024836e-07
by O 0 5.4556675621597606e-08
descent O 0 4.976867785444483e-06
for O 0 9.741148687680834e-08
a O 0 1.8689408420868858e-07
mutation O 0 8.079516078396409e-07
in O 0 3.7523690821217315e-08
the O 0 1.335261856638681e-07
founder O 0 0.00018633108993526548
population O 0 1.7279489838983864e-06
. O 0 2.471000698278658e-06

The O 0 1.989846623473568e-06
identification O 0 1.7655568171903724e-06
of O 0 5.014816792936472e-07
common O 0 8.976910976343788e-06
BRCA1 O 0 0.0005298245814628899
and O 0 5.9215449255134445e-06
BRCA2 O 0 0.0012966692447662354
mutations O 0 4.1147177398670465e-06
will O 0 1.737093491271935e-08
facilitate O 0 1.237283555610702e-07
carrier O 0 3.6888891372655053e-06
detection O 0 1.4414690667763352e-06
in O 0 9.430449665615015e-08
French O 0 4.502930460148491e-05
Canadian O 0 0.03827144578099251
breast B-Disease 1 0.9957504272460938
cancer I-Disease 1 0.9565946459770203
and O 0 0.021287817507982254
breast B-Disease 1 0.9998706579208374
/ I-Disease 1 0.9998983144760132
ovarian I-Disease 1 0.9999980926513672
cancer I-Disease 1 0.9999251365661621
families O 0 0.000971601577475667
. O 0 6.29486603429541e-05

Are O 0 1.5800134860910475e-05
Dp71 O 0 0.002699279459193349
and O 0 6.678943918814184e-06
Dp140 O 0 0.0017786233220249414
brain O 0 0.0010636780643835664
dystrophin O 0 0.00012774358037859201
isoforms O 0 1.1230523568883655e-06
related O 0 6.8621457103290595e-06
to O 0 1.5807481759111397e-06
cognitive B-Disease 0 0.018548745661973953
impairment I-Disease 1 0.9867455363273621
in O 0 0.0007852644193917513
Duchenne B-Disease 1 0.9998592138290405
muscular I-Disease 1 0.9997743964195251
dystrophy I-Disease 1 0.9995823502540588
? O 0 0.013935861177742481

Molecular O 0 0.00031313422368839383
study O 0 7.104747510311427e-06
and O 0 1.2992966276215157e-06
neuropsychological O 0 0.0003833028895314783
analysis O 0 3.784155637731601e-07
were O 0 8.663297279554172e-08
performed O 0 6.65612773786961e-08
concurrently O 0 9.439051495974127e-08
on O 0 5.693119646821287e-07
49 O 0 0.0004092876042705029
patients O 0 0.0010482141515240073
with O 0 0.00034038780722767115
Duchenne B-Disease 1 0.9999910593032837
muscular I-Disease 1 0.9999876022338867
dystrophy I-Disease 1 0.9999840259552002
( O 0 0.002988891676068306
DMD B-Disease 1 0.9999873638153076
) O 0 4.181939402769785e-06
in O 0 1.1105196051630628e-07
order O 0 6.982111244724365e-08
to O 0 5.20414422666704e-09
find O 0 2.4611173543576115e-08
a O 0 1.3478378413367409e-08
molecular O 0 4.678823302128876e-07
explanation O 0 3.901444856069247e-08
for O 0 2.4707546231184097e-08
the O 0 3.2483251288795145e-07
cognitive B-Disease 0 0.003560739103704691
impairment I-Disease 1 0.5846243500709534
observed O 0 6.9365883064165246e-06
in O 0 1.5428848882947932e-06
most O 0 6.691282760584727e-05
DMD B-Disease 1 0.9999657869338989
patients O 0 0.1500997245311737
. O 0 2.49055683525512e-05

Complete O 0 9.65707022260176e-06
analysis O 0 1.0794440186145948e-06
of O 0 7.506673682655673e-08
the O 0 1.0589721455289691e-07
dystrophin O 0 5.224095730227418e-05
gene O 0 7.782861644045624e-07
was O 0 1.9923461991311342e-07
performed O 0 6.114137107715578e-08
to O 0 4.326599523096775e-09
define O 0 4.56274733551254e-08
the O 0 8.891009706246678e-09
localization O 0 5.2519607152135e-07
of O 0 2.7406880320768323e-08
deletions O 0 1.0409679816802964e-05
and O 0 2.571740651546861e-07
duplications O 0 1.76986723090522e-05
in O 0 6.03096452778118e-08
relation O 0 2.268479732947526e-07
to O 0 3.167994577779609e-08
the O 0 1.2267831550616393e-07
different O 0 7.714456842222717e-07
DMD B-Disease 1 0.9983325600624084
promoters O 0 0.001028644386678934
. O 0 8.504766810801812e-06

Qualitative O 0 4.787647048942745e-05
analysis O 0 1.7175066204799805e-06
of O 0 1.3425886891127448e-07
the O 0 1.5466548575204797e-07
Dp71 O 0 0.00019259918190073222
transcript O 0 2.9816119422321208e-06
and O 0 1.2345125810497848e-07
testing O 0 1.3631176898343256e-07
for O 0 5.804646097118393e-09
the O 0 3.0949605100971667e-09
specific O 0 3.1554858725968415e-09
first O 0 1.123262460822616e-08
exon O 0 4.016362254333217e-06
of O 0 4.2288274215707133e-08
Dp140 O 0 1.2139837963331956e-05
were O 0 8.691781516745323e-08
also O 0 2.650681985016945e-08
carried O 0 7.434006477069488e-08
out O 0 2.5466241027061187e-07
. O 0 1.9005822196049849e-06

Neuropsychological O 0 0.020149318501353264
analysis O 0 3.682519309222698e-05
assessed O 0 0.00032063707476481795
verbal O 0 0.00011385195830371231
and O 0 5.172231794858817e-06
visuospatial O 0 0.002403717488050461
intelligence O 0 5.171683005755767e-05
, O 0 1.2779726148437476e-06
verbal O 0 2.4780098101473413e-05
memory O 0 7.065261161187664e-05
, O 0 4.811346343558398e-07
and O 0 3.5655025953929e-07
reading O 0 6.600188953598263e-06
skills O 0 1.541779056424275e-05
. O 0 2.9193927275628084e-06

Comparison O 0 8.544087904738262e-06
of O 0 3.7983107858963194e-07
molecular O 0 1.098071334126871e-05
and O 0 7.307608029805124e-07
psychometric O 0 0.00010841625044122338
findings O 0 3.4619233701960184e-06
demonstrated O 0 1.6029516700655222e-06
that O 0 2.1686251017172253e-08
deletions O 0 1.4314524605651968e-06
and O 0 9.778715792663206e-08
duplications O 0 1.0690787348721642e-05
that O 0 4.160764888183621e-08
were O 0 6.413258546444922e-08
localized O 0 1.1198886795682483e-06
in O 0 3.755605249011751e-08
the O 0 9.033334436026053e-08
distal O 0 9.308111475547776e-05
part O 0 1.803176843395704e-07
of O 0 2.1835337093989438e-08
the O 0 1.1608249650407743e-07
gene O 0 7.822120551281841e-07
seemed O 0 3.9017280073494476e-07
to O 0 6.9283285775156855e-09
be O 0 8.537396567476208e-09
preferentially O 0 1.4604316902477876e-06
associated O 0 1.282766447729955e-06
with O 0 5.027012321079383e-06
cognitive B-Disease 0 0.021717451512813568
impairment I-Disease 1 0.7425877451896667
. O 0 2.831113488355186e-05

Two O 0 8.492755114275496e-06
altered O 0 7.26318103261292e-05
Dp71 O 0 0.0004403409257065505
transcripts O 0 7.174210168159334e-06
and O 0 1.4755497090845893e-07
two O 0 1.035382268810281e-08
deleted O 0 2.6053331225739385e-07
Dp140 O 0 1.1923528973056818e-06
DNA O 0 2.1133125471806125e-07
sequences O 0 2.4380273799806673e-08
were O 0 4.220254012921032e-08
found O 0 6.99077276067328e-08
in O 0 3.3229184737137984e-08
four O 0 4.686871761805378e-06
patients O 0 0.003710422432050109
with O 0 0.000839082757011056
severe O 1 0.9982043504714966
cerebral B-Disease 1 0.9996665716171265
dysfunction I-Disease 1 0.9974332451820374
. O 0 0.00021963963808957487

These O 0 3.2480604659212986e-06
findings O 0 1.4809090316703077e-05
suggest O 0 8.014163768166327e-07
that O 0 9.8154497862879e-09
some O 0 1.6771640742874183e-09
sequences O 0 1.2240340296898466e-08
located O 0 2.2531043697426867e-08
in O 0 5.312579265392969e-09
the O 0 1.943905836299109e-08
distal O 0 3.778043173952028e-05
part O 0 1.4773773671095114e-07
of O 0 2.5150205473778442e-08
the O 0 1.1026574497918773e-07
gene O 0 4.528095018940803e-07
and O 0 1.1980310432591068e-07
, O 0 4.902420513985817e-08
in O 0 1.4216711363701506e-08
particular O 0 3.463814124415876e-08
, O 0 5.46033156467729e-08
some O 0 3.018082139760736e-08
DMD B-Disease 1 0.9528371691703796
isoforms O 0 1.2261145911907079e-06
expressed O 0 6.520052124869835e-07
in O 0 3.99369817216666e-08
the O 0 5.891336627428245e-07
brain O 0 0.003415288170799613
may O 0 2.231231064797612e-06
be O 0 3.9734189272166986e-08
related O 0 7.103143957465363e-07
to O 0 6.1031734333028e-08
the O 0 2.419072188786231e-06
cognitive B-Disease 0 0.2256496101617813
impairment I-Disease 1 0.9716702699661255
associated O 0 8.0977137258742e-05
with O 0 6.203469820320606e-05
DMD B-Disease 1 0.9999001026153564
. O 0 2.6927151338895783e-05
. O 0 1.416399663867196e-05

I1307K O 0 0.010532325133681297
APC O 0 0.003912901505827904
and O 0 1.4252626897359733e-05
hMLH1 O 0 0.001270996406674385
mutations O 0 1.3503627087629866e-05
in O 0 5.794073842935177e-08
a O 0 1.6165824945346685e-07
non O 0 1.0573949111858383e-05
- O 0 0.0006824953597970307
Jewish O 0 1.4139865925244521e-05
family O 0 4.903547051071655e-06
with O 0 4.078035090060439e-06
hereditary B-Disease 0 0.4763120412826538
non I-Disease 0 0.423775315284729
- I-Disease 1 0.9999204874038696
polyposis I-Disease 1 0.9999717473983765
colorectal I-Disease 1 0.9999986886978149
cancer I-Disease 1 0.9999282360076904
. O 0 0.00015868387708906084

We O 0 2.7448918444861192e-06
describe O 0 2.549506689319969e-06
a O 0 5.753975074185291e-07
French O 0 4.2576681153150275e-05
Canadian O 0 0.0007145095732994378
hereditary B-Disease 1 0.9092081189155579
non I-Disease 1 0.9183724522590637
- I-Disease 1 0.999984860420227
polyposis I-Disease 1 0.9999963045120239
colorectal I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999963045120239
( O 0 0.0005429747398011386
HNPCC B-Disease 1 0.9993067979812622
) O 0 4.699166311183944e-06
kindred O 0 0.00014617251872550696
which O 0 2.969602697078244e-08
carries O 0 2.3428405881986691e-07
a O 0 5.9051522782738175e-08
novel O 0 7.525374599026691e-07
truncating O 0 0.00026560481637716293
mutation O 0 1.0250611012452282e-05
in O 0 8.213608566620678e-07
hMLH1 O 0 0.0011238802690058947
. O 0 9.47609714785358e-06

Interestingly O 0 0.00023412422160618007
, O 0 3.22228606819408e-06
the O 0 3.522629015151324e-07
I1307K O 0 0.0001293985260417685
APC O 0 0.00012951433018315583
polymorphism O 0 5.09329438500572e-05
, O 0 5.212978635427135e-07
associated O 0 2.1662650340203982e-07
with O 0 3.006327631283057e-08
an O 0 1.8647908461844054e-07
increased O 0 2.924514228652697e-05
risk O 0 0.0019240772817283869
of O 0 0.004378666169941425
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999901056289673
, O 0 1.9967159460065886e-05
is O 0 3.471218690265232e-07
also O 0 2.260092770711708e-07
present O 0 5.3542901667924525e-08
in O 0 3.223688693765325e-08
this O 0 5.911755707188604e-08
family O 0 9.849575690168422e-06
. O 0 9.936392416420858e-06

The O 0 1.054192125593545e-05
I1307K O 0 0.0007257325924001634
polymorphism O 0 0.00029143146821297705
has O 0 1.7949772654901608e-06
previously O 0 1.2528349770946079e-06
only O 0 1.4058132435934567e-08
been O 0 1.5160658506374602e-07
identified O 0 2.6855701662498177e-07
in O 0 1.654182746335664e-08
individuals O 0 5.817095427573804e-08
of O 0 5.9448641565040816e-08
self O 0 2.0591820430126972e-05
- O 0 0.017121734097599983
reported O 0 0.00012954864359926432
Ashkenazi O 0 0.00017239985754713416
Jewish O 0 9.703293471829966e-06
origins O 0 7.341693162743468e-06
. O 0 4.043036824441515e-06

In O 0 6.88702584739076e-06
addition O 0 3.7518186672969023e-06
, O 0 2.782839487736055e-07
in O 0 4.1946062623310354e-08
this O 0 1.1015282019855022e-08
family O 0 6.568819799213088e-07
, O 0 9.624521624118643e-08
there O 0 2.773348661833097e-08
appears O 0 3.509628925257857e-07
to O 0 1.542417749078595e-08
be O 0 1.1669592403507068e-08
no O 0 1.6963038973472067e-08
relationship O 0 1.0601301170254374e-07
between O 0 2.0136385003866053e-08
the O 0 5.956395554562732e-08
I1307K O 0 0.00010510052379686385
polymorphism O 0 2.5783301680348814e-05
and O 0 3.167617421695468e-07
the O 0 5.646710121709475e-08
presence O 0 5.534524802897067e-07
or O 0 3.0456115496235725e-07
absence O 0 7.057591574266553e-06
of O 0 7.757040293654427e-06
cancer B-Disease 0 0.07383859902620316
. O 0 1.441829340365075e-06
. O 0 4.130333763896488e-06

Identification O 0 1.0588389159238432e-05
of O 0 4.964439881405269e-07
a O 0 3.693704968554812e-07
novel O 0 5.776219609288091e-07
mutation O 0 4.314619843626133e-07
of O 0 8.660220984779698e-09
the O 0 2.5911910839226948e-08
CPO O 0 1.1521221495058853e-05
gene O 0 9.526900868195298e-08
in O 0 1.1547395040167885e-08
a O 0 1.4705933892855683e-07
Japanese O 0 5.474724093801342e-05
hereditary B-Disease 0 0.07814982533454895
coproporphyria I-Disease 0 0.41256266832351685
family O 0 0.00014828714483883232
. O 0 9.00508530321531e-06

Hereditary B-Disease 1 0.9949136972427368
coproporphyria I-Disease 1 0.9693859219551086
( O 0 0.00018380700203124434
HCP B-Disease 1 0.9028133749961853
) O 0 5.770835741714109e-06
is O 0 7.152801231313788e-07
an O 0 3.3934104521904374e-06
autosomal B-Disease 0 0.12568451464176178
dominant I-Disease 0 0.4630059599876404
disease I-Disease 1 0.6468334794044495
characterized O 0 0.0003459592699073255
by O 0 1.388286727888044e-05
a O 0 0.0008459642413072288
deficiency B-Disease 1 0.8669012188911438
of I-Disease 0 6.420272029572516e-07
coproporphyrinogen I-Disease 0 0.06668801605701447
oxidase I-Disease 0 0.00011848998110508546
( O 0 3.842882563276362e-07
CPO O 0 9.759126987773925e-05
) O 0 1.1324323168082628e-07
caused O 0 4.079320206074044e-07
by O 0 1.6502655242334185e-08
a O 0 7.096528520378342e-08
mutation O 0 5.148655191078433e-07
in O 0 2.505812801700813e-08
the O 0 1.7715092326398008e-07
CPO O 0 0.0003399872512090951
gene O 0 4.40326630268828e-06
. O 0 2.37708854911034e-06

Only O 0 1.4081111885388964e-06
11 O 0 2.2325273221213138e-06
mutations O 0 1.8059664625980076e-06
of O 0 1.3931527931276833e-08
the O 0 3.9381234273605514e-08
gene O 0 1.7959071385575953e-07
have O 0 3.9025014331173224e-08
been O 0 1.929069384232207e-07
reported O 0 5.248843990557361e-06
in O 0 4.472338332561776e-06
HCP B-Disease 1 0.9764942526817322
patients O 0 0.006259530782699585
. O 0 1.2534787856566254e-05

We O 0 2.5330361950182123e-06
report O 0 6.476244038822188e-07
another O 0 1.5864826252709463e-07
mutation O 0 5.745837370341178e-07
in O 0 2.1236399305735176e-08
a O 0 2.1943058925444348e-07
Japanese O 0 3.3607622754061595e-05
family O 0 1.80248316610232e-05
. O 0 5.783645065093879e-06

Polymerase O 0 0.0008960261475294828
chain O 0 0.00031935577862896025
reaction O 0 8.168416570697445e-06
- O 0 3.681585440062918e-05
single O 0 4.723748077140044e-07
strand O 0 1.9274715668871067e-05
conformational O 0 3.581564897103817e-06
polymorphism O 0 2.8827980713685974e-06
and O 0 1.885928213596344e-08
direct O 0 6.2375562492889e-09
sequence O 0 9.29644894398507e-09
analyses O 0 1.265913738279778e-07
demonstrated O 0 6.24137896920729e-07
a O 0 3.337534337788384e-08
C O 0 2.3753641471557785e-06
to O 0 1.6019072290873737e-08
T O 0 2.1778952941531315e-05
substitution O 0 3.317466479302311e-08
in O 0 6.708918753872695e-09
exon O 0 1.215432916978898e-06
1 O 0 1.190454579358402e-08
of O 0 1.5956855836662953e-09
the O 0 4.710869916380034e-09
CPO O 0 1.3059303682894097e-06
gene O 0 1.3514648955492703e-08
at O 0 6.599718105348984e-09
nucleotide O 0 1.7668845941898326e-07
position O 0 8.322390243620248e-08
85 O 0 4.0046140270533215e-07
, O 0 4.043696577582523e-08
which O 0 6.124616369618252e-09
lies O 0 7.601421003755604e-08
in O 0 7.324671535968719e-09
the O 0 2.1442227549073323e-08
putative O 0 1.598255585122388e-05
presequence O 0 0.00011336607713019475
for O 0 5.7635535455347053e-08
targeting O 0 1.1883342949658982e-06
to O 0 2.759474853064603e-07
mitochondria O 0 1.3426079931377899e-05
. O 0 2.7296598545945017e-06

This O 0 2.4421103717031656e-06
mutation O 0 8.653090844745748e-06
changes O 0 1.3577400181929988e-07
the O 0 8.243537408247903e-09
codon O 0 1.2732193965803162e-07
for O 0 7.446051775161777e-09
glutamine O 0 1.1888122486425345e-07
to O 0 4.146731846788043e-09
a O 0 8.417806895977265e-09
termination O 0 9.486778935752227e-07
codon O 0 2.695379350825533e-07
at O 0 1.4940768267024396e-07
amino O 0 4.0962552816381503e-07
acid O 0 2.219740736109088e-06
position O 0 5.146097805663885e-07
29 O 0 7.614409696543589e-06
. O 0 1.8147038645111024e-06

MaeI O 0 0.01113537885248661
restriction O 0 1.2994308235647622e-05
analysis O 0 1.3421717994788196e-06
showed O 0 1.8187807881986373e-06
two O 0 4.361092820204249e-08
other O 0 5.3882416750639095e-08
carriers O 0 4.371680461190408e-06
in O 0 3.379833657390918e-08
the O 0 1.2424911233210878e-07
family O 0 4.628104306902969e-06
. O 0 4.472859018278541e-06

The O 0 1.3590612979896832e-05
C O 0 0.0015525593189522624
- O 0 0.4835273027420044
T O 1 0.7308006286621094
mutation O 0 1.0910835953836795e-05
is O 0 3.833441653000591e-08
located O 0 4.089747562829871e-08
within O 0 9.811818024729746e-09
a O 0 1.1387308518351347e-07
recently O 0 4.5337742449191865e-06
proposed O 0 3.675432651562005e-07
putative O 0 1.8108402173311333e-06
alternative O 0 3.3194851312146056e-08
translation O 0 2.0276672785257688e-08
initiation O 0 1.3134852849816525e-07
codon O 0 4.623682912097138e-07
( O 0 6.931568918844278e-08
TIC O 0 8.178655843948945e-05
- O 0 1.701432847767137e-05
1 O 0 1.496802184419721e-07
) O 0 7.357744635783092e-09
, O 0 5.95464344499419e-09
supporting O 0 1.127334527950552e-07
that O 0 3.090066513777856e-08
TIC O 0 0.0002612211974337697
- O 0 3.0075434551690705e-05
1 O 0 1.4402556303139136e-07
is O 0 8.001363127618788e-09
the O 0 6.642783212384984e-09
real O 0 4.7376795464515453e-07
TIC O 0 0.00022583582904189825
rather O 0 4.164186861999042e-08
than O 0 4.381620399840358e-08
TIC O 0 0.0002153459208784625
- O 0 3.5580269468482584e-05
2 O 0 4.159853403962188e-07
. O 0 1.6151787463059009e-07
. O 0 9.256268072022067e-07

Human B-Disease 0 0.00012462696759030223
complement I-Disease 0 0.0002879542298614979
factor I-Disease 0 0.003597769420593977
H I-Disease 1 0.9997126460075378
deficiency I-Disease 1 0.9993377327919006
associated O 0 0.0037809270434081554
with O 0 0.3247072100639343
hemolytic B-Disease 1 0.999967098236084
uremic I-Disease 1 0.9999881982803345
syndrome I-Disease 1 0.9999234676361084
. O 0 0.0008715380099602044

This O 0 1.0919818578258855e-06
study O 0 6.632466806877346e-07
reports O 0 2.800258300794667e-07
on O 0 1.1539837174723289e-07
six O 0 1.049408751896408e-06
cases O 0 9.568432687956374e-06
of O 0 1.8667566109797917e-05
deficiency B-Disease 1 0.8860477805137634
in I-Disease 0 8.595682743361976e-08
the I-Disease 0 3.852183638741735e-08
human I-Disease 0 8.293676501125447e-08
complement I-Disease 0 3.8679181102452276e-07
regulatory I-Disease 0 3.1690090054325992e-06
protein I-Disease 0 3.750412815861637e-07
Factor I-Disease 0 7.042027618808788e-07
H I-Disease 0 0.03346122056245804
( O 0 2.0780304055278975e-07
FH O 0 9.815629891818389e-05
) O 0 1.8635121890042683e-08
in O 0 3.979105045459619e-09
the O 0 4.3391117365843e-09
context O 0 3.905971368567407e-08
of O 0 9.417819342161238e-07
an O 0 0.004235736560076475
acute B-Disease 1 0.9998965263366699
renal I-Disease 1 0.9999977350234985
disease I-Disease 1 0.999900221824646
. O 0 0.00028196658240631223

Five O 0 4.258884473529179e-06
of O 0 2.131600638222153e-07
the O 0 1.2894938095087127e-07
cases O 0 1.5477113493034267e-06
were O 0 2.796362252865947e-07
observed O 0 3.0279943530331366e-07
in O 0 6.419401898938304e-08
children O 0 3.573662752387463e-06
presenting O 0 0.00039194352575577796
with O 0 0.3378629684448242
idiopathic O 1 0.9999860525131226
hemolytic B-Disease 1 0.9999978542327881
uremic I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999959468841553
( O 0 0.03030860610306263
HUS B-Disease 1 0.9998893737792969
) O 0 0.00015969996456988156
. O 0 2.7456188036012463e-05

Two O 0 1.7901666069519706e-06
of O 0 2.466371427090053e-07
the O 0 3.2837550634212676e-07
children O 0 3.837070835288614e-06
exhibited O 0 6.661912630079314e-05
a O 0 4.1706804040586576e-05
homozygous O 1 0.7348951101303101
deficiency O 1 0.9862231612205505
characterized O 0 4.507888661464676e-05
by O 0 3.591822235193831e-07
the O 0 2.6747355263978534e-07
absence O 0 1.053132336892304e-06
of O 0 9.783301280208434e-09
the O 0 3.170956830444993e-08
150 O 0 4.717031458767451e-07
- O 0 0.00022374102263711393
kD O 0 0.00014193766401149333
form O 0 8.699427667124837e-08
of O 0 2.660645570529141e-08
Factor O 0 7.017825396360422e-07
H O 0 0.009110571816563606
and O 0 8.444021659670398e-08
the O 0 2.4923709318613874e-08
presence O 0 1.7946059926998714e-07
, O 0 2.4382041274861876e-08
upon O 0 3.6429263161608105e-08
immunoblotting O 0 2.6953770429827273e-05
, O 0 1.2824903805608301e-08
of O 0 2.200053916823208e-09
the O 0 7.647517286102357e-09
42 O 0 7.522884288846399e-07
- O 0 6.79890436003916e-05
kD O 0 0.00017965640290640295
Factor O 0 7.153851697694336e-07
H O 0 0.00042024918366223574
- O 0 1.4440502127399668e-05
like O 0 8.899412051732725e-08
protein O 0 2.3882556376975117e-08
1 O 0 2.9222366748626882e-08
( O 0 2.0895559060818414e-08
FHL O 0 2.690856490517035e-05
- O 0 2.0262374164303765e-05
1 O 0 1.3109949748013605e-07
) O 0 7.180068539724971e-09
and O 0 7.708967686426149e-09
other O 0 2.052625625026394e-08
FH O 0 0.0002812870079651475
- O 0 0.0002520946436561644
related O 0 9.173345461022109e-06
protein O 0 2.889297263664048e-07
( O 0 1.349253011539986e-07
FHR O 0 0.0003968999080825597
) O 0 2.459923393871577e-07
bands O 0 3.2888806344999466e-06
. O 0 1.1670905450955615e-06

Southern O 0 3.684753755806014e-05
blot O 0 0.000364028790500015
and O 0 7.032296593934007e-07
PCR O 0 6.919640782143688e-06
analysis O 0 9.812795553898468e-08
of O 0 1.748715483529395e-08
DNA O 0 8.593204938733834e-07
of O 0 3.539577164701768e-08
one O 0 3.448271286288218e-07
patient O 0 1.946638985828031e-05
with O 0 4.884564987150952e-06
homozygous O 0 0.0526590570807457
deficiency O 1 0.6266128420829773
ruled O 0 8.266840268333908e-06
out O 0 1.670472471460016e-07
the O 0 5.427892446618898e-08
presence O 0 1.0526447624670254e-07
of O 0 7.253461831169261e-09
a O 0 4.0520117039477554e-08
large O 0 1.3772221052477107e-07
deletion O 0 6.248597514968424e-07
of O 0 1.8378290889131677e-08
the O 0 7.713354222005364e-08
FH O 0 0.0019145447295159101
gene O 0 5.552658990382042e-07
as O 0 4.100596484590824e-08
the O 0 3.361582230354543e-07
underlying O 0 0.00038259028224274516
defect O 0 0.004057647194713354
for O 0 8.650005838717334e-06
the O 0 0.00020044876146130264
deficiency O 1 0.857602596282959
. O 0 2.7526919438969344e-05

The O 0 1.8449538856657455e-06
other O 0 2.0094340413834288e-07
four O 0 2.070772069373561e-07
children O 0 8.356276453014289e-07
presented O 0 1.4728644828210236e-06
with O 0 2.6117663765035104e-06
heterozygous O 0 0.0018819449469447136
deficiency O 0 0.4448574483394623
and O 0 6.002442205499392e-07
exhibited O 0 1.4714110875502229e-05
a O 0 3.7170343603065703e-07
normal O 0 2.480292948803253e-07
immunoblotting O 0 0.00011163955787196755
pattern O 0 4.367023791473912e-07
of O 0 1.756098910732362e-08
proteins O 0 2.669693976997678e-08
of O 0 2.357596962099251e-08
the O 0 7.176633971539559e-07
FH O 0 0.12433407455682755
family O 0 4.469586201594211e-05
. O 0 5.4336687753675506e-06

Factor B-Disease 0 0.2073797732591629
H I-Disease 1 0.9997324347496033
deficiency I-Disease 1 0.9939882755279541
is O 0 2.818528059833625e-07
the O 0 1.385080281579576e-07
only O 0 5.719737146137049e-07
complement B-Disease 1 0.537686824798584
deficiency I-Disease 1 0.9998732805252075
associated O 0 3.7022167816758156e-05
with O 0 4.097854616702534e-05
HUS B-Disease 1 0.9984205961227417
. O 0 4.234340667608194e-05

These O 0 1.878649186437542e-06
observations O 0 2.513817889848724e-06
suggest O 0 1.4293788126451545e-06
a O 0 1.0549964457595706e-07
role O 0 2.448989846470795e-07
for O 0 6.396546581299845e-08
FH O 0 0.0008189514046534896
and O 0 7.291095585060248e-07
/ O 0 1.2218412848596927e-05
or O 0 1.0925339211098617e-06
FH O 0 0.005376263987272978
receptors O 0 1.0588327313598711e-05
in O 0 5.482936416001394e-08
the O 0 2.4226542905125825e-07
pathogenesis O 0 0.0008558134431950748
of O 0 2.750464409473352e-05
idiopathic O 1 0.998770534992218
HUS B-Disease 1 0.9996201992034912
. O 0 2.114101152983494e-05
. O 0 1.2185724699520506e-05

Further O 0 9.615064300305676e-06
evidence O 0 3.0148828500387026e-06
for O 0 1.2887868194866314e-07
a O 0 2.2096038776453497e-07
major O 0 3.318844619570882e-06
ancient O 0 7.509762326662894e-06
mutation O 0 0.001506177126429975
underlying O 1 0.6065847277641296
myotonic B-Disease 1 0.9999816417694092
dystrophy I-Disease 1 0.9999713897705078
from O 0 3.4015116398222744e-05
linkage O 0 0.0008013616316020489
disequilibrium O 0 0.07026846706867218
studies O 0 6.6327852437098045e-06
in O 0 8.587554845007617e-08
the O 0 1.2768417434472212e-07
Japanese O 0 2.6193187295575626e-05
population O 0 1.5094943819349282e-06
. O 0 3.3608496323722648e-06

The O 0 0.011471020057797432
myotonic B-Disease 1 0.9999052286148071
dystrophy I-Disease 1 0.9999524354934692
( O 0 0.0021777639631181955
DM B-Disease 1 0.9999690055847168
) O 0 3.13256387016736e-05
mutation O 0 4.46423509856686e-05
is O 0 2.079563046208932e-07
an O 0 6.675816166534787e-07
unstable O 0 0.0015395977534353733
( O 0 1.6140328398250858e-06
CTG O 0 0.001402710098773241
) O 0 1.1509897746009301e-07
n O 0 2.904277835114044e-06
repeat O 0 2.1306138933141483e-06
, O 0 6.549660724886053e-08
present O 0 1.342677879989651e-08
at O 0 2.394285303353172e-08
a O 0 1.340625477297408e-08
copy O 0 1.0496314217789404e-07
number O 0 5.607542874486171e-09
of O 0 3.6923111235154238e-09
5 O 0 4.8184684686702894e-08
- O 0 5.7329702940478455e-06
37 O 0 2.3091858736279391e-07
repeats O 0 3.586386299048172e-08
on O 0 8.8692617694619e-09
normal O 0 6.698944954308672e-09
chromosomes O 0 6.153751996862411e-08
but O 0 2.5363360300900695e-09
amplified O 0 1.1776590014278554e-07
to O 0 2.5057256269889194e-09
50 O 0 1.273833394321855e-08
- O 0 2.015213567574392e-06
3000 O 0 5.849081503583875e-07
copies O 0 1.9503760029238038e-07
on O 0 1.4476437399935094e-06
DM B-Disease 1 0.9711146950721741
chromosomes O 0 7.665653538424522e-05
. O 0 4.289014214009512e-06

Previous O 0 2.167768616345711e-05
findings O 0 2.098445656883996e-05
in O 0 4.617703268650075e-07
Caucasian O 0 0.00013552415475714952
populations O 0 1.8874305851568351e-06
of O 0 9.242034337830773e-08
a O 0 6.41731185169192e-06
DM B-Disease 1 0.999950647354126
founder O 0 0.17028412222862244
chromosome O 0 0.0007968502468429506
raise O 0 4.501908279053168e-06
a O 0 5.547335035771539e-08
question O 0 4.108551010517658e-08
about O 0 1.0357378066316869e-08
the O 0 7.451806283143014e-09
molecular O 0 2.468903801400302e-07
events O 0 2.0387663113297094e-08
involved O 0 1.902736954662032e-07
in O 0 1.8891432418399745e-08
the O 0 9.481581031423048e-08
expansion O 0 2.3430611690855585e-05
mutation O 0 2.2188893126440234e-05
. O 0 5.128204065840691e-06

To O 0 3.83135920856148e-06
investigate O 0 1.9180339222657494e-05
whether O 0 1.464933120587375e-06
a O 0 4.5333359821597696e-07
founder O 0 0.00011966440069954842
chromosome O 0 2.4127355573000386e-05
for O 0 2.24140137561335e-07
the O 0 1.0906715033343062e-06
DM B-Disease 1 0.9999113082885742
mutation O 0 2.907287489506416e-05
exists O 0 1.6127360424889048e-07
in O 0 2.008038890721764e-08
the O 0 4.2917037035294925e-08
Japanese O 0 6.519139333249768e-06
population O 0 6.913349182013917e-08
, O 0 5.781643253044422e-08
we O 0 1.5873023784251927e-08
genotyped O 0 1.9749470084207132e-05
families O 0 9.471639828007028e-08
using O 0 4.220721194769794e-08
polymorphic O 0 1.693907870503608e-05
markers O 0 7.715604624536354e-06
near O 0 5.340837105904939e-07
the O 0 4.1291496444273434e-08
( O 0 1.3877405535822618e-07
CTG O 0 0.0001622522104298696
) O 0 5.485174980890406e-08
n O 0 7.397626404781477e-07
repeat O 0 1.177489821202471e-06
region O 0 2.46878613552326e-07
and O 0 1.6077851228146756e-07
constructed O 0 5.475920715980465e-06
haplotypes O 0 0.00016102845256682485
. O 0 4.916335001325933e-06

Six O 0 6.530956852657255e-06
different O 0 4.776313176080293e-07
haplotypes O 0 5.9646787121891975e-05
were O 0 6.741206561855506e-07
found O 0 1.249719389306847e-06
and O 0 3.2089340038510272e-06
DM B-Disease 1 0.9998325109481812
alleles O 0 2.0019939256599173e-05
were O 0 9.100249371840619e-07
always O 0 6.557397682627197e-07
haplotype O 0 2.309716546733398e-05
A O 0 2.58451109402813e-06
. O 0 4.646390607376816e-06

To O 0 5.031645287090214e-06
find O 0 1.2219821883263648e-06
an O 0 4.8364878324491656e-08
origin O 0 2.1437360331333366e-08
of O 0 9.994124638978974e-09
the O 0 2.873728632835082e-08
( O 0 1.0238316150434912e-07
CTG O 0 7.951376755954698e-05
) O 0 2.441508328843156e-08
n O 0 6.027745484971092e-07
repeat O 0 1.659688564359385e-06
mutation O 0 5.003919909540855e-07
and O 0 2.8404274488025294e-08
to O 0 4.785100760074101e-09
investigate O 0 1.586900140182479e-07
the O 0 7.043691407915276e-09
mechanism O 0 2.9838538750937005e-08
of O 0 6.375496575117268e-09
the O 0 8.740387968941832e-09
expansion O 0 5.143006660546234e-07
mutation O 0 2.597971331397275e-07
in O 0 5.948263659405484e-09
the O 0 1.743526389930139e-08
Japanese O 0 1.8818788021235378e-06
population O 0 2.3796253856289695e-08
we O 0 4.309756551634791e-09
have O 0 3.4530140968769274e-09
studied O 0 4.198880532158e-08
90 O 0 8.303300802481317e-08
Japanese O 0 1.098741813621018e-05
DM B-Disease 1 0.9932671785354614
families O 0 1.2661276969083701e-06
comprising O 0 9.784870371731813e-07
190 O 0 7.368079877778655e-06
affected O 0 9.696129836811451e-07
and O 0 2.847083635515446e-07
130 O 0 9.299764315073844e-06
unaffected O 0 8.308485121233389e-05
members O 0 2.112993115588324e-06
. O 0 2.2975989395490615e-06

The O 0 2.5522460873617092e-06
results O 0 4.663544132199604e-06
suggest O 0 1.3777938647763222e-06
that O 0 1.578868769058772e-08
a O 0 2.8515065864098688e-08
few O 0 3.783848256944111e-08
common O 0 2.5078409748857666e-07
ancestral O 0 3.2310992992279353e-06
mutations O 0 1.757124323376047e-06
in O 0 1.4127347292003378e-08
both O 0 4.509074003067326e-08
Caucasian O 0 2.9168379114707932e-05
and O 0 6.92103981236869e-07
Japanese O 0 2.2438713131123222e-05
populations O 0 2.0498964659054764e-06
have O 0 4.9619778508258605e-08
originated O 0 2.443306534871681e-08
by O 0 1.0674870765114974e-08
expansion O 0 1.3731879278111592e-07
of O 0 8.783153759850393e-09
an O 0 5.10130959696653e-08
ancestral O 0 1.4532458862959174e-06
n O 0 5.0131184252677485e-06
= O 0 1.7077509255614132e-06
5 O 0 8.276862928369155e-08
repeat O 0 2.1847279185749358e-07
to O 0 5.7057767399726345e-09
n O 0 4.563156608128338e-07
= O 0 1.2174306220913422e-06
19 O 0 3.738367979622126e-07
- O 0 2.25202165893279e-05
37 O 0 1.9938545392506057e-06
copies O 0 3.019343012056197e-06
. O 0 2.599463641672628e-06

These O 0 8.044548849284183e-07
data O 0 4.714588897059002e-07
support O 0 2.3452436437310098e-07
multistep O 0 2.484111746525741e-06
models O 0 4.6071374981693225e-07
of O 0 2.8155561437870347e-08
triplet O 0 5.7477911468595266e-05
repeat O 0 2.47130697061948e-06
expansion O 0 5.464034416036156e-07
that O 0 1.0666912686474461e-08
have O 0 1.11103606315055e-08
been O 0 1.660980153417313e-08
proposed O 0 9.919038745920261e-08
for O 0 4.563304756288744e-08
both O 0 9.314038038610306e-07
DM B-Disease 1 0.9998258948326111
and O 0 0.00010773020767373964
Friedreichs B-Disease 1 0.6481167674064636
ataxia I-Disease 1 0.5831655859947205
. O 0 2.2176309357746504e-06
. O 0 3.924330485460814e-06

The O 0 2.1636358269461198e-06
molecular O 0 5.649829745379975e-06
basis O 0 7.303051461349241e-07
of O 0 2.4911530999816023e-05
C6 B-Disease 1 0.9999892711639404
deficiency I-Disease 1 0.9999587535858154
in O 0 2.5279922510890174e-07
the O 0 6.965790078083955e-08
western O 0 1.5201342193904566e-06
Cape O 0 4.8512920329812914e-05
, O 0 5.980004402772465e-07
South O 0 3.843432295980165e-06
Africa O 0 6.195305559231201e-06
. O 0 3.518117637213436e-06

Deficiency B-Disease 1 0.9855664968490601
of I-Disease 0 7.496349780922174e-07
the I-Disease 0 1.8324674044833955e-07
sixth I-Disease 0 6.376159035426099e-06
component I-Disease 0 1.0581054539215984e-06
of I-Disease 0 5.276852377278374e-08
human I-Disease 0 2.8237531068953103e-07
complement I-Disease 0 1.1490620863696677e-06
( O 0 3.305655127405771e-07
C6 O 0 0.031223073601722717
) O 0 2.673656638307875e-07
has O 0 1.0132574601584565e-07
been O 0 5.1766843256473294e-08
reported O 0 2.610618139442522e-07
in O 0 6.3850134068843545e-09
a O 0 8.587926814129787e-09
number O 0 8.843889176546327e-09
of O 0 8.756189551206717e-09
families O 0 1.7459316836720973e-07
from O 0 2.7762540710796202e-08
the O 0 3.366650602742993e-08
western O 0 8.627611123301904e-07
Cape O 0 2.106919782818295e-05
, O 0 2.870710886782035e-07
South O 0 8.144965590872744e-07
Africa O 0 1.4488730357697932e-06
. O 0 2.1854768874618458e-06

Meningococcal B-Disease 1 0.999159574508667
disease I-Disease 1 0.9981569647789001
is O 0 5.2800605772063136e-05
endemic O 0 0.0006109261885285378
in O 0 2.189706833632954e-07
the O 0 1.6827796400775696e-07
Cape O 0 3.3601791074033827e-05
and O 0 1.5012352605481283e-07
almost O 0 9.000070022580076e-09
all O 0 3.613561672111132e-09
pedigrees O 0 7.024555088719353e-07
of O 0 1.2871360866029136e-07
total O 0 0.0002908779715653509
C6 B-Disease 1 0.9999971389770508
deficiency I-Disease 1 0.9999727010726929
( O 0 2.629262780828867e-06
C6Q0 O 0 0.03539208322763443
) O 0 4.77236540064041e-07
have O 0 6.305622690661039e-08
been O 0 1.6523891588349215e-07
ascertained O 0 9.677279194875155e-06
because O 0 7.057020070533326e-07
of O 0 6.044858309905976e-06
recurrent O 1 0.9373002052307129
disease O 0 0.20708417892456055
. O 0 3.254062539781444e-05

We O 0 1.9718963812920265e-06
have O 0 2.2141158240174263e-07
sequenced O 0 6.392485261130787e-07
the O 0 2.044092717312651e-08
expressed O 0 2.2854448999964916e-08
exons O 0 8.482069091542144e-08
of O 0 4.688746280123723e-09
the O 0 1.7591965217889083e-08
C6 O 0 0.0013602101244032383
gene O 0 1.6579359396473592e-07
from O 0 2.8782762839796305e-08
selected O 0 8.827209541095726e-08
cases O 0 2.8543260555125016e-07
and O 0 1.4475980947281641e-07
have O 0 6.589356615904762e-08
found O 0 5.327691710022009e-08
three O 0 8.586997779502781e-08
molecular O 0 0.0004810151585843414
defects O 1 0.8060341477394104
leading O 0 5.338543269317597e-05
to O 0 8.139840588228253e-07
total O 0 4.5113807573216036e-05
deficiency O 1 0.6408789157867432
879delG O 0 0.00128211360424757
, O 0 4.4718811409438786e-07
which O 0 2.2593873438836454e-08
is O 0 1.7575397137647997e-08
the O 0 9.38526625304803e-08
common O 0 4.386480668472359e-06
defect O 0 0.0003055105044040829
in O 0 7.021093040293636e-08
the O 0 1.4121937397248985e-07
Cape O 0 8.615093247499317e-05
and O 0 1.386765688948799e-06
hitherto O 0 4.8361322114942595e-05
unreported O 0 4.31403677794151e-05
, O 0 2.562870236033632e-07
and O 0 1.2311572561429784e-07
1195delC O 0 6.646207475569099e-05
and O 0 3.473109870810731e-07
1936delG O 0 9.844810847425833e-05
, O 0 4.9616939890029244e-08
which O 0 5.340681230592281e-09
have O 0 1.5539400877173648e-08
been O 0 8.524008876520384e-08
previously O 0 8.564912263864244e-07
reported O 0 1.093847572519735e-06
in O 0 6.033069865907237e-08
African O 0 3.2954237667581765e-06
- O 0 0.0012103389017283916
Americans O 0 6.347163434838876e-05
. O 0 5.01706927025225e-06

We O 0 4.706414074462373e-06
also O 0 4.1209284518117784e-07
show O 0 9.296097402966552e-08
that O 0 8.691827702023147e-09
the O 0 3.4858047115449153e-08
879delG O 0 0.00021219327754806727
and O 0 1.046916440827772e-05
1195delC O 1 0.7162140011787415
defects O 1 0.9622499346733093
are O 0 4.590975208884629e-07
associated O 0 6.256635174395342e-07
with O 0 4.979546588401718e-07
characteristic O 0 1.3166840290068649e-05
C6 O 1 0.6906137466430664
/ O 0 0.0004598607774823904
C7 O 0 0.29720738530158997
region O 0 2.820081817844766e-06
DNA O 0 2.6927151338895783e-05
marker O 0 0.00011716096196323633
haplotypes O 0 0.00013697783288080245
, O 0 3.7356662119236717e-07
although O 0 6.426765253308986e-08
small O 0 9.87038575317456e-08
variations O 0 7.626391038684233e-07
were O 0 7.382896001217887e-07
observed O 0 3.354842192493379e-06
. O 0 3.503827201711829e-06

The O 0 3.441573426243849e-05
1936delG O 0 0.08265527337789536
defect O 0 0.10926323384046555
was O 0 8.83351549418876e-06
observed O 0 6.384248649737856e-07
only O 0 7.827589243447619e-09
once O 0 5.65619622250324e-08
in O 0 4.5360368794433725e-09
the O 0 2.3656870240529315e-08
Cape O 0 1.104391321860021e-05
, O 0 6.063594781835491e-08
but O 0 2.2065561822159907e-08
its O 0 6.028423626958102e-08
associated O 0 1.9495203105179826e-06
haplotype O 0 1.2739733392663766e-05
could O 0 2.9987339189574413e-07
be O 0 7.96698103044946e-08
deduced O 0 3.6899239148624474e-06
. O 0 2.2560323031939333e-06

The O 0 1.2927953321195673e-06
data O 0 5.223772632234613e-07
from O 0 1.6550102088785934e-07
the O 0 9.966544922690446e-08
haplotypes O 0 4.907051697955467e-05
indicate O 0 6.761106874364486e-07
that O 0 7.1577255233989945e-09
these O 0 3.2155871299011096e-09
three O 0 7.770248089400411e-08
molecular O 0 0.0002822540991473943
defects O 1 0.5214141607284546
account O 0 1.1110901141364593e-06
for O 0 2.850039209079114e-07
the O 0 2.0867394141532714e-06
defects O 0 0.18486949801445007
in O 0 2.274035004745656e-08
all O 0 3.917160817934473e-09
the O 0 2.160578382870426e-08
38 O 0 9.363848221255466e-06
unrelated O 0 0.00018329735030420125
C6Q0 O 0 0.07743392139673233
individuals O 0 4.84352199237037e-07
we O 0 1.723516263041347e-08
have O 0 1.764819046456978e-08
studied O 0 8.229292092210017e-08
from O 0 4.479072757135327e-08
the O 0 2.0967127056792378e-07
Cape O 0 5.225012864684686e-05
. O 0 3.075677568631363e-06

We O 0 4.4707262532028835e-06
have O 0 5.378024638957868e-07
also O 0 6.707079336365496e-08
observed O 0 9.174906523412574e-08
the O 0 5.0653191863148095e-08
879delG O 0 0.0004164267738815397
defect O 0 9.841928113019094e-05
in O 0 1.857465292687266e-08
two O 0 1.3053596603640472e-07
Dutch O 0 0.07300036400556564
C6 B-Disease 1 0.9999510049819946
- I-Disease 1 0.9973491430282593
deficient I-Disease 1 0.9928494691848755
kindreds O 0 0.0014392806915566325
, O 0 3.6394888525137503e-07
but O 0 2.6368402572529703e-08
the O 0 8.872819279304167e-08
879delG O 0 0.001233529532328248
defect O 0 0.0005362947704270482
in O 0 4.2825785584454934e-08
the O 0 1.9951622221014986e-07
Cape O 0 0.000142741555464454
probably O 0 9.90072976492229e-07
did O 0 3.6223685384584314e-08
not O 0 4.288150723397166e-09
come O 0 5.496860300269191e-09
from O 0 8.767989001512433e-09
The O 0 2.793767883702003e-08
Netherlands O 0 1.0250766536046285e-05
. O 0 3.4565616147119727e-07
. O 0 2.227191771453363e-06

Complement B-Disease 1 0.8143340945243835
C7 I-Disease 1 0.9999005794525146
deficiency I-Disease 1 0.9998892545700073
: O 0 3.910037321475102e-06
seven O 0 1.4554706240232917e-06
further O 0 2.193838327002595e-06
molecular O 0 0.0017930908361449838
defects O 1 0.8884973526000977
and O 0 2.469106675562216e-06
their O 0 7.738374847576779e-07
associated O 0 1.3638445125252474e-05
marker O 0 0.00020097868400625885
haplotypes O 0 0.0007910625427030027
. O 0 1.1026864740415476e-05

Seven O 0 9.522314940113574e-06
further O 0 1.5530681594100315e-06
molecular O 0 9.266317647416145e-06
bases O 0 1.1067826562793925e-05
of O 0 0.00014930256293155253
C7 B-Disease 1 0.9999905824661255
deficiency I-Disease 1 0.9999727010726929
are O 0 5.499822691490408e-06
described O 0 5.374868123908527e-05
. O 0 8.790757419774309e-06

All O 0 6.636617513322562e-07
these O 0 1.190161071917828e-07
new O 0 1.1364605825292529e-06
molecular O 0 0.00010323060269001871
defects O 0 0.02642413228750229
involve O 0 1.0923162108156248e-06
single O 0 3.043201957098063e-07
- O 0 0.00015734488260932267
nucleotide O 0 3.3107580748037435e-06
events O 0 7.100997123643538e-08
, O 0 6.239522321038748e-08
deletions O 0 1.7325954786429065e-06
and O 0 1.2563079110350373e-07
substitutions O 0 8.464442657896143e-07
, O 0 2.2668983135076815e-08
some O 0 1.1980253455945444e-09
of O 0 2.6131270480789226e-09
which O 0 9.419102831031978e-09
alter O 0 9.604585784472874e-07
splice O 0 3.38931567966938e-06
sites O 0 2.3188383124761458e-07
, O 0 5.4144091876651146e-08
and O 0 1.23951110708731e-07
others O 0 1.174865133179992e-06
codons O 0 1.8504817489883862e-05
. O 0 2.2493743472296046e-06

They O 0 2.325274408576661e-06
are O 0 3.225711964205402e-08
distributed O 0 2.8687123787562996e-08
along O 0 2.4362796224863814e-08
the O 0 4.9165134186068826e-08
C7 O 0 0.01674364134669304
gene O 0 8.049168513935001e-07
, O 0 2.5678506432313952e-08
but O 0 3.206638732322631e-09
predominantly O 0 7.054675954520917e-09
towards O 0 1.6682889736330253e-08
the O 0 1.9470228096452047e-08
3 O 0 3.9861646428107633e-07
end O 0 2.470204435667256e-06
. O 0 3.2914974781306228e-06

All O 0 1.0703596444727737e-06
were O 0 7.56896156417497e-07
found O 0 2.881237435303774e-07
in O 0 7.773584087544805e-08
compound O 0 2.1963314793538302e-06
heterozygous O 0 9.699250767880585e-06
individuals O 0 5.5167474783957005e-06
. O 0 6.343927907437319e-06

The O 0 3.535416180966422e-05
C6 O 1 0.5050916075706482
/ O 0 0.0023841497022658587
C7 O 1 0.8445294499397278
marker O 0 0.0011128400219604373
haplotypes O 0 0.0013174584601074457
associated O 0 1.0751264198916033e-05
with O 0 9.565535492583876e-07
most O 0 9.990799298975617e-06
C7 B-Disease 1 0.9997420907020569
defects I-Disease 1 0.9967339038848877
are O 0 1.329816882389423e-06
tabulated O 0 0.0003236625634599477
. O 0 1.0919870874204207e-06
. O 0 4.216233719489537e-06

A O 0 2.045969267783221e-05
genome O 0 3.215429023839533e-05
- O 0 7.92994032963179e-05
wide O 0 7.04892840985849e-07
search O 0 1.713194563990328e-07
for O 0 9.705892978217889e-08
chromosomal O 0 0.0002389095170656219
loci O 0 1.2851448445871938e-05
linked O 0 0.0004158247902523726
to O 0 5.668394805979915e-06
mental O 0 0.23101069033145905
health O 0 0.0005271630943752825
wellness O 0 0.0002661840699147433
in O 0 4.776928221872367e-07
relatives O 0 1.5799878383404575e-05
at O 0 2.6169373086304404e-06
high O 0 0.0003308761224616319
risk O 0 0.0006701291422359645
for O 0 0.00012836400128435344
bipolar B-Disease 1 0.9999710321426392
affective I-Disease 1 0.9999710321426392
disorder I-Disease 1 0.9986628293991089
among O 0 1.023845743475249e-05
the O 0 7.007272415648913e-07
Old O 0 6.476157432189211e-05
Order O 0 2.751257852651179e-06
Amish O 0 0.0010455959709361196
. O 0 1.1611360605456866e-05

Bipolar B-Disease 1 0.9997919201850891
affective I-Disease 1 0.9998219609260559
disorder I-Disease 1 0.9998936653137207
( O 0 0.001991033088415861
BPAD B-Disease 1 0.9999141693115234
; O 0 0.027518311515450478
manic B-Disease 1 0.9999188184738159
- I-Disease 1 0.9999847412109375
depressive I-Disease 1 0.9999960660934448
illness I-Disease 1 0.9936948418617249
) O 0 2.2862091100250836e-06
is O 0 1.8611966368098365e-07
characterized O 0 1.5884279491729103e-06
by O 0 3.647160440323205e-08
episodes O 0 1.3394861753113219e-07
of O 0 2.170059332229357e-07
mania B-Disease 0 0.04221905395388603
and O 0 4.708034339273581e-06
/ O 0 8.409653673879802e-05
or O 0 2.175603412979399e-06
hypomania B-Disease 0 0.023269452154636383
interspersed O 0 4.2156618292210624e-05
with O 0 1.200935798806313e-06
periods O 0 5.442760084406473e-06
of O 0 9.456443876842968e-06
depression B-Disease 0 0.1046735867857933
. O 0 5.026820508646779e-05

Compelling O 0 9.538216545479372e-05
evidence O 0 2.589473115222063e-05
supports O 0 9.965145181922708e-06
a O 0 6.199390440997377e-07
significant O 0 7.832668416085653e-07
genetic O 0 2.4486751044605626e-06
component O 0 7.525496243943053e-07
in O 0 4.5099341150489636e-08
the O 0 2.1409415751350025e-07
susceptibility O 0 6.341318658087403e-05
to O 0 9.041416433319682e-07
develop O 0 7.827984518371522e-05
BPAD B-Disease 1 0.9832788109779358
. O 0 3.346344965393655e-05

To O 0 2.6158518267038744e-06
date O 0 3.3231581255677156e-06
, O 0 4.4076134031456604e-07
however O 0 8.610696511368587e-08
, O 0 5.51921921498888e-08
linkage O 0 3.2566088066232624e-06
studies O 0 4.691817139246268e-07
have O 0 3.483970090201183e-08
attempted O 0 7.631709877387038e-07
only O 0 2.945884869376414e-09
to O 0 6.642365324438515e-09
identify O 0 2.818942164140026e-07
chromosomal O 0 0.00018559453019406646
loci O 0 5.725298706238391e-06
that O 0 3.693102428314887e-07
cause O 0 5.121811227581929e-06
or O 0 2.8409266406015377e-07
increase O 0 1.809863078960916e-06
the O 0 5.32017224941228e-07
risk O 0 3.692044992931187e-05
of O 0 2.44236662183539e-06
developing O 0 0.0008671509567648172
BPAD B-Disease 1 0.9979829788208008
. O 0 4.117127537028864e-05

To O 0 2.6023633381555555e-06
determine O 0 2.1358096091717016e-06
whether O 0 5.462664489641611e-07
there O 0 2.966398682247018e-08
could O 0 4.810084419659688e-08
be O 0 1.5740607040015675e-08
protective O 0 1.605070792720653e-05
alleles O 0 5.150005790710566e-07
that O 0 5.5792742870153234e-08
prevent O 0 3.1568231406708946e-06
or O 0 2.4506815066160925e-07
reduce O 0 6.05071863901685e-06
the O 0 1.9215816848827671e-07
risk O 0 6.513074822578346e-06
of O 0 1.0879626444193491e-07
developing O 0 0.00017873235628940165
BPAD B-Disease 1 0.9987687468528748
, O 0 1.0146484328288352e-06
similar O 0 1.0310628084653217e-07
to O 0 1.7527593598742897e-08
what O 0 1.1137943900507707e-08
is O 0 1.8073427199283287e-08
observed O 0 1.3445017543745053e-07
in O 0 1.4496288258669665e-07
other O 0 1.304933539358899e-05
genetic B-Disease 1 0.9979925155639648
disorders I-Disease 1 0.9999498128890991
, O 0 1.2038222848786972e-05
we O 0 1.488858174525376e-06
used O 0 5.303419675328769e-05
mental O 1 0.8055062294006348
health O 0 0.015039266087114811
wellness O 0 0.0066472687758505344
( O 0 1.8916438193627982e-06
absence O 0 3.138901092825108e-06
of O 0 3.8809349689472583e-07
any O 0 4.023108340334147e-05
psychiatric B-Disease 1 0.9990050196647644
disorder I-Disease 1 0.9860895872116089
) O 0 1.1668433899103547e-06
as O 0 1.5342908454840654e-07
the O 0 1.26306545666921e-07
phenotype O 0 1.0349900549044833e-05
in O 0 2.850250524488729e-08
our O 0 3.369046552847976e-08
genome O 0 1.0868194522117847e-06
- O 0 7.555847696494311e-05
wide O 0 2.696772753552068e-06
linkage O 0 5.844392489962047e-06
scan O 0 8.498791430611163e-06
of O 0 2.381750441315944e-08
several O 0 4.495849026397991e-08
large O 0 5.453596259030746e-07
multigeneration O 0 0.00028650261810980737
Old O 0 3.5942148315371014e-06
Order O 0 7.679473412736115e-08
Amish O 0 1.6510437490069307e-05
pedigrees O 0 2.960578422062099e-05
exhibiting O 0 1.6903366486076266e-05
an O 0 2.242027647980649e-07
extremely O 0 4.216129582346184e-06
high O 0 6.509965169243515e-05
incidence O 0 0.0003029820800293237
of O 0 4.811608050658833e-06
BPAD B-Disease 1 0.9985692501068115
. O 0 6.082917025196366e-05

We O 0 7.028983873169636e-06
have O 0 6.724576451233588e-07
found O 0 2.8774977067769214e-07
strong O 0 8.319422306612978e-08
evidence O 0 5.814655068547836e-08
for O 0 8.95838514480829e-09
a O 0 3.544008819744704e-08
locus O 0 1.6318909956680727e-06
on O 0 1.0696453500713687e-06
chromosome O 0 9.162216156255454e-05
4p O 0 0.2744511067867279
at O 0 1.2204320682940306e-06
D4S2949 O 0 1.1592287592065986e-05
( O 0 1.7370240357195144e-08
maximum O 0 9.37569382131187e-08
GENEHUNTER O 0 6.250780279515311e-05
- O 0 1.3548039532906841e-05
PLUS O 0 1.8681868141356972e-06
nonparametric O 0 2.4584535367466742e-06
linkage O 0 5.757504482062359e-07
score O 0 7.019927750206989e-08
= O 0 4.1855474819385563e-07
4 O 0 3.200255349611325e-08
. O 0 6.259258888974273e-09
05 O 0 8.201562877729884e-07
, O 0 3.43174946237923e-08
P O 0 5.187272563489387e-06
= O 0 7.64203718972567e-07
5 O 0 3.28198233034982e-08
. O 0 5.526653357179612e-09
22 O 0 7.53147020304823e-08
x O 0 3.714266938459332e-07
10 O 0 3.192086595049659e-08
( O 0 1.2435611651540057e-08
- O 0 8.006479220057372e-06
4 O 0 1.7485561443209008e-07
) O 0 1.2942858340636576e-08
; O 0 2.183908698327741e-08
SIBPAL O 0 2.8009715606458485e-05
Pempirical O 0 2.2721160348737612e-05
value O 0 2.262388676399496e-08
< O 0 3.202301570581767e-07
3 O 0 3.085519750811727e-08
x O 0 4.376358901936328e-07
10 O 0 4.0387249100604095e-08
( O 0 1.9619042390672803e-08
- O 0 2.214504638686776e-05
5 O 0 3.5656555041896354e-07
) O 0 1.6022372761881343e-08
) O 0 5.022122717690536e-09
and O 0 1.4171715356781078e-08
suggestive O 0 2.5126289528998313e-06
evidence O 0 8.36339779652917e-08
for O 0 1.4789189428654481e-08
a O 0 7.715532035490469e-08
locus O 0 3.6350252230477054e-06
on O 0 2.139646539944806e-06
chromosome O 0 0.00032138536334969103
4q O 1 0.825883686542511
at O 0 4.6218187890190165e-06
D4S397 O 0 2.0229204892530106e-05
( O 0 2.1789489323964517e-08
maximum O 0 8.617712410341483e-08
GENEHUNTER O 0 5.937822788837366e-05
- O 0 1.9124941900372505e-05
PLUS O 0 1.205348780786153e-06
nonparametric O 0 1.534778220957378e-06
linkage O 0 9.348816547571914e-07
score O 0 8.519458560840576e-08
= O 0 7.479133614651801e-07
3 O 0 6.893703385912886e-08
. O 0 1.0213229373334798e-08
29 O 0 4.676691105487407e-07
, O 0 3.084731403646401e-08
P O 0 7.952912710607052e-06
= O 0 7.277729423549317e-07
2 O 0 2.2419543554974553e-08
. O 0 3.761797984225268e-09
57 O 0 2.0148030444033793e-07
x O 0 6.422243359338609e-07
10 O 0 8.294183118096043e-08
( O 0 2.4430175216139105e-08
- O 0 9.305788807978388e-06
3 O 0 1.7740705970936688e-07
) O 0 1.9629187164582618e-08
; O 0 3.345035537449803e-08
SIBPAL O 0 3.956532236770727e-05
Pempirical O 0 1.3067528925603256e-05
value O 0 2.112425434575016e-08
< O 0 2.392195312950207e-07
1 O 0 2.459643866359329e-08
x O 0 3.4203696941403905e-07
10 O 0 6.19955642378045e-08
( O 0 2.2755232365057054e-08
- O 0 1.898280970635824e-05
3 O 0 3.8918946643207164e-07
) O 0 3.181777330496516e-08
) O 0 8.185987887543433e-09
that O 0 4.017579158244189e-09
are O 0 2.2223233031581913e-08
linked O 0 5.683875860995613e-05
to O 0 7.197537343017757e-06
mental O 1 0.6414687633514404
health O 0 0.0076539721339941025
wellness O 0 0.016208186745643616
. O 0 5.157483246875927e-05

These O 0 6.018479780323105e-06
findings O 0 1.7814822058426216e-05
are O 0 7.799231838134801e-08
consistent O 0 1.21549618370409e-07
with O 0 3.3347536287919866e-08
the O 0 1.5829426658342527e-08
hypothesis O 0 1.3822327105117438e-07
that O 0 7.560482906399102e-09
certain O 0 1.4782477464336807e-08
alleles O 0 4.09778266430294e-07
could O 0 2.1769616864730779e-07
prevent O 0 1.1371142818461522e-06
or O 0 1.1813462919008089e-07
modify O 0 2.915853428930859e-06
the O 0 2.0113091636630998e-07
clinical O 0 1.4536198250425514e-05
manifestations O 0 5.338776645658072e-06
of O 0 1.0777941952255787e-06
BPAD B-Disease 1 0.9995779395103455
and O 0 1.1276973054918926e-05
perhaps O 0 6.607658178836573e-06
other O 0 4.183263627055567e-06
related O 0 0.002771309344097972
affective B-Disease 1 0.9993096590042114
disorders I-Disease 1 0.9991182684898376
. O 0 0.0002421203680569306

Segregation O 0 0.012288706377148628
distortion O 0 0.1573290228843689
in O 0 0.004071647766977549
myotonic B-Disease 1 0.9993384480476379
dystrophy I-Disease 1 0.9996408224105835
. O 0 0.0022397851571440697

Myotonic B-Disease 1 0.999683141708374
dystrophy I-Disease 1 0.9999158382415771
( O 0 0.043535977602005005
DM B-Disease 1 0.9999457597732544
) O 0 9.653870074544102e-05
is O 0 2.8118829504819587e-06
an O 0 7.41549320082413e-06
autosomal B-Disease 0 0.4435635805130005
dominant I-Disease 1 0.6426554322242737
disease I-Disease 0 0.2577108144760132
which O 0 4.5816545934940223e-07
, O 0 2.025151815132631e-07
in O 0 3.433516937434433e-08
the O 0 9.821726365544237e-08
typical O 0 4.416653155203676e-06
pedigree O 0 0.00015832115605007857
, O 0 1.3021059430684545e-07
shows O 0 1.802904670000771e-08
a O 0 1.5676400622055553e-08
three O 0 4.608772030678665e-08
generation O 0 1.6621119357296266e-05
anticipation O 0 6.266255513764918e-05
cascade O 0 0.0007760822190903127
. O 0 6.561653208336793e-06

This O 0 2.2411607005778933e-06
results O 0 1.4654803635494318e-05
in O 0 3.540706529747695e-05
infertility B-Disease 1 0.9993120431900024
and O 1 0.9702717661857605
congenital B-Disease 1 0.9999985694885254
myotonic I-Disease 1 0.9999992847442627
dystrophy I-Disease 1 0.9999983310699463
( O 0 0.0007387790246866643
CDM B-Disease 0 0.0904727578163147
) O 0 2.6988544732375885e-07
with O 0 5.046764783855906e-08
the O 0 3.0636577719178604e-08
disappearance O 0 1.1229624760744628e-05
of O 0 8.81847370237665e-07
DM B-Disease 1 0.9998393058776855
in O 0 2.310393711013603e-06
that O 0 5.356946530810092e-07
pedigree O 0 0.00015219357737805694
. O 0 5.994100774842082e-06

The O 0 1.0937391152765485e-06
concept O 0 4.75155246704162e-07
of O 0 1.4316938745650987e-07
segregation O 0 1.071491715265438e-05
distortion O 0 9.995175059884787e-05
, O 0 4.208012569506536e-07
where O 0 4.958534205456999e-08
there O 0 5.841185313215647e-09
is O 0 5.259486623998555e-09
preferential O 0 2.529352229885262e-07
transmission O 0 2.1904899938363087e-07
of O 0 5.598693952890699e-09
the O 0 1.0549277007498858e-08
larger O 0 7.796094081413685e-08
allele O 0 2.333283930511243e-07
at O 0 1.9558595454327588e-07
the O 0 2.722869112403714e-07
DM B-Disease 1 0.9986039996147156
locus O 0 4.309591531637125e-05
, O 0 3.6997792562942777e-07
has O 0 7.588875661213024e-08
been O 0 2.332362214474415e-08
put O 0 4.710081569214708e-08
forward O 0 1.5624556226612185e-07
to O 0 1.8875585539035455e-08
explain O 0 1.8527140355217853e-07
partially O 0 1.0462191539772903e-06
the O 0 1.9466291689695936e-08
maintenance O 0 3.0472519938484766e-06
of O 0 6.414054496417521e-07
DM B-Disease 1 0.9997227787971497
in O 0 5.282220172375673e-07
the O 0 4.15208120330135e-07
population O 0 1.1028673725377303e-06
. O 0 3.3812671063060407e-06

In O 0 3.6598648875951767e-06
a O 0 5.550213018068462e-07
survey O 0 1.3558408227254404e-06
of O 0 4.981883421351085e-07
DM B-Disease 1 0.9991051554679871
in O 0 2.799772573780501e-07
Northern O 0 3.530084882186202e-07
Ireland O 0 1.5833205679882667e-06
, O 0 1.602742258910439e-07
59 O 0 4.843600436288398e-06
pedigrees O 0 1.8821709090843797e-05
were O 0 8.916255751501012e-07
ascertained O 0 3.069365266128443e-05
. O 0 3.673113496915903e-06

Sibships O 0 0.009649323299527168
where O 0 3.231123855584883e-06
the O 0 1.6603141261839482e-07
status O 0 1.3207215943111805e-07
of O 0 6.841501143384221e-09
all O 0 4.352962879039524e-09
the O 0 1.3475370153059885e-08
members O 0 1.162066638471515e-07
had O 0 4.006317908533674e-07
been O 0 1.3503536422376783e-07
identified O 0 5.205546926845273e-07
were O 0 2.1199961963702663e-07
examined O 0 4.363682819530368e-06
to O 0 1.4370090006821101e-08
determine O 0 2.0788663235293825e-08
the O 0 5.108472755921412e-09
transmission O 0 8.655138117319439e-08
of O 0 1.4376230872414908e-08
the O 0 3.102906873664324e-07
DM B-Disease 1 0.9996511936187744
expansion O 0 2.551268698880449e-05
from O 0 9.94775859908259e-07
affected O 0 2.6451020858075935e-06
parents O 0 4.264629751560278e-07
to O 0 2.853748171105508e-08
their O 0 2.560915390859009e-07
offspring O 0 1.1915392860828433e-05
. O 0 2.516429958632216e-06

Where O 0 6.473993380495813e-06
the O 0 9.967436653823825e-07
transmitting O 0 0.00012196460738778114
parent O 0 9.175312879960984e-05
was O 0 3.538143801051774e-06
male O 0 6.122807008068776e-06
, O 0 8.002379559002293e-07
58 O 0 3.5047411074629053e-05
. O 0 5.20639332535211e-06

3 O 0 8.376099685847294e-06
% O 0 4.363806169749296e-07
of O 0 6.959933074313085e-08
the O 0 8.906918225193294e-08
offspring O 0 6.871851383039029e-06
were O 0 4.828026476388914e-07
affected O 0 1.005343165161321e-06
, O 0 7.079575681245842e-08
and O 0 5.398518609922576e-08
in O 0 8.884686764076832e-09
the O 0 2.1220083468165285e-08
case O 0 2.2929030762952607e-07
of O 0 1.5963987465283935e-08
a O 0 3.3335078342133784e-07
female O 0 9.749792297952808e-06
transmitting O 0 0.00013976209447719157
parent O 0 3.660957372630946e-05
, O 0 1.7756527768142405e-06
68 O 0 3.8006102840881795e-05
. O 0 4.5602691898238845e-06

7 O 0 0.00012413690274115652
% O 0 1.142307428381173e-05
were O 0 7.927121259854175e-06
affected O 0 3.620385177782737e-05
. O 0 8.27413623483153e-06

Studies O 0 1.4245032616599929e-05
on O 0 9.923502375386306e-07
meiotic O 0 0.00037713279016315937
drive O 0 2.8738561013597064e-05
in O 0 2.7135313303006114e-06
DM B-Disease 1 0.9997325539588928
have O 0 1.7780724874683074e-06
shown O 0 1.5083706728091784e-07
increased O 0 5.489884813414392e-08
transmission O 0 6.809270303165249e-08
of O 0 3.3478932959241092e-09
the O 0 7.355864362068587e-09
larger O 0 9.592341143616068e-08
allele O 0 2.0394378452692763e-07
at O 0 1.165374925449214e-07
the O 0 2.0896200680908805e-07
DM B-Disease 1 0.9916067123413086
locus O 0 1.0539629329286981e-05
in O 0 1.5424215860093682e-07
non O 0 2.570164724602364e-05
- O 0 0.1273871660232544
DM O 1 0.9996801614761353
heterozygotes O 0 0.0021216797176748514
for O 0 4.76251307190978e-06
CTGn O 0 0.0015713763423264027
. O 0 8.41592645883793e-06

This O 0 2.1536206986638717e-06
study O 0 1.8872110558731947e-06
provides O 0 2.0243099640993023e-07
further O 0 7.332138807214506e-08
evidence O 0 1.1666782739894188e-07
that O 0 1.2448616359961306e-08
the O 0 1.5429584721005085e-07
DM B-Disease 1 0.9994394183158875
expansion O 0 2.3293796402867883e-05
tends O 0 1.2360693517621257e-06
to O 0 2.5801980996220664e-08
be O 0 2.9202308127196375e-08
transmitted O 0 1.6964239648586954e-06
preferentially O 0 1.2542596778075676e-05
. O 0 2.936254531960003e-06

Diagnosis O 1 0.6479454636573792
of O 0 0.0011398568749427795
hemochromatosis B-Disease 1 0.9985499978065491
. O 0 0.0009020838770084083

If O 0 0.0006031923112459481
untreated O 1 0.9698450565338135
, O 0 0.0007475964375771582
hemochromatosis B-Disease 1 0.9999713897705078
can O 0 0.0003282139077782631
cause O 0 0.08635050058364868
serious O 0 0.48480886220932007
illness O 0 0.14206889271736145
and O 0 3.597139766498003e-06
early B-Disease 0 7.251511306094471e-06
death I-Disease 0 3.5483659303281456e-05
, O 0 8.984703754322254e-07
but O 0 3.3546010058671527e-07
the O 0 2.2107492441136856e-06
disease O 0 0.0007900075288489461
is O 0 2.0662487543177122e-07
still O 0 2.5367348825966474e-06
substantially O 0 1.8680102584767155e-05
under O 0 1.9105218598269857e-05
- O 1 0.9921841025352478
diagnosed O 1 0.9843759536743164
. O 0 1.1999252819805406e-05

The O 0 5.505075023393147e-06
cornerstone O 0 0.00018498004646971822
of O 0 2.3937698756526515e-07
screening O 0 3.018079041794408e-06
and O 0 2.124092191024829e-07
case O 0 6.694987746413972e-07
detection O 0 1.023910158437502e-06
is O 0 6.134144303615585e-09
the O 0 4.14570378026724e-09
measurement O 0 1.0626830260207498e-07
of O 0 3.9097578508062725e-08
serum O 0 9.759774911799468e-06
transferrin O 0 1.056091787177138e-05
saturation O 0 4.377857294457499e-07
and O 0 4.745981740938987e-08
the O 0 7.224345210943284e-08
serum O 0 1.036369849316543e-05
ferritin O 0 3.964202551287599e-05
level O 0 1.94923950402881e-06
. O 0 1.4760607882635668e-06

Once O 0 9.975150896934792e-05
the O 0 4.110427198611433e-06
diagnosis O 0 0.0005997790140099823
is O 0 5.927201414124283e-07
suspected O 0 0.00014443026157096028
, O 0 1.3910731695432332e-06
physicians O 0 1.0379613740951754e-05
must O 0 1.5726474345001407e-08
use O 0 2.795094999896719e-08
serum O 0 7.817870937287807e-06
ferritin O 0 2.6326893930672668e-05
levels O 0 5.397147901931021e-07
and O 0 3.9372380911117943e-07
hepatic O 0 0.0600590817630291
iron O 0 0.0019520442001521587
stores O 0 4.796987923327833e-06
on O 0 9.993162166210823e-06
liver O 0 0.09039362519979477
biopsy O 0 0.007775031495839357
specimens O 0 3.432680750847794e-05
to O 0 5.482444294102606e-07
assess O 0 0.00011528769391588867
patients O 0 1.370535755995661e-05
for O 0 2.9843544524510435e-08
the O 0 8.046054489341259e-08
presence O 0 1.2910555824419134e-06
of O 0 9.921751598085393e-07
iron B-Disease 0 0.060389138758182526
overload I-Disease 0 0.024284545332193375
. O 0 1.3372960893320851e-05

Liver O 1 0.9991852641105652
biopsy O 1 0.5547433495521545
is O 0 5.47723675481393e-06
also O 0 4.0401280898549885e-07
used O 0 2.1780016012939996e-08
to O 0 5.564477767450171e-09
establish O 0 3.876876064623502e-08
the O 0 3.5426300115659615e-08
presence O 0 4.366557675439253e-07
or O 0 1.9602984480115992e-07
absence O 0 2.104223540300154e-06
of O 0 1.1774001222875086e-06
cirrhosis B-Disease 1 0.9001563191413879
, O 0 3.4166603199992096e-06
which O 0 5.449218747344275e-07
can O 0 7.136135309337988e-07
affect O 0 5.437522486317903e-05
prognosis O 0 0.052613429725170135
and O 0 1.790671558410395e-05
management O 0 0.000294391909847036
. O 0 1.050877745001344e-05

A O 0 1.1720579095708672e-05
DNA O 0 3.163793371641077e-05
- O 0 0.00010478740296093747
based O 0 6.296560854934796e-07
test O 0 1.6979117845039582e-07
for O 0 9.681908608172307e-09
the O 0 1.5729924029983522e-08
HFE O 0 0.00011326700041536242
gene O 0 1.516207674967518e-07
is O 0 7.33778771078164e-09
commercially O 0 1.001851899218309e-07
available O 0 2.4864165837357177e-08
, O 0 2.0950672308117646e-08
but O 0 4.708112122386865e-09
its O 0 4.704117539944264e-09
place O 0 5.897472732385722e-09
in O 0 1.0076314005402764e-08
the O 0 1.4411651250156865e-07
diagnosis O 0 6.621044303756207e-05
of O 0 3.54234043697943e-06
hemochromatosis B-Disease 1 0.999971866607666
is O 0 4.9616264732321724e-06
still O 0 3.7432057524711126e-06
being O 0 3.204572976756026e-06
evaluated O 0 5.2292893087724224e-05
. O 0 4.5613828660862055e-06

Currently O 0 7.022982026683167e-05
, O 0 1.1539709703356493e-06
the O 0 6.389352336100274e-08
most O 0 2.892563166767559e-08
useful O 0 4.949746212901118e-08
role O 0 9.101631803787313e-08
for O 0 1.1850763037557499e-08
this O 0 4.28834701082792e-09
test O 0 1.383209848881961e-07
is O 0 5.699022143090815e-09
in O 0 2.268860876952772e-09
the O 0 9.772819886677553e-09
detection O 0 3.857635874737753e-06
of O 0 2.0143318124610232e-06
hemochromatosis B-Disease 1 0.999852180480957
in O 0 5.801250608783448e-07
the O 0 2.9873791618229006e-07
family O 0 1.922123828990152e-06
members O 0 3.643465333880158e-07
of O 0 4.692792856531014e-07
patients O 0 2.0704708731500432e-05
with O 0 2.5167560124828015e-07
a O 0 6.437855972762918e-07
proven O 0 4.422978963702917e-05
case O 0 1.559188376631937e-06
of O 0 4.3573390939855017e-07
the O 0 2.5475148504483514e-05
disease O 0 0.00527201360091567
. O 0 1.280554715776816e-05

It O 0 2.853511659850483e-06
is O 0 7.551362273261475e-07
crucial O 0 8.499860996380448e-06
to O 0 4.659232217818499e-06
diagnose O 1 0.8362357020378113
hemochromatosis B-Disease 1 0.9998651742935181
before O 0 0.008875868283212185
hepatic B-Disease 1 0.999788224697113
cirrhosis I-Disease 1 0.9993669390678406
develops O 0 0.002134933602064848
because O 0 1.8731692762230523e-05
phlebotomy O 1 0.5962578654289246
therapy O 0 0.00042725226376205683
can O 0 2.8738111268467037e-06
avert O 1 0.9657601118087769
serious O 1 0.99979168176651
chronic O 1 0.9999964237213135
disease O 1 0.7887628674507141
and O 0 8.703344974492211e-06
can O 0 3.697987551731785e-07
even O 0 1.9323506705859472e-07
lead O 0 1.7377501535520423e-06
to O 0 2.6788242735165113e-08
normal O 0 9.826186442296603e-08
life O 0 4.6659812369398423e-07
expectancy O 0 1.4353634469443932e-05
. O 0 3.6041816997567366e-07
. O 0 2.1763648874184582e-06

Prevalence O 0 0.0014168539782986045
of O 0 1.1648643294392969e-06
the O 0 5.371381348595605e-07
I1307K O 0 0.0001512491871835664
APC B-Disease 0 0.00010463692160556093
gene O 0 5.930712063673127e-07
variant O 0 7.681757665523037e-07
in O 0 1.585580555740762e-08
Israeli O 0 3.1536708888779685e-07
Jews O 0 1.2506703228609695e-07
of O 0 7.909231491964874e-09
differing O 0 7.752365860369537e-08
ethnic O 0 1.6954733439433767e-07
origin O 0 4.902944397144893e-07
and O 0 8.998818884720095e-06
risk O 0 0.01002251822501421
for O 0 0.03633353114128113
colorectal B-Disease 1 0.9999985694885254
cancer I-Disease 1 0.9999325275421143
. O 0 0.0002727229439187795

BACKGROUND O 0 0.00025921882479451597
& O 0 0.00015559644089080393
AIMS O 0 5.3082421800354496e-05
Israeli O 0 1.1105847988801543e-05
Jews O 0 1.3057086789558525e-06
of O 0 1.079658673575068e-07
European O 0 5.909421361138811e-06
birth O 0 1.1525715308380313e-05
, O 0 4.319247182138497e-07
i O 0 1.8771201837353146e-07
. O 0 9.677496137783237e-09
e O 0 1.027230723593675e-06
. O 0 1.0615663903479344e-08
, O 0 2.6006580000625945e-08
Ashkenazim O 0 1.2073543075530324e-05
, O 0 8.535283768651425e-08
have O 0 2.4990161051618998e-08
the O 0 5.482569918058289e-07
highest O 1 0.7210404276847839
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999886751174927
incidence O 0 0.0014703142223879695
of O 0 1.356165029164913e-07
any O 0 6.464175328346755e-08
Israeli O 0 6.628561550314771e-06
ethnic O 0 4.407379492477048e-06
group O 0 4.640026963897981e-05
. O 0 7.0486253207491245e-06

The O 0 9.92904188024113e-06
I1307K O 0 0.0005693332059308887
APC B-Disease 0 0.0008914897916838527
gene O 0 9.452999620407354e-06
variant O 0 2.8535623641801067e-05
was O 0 1.323523747487343e-06
found O 0 4.6398983499784663e-07
in O 0 1.767487844972493e-07
6 O 0 6.986732842051424e-06
. O 0 5.100641828903463e-06

1 O 0 1.3686039892490953e-05
% O 0 9.80697336672165e-07
of O 0 1.0339045530827207e-07
American O 0 1.6202480992433266e-06
Jews O 0 1.6553826753806788e-06
, O 0 7.491912157320257e-08
28 O 0 3.2209726441578823e-07
% O 0 2.3922904546225254e-08
of O 0 9.235092335302397e-08
their O 0 0.0001919981586979702
familial O 1 0.9999568462371826
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
cases O 0 0.0029916195198893547
, O 0 5.870132099516923e-06
but O 0 2.797277147692512e-07
not O 0 2.4721639846347898e-08
in O 0 5.236636724248456e-08
non O 0 8.196978342311922e-06
- O 0 0.0007987436256371439
Jews O 0 4.7636651288485155e-05
. O 0 5.301192231854657e-06

We O 0 6.672011750197271e-06
assessed O 0 3.706194183905609e-05
the O 0 3.668908448162256e-07
I1307K O 0 0.00032535361242480576
prevalence O 0 3.9452894270652905e-05
in O 0 2.9690477632016155e-08
Israeli O 0 4.059245384269161e-07
Jews O 0 1.3331013803963288e-07
of O 0 8.405340423678354e-09
differing O 0 8.172496279712504e-08
ethnic O 0 2.0890284702090867e-07
origin O 0 8.081981945906591e-07
and O 0 9.951385436579585e-06
risk O 0 0.01409536600112915
for O 0 0.02726626954972744
colorectal B-Disease 1 0.9999979734420776
cancer I-Disease 1 0.9998835325241089
. O 0 0.0002978124830406159

METHODS O 0 1.1425035154388752e-05
DNA O 0 2.8410231607267633e-05
samples O 0 1.3440238717521424e-06
from O 0 1.620974643401496e-07
500 O 0 6.323278967101942e-07
unrelated O 0 7.338136583712185e-06
Jews O 0 2.6233288963339874e-07
of O 0 2.489472805677906e-08
European O 0 8.814117791189346e-07
or O 0 1.0367738667582671e-07
non O 0 4.816419277631212e-06
- O 0 0.000663619430270046
European O 0 2.8379283776303055e-06
origin O 0 1.3598807413472969e-07
, O 0 3.066633524895224e-08
with O 0 2.352395434002119e-08
or O 0 5.601485142392448e-08
without O 0 6.490514437018646e-08
a O 0 5.140486081245399e-08
personal O 0 2.209493231930537e-06
and O 0 1.591196451045107e-06
/ O 0 4.317139973863959e-05
or O 0 1.2399146953612217e-06
family O 0 1.6254450656560948e-06
history O 0 1.0462714783443516e-07
of O 0 2.9442639970511664e-07
neoplasia B-Disease 0 0.2623925805091858
, O 0 2.0523182229226222e-06
were O 0 4.1093471736530773e-07
examined O 0 2.7893861442862544e-06
for O 0 2.1314475517897336e-08
the O 0 3.007606252936057e-08
I1307K O 0 1.252169386134483e-05
variant O 0 4.687648811341205e-07
by O 0 1.08196305248498e-08
the O 0 1.1178166836600667e-08
allele O 0 2.3103113733213831e-07
- O 0 1.4993900549598038e-05
specific O 0 8.160019859815293e-08
oligonucleotide O 0 6.13458760199137e-05
( O 0 5.054057510278653e-07
ASO O 0 0.0009729114244692028
) O 0 1.7766831206245115e-07
method O 0 5.526887889573118e-07
. O 0 2.6131642698601354e-06

RESULTS O 0 8.275109576061368e-05
In O 0 8.830255069369741e-07
persons O 0 7.999854005902307e-07
at O 0 1.1450223382780678e-06
average O 0 3.942126204492524e-05
risk O 0 0.01556794811040163
for O 0 0.019742729142308235
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999778270721436
, O 0 2.110962122969795e-05
I1307K O 0 0.0037579406052827835
was O 0 4.42793088950566e-06
found O 0 5.878932824998628e-07
in O 0 1.0848378906302969e-07
5 O 0 1.6590824998274911e-06
. O 0 2.980105364258634e-06

0 O 0 1.7117919924203306e-05
% O 0 5.338718551683996e-07
of O 0 7.273344948544036e-08
120 O 0 3.1997097948988085e-07
European O 0 9.92855689219141e-07
and O 0 3.7087380633238354e-07
1 O 0 1.5869773051235825e-06
. O 0 2.851525550795486e-06

6 O 0 1.7146201571449637e-05
% O 0 5.517308636626694e-07
of O 0 8.158308162364847e-08
188 O 0 7.096553872543154e-06
non O 0 5.309317202772945e-06
- O 0 0.00025164391263388097
European O 0 2.2519202502735425e-06
Jews O 0 1.3848400612914702e-06
( O 0 9.106181408924385e-08
P O 0 1.7819069398683496e-05
= O 0 3.323627197460155e-06
0 O 0 2.7835295668410254e-07
. O 0 4.6478788817694294e-08
08 O 0 3.3770743357308675e-06
) O 0 3.6117756962994463e-07
. O 0 1.0238330787615268e-06

It O 0 2.4387029498029733e-06
occurred O 0 3.6326168810774107e-06
in O 0 5.764795218965446e-07
15 O 0 4.288359832571587e-06
. O 0 4.80116204926162e-06

4 O 0 1.1684041055559646e-05
% O 0 5.508118192665279e-07
of O 0 7.601610008123316e-08
52 O 0 1.4568339793186169e-05
Ashkenazi O 0 0.0006124042556621134
Israelis O 0 3.4970355045516044e-05
with O 0 4.103775791008957e-05
familial O 1 0.9858940839767456
cancer B-Disease 1 0.8880288004875183
( O 0 1.116164412451326e-06
P O 0 0.00025718589313328266
= O 0 1.601285293872934e-05
0 O 0 1.0128881058335537e-06
. O 0 5.93464513087838e-08
02 O 0 9.145140211330727e-06
) O 0 1.991120512911948e-08
and O 0 3.147390614799406e-08
was O 0 1.3306042490057735e-07
not O 0 7.492523934615747e-09
detected O 0 2.3822144612495322e-07
in O 0 7.562487525092365e-09
51 O 0 7.374677011284803e-07
non O 0 2.115067673003068e-06
- O 0 2.3004598915576935e-05
European O 0 1.0905686167461681e-06
Jews O 0 1.3513240446627606e-06
at O 0 5.677776243828703e-06
increased O 0 0.00013688004401046783
cancer B-Disease 0 0.12466239184141159
risk O 0 0.00028324368759058416
. O 0 9.737090294947848e-06

Colorectal B-Disease 1 0.9994221925735474
neoplasia I-Disease 1 0.9943276047706604
occurred O 0 0.0010061940411105752
personally O 0 0.0006594964652322233
or O 0 1.2313021215959452e-06
in O 0 6.3055622945285e-08
the O 0 3.0528198635693116e-08
families O 0 1.733445316176585e-07
of O 0 1.1959301993158533e-08
13 O 0 2.602827464670554e-07
of O 0 3.357243727464265e-08
20 O 0 8.064235998972435e-07
Ashkenazi O 0 0.00036749563878402114
I1307K O 0 3.929803642677143e-05
carriers O 0 2.0982997739338316e-06
, O 0 1.518820624824002e-08
8 O 0 2.4217552407890253e-08
of O 0 2.2838063884478288e-08
whom O 0 4.034324319945881e-06
also O 0 2.3817602823328343e-07
had O 0 3.195087003859953e-07
a O 0 5.502380773236837e-08
personal O 0 3.6389408251125133e-06
or O 0 7.614552828272281e-07
family O 0 1.741845153446775e-06
history O 0 5.440205086415517e-07
of O 0 2.399310687906109e-06
noncolonic O 0 0.17548468708992004
neoplasia B-Disease 1 0.8173760771751404
. O 0 4.465099482331425e-05

CONCLUSIONS O 0 5.409613731899299e-05
The O 0 2.2308993266051402e-06
I1307K O 0 0.001022457261569798
APC O 0 0.0016426092479377985
variant O 0 0.00012385574518702924
may O 0 7.906743348939926e-07
represent O 0 3.812129278912835e-08
a O 0 1.434921017562374e-07
susceptibility O 0 3.345655932207592e-05
gene O 0 1.637209606997203e-06
for O 0 7.935735993669368e-06
colorectal B-Disease 1 0.9999836683273315
, I-Disease 0 8.440110832452774e-06
or I-Disease 0 7.492240570172726e-07
other I-Disease 0 6.98639325946715e-07
, I-Disease 0 1.708310446701944e-05
cancers I-Disease 0 0.07681144773960114
in O 0 5.086134251541807e-07
Ashkenazi O 0 0.001176635385490954
Jews O 0 6.17491377852275e-06
, O 0 3.670462263016816e-07
and O 0 3.3738251659087837e-07
partially O 0 6.842757102276664e-06
explains O 0 4.366436883174174e-07
the O 0 5.7569067735130375e-08
higher O 0 6.594312708330108e-06
incidence O 0 0.015729276463389397
of O 0 0.042534660547971725
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999557733535767
in O 0 3.981563168053981e-06
European O 0 4.3085772631457075e-05
Israelis O 0 0.00019036015146411955
. O 0 1.6105434042401612e-05

Systematic O 0 2.2824688130640425e-05
analysis O 0 2.1228945570328506e-06
of O 0 5.56589156985865e-07
coproporphyrinogen O 0 0.004402471706271172
oxidase O 0 0.0002820972877088934
gene O 0 6.77884163451381e-05
defects O 0 0.17310397326946259
in O 0 1.6664100712660002e-06
hereditary B-Disease 0 0.08034826815128326
coproporphyria I-Disease 0 0.08686220645904541
and O 0 8.239716407842934e-06
mutation O 0 1.3878896425012499e-05
update O 0 4.220666232868098e-05
. O 0 7.750746590318158e-06

Hereditary B-Disease 1 0.9920186400413513
coproporphyria I-Disease 1 0.9053341150283813
( O 0 0.00010608386219246313
HC B-Disease 1 0.9927635788917542
) O 0 1.7732105334289372e-05
is O 0 3.960166850447422e-06
an O 0 9.800926636671647e-05
acute O 1 0.9986114501953125
hepatic B-Disease 1 0.9999557733535767
porphyria I-Disease 1 0.9998308420181274
with O 0 0.007556736934930086
autosomal O 1 0.837134063243866
dominant O 0 0.01375532429665327
inheritance O 0 0.038737207651138306
caused O 0 0.00139764288906008
by O 0 9.146143383986782e-06
deficient B-Disease 0 0.0011071342742070556
activity I-Disease 0 2.8424418019312725e-07
of I-Disease 0 2.089640105396029e-07
coproporphyrinogen I-Disease 0 0.02602844312787056
III I-Disease 0 0.021967118605971336
oxidase I-Disease 0 9.731416503200307e-05
( O 0 8.982921713140968e-07
CPO O 0 0.00012312823673710227
) O 0 5.989610372125753e-07
. O 0 1.2011512353637954e-06

Clinical O 0 0.027567291632294655
manifestations O 0 0.00040181627264246345
of O 0 4.439177246240433e-06
the O 0 3.543213097145781e-05
disease O 0 0.21362267434597015
are O 0 5.737656465498731e-07
characterized O 0 0.000105891733255703
by O 0 4.440445627551526e-05
acute O 0 0.38179877400398254
attacks O 0 0.00019861210603266954
of O 0 0.0022408352233469486
neurological B-Disease 1 0.9999799728393555
dysfunction I-Disease 1 0.9958266615867615
often O 0 2.0739746105391532e-05
precipitated O 0 0.0009382859570905566
by O 0 2.1064722659502877e-06
drugs O 0 2.4105944248731248e-05
, O 0 3.9667031614953885e-07
fasting O 0 1.744248834256723e-06
, O 0 1.074569468073605e-06
cyclical O 0 0.0014963612193241715
hormonal O 0 0.0005686916410923004
changes O 0 1.927421408254304e-06
, O 0 6.937508260307368e-06
or O 0 0.00019307118782307953
infectious B-Disease 1 0.9354128837585449
diseases I-Disease 0 0.3902210295200348
. O 0 2.2693333448842168e-05

Skin O 1 0.9979204535484314
photosensitivity O 1 0.9970701932907104
may O 0 0.0015667544212192297
also O 0 9.63355978456093e-06
be O 0 5.320634386407619e-07
present O 0 1.7222139376826817e-06
. O 0 4.221951257932233e-06

The O 0 1.5962881434461451e-06
seven O 0 1.1628775382632739e-06
exons O 0 5.583885013038525e-06
, O 0 1.0667059058278028e-07
the O 0 1.7908099891883467e-08
exon O 0 5.603436420642538e-06
/ O 0 3.409609917071066e-06
intron O 0 4.3940090108662844e-05
boundaries O 0 8.568738962821953e-08
and O 0 2.12568238566746e-08
part O 0 8.731307232778818e-09
of O 0 3.1124003374571885e-09
3 O 0 5.906424860313564e-08
noncoding O 0 2.895522129620076e-06
sequence O 0 4.335306336145095e-09
of O 0 2.5535094039241812e-09
the O 0 8.194234624170349e-09
CPO O 0 8.116392564261332e-06
gene O 0 4.268217779213046e-08
were O 0 5.758803212074781e-09
systematically O 0 2.394902480773453e-07
analyzed O 0 9.533972189501583e-08
by O 0 7.829022763417015e-09
an O 0 6.529065288418678e-09
exon O 0 3.2139353152160766e-06
- O 0 4.106113465240924e-06
by O 0 4.748182647063004e-08
- O 0 1.5084586266311817e-05
exon O 0 2.5989877030951902e-05
denaturing O 0 7.043532241368666e-05
gradient O 0 1.394093760609394e-05
gel O 0 0.00011880019155796617
electrophoresis O 0 7.88814140832983e-05
( O 0 1.0001355121858069e-07
DGGE O 0 8.574017556384206e-05
) O 0 1.28756152406595e-08
strategy O 0 2.048624381245645e-08
followed O 0 4.455094515520841e-09
by O 0 1.9769288428506115e-09
direct O 0 2.942335930455897e-09
sequencing O 0 6.143712738548857e-08
in O 0 6.57233334422358e-09
seven O 0 9.045162130405515e-08
unrelated O 0 2.9554837965406477e-05
heterozygous O 0 7.174488564487547e-05
HC B-Disease 1 0.999550998210907
patients O 0 0.0045888773165643215
from O 0 3.158823744797701e-07
France O 0 7.172061941673746e-06
, O 0 5.099636268823815e-07
Holland O 0 3.2853993616299704e-05
, O 0 2.0022052638069e-07
and O 0 2.678597752492351e-07
Czech O 0 5.5149350373540074e-05
Republic O 0 1.2371257980703376e-05
. O 0 6.05564855504781e-06

Seven O 0 2.804654650390148e-05
novel O 0 2.3589909687871113e-05
mutations O 0 2.343315827602055e-05
and O 0 1.3026499345869524e-07
two O 0 7.58485256824315e-08
new O 0 1.7566032965987688e-06
polymorphisms O 0 0.0001593055931152776
were O 0 3.2339414701709757e-06
detected O 0 3.133720383630134e-05
. O 0 3.151174269078183e-06

Among O 0 3.0443296054727398e-05
these O 0 3.325747002236312e-07
mutations O 0 4.8584693104203325e-06
two O 0 8.175739196758514e-08
are O 0 8.903809600724344e-08
missense O 0 5.013367990613915e-05
( O 0 2.2067609961595736e-07
G197W O 0 5.446567593025975e-05
, O 0 2.2942154487282096e-07
W427R O 0 1.1509658179420512e-05
) O 0 2.0067599137973957e-08
, O 0 6.1948965957014934e-09
two O 0 6.381214667783297e-09
are O 0 1.0763643309985582e-08
nonsense O 0 1.7784151395972003e-06
( O 0 4.55127455722959e-08
Q306X O 0 8.081835403572768e-06
, O 0 2.1399861793724995e-07
Q385X O 0 1.0526129699428566e-05
) O 0 2.6910946360203525e-08
, O 0 7.847351213285947e-09
two O 0 5.298169902800964e-09
are O 0 6.373162442230296e-09
small O 0 1.6159567906015582e-07
deletions O 0 9.299409612140153e-06
( O 0 1.1939135902139242e-07
662de14bp O 0 1.7350694179185666e-05
; O 0 1.1393870380516091e-07
1168del3bp O 0 3.115437357337214e-05
removing O 0 9.444252100365702e-07
a O 0 2.4696378275734787e-08
glycine O 0 1.0399312486697454e-06
at O 0 8.986796729004709e-08
position O 0 6.705288058128644e-08
390 O 0 1.863812713054358e-06
) O 0 2.2789372167153488e-08
, O 0 1.156432283266895e-08
and O 0 1.2845982944043044e-08
one O 0 5.368481659218105e-09
is O 0 2.879103844222186e-09
a O 0 5.622322607479191e-09
splicing O 0 5.729859253733594e-07
mutation O 0 4.335854839609965e-07
( O 0 3.1283821755323515e-08
IVS1 O 0 6.851232319604605e-05
- O 0 8.502344280714169e-05
15c O 0 3.229020148864947e-05
- O 0 3.76684038201347e-05
- O 0 0.00012841727584600449
> O 0 4.535244443104602e-06
g O 0 1.2750782843795605e-05
) O 0 8.176374244328599e-09
which O 0 3.5305134371554914e-09
creates O 0 5.111311907057825e-08
a O 0 2.1889130508156995e-08
new O 0 2.603835298486956e-07
acceptor O 0 5.913937002333114e-06
splice O 0 2.8449025194277056e-05
site O 0 5.846198291692417e-06
. O 0 2.576805400167359e-06

The O 0 1.2856438843300566e-05
pathological O 0 0.0006406529573723674
significance O 0 1.7448976450396003e-06
of O 0 6.519324102782775e-08
the O 0 7.499632914687027e-08
point O 0 6.924063313817896e-07
mutations O 0 1.969483037100872e-06
G197W O 0 1.982039430004079e-05
, O 0 1.615623830275581e-07
W427R O 0 1.97727440536255e-05
, O 0 5.5684303390535206e-08
and O 0 1.2668890825295875e-08
the O 0 4.929102015438502e-09
in O 0 1.5392350505294417e-08
- O 0 7.298980199266225e-05
frame O 0 5.421688547357917e-05
deletion O 0 6.693822797387838e-05
390delGly O 0 0.00025237866793759167
were O 0 2.994367207520554e-07
assessed O 0 1.5075522696861299e-06
by O 0 1.6074960029754948e-08
their O 0 8.151382679955077e-09
respective O 0 3.8169456928471845e-08
expression O 0 2.96998798887671e-08
in O 0 3.931974745796651e-09
a O 0 1.768852975203572e-08
prokaryotic O 0 4.658622856368311e-07
system O 0 4.5974022810924e-08
using O 0 2.184925129711246e-08
site O 0 2.3321115349972388e-07
- O 0 1.8311082385480404e-05
directed O 0 2.647630935825873e-06
mutagenesis O 0 0.00010499265044927597
. O 0 2.799748244797229e-06

These O 0 2.5577453470759792e-06
mutations O 0 4.806068682228215e-05
resulted O 0 1.0352516255807132e-05
in O 0 1.8654898781278462e-07
the O 0 1.5122249408250354e-07
absence O 0 3.3028268262569327e-06
or O 0 6.878440927948759e-08
a O 0 1.042182518062873e-07
dramatic O 0 2.875911377486773e-06
decrease O 0 4.692059519584291e-06
of O 0 2.261675291492793e-07
CPO O 0 0.0005676394212059677
activity O 0 3.2548759918427095e-06
. O 0 2.5640583771746606e-06

The O 0 1.8175495597461122e-06
two O 0 7.356505307143379e-07
polymorphisms O 0 0.00011446013377280906
were O 0 4.805710887012538e-07
localized O 0 4.299362444726285e-06
in O 0 8.26042878543376e-08
noncoding O 0 4.3305080907884985e-05
part O 0 6.605790758840158e-08
of O 0 6.559371712455686e-09
the O 0 1.1984169212553297e-08
gene O 0 2.9804240853081865e-08
1 O 0 2.1937612615374746e-08
) O 0 7.915237354438887e-09
a O 0 2.3969903395482106e-08
C O 0 5.262231297820108e-06
/ O 0 8.52058110467624e-06
G O 0 5.059808609075844e-05
polymorphism O 0 3.3242517929465976e-06
in O 0 2.856863545730448e-08
the O 0 3.559196315450208e-08
promotor O 0 0.0003989840915892273
region O 0 5.454990059661213e-07
, O 0 3.8145877567785647e-08
142 O 0 1.3978154811411514e-06
bp O 0 1.7057836885214783e-05
upstream O 0 1.113714063194493e-07
from O 0 3.93828702982546e-09
the O 0 1.503222324394926e-09
transcriptional O 0 3.353122224325489e-08
initiation O 0 1.173495078887754e-07
site O 0 1.334976786893094e-07
( O 0 1.9816864593735772e-08
- O 0 3.4070566471200436e-05
142C O 0 4.303489185986109e-05
/ O 0 8.108801921480335e-06
G O 0 2.2757136321160942e-05
) O 0 1.6942376390716163e-08
, O 0 7.561160586533333e-09
and O 0 8.247358351809453e-09
2 O 0 4.025858046929898e-08
) O 0 4.112429508040805e-09
a O 0 5.046146167586585e-09
6 O 0 1.4661821978734224e-07
bp O 0 1.4685218047816306e-05
deletion O 0 1.711856839392567e-06
polymorphism O 0 1.6119807924042107e-06
in O 0 1.1108368447310113e-08
the O 0 9.746944584776429e-09
3 O 0 1.4598256825593126e-07
noncoding O 0 9.717229659145232e-06
part O 0 2.4720886671047992e-08
of O 0 3.7228393701127516e-09
the O 0 1.3600915949041337e-08
CPO O 0 1.5794033970450982e-05
gene O 0 9.322252481069881e-08
, O 0 1.6445811823473377e-08
574 O 0 5.556882570090238e-06
bp O 0 1.4634328181273304e-05
downstream O 0 1.4338814935399569e-07
of O 0 2.778090868460481e-09
the O 0 6.285398868044467e-09
last O 0 1.072724842288153e-07
base O 0 5.0588212729962834e-08
of O 0 6.833532850691881e-09
the O 0 2.7682171221954377e-08
normal O 0 1.7635360904932895e-07
termination O 0 1.0906384886766318e-05
codon O 0 2.4555456548114307e-06
( O 0 2.2196338989033393e-07
+ O 0 7.598066531500081e-06
574 O 0 0.0001706479088170454
delATTCTT O 0 0.00033227528911083937
) O 0 8.42791394006781e-07
. O 0 1.4867612208036007e-06

Five O 0 8.432621689280495e-05
intragenic O 0 0.048958051949739456
dimorphisms O 0 0.031288307160139084
are O 0 1.4077526202527224e-06
now O 0 7.241893626996898e-07
well O 0 1.6155468074430246e-07
characterized O 0 3.862071480398299e-06
and O 0 4.313187673687935e-08
the O 0 2.282543576370699e-08
high O 0 2.0049540125910426e-06
degree O 0 2.957727645025443e-07
of O 0 2.8941746776922628e-08
allelic O 0 6.95871640346013e-05
heterogeneity O 0 9.106651850743219e-05
in O 0 9.350911795991124e-07
HC B-Disease 1 0.9477194547653198
is O 0 5.593919922830537e-07
demonstrated O 0 8.183912427739415e-07
with O 0 2.9659911859880594e-08
seven O 0 8.101955728534449e-08
new O 0 1.1656161547080046e-07
different O 0 3.5788405572390047e-09
mutations O 0 2.088179940074042e-07
making O 0 2.1301387320704634e-08
a O 0 8.109249272081342e-09
total O 0 1.496494661523684e-08
of O 0 1.1651867026785112e-08
nineteen O 0 2.4815001324896002e-06
CPO O 0 0.0009474461548961699
gene B-Disease 0 1.118487307394389e-05
defects I-Disease 0 0.12033355981111526
reported O 0 9.52546724874992e-06
so O 0 1.0178519715964285e-07
far O 0 2.528614402308449e-07
. O 0 1.4696905736855115e-07
. O 0 1.6884683873286122e-06

Coincidence O 0 2.405725717835594e-05
of O 0 6.000043981657655e-07
two O 0 1.3295412770730763e-07
novel O 0 1.0052588095277315e-06
arylsulfatase O 0 0.00041975508793257177
A O 0 4.7222883381436986e-07
alleles O 0 8.105308211270312e-07
and O 0 2.006312769253782e-07
mutation O 0 1.1412492995077628e-06
459 O 0 3.697947249747813e-05
+ O 0 1.5238400919770356e-05
1G O 0 0.00021308878785930574
> O 0 4.452295343071455e-06
A O 0 1.4856567531751352e-07
within O 0 2.2147572664721338e-08
a O 0 3.147919471757632e-07
family O 0 5.009424512536498e-06
with O 0 1.2853238331445027e-05
metachromatic B-Disease 1 0.9999313354492188
leukodystrophy I-Disease 1 0.9998005032539368
: O 0 3.722255996763124e-07
molecular O 0 6.178621561048203e-07
basis O 0 2.8721123257469117e-08
of O 0 2.2099432328559487e-07
phenotypic O 0 4.5249442337080836e-05
heterogeneity O 0 0.0006706440472044051
. O 0 1.7854090401669964e-05

In O 0 1.1367802471795585e-05
a O 0 2.753772605501581e-06
family O 0 2.922074827438337e-06
with O 0 2.3129766191232193e-07
three O 0 3.467856970473804e-07
siblings O 0 3.476824349490926e-05
, O 0 6.681274555830896e-08
one O 0 2.031096713039915e-08
developed O 0 4.510394262524642e-07
classical O 0 2.1012156139477156e-06
late O 0 7.879061013227329e-05
infantile O 1 0.8761064410209656
metachromatic B-Disease 1 0.999923825263977
leukodystrophy I-Disease 1 0.9999575614929199
( O 0 5.068921745987609e-05
MLD B-Disease 1 0.9985256791114807
) O 0 1.5234663806040771e-06
, O 0 7.479789019271266e-07
fatal O 0 0.00025120427017100155
at O 0 1.3872419231120148e-06
age O 0 2.2152614747028565e-06
5 O 0 5.577358024311252e-07
years O 0 4.927750865135749e-07
, O 0 1.3618105754176213e-07
with O 0 8.520365781805594e-07
deficient O 0 0.005421425681561232
arylsulfatase O 0 0.0008119947742670774
A O 0 8.752159033065254e-07
( O 0 3.1656756505071826e-07
ARSA O 0 0.00587935745716095
) O 0 5.606668906921186e-08
activity O 0 3.3996567339045214e-08
and O 0 5.916133005712254e-08
increased O 0 9.834845968725858e-07
galactosylsulfatide O 0 0.0008737547323107719
( O 0 8.443230967714044e-07
GS O 0 0.38068687915802
) O 0 2.0889535790047375e-06
excretion O 0 4.045607056468725e-05
. O 0 3.5154380384483375e-06

The O 0 1.946913471329026e-06
two O 0 4.396043777887826e-07
other O 0 4.599683052219916e-07
siblings O 0 3.4163160307798535e-05
, O 0 9.33455339691136e-07
apparently O 0 7.257031938934233e-06
healthy O 0 5.23466951563023e-07
at O 0 7.56321227868284e-08
12 O 0 1.1929644472274958e-07
( O 0 1.8283158098597596e-08
1 O 0 3.6308630768644434e-08
/ O 0 9.306065180680889e-07
2 O 0 7.844361959996604e-08
) O 0 6.016038778255961e-09
and O 0 8.86150086643056e-09
15 O 0 5.6391115776932565e-08
years O 0 9.62619282063315e-08
, O 0 4.4269409471553445e-08
respectively O 0 4.0557469560553727e-07
, O 0 4.692542177053838e-08
and O 0 6.532543039838856e-08
their O 0 8.618501823320912e-08
father O 0 4.457848717720481e-06
, O 0 7.254446927618119e-07
apparently O 0 1.0767734238470439e-05
healthy O 0 1.0451420848767157e-06
as O 0 2.0270253031640095e-08
well O 0 2.4410100607497043e-08
, O 0 5.7996132341031625e-08
presented O 0 2.4748189844103763e-06
ARSA O 0 0.02116425521671772
and O 0 1.0606413525238167e-06
GS O 0 0.045640621334314346
values O 0 7.017665382136329e-08
within O 0 3.1663498489820086e-09
the O 0 1.1603873417698196e-08
range O 0 1.3971783801025595e-06
of O 0 9.276158380089328e-06
MLD B-Disease 1 0.9997820258140564
patients O 0 0.07093097269535065
. O 0 1.1503469067974947e-05

Mutation O 0 0.00011981386342085898
screening O 0 5.8172781791654415e-06
and O 0 1.1081878170671189e-07
sequence O 0 4.871009906537438e-08
analysis O 0 1.1770402608135555e-07
disclosed O 0 6.118365035945317e-06
the O 0 1.035785146541457e-08
involvement O 0 6.714016080877627e-07
of O 0 6.783548833766417e-09
three O 0 1.98112708460485e-08
different O 0 2.8924695527621225e-08
ARSA O 0 0.07267538458108902
mutations O 0 4.344561148172943e-06
being O 0 3.168321072166691e-08
the O 0 5.338949726763076e-09
molecular O 0 2.526498121824261e-07
basis O 0 2.8475389157733844e-08
of O 0 1.4828060557192657e-07
intrafamilial O 0 0.0017590532079339027
phenotypic O 0 7.324653415707871e-05
heterogeneity O 0 0.000654568721074611
. O 0 2.1231930077192374e-05

The O 0 2.555381433921866e-05
late O 0 0.0005358568159863353
infantile O 1 0.9778792262077332
patient O 1 0.5235157608985901
inherited O 1 0.5635265111923218
from O 0 5.8983864619222e-06
his O 0 5.831764610775281e-06
mother O 0 7.095775345078437e-06
the O 0 2.0918088594612527e-08
frequent O 0 2.9954583169455873e-07
0 O 0 2.712990863074083e-07
- O 0 0.00023199321003630757
type O 0 1.6890836604943615e-06
mutation O 0 3.184783281540149e-07
459 O 0 6.868012405902846e-06
+ O 0 3.9806595850677695e-06
1G O 0 5.54304824618157e-05
> O 0 2.108578655679594e-06
A O 0 1.6740702335482638e-07
, O 0 5.7999120173235497e-08
and O 0 7.15637682446868e-08
from O 0 1.2232572998982505e-07
his O 0 6.232011742213217e-07
father O 0 2.196497007389553e-06
a O 0 2.8795227535738377e-08
novel O 0 6.752003400833928e-08
, O 0 2.5978122764058753e-08
single O 0 5.400753266826541e-08
basepair O 0 6.196032336447388e-05
microdeletion O 0 1.2685446563409641e-05
of O 0 8.152331254507317e-09
guanine O 0 7.123386467355886e-07
at O 0 2.2279893485688262e-08
nucleotide O 0 1.539389842264427e-07
7 O 0 1.043865580641068e-07
in O 0 2.1139369366096616e-08
exon O 0 5.673100076819537e-06
1 O 0 3.589538266624004e-07
( O 0 2.559360154918977e-07
7delG O 0 0.000119265794637613
) O 0 4.6100512918201275e-07
. O 0 1.9393435195524944e-06

The O 0 3.7220149806671543e-06
two O 0 4.835159415961243e-06
clinically O 0 0.007942479103803635
unaffected O 0 0.00027063576271757483
siblings O 0 2.6778112442116253e-05
carried O 0 2.4076030058495235e-07
the O 0 4.834652500562697e-08
maternal O 0 8.9490104073775e-06
mutation O 0 8.566905762563692e-07
459 O 0 1.6016212612157688e-05
+ O 0 5.75934018343105e-06
1G O 0 7.82896313467063e-05
> O 0 2.4814432890707394e-06
A O 0 2.1685511342184327e-07
and O 0 8.860423150736096e-08
, O 0 2.6057872304363627e-08
on O 0 2.6085668736186562e-08
their O 0 2.9061450135259292e-08
paternal O 0 4.000360604550224e-06
allele O 0 3.4568847695481963e-07
, O 0 1.7775381166984516e-08
a O 0 4.019180988024118e-09
novel O 0 2.1696013874361597e-08
cytosine O 0 1.0665446552593494e-06
to O 0 7.510895905227244e-09
thymidine O 0 1.3405867775873048e-06
transition O 0 8.190394851226301e-08
at O 0 3.96090342746902e-08
nucleotide O 0 5.474868203236838e-07
2435 O 0 4.27023260272108e-05
in O 0 1.884716382960505e-08
exon O 0 4.806737251783488e-06
8 O 0 1.6875429764695582e-07
, O 0 2.2776029950932752e-08
resulting O 0 4.038116330207231e-08
in O 0 2.8922915173978936e-09
substitution O 0 9.694326230658135e-09
of O 0 9.72484581751587e-09
alanine O 0 1.8472144802217372e-05
464 O 0 3.297663351986557e-05
by O 0 6.929044502612669e-07
valine O 0 0.0005014374037273228
( O 0 7.770528327455395e-07
A464V O 0 8.153105591190979e-05
) O 0 5.500249926626566e-07
. O 0 1.3312583178048953e-06

The O 0 7.038938292680541e-06
fathers O 0 3.8216352550080046e-05
genotype O 0 0.00013849607785232365
thus O 0 3.3364574392180657e-06
was O 0 7.53137237552437e-06
7delG O 0 0.0005940120317973197
/ O 0 0.00022684170107822865
A464V O 0 0.001100351451896131
. O 0 1.0162968465010636e-05

Mutation O 0 0.0018602658528834581
A464V O 0 0.002539374865591526
was O 0 7.413386356347473e-06
not O 0 5.8385822399031895e-08
found O 0 8.387535643805677e-08
in O 0 4.475973014450574e-08
18 O 0 3.3239823551411973e-06
unrelated O 0 0.004481580574065447
MLD B-Disease 1 0.9999502897262573
patients O 0 0.021332306787371635
and O 0 1.5998468825273449e-06
50 O 0 3.914749868272338e-06
controls O 0 1.3538739040086512e-05
. O 0 4.590143817040371e-06

A464V O 0 0.01333535835146904
, O 0 8.6806649051141e-06
although O 0 9.547781019136892e-07
clearly O 0 8.897526413420564e-07
modifying O 0 1.6638561646686867e-05
ARSA O 0 0.026640478521585464
and O 0 2.7033286187361227e-06
GS O 1 0.9421918392181396
levels O 0 1.2519043593783863e-05
, O 0 6.945835480109963e-07
apparently O 0 6.6653401518124156e-06
bears O 0 4.986221938452218e-06
little O 0 8.815751328938859e-08
significance O 0 8.113244831520205e-08
for O 0 1.2646491143186722e-07
clinical O 0 1.350270031252876e-05
manifestation O 0 7.732024641882163e-06
of O 0 1.0238037475573947e-06
MLD B-Disease 1 0.9981210827827454
, O 0 2.229810206699767e-06
mimicking O 0 3.2219486456597224e-05
the O 0 4.649492950647982e-07
frequent O 0 1.9812665414065123e-05
ARSA O 0 0.14494088292121887
pseudodeficiency O 0 0.005823956336826086
allele O 0 5.1202492613811046e-05
. O 0 7.192707016656641e-06

Our O 0 5.292352852848126e-06
results O 0 2.6052164230350172e-06
demonstrate O 0 2.6024947601399617e-06
that O 0 3.479626542457481e-08
in O 0 3.0042581755651554e-08
certain O 0 7.641557431270485e-08
genetic O 0 1.7163494703709148e-05
conditions O 0 5.131169018568471e-05
MLD B-Disease 1 0.9976170063018799
- O 0 0.05251198261976242
like O 0 2.122608020727057e-05
ARSA O 0 0.1753873974084854
and O 0 1.0257114126943634e-06
GS O 0 0.17086900770664215
values O 0 7.511407034144213e-07
need O 0 8.519750593904973e-08
not O 0 3.679116122867754e-09
be O 0 3.626652977928302e-09
paralleled O 0 2.2584906673728256e-06
by O 0 7.977204404596705e-06
clinical O 0 0.0831744521856308
disease O 0 0.0066873785108327866
, O 0 2.7478333208819095e-07
a O 0 1.2402891513829672e-07
finding O 0 2.4386706627410604e-06
with O 0 6.192015462147538e-06
serious O 0 0.014092443510890007
diagnostic O 0 0.004892443772405386
and O 0 9.235152538167313e-05
prognostic O 1 0.8261511325836182
implications O 0 0.0031079663895070553
. O 0 3.2524305424885824e-05

Moreover O 0 0.00012680678628385067
, O 0 2.387095491940272e-06
further O 0 1.0152311915589962e-06
ARSA O 0 0.010356556624174118
alleles O 0 1.532546230009757e-05
functionally O 0 1.783749758033082e-05
similar O 0 2.65988006731277e-07
to O 0 9.085882624049191e-08
A464V O 0 0.00013632499030791223
might O 0 7.192077191575663e-07
exist O 0 1.6866701813000873e-08
which O 0 6.683782860505971e-09
, O 0 1.3259320752467829e-08
together O 0 1.4028668005039435e-08
with O 0 2.6102840777753045e-08
0 O 0 1.1692841326294001e-06
- O 0 0.009562649764120579
type O 0 2.473719541740138e-05
mutations O 0 2.7445061277830973e-05
, O 0 1.7877781601782772e-06
may O 0 8.113691364997067e-06
cause O 0 8.221938514907379e-06
pathological O 0 0.00018629059195518494
ARSA O 1 0.6247966885566711
and O 0 1.3099320312903728e-05
GS O 1 0.9911479949951172
levels O 0 1.034168144542491e-05
, O 0 1.429919933571e-07
but O 0 4.2992414961418035e-08
not O 0 3.1140174883148575e-08
clinical O 0 7.6936212280998e-06
outbreak O 0 9.608483196643647e-06
of O 0 3.1908422215565224e-07
the O 0 3.5866185498889536e-05
disease O 0 0.010981949046254158
. O 0 1.3844506838722737e-06
. O 0 7.610677585034864e-06

Human O 0 0.0668046623468399
MLH1 O 1 0.9983362555503845
deficiency O 1 0.9993754029273987
predisposes O 0 0.27333006262779236
to O 0 8.879968663677573e-05
hematological B-Disease 1 0.9977443218231201
malignancy I-Disease 1 0.9985758066177368
and O 0 0.0005524307489395142
neurofibromatosis B-Disease 1 0.9990046620368958
type I-Disease 0 0.0001379243767587468
1 I-Disease 0 1.3055408089712728e-05
. O 0 1.096740106731886e-05

Heterozygous O 0 0.0005597085691988468
germ O 0 0.00884766411036253
- O 0 0.004548624157905579
line O 0 3.550240944605321e-05
mutations O 0 4.177323717158288e-06
in O 0 2.2311574809918966e-08
the O 0 4.9231573484576074e-08
DNA O 0 2.4112519895425066e-05
mismatch O 0 0.055307939648628235
repair O 0 0.06072670966386795
genes O 0 9.000345926324371e-06
lead O 0 4.325991903897375e-05
to O 0 1.4206935702532064e-05
hereditary B-Disease 1 0.9927269220352173
nonpolyposis I-Disease 1 0.9999001026153564
colorectal I-Disease 1 0.9999983310699463
cancer I-Disease 1 0.999943733215332
. O 0 0.00038211062201298773

The O 0 0.000450399296823889
disease O 1 0.7833337187767029
susceptibility O 0 0.0014047968434169888
of O 0 1.9090618934569648e-06
individuals O 0 1.4129971532383934e-05
who O 0 5.1321279897820204e-05
constitutionally O 0 0.0001189853428513743
lack O 0 1.388208033858973e-06
both O 0 7.655343381429702e-08
wild O 0 3.941839167964645e-06
- O 0 0.0015789814060553908
type O 0 1.0940218999166973e-05
alleles O 0 3.3549858926562592e-06
is O 0 4.815978513761365e-07
unknown O 0 4.498607722780434e-06
. O 0 4.410549991007429e-06

We O 0 7.406037639157148e-06
have O 0 7.631112453054811e-07
identified O 0 6.599254902539542e-07
three O 0 4.874048897818284e-08
offspring O 0 3.210127715647104e-06
in O 0 1.4810197512815648e-07
a O 0 1.1687930054904427e-05
hereditary B-Disease 1 0.9977816939353943
nonpolyposis I-Disease 1 0.9999897480010986
colorectal I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999969005584717
family O 0 0.013228907249867916
who O 0 0.0009674477041698992
developed O 0 0.001051918021403253
hematological B-Disease 1 0.9989107847213745
malignancy I-Disease 1 0.9786294102668762
at O 0 3.3395072023267858e-06
a O 0 2.5899689148900507e-07
very O 0 4.6689546451261776e-08
early O 0 3.2524326343263965e-07
age O 0 9.923747938955785e-07
, O 0 7.847983596320773e-08
and O 0 4.468440550908781e-08
at O 0 7.849959615668922e-08
least O 0 2.588433245520605e-09
two O 0 3.725595387749081e-09
of O 0 7.154313141910507e-09
them O 0 2.589303704780832e-08
displayed O 0 4.49741537522641e-06
signs O 0 1.3331080481293611e-05
of O 0 2.0105105704715243e-06
neurofibromatosis B-Disease 1 0.984961986541748
type I-Disease 0 3.18572529067751e-05
1 I-Disease 0 6.344339453789871e-06
( O 0 3.441454964558943e-06
NF1 B-Disease 0 0.006912958342581987
) O 0 3.4665285966184456e-06
. O 0 2.7484625206852797e-06

DNA O 0 2.9317490771063603e-05
sequence O 0 7.054691764096788e-07
analysis O 0 3.6508635048448923e-07
and O 0 1.3812127974688337e-07
allele O 0 5.197123869038478e-07
- O 0 1.2405141205817927e-05
specific O 0 2.8694676856844126e-08
amplification O 0 2.597659431557986e-06
in O 0 1.2706763641290308e-08
two O 0 2.8935620122183536e-08
siblings O 0 1.685620009084232e-05
revealed O 0 2.3737266019452363e-06
a O 0 2.935401539616578e-07
homozygous O 0 2.720669908740092e-05
MLH1 O 0 0.0646098405122757
mutation O 0 8.168401109287515e-06
( O 0 1.7769390581179323e-07
C676T O 0 5.414077895693481e-05
- O 0 0.001500351121649146
- O 0 0.0062589459121227264
> O 0 0.0001421032939106226
Arg226Stop O 0 0.001728756702505052
) O 0 1.5602087160004885e-06
. O 0 1.6850403881107923e-06

Thus O 0 1.9810020603472367e-05
, O 0 1.0962191936414456e-06
a O 0 4.624714904366556e-07
homozygous O 0 1.3096209841023665e-05
germ O 0 0.00042773556197062135
- O 0 0.0007581330137327313
line O 0 4.0759823605185375e-05
MLH1 O 0 0.11706367135047913
mutation O 0 2.6688987418310717e-05
and O 0 6.099332040321315e-06
consequent O 0 0.3483418822288513
mismatch O 1 0.9997243285179138
repair O 1 0.9998536109924316
deficiency O 1 0.9967978596687317
results O 0 2.2724018435837934e-06
in O 0 1.0779138648331354e-07
a O 0 9.919954209181014e-07
mutator O 0 0.2905900180339813
phenotype O 0 0.0014111134223639965
characterized O 0 0.00011222766624996439
by O 0 9.35094867600128e-05
leukemia B-Disease 1 0.9997001886367798
and O 0 0.00011261413601459935
/ O 0 0.4620000720024109
or O 0 0.22575528919696808
lymphoma B-Disease 1 0.999998927116394
associated O 0 0.001236469717696309
with O 0 0.00023813948791939765
neurofibromatosis B-Disease 1 0.9995718598365784
type I-Disease 0 7.214294600998983e-05
1 I-Disease 0 7.0062292252259795e-06
. O 0 1.3303496189109865e-06
. O 0 5.003842943551717e-06

Missense O 0 0.01576702855527401
mutations O 0 0.0012915615225210786
in O 0 6.568695312125783e-07
the O 0 6.627345783272176e-08
most O 0 1.9182854416044393e-08
ancient O 0 5.2844470133095456e-08
residues O 0 1.0710851228168394e-07
of O 0 8.51156034542555e-09
the O 0 3.59845948594284e-08
PAX6 O 0 0.0003404900198802352
paired O 0 4.6870013648003805e-06
domain O 0 2.640242939833115e-07
underlie O 0 1.2576218068716116e-05
a O 0 3.004728341693408e-07
spectrum O 0 2.3180467906058766e-05
of O 0 3.387746983207762e-05
human O 1 0.5672093629837036
congenital B-Disease 1 0.999982476234436
eye I-Disease 1 0.999683141708374
malformations I-Disease 1 0.9998264908790588
. O 0 0.0004112290043849498

Mutations O 0 0.0004944356041960418
of O 0 6.827939387221704e-07
the O 0 4.474910326734971e-07
human O 0 4.141974386584479e-06
PAX6 O 0 0.02821558527648449
gene O 0 9.928689541993663e-05
underlie O 0 0.39351484179496765
aniridia B-Disease 1 0.9999758005142212
( O 0 0.020679336041212082
congenital B-Disease 1 0.9999620914459229
absence I-Disease 0 7.078613998601213e-05
of I-Disease 0 3.9679062524555775e-07
the I-Disease 0 1.3830068610332091e-06
iris I-Disease 0 0.4540264308452606
) O 0 7.262788130901754e-07
, O 0 3.725327815118362e-07
a O 0 1.386521034874022e-06
rare O 0 0.00022009517124388367
dominant O 0 0.002374898176640272
malformation B-Disease 1 0.9984951019287109
of I-Disease 0 5.610687367152423e-06
the I-Disease 0 2.5704834115458652e-05
eye I-Disease 0 0.06722867488861084
. O 0 4.4567492295755073e-05

The O 0 3.440188265813049e-06
spectrum O 0 9.210231837641913e-06
of O 0 7.869145406402822e-07
PAX6 O 0 0.11635889112949371
mutations O 0 0.0001657559332670644
in O 0 5.546198735828511e-06
aniridia B-Disease 1 0.99994957447052
patients O 0 0.014323984272778034
is O 0 1.736279529040985e-07
highly O 0 3.9211400348904135e-07
biased O 0 1.616775080037769e-06
, O 0 6.821385767352695e-08
with O 0 3.250639935004074e-08
92 O 0 2.107856971633737e-06
% O 0 2.491211148480943e-08
of O 0 4.663843533592171e-09
all O 0 1.3745814264609635e-08
reported O 0 4.987567990610842e-06
mutations O 0 3.2876200748432893e-06
leading O 0 2.977988742713933e-06
to O 0 9.571980541522862e-08
premature O 0 8.726283340365626e-06
truncation O 0 2.0756410776812118e-06
of O 0 2.0784538534712738e-08
the O 0 4.699206002101164e-08
protein O 0 1.4066063158679754e-07
( O 0 1.344348632414949e-08
nonsense O 0 4.344381068221992e-07
, O 0 8.470294687867863e-09
splicing O 0 7.965977744106567e-08
, O 0 1.2041931896078495e-08
insertions O 0 6.900187372593791e-07
and O 0 9.752415763841782e-08
deletions O 0 4.2484593905101065e-06
) O 0 1.9515811189307897e-08
and O 0 1.1447878200954165e-08
just O 0 1.4287117267031135e-08
2 O 0 8.641941917630902e-08
% O 0 2.6424590515716773e-08
leading O 0 2.2894070639267738e-07
to O 0 1.8599389806084332e-09
substitution O 0 7.024586690107526e-09
of O 0 2.095761564291365e-09
one O 0 8.58889404042884e-09
amino O 0 1.4649299373559188e-07
acid O 0 8.048231734392175e-07
by O 0 2.122643927293666e-08
another O 0 1.3549821176184196e-07
( O 0 3.392558198811457e-07
missense O 0 6.008866330375895e-05
) O 0 1.2101171478207107e-06
. O 0 2.645750328156282e-06

The O 0 4.921748768538237e-06
extraordinary O 0 1.558215808472596e-05
conservation O 0 2.1398791432147846e-06
of O 0 2.7990802564659134e-08
the O 0 4.116528273812037e-08
PAX6 O 0 0.0002630413800943643
protein O 0 6.353696591077096e-08
at O 0 1.2973927709936106e-08
the O 0 5.5766968820591956e-09
amino O 0 6.309063849130325e-08
acid O 0 1.0236319667455973e-06
level O 0 8.307482346481265e-08
amongst O 0 3.195480076101376e-07
vertebrates O 0 2.057452547887806e-06
predicts O 0 7.718453161942307e-06
that O 0 5.3263807586745315e-08
pathological O 0 4.747212733491324e-05
missense O 0 0.0004659886471927166
mutations O 0 2.4905899408622645e-05
should O 0 9.420723756647931e-08
in O 0 2.9768163045673646e-08
fact O 0 8.385936212107481e-08
be O 0 2.6866429081451315e-08
common O 0 2.3956152972459677e-07
even O 0 2.4421609623459517e-07
though O 0 1.654123593652912e-07
they O 0 1.901462987063951e-08
are O 0 1.0315069687294454e-08
hardly O 0 2.7368963628759957e-07
ever O 0 2.7718897399608977e-07
seen O 0 2.0281488559703575e-06
in O 0 2.844214350261609e-06
aniridia B-Disease 1 0.9996140599250793
patients O 0 0.007363991346210241
. O 0 6.719615612382768e-06

This O 0 2.9092509521433385e-06
indicates O 0 8.640648047730792e-06
that O 0 6.222289528068359e-08
there O 0 8.680164143015645e-09
is O 0 5.21501419825654e-09
a O 0 3.288530692202585e-08
heavy O 0 3.389298217371106e-05
ascertainment O 0 0.002837277017533779
bias O 0 4.822274422622286e-05
in O 0 6.377955941161417e-08
the O 0 2.2222257811677082e-08
selection O 0 1.1366270769030962e-07
of O 0 3.2715362863200426e-07
patients O 0 3.247168569942005e-05
for O 0 2.6074036441059434e-07
PAX6 O 0 0.005011456552892923
mutation O 0 2.3282900656340644e-06
analysis O 0 8.510590276955554e-08
and O 0 1.1977991221101547e-07
that O 0 1.1174756231469019e-08
the O 0 4.046728818707379e-08
missing O 0 1.4174591342452914e-05
PAX6 O 0 0.022346189245581627
missense O 0 0.004827943630516529
mutations O 0 0.00024477296392433345
frequently O 0 1.233261082234094e-05
may O 0 5.879970103706e-06
underlie O 0 0.0002837156062014401
phenotypes O 0 6.649548595305532e-05
distinct O 0 7.652517410861037e-07
from O 0 2.9094064757373417e-06
textbook O 0 0.004010207485407591
aniridia B-Disease 1 0.9972707629203796
. O 0 4.3647291022352874e-05

Here O 0 6.2291451286000665e-06
we O 0 1.929960120605756e-07
present O 0 5.117066947946114e-08
four O 0 4.990214108602231e-08
novel O 0 9.885559393296717e-07
PAX6 O 0 0.0019543590024113655
missense O 0 0.00020787357061635703
mutations O 0 1.625247205083724e-05
, O 0 8.11617013596333e-08
two O 0 3.8214984954265674e-08
in O 0 1.3772049101135053e-07
association O 0 4.407446795084979e-06
with O 0 1.3914990404373384e-06
atypical O 0 0.0004731939407065511
phenotypes O 0 0.0017916494980454445
ectopia B-Disease 0 0.2703092098236084
pupillae I-Disease 0 0.12918397784233093
( O 0 1.0887438293138985e-06
displaced B-Disease 0 1.5013803931651637e-05
pupils I-Disease 0 2.163978570024483e-05
) O 0 1.3541687167162308e-06
and O 0 0.0001621736300876364
congenital B-Disease 1 0.9999496936798096
nystagmus I-Disease 1 0.6923578977584839
( O 0 6.724204695274238e-07
searching B-Disease 0 5.878803676750977e-06
gaze I-Disease 0 0.0001888941478682682
) O 0 1.0877032963207967e-07
, O 0 1.8359791909006162e-08
and O 0 1.5006335729594866e-08
two O 0 2.1561117335977542e-08
in O 0 4.118318841506152e-08
association O 0 5.696535936294822e-07
with O 0 1.7618769732052897e-07
more O 0 3.433963229326764e-07
recognizable O 0 0.0002656741999089718
aniridia B-Disease 1 0.9825562238693237
phenotypes O 0 0.0023082438856363297
. O 0 1.2610336852958426e-05

Strikingly O 0 0.0008968178881332278
, O 0 1.8503368437450263e-06
all O 0 2.651031039135887e-08
four O 0 1.7604023128114932e-07
mutations O 0 2.1966393433103804e-06
are O 0 1.1046546788406886e-08
located O 0 3.885952537530102e-08
within O 0 6.803166474611544e-09
the O 0 5.835865124481643e-08
PAX6 O 0 0.0008759611519053578
paired O 0 5.517236786545254e-06
domain O 0 1.0257274851710463e-07
and O 0 5.928139756861128e-08
affect O 0 7.884743524755322e-08
amino O 0 1.3466858206356846e-07
acids O 0 2.0201210304549022e-07
which O 0 6.42755937363404e-09
are O 0 5.29788701797429e-09
highly O 0 7.982632155290048e-08
conserved O 0 4.955338894774286e-08
in O 0 6.122444329292875e-09
all O 0 6.421898124386871e-09
known O 0 4.074491073424724e-07
paired O 0 5.226406756264623e-06
domain O 0 1.4595850643672748e-06
proteins O 0 1.3771947351415292e-06
. O 0 2.195102297264384e-06

Our O 0 6.089074304327369e-06
results O 0 3.663618599603069e-06
support O 0 4.0349297592001676e-07
the O 0 1.985916675550925e-08
hypothesis O 0 2.780743670882657e-07
that O 0 5.468499875149746e-09
the O 0 5.956392268302579e-09
under O 0 3.8484088804580097e-08
- O 0 1.1066781553381588e-05
representation O 0 8.458803790745151e-08
of O 0 7.880082364408736e-08
missense O 0 0.00037561042699962854
mutations O 0 4.474815068533644e-05
is O 0 1.9568987852380815e-07
caused O 0 3.7710240121668903e-06
by O 0 2.802328822326672e-07
ascertainment O 0 0.06558386981487274
bias O 0 0.002137194387614727
and O 0 2.6327754767407896e-06
suggest O 0 8.806824780549505e-07
that O 0 1.2762994217041523e-08
a O 0 6.885069581130665e-08
substantial O 0 2.4630155621707672e-06
burden O 0 7.107103010639548e-05
of O 0 6.696404852846172e-07
PAX6 B-Disease 1 0.5574890971183777
- I-Disease 1 0.934788703918457
related I-Disease 0 0.41643276810646057
disease I-Disease 0 0.1649811565876007
remains O 0 1.2794073882105295e-05
to O 0 1.540105074582243e-07
be O 0 1.1302614666419686e-07
uncovered O 0 2.9331979021662846e-05
. O 0 8.002066920198558e-07
. O 0 3.8524412957485765e-06

The O 0 8.391939445573371e-06
chromosomal O 0 0.002107711276039481
order O 0 6.455759375967318e-07
of O 0 1.2171467744792608e-07
genes O 0 6.354454171741963e-07
controlling O 0 6.705603027512552e-06
the O 0 1.2708247254522576e-07
major O 0 5.956712811894249e-06
histocompatibility O 0 0.07524406909942627
complex O 0 5.30915531271603e-06
, O 0 6.376374699357257e-07
properdin O 0 0.0019417060539126396
factor O 0 4.314613306632964e-06
B O 0 4.3605559767456725e-05
, O 0 1.0819774161063833e-06
and O 0 6.076063073123805e-06
deficiency B-Disease 0 0.0038038487546145916
of I-Disease 0 1.0594303212485556e-08
the I-Disease 0 2.289904266206122e-08
second I-Disease 0 3.5084840988020005e-07
component I-Disease 0 1.0856778089873842e-06
of I-Disease 0 1.6732259666696336e-07
complement I-Disease 0 8.698324563738424e-06
. O 0 3.2585596727585653e-06

The O 0 5.498149675986497e-06
relationship O 0 5.127059921505861e-06
of O 0 3.8287431891603774e-08
the O 0 2.3234907331470822e-08
genes O 0 9.728374550377339e-08
coding O 0 3.543867705957382e-07
for O 0 9.286457469670495e-08
HLA O 0 9.666988626122475e-05
to O 0 2.083502614880217e-08
those O 0 1.8361333786742762e-08
coding O 0 3.1930278510117205e-07
for O 0 6.721934653342032e-08
properdin O 0 0.00028021473553963006
Factor O 0 1.0220926469628466e-06
B O 0 1.1319704753987025e-05
allotypes O 0 0.00033954804530367255
and O 0 7.41957137506688e-07
for O 0 5.738068011851283e-06
deficiency B-Disease 0 0.007241874001920223
of I-Disease 0 9.265046507778152e-09
the I-Disease 0 1.2050019648768284e-08
second I-Disease 0 7.501664356368565e-08
component I-Disease 0 1.3805477294681623e-07
of I-Disease 0 1.5620853943687507e-08
complement I-Disease 0 1.2303654557399568e-06
( O 0 2.880157978779607e-07
C2 O 0 0.0008683077176101506
) O 0 1.4703577733143902e-07
was O 0 1.708471160100089e-07
studied O 0 8.602899015386356e-08
in O 0 1.398653548534412e-08
families O 0 4.7004607495182427e-07
of O 0 2.4298863081639865e-06
patients O 0 0.00562201626598835
with O 0 0.00043685213313438
connective O 1 0.9993667006492615
tissue O 1 0.9996448755264282
disorders O 1 0.998996913433075
. O 0 0.00010437791934236884

Patients O 0 0.1845802664756775
were O 0 6.1773166635248344e-06
selected O 0 7.1819260938355e-07
because O 0 1.7567865029377572e-07
they O 0 2.109703345354319e-08
were O 0 6.99452016306168e-08
heterozygous O 0 5.54053485757322e-07
or O 0 4.787399348060717e-07
homozygous O 0 3.5583183489507064e-05
for O 0 9.121758193941787e-05
C2 B-Disease 1 0.9998760223388672
deficiency I-Disease 1 0.9998304843902588
. O 0 6.487178325187415e-05

12 O 0 3.810986163443886e-05
families O 0 4.262423772161128e-06
with O 0 2.9310768923096475e-07
15 O 0 5.057254384155385e-07
matings O 0 3.615113746491261e-05
informative O 0 1.4569271115760785e-05
for O 0 0.00022504740627482533
C2 B-Disease 1 0.9999696016311646
deficiency I-Disease 1 0.9999494552612305
were O 0 1.5224775779643096e-05
found O 0 1.0330562872695737e-05
. O 0 5.692631930287462e-06

Of O 0 4.4713151510222815e-06
57 O 0 2.858423613361083e-05
informative O 0 5.587619398284005e-06
meioses O 0 0.0007335214177146554
, O 0 1.3513829344447004e-07
two O 0 1.544958827537357e-08
crossovers O 0 2.2927988538867794e-06
were O 0 1.6326056595517002e-07
noted O 0 1.5280149057161907e-07
between O 0 8.890335578826125e-08
the O 0 9.44797011470655e-06
C2 B-Disease 1 0.9999876022338867
deficiency I-Disease 1 0.9999030828475952
gene O 0 9.455058034291142e-07
and O 0 5.623397925091922e-08
the O 0 7.295784598682076e-08
HLA O 0 0.001319218659773469
- O 0 0.01374942995607853
B O 0 0.00012229850108269602
gene O 0 2.2200995886123565e-07
, O 0 9.112641308206548e-09
with O 0 5.285855753101032e-09
a O 0 1.3475061955148249e-08
recombinant O 0 5.590282512457634e-07
fraction O 0 3.558990044894017e-07
of O 0 1.1984766956629755e-07
0 O 0 5.03465980727924e-06
. O 0 2.6949114726448897e-06

035 O 1 0.5601511001586914
. O 0 0.0020871248561888933

A O 0 2.01670281967381e-05
lod O 0 0.0003517042496241629
score O 0 7.161783628362173e-07
of O 0 7.98761234932499e-08
13 O 0 3.137061526103935e-07
was O 0 5.777652845040393e-08
calculated O 0 2.40493562841948e-08
for O 0 2.0786758980761988e-08
linkage O 0 8.961343155533541e-06
between O 0 5.581456935033202e-05
C2 B-Disease 1 0.9999868869781494
deficiency I-Disease 1 0.9999573230743408
and O 0 1.277502906305017e-05
HLA O 0 0.022964119911193848
- O 0 0.004080361686646938
B O 0 1.5199706467683427e-05
at O 0 5.39420597078788e-08
a O 0 8.609149837468522e-09
maximum O 0 4.627798588785481e-08
likelihood O 0 1.6572924721458548e-07
value O 0 5.019288096264063e-09
of O 0 1.98937311068903e-09
the O 0 6.371144500860737e-09
recombinant O 0 4.0094900555232016e-07
fraction O 0 2.799812364173704e-07
of O 0 8.905049497798245e-08
0 O 0 3.988897788076429e-06
. O 0 3.110804982497939e-06

04 O 0 0.03818029537796974
. O 0 0.0010303643066436052

18 O 0 5.2865703764837235e-05
families O 0 7.99938879936235e-06
with O 0 4.124907491132035e-07
21 O 0 5.849488502462918e-07
informative O 0 3.068974763209553e-07
matings O 0 7.303320671780966e-06
for O 0 7.733402895837571e-08
both O 0 1.329325840515594e-07
properdin O 0 0.00033012122730724514
Factor O 0 6.085876975703286e-07
B O 0 5.611548658635002e-06
allotype O 0 4.664160587708466e-05
and O 0 5.754556582360237e-07
HLA O 0 0.0006058726576156914
- O 0 0.0007507098489440978
B O 0 3.115413710474968e-05
were O 0 9.333948014500493e-07
found O 0 2.189985707445885e-06
. O 0 2.1557104901148705e-06

Of O 0 4.741231805382995e-06
72 O 0 2.1401063349912874e-05
informative O 0 5.942816642345861e-06
meioses O 0 0.0008326243842020631
, O 0 2.484639765043539e-07
three O 0 5.0873758539182745e-08
recombinants O 0 0.00045870139729231596
were O 0 1.9502476789057255e-07
found O 0 9.929412669862359e-08
, O 0 1.263546867136256e-08
giving O 0 1.7951256481296696e-08
a O 0 2.5834875572172677e-08
recombinant O 0 1.2414257071213797e-06
fraction O 0 4.140822795761778e-07
of O 0 5.085396637127815e-08
0 O 0 3.201023673682357e-06
. O 0 2.5888255095196655e-06

042 O 0 0.07237023860216141
. O 0 0.0011329357512295246

A O 0 1.1698557500494644e-05
lod O 0 0.00013880398182664067
score O 0 3.932089782665571e-07
of O 0 3.645685708875135e-08
16 O 0 2.1559313267971447e-07
between O 0 6.698130050608597e-08
HLA O 0 0.0006837013643234968
- O 0 0.0009664433891884983
B O 0 1.3514952115656342e-05
and O 0 2.763029840480158e-07
Factor O 0 2.950644670818292e-07
B O 0 1.5910173942756956e-06
allotypes O 0 2.1000752894906327e-05
was O 0 4.1952784357590645e-08
calculated O 0 1.2852723330070148e-08
at O 0 1.3053928604733755e-08
a O 0 3.5413851851018308e-09
maximum O 0 2.365975859675018e-08
likelihood O 0 2.1806958727665915e-07
value O 0 1.0271289596630595e-08
of O 0 2.259679110494517e-09
the O 0 7.119546729938975e-09
recombinant O 0 6.795983722440724e-07
fraction O 0 3.2595372090327146e-07
of O 0 7.516402433793701e-08
0 O 0 4.225834345561452e-06
. O 0 2.4002031295822235e-06

04 O 0 0.04475869983434677
. O 0 0.0006737395888194442

A O 0 6.429023869714001e-06
crossover O 0 9.083514669327997e-06
was O 0 5.037224127590889e-06
shown O 0 1.672104588124057e-07
to O 0 1.0538798278503236e-08
have O 0 8.469648982156741e-09
occurred O 0 2.190274450697416e-08
between O 0 1.7306414079598653e-08
genes O 0 7.858843531494131e-08
for O 0 4.0267028822427164e-08
Factor O 0 3.4113526226065005e-07
B O 0 8.183903446479235e-06
and O 0 8.719442803339916e-07
HLA O 0 0.0030611881520599127
- O 0 0.06144004315137863
D O 0 0.07701393216848373
, O 0 1.1881457595563916e-07
in O 0 9.172470782914388e-09
which O 0 3.370833567828413e-08
HLA O 0 0.0004066915425937623
- O 0 0.015164189971983433
D O 0 0.018702927976846695
segregared O 0 9.412542567588389e-05
with O 0 3.2399071869804175e-07
HLA O 0 0.00028086037491448224
- O 0 0.00011596200783969834
A O 0 6.528221092594322e-07
and O 0 1.1405018085497431e-06
B O 0 3.196833131369203e-05
. O 0 2.9104692202963633e-06

These O 0 2.7766070616053184e-06
studies O 0 6.485802714450983e-06
suggest O 0 9.169446002488257e-07
that O 0 1.2162122864367575e-08
the O 0 6.367451899080834e-09
genes O 0 3.011992433243904e-08
for O 0 2.3108064794996608e-08
Factor O 0 1.2433177971615805e-06
B O 0 0.0001414468279108405
and O 0 0.000896763289347291
C2 B-Disease 1 0.9999939203262329
deficiency I-Disease 1 0.9999171495437622
are O 0 1.3643740714996966e-07
located O 0 1.0080315604454881e-07
outside O 0 4.5508315338338434e-08
those O 0 2.4254857677874497e-08
for O 0 1.3155765543615416e-07
HLA O 0 0.000743551179766655
, O 0 1.0152790252959676e-07
that O 0 1.964277185351193e-09
the O 0 1.6630778976178817e-09
order O 0 6.1151146368843e-09
of O 0 1.5228353689167307e-08
genese O 0 0.00016751803923398256
is O 0 9.804413991787442e-08
HLA O 0 8.925778820412233e-05
- O 0 4.0498409362044185e-05
A O 0 4.358552985195274e-07
, O 0 2.6777345851769496e-07
- O 0 0.0005161608569324017
B O 0 3.2477695640409365e-05
, O 0 3.839626003809826e-07
- O 0 0.0008278167806565762
D O 0 0.015082315541803837
, O 0 1.883843623318171e-07
Factor O 0 3.947343714116869e-07
B O 0 2.584149297035765e-05
allotype O 0 0.04561784118413925
, O 0 0.00039941255818121135
C2 B-Disease 1 0.9999822378158569
deficiency I-Disease 1 0.9999085664749146
, O 0 1.4621274146975338e-07
that O 0 4.464962177763709e-09
the O 0 7.400079216068889e-09
genes O 0 9.895871500020803e-08
coding O 0 9.29800808080472e-06
for O 0 0.00012448255438357592
C2 B-Disease 1 0.9999936819076538
deficiency I-Disease 1 0.9999634027481079
and O 0 3.518852281558793e-06
Factor O 0 1.535971478006104e-06
B O 0 8.01927217253251e-06
allotypes O 0 3.636947076302022e-05
are O 0 5.9039555466711136e-09
approximately O 0 1.370089819374698e-08
3 O 0 9.040557102935054e-08
- O 0 3.0860206607030705e-05
- O 0 3.105206633335911e-05
5 O 0 1.243967346908903e-07
centimorgans O 0 5.815325494040735e-06
from O 0 8.464513534534035e-09
the O 0 1.0922475368602136e-08
HLA O 0 2.9456692573148757e-05
- O 0 2.334995224373415e-05
A O 0 1.9072207635417726e-07
and O 0 3.294222210570297e-07
HLA O 0 0.0003225324326194823
- O 0 0.00029927919968031347
B O 0 9.602720638213214e-06
loci O 0 5.282643087411998e-07
, O 0 2.0105911602286142e-08
and O 0 1.762541756988867e-08
that O 0 4.618907922804283e-09
the O 0 2.1171690178789504e-08
apparent O 0 2.777298277578666e-06
lack O 0 2.1623226587053068e-07
of O 0 2.1061653754372855e-08
recombinants O 0 7.03106343280524e-05
between O 0 2.6416829612685433e-08
the O 0 5.004320868806644e-08
Factor O 0 5.431330123428779e-07
B O 0 1.3494859558704775e-05
gene O 0 3.5435027712082956e-06
and O 0 0.0001541074743727222
C2 B-Disease 1 0.9999872446060181
deficiency I-Disease 1 0.9999433755874634
gene O 0 3.9640135582885705e-06
suggests O 0 9.127149382948119e-07
that O 0 5.541515690765664e-09
these O 0 8.931679285062444e-10
two O 0 9.531731848255731e-09
genes O 0 1.927662509615402e-07
lie O 0 7.603870244565769e-07
in O 0 3.13197041634794e-08
close O 0 2.873902076316881e-07
proximity O 0 2.072200402380986e-07
to O 0 1.7074345493028886e-08
one O 0 4.768784833686368e-08
another O 0 7.967252031448879e-07
. O 0 2.2502283627545694e-06

Distribution O 0 7.173655831138603e-06
of O 0 1.0841527000593487e-06
emerin O 0 0.0017268832307308912
and O 0 3.0105045425443677e-06
lamins O 0 0.007362158969044685
in O 0 1.7292300924509618e-07
the O 0 3.515678770327213e-07
heart O 0 3.611347347032279e-05
and O 0 3.917925539553835e-07
implications O 0 1.0823492630152032e-05
for O 0 2.090950829369831e-06
Emery B-Disease 0 0.26556503772735596
- I-Disease 1 0.9988265633583069
Dreifuss I-Disease 1 0.9996458292007446
muscular I-Disease 1 0.9996637105941772
dystrophy I-Disease 1 0.9991355538368225
. O 0 0.0002398448414169252

Emerin O 0 0.015347165055572987
is O 0 1.044779310177546e-06
a O 0 3.0269492867773806e-07
nuclear O 0 1.8088474462274462e-05
membrane O 0 1.4184298606778611e-06
protein O 0 9.918245069684417e-08
which O 0 7.320201778071578e-09
is O 0 1.2726580678190658e-08
missing O 0 7.367352736764587e-07
or O 0 1.4834071748737188e-07
defective O 0 0.00019444718782324344
in O 0 1.0049377578980057e-06
Emery B-Disease 0 0.14601373672485352
- I-Disease 1 0.9994133710861206
Dreifuss I-Disease 1 0.9999430179595947
muscular I-Disease 1 0.9999606609344482
dystrophy I-Disease 1 0.999931812286377
( O 0 0.0005995001411065459
EDMD B-Disease 1 0.9996494054794312
) O 0 2.3446391423931345e-05
. O 0 7.352517968683969e-06

It O 0 3.979938355769264e-06
is O 0 1.885802873857756e-07
one O 0 3.575512863562835e-08
member O 0 8.388367689349252e-08
of O 0 1.0892598822920263e-08
a O 0 1.3331039383501775e-07
family O 0 6.637415594923368e-07
of O 0 1.0265299721368137e-07
lamina O 0 0.1184399202466011
- O 0 0.024704525247216225
associated O 0 2.034217686741613e-06
proteins O 0 3.3431856394372517e-08
which O 0 4.671615982942967e-09
includes O 0 9.720863403117619e-08
LAP1 O 0 0.000687833409756422
, O 0 6.271905022003921e-07
LAP2 O 0 0.0007615039357915521
and O 0 2.0316838345024735e-06
lamin O 0 0.0919995903968811
B O 0 0.0022279093973338604
receptor O 0 9.486142516834661e-05
( O 0 3.854160695482278e-06
LBR O 0 0.12119536846876144
) O 0 3.1450315418624086e-06
. O 0 2.956733624159824e-06

A O 0 1.5406707461806946e-05
panel O 0 2.6261697712470777e-05
of O 0 2.6670048214327835e-07
16 O 0 5.0831113185267895e-06
monoclonal O 0 8.005653944564983e-05
antibodies O 0 6.099197889852803e-06
( O 0 8.370835047344372e-08
mAbs O 0 2.2666601580567658e-05
) O 0 3.250422864198299e-08
has O 0 2.4358614680863866e-08
been O 0 2.0571407688407817e-08
mapped O 0 4.964970230503241e-07
to O 0 6.017025544480248e-09
six O 0 1.2321950570992612e-08
specific O 0 2.634551687918929e-09
sites O 0 8.232412973541159e-09
throughout O 0 1.9747881108145293e-09
the O 0 4.507042294932262e-09
emerin O 0 5.711294761567842e-06
molecule O 0 3.706870543851437e-08
using O 0 9.874487005845367e-09
phage O 0 2.423221303615719e-06
- O 0 6.074683824408567e-06
displayed O 0 4.752513405037462e-07
peptide O 0 3.2994034881994594e-07
libraries O 0 2.0058338989770164e-08
and O 0 1.9337656809170767e-08
has O 0 2.5603238640314885e-08
been O 0 1.4820306759588675e-08
used O 0 9.12137121389378e-09
to O 0 9.930166022797948e-09
localize O 0 4.708456799562555e-06
emerin O 0 7.846146036172286e-05
in O 0 6.071164193599543e-08
human O 0 4.1171296061293106e-07
and O 0 2.7431308353698114e-06
rabbit O 0 0.0012519486481323838
heart O 0 0.0006670886650681496
. O 0 8.508157407050021e-06

Several O 0 1.1027453183487523e-05
mAbs O 0 0.00034762921859510243
against O 0 5.883004632778466e-06
different O 0 2.927375533090526e-07
emerin O 0 0.00252760061994195
epitopes O 0 0.0012394728837534785
did O 0 5.23890435033536e-07
not O 0 2.071069538089887e-08
recognize O 0 1.7294065912665246e-07
intercalated O 0 2.5756389732123353e-05
discs O 0 1.3536905498767737e-05
in O 0 5.771000743948207e-08
the O 0 2.8427697884580994e-07
heart O 0 3.329036553623155e-05
, O 0 1.5977275324985385e-07
though O 0 6.414506970031653e-08
they O 0 2.2905419783114667e-08
recognized O 0 1.7171906563362427e-07
cardiomyocyte O 0 0.00011613698006840423
nuclei O 0 8.515780791640282e-06
strongly O 0 5.848590376444918e-07
, O 0 1.4775091372598581e-08
both O 0 4.616934390355709e-09
at O 0 3.2621798595755536e-08
the O 0 2.1340875733244502e-08
rim O 0 1.970017001440283e-05
and O 0 1.4953170079934353e-07
in O 0 1.0323616095320176e-07
intranuclear O 0 0.00024248908448498696
spots O 0 1.8527999827711028e-06
or O 0 1.9027915243441385e-07
channels O 0 1.658731321185769e-06
. O 0 2.5046572318387916e-06

A O 0 5.916311056353152e-05
polyclonal O 0 0.0013629923341795802
rabbit O 0 0.0004593711346387863
antiserum O 0 0.0015544877387583256
against O 0 4.4365267967805266e-05
emerin O 0 0.0036740622017532587
did O 0 4.646248328299407e-07
recognize O 0 1.3438491919259832e-07
both O 0 1.1809516031746625e-08
nuclear O 0 6.598791514988989e-06
membrane O 0 5.443412192107644e-07
and O 0 1.1205346339693278e-07
intercalated O 0 0.0001045165627147071
discs O 0 2.5278470275225118e-05
but O 0 6.686615705575605e-08
, O 0 1.8463952144998075e-08
after O 0 5.2887422441472154e-08
affinity O 0 1.1511708919442754e-07
purification O 0 2.191582950672455e-07
against O 0 4.7519602475176725e-08
a O 0 1.7579990796434686e-08
pure O 0 1.328610892414872e-07
- O 0 0.0002215665444964543
emerin O 0 0.000725508900359273
band O 0 8.77757031503279e-07
on O 0 1.9321879207723214e-08
a O 0 1.3785145469569215e-08
western O 0 5.72554448297069e-08
blot O 0 2.1037116312072612e-05
, O 0 1.6178734085769975e-07
it O 0 1.3015095667867627e-08
stained O 0 0.00023312029952649027
only O 0 8.217179825464882e-09
the O 0 5.99555889380099e-08
nuclear O 0 7.458573236363009e-05
membrane O 0 2.19960929825902e-05
. O 0 2.296028469572775e-06

These O 0 1.723784862406319e-06
results O 0 3.953849954996258e-06
would O 0 2.0151067303686432e-07
not O 0 1.284578665661229e-08
be O 0 7.922381861646954e-09
expected O 0 5.675496694834692e-08
if O 0 1.8477551932960523e-08
immunostaining O 0 1.7079095414374024e-05
at O 0 2.0533289557533863e-07
intercalated O 0 0.00012327180593274534
discs O 0 7.301833829842508e-05
were O 0 5.558317184295447e-07
due O 0 1.4107212109593092e-07
to O 0 2.8941786744951514e-09
a O 0 9.734366201996636e-09
product O 0 2.954292810386505e-08
of O 0 7.40377847918694e-09
the O 0 5.625071253234637e-08
emerin O 0 0.0005096906097605824
gene O 0 3.6787395174542326e-07
and O 0 9.433129832814302e-08
, O 0 1.1748097250574574e-07
therefore O 0 3.9863007117446614e-08
, O 0 4.0954379443292055e-08
cast O 0 2.189297561017156e-07
some O 0 9.265788136758601e-09
doubt O 0 1.3112500596434984e-07
upon O 0 1.0244836090578247e-08
the O 0 1.7929835394170368e-08
hypothesis O 0 1.5245317399603664e-06
that O 0 2.8831557301600697e-06
cardiac B-Disease 1 0.848626434803009
defects I-Disease 1 0.9366667866706848
in O 0 8.542303476133384e-06
EDMD B-Disease 1 0.999920129776001
are O 0 4.323572284192778e-06
caused O 0 1.6438229067716748e-05
by O 0 3.1536166034129565e-07
absence O 0 2.007347347898758e-06
of O 0 2.0107184184325888e-07
emerin O 0 0.007123766001313925
from O 0 4.856417035625782e-06
intercalated O 0 0.00330525659956038
discs O 0 0.0010831346735358238
. O 0 9.638788469601423e-06

Although O 0 6.238120113266632e-05
emerin O 0 0.005525505635887384
was O 0 4.293478468753165e-06
abundant O 0 2.7235415700488375e-07
in O 0 1.5955462728811654e-08
the O 0 8.683509911122655e-09
membranes O 0 5.531570081984682e-07
of O 0 3.090007538730788e-08
cardiomyocyte O 0 0.0007548608118668199
nuclei O 0 1.5170381630014163e-05
, O 0 1.3604021376067976e-07
it O 0 9.788564625523577e-09
was O 0 1.7068067847958446e-07
absent O 0 5.133989589012344e-07
from O 0 1.7411105446285546e-08
many O 0 1.4017113691977556e-08
non O 0 2.378474164288491e-06
- O 0 0.008279905654489994
myocyte O 0 0.0765952616930008
cells O 0 5.020467597205425e-06
in O 0 7.73780044482919e-08
the O 0 1.0524636309128255e-06
heart O 0 0.00032725557684898376
. O 0 8.02691556600621e-06

This O 0 4.918624085803458e-07
distribution O 0 2.924222428646317e-07
of O 0 1.2520808923000004e-07
emerin O 0 0.0011864900588989258
was O 0 1.0017704425990814e-06
similar O 0 4.4891482531284055e-08
to O 0 6.957276088570552e-09
that O 0 2.906326512785995e-09
of O 0 2.3923497849409614e-08
lamin O 0 0.004318622872233391
A O 0 8.12084408607916e-07
, O 0 9.447498428016843e-08
a O 0 6.211155323398998e-08
candidate O 0 5.744160489484784e-07
gene O 0 1.0689340257385993e-07
for O 0 6.618604686536855e-08
an O 0 1.197593974211486e-06
autosomal O 0 0.00022306939354166389
form O 0 3.026997774213669e-06
of O 0 2.0811627109651454e-05
EDMD B-Disease 1 0.9994879961013794
. O 0 0.00013021868653595448

In O 0 8.064265784923919e-06
contrast O 0 3.3647036616457626e-05
, O 0 7.021239071036689e-06
lamin O 0 0.30906063318252563
B1 O 1 0.7056477069854736
was O 0 1.3336268239072524e-05
absent O 0 8.125623935484327e-06
from O 0 1.4422568028749083e-07
cardiomyocyte O 0 0.00012243175297044218
nuclei O 0 2.4134840259648627e-06
, O 0 8.189707756400821e-08
showing O 0 1.2428839681888348e-06
that O 0 7.949569891252395e-08
lamin O 0 0.04495669901371002
B1 O 0 0.28594133257865906
is O 0 1.1445612102534142e-07
not O 0 4.861326896588025e-09
essential O 0 1.1866777782643112e-08
for O 0 6.118999973381278e-09
localization O 0 2.0067395212208794e-07
of O 0 2.605344917583352e-08
emerin O 0 0.0001335171255050227
to O 0 6.154996157192727e-08
the O 0 2.843542574737512e-07
nuclear O 0 0.00037833588430657983
lamina O 0 0.01250689011067152
. O 0 7.108257705112919e-06

Lamin O 1 0.967567503452301
B1 O 1 0.9374866485595703
is O 0 7.596081559313461e-06
also O 0 9.580453479429707e-07
almost O 0 1.9463161038402177e-07
completely O 0 2.0357099401735468e-06
absent O 0 2.1840558474650607e-05
from O 0 8.289868674182799e-06
skeletal O 0 0.2845918834209442
muscle O 0 0.007127691991627216
nuclei O 0 0.00041304886690340936
. O 0 1.1047936823160853e-05

In O 0 5.673072882927954e-05
EDMD B-Disease 1 0.9872510433197021
, O 0 2.001400844164891e-06
the O 0 5.5587523917211e-08
additional O 0 1.5074171244577883e-07
absence O 0 7.597180342600041e-07
of O 0 1.4346146315347141e-07
lamin O 0 0.4155556857585907
B1 O 1 0.6950509548187256
from O 0 1.648168108658865e-05
heart O 0 0.00022365803306456655
and O 0 8.763109690335114e-06
skeletal O 0 0.22828778624534607
muscle O 0 0.0012825526064261794
nuclei O 0 1.3194832717999816e-05
which O 0 6.180218292684003e-07
already O 0 1.1812953744083643e-05
lack O 0 2.573116944404319e-06
emerin O 0 0.00739272590726614
may O 0 1.7022176734826644e-06
offer O 0 1.3375650098623737e-07
an O 0 1.9673866091807213e-08
alternative O 0 9.531353839520307e-08
explanation O 0 4.018355070911639e-08
of O 0 1.6072323916205278e-08
why O 0 2.1721236009852873e-07
these O 0 3.039700402496237e-08
tissues O 0 5.187227998249e-06
are O 0 4.447337076385338e-08
particularly O 0 1.1540810191945639e-06
affected O 0 1.8491249420549138e-06
. O 0 4.901419856651046e-07
. O 0 2.4872006179066375e-06

Genetic O 0 0.00030029696063138545
mapping O 0 1.1758956134144682e-05
of O 0 9.433990726392949e-07
the O 0 1.4950844615668757e-06
copper B-Disease 0 0.004463531076908112
toxicosis I-Disease 0 0.01607365533709526
locus O 0 1.8258737327414565e-05
in O 0 2.668269303285342e-07
Bedlington O 0 0.0005335749010555446
terriers O 0 0.0002572648227214813
to O 0 1.6162186966539593e-07
dog O 0 8.627713214082178e-06
chromosome O 0 7.040187483653426e-06
10 O 0 1.729612648659895e-07
, O 0 3.310879392870447e-08
in O 0 9.967472180960613e-09
a O 0 4.261986674691798e-08
region O 0 9.066490633813373e-07
syntenic O 0 0.0002689624670892954
to O 0 9.459543548473448e-08
human O 0 8.789548360255139e-07
chromosome O 0 3.689394725370221e-05
region O 0 6.886198207212146e-06
2p13 O 0 0.00037606401019729674
- O 0 0.0041219498962163925
p16 O 0 0.00040582011570222676
. O 0 4.4334487938613165e-06

Abnormal O 1 0.9654635787010193
hepatic B-Disease 1 0.9990050196647644
copper I-Disease 1 0.6246198415756226
accumulation I-Disease 0 0.004502996802330017
is O 0 2.4949786165961996e-06
recognized O 0 3.0648875508632045e-06
as O 0 9.046401601153775e-07
an O 0 3.8963942643022165e-05
inherited B-Disease 1 0.9999872446060181
disorder I-Disease 1 0.9999234676361084
in O 0 6.9396646722452715e-06
man O 0 0.00048261714982800186
, O 0 5.71990676689893e-06
mouse O 0 0.00012081644672434777
, O 0 3.9977021515369415e-06
rat O 0 0.0008434480405412614
and O 0 4.623727818398038e-06
dog O 0 8.590441575506702e-05
. O 0 4.945739874528954e-06

The O 0 1.4187966371537186e-05
major O 0 8.188042556867003e-05
cause O 0 2.803306961141061e-05
of O 0 1.5274088127625873e-06
hepatic B-Disease 1 0.9955925345420837
copper I-Disease 0 0.3848002851009369
accumulation I-Disease 0 0.00015859733684919775
in O 0 2.0465473937747447e-07
man O 0 6.992898761382094e-06
is O 0 6.095553573004509e-08
a O 0 2.7649858225231583e-07
dysfunctional O 0 0.0007295793620869517
ATP7B O 0 0.083283431828022
gene O 0 5.58783222004422e-06
, O 0 5.005436833016574e-06
causing O 0 0.007887221872806549
Wilson B-Disease 1 0.6275186538696289
disease I-Disease 0 0.20298387110233307
( O 0 2.3471226086257957e-05
WD B-Disease 1 0.6530610918998718
) O 0 7.66919220041018e-06
. O 0 5.869482720299857e-06

Mutations O 0 0.0006890902877785265
in O 0 8.489366223329853e-07
the O 0 2.583744560524792e-07
ATP7B O 0 0.0019659355748444796
genes O 0 1.0998506922987872e-06
have O 0 5.49228325041895e-08
also O 0 4.705286826833799e-08
been O 0 8.392688499725409e-08
demonstrated O 0 4.7496769184363075e-07
in O 0 3.626537292689136e-08
mouse O 0 1.4114121768216137e-05
and O 0 5.587187843048014e-06
rat O 0 0.0012694110628217459
. O 0 4.8068845899251755e-06

The O 0 7.538112640759209e-06
ATP7B O 0 0.007022985722869635
gene O 0 1.4104447473073378e-05
has O 0 3.9851840938354144e-07
been O 0 1.2093725842987624e-07
excluded O 0 8.643125966045773e-07
in O 0 1.0043905263046327e-08
the O 0 1.795776327639942e-08
much O 0 1.3206297921897203e-07
rarer O 0 7.467349496437237e-05
human O 0 2.167766615457367e-05
copper B-Disease 1 0.5066669583320618
overload I-Disease 1 0.8848365545272827
disease O 0 0.02843521535396576
non B-Disease 0 6.7814216890838e-05
- I-Disease 0 0.1807035505771637
Indian I-Disease 0 0.0038951446767896414
childhood I-Disease 0 0.0791357234120369
cirrhosis I-Disease 1 0.9092628359794617
, O 0 3.491411916911602e-06
indicating O 0 4.980464291293174e-05
genetic O 0 5.9395730204414576e-05
heterogeneity O 0 0.0009620209457352757
. O 0 1.7912623661686666e-05

By O 0 1.5794772480148822e-05
investigating O 0 0.0004537552304100245
the O 0 1.755613811837975e-05
common O 0 0.00030205276561900973
autosomal O 1 0.6409395337104797
recessive O 1 0.9246529936790466
copper B-Disease 1 0.992173433303833
toxicosis I-Disease 1 0.9995686411857605
( O 0 2.6602743673720397e-05
CT B-Disease 0 0.08495333045721054
) O 0 1.4691075023165467e-07
in O 0 7.385164479956075e-08
Bedlington O 0 0.0003921670140698552
terriers O 0 0.0011436711065471172
, O 0 3.482960835299309e-07
we O 0 1.1718596759635602e-08
have O 0 8.736170897805096e-09
identified O 0 3.415131288875273e-08
a O 0 7.321039774410565e-09
new O 0 2.0716313997581892e-07
locus O 0 4.528812951321015e-06
involved O 0 1.1570991773623973e-05
in O 0 5.3857504099141806e-05
progressive O 1 0.9994611144065857
liver B-Disease 1 0.9999819993972778
disease I-Disease 1 0.9992018342018127
. O 0 8.595277176937088e-05

We O 0 7.287978405656759e-06
examined O 0 5.453713674796745e-05
whether O 0 5.087943577564147e-07
the O 0 1.7080378711398225e-07
WD B-Disease 0 0.023079125210642815
gene O 0 2.922570956798154e-06
ATP7B O 0 0.0018863558070734143
was O 0 2.8317672331468202e-06
also O 0 2.4776946361271257e-07
causative O 0 4.655563316191547e-06
for O 0 1.286419433199626e-07
CT B-Disease 0 0.0008003928232938051
by O 0 1.0153254947908863e-07
investigating O 0 6.973194103920832e-06
the O 0 1.5022692423372064e-07
chromosomal O 0 0.001840615994296968
co O 0 0.0006809646729379892
- O 0 0.0005220951861701906
localization O 0 1.233526836585952e-05
of O 0 2.0971104675027163e-07
ATP7B O 0 0.0008121452992781997
and O 0 3.4174840379819216e-07
C04107 O 0 5.981099093332887e-06
, O 0 7.4255579463056165e-09
using O 0 7.188989403772439e-09
fluorescence O 0 2.1519379345136258e-07
in O 0 3.4705067264440004e-08
situ O 0 4.8715023694967385e-06
hybridization O 0 5.946536020928761e-06
( O 0 9.585461384631344e-07
FISH O 0 8.410839654970914e-06
) O 0 1.032747150020441e-06
. O 0 2.4696907985344296e-06

C04107 O 0 0.007987480610609055
is O 0 3.1565855351800565e-06
an O 0 2.3214978739360959e-07
anonymous O 0 1.5419258261317736e-06
microsatellite O 0 0.00028359497082419693
marker O 0 4.688062108471058e-05
closely O 0 3.851717337965965e-06
linked O 0 9.596724703442305e-05
to O 0 2.0519562440313166e-06
CT B-Disease 0 0.028290968388319016
. O 0 1.1985985111095943e-05

However O 0 1.2268747923371848e-05
, O 0 1.289492843170592e-06
BAC O 0 1.5460662325494923e-05
clones O 0 1.310006973653799e-05
containing O 0 7.731647428954602e-07
ATP7B O 0 0.0002841674431692809
and O 0 2.4187758640437096e-07
C04107 O 0 7.423340321111027e-06
mapped O 0 1.5376408555312082e-06
to O 0 1.6905769228969802e-08
the O 0 3.447336638373599e-08
canine O 0 6.213825690792874e-05
chromosome O 0 6.998713797656819e-05
regions O 0 9.192753509523754e-07
CFA22q11 O 0 0.0003021947923116386
and O 0 2.5496988200757187e-06
CFA10q26 O 0 0.002030587987974286
, O 0 1.4103754608640884e-07
respectively O 0 2.866880777219194e-07
, O 0 3.116762314903099e-08
demonstrating O 0 8.299680871459714e-07
that O 0 7.172734228788613e-08
WD B-Disease 0 0.013458496890962124
cannot O 0 1.277584686931732e-07
be O 0 1.840031771394024e-08
homologous O 0 1.9235578747611726e-06
to O 0 6.236315925889357e-07
CT B-Disease 0 0.006560381967574358
. O 0 6.221196144906571e-06

The O 0 6.503987606265582e-06
copper O 0 0.00025638798251748085
transport O 0 1.0152457434742246e-05
genes O 0 1.566288460708165e-06
CTR1 O 0 0.0002448511659167707
and O 0 3.404443020826875e-07
CTR2 O 0 0.001249133376404643
were O 0 3.743712397863419e-07
also O 0 1.371306126429772e-07
excluded O 0 1.3559235867433017e-06
as O 0 2.255090691960504e-08
candidate O 0 1.5770471861742408e-07
genes O 0 3.53511069306478e-08
for O 0 6.674600427913902e-08
CT B-Disease 0 0.00208628480322659
since O 0 1.58348058221236e-07
they O 0 5.7005875575555365e-09
both O 0 1.0552053453238841e-08
mapped O 0 2.431963139315485e-06
to O 0 3.614074159941083e-07
canine O 0 0.0006536734290421009
chromosome O 0 0.00028778379783034325
region O 0 3.420045322855003e-05
CFA11q22 O 0 0.004232562147080898
. O 0 1.1225363778066821e-05

2 O 0 0.0001459580089431256
- O 0 0.0061533041298389435
22 O 0 0.00014835585898254067
. O 0 2.2830587113276124e-05

5 O 0 0.0007715225801803172
. O 0 0.00022135538165457547

A O 0 7.1054250838642474e-06
transcribed O 0 3.100684352830285e-06
sequence O 0 3.6900607369716454e-07
identified O 0 5.387850023907959e-07
from O 0 2.0687954460640867e-08
the O 0 1.730766818752727e-08
C04107 O 0 6.198094524734188e-06
- O 0 2.6169544071308337e-05
containing O 0 1.067718130798312e-06
BAC O 0 3.058011770917801e-06
was O 0 1.7908857330439787e-07
found O 0 2.925660780306316e-08
to O 0 2.9026372416751656e-09
be O 0 3.0037121678816447e-09
homologous O 0 8.643062443525196e-08
to O 0 3.8387302225828535e-09
a O 0 1.732289511835461e-08
gene O 0 8.57298942946727e-08
expressed O 0 8.028655429370701e-08
from O 0 2.8839746590847426e-08
human O 0 2.3405358717809577e-07
chromosome O 0 1.6095331375254318e-05
2p13 O 0 0.00010298577399225906
- O 0 0.0013093437300994992
p16 O 0 2.024340574280359e-05
, O 0 3.632137790532397e-08
a O 0 2.0832166214290737e-08
region O 0 8.17977863221131e-08
devoid O 0 3.5758543504016416e-07
of O 0 1.6730753671367893e-08
any O 0 3.32847527317881e-08
positional O 0 7.279837518581189e-06
candidate O 0 7.357238700933522e-06
genes O 0 3.1816214232094353e-06
. O 0 1.4926768017176073e-06

Molecular O 0 5.0596830988069996e-05
analysis O 0 1.3184117051423527e-06
of O 0 1.0573111097755827e-07
the O 0 8.247204874578529e-08
APC B-Disease 0 4.315357728046365e-05
gene O 0 1.7415530351172492e-07
in O 0 1.8213164310054708e-08
205 O 0 3.0461012556770584e-06
families O 0 7.325980391215126e-07
: O 0 6.255346818306862e-08
extended O 0 4.0559871195000596e-07
genotype O 0 1.6331243386957794e-05
- O 0 0.0009179831831716001
phenotype O 0 1.9664597857627086e-05
correlations O 0 6.791462510591373e-06
in O 0 2.04851360763314e-07
FAP B-Disease 0 0.0002882536209654063
and O 0 3.555153398338007e-07
evidence O 0 3.3703005897223193e-07
for O 0 1.671046945261878e-08
the O 0 1.364545276771878e-08
role O 0 6.706119393129484e-08
of O 0 1.6976924754885658e-08
APC B-Disease 0 2.507585122657474e-05
amino O 0 1.9406718365644338e-06
acid O 0 2.1214484149822965e-05
changes O 0 3.5882862903235946e-06
in O 0 0.00022797328711021692
colorectal B-Disease 1 0.9999984502792358
cancer I-Disease 1 0.9999783039093018
predisposition O 1 0.9387601017951965
. O 0 6.701295933453366e-05

BACKGROUND O 0 8.93342585186474e-05
/ O 0 6.840616697445512e-05
AIMS O 0 2.2301028366200626e-05
The O 0 2.9813057267347176e-07
development O 0 4.2756432776513975e-06
of O 0 0.002002113265916705
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999911785125732
and O 0 5.076479283161461e-06
a O 0 5.164002345736662e-07
variable O 0 1.6052156297519105e-06
range O 0 2.357944367759046e-06
of O 0 9.857983513938962e-07
extracolonic O 0 0.49751076102256775
manifestations O 0 0.0011727074161171913
in O 0 5.27027586940676e-05
familial B-Disease 1 0.9999129772186279
adenomatous I-Disease 1 0.9999806880950928
polyposis I-Disease 1 0.999991774559021
( O 0 9.896777919493616e-05
FAP B-Disease 0 0.16635166108608246
) O 0 4.556316355319723e-07
is O 0 1.767220858539531e-08
the O 0 8.618892266554212e-09
result O 0 5.120786994439186e-08
of O 0 1.735295462879094e-08
the O 0 2.0257544974811026e-07
dominant O 0 3.2418090995633975e-05
inheritance O 0 0.0005277837044559419
of O 0 0.0008683813503012061
adenomatous B-Disease 1 0.9999858140945435
polyposis I-Disease 1 0.9999793767929077
coli I-Disease 1 0.9998489618301392
( O 0 3.3362444810336456e-05
APC B-Disease 0 0.0016326910117641091
) O 0 1.579176569066476e-06
gene O 0 7.80464233685052e-06
mutations O 0 2.8830409064539708e-05
. O 0 5.358097951102536e-06

In O 0 6.4961400312313344e-06
this O 0 1.3184978797653457e-07
study O 0 2.3243690350227553e-07
, O 0 1.9408751938954083e-08
direct O 0 1.4142498727665043e-08
mutation O 0 6.926190820877309e-08
analysis O 0 8.27840640482691e-09
of O 0 6.493509285832033e-09
the O 0 3.130907089143875e-08
APC B-Disease 0 5.317123213899322e-05
gene O 0 2.493122792657232e-07
was O 0 7.060871354269693e-08
performed O 0 2.3806832061268324e-08
to O 0 3.297712103389472e-09
determine O 0 6.089243953510959e-08
genotype O 0 5.1855954552593175e-06
- O 0 0.00024251986178569496
phenotype O 0 7.5398015724204015e-06
correlations O 0 2.0701909306808375e-06
for O 0 1.1624612739069562e-07
nine O 0 2.2204374090506462e-06
extracolonic O 0 0.018899839371442795
manifestations O 0 1.1769929187721573e-05
and O 0 1.029803016194819e-07
to O 0 1.3033030654696631e-08
investigate O 0 6.13020517903351e-07
the O 0 4.017144306089904e-08
incidence O 0 7.266852662723977e-06
of O 0 1.2116561265429482e-07
APC B-Disease 0 0.00025193989858962595
mutations O 0 6.451010904129362e-06
in O 0 5.87102192639577e-07
non O 0 0.002551735145971179
- O 1 0.9995680451393127
FAP O 1 0.9997915625572205
colorectal B-Disease 1 0.9999974966049194
cancer I-Disease 1 0.9998363256454468
. O 0 0.00014166980690788478

METHODS O 0 1.3247612514533103e-05
The O 0 1.160792294285784e-06
APC B-Disease 0 7.784370973240584e-05
gene O 0 1.0525078550926992e-06
was O 0 1.5101495876024273e-07
analysed O 0 5.19034813351027e-07
in O 0 1.7547829855857344e-08
190 O 0 4.117565595151973e-07
unrelated O 0 1.4880610251566395e-05
FAP B-Disease 0 0.00014557149552274495
and O 0 2.18625558545682e-07
15 O 0 8.232131563090661e-07
non O 0 0.0001533396716695279
- O 1 0.99856036901474
FAP O 1 0.9999381303787231
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999874830245972
patients O 0 0.00027626691735349596
using O 0 5.335430728337087e-07
denaturing O 0 0.00048114449600689113
gradient O 0 9.197213512379676e-05
gel O 0 0.0005253454437479377
electrophoresis O 0 6.254106847336516e-05
, O 0 6.21160580749347e-08
the O 0 6.319321954606494e-09
protein O 0 1.729199539113324e-08
truncation O 0 9.425914981875394e-07
test O 0 2.4798484332677617e-07
, O 0 2.2189306392306207e-08
and O 0 3.752440846938043e-08
direct O 0 1.5980765510903439e-07
sequencing O 0 9.706190212455112e-06
. O 0 4.419611286721192e-06

RESULTS O 0 8.593130041845143e-05
Chain O 0 5.030047395848669e-05
terminating O 0 2.0918361769872718e-05
signals O 0 1.2874063486378873e-06
were O 0 9.153634294989388e-08
only O 0 1.0096513847202004e-08
identified O 0 7.67145706959127e-07
in O 0 1.4741065967882605e-07
patients O 0 5.836895070387982e-06
belonging O 0 1.3719643447984708e-06
to O 0 2.2152855549961714e-08
the O 0 1.5717364476586226e-07
FAP B-Disease 0 0.0022370857186615467
group O 0 1.1197477761015762e-05
( O 0 8.923707355279475e-07
105 O 0 4.4596574298338965e-05
patients O 0 0.00023709800734650344
) O 0 8.12938310446043e-07
. O 0 2.4386265522480244e-06

Amino O 0 5.037848313804716e-05
acid O 0 5.1237169827800244e-05
changes O 0 6.078776664253382e-07
were O 0 8.616923707904789e-08
identified O 0 2.972754487018392e-07
in O 0 1.5969286337735866e-08
four O 0 7.001394237704517e-07
patients O 0 5.024931670050137e-05
, O 0 3.410184135077543e-08
three O 0 2.0958024649075924e-08
of O 0 9.319425942067028e-08
whom O 0 1.0846556506294291e-05
belonged O 0 3.2200525765802013e-06
to O 0 1.1892380413769388e-08
the O 0 3.7346186587683405e-08
non O 0 3.2581494906480657e-06
- O 0 0.0073510161601006985
FAP O 0 0.01426664274185896
group O 0 0.00022594955225940794
of O 0 0.014780755154788494
colorectal B-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999843835830688
patients O 0 0.3440796732902527
. O 0 4.048562914249487e-05

Genotype O 0 0.01062452606856823
- O 0 0.21313586831092834
phenotype O 0 0.007213498465716839
correlations O 0 0.0010428836103528738
identified O 0 8.692051778780296e-05
significant O 0 3.3520916531415423e-06
differences O 0 4.8987467380356975e-06
in O 0 4.152099819521027e-08
the O 0 3.7010494224887225e-08
nature O 0 1.9736411616122496e-07
of O 0 4.292244426551406e-08
certain O 0 2.1352302326249628e-07
extracolonic O 0 0.01009187288582325
manifestations O 0 3.1277581001631916e-05
in O 0 2.1006405859225197e-06
FAP B-Disease 0 0.3423241078853607
patients O 0 0.0008845734409987926
belonging O 0 3.0083749607001664e-06
to O 0 4.5606768139805354e-08
three O 0 3.698029615861742e-07
mutation O 0 9.720946763991378e-06
subgroups O 0 6.469756044680253e-05
. O 0 8.582070222473703e-06

CONCLUSIONS O 0 6.000540452077985e-05
Extended O 0 2.486026642145589e-05
genotype O 0 0.0005586910992860794
- O 0 0.01705707237124443
phenotype O 0 0.00043504542554728687
correlations O 0 4.309398354962468e-05
made O 0 3.5522728580872354e-07
in O 0 4.5677282400902186e-08
this O 0 1.2433287288615702e-08
study O 0 3.0324792987812543e-07
may O 0 3.8289226722554304e-07
have O 0 1.4208145771021918e-08
the O 0 9.290120672744706e-09
potential O 0 2.714634490530443e-07
to O 0 3.953761318342686e-09
determine O 0 1.2709309160641169e-08
the O 0 7.051272454816626e-09
most O 0 4.213190241131315e-09
appropriate O 0 1.1163508339961936e-08
surveillance O 0 8.115827085930505e-07
and O 0 8.196003022931109e-07
prophylactic O 0 0.0005779623170383275
treatment O 0 5.970049824099988e-05
regimens O 0 1.392242938891286e-05
for O 0 1.5947802012306056e-07
those O 0 1.4203926639311248e-06
patients O 0 4.435071241459809e-05
with O 0 1.9209601305192336e-06
mutations O 0 6.054506957298145e-05
associated O 0 3.053384034501505e-06
with O 0 1.1178079830642673e-06
life O 0 7.495664613088593e-05
threatening O 0 0.07922535389661789
conditions O 0 9.747650619829074e-05
. O 0 1.09798866105848e-05

This O 0 2.146253791579511e-06
study O 0 3.023662429768592e-06
also O 0 1.6332286634224147e-07
provided O 0 5.878899855815689e-08
evidence O 0 1.7758954129476479e-07
for O 0 2.9096892006919006e-08
the O 0 6.922717687984914e-08
pathological O 0 2.4106633645715192e-05
nature O 0 9.568001502202605e-08
of O 0 3.2247896797343856e-08
amino O 0 7.18205683369888e-07
acid O 0 4.654178610508097e-06
changes O 0 4.413653442725263e-08
in O 0 2.6027521471405635e-08
APC O 0 5.723986396333203e-05
associated O 0 2.7277761205368733e-07
with O 0 3.502653100895259e-08
both O 0 1.5540977926775668e-07
FAP B-Disease 0 0.0004819872847292572
and O 0 5.5574973885086365e-06
non O 0 0.0025825765915215015
- O 1 0.9996615648269653
FAP O 1 0.9999339580535889
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999940395355225
patients O 0 0.2581442892551422
. O 0 4.067141162522603e-06
. O 0 7.39635333957267e-06

Inherited B-Disease 1 0.9996127486228943
colorectal I-Disease 1 0.9999834299087524
polyposis I-Disease 1 0.9999431371688843
and O 1 0.8796488046646118
cancer B-Disease 1 0.9997400641441345
risk O 0 0.0013463611248880625
of O 0 4.296823021832097e-07
the O 0 2.5892404664773494e-06
APC O 0 0.004389628767967224
I1307K O 0 0.0028426731005311012
polymorphism O 0 0.0005237112636677921
. O 0 1.3813163604936562e-05

Germ O 0 0.015225125476717949
- O 0 0.0013366846833378077
line O 0 7.2749658102111425e-06
and O 0 3.0604692824454105e-07
somatic O 0 1.7185147953568958e-05
truncating O 0 0.00015315235941670835
mutations O 0 3.1539975680061616e-06
of O 0 2.5472358444744714e-08
the O 0 8.724052946718075e-08
APC B-Disease 0 6.745059363311157e-05
gene O 0 1.430350948794512e-07
are O 0 9.098504172300181e-09
thought O 0 4.7455749552227644e-08
to O 0 1.213163898228231e-07
initiate O 0 0.0008973816293291748
colorectal B-Disease 1 0.9999860525131226
tumor I-Disease 1 0.9398295879364014
formation O 0 0.005715860519558191
in O 0 0.001007867162115872
familial B-Disease 1 0.9999581575393677
adenomatous I-Disease 1 0.9999856948852539
polyposis I-Disease 1 0.9999979734420776
syndrome I-Disease 1 0.9999810457229614
and O 0 0.0004937979392707348
sporadic O 0 0.374575138092041
colorectal O 1 0.9999920129776001
carcinogenesis O 1 0.9993821382522583
, O 0 0.00014446194109041244
respectively O 0 0.00010737638513091952
. O 0 8.625837836007122e-06

Recently O 0 0.0004145407001487911
, O 0 1.4361041849042522e-06
an O 0 1.833537197626356e-07
isoleucine O 0 0.00020391946600284427
- O 0 0.001052488456480205
- O 0 0.00038982811383903027
> O 0 5.652610980177997e-06
lysine O 0 1.6773889001342468e-05
polymorphism O 0 2.5744252525328193e-06
at O 0 1.008697054771801e-07
codon O 0 7.19907006896392e-07
1307 O 0 3.291112807346508e-05
( O 0 8.407108254004925e-08
I1307K O 0 3.3152098239952466e-06
) O 0 3.895776590212563e-09
of O 0 9.125890598760122e-10
the O 0 8.967667497472576e-09
APC B-Disease 0 1.6365745977964252e-05
gene O 0 1.2573447349950584e-07
has O 0 2.8297582943537236e-08
been O 0 3.0856494248610034e-08
identified O 0 1.3549239952226344e-07
in O 0 7.711232541396384e-09
6 O 0 2.9642447429978347e-07
% O 0 4.6838060541176674e-08
- O 0 2.848559415724594e-05
7 O 0 3.6787255908166117e-07
% O 0 1.2578791341866236e-08
of O 0 1.0262202643218643e-08
the O 0 1.3505378149147873e-07
Ashkenazi O 0 0.0001841069315560162
Jewish O 0 1.0009282050305046e-05
population O 0 8.922082770368434e-07
. O 0 1.5461608882105793e-06

To O 0 4.007156803709222e-06
assess O 0 2.905239125539083e-05
the O 0 7.901714980107499e-07
risk O 0 1.2540468560473528e-05
of O 0 1.789573822463808e-08
this O 0 9.92933291144027e-09
common O 0 1.499212203270872e-07
APC B-Disease 0 3.6627945519285277e-05
allelic O 0 0.0001585979334777221
variant O 0 0.00010763862519524992
in O 0 1.5121084288693964e-05
colorectal O 1 0.9999903440475464
carcinogenesis O 1 0.9908204674720764
, O 0 1.246152078238083e-05
we O 0 1.1106297392871056e-07
have O 0 3.716037966228214e-08
analyzed O 0 3.0070501111367776e-07
a O 0 3.475275889286422e-08
large O 0 1.8120374534191797e-07
cohort O 0 1.1763151633203961e-05
of O 0 1.4958247618324094e-07
unselected O 0 0.0008902127156034112
Ashkenazi O 0 0.0002376055927015841
Jewish O 0 2.9401267056528013e-06
subjects O 0 2.9283685307746055e-06
with O 0 4.627318958227988e-06
adenomatous B-Disease 1 0.9972621202468872
polyps I-Disease 1 0.8478425741195679
and O 0 5.42144380233367e-06
. O 0 6.289590601227246e-06
or O 0 0.05075865983963013
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999557733535767
, I-Disease 0 1.6326008562828065e-06
for O 0 3.5890488447876123e-07
the O 0 1.5282757885870524e-06
APC O 0 0.001670962548814714
I1307K O 0 0.0006562883500009775
polymorphism O 0 0.00021659072081092745
. O 0 1.1622595593507867e-05

The O 0 1.1763442671508528e-05
APC O 0 0.0007765829795971513
I1307K O 0 0.00029398236074484885
allele O 0 8.326332135766279e-06
was O 0 1.0680429340936826e-06
identified O 0 5.468423864840588e-07
in O 0 1.7723856160500873e-08
48 O 0 4.174954995050939e-07
( O 0 2.260516573926452e-08
10 O 0 2.0758864849312886e-08
. O 0 7.624331388456085e-09
1 O 0 3.160329953288965e-08
% O 0 2.930089415542625e-08
) O 0 1.9419195140812917e-08
of O 0 1.0622493107348419e-07
476 O 0 0.007560649421066046
patients O 0 0.0010089639108628035
. O 0 7.705097232246771e-06

Compared O 0 5.10534955537878e-05
with O 0 3.1353059171124187e-07
the O 0 2.2413429334733337e-08
frequency O 0 2.6409272990690624e-08
in O 0 2.6977637901381968e-09
two O 0 2.5355717525599175e-09
separate O 0 2.800805276592655e-08
population O 0 1.8656139744166467e-08
control O 0 9.587932936483412e-08
groups O 0 2.9128209177997633e-08
, O 0 1.1584501358186117e-08
the O 0 1.5456603108532363e-08
APC O 0 1.7684737031231634e-05
I1307K O 0 3.151819691993296e-05
allele O 0 6.196406729941373e-07
is O 0 1.6002703162598664e-08
associated O 0 7.44146859688044e-08
with O 0 2.113239361278829e-08
an O 0 5.805446079421017e-08
estimated O 0 5.3173944252193905e-06
relative O 0 1.2774334209098015e-05
risk O 0 1.9259889086242765e-05
of O 0 1.3545054855512717e-07
1 O 0 5.906373189645819e-06
. O 0 7.810411261743866e-06

5 O 0 0.0001106138079194352
- O 0 0.0018862411379814148
1 O 0 3.148083123960532e-05
. O 0 1.5649427950847894e-05

7 O 0 0.00022497786267194897
for O 0 0.00045239581959322095
colorectal B-Disease 1 0.999964714050293
neoplasia I-Disease 1 0.9971446394920349
( O 0 7.962747986312024e-06
both O 0 9.984846656152513e-07
P O 0 0.0010074112797155976
= O 0 5.6152184697566554e-05
. O 0 3.0518802418555424e-07
01 O 0 0.00018899502174463123
) O 0 1.4002397392687271e-06
. O 0 1.9016789565284853e-06

Furthermore O 0 9.00006853044033e-05
, O 0 1.9808869637927273e-06
compared O 0 2.715988330237451e-06
with O 0 3.2133880267792847e-07
noncarriers O 0 0.0012587981764227152
, O 0 7.167358830884041e-07
APC O 0 7.475385791622102e-05
I1307K O 0 7.875874871388078e-05
carriers O 0 9.560441867506597e-06
had O 0 1.3965880896193994e-07
increased O 0 4.675540665743938e-08
numbers O 0 2.1125462268400952e-08
of O 0 1.1216829420845897e-07
adenomas B-Disease 1 0.5783162713050842
and O 0 0.003144606715068221
colorectal B-Disease 1 0.9999985694885254
cancers I-Disease 1 0.9987685084342957
per O 0 2.254746505059302e-05
patient O 0 0.0003743945562746376
( O 0 5.946122314526292e-07
P O 0 0.00022662831179331988
= O 0 9.664403478382155e-06
. O 0 5.306121408921172e-08
03 O 0 1.5262223314493895e-05
) O 0 3.319206598462188e-08
, O 0 1.3234357609803737e-08
as O 0 5.054912488589025e-09
well O 0 5.227881683111946e-09
as O 0 7.013769121044788e-09
a O 0 8.11408042977746e-08
younger O 0 1.0811278116307221e-05
age O 0 7.65430013416335e-06
at O 0 1.923635500133969e-05
diagnosis O 0 0.0009718824876472354
. O 0 1.2723039617412724e-05

We O 0 3.0042322123335907e-06
conclude O 0 3.3249018542846898e-06
that O 0 3.741877208085498e-08
the O 0 1.9726432043398745e-08
APC O 0 1.1305183761578519e-05
I1307K O 0 2.2753751181880943e-05
variant O 0 4.587535840983037e-06
leads O 0 2.390879899394349e-06
to O 0 1.3823961353409686e-07
increased O 0 1.8893229935201816e-05
adenoma B-Disease 1 0.9986019730567932
formation O 0 1.6769568901509047e-05
and O 0 1.4491644151348737e-07
directly O 0 3.6645857903749857e-08
contributes O 0 2.068376119268578e-07
to O 0 5.644262834891833e-09
3 O 0 5.16855465093613e-08
% O 0 2.9076254293158854e-08
- O 0 1.1484724382171407e-05
4 O 0 8.71565433158139e-08
% O 0 7.07649494557927e-09
of O 0 9.272152823314173e-09
all O 0 2.0071090034434746e-07
Ashkenazi O 0 0.03545722737908363
Jewish O 0 0.24964022636413574
colorectal B-Disease 1 0.9999958276748657
cancer I-Disease 1 0.9997896552085876
. O 0 6.580926856258884e-05

The O 0 3.5194261727156118e-06
estimated O 0 1.677297768765129e-05
relative O 0 1.7306241716141813e-05
risk O 0 5.804071406600997e-05
for O 0 2.7897218046746275e-07
carriers O 0 4.48666833108291e-05
may O 0 8.567428722017212e-07
justify O 0 6.189762302710733e-07
specific O 0 2.7780339806326992e-08
clinical O 0 9.762127319845604e-07
screening O 0 1.6435016902960342e-07
for O 0 1.0320127863394646e-08
the O 0 6.880078284865476e-09
360 O 0 3.333679501338338e-07
, O 0 1.0263811844879456e-07
000 O 0 7.34944421765249e-07
Americans O 0 6.238135483727092e-07
expected O 0 1.1503313857019748e-07
to O 0 1.8557372527538973e-08
harbor O 0 8.429919944319408e-06
this O 0 2.08637285226132e-09
allele O 0 8.788620675659331e-08
, O 0 1.7353285031163068e-08
and O 0 3.8253784140351854e-08
genetic O 0 3.527416083670687e-07
testing O 0 1.5740855019430455e-07
in O 0 6.65028832003145e-09
the O 0 4.738444747687254e-09
setting O 0 9.584787363792202e-08
of O 0 7.569619953073925e-08
long O 0 5.042410066380398e-06
- O 0 0.0043945470824837685
term O 0 8.377609447052237e-06
- O 0 0.00010774994007078931
outcome O 0 1.0655462574504782e-06
studies O 0 2.97658175441029e-07
may O 0 5.453102289720846e-07
impact O 0 4.641430678020697e-06
significantly O 0 0.00010251957428408787
on O 0 0.1622828245162964
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999918937683105
prevention O 0 0.0022682955022901297
in O 0 6.765035323041957e-07
this O 0 1.9747332657971128e-07
population O 0 2.2715025806974154e-06
. O 0 7.4528702498355415e-06

Localization O 0 9.467291238252074e-05
of O 0 2.3684874577156734e-06
human O 0 8.668569535075221e-06
BRCA1 O 0 0.00011487464507808909
and O 0 3.4074020049956744e-07
its O 0 2.1200871458404436e-07
loss O 0 2.4239372578449547e-05
in O 0 7.301854765273674e-08
high O 0 1.0516647307667881e-05
- O 0 0.0036108132917433977
grade O 0 7.966921111801639e-05
, O 0 2.645727590788738e-06
non B-Disease 0 0.0002377780620008707
- I-Disease 1 0.9702090620994568
inherited I-Disease 1 0.992493212223053
breast I-Disease 1 0.998195230960846
carcinomas I-Disease 1 0.9997476935386658
. O 0 0.00013822705659549683

Although O 0 4.564833943732083e-06
the O 0 1.985343516253124e-07
link O 0 1.0839831929843058e-06
between O 0 1.257610904303874e-07
the O 0 7.792256724314939e-07
BRCA1 O 0 0.023978019133210182
tumour B-Disease 1 0.9971951246261597
- O 0 0.011328783817589283
suppressor O 0 0.001559721538797021
gene O 0 4.035443907923764e-06
and O 0 1.4341538189910352e-05
hereditary B-Disease 1 0.9913523197174072
breast I-Disease 1 0.9998633861541748
and I-Disease 1 0.9987407326698303
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999779462814331
is O 0 1.955972948053386e-06
established O 0 1.543352937005693e-06
, O 0 3.0061042366469337e-07
the O 0 7.006203617265783e-08
role O 0 1.2331705647739e-06
, O 0 1.81483571282115e-07
if O 0 1.4830345840266546e-08
any O 0 5.333514963012931e-09
, O 0 2.3366368395727477e-08
of O 0 4.8691333631722955e-08
BRCA1 O 0 4.2623352783266455e-05
in O 0 5.345372073861654e-07
non B-Disease 0 0.0004045310488436371
- I-Disease 1 0.9857991933822632
familial I-Disease 1 0.9966557025909424
cancers I-Disease 1 0.9928334951400757
is O 0 1.5597267974953866e-06
unclear O 0 9.45751708059106e-06
. O 0 6.771122571080923e-06

BRCA1 O 1 0.7362015247344971
mutations O 0 0.0038462490774691105
are O 0 2.5548054054524982e-06
rare O 0 1.4991598618507851e-05
in O 0 9.150358550868987e-07
sporadic B-Disease 0 0.0023199233692139387
cancers I-Disease 1 0.944846510887146
, O 0 2.866458999051247e-06
but O 0 5.521160915122891e-07
loss O 0 2.346477958781179e-05
of O 0 1.827540501153635e-07
BRCA1 O 0 0.00016609182057436556
resulting O 0 3.8299194784485735e-06
from O 0 2.510659840027074e-07
reduced O 0 2.3869090455264086e-06
expression O 0 1.4061100728213205e-07
or O 0 2.1567450048110004e-08
incorrect O 0 1.5652534557375475e-07
subcellular O 0 2.3585021153849084e-06
localization O 0 4.289034677640302e-06
is O 0 6.458259349528817e-08
postulated O 0 1.5159083659455064e-06
to O 0 2.1034917807583042e-08
be O 0 6.2792402388822666e-09
important O 0 9.529550482056948e-09
in O 0 3.213785859657037e-08
non B-Disease 0 6.674700853182003e-05
- I-Disease 1 0.9553438425064087
familial I-Disease 1 0.9947861433029175
breast I-Disease 1 0.9994766116142273
and I-Disease 1 0.9270936846733093
ovarian I-Disease 1 0.9999914169311523
cancers I-Disease 1 0.9998714923858643
. O 0 0.00018984895723406225

Epigenetic O 0 0.4568402171134949
loss O 0 0.13580618798732758
, O 0 1.133664591179695e-05
however O 0 5.519608521353803e-07
, O 0 1.3831332523750461e-07
has O 0 4.387390717397466e-08
not O 0 5.193731666963686e-09
received O 0 4.437533362988688e-08
general O 0 1.1502535102181355e-07
acceptance O 0 2.5558458673913265e-06
due O 0 4.538089797279099e-07
to O 0 1.3467661652555307e-08
controversy O 0 3.246878748086601e-07
regarding O 0 2.8692431541799124e-08
the O 0 7.234257193289295e-09
subcellular O 0 7.630442837580631e-07
localization O 0 1.0140109907297301e-06
of O 0 1.1937838451103744e-07
BRCA1 O 0 5.763351509813219e-05
proteins O 0 8.174367138735761e-08
, O 0 1.3093451656231991e-08
reports O 0 2.2376566377602103e-08
of O 0 4.401914832641296e-09
which O 0 1.1979940595097105e-08
have O 0 1.65571680810217e-08
ranged O 0 5.380287007028528e-07
from O 0 2.4579458468565463e-08
exclusively O 0 1.694450020295335e-07
nuclear O 0 1.3794273399980739e-05
, O 0 3.059675179883925e-08
to O 0 1.3007625199179529e-08
conditionally O 0 2.5975754397222772e-05
nuclear O 0 8.073068784142379e-06
, O 0 1.9410160589927727e-08
to O 0 4.090860983296807e-09
the O 0 2.0154983459974574e-08
ER O 0 2.4985069103422575e-05
/ O 0 9.30601072468562e-06
golgi O 0 4.869242911809124e-05
, O 0 3.64654795248498e-08
to O 0 9.199558448358403e-09
cytoplasmic O 0 1.2497480383899529e-06
invaginations O 0 1.372718998027267e-05
into O 0 3.8720212813814214e-08
the O 0 7.812050739630649e-08
nucleus O 0 4.693733444582904e-06
. O 0 2.0858385596511653e-06

In O 0 4.690198693424463e-06
an O 0 3.602388005674584e-07
attempt O 0 1.9915476059395587e-06
to O 0 7.324842243860985e-08
resolve O 0 7.82047300162958e-06
this O 0 1.6487931020492397e-08
issue O 0 4.692667516792426e-07
, O 0 4.560033062261937e-08
we O 0 8.490287584095313e-09
have O 0 2.007724830832558e-08
comprehensively O 0 4.747869024868123e-05
characterized O 0 5.580227934842696e-06
19 O 0 2.638466185089783e-06
anti O 0 0.0002069389884127304
- O 0 0.11549784988164902
BRCA1 O 0 0.001948656514286995
antibodies O 0 1.8201953935204074e-05
. O 0 1.6090996268758317e-06

These O 0 2.7002442948287353e-06
reagents O 0 7.068825652822852e-05
detect O 0 9.340465112472884e-06
a O 0 5.2223732893708075e-08
220 O 0 2.9242670507301227e-07
- O 0 0.0001017971444525756
kD O 0 0.0001365348434774205
protein O 0 1.4177642526647105e-07
localized O 0 1.472538571078985e-07
in O 0 4.4817878297465086e-09
discrete O 0 4.022112776169706e-08
nuclear O 0 1.8482083760318346e-05
foci O 0 9.855476491793524e-06
in O 0 2.189276138153673e-08
all O 0 1.4228594302778674e-08
epithelial O 0 0.0004177766677457839
cell O 0 3.693090911838226e-05
lines O 0 5.242775841907132e-06
, O 0 8.827882425066491e-08
including O 0 2.451574516726396e-07
those O 0 1.573566237311752e-07
derived O 0 9.265382914236397e-07
from O 0 1.2101715583412442e-05
breast B-Disease 0 0.43085968494415283
malignancies I-Disease 0 0.3880583643913269
. O 0 3.595708039938472e-05

Immunohistochemical O 0 0.014504452235996723
staining O 0 0.0022687853779643774
of O 0 1.539616278023459e-05
human O 0 0.00018909199570771307
breast O 1 0.6090103387832642
specimens O 0 0.00024165403738152236
also O 0 2.399292270638398e-06
revealed O 0 4.700870340457186e-05
BRCA1 O 0 0.0006768135353922844
nuclear O 0 0.0005578612326644361
foci O 0 0.0006987761589698493
in O 0 2.0932888219249435e-05
benign O 1 0.800447404384613
breast O 1 0.9665012955665588
, O 0 0.0007213794742710888
invasive B-Disease 1 0.9842544794082642
lobular I-Disease 1 0.9999642372131348
cancers I-Disease 1 0.9988277554512024
and O 0 5.271175905363634e-05
low B-Disease 0 0.001969848060980439
- I-Disease 1 0.9406908750534058
grade I-Disease 1 0.7416638731956482
ductal I-Disease 1 0.9994755387306213
carcinomas I-Disease 1 0.9996546506881714
. O 0 0.000129317631945014

Conversely O 0 0.00044479037751443684
, O 0 1.0442680832056794e-05
BRCA1 O 0 0.00032696244306862354
expression O 0 1.8199743863078766e-06
was O 0 1.488491875534237e-06
reduced O 0 1.8089847344526788e-06
or O 0 2.734845452323498e-07
undetectable O 0 3.094050407526083e-05
in O 0 1.490603551701497e-08
the O 0 9.8019423688811e-09
majority O 0 1.2087417644579546e-07
of O 0 2.87527495146378e-08
high O 0 2.1829273464391008e-05
- O 0 0.022772707045078278
grade O 0 0.0005884800339117646
, O 0 6.504342309199274e-05
ductal B-Disease 1 0.999206006526947
carcinomas I-Disease 1 0.9998693466186523
, O 0 6.9523175625363365e-06
suggesting O 0 1.2894097380922176e-05
that O 0 6.306704847247602e-08
absence O 0 5.644265570481366e-07
of O 0 1.9315547206133488e-07
BRCA1 O 0 0.0015795300714671612
may O 0 2.554593493186985e-06
contribute O 0 2.163709069691322e-07
to O 0 1.916515302013977e-08
the O 0 4.973149003717481e-08
pathogenesis O 0 1.091204376280075e-05
of O 0 1.3444743096613365e-08
a O 0 7.446267602517764e-08
significant O 0 1.5714007872702496e-07
percentage O 0 2.8588640361704165e-06
of O 0 1.1052563877456123e-06
sporadic B-Disease 0 0.02086820639669895
breast I-Disease 1 0.9993657469749451
cancers I-Disease 1 0.9797930717468262
. O 0 4.094800715392921e-06
. O 0 1.0779714102682192e-05

